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S1 Class D carbapenemases: origins, activity, expression and
epidemiology of their producers
L. Poirel (Le Kremlin Bicetre, FR)
Oxacillinases are class D b-lactamases, grouping very diverse enzymes
usually not sensitive to b-lactamase inhibitors. Some oxacillinases
hydrolyse only narrow-spectrum b-lactams, some others expanded-
spectrum cephalosporins, but more worrying are those oxacillinases
hydrolysing carbapenems. Those latter oxacillinases named CHDLs for
“Carbapenem-Hydrolysing class D b-Lactamases” have been identiﬁed
in a variety of Gram-negative bacterial species. They do hydrolyse
penicillins and carbapenems at a low level, but their hydrolysis spectrum
does not include expanded-spectrum cephalosporins. They are not
inhibited by clavulanic acid but are inhibited by NaCl in vitro.
Some CHDLs correspond to naturally-occurring b-lactamases encoded
on the chromosome of a variety of species, such as Acinetobacter
baumannii, Pseudomonas aeruginosa, and Ralstonia pickettii. The
corresponding genes are often poorly expressed, and the impact of those
carbapenemases on the carbapenem susceptibility of the corresponding
species seems marginal. However, it has been demonstrated that
overexpression of the naturally-occurring blaOXA-51-like gene of
A. baumannii (linked to insertion of an IS element upstream of that
gene) can lead to decreased susceptibility to imipenem.
By contrast, other CHDLs are considered as acquired, leading to
esistance to carbapenems. Most of these acquired CHDLs have been
identiﬁed in A. baumannii, being of three types (OXA-23, OXA-
40, and OXA-58). Those acquired enzymes may be either plasmid-
or cchromosome-encoded. Those oxacillinases have been identiﬁed
worldwide, always identiﬁed in carbapenem-resistant isolates, those latter
being very often at the origin of nosocomial outbreaks. Interestingly, the
source of the OXA-23-encoding gene has been very recently identiﬁed,
being the chromosome of the carbapenem-susceptible Acinetobacter
radioresistens species, in which blaOXA-23 is poorly expressed.
Another acquired CHDL is OXA-48 identiﬁed ﬁrstly in a carbapenem-
resistant Klebsiella pneumoniae isolate from Turkey, which has now
widely disseminated in Istanbul, responsible for large outbreaks. The
blaOXA-48 gene is plasmid-encoded and has been recently evidenced
in other enterobacterial species in the same country. Interestingly, the
source of that acquired CHDL was shown to be the Gram-negative,
environmental and waterborne species Shewanella oneidensis.
In conclusion, besides the acquisition of metallo-b-lactamases or even
class A carbapenemase suck as the KPC-type enzymes conferring
carbapenem resistance in Gram negatives, the current emergence and
spread of CHDLs represents a worrying threat. The dissemination of
such mechanism is difﬁcult to trace and thus to control, considering that
no currently available test allows detection of CHDLs.
S2 Metallo-b-lactamase-producing Enterobacteriaceae:
phenotypes, genetics, prevalence and clinical signiﬁcance
V. Miriagou (Athens, GR)
While production of serine b-lactamases of the molecular classes
A and C remains the most clinically signiﬁcant b-lactam resistance
mechanism among enterobacteria, there is an increasing concern as
to the dissemination of strains with zinc-dependent class B metallo-
b-lactamases (MBLs). These acquired enzymes display an extremely
wide spectrum of hydrolysis that includes also carbapenems. The MBL-
encoding genes commonly occur as cassettes in integrons carried by
a variety of transferable plasmids and enterobacterial chromosomes
underscoring their spreading potential. Indeed, a physical linkage of
MBL integrons with transposable elements has been, in some instances,
documented. VIM and IMP b-lactamases – the main MBL types found
in enterobacteria – have already achieved a global spread, the southern
Europe and the Far East being the most affected regions. There are
quite a few epidemiological studies unveiling the mode of spread
of MBL-producing enterobacteria. Nevertheless, our understanding of
what MBL production entails in terms of clinical impact is still
limited. It is not yet clear if MICs of MBL producers must be
consider at face value or these isolates must be reported as potentially
resistant to carbapenems. Moreover, performance of the routine detection
methods based on EDTA-b-lactam synergy is not optimal and not yet
standardised. The aim of this presentation is to discuss recent advances
on genetics, epidemiology and clinical signiﬁcance of MBL-producing
enterobacteria.
State-of-the-art treatment of imported
parasitic diseases
S6 How to deal with chronic infections of Trichinella
C.M. Cretu (Bucharest, RO)
Trichinellosis, parasitic disease due to the presence of Trichinella spp.
larvae in muscle tissue, is an emerging disease and seems to become a
re-emerging disease, as in many endemic countries human clinical cases
are related and consequent to a breakdown of local legislation.
In Central and Eastern Europe, Trichinella infection still represents an
important health problem, according to the statistical data registered by
ICT.
Many species of Trichinella larvae, encapsulated or not, are responsible
for human cases, according to data collected in Reference Laboratory in
Rome, each one having a typical clinical appearance and geographical
distribution: T. spiralis, T. pseudospiralis, T. britovi, T. nativa, T. nelsoni,
T. murelli, T. papuae.
In endemic countries, medical attention should be paid on both acute and
chronic trichinellosis. Acute trichinellosis is familiar for medical doctors:
short incubation period, followed by gastrointestinal phase (20−30 days),
acute stage (weakness, chills, fever, headache, sweating, tachycardia,
eyelid/periocular/generalised oedema, muscle pain) and, sometime,
complications (cardiovascular, ocular, neurological, respiratory etc).
Differentiations between convalescent stage (residual myalgia), sequels
or chronic trichinellosis still remain not very well deﬁned.
Chronic trichinellosis is either symptomatic (general discomfort, chronic
muscle pain, tingling, neuropsychiatric signs, persistent sweating), in
patients with history of trichinellosis, or asymptomatic, accidentally
discovered, when muscle biopsy is examined for other reasons (i.e.
laryngeal or tongue neoplasm), when residual IgG antibodies level is
proved (persistence of residual viable larvae), chronic hypereosinophilia
or when bioelectric muscle disturbances persist.
The role of chronic trichinellosis larvae as co-factor in the development
of cancer is under debate, but further studies are necessary to be
conducted in order to conﬁrm the direct relationship between Trichinella
larvae and neoplasm (chronic inﬂammation, direct carcinogenetic role,
co-factor in carcinogenesis?).
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The algorithms for diagnosis of acute or chronic trichinellosis should be
taken into account, in order to initiate the appropriate treatment and to
prevent severe complications.
Laboratory diagnosis is simple and relevant during the acute stage, while,
during the chronic stage or in people who received corticosteroids,
ELISA can be negative and only conﬁrmation tests (imunobloting,
multiplex PCR) or muscle biopsy can determine the diagnosis.
Epidemiology should evaluate the geographical regions and the different
Trichinella species, as clinical evolution of the disease is closely related
to the parasitic burden, parasitic species and host immune response.
S7 How to cope with the wormy world? Treatment of helminths
A.M.L. Van Gompel (Antwerp, BE)
Helminth infections are among the most common infections in men.
The different helminthic infections that currently may be imported in our
European countries by returning travellers, expatriates, immigrants and
refugees coming from endemic countries will be succinctly presented in
the following way:
• nematodes or roundworms (intestinal nematodes: ancylostomia-
sis and other hookworm infections, angiostrongyliasis, ascaria-
sis, capillariasis, enterobiasis, strongyloidiasis, trichostrongyliasis,
trichuriasis; ﬁlarial nematodes and diroﬁlariasis; tissue nematodes,
e.g.: angiostrongyliasis, cutaneous larva migrans, gnathostomiasis,
toxocariasis, trichinosis),
• cestodes or tapeworms (cysticercosis, diphyllobothriasis, echinococ-
cosis, taeniasis and other intestinal tapeworms) and
• trematodes or ﬂukes (chlonorchiasis and opistorchiasis, fasciolasis;
intestinal ﬂukes; paragonimiasis; schistosomiasis)
... and their treatment modalities will be highlighted.
The number of effective antihelminthic agents is small relative to
the vast array of antibacterial agents. The mechanism of action of
most antiparasitic drugs is not always well understood. Especially
the role of the following very frequently used anthelmintics will be
illustrated: the benzimidazoles (albendazole, mebendazole, ﬂubendazole,
triclabendazole), ivermectin, praziquantel and diethylcarbamazine; but
other products still in use will also brieﬂy be mentioned. Newer “players”
as nitazoxanide, the artemisinin-derivatives (possibly new player for the
early stages of schistosomiasis? fasciolase) and doxycycline (adjunctive
role in the treatment of ﬁlariasis) will be highlighted.
An opportunity to obtain an electronic copy in pdf of the powerpoint
will be offered at the end of the lecture.
European MIC breakpoints for antimicrobial
susceptibility testing are now harmonised
by EUCAST (Symposium arranged with
EUCAST)
S9 Why European harmonisation?
D. Brown (Cambridge, UK)
At least seven different MIC breakpoint committee guidelines for antimi-
crobial susceptibility testing have been used in Europe. Consequently
Europe has had several different sets of antimicrobial breakpoints and
a range of variations in technical methods. It became increasingly
evident that harmonisation of breakpoints was necessary both for therapy
and resistance surveillance. ESCMID set up EUCAST in 1997 with a
representative from each European country and 6 representatives from
industry. In 2002 EUCAST was restructured and the major responsibility
for the work of EUCAST was taken on by the active national breakpoint
committees in Europe. A Steering Committee was formed, currently
comprised of a representative from the 6 active national breakpoint
committees, 2 from the EUCAST General Committee (which has a
representative from each European country), a Chairperson, a Scientiﬁc
Secretary and a Clinical Data Coordinator. A decision making process
was established whereby proposals made by the Steering Committee
are distributed to the EUCAST General Committee, relevant expert
groups and industry for consultation. The ﬁnal decision is made by
consensus in the Steering Committee, taking account of any comments
made during consultations. In this process the expertise of the national
breakpoint committees is utilised, there is wide consultation on proposals
and the national committees take responsibility for implementation
of decisions. Subcommittees have been set up to deal with speciﬁc
topics including susceptibility testing of fungi and anaerobes, and
expert rules in susceptibility testing. A website has been established
(http://www.EUCAST.org) that gives details of EUCAST activities,
EUCAST breakpoints and publications. Another website has been
developed for the collection of MIC data and its presentation as species-
speciﬁc wild type MIC distributions. EUCAST has been funded by
ESCMID, the national breakpoint committees, a grant from the EU and
now by ECDC. Industry does not contribute ﬁnancially but is asked to
contribute data required for determining breakpoints and to comment
on proposed breakpoints. EUCAST has achieved harmonisation of most
existing breakpoints in Europe. It has a formal relationship with EMEA
regarding the setting of breakpoints for new agents and the revision of
breakpoints for existing agents. The process has been applied to several
new drugs. Documents on various aspects of susceptibility testing have
also been published.
S12 Implementation of European breakpoints and the future of
EUCAST
G. Kahlmeter on behalf of EUCAST
EUCAST will soon have harmonised European breakpoints for existing
antimicrobials. Also, as part of the EMEA process for approval of new
drugs, EUCAST has determined breakpoints for several antimicrobials.
The work of the committee now enters a wider implementation phase.
Existing classes of drugs: At the end of 2008 there will be a complete
set of EUCAST clinical breakpoints and epidemiological cut-off values.
By early 2009 the clinical breakpoints will be implemented in the AST
systems of BSAC (UK), CA-SFM (France), CRG (Netherlands), DIN
(Germany), NWGA (Norway) and SRGA (Sweden).
New antimicrobials: EUCAST determines breakpoints as part of the
EMEA approval process for new antimicrobials. EUCAST breakpoints
are the only breakpoints included in the Summary of Product
Characteristics (SPC). Daptomycin and tigecycline are already approved
and another 4−6 drugs will be handled during 2007−9.
Antimicrobial susceptibility testing devices: Work is ongoing to
implement EUCAST clinical breakpoints in Phoenix (BD) and VITEK2
(BioMerieux) and it is expected that EUCAST breakpoints will be
available for both in early 2009. The fact that EUCAST breakpoints
and national breakpoints will be the same will simplify the development
of test panels as well as beneﬁting users.
EUCAST disk diffusion method: Preliminary results from a questionnaire
to determine the expectations of clinical microbiologists in Europe
indicate that EUCAST should take the lead in developing a disk diffusion
test based on Mueller-Hinton agar.
The future of EUCAST : EUCAST has been ﬁnanced by ESCMID and the
national breakpoint committees of France, Germany, Norway, Sweden,
The Netherlands and the UK for many years. Over the last 4 years the
EU and ECDC have contributed ﬁnancially. It is hoped that this will be
continued by ECDC.
There is a need to sustain a European Committee on Antimicrobial
Susceptibility Testing beyond the breakpoint harmonisation process.
New antimicrobials will need breakpoints. Companies with approved
antimicrobials will seek approval for extensions of clinical or microbi-
ological indications or modiﬁed dosages. New resistance mechanisms
occasionally necessitate the review of existing breakpoints. The
establishment of a European disk diffusion test is a major undertaking
and there will be a need continually to develop it to accommodate new
antimicrobials and new resistance mechanisms. All these efforts are best
served by a common European committee, EUCAST.
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New bugs – old drugs: frustrations in
antimicrobial treatment in primary care
S17 Urinary tract infections
T. Christiaens (Ghent, BE)
Urinary tract infections (UTI) are the most common bacterial infections
in women. The spectrum includes an umpteenth, patient-familiar episode
of a recurrent cystitis to a fatal UTI-linked gramnegative sepsis. In
primary healthcare (PHC) three major clinical pictures are important:
acute cystitis or uncomplicated lower UTI, recurrent cystitis and acute
pyelonephritis.
Discussing treatment of cystitis in PHC regards essentially (1) the grow-
ing resistance of uropathogens against familiar drugs used in cystitis,
(2) the place of newer drugs such as the oral chinolones, (3) and the
duration of therapy. Therapeutic dilemmas in community acquired acute
pyelonephritis are: (1) which patients can be treated ambulatory and
(2) with which drug.
In acute and recurrent cystitis treatment choices are mostly empirical.
This implies that bacterial species and resistance have to be anticipated
reliably. In recent years alarming resistance data in uropathogens have
persuaded physicians to choose broadspectrum antimicrobial agents. But
most of these data come from surveillance studies on all uropathogens
in regional bacteriological laboratories. Important selection of urine
samples occur in this setting: most samples sent to the bacteriological
laboratory came from complicated infections, immune-incompetent
patients or people with urologic problems such as pyelum stones. In
contrast, the majority of cystitis is encountered in healthy women,
so extrapolation of these resistance data is speculative. We performed
a surveillance in this healthy population with cystitis and found no
alarming resistance at all; moreover, a new surveillance 10 years later
showed no increase of resistance in uropathogens encountered in these
women. This means that nitrofurantoin remains the ﬁrst choice in the
Belgian GP-guideline (the same applies to the Dutch and the French
guideline) Trimethoprim can still be useful but in GB and in the
Netherlands more resistance has been observed. Chinolones are efﬁcient
but not superior. Because of high resistance, amoxicillines cannot be
given empirically, which is a major problem in pregnant women for
whom it is the safest drug.
The ideal duration of treatment remains controversial, but a recent
Cochrane review showed equivalence in success in treatment s of 3
days compared with 5 days or more in all studied drugs. In this case,
we are more uncertain about the use of nitrofurans, they are frequently
prescribed for ﬁve days because of lack of data for 3 days. Physicians
have to be aware that with these short treatments most patients will still
have symptoms at the moment in which drug intake is stopped.
The ﬁeld of recurrent cystitis is very unpopular, so study data are scarse.
Nitrofurans seem most active; of course renal impairment should be
taken into account. By resulting in less drug intake for equal efﬁcacity,
self-treatment is more attractive than chronic use.
Acute pylonephritis is not so common as the former infections, but it
is of course a potential life-threatening situation. Hospitalisation has
been the rule until recently the chinolones has proven to be a safe
ambulatory oral treatment in otherwise healthy individuals. Only by
reserving chinolones for serious infections we do not induce chinolone-
resistance in Gram-negative bacteria and spoil life-saving drugs in
uncomplicated infections. UTI are an interesting ﬁeld to develop and
to study rational antbiotherapy.
S18 How to single out the sinusitis patients who can beneﬁt from
antibiotic treatment
M. Lindbaek (Oslo, NO)
Background: Respiratory tract infections (RTIs) are common in general
practice and comprise approximately 15% of daily practice consultations.
They often result in antibiotic prescription and make up more than 60%
of all antibiotic prescriptions in general practice. Thus they play an
important part in the development of antimicrobial resistance. A 10-fold
difference in proportion of penicillin resistant pneumococci has been
demonstrated between the highest and lowest prescribing countries in
Europe.
The need of antibiotic prescription for the most common RTIs such as
acute otitis media, sore throat, acute bronchitis and acute sinusitis has
been highly debated for many years. Many studies have demonstrated
only limited beneﬁt from antibiotics for most of such patients in
general practice, and most studies have failed in demonstrating clinically
signiﬁcant differences between antibiotic treatment and placebo. In the
US and UK more than 90% receive antibiotics for acute sinusitis, while
in Holland and Scandinavia, the proportion is lower – 68−80%. For this
condition the situation is particular since two different guidelines for the
treatment of acute sinusitis have been published in Clinical Evidence:
One for patients with a conﬁrmed sinusitis, stating that antibiotics have
a moderate effect, and one for patients with a clinical sinusitis where no
antibiotics is recommended.
Diagnostic problems in acute bacterial sinusitis: In general practice
setting it is difﬁcult to distinguish between bacterial and viral sinusitis.
A number of studies have, by use of various reference standards,
demonstrated some ﬁndings that may be of value. However, they have
not proven to be of prognostic value as to duration of disease in non-
selected populations. Furthermore: Even in the studies with reference
standards, more than half of the patients had less or none symptoms
by day 10. Also in patients with a high predictive value for bacterial
infection, the spontaneous rate of recovery is high.
Treatment challenges: A high proportion of spontaneous recovery has
been demonstrated in patients with bacterial sinusitis. A study of risk
factors for long duration of symptoms among patients with acute
sinusitis, showed signiﬁcant differences for the most affected and the
older patients. However, newer relevant studies have demonstrated few
predictors for long/short duration. A Danish study demonstrated that a
high CRP-value was predictive of higher cure rate with antibiotics in
patients with much pain as compared to placebo.
Still, a small proportion of patients with acute sinusitis that has high
fever, much pain and a deteriorated general condition, will beneﬁt from
antibiotic treatment. Otherwise a wait-and-see approach is reasonable. In
our own studies a delayed prescription strategy has been demonstrated
to reduce antibiotic treatment as less than 50% of the prescriptions have
been dispensed from the pharmacy. This demonstrates that a considerable
proportion of antibiotics prescribed for acute sinusitis in general practice
can be avoided. The role of topical steroids is also debated as the results
of various studies have given conﬂicting results.
S19 Acute exacerbations of chronic obstructive pulmonary disease
A. Torres (Barcelona, ES)
Exacerbations of chronic obstructive pulmonary disease (COPD) are
a frequent clinical problem both in the primary care and in the
hospital. The microorganisms that are associated with exacerbations are
well recognised and include viruses, Chlamydia and bacteria such as
S. pneumoniae, H. inﬂuenzae and P. aeruginosa. The severity of the
COPD and the exacerbation are associated with different pathogens.
In the primary care setting usually these exacerbations are mild and
do not need hospitalisation. The routine care of these patients is to
administer antibiotics. According to some investigations a great part of
these mild exacerbations would not require antibiotic treatment because
they are viral in origin or because they are not infectious. However, in the
clinical practice is difﬁcult to distinguish between these two situations.
A recent study from our group in COPD exacerbated patients conﬁrms
that the existence of sputum purulence referred by the patient is a
sensitive and speciﬁc variable associated with positive bacterial cultures
in bronchoscopic samples.
We do not know if this information can be extrapolated to ambulatory
patients but probably yes.
Of course, there are patients that cannot expectorate and some of them
may have a bacterial infection. In these
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Cases, perhaps biological markers could help to differentiate between
viral and bacterial infections. Procalcitonin (PCT) has been studied in
COPD exacerbation and in one randomised trial it has been useful
continuing or discontinuing antibiotics without recurrence problems.
The limitations of this method are the need of a blood sample and the
availability of methods able to detect small amounts of PCT.
In terms of pathogens one of the most controversial issue is the role of
Pseudomonas aeruginosa. Some studies in some countries conﬁrm that
Pseudomonas aeruginosa is isolated in around 10 to 15% of exacerba-
tions. However, the pathogenic mechanisms of Pseudomonas aeruginosa
in COPD exacerbations is unclear but the current recommendations
advise to treat these patients with antipseudomonal antibiotics
Risk factors are known from individual studies. The ERS guidelines
include among them the following: FEV1< 30%; prior antibiotic
treatment, long-term treatment with steroids and prior colonisation or
isolation of P. aeruginosa. When two out of these four variables are
present antipseudomonal treatment is recommended.
S20 Skin infections by community-acquired MRSA
S. Kaplan (Houston, US)
Meticillin-resistant S. aureus isolates causing community-acquired
infections (CA-MRSA) are a major problem around the world. In some
communities, CA-MRSA account for more than 70% of community
S. aureus isolates. These isolates typically have a unique staphylococcal
chromosomal cassette (SCCmec IV) that carries the antibiotic resistant
genes and is lower in molecular weight than the cassette carried by
the typical nosocomial MRSA isolates. CA-MRSA isolates generally
are susceptible to clindamycin, trimethoprim-sulfamethoxazole and
doxycycline. CA-MRSA S. aureus isolates also typically carry the genes
coding for Panton-Valentine leukocidin (PVL) although the role of
PVL in the pathogenesis of infections remains unclear. In the United
States one particular clone identiﬁed by pulsed ﬁeld gel electrophoresis
(PFGE), USA300, accounts for the vast majority of CA-MRSA isolates.
Other clones predominate in different areas of the world. The genomes
of two CA-MRSA isolates, USA300 and USA400 (MW-2) have been
fully sequenced and may eventually provide clues to why USA300 has
been so successful in spreading and causing infection. By far the most
common infections associated with CA-MRSA isolates are skin and
soft tissue infections including abscesses and cellulitis. CA-MRSA as
a common aetiology of abscesses is much better documented because of
the ease of culturing purulent drainage. In children the most common
sites of infection are the buttock, perineum and extremities. CA-MRSA
isolates are also associated with serious invasive infections, especially
osteomyelitis and pneumonia. Recurrent soft tissue infections and
infections within the family caused by CA-MRSA isolates are common.
The most important aspect of management of superﬁcial skin and soft
tissue infections is appropriate surgical drainage. Most clinicians also
administer an effective oral agent such as TMP-SMX or clindamycin,
although the contribution of antibiotic therapy after surgical incision and
drainage is under investigation. Empiric vancomycin or clindamycin is
typically administered for more serious and invasive infections such as
osteomyelitis, septic arthritis or suspected Staphylococcal pneumonia in
regions where CA-MRSA is common (>5−10% of community S. aureus
isolates). Clindamycin is efﬁcacious in treating CA-MRSA infections
caused by susceptible organisms. Effective measures to prevent CA-
MRSA infections remain unclear.
Epidemiology of community-acquired
meticillin-resistant Staphylococcus aureus
S21 Origins and evolution of MRSA clonal lineages
A. van Belkum (Rotterdam, NL)
Staphylococcus aureus essentially is a clonal bacterial species. This
implies that various lineages exist that appear to be ecologically highly
succesfull. For both meticillin susceptible and resistant strains it has
been demonstrated that many of these belong to such pandemic clones.
Based on these observations as well as on the comparative analysis
of the many available staphylococcal genome sequences it has been
suggested that genome complexity in S. aureus can be pictured in a
simple model. The genome of S. aureus consists of a core element
(approximately 80% of the entire genome), a core variable element and
a so called variable or accessory genome. This model, attractive because
of its simplicity, would suggest that the core genome would encode
the overall S. aureus-characteristic traits whereas the core variable and
variable moieties encode factors that provide S. aureus with more strain
or clone speciﬁc traits.
The talk will describe the genomic tools available for deﬁning S. aureus
population structures and how these stucutres can be used to deﬁne
the emergenc of novel lineages. In addition, those factors as present
in the accessory genome and deﬁning traits such as host speciﬁcity,
invasiveness or epidemicity will be discussed. Finally, recent research
has suggested that not all human individuals share genotypes that
would permit S. aureus to colonise the nasopharynges. This would also
suggest that the interaction between S. aurteus and humans requires
intricate matching of both bacterial and human features. The relevance
of S. aureus genome ﬂexibility in establishing host-microbe ointeractions
will be discussed.
S22 Emergence and dissemination of community-acquired
meticillin-resistant Staphylococcus aureus in Europe
M.A. Dominguez (Hospitalet. Barcelona, ES)
During the past decade, meticillin-resistant Staphylococcus aureus
(MRSA) has emerged as cause of community acquired (CA) infections,
among patients without established risk factors for MRSA. The
differentiation between CA-MRSA and hospital-associated (HA) MRSA
is becoming difﬁcult since CA-MRSA could spread into hospitals.
CA-MRSA cause skin and soft-tissue infections, but can also cause
necrotising tissue infections and fulminant pneumonia. Most CA-MRSA
strains produce the Panton-Valentine leucocidin (PVL), a leukocyte pore-
forming toxin strongly associated with invasive disease and virulence.
Transmission of CA-MRSA from person to person has been well
documented and ascribed to close contact, e.g. during sport practice
or prison stays. Also transmission can occur among family members. In
the United States, CA-MRSA has been reported as the most frequent
cause of soft-tissue infections. The predominant CA-MRSA clone is
the USA300, belonging to Clonal Complex (CC) 8, characterised by
a particular pulsed ﬁeld gel electrophoresis pattern, SCCmec type IV,
and encoding PVL production. The CA-MRSA prevalence in Europe
is diverse. Although rates of HA-MRSA are very high in England and
South Mediterranean countries, CA-MRSA has been more frequently
reported in Northern and Central European countries. Isolates of CC80-
SCCmecIV have been the predominant genotype in many European
countries since late 1990s (Denmark, Sweden, Norway, Netherlands,
Germany, England, France or Switzerland). However, another dominant
genotype, CC8-SCCmecIV, related to clone USA 300, emerged in
2003 and spread through many countries (Netherlands, France, Spain,
Switzerland, Greece or Norway). In Spain, with high endemic rates of
HA-MRSA, isolation of PVL-positive CA-MRSA has been increasing
in the last years. The predominant clone of CA-MRSA in Spain is the
CC8-SCCmecIV, affecting family groups and patients with recent travel
or family relation to countries in South America. A worrisome feature is
that isolates of pandemic genotype CC5-SCCmecIV (paediatric clone),
highly prevalent among HA-MRSA in many European countries, have
been found to carry PVL toxin and to be CA-MRSA. Prevention and
control of CA-MRSA infections outside the healthcare setting represent
a real challenge for the health system and may be a serious problem in
containing the spread of CA-MRSA within the hospital population.
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S24 Animals as a source of MRSA infections in humans
J.S. Weese (Guelph, CA)
As MRSA has emerged as a signiﬁcant community-associated (CA)
pathogen, it is perhaps not surprising that MRSA has been identiﬁed
in various animal species. MRSA is a prime example of the often-
overlooked close relationship between humans and animals, with a
potential for transmission of pathogens in both directions. Animals
could play a role in human MRSA by direct contact, environmental
contamination or food, however direct contact is the only route that has
been clearly demonstrated. Animal populations could also be reservoirs
of MRSA. The epidemiology, clinical aspects and human risks of MRSA
in animals vary greatly between species.
Direct transmission of MRSA between household pets and their human
contacts has been demonstrated, and pets may be particularly important
in recurrent MRSA in households. MRSA strains found in pets tend to
be the predominant strains found in humans in the geographic area and
it is likely that humans are the source of MRSA for most household
pets.
The epidemiology is different in horses, where an uncommon human
epidemic clone has predominated, suggesting it is relatively horse-
adapted. Zoonotic infections of horse owners and veterinary personnel
have been identiﬁed. These groups also have high rates of MRSA
colonisation and tend to be colonised with the clone most commonly
found in horses, suggesting frequent zoonotic transmission.
In contrast, recent reports involving food animals, particularly pigs, have
described predominance of ST398 strains that have not historically been
important causes of human disease. This clone is now an important
cause of CA-MRSA infection, ﬁrst in persons with pig contact and now
in the general population in some regions. There is signiﬁcant concern
that a reservoir of MRSA in may complicate aggressive MRSA control
programmes. Identiﬁcation of MRSA in food animals logically leads
to concerns about the potential for foodborne transmission of MRSA.
These risks are currently unclear but are being investigated.
The overall role of animals in human MRSA infections is still unclear but
it is likely that animals can play a direct or indirect role in at least some
cases. The apparent spread of ST398 from pigs to the broader community
in Europe and the potential role of pets as household reservoirs are
perhaps the greatest concerns. Failure to properly investigate the role of
animals in human MRSA infection and in the changing epidemiology of
CA-MRSA could compromise control measures.
Community-acquired bacterial infections of
the respiratory tract
O25 Severe disease due to inﬂuenza in adults in Toronto, Canada,
2005–2007: impact of antiviral therapy
A. McGeer, K. Green, J. Raboud, D.E. Low on behalf of the Toronto
Invasive Bacterial Diseases Network
Background: Few data describe the clinical features and outcomes
of severe inﬂuenza (FLU)-associated illness, or the impact of speciﬁc
therapy.
Methods: Since 1/1/2005, TIBDN has performed population-based
surveillance for laboratory conﬁrmed FLU associated with hospital
admission in Toronto/Peel (population 3.8M). Consenting patients
hospitalised for illness associated with a rapid antigen test, culture,
and/or PCR positive for FLU are enrolled.
Results: From 1/1/2005 to 30/4/2007, 485 adult (>15yo) patients with
community-acquired disease have been identiﬁed. Median age was
76.7yrs (range 15.1−98.8y), 250 (52%) were male, 105 (225) had no
chronic underlying illness; 279/426 (65%) for whom data were available
had received inﬂuenza vaccine; 86 (18%) were residents of nursing
homes. There were 415 cases (86%) of FLUA, and 70 (14%) of FLUB.
For CA cases, the most common diagnoses were: inﬂuenza (with/without
other diagnoses): 266 (55%), pneumonia 111 (23%), other respiratory
infection: 28 (6%), fever/viral syndrome 26 (5%), other respiratory
diagnosis (eg. COPD) 23 (5%). 27 patients (5.6%) had culture-conﬁrmed
complicating bacterial infection (15 S. aureus, 7 S. pneumoniae, 3
H. inﬂuenzae, 1 group A streptococcus, 1 E. coli, 1 M. catarrhalis). 87
(18%) required ICU admission. Median LOS was 4 days (range 1−45d)
for those <65yrs, and 6 days (range 1–103d) for those 65 years of age
and older. 421 (88%) of patients were treated with antibacterials; 160
(33%) received antivirals: 3 amantadine, 157 oseltamivir. 106/154 (69%)
treated cases received their 1st dose of oseltamivir >48h after symptom
onset. Fifteen day mortality was 8.5% (41/485). In multivariable survival
analysis, ICU admission (OR 7.3, 95% CI 4.1, 13, P< 0.001), nursing
home residence (OR 2.1, 95% CI 1.1, 4.0, P = 0.02), charlson co-
morbidity index (OR per point 1.2, 95%CI 1.0, 1.3, P = 0.04), shorter
time from symptom onset to hospital admission (OR per 10 hrs 1.3,
95% CI 1.1, 1.4, P = 0.002), and failure to treat with antivirals (OR 2.0,
95% CI 1.1, 5.0, P = 0.03) were associated with death.
Conclusions: Seasonal inﬂuenza is a signiﬁcant cause of serious illness.
Oseltamivir treatment signiﬁcantly reduces mortality in severely ill
patients even when therapy is started late.
O26 Healthcare-associated bacteraemic pneumonia: aetiology,
severity of disease and outcomes
M. Salvado, L. Lozano, E. Calbo, N. Freixes, M. Riera, M. Xercavins,
M. Rodriguez-Carballeira, J. Garau (Terrassa, ES)
Introduction: Recent studies have been focused on healthcare-associated
pneumonia (HCAP) trying to distinguish them from truly community-
acquired (CAP) or hospital acquired pneumonia (HAP). The aim of
our study was to describe the aetiology and outcomes of a cohort of
patients with bacteraemic pneumonia (BP), regarding their relation to
the healthcare-system.
Material and Methods: From Jan 2004 to June 2007, consecutive
patients with BP were identiﬁed through the records of the Clinical
Microbiology Laboratory in a 450-bed acute care teaching hospital.
Data obtained included demographics, co morbidities, aetiology, severity
of disease (Pitt score), presence of shock, relation with the healthcare-
system and in-hospital mortality.
Results: 175 episodes of BP were identiﬁed. HAP was diagnosed in
25 patients (14.2%), CAP in 115 (65.3%) and HCAP in 36 (20.5%);
mean age was 62.5 (SD 17.3), 57.8 (SD 20), and 75.6 y (SD 12.48),
respectively (p = 0.001). Men represented 56%, 69.6% and 55.6% of the
HAP, CAP and HCAP (p = 0.2), respectively. Co morbidity, measured
by Charlson score, was 2.57 in HA, 1.55 in CAP and 2.03 in HCAP
(p = 0.05). Streptococcus pneumoniae was isolated in 36%, 93% and
71.4% (p = 0.001); Staphylococcus aureus was present in 12%, 1.7% and
2.8 (p = 0.037) and Pseudomonas aeruginosa in 24%, 0.9% and 11% of
the HAP, CAP and HCAP (p = 0.001). Pitt score was 2.8, 1.03 and 1.14,
respectively (p = 0.01). Shock was present on admission in 20% of HAP,
10.4% CAP and in 11% of HCAP (p = 0.4). The in-hospital mortality
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rate was 40% in HAP, 10% in CAP and 43% in HCAP (p = 0.001). In
the multivariate analysis, severity of disease (OR=1.2; CI95% 1.06−1.5,
p = 0.007), HAP (OR=3.9 CI95% 1.2−13, p = 0.02) and HCAP (OR=5.6;
CI95% 1.9−16.6, p = 0.001) were independent predictive factors for
increased mortality.
Conclusions: The majority of BP are seen in patients with CAP.
Severity of disease and relation with the healthcare-system are important
predictive factors of increased mortality. Although the aetiology in
HCAP is similar to CAP, its mortality parallels that of HAP, showing
the great impact of host factors on outcome.
O27 Factors associated with prolonged length of hospital stay in
community-acquired pneumonia
C. Garcia-Vidal, V. Dı´az, J. Dorca, F. Manresa, F. Gudiol, J. Carratala`
(L’Hospitalet, Barcelona, ES)
Objectives: Considerable variability exists in length of hospital stay
(LOS) for patients with community-acquired pneumonia, in spite of
being a key point in the quality and cost of care. The objective of the
study was to identify factors associated with prolonged LOS (>8 days).
Methods: Observational analysis of a prospective cohort of nonseverely
immunosuppresed adults with community-acquired pneumonia requiring
hospitalisation from February 1995 through December 2006.
Results: We documented a total of 2,739 consecutive episodes of
community-acquired pneumonia. Patients who required intensive care
unit admission from the emergency department (n= 107), those who
died during hospitalisation (n= 367), or patients with LOS >30 days (n=
60) were excluded from the analysis. The median duration of hospital
stay was 8.0 days (IQR 6.0−11.0). No differences were found regarding
time to institution of initial antibiotic therapy (door-to-needle time) when
comparing patients with prolonged LOS and the remaining patients
(5.8 vs 5.9 hours). Factors independently associated with prolonged
LOS by step-wise multiple logistic regression analysis were female
sex (OR 1.26; 95% CI 1.03−1.53), alcohol abuse (OR 1.48; 95% CI
1.16−1.86), high-risk Pneumonia Severity Index class (OR 2.02; 95%
CI 1.65−2.48), bacteraemia (OR 1.75; 95% CI 1.30−2.37), aspiration
pneumonia (OR 1.84; 95% CI 1.18−2.87), pleural empyema (OR 2.73;
95% CI 1.85−4.02), phlebitis (OR 1.42; 95% CI 1.05−1.91) and prior
outpatient antibiotic therapy for current episode of pneumonia (OR 0.72;
95% CI 0.58−0.89). Time to switch from intravenous to oral antibiotics
was longer among patients with prolonged LOS as compared with the
remaining patients (6.1 vs 3.4 days; p< 0.001).
Conclusion: According to our data, several independent factors
increased LOS in adult patients with community-acquired pneumonia.
These factors should be considered when evaluating the adequacy of the
duration of hospitalisation in a determined institution as well in future
studies investigating new strategies aimed to reduce LOS.
O28 Repetitive C-reactive protein measurements in follow-up can
predict adequacy of empiric antibiotic therapy in patients
with severe community-acquired pneumonia
A.H.W. Bruns, J.J. Oosterheert, E. Hak, I.M. Hoepelman (Utrecht, NL)
Objectives: Despite the introduction of new inﬂammatory markers, C-
reactive protein (CRP) remains commonly used in community-acquired
pneumonia (CAP), however evidence for its diagnostic and prognostic
value is still unclear. We therefore studied the discriminative value of
CRP in aetiology and the value of repetitive CRP measurements in
follow-up.
Methods: In a prospective multicentre trial, CRP levels were measured
on admission, day 3 and day 7 in patients hospitalised with severe
CAP. Patients were clinically followed for 28 days. Aetiology was
determined by standard microbiological cultures, urinary antigen
tests for Streptococcus pneumoniae and Legionella pneumophila and
serological examinations for L. pneumophila, Chlamydia pneumoniae
and Mycoplasma pneumoniae.
Results: 289 patients with severe CAP were included (mean PSI score
113±25.7; age 69.7±13.8 year). In 137 patients (47.4%) aetiology
could be determined. Median admission CRP levels were signiﬁcantly
higher in S. pneumoniae infection (278.0mg/l; p< 0.001), lower in
M. pneumoniae infection (49.0mg/l; p = 0.05) and lower in patients
with unknown aetiology (140mg/l; p = 0.002) as compared to patients
with other aetiologic diagnoses. However, the diagnostic value of
CRP for any aetiologic diagnosis was low (Area Under receiving
operator Curve <0.70). In follow-up, normalisation patterns of CRP
were different among aetiologic pathogens and slowest in L. pneumophila
infection (ANOVA p= 0.05). In multivariate linear regression analysis,
S. pneumoniae infection (beta coefﬁcient (b) = 0.23) and chronic
obstructive pulmonary disease (COPD) as comorbidity (b = 0.30) were
independently associated with a rapid decline in CRP levels within the
ﬁrst three days of hospitalisation, whereas antibiotic treatment prior to
hospital admission (b = −0.17) was associated with a slow decline in CRP
levels (p< 0.008). A <60% decline in CRP levels within the ﬁrst three
days of hospitalisation was independently associated with inappropriate
empiric antibiotic treatment (odds ratio 5.1; 95%CI 1.2−22.8; p = 0.03).
Conclusions: CRP is useful in follow-up rather than in establishing a
bacterial aetiologic diagnosis. Repetitive CRP measurements in follow-
up of severe CAP provide important information about adequacy of
empiric therapy. Nevertheless the causative micro-organism, comorbidity
as COPD and previous antibiotic use need to be considered when
interpreting CRP measurements in follow-up correctly.
O29 Severe community-acquired pneumonia: validation of the
ATS/IDSA guidelines to predict admission to the ICU
M. Ferrer, A. Liapikou, E. Polverino, V. Balasso, M. Esperatti,
R. Pin˜er, J. Mensa, M.A. Marcos, A. Torres (Barcelona, ES)
Background: In the recent ATS/IDSA guidelines for the management of
adults with CAP the decision for ICU admission is based on a predictive
rule that identiﬁes patients with severe CAP (CID 2007;44:S27−72). The
purpose of this study was to validate this rule in the clinical practice.
Methods: We studied 2199 episodes of CAP (1574 men (62%), age
65±19 yrs) admitted to a university hospital from 2000 to 2006. The
predictive rule consists of at least 1 of 2 major (shock or need of
mechanical ventilation) or 3 of 9 minor (tachypnea, hypoxaemia, multilo-
bar, confusion, uraemia, leucopenia, thrombocytopenia, hypothermia and
hypotension) criteria. We assessed the agreement between the predictive
rule and the clinical decision for ICU admission and the operative
indices.
Results: 241 (11%) episodes were admitted to the ICU, while the
predictive rule identiﬁed 456 (21%) episodes of severe CAP. The
agreement between the predictive rule and the clinical decision for
ICU admission was 1852 (84%) episodes (kappa coefﬁcient 0.4, RR for
admission to the ICU of severe CAP 12.3, 95% CI 9.1−16.6, p< 0.001).
The predictive rule was highly accurate for ICU admission; ROC curves
identiﬁed 1 major or 3 minor criteria as optimal predictor (AUC 0.868,
sensitivity 76%, speciﬁcity 85%, positive predictive value 34%, negative
predictive value of 97%, p< 0.001). The presence of minor criteria only
was also accurate to predict ICU admission; ROC curves showed 2
criteria as the optimal predictor (AUC 0.793, sensitivity 78%, speciﬁcity
67%, p< 0.001). Mortality was 4% in the ward and 18% in the ICU.
Conclusion: The predictive rule of the ATS/IDSA guidelines to identify
severe CAP for ICU admission is accurate in the daily clinical practice.
Funded By: CibeRes (CB06/06/0028), 2005 SGR 00822, ERS Fellow-
ship, IDIBAPS
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O30 Community-acquired pneumonia occurring in
immunocompromised older patients: incidence, causative
organisms, and outcome
D. Sousa, I. Justo, A. Manzur, C. Izquierdo, L. Ruiz, M. Nebot,
J.M. Bayas, J.M. Celorrio, W. Varona, A. Dominguez, P. LLinares,
J. Carratala for the Pneumoccocal Vaccination in Older Patients
Spanish Study Group
Objectives: We sought to determine the incidence, causative organisms
and outcome of community-acquired pneumonia (CAP) occurring in
immunocompromised older patients.
Methods: Prospective observational multicentre study of a cohort of
patients aged 65 years or older hospitalised with CAP from May
2005 to January 2007 in 5 teaching hospitals in Spain. A comparison
between cases of CAP occurring in immunocompromised patients and
the remaining cases was performed.
Results: Over the study period, we documented a total of 320 cases of
CAP; 115 (36%) of which occurred in immunocompromised patients.
Main underlying conditions among these patients included one or
more of the following: solid cancer or haematological malignancy (97
patients), treatment with corticosteroids or other immunosuppressive
drugs (44), solid organ or stem cell transplant (5), and other conditions
(8). An aetiologic diagnosis of CAP was more frequently established
in immunocompromised patients than in the remaining cases (44% vs
32%; p = 0.03). The most common causative organism was Streptococcus
pneumoniae in both groups (29% vs 21%; p = 0.08). No signiﬁcant
differences were observed between groups regarding the incidence of
Haemophilus inﬂuenzae (2% vs 1%), Legionella pneumophila (3% vs
6%) and atypical agents (1% vs 2%). Gram-negative bacilli were more
frequently encountered among immunocompromised patients (5% vs
0.5%; p = 0.009), particularly Pseudomonas aeruginosa (3% vs 0%;
p = 0.04). Nocardiosis was only observed among immunocompromised
patients (2 cases). The occurrence of bacteraemia was similar in
both groups of patients (12% vs 9%). Most patients were given
initial empirical antibiotic monotherapy (61% vs 62%). No signiﬁcant
differences were found concerning the percentage of patients requiring
ICU admission (8%, in both groups), and length of hospital stay
(12.5 vs 10. 4 days). The early (<48 hours) (3.5 vs 0.5%; p = 0.05)
and overall case-fatality rates (12% vs 3%; p = 0.003) were higher in
immunocompromised patients.
Conclusions: A substantial number of older patients currently hospi-
talised for CAP are immunocompromised. Although relatively uncom-
mon, CAP due to Gram-negative bacilli, including P. aeruginosa, is more
frequent among these patients. CAP occurring in immunocomprised
patients causes signiﬁcant case-fatality rates.
O31 Pseudomonas aeruginosa in sputum at admission in
hospitalised patients for acute COPD exacerbation:
prognostic implications
M. Salvado´, C. Garcia Vidal, H. Monzo´n, M. Rodriguez-Carballeira,
E. Cuchi, J.L. Heredia, J. Garau, P. Almagro (Terrassa, ES)
Background: Pseudomonas aeruginosa (PA) isolation in sputum in
hospitalised patients for acute COPD exacerbation has been associated
with an advanced stage of the pulmonary disease. However, information
regarding the relation between PA isolation and mortality is lacking.
The aim of this study was to analyse the relation between PA isolation
in patients hospitalised for COPD exacerbation and long-term mortality.
Methods: We prospectively recorded clinical information and sputum
cultures of all COPD patients with an acute exacerbation that were
admitted to our hospital between June 2003 and September 2004. All
readmissions during the following year were recorded. Mortality was
assessed on January 2007 and Kaplan-Meyer analysis was made.
Results: 188 patients with a mean of age 72 years (SD 11) were included.
Ninety ﬁve (50.5%) patients were classiﬁed as severe disease and 26
patients (13.8%) as very severe disease following Gold criteria. Among
this cohort, a total of 469 episodes of hospital admission due to COPD
exacerbation were recorded. Valid sputum was collected in 220 episodes,
49% of these had mouth ﬂora. The prevalence of PA isolation was
23.2% of all episodes, becoming the most frequently isolated species.
H. inﬂuenzae (11%) and S. pneumoniae (10%) remained a common
aetiology. Overall mortality at 3 years was 61.3% in patients with PA
isolation versus 37.2% in patients without PA isolation (OR 2.18; CI 95%
1.28−3.71; p = 0.004). After adjustment for age and FEV1, the relation
between PA isolation and mortality remained signiﬁcant.
Conclusion: PA isolation in sputum in hospitalised patients for acute
COPD exacerbation is a marker of high 3-year mortality, independently
of respiratory function and age.
O32 Fluoroquinolones versus b-lactam antibiotics for the treatment
of acute bacterial sinusitis: a meta-analysis of randomised
controlled trials
D. Karageorgopoulos, K. Giannopoulou, A. Grammatikos,
G. Dimopoulos, M. Falagas (Athens, GR)
Background: The presumed, based on laboratory data, superiority of
newer ﬂuoroquinolones for the treatment of acute bacterial sinusitis is
not established on clinical grounds.
Methods: We performed a meta-analysis of randomised controlled trials
(RCTs) comparing the effectiveness and safety of ﬂuoroquinolones to
b-lactams in acute bacterial sinusitis.
Results: Eight RCTs involving moxiﬂoxacin, levoﬂoxacin, and gat-
iﬂoxacin as the newer ﬂuoroquinolone agents, were identiﬁed. In
the primary effectiveness analysis, involving the intention-to-treat
population, clinical cure or improvement was not different, between
ﬂuoroquinolones and b-lactams [ﬁxed effect model (FEM), odds ratio
(OR)=1.09, 95% conﬁdence interval (CI)=0.85−1.39, 5 RCTs, 2133
patients] at the test-of-cure assessment (the time of determination of
the primary clinical effectiveness outcome, which varied between 10−31
days after the beginning of treatment). Fluoroquinolones were associated
with a higher chance of clinical success in the clinically evaluable
population (including patients who satisﬁed the eligibility criteria for
clinical evaluation), (FEM, OR=1.29, 95% CI=1.03−1.63, 8 RCTs, 2797
patients), and in the analysis limited to 4 blinded RCTs. Findings were
not statistically signiﬁcant in the comparison of ﬂuoroquinolones to
amoxicillin/clavulanate. Bacteriologic success (eradication or presumed
eradication of pre-treatment isolated pathogens) was more likely with
ﬂuoroquinolone treatment (FEM, OR=2.11, 95% CI=1.09−4.08, 3 RCTs,
506 patients). In the primary safety analysis, adverse events did not
differ between compared treatments (random effects model, OR=1.17,
95% CI=0.86−1.59, 6 RCTs, 2732 patients). More adverse events were
related to ﬂuoroquinolone use in 2 blinded RCTs. The above associations
were generally consistent when 3 more studies involving ciproﬂoxacin
and sparﬂoxacin were included in the analysis.
S8 18th ECCMID, Oral presentations
Conclusion: Fluoroquinolone treatment for acute bacterial sinusitis did
not differ compared to b-lactams, with regard to the primary effectiveness
and safety outcomes of this meta-analysis.
O33 Should Legionella urinary antigen test be applied in any case
of community-acquired pneumonia?
M.L. Pedro-Botet, N. Sopena, P. Tudela, S. Roure, L. Mateu, E. Heras,
C. Rey-Joly, M. Sabria` (Badalona, ES)
Objectives: Despite the availability of a simple and rapid test such
as Legionella urinary antigen (LUA), that allows the diagnosis of up
80% of infections caused by L. pneumophila sg 1, its systematic use in
community-acquired pneumonia (CAP) is controversial. In this study we
evaluated the incidence of Legionella infection observed during periods
of routine and non routine use of the LUA test in our hospital.
Methods: Four different periods were evaluated (Table 1). During period
I the LUA test was never applied. In period II a prospective study on the
aetiology of CAP was carried out and the LUA test was used in almost all
cases of CAP. At the end of this study the use of the LUA test decreased
and was limited to patients with epidemiologically or clinically suspected
LD (period III). From February 1998 to October 2006, the use of the
LUA test was included in the hospital CAP guidelines and routinely
performed (period IV).
Results: Table 1 shows the number of diagnoses of CAP by Legionella
in each period related to the cases of CAP admitted to the hospital during
the same period.
Table 1. Periods studied and cases of Legionnaires disease (LD)
Period Number
of CAP
Number
CAP/year
LD
cases
Number
LD/1 000
Period I (30 months)
(January 1992–June 1994)
540 216 1 1.85/1000
Period II (20 months)
(July 1994–February 1996)
582 350 42 72.16/1000
Period III (23 months)
(March 1996–January 1998)
832 435 6 6/1000
Period IV (105 months)
(February 1998–October 2006)
4201 480 148 35.22/1000
Conclusions: As observed in this study, the incidence of CAP by
Legionella rose notably when doctors considered this entity because
of an ongoing investigation or a hospital policy that considered the
use of LUA when pneumonia is diagnosed. To the contrary, when
Legionella infection was considered a rare entity (period I) or it was
only investigated when clinical data was suggestive of LD the incidence
declined signiﬁcantly (period III). When extrapolating these data to all
the cases of CAP, this ﬁgure would increase considerably and probably
thousands of patients would not be diagnosed with LD worldwide.
O34 Viral aetiology of hospitalised patients with community-
acquired pneumonia in Hong Kong
M. Ip, N. Lee, T. Rainer, G. Antonio, G. Lui, S. Chau, F. Ng, E. Leung,
D. Hui, P. Chan (Hong Kong, HK)
Objectives: Community-acquired pneumonia (CAP) is a leading
infectious cause of death throughout the world. Pandemic avian inﬂuenza
is an impending concern and prevention remains one of highest
priority in Hong Kong where previous H5N1 inﬂuenza cases occurred.
Diagnostic exclusion remains one of importance in the exclusion of new
pathogen. A multiplex PCR that examined 17 viruses, and including
inﬂuenza H typing was applied to nasopharyngeal aspirates from 857
adults hospitalised with community acquired pneumonia during 2004−5.
Methods: A prospective observational study of consecutive inpatients
with CAP was performed in a university hospital in the New Territories
of Hong Kong. Adult patients with CAP were recruited prospectively
from Jan, 2004 to June, 2005. Nasopharyngeal aspirates (NPA) were
collected and assessed by polymerase chain reaction (PCR) and viral
isolation. Five groups of nested multiplex PCR assays targeting 17
respiratory viruses, namely inﬂuenza virus type A subtypes H1N1,
H3N2, H5N1, inﬂuenza virus type B, Parainﬂuenza viruses group 1
to 4, human respiratory syncytial viruses A and B, Coronaviruses incl.
SARS, OC43 and 229E, human adenovirus, Metapneumonvirus, human
rhinovirus, human enterovirus, were included.
Results: 857 episodes of CAP cases were recruited. The F:M ratio
of this cohort was 1:1.4. The mean age was 70.1 yrs (median
75 yrs, IR25% 62 yrs, IR75% 83 yrs, range 17–103 yrs old).
Elderly subjects of 65 yrs of age constituted 73% of all cases.
One hundred seventy six episodes (41.5%) yielded positive viral
aetiology by PCR/and or by virus isolation. The viruses identiﬁed
were inﬂuenza virus types A/B (25.9%), Metapneumovirus (4.5%),
RSV A/B (3.1%), rhinovirus (3.1%), parainﬂuenza viruses group 1−4
(2.6%), Coronaviruses OC43/229 (2.1%) and Adenovirus (0.2%). Avian
inﬂuenza H5N1, SARS coronavirus and human enteroviruses were not
detected. The overall mortality rate was 5.0% in this cohort and there
was no statistical difference to those who were PCR positive to a viral
pathogen to those who were negative.
Conclusion: Inﬂuenza virus types A/B, Metapneumovirus, and RSV
viruses were the common viral aetiological agents in patients hospitalised
with CAP in Hong Kong.
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O35 Transmission of viruses through the kidney graft: a study in
paediatric transplant recipients
M. Pacenti, L. Barzon, M. Biasolo, L. Squarzon, L. Murer, G. Palu`
(Padua, IT)
Objectives: Viral infections, which are serious complications in kidney
transplant recipients, can be transmitted from the donor through the
kidney graft, by means of infected resident cells or blood cells. Aim
of this study is to investigate the presence of viral genome sequences in
the kidney graft from young donors and the risk of viral transmission to
paediatric recipients.
Methods: In order to set-up a sensitive and non-invasive test for
diagnosis of viral infections of the graft before implantation, the presence
of EBV, HCMV, BKV, and parvovirus B19 DNA was investigated by
TaqMan real-time PCR in graft preservation (PS) and washing solutions
(WS), besides in donor kidney biopsies (B). Results were correlated with
serological data, viral DNAemia, and clinical data on infections during
the ﬁrst 12 months post-transplantation. A total of 75 consecutive grafts
from deceased donors (median age, 12 yr, range 1−58) and their 75
recipients (median age13 yr, range 2−27) were studied.
Results: Overall, considering viral DNA detection in at least one type of
sample (B, PS, WS), 68% donor kidney units were positive for at least
one virus; B19 was detected in 35 (47%) graft units, EBV in 21 (28%),
HCMV in 9 (12%), and BKV in 3 (4%). The prevalence of EBV, HCMV,
and BKV DNA was higher in PS and WS than in B, whereas B19 was
consistently detected in B, PS, and WS. All EBV-seronegative recipients
of an EBV-positive graft showed primary EBV infection with DNAemia
within the ﬁrst months post-transplantation, earlier than in recipients
of an EBV-negative graft. Likewise, the only two HCMV-seronegative
recipients of positive grafts showed HCMV DNAemia immediately after
transplantation and a recipient of a BKV-positive graft developed acute
rejection followed by severe BKV-associated nephropathy. Follow-up
of B19-positive grafts gave discordant results, with 6 cases of acute
prolonged infection, but also several cases of persistent B19 DNA
detection in the allograft but lack of seroconversion and DNAemia.
Conclusions: Viral genomes are frequently detectable in donor renal
graft units, especially in PS and WS, suggesting that they are mainly
carried by circulating blood cells, but, in the case of B19, also by
resident kidney cells. The presence of viral DNA in renal graft units
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is a signiﬁcant risk factor for symptomatic infections in seronegative
recipients in the early post-transplant period.
O36 Clinical utility of Septifast PCR in neutropenic cancer
patients with persistent fever despite antibacterial therapy
F. Lamoth, K. Jaton-Ogay, J. Bille, G. Prodhom, L. Senn, T. Calandra,
O. Marchetti (Lausanne, CH)
Background: Blood cultures are the standard technique for the
microbiological documentation of fever during neutropenia. However,
no pathogen is identiﬁed in the majority of patients with persistent fever
despite broad-spectrum antibacterial therapy. This results in multiple
investigations and empirical modiﬁcations of antimicrobial therapy.
Septifast (Roche) is a new PCR test for the detection of bacterial and
fungal DNA in blood.
Objective: To assess the clinical utility of Septifast in neutropenic cancer
patients with persistent fever despite antibacterial therapy.
Method: 48 consecutive adult neutropenic patients with persistent
fever during 3 days after myeloablative chemotherapy for hematogical
malignancies were studied. Febrile episodes were classiﬁed as microbi-
ologically (MDI) or clinically documented infection (CDI) and fever
of unknown origin (FUO) (ICHS, JID, 1990). Blood cultures were
performed on D0 (onset of fever) and D3 (persistent fever). Blood
samples for Septifast were drawn on D3. Septifast results were compared
with microbiological and clinical documentation of infection.
Results: 53 episodes of persistent fever were analysed (20 MDI, 22 CDI,
11 FUO). Blood cultures detected pathogens in 11/53 (21%) episodes
on D0. On D3, blood cultures and Septifast were positive in 4/53 (8%)
episodes and 20/53 (38%; p< 0.001), respectively. Septifast detected
4 pathogens identiﬁed by blood cultures (D0 or D3). In addition, 21
bacterial pathogens (7 G+, 14 G−) were detected by SF only (86% with
documented site of infection): these results are summarised in the Table.
6 fungi were detected by Septifast, none by blood cultures. 5 of these
positive results were observed in possible or probable invasive mycoses
(EORTC-MSG criteria, CID, 2001).
Bacteria detected by Septifast only (D3)
Site of infection
Upper/lower
GI tract
(n = 16)
Cath/skin
(n = 1)
Airways
(n = 1)
No site
of
infection
Gram-positives (n = 7)
S. aureus 2 1
E. faecium 3
S. pneumoniae 1
Gram-negatives (n = 14)
P. aeruginosa 6 1 2
Enterobacteria 4
A. baumannii 1
Conclusions: Septifast PCR is clinically useful in neutropenic cancer
patients with persistent fever despite antibacterial therapy.
O37 Post-operative risk factors as a cause of infection after
heart transplantation in a cardiovascular clinic in Medellin,
Colombia
P.A. Bedoya, M.F. Gomez, M.A. Mejia, G. Franco, R.L. Fernandez,
J.C. Gonzalez (Medellin, CO)
Objectives: We tried to identify possible risk factors to acquire
infections after heart transplantation. The procedures were performed
in a Cardiovascular Clinic in Medellin, Colombia, between January of
1997 and July of 2007. Our Clinic is the leader Institution in heart and
lung transplantation in Colombia (South America) and this is the ﬁrst
time we tried to ﬁnd out the scope of our transplant-related infections.
Methods: A cross sectional study with case and control analysis was
made. A case was deﬁned as an episode of postoperative infection
in a heart transplant receptor, while a control was a patient who
did not develop infection after a similar surgery. A review of the
medical charts of all patients infected and not infected was done.
Presumed preoperative (sex, age, diabetes, COPD, renal failure, previous
hospitalisations), surgical (duration of ischemy and perfusion time) and
postoperative (cardiac tamponade, bleeding, diabetes, ventricular failure,
graft rejection, etc.) risk factors were assessed.
Results: 141 patients were included in the study. 62 of them appeared
with at least one episode of infection as deﬁned by CDC criteria.
An association was found (p< 0.05) with the following post transplant
events: acute renal failure, diabetes, delay to start of cyclosporin therapy,
hours of mechanical ventilation, prolonged stay at ICU. Among surgical
events only the duration of ischemy during the procedure had statistic
relevance.
Conclusion: In our study the main risk factors to acquire a heart
transplant related infection were postoperative. It is important to attempt
to control the factors that depend on medical interventions like stay at an
ICU, days of mechanical ventilation and onset of cyclosporine therapy
as a measure to prevent the presence of infections.
O38 Investigation of viral infections in kidney transplant recipients
unveils the pathogenic role of Parvovirus B19 in chronic
allograft injury
L. Barzon, M. Pacenti, M. Biasolo, L. Murer, G. Palu` (Padua, IT)
Objectives: The relevance of viral infection of the kidney allograft in the
development of allograft lesions is still unclear, although some viruses
have been implicated. Aim of this study is the investigation of both
systemic and intrarenal viral infections in kidney transplant recipients
and their association with the risk of acute rejection and chronic allograft
injuries predictive of long-term dysfunction.
Methods: Screening for genome sequences of all human herpesviruses,
polyomaviruses, and parvovirus B19 in baseline and 6, 12, 24 months
follow-up allograft biopsies performed in 69 transplanted children.
Correlation of virological ﬁndings with clinical data, viral DNAemia,
renal function tests, and allograft histology.
Results: Overall, viral DNA was detectable in 46% baseline biopsies and
in about 70% follow-up biopsies. The most frequently detected viruses
were parvovirus B19 and HHV-6, already present in donor kidneys, and
BKV and EBV, usually acquired during follow-up. In most cases, viral
DNA persisted in the kidney allograft during follow-up. Univariate and
multivariate cox-proportional hazard regression analysis demonstrated
that, among viruses, only the intrarenal persistence of B19 DNA was
signiﬁcantly associated with the development of chronic allograft injury,
whereas HCMV DNAemia, but not allograft infection, was a risk factor
for acute rejection. Analysis of matched data on intrarenal viral DNA
detection and DNAemia indicated that HCMV did not involve the kidney
allograft in the course of systemic infection. Instead, B19 targeted the
kidney, where it established prolonged infection. Both the early transcript
NS1 and the late lytic transcripts VP1, VP-2, and 11kDa were expressed
in biopsies from patients with primary acute infection and DNAemia,
whereas only NS1 was expressed in biopsies from patients without
DNAemia. These results indicate that, after acute infection, characterised
by expression of all viral genes, B19 establishes persistent infection in the
kidney, characterised by expression of the early gene NS1 only. Kidney
injury might be linked to persistent B19 replication in the allograft, but
also to expression of the pro-apoptotic NS1 protein.
Conclusions: Unprecedented so far, this study demonstrates that
persistent intrarenal parvovirus B19 infection is associated with chronic
allograft injury in kidney transplant recipients. Moreover, this study
underlines the role of HCMV as risk factor for acute rejection.
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O39 A clinical model for predicting severe medical complications
in cancer patients with bloodstream infections
R.D. Portugal, E. Velasco, M.M. Loureiro (Rio de Janeiro, BR)
Objective: Cancer patients with bloodstream infections (BSI) and
concurrent medical conditions are at high risk of mortality. This study
aimed to identify patients at low risk of developing severe medical
complications and death.
Patients and Methods: A prediction score was derived from a
prospective cohort study involving 773 consecutive episodes of BSI
(2003–2005) in cancer patients hospitalised at National Cancer Institute
in Brazil. Main outcome was the development of severe medical
complications in the ﬁrst 72 h of hospitalisation, and deﬁned as the
presence of acute respiratory failure, septic shock, persistent infection
and severe bleeding. All variables reaching statistical signiﬁcance
(P< 0.05) in the univariate analysis were included in a stepwise,
multivariate logistic regression analysis. A simple model score was
developed, assigning one point to the presence of each statistical
signiﬁcant independent variable. The model was validated with 2000–
2002 data from the same hospital, on 859 episodes of BSI. Discriminative
capability of the score was assessed by area under receiver operating
characteristic (AUROC) curves.
Results: On the derivation set, 315 patients (40.7%) had severe medical
complications and 81 died (25.7%). There were no deaths in the group
of 458 patients without severe medical complications. Multivariate
analysis identiﬁed poor PS (<70), more than 2 coexisting illnesses,
polymicrobial infection, isolation of Pseudomonas aeruginosa and the
presence of other sites of infection as independently associated with
severe medical complications. The score points varied from 0 to 5 and
all necessary information was available in the ﬁrst 72 h. In this group, the
AUROC curve was 0.751 and 0.847 for the prediction of severe medical
complications and death, respectively. The validation set comprised a
group of patients with an overall mortality rate of 25.1% (216 deaths)
and with an AUROC curve of 0.752 for the prediction of death. In this
group, a cut-off point of 1.5 was able to obtain 86.1% of sensitivity,
51.8% of speciﬁcity, 90.6% of negative predictive value and 37.7% of
positive predictive value.
Conclusion: The prognostic score is able to identify in the ﬁrst 72h,
cancer patients with BSI at low risk of severe medical complications.
These results encourage a less aggressive management strategy for
a selected subgroup of patients, who might beneﬁt of early hospital
discharge with oral therapy.
O40 Prospective study on chemotherapy-induced febrile
neutropenia in patients with solid neoplasm in the era of risk
stratiﬁcation
M. Gayol, M.L. Pedro-Botet, N. Gonzalez, J. Trelis, A. Font,
C. Rey-Joly, M. Sabria´ (Badalona, ES)
Aims: (1) Describe chemotherapy-induced febrile neutropenia (FN) in
patients with solid neoplasms stratiﬁed according to the scale of the
Multinational Association of Support Treatment in Cancer (MASCC).
(2) Validate the MASCC scale. (3) Describe the patients with FN who
may be discharged early (<3 days of hospitalisation) and (4) Evaluate
whether the use of the MASCC scale is useful for reducing hospital
costs and improving the quality of life of these patients.
Material and Method: We performed a prospective study on the
incidence of chemotherapy-induced FN in patients with solid neoplasms
from December 2005 to November 2006 and calculated the sensitivity
and speciﬁcity of the MASCC scale for complications and/or death.
We compared the rate of G-CSF administration, mean hospital stay,
percentage of FN as the reason for admission in the Oncology
Department and mean economic cost in euros per episode of FN derived
from antibiotic treatment before and after (periods 1 and 2) the inclusion
of the MASCC scale for patient stratiﬁcation.
Results: We included 80 episodes of FN in 73 patients (7.6
episodes/1,000 chemotherapy cycles), 56.3% being males (45/80) with a
mean age of 57.8 years (31−85). Lung and breast cancer were the most
prevalent and the cancer was disseminated in 61.3% (49/89). 48.8%
(39/80) were of low risk on the MASCC scale. The mean number
of granulocytes was of 217.3 (0–500) with 30% having <100. 58.8%
(47/80) had no clinical or microbiologic foci with microbiologic foci in
21 (26.3%); the urinary and respiratory tracts and abdomen being the
most frequent origin of the latter. Gram-negative bacilli predominated
with Pseudomonas and enterobacteria being of note. 16.2% (13/80) of
the episodes were bacteremic. The related mortality was of 3.7%. The
sensitivity and the speciﬁcity of the MASCC scale were 86.3% (19/22)
and 62% (26/58), respectively. 16 (20%) patients were discharged in <3
days. The use of G-CSF, the percentage of FN among the total number
of admissions to oncology and the mean cost per episode and day in
euros derived from antibiotic treatment were signiﬁcantly lower during
period 2 than period 1.
Conclusions: The MASCC scale is a safe tool for stratifying the risk
of cancer patients and chemotherapy-induced FN. However, greater
speciﬁcity would allow a greater reduction in hospital costs for this
oncologic emergency and improve the quality of life of these patients.
O41 A prospective comparative study of hospitalised adult and
paediatric cancer patients with candidaemia: clinical char-
acteristics, comorbid conditions and inﬂuences on mortality
E. Velasco, R. Bigni (Rio de Janeiro, BR)
Objective: Candida species are among the most common causes of
invasive fungal infections in cancer patients and are associated with high
morbidity and mortality rates. The study aimed to compare the prognostic
impact of the epidemiological characteristics, concurrent illnesses and
clinical microbiological data of adults and children with candidaemia.
Patients and Methods: Between January 2001 and June 2005 a
prospective cohort study of hospitalised adults (n = 99) and children
(n = 130) cancer patients with candidaemia was conducted at a tertiary
cancer centre in Brazil.
Results: The crude mortality was higher among adults than in children
(37.4% vs. 7.7%). Univariate analysis indicated that in the adult
population lymphoma, neutropenia, presence of comorbidities, a poor
performance status, an absence of CVC, use of steroid, previous surgery,
hypotension, hepatic, severe respiratory dysfunctions and the species
Candida glabrata, krusei and tropicalis were risk factors signiﬁcantly
associated with death. Among children the predictors of mortality were
acute leukaemia, neutropenia, presence of comorbidities, an absence of
CVC, a poor performance status, hypotension, concomitant infected sites
besides bloodstream infection, pulmonary inﬁltrates, severe respiratory
dysfunction and the species Candida glabrata, krusei and tropicalis. The
survival rates following fungaemia with C. albicans and all Candida
non-albicans species were similar in both groups. In multivariate
analysis, the presence of comorbidities (odds ratio [OR] 2.61; 95%
conﬁdence interval [CI] 1.46−4.67) and neutropenia (OR 10.27; 95%
CI 1.80−58.49) affected independently the adults outcome. In children,
only comorbidities were associated with mortality (OR 2.22; 95% CI
1.22−4.03).
Conclusion: The study showed important differences of epidemiological,
clinical characteristics and risk factors for death between both groups.
O42 Increasing use of immunosuppression and biological
therapies: the establishment of a designated clinic to prevent
infectious complications
R. Mac Nicholas, S.E. Ahmed, M. Hamed, E. De Barra, O. El Shariff,
C. Bergin, S. Norris, P.W.N. Keeling, N. Mahmud (Dublin, IE)
Introduction: Many patients with Inﬂammatory bowel disease (IBD)
are young and require long term treatment with immunosuppressants
to control their disease. Corticosteroids, immunomodulators and more
recently biological therapies increase the risk of infections. Current Irish
guidelines recommend vaccination against inﬂuenza, pneumococcus,
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tetanus and varicella zoster virus in patients immunosuppressed by
disease or treatment (1).
Aims: To assess the vaccination history and exposure to vaccine
preventable diseases in IBD patients on immunosuppression prior to the
establishment of a chronic inﬂammatory diseases assessment clinic.
Method:We conducted a prospective survey of consecutive IBD patients
on immunosuppressant medications. A thorough vaccination history was
obtained and blood samples were taken to assess past exposure and
vaccination status.
Results: A total of 70 IBD patients were assessed (53% Crohn’s disease,
33% Ulcerative Colitis, 4% Indeterminate). History of immunosup-
pressant use included; Azathioprine (51%), Prednisolone (44%) and
Methotrexate (2%), Anti-TNF (6%).
91% of patients did not receive their annual inﬂuenza vaccination and
80% had never been vaccinated. 97% of patients were not adequately
vaccinated against pneumococcus and 86% had never been vaccinated.
Varicella Zoster Virus IgG was detected in 100% of patients, 43% had
a previous history of chickenpox and 11% had a previous history of
shingles. 94% of patients were not vaccinated against hepatitis B, 3%
had chronic hepatitis B infection and only 3% were vaccinated.
Conclusion: This study indicates that vaccination uptake amongst IBD
patients on immunosuppressant regimens is extremely poor. Current
Irish guidelines recommend vaccination in these patients. Ignoring these
guidelines puts patients at risk of preventable diseases.
The establishment of a designated infectious disease assessment clinic
will commence to address vaccination requirements and provide health-
care advice pertaining to infectious complications of immunosuppressive
therapies in particular biological agents. We intend to expand this service
to other medical specialties utilising these immunosuppressive regimens.
O43 Virological and immunological monitoring of human
cytomegalovirus infection in heart and small
bowel/multivisceral transplantation
T. Lazzarotto, A. Chiereghin, L. Gabrielli, A.D. Pinna, A. Lauro,
A. Dazzi, C. Zanﬁ, M. Cescon, L. Potena, C. Magelli, E. Petrisli,
P. Monari, S. Pop, M.P. Landini (Bologna, IT)
Objectives: This study was carried out to assess the diagnostic
and prognostic value of cytomegalovirus (CMV) determination in
whole blood (heart and intestinal recipients) and in biopsy tissue
samples (intestinal recipients) from transplant patients during virological
surveillance and analyse the CMV T cell response after transplantation.
Methods:We monitored 30 heart transplant recipients (HTR) comprising
three R−/D+ and 34 intestinal/multivisceral transplant (SBMTR)
comprising three R−/D+. CMV pp65 antigenaemia and Real Time PCR
were monitored once or twice weekly during the ﬁrst month, every week
for the next two months, every two weeks until the sixth month and
monthly from then onwards. Additional blood and biopsy samples were
taken if clinically indicated.
Immunological surveillance was done in 12 HTR and 9 SBMTR. The
study of the CMV-speciﬁc T-cell response consisted of two stages: i) the
collection of a blood sample per patient at the time of transplantation
and ii) the collection of a sample per patient each month during the post-
transplant follow-up. T lymphocyte suspensions obtained using a Ficoll
gradient were processed by ELISPOT, an immunoenzymeassay based on
the search for T cells with viral speciﬁc antigens of one of the protein
markers of cell activation (IFN-gamma).
Around 2000 blood samples and 1200 intestinal biopsy specimens were
processed for virological tests and 56 were analysed by ELISPOT.
Results: 70% (21/30) and 44% (15/34) of HTR and SBMTR developed
active CMV infection, respectively. Of the 21 HTR infected four had a
mild-moderate symptomatic infection (leucopenia and fever). Of the 15
SBMTR infected patients two had a severe symptomatic CMV infection
(pneumonia, enteritis and rejection) which led to the patient’s death and
three had a mild infection (fever).
Conclusion: Quantitative determination of CMV in blood and organ
biopsy by molecular tests is the elective assay for monitoring viral load,
since it directly correlates with viral replication and clinical symptoms.
The preliminary outcome of immunological monitoring shows i) a CMV
T-cell immune response in the ﬁrst month after transplantation was
associated with a reduction in mean and peak CMV viral load and;
ii) a good and early reconstitution or development of the CMV-speciﬁc
T-cell response can shorten the duration of CMV infection and control
the risk to incur repeated episodes linked to a recurrent infection.
O44 Listeria monocytogenes outbreak in a comprehensive cancer
and transplantation centre
E. Lingaas, B.O. Johnsen, D. Torfoss, D.H. Dorenberg, C.T. Andersen,
F. Mu¨ller, A. Ingebretsen, P. Gaustad, T.M. Leegaard, I. Nordoey
(Oslo, NO)
Objective: Listeria monocytogenes infection is rare in man, but known
to occur in the immunocompromised host with high fatality rates.
L. monocytogenes is widely distributed in the environment, has the ability
to multiply even at low temperatures and is a feared food-borne pathogen.
We describe an outbreak in a university hospital in Oslo, Norway. The
hospital is primarily a cancer and transplantation centre.
Methods: Identiﬁcation of L. monocytogenes was based on Gram
stain, beta-haemolysis, catalase, VITEK2 identiﬁcation and CAMP-test.
Resistance pattern, serotyping and MLVA were performed to conﬁrm an
outbreak.
Results: From the 1st until the 30th of October, L. monocytogenes was
isolated from blood cultures (N = 13), pus (N= 1) or faeces (N = 1) from
10 women and 5 men with a median age of 65 years (range 37−84).
Fourteen of the patients had predisposing underlying disease, 13 had
received immuno-modulating therapy and 7 had received antacids.
Thirteen patients had fever, 6 patients had diarrhoea, none had classical
symptoms of meningitis, but 6 were somnolent and/or had a headache.
Three patients (20%) died before the diagnosis was conﬁrmed. The
remaining patients received appropriate treatment after L. monocytogenes
was isolated, and have recovered. Eight patients received empirical
monotherapy with cephalosporins after onset of fever – 2 of these
patients died.
All blood cultures were positive within 2 days. Further identiﬁcation
conﬁrmed that the isolates from our 15 patients were of serotype 1 and
had identical MLVA proﬁles (7−7–9–10−6) and patterns of resistance.
A pasteurised camembert cheese was the source of the outbreak.
Conclusions: We report a L. monocytogenes outbreak with a mortality
of 20% in a setting of predominately immunocompromised patients.
The use of empirical cephalosporins as monotherapy in a setting with
immunocompromised patients may be hazardous as L. monocytogenes
is resistant to these antibiotics. Food-regulations in hospitals seem
warranted.
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S57 MLST – 10 years of experience
M. Maiden (Oxford, UK)
MLST was proposed in 1998 as a portable approach to the identiﬁcation
of bacterial clones. It was based on three developments: (i) the increasing
availability and decreasing cost of high-throughput sequencing; (ii)
the improving understanding of bacterial population biology and its
implications for epidemiology; and (iii) the increasing availability and
power of the Internet as a means of data sharing. Since that time MLST
has become a gold standard method for the characterisation of many
bacterial pathogens and a number of non-pathogens. MLST has made
it possible to compare the bacterial isolates obtained in different parts
of the world and at different times simply and accurately using generic
techniques but without the necessity of sharing reagents or isolates. In
addition to solving many of the problems inherent in the characterisation
of isolates from diverse recombinogenic bacteria, MLST has also
provided data that have enabled extensive studies of bacterial population
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genetics, speciation, and evolution, providing substantial added value to
epidemiological studies. The MLST approach also provides indications
as to the most efﬁcient means of exploiting the next generation of DNA
sequencing machines.
S58 Use of DNA microarrays in molecular typing
J. Lindsay (London, UK)
Microarrays are solid supports spotted with thousands of tiny DNA
probes that can be used to quickly determine which genes are present
in a bacterium or sample. They have caused a revolution in our
understanding of bacterial population structures and how they vary
and evolve, and have also helped to identify markers of virulence or
epidemiology. Microarrays are also extremely valueable for developing
and validating improved routine typing methods. In the typing laboratory
where methods need to be cheap, rapid, accurate and reproduceable,
microarrays technology is expensive and experimental. But this is
changing. When printed with appropriate probes and validated, their
uses are endless, and are only limited by our ability to interpret the data
generated.
S59 MLVA and CRISPR web services for bacterial genotyping
G. Vergnaud, P. Bouchon, I. Grissa, C. Pourcel (Orsay, FR)
Multiple loci variable number of tandem repeats (VNTR) analysis
(MLVA) is a typing technique based on the polymorphism of
certain tandemly repeated DNA sequences. Although their biological
function and evolution mechanism are not fully understood, they have
diverse practical applications including strain identiﬁcation in bacterial
epidemiology. In a typical MLVA assay, a few to more than twenty
VNTRs, distributed over the entire bacterial genome, are analysed,
and a code corresponding to the number of repeats at each locus is
determined. This code is easily stored into databases and can be used
for strain clustering and epidemiological studies. We will show a list of
the currently proposed MLVA assays and brieﬂy describe representative
examples, including open questions. We will compare MLVA to other
approaches, and discuss issues related to standardisation and possibilities
offered by the internet in terms of shared databases for MLVA (MLVA
Web Services).
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs)
loci are part of a recently discovered mechanism used by some bacteria
and most archaea as a defence against genetic elements in particular
phages. These structures consist in repeated sequences (23−47bp long)
called direct repeats (DR) separated by unique sequences of similar size
called spacers. Their polymorphism can be used to differentiate strains
inside a species. It is due to either acquisition of new motifs (a DR
and a spacer) in a polarised fashion or to the interstitial deletion of
one or several consecutive motifs. The spoligotyping method which has
been widely applied to the genotyping of Mycobacterium tuberculosis,
is based on the analysis of a CRISPR locus. To assess the interest of
CRISPR analysis as a genotyping method it is important to ﬁrst identify
these structures in the genomes of interest, then extract and classify the
constituting elements.
When a CRISPR has been identiﬁed in a sequenced strain (in silico
analysis, Phase 1) then its polymorphism is investigated in the species
by PCR ampliﬁcation and sequencing (Phase 2). The last phase consists
in the classiﬁcation and numbering of the spacers in order to compare
the strains and produce a tentative phylogenetic tree. We will present
the Web services tools we have developed for these purposes, and will
discuss the efﬁciency and informativity of the CRISPR analysis as a
genotyping tool, depending on the species diversity.
Infection control guidelines
S62 Copy and paste – is the search and destroy policy suitable for
Europe?
C.M.J.E. Vandenbroucke-Grauls (Amsterdam, NL)
Since the early 1980s the Netherlands has adopted a search and
destroy policy with respect to meticillin-resistant Staphylococcus aureus
(MRSA). This policy implies a national guideline for control, with search
for carriers among deﬁned groups of patients and healthcare workers,
strict isolation of carriers, and treatment of carriers. The guideline is
enforced by the Health Inspectorate. In addition, a national surveillance
system has been implemented. From this surveillance we know that, as of
2006, MRSA was detected in approximately 2000 persons (both patients
and healthcare workers; the number comprises carriers and infected
persons). This very low number is conﬁrmed by the EARSS data: the
Netherlands is one of the countries in Europe with the lowest burden of
MRSA.
The stringent Dutch policy has been applicable for so many years,
because the number of carriers is so low. We realize that screening
and strict isolation “the Dutch way” are impossible when the number of
MRSA carriers becomes too high. From the Dutch experience, however,
lessons can be learned and might provide a basis for “copy and paste” of
part of the Dutch approach in countries with a higher burden of MRSA.
Among these are the national approach and the national surveillance,
which provide support to all healthcare workers involved and motivation
to keep up the efforts.
S63 epic2: National evidence-based guidelines for preventing
healthcare-associated infections in National Health Service
facilities in England
R.J. Pratt (Brentford, UK)
All successful strategies for preventing healthcare-associated infections
require a multifaceted evidence-based approach that includes providing
practitioners with best evidence for clinically effective practice and
then supporting them to understand and use this evidence to minimise
infection risks and increase patient safety. This presentation will describe
how national evidence-based guidelines from the Department of Health
and the National Institute for Health and Clinical Excellence in England
form the foundations for ensuring the availability of best evidence
to practitioners in the National Health Service (NHS) and, how the
development of an associated e-learning/blended learning programme
is now supporting all practitioners to effectively use this evidence to
protect patients from the risk of preventable infections during care. By
incorporating these national guidelines into local policies and protocols
and then into routine daily clinical practice, patient safety can be
enhanced and the risk of patients acquiring an infection during episodes
of healthcare in NHS facilities in England minimised.
Emerging infections in Europe
S66 Bartonellosis and other emerging infection in homeless people
in Europe
P. Brouqui (Marseille, FR)
Homeless people are particularly exposed to ectoparasite. The living
conditions and the crowded shelters provide ideal conditions for the
spread of lice, ﬂea, ticks and mites. Body lice have long been recognised
as human parasites and although typically prevalent in rural communities
in upland areas of countries close to the equator, it is now increasingly
encountered in developed countries especially in homeless people or
inner city economically deprived population. Fleas are widespread but
are not adapted to a speciﬁc host and may occasionally bite humans. Most
common ﬂeas that parasite humans are the cat, the rat and the human
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ﬂeas, Ctenocephalides felis, Xenopsylla cheopis and Pulex irritans,
respectively. Ticks belonging to the family Ixodidae, in particular the
genera Dermacentor, Rhipicephalus and Ixodes, are frequent parasites
in humans. Sarcoptes scabiei var. hominis is a mite (Arachnida class)
responsible for scabies. It is an obligate parasite of human skin. The
hematophagic biting mite, Liponyssoides sanguineus, is a mite of the
rat, mouse and other domestic rodents but can also bite humans. The
threat posed by the ectoparasite in homeless is not the ectoparasite
themselves but the associated infectious diseases that they may transmit
to humans. Except for scabies all these ectoparasites are potential vector
for infectious agents.
Three louse borne diseases are known at this time. Trench fever
caused by Bartonella quintana, epidemic typhus caused by Rickettsia
prowazekii and relapsing fever caused by the spirochete Borrelia
recurrentis. Fleas transmit plague (Xenopsylla cheopis, Pulex irritans),
murine typhus (Xenopsylla cheopis), ﬂea-borne spotted rickettsiosis
due to the recently described species Rickettsia felis (Ctenocephalides
felis), and occasionally cat-scratch disease due to Bartonella henselae
(Ctenocephalides felis). The role of ﬂeas as potential vector of
B. quintana has recently been suggested. Among the hematophagic biting
mites, Liponyssoides sanguineus, is responsible for the transmission of
Rickettsia akari, the aetiologic agent of rickettsialpox. Virtually, no data
are available on tick-borne disease in this population.
This review will deal with epidemiology, diagnosis, prevention and
treatment of these ectoparasite and the infectious diseases they transmit
to the homeless people.
S67 Hantavirus infections
T. Avsic-Zupanc (Ljubljana, SI)
Hantaviruses belong to the emerging pathogens having gained more
and more attention in the last decades. These viruses are members
of the family Bunyaviridae and are grouped into a separate genus
known as Hantavirus. Unlike most other Bunyaviridae, hantaviruses are
not arthropod-borne (arboviruses), but are ROdent-BOrne, roboviruses.
Each hantavirus is primarily carried by a distinct rodent/insectivore
species although a few host switches seem to have occurred during
the tens of millions of years of their co-evolution with their carrier
animals. Hantaviruses are maintained by cyclical transmission between
persistently infected rodents, with incidental infection of humans.
Transmission occurs primarily by inhalation of aerosols from infected
rodents’ urine, faeces or saliva. Hantaviruses are found worldwide
and are known to cause two serious and often fatal human diseases:
haemorrhagic fever with renal syndrome (HFRS) and hantavirus
cardiopulmonary syndrome (HCPS). More than 20 hantaviruses have
been identiﬁed, approximately half of which are known to cause
HFRS or HPS. The serotypes Hantaan (HTN), Seoul (SEO), Puumala
(PUU), and Dobrava (DOB) virus predominantly cause haemorrhagic
fever with renal syndrome (HFRS), a disease characterised by renal
failure, haemorrhages, and shock. Whereas hantavirus cardiopulmonary
syndrome (HCPS) is a severe cardiopulmonary illness most often caused
by the Sin Nombre virus. The illness begins as a nonspeciﬁc febrile
prodrome, and then patients quickly develop noncardiogenic pulmonary
edema, respiratory failure, and shock. The overall case fatality rate
of HCPS is approximately 40 percent. The pathogenesis of HFRS
is poorly understood. However, it is known that b3 integrins can
mediate the entry of pathogenic hantaviruses and that hantaviruses can
regulate apoptosis. Also there is evidence and that increased capillary
permeability is an essential component in the pathogenesis of both
HFRS and HCPS, although different target tissues, kidneys and lungs
are affected in the two diseases. HFRS patients show locally increased
levels of TNF-a in the plasma and kidneys and high levels of urinary
secretion of the proinﬂammatory cytokine IL-6. The diagnosis of acute
hantavirus infection is primarily based on serology, since viral RNA
cannot be regularly detected in the blood or urine of patients. Both
immunoﬂuorescence tests and enzyme immunoassays are widely used for
detection of speciﬁc IgM or low-avidity IgG antibodies, characteristic of
acute infection. Vaccines against hantavirus infections have been used for
years in China and Korea, but not in Europe or the Americas. No speciﬁc
therapy is used in Europe, although both Ribavirin and interferon-a have
been successfully used in trials in China. The high rate of mortality could
be reduced if effective therapeutics could be discovered for treatment of
this illness.
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S69 TREM-1 improves the inﬂammatory response and outcome
to Streptococcus pneumoniae infection by reducing levels of
negative regulators in the lung
H. Lagler, O. Sharif, I. Haslinger, U. Matt, K. Stich, T. Furtner,
K. Schmidt, S. Knapp (Vienna, AT)
Background: Triggering receptor expressed on myeloid cells (TREM-
1) is a cell surface receptor present on both monocytes/macrophages
and neutrophils that has been shown to amplify cytokine and chemokine
production in response to bacterial Toll like receptor (TLR) ligands.
Blocking studies revealed TREM-1 as a valuable target to prevent
overwhelming inﬂammation during sepsis. At the same time, TREM-
1 is highly expressed within the pulmonary compartment with soluble
TREM-1 being a valuable marker indicating the presence of pneumonia
in humans. The biological role of TREM-1 during community acquired
pneumonia, such as pneumococcal pneumonia is not known. The aim
of the present study was to determine the function of TREM-1 in the
inﬂammatory response to Streptococcus pneumoniae infection in vivo,
the mechanism where by this occurred, and the outcome of this on
infection.
Methods: C57BL/6 mice were intranasally infected with S. pneumoniae
followed by i.p. treatment with PBS, isotype Ab or agonistic
TREM-1 mAb. Bacterial counts, lung histology, neutrophil inﬂux,
chemokine/cytokine responses and signaling mediators as well as
survival were evaluated in vivo in a time dependent manner. In
vitro, immortalised lung alveolar macrophages (MHS) and respiratory
epithelial cells were utilised to study the response to S. pneumoniae
treatment.
Results: Mice pre-treated with agonistic TREM-1 displayed a signiﬁ-
cantly ampliﬁed cytokine and chemokine responses (TNF, MIP-2 and
IL-6) as well as neutrophil inﬂux to the lungs 6h after induction of
pneumonia. This enhanced early inﬂammation was associated with lower
numbers of bacteria in the lungs and reduced pulmonary inﬂammation at
48hr, resulting in improved survival. In vitro studies corroborated these
results at the early time point. A reduction of negative regulators of
TLR signaling in lungs was observed in mice pre-treated with TREM-1
in vivo.
Conclusion: TREM-1 boosts the early inﬂammatory response during
S. pneumoniae infection in vivo through lowering levels of negative
regulators in the lung, which results in accelerated bacterial clearance
and ultimately improved survival.
S72 Tropical sepsis
T. van der Poll (Amsterdam, NL)
Sepsis is as a clinical syndrome that results from a systemic response
of the host to an infection. The outcome of sepsis is poor, and
even in the developed world mortality rates remain as high as
30−40%. In the western world, sepsis most frequently is caused by
bacteria. The most commonly isolated pathogens in Gram-positive
sepsis are Staphylococcus aureus and Streptococcus pneumoniae, the
most common Gram-negative causative bacteria are Escherichia coli,
Klebsiella sp. and Pseudomonas aeruginosa. Although these bacteria
also are isolated from patients with sepsis in tropical areas, several other
causes must be considered. Potentially lethal causes of sepsis in the
tropics include malaria, viral haemorrhagic fevers, leptospirosis, typhoid
fever and melioidosis. Many aspects of the host response to these tropical
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infections resemble the host response to sepsis as seen in the western
world, including activation of inﬂammatory and procoagulant pathways.
Studies comparing the host response to “western sepsis” with that to
“tropical sepsis” will be discussed.
S73 Innate immunomodulating therapies
T. Calandra (Lausanne, CH)
The innate immune system assumes an essential role in the natural
host defences against microbes. Sensing of microbial pathogens,
either in tissue in contact with the host’s environment or in the
systemic circulation after invasion of the bloodstream, is carried out
by macrophages, dendritic cells, natural killer cells, granulocytes and
monocytes acting as sentinels of the innate immune system. Recognition
of invasive pathogens by immune cells relies on their capacity to
detect microbial molecular motifs, such as endotoxin, peptidoglycan
subcomponents, lipopeptides, glucans, mannans, ﬂagellin and nucleic
acids via microbial-recognition receptors. Microbe-associated molecular
motifs bind to a family of microbial recognition molecules expressed
by immune and non-immune cells, including CD14, Toll-like receptors,
peptidoglycan-recognition proteins, nucleotide-binding oligomerisation
domain-like receptors, helicase-domain-containing like receptors, such
as retinoic acid-inducible gene I (RIG-I) or melanoma-differentiation-
associated gene 5 (Mda5), C-type lectin receptors (such as dectin-1) and
the triggering receptors expressed on myeloid cells (TREM) receptor
family. Ligand-activated receptors turn on signal transduction pathways
and the transcription of immune genes resulting in the expression
of co-stimulatory molecules at the cell surface and in the release of
immunoregulatory effector molecules in the extracellular compartment.
Until recently increased knowledge of the pathophysiological basis of
sepsis did not translate into clinical beneﬁt. Lately, however, several
treatment approaches have for the ﬁrst time yielded encouraging,
albeit still arguable results (i.e. early-goal directed therapy, activated
protein C, hydrocortisone therapy, and intensive insulin therapy). New
immunomodulating therapies targeting components of the innate immune
system, such as TLR4, are currently underway.
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O74 Efﬁcacy and safety of novel amoxicillin/clavulanic acid
formulation versus originator ﬁlm-coated tablets in adult
patients with lower respiratory tract infections
I. Guchev, S. Ratchina, R. Kozlov (Smolensk, RU)
Objectives: To compare tolerability and clinical efﬁcacy of novel
formulation of amoxicillin/clavulanic acid (ACA) – dispersible tablets –
with originator ﬁlm-coated tablets in hospitalised adults with bacterial
lower respiratory tract infections (LRTIs).
Methods: In this comparative, two-centre, open-label study adult patients
hospitalised for non-severe community-acquired pneumonia (CAP) or
bacterial exacerbation of chronic obstructive pulmonary disease (COPD)
were randomly assigned (1:1) to receive 5−10-days course of treatment
with either ACA dispersible tablets, 500/125 mg, t.i.d. (group A) or ACA
ﬁlm-coated tablets, 500/125 mg, t.i.d. (group B). Clinical outcomes were
assessed at test of cure and follow-up visits (5−10 days and 25−30 days
after the end of treatment, respectively), tolerability at day 3 of treatment,
end of treatment (5−10 days), test of cure and follow-up visits on the
basis of reported adverse events (AE) and laboratory abnormalities.
Because all treatment regimens were routine and no other than standard
procedures implemented, there was no necessity for approval of the study
by the Ethics Committee.
Results: Per-protocol (PP) population comprised 200 patients. CAP was
diagnosed in 81 and 70 of patients in group A and B, respectively.
There were no signiﬁcant differences in demographic data and clinical
presentation at baseline between groups. Clinical success rate at follow-
up visit was 95/100 (95%) and 94/100 (94%) for group A and group B.
No difference in symptoms resolution of LRTIs was observed. AE were
recorded in 15% and 31% (P = 0.01) of patients in group A and group
B respectively and comprised predominantly gastrointestinal complaints
(diarrhoea, nausea, meteorism, abdominal pain). Tendency towards less
percentage of diarrhoea in group A patients on comparison with those
in group B was observed (6% vs. 17%, P = 0.027). There were no
clinically signiﬁcant laboratory abnormalities revealed. AEs resulting to
withdrawal were registered in 2% and 4% in group A and B, respectively
(P> 0.05).
Conclusion: A novel formulation of ACA dispersible tablets given at
the dosage of 500/125 mg t.i.d. for 5−10 days in hospitalised adults
with bacterial LRTIs was as effective as originator ﬁlm-coated tablets.
Tendency towards lesser gastrointestinal AE (mainly diarrhoea) was
observed in group A, however this required to be proven in large-scale
clinical trials.
O75 Telavancin for hospital-acquired pneumonia, including
ventilator-associated pneumonia: the ATTAIN studies
E. Rubinstein, G.R. Corey, M.E. Stryjewski, H.W. Boucher, R.N. Daly,
F.C. Genter, S.L. Barriere, M.M. Kitt, H.D. Friedland (Winnipeg,
CA; Durham, South San Francisco, Boston, US; Buenos Aires, AR)
Objectives: Telavancin (TLV), a rapidly bactericidal, investigational,
lipoglycopeptide with a multifunctional mechanism of action, is active
against a broad range of clinically relevant Gram-positive bacteria,
including meticillin-resistant Staphylococcus aureus (MRSA). MRSA
is an important pathogen causing hospital-acquired pneumonia (HAP)
worldwide. The ATTAIN studies were designed to compare the efﬁcacy
and safety of TLV with vancomycin (VAN) in patients with HAP,
including patients with ventilator-associated pneumonia (VAP).
Methods: ATTAIN 1&2 were identical, multinational, multicentre,
randomised, double-blind, Phase 3 studies. Patients 18 years with
HAP caused by suspected or conﬁrmed Gram-positive pathogens were
randomised (1:1) to TLV 10 mg/kg IV every 24h or VAN 1 g IV
every 12h (dosages adjusted per site-speciﬁc guidelines) for 7−21 days.
The primary efﬁcacy analysis in each study was non-inferiority of TLV
compared with VAN in clinical cure rates in clinically evaluable (CE)
patients. In addition, pooled analyses of the two studies were speciﬁed
prospectively.
Results: A total of 1503 patients were randomised and treated
(TLV=749, VAN=754); 658 of these patients were CE. In each study,
the demographic and baseline characteristics were similar in the two
treatment groups. Non-inferiority was achieved for both the All-treated
(AT) and CE populations in each study as well as in the pooled analysis.
The pooled clinical cure rates are displayed in the table below. Further,
the clinical cure rate in CE patients with VAP was numerically higher
in the TLV group (Table).
Clinical Cure Rate Difference, TLV−VAN
TLV VAN (95% CI)
Hospital-acquired Pneumonia
AT (n = 1503) 58.9% 59.5% −0.7% (−5.6%, 4.3%)
CE (n = 658) 82.7% 80.9% 1.8% (−4.1%, 7.7%)
Ventilator-associated Pneumonia
AT (n = 427) 49.1% 53.1% −4.0% (−13.5%, 5.5%)
CE (n = 139) 80.3% 67.6% 13.2% (−1.8%, 26.8%)
AT = All-treated; CE = Clinically-evaluable; TLV = telavancin; VAN =
vancomycin; CI = conﬁdence interval.
The overall incidence of adverse events (AEs) in both groups was
comparable (82% for TLV, 81% for VAN). The most common AEs,
which occurred at similar rates in both groups, were diarrhoea,
constipation, and anaemia.
Conclusion: To our knowledge, ATTAIN was the largest programme
conducted in patients with HAP due to Gram-positive bacteria. Data
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from the ATTAIN studies support the once-daily use of TLV for the
treatment of Gram-positive HAP, including patients with VAP.
O76 Genotyping of Gram-negative uropathogens isolated pre and
post-treatment from subjects in a doripenem clinical trial for
complicated urinary tract infections
T. Davies, W. Shang, R. Redman, K. Bush, R. Flamm (Raritan, US)
Objectives: Doripenem (DOR) a parenteral carbapenem was approved
in the US for treatment of complicated intraabdominal and complicated
urinary tract infections including pyelonephritis (cUTI). In a cUTI trial
comparing DOR and IV levoﬂoxacin (LVX), the microbiologic cure rate
at test of cure (TOC, day 6−11 post therapy) for the microbiologically
evaluable population was 82.1% (230 / 280) in the DOR group and
83.4% (221 / 265) in the LVX group. Gram-negative pathogens isolated
from the same subject pre- and post-treatment (microbiological failures)
were genotyped to determine if the pre-treatment isolate persisted or if
a new infection occurred.
Methods: Baseline Escherichia coli, Klebsiella pneumoniae, Proteus
mirabilis, and Pseudomonas aeruginosa isolates were compared to TOC
or late follow-up (LFU, day 28−35 post therapy) isolates by pulsed-ﬁeld
gel electrophoresis (PFGE). TOC and LFU isolates with 6 DNA band
differences to the matched baseline isolate were classiﬁed as persistent
infections; isolates with >6 differences were considered to be a different
strain (new infection). Isolates producing smears by PFGE were non-
typeable (NT).
Results: For P. mirabilis, P. aeruginosa, and K. pneumoniae microbi-
ologic failures in the DOR and LVX treatment groups were usually
due to persistence of the baseline pathogen. For E. coli, microbiologic
failures due to a new infection were higher in the DOR treatment group
(44%) then the LVX group (29%) for TOC isolates. Prevalence of
new E. coli infections increased at LFU to about two-thirds for both
treatment groups. When a LVX-resistant E. coli was present at baseline,
microbiologic failures due to persistence was 78% and 57% in the LVX
and DOR treatment groups, respectively.
No. Microbiologic Failures (%)
DOR Treatment Group LVX Treatment Group
Baseline
Pathogen
Isolate N Persist New
Infect
N Persist New
Infect
E. coli TOC 23* 9 (39) 10 (44) 14* 6 (43) 4 (29)
LFU 31* 8 (26) 19 (61) 26* 6 (23) 18 (69)
P. mirabilis TOC 6 6 (100) − 2 2 (100) −
LFU 4 4 (100) − 2 1 (50) 1 (50)
P. aeruginosa TOC 5 4 (80) 1 (20) 2 2 (100) −
LFU 2 1 (50) 1 (50) 1 1 (100) −
K. pneumoniae TOC 1 1 (100) − 2 2 (100) −
LFU 0 − − 2* 1 (50) −
1 *Some isolates were NT and not analysed.
Conclusion: In a cUTI trial, microbiologic failures in the DOR and LVX
treatment groups for P. mirabilis, P. aeruginosa, and K. pneumoniae were
usually (>80%) due to persistence of the baseline isolate. E. coli failures
were due to replacement of the baseline isolate (new infection) in >50%
of the cases.
O77 Justiﬁcation for non-inferiority margin in community-
acquired pneumonia
R. Echols, G. Tillotson, R. Tosiello, S. Kowalsky, A. Verderame
(Milford, US)
Objective: To determine the NI margin for clinical trials in
mild-moderate community-acquired pneumonia (CAP) when placebo-
controlled trials of adequate design are unavailable.
Methods: ICH guidelines identify 5 types of control groups: placebo,
no treatment, different dose, different active treatment, external or
historical. Efﬁcacy is established when new drug demonstrates clinically
meaningful superiority over a control regimen. An active control trial
can demonstrate efﬁcacy when a new treatment is similar (non-inferior)
to a known effective treatment when the new treatment is not less
effective than control by a predetermined margin (M2), identifying the
lower boundary of a 95% CI. M2 can only be determined after the
beneﬁt of the active control over placebo (M1) has been demonstrated in
studies showing superiority over placebo or a less effective active control.
No placebo-controlled trials have been conducted in CAP. Historical
evidence of antibiotic efﬁcacy in CAP has been derived from estimates
of mortality. Thus, an estimate of clinical response for M1 can only
be derived indirectly. Some assumptions are made:1) efﬁcacy can only
be estimated for an antibiotic with in vitro activity; 2) efﬁcacy in CAP
is derived from patients with bacterial infection; 3) clinical response
results in improvement within 72 hrs; 4) M2 should preserve 50% of M1.
The natural history of spontaneously resolving (non-fatal) pneumococcal
pneumonia in the pre-antibiotic era was estimated. Publications and
Summary Basis of Approvals for antibiotics from 1996–2006 were
reviewed for microbial aetiology and treatment response.
Results: For contemporary CAP, 30% are caused by typical bacteria,
20% atypical pathogens and 50% viral or other causes. Clinical success
is 87% in mild-moderate CAP. Clinical improvement does not occur
before 72 hrs in untreated non-fatal pneumococcal pneumonia. Thus,
for an antibiotic with activity against only typical bacteria, M1 equals
0.30(% CAP typical pathogens) × 0.87 (clinical response). Using these
data and assumptions a M2 margin of 13% would provide evidence of
treatment efﬁcacy in mild-moderate CAP when an appropriate control
drug is used.
Conclusion: The M2 margin for CAP can be derived from knowledge of
spontaneous recovery in the pre-antibiotic era combined with a careful
analysis of contemporary aetiologies and treatment response of CAP.
O78 Comparison of antibiotics with placebo for the treatment
of presumed acute bacterial sinusitis: a meta-analysis of
randomised controlled trials
M. Falagas, K. Giannopoulou, K. Vardakas, G. Dimopoulos,
D. Karageorgopoulos (Athens, GR)
Objectives: There is controversy regarding the beneﬁt of antibiotics for
the treatment of patients with presumed acute bacterial sinusitis.
Methods: We performed a meta-analysis of randomised, placebo-
controlled trials (RCTs) evaluating the effectiveness and safety of
antibiotics for this indication.
Results: Sixteen RCTs were included, (among which 3 performed
exclusively in children), involving 21 antibiotic arms (8 amoxicillin,
4 penicillin V, 3 amoxicillin/clavulanate, and 6 other antibiotics).
Compared to placebo, use of antibiotics is associated with higher
proportion of cure or improvement [2785 patients, random effects model
(REM) odds ratio (OR)=1.60, 95% conﬁdence interval (CI)=1.31−1.96,
data from 16 RCTs], speedier resolution of symptoms, and a trend
towards fewer complications (1840 patients, REM, OR=0.36, 95%
CI=0.10−1.30, 9 RCTs). However, it is also associated with higher
proportion of adverse events (2228 patients, REM, OR=1.94, 95%
CI=1.29−2.92, 13 RCTs) although it is not associated with signiﬁcantly
more withdrawals due to adverse events (2705 patients, REM, OR=1.42,
95% CI=0.74−2.72, 15 RCTs).
Conclusion: Antibiotic treatment of presumed acute bacterial sinusitis
compared to placebo is associated with a rounded 10% added beneﬁt in
clinical outcomes, at a cost of an approximately equal increase in the rate
of adverse events. Considering that observed adverse events are generally
not serious, and that not using antibiotics may carry an appreciable risk
of disease complications, we believe that clinical beneﬁts obtained from
antibiotic use, justify the risks associated with such treatment.
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O79 Ertapenem for complicated intra-abdominal infections: a
meta-analysis of randomised controlled trials
M. Falagas, G. Peppas, G. Makris, D. Karageorgopoulos, D. Matthaiou
(Athens, GR)
Objective: Ertapenem has been FDA approved, among other indications,
for the treatment of complicated intra-abdominal infections (cIAIs).
Additional studies have been performed on its clinical use for this
important type of infections. We evaluated the effectiveness and safety
of ertapenem treatment for cIAIs.
Methods: We performed a meta-analysis of randomised controlled
trials (RCTs) that compared treatment with ertapenem versus other
antimicrobial regimens, in patients of all ages, with cIAIs. The primary
outcomes evaluated were clinical success (cure or improvement) in the
modiﬁed intention-to-treat population, and clinical adverse events. We
searched in PubMed, the Cochrane Central Register of Controlled Trials,
and Scopus database for relevant studies.
Results: Six RCTs (3 with a double-blind design; one per-
formed in children) that compared ertapenem treatment against
piperacillin/tazobactam, ceftriaxone plus metronidazole, and ticar-
cillin/clavulanic acid (in 3, 2 and 1 RCTs, respectively) were
included. No difference was found between patients treated with
ertapenem versus comparators, regarding clinical success (6 RCTs, 2067
patients, ﬁxed effect model (FEM), odds ratio =1.13, 95% conﬁdence
interval=0.90−1.41); clinical adverse events (5 RCTs, 1635 patients,
FEM, OR=0.81, 95% CI 0.59−1.13); microbiological success; mortality;
and withdrawals due to adverse events. Ertapenem was associated with
more laboratory adverse events (5 RCTs, 1633 patients, FEM, OR=1.63,
95% CI 1.09−2.44), but none was reported as serious.
Conclusion: This meta-analysis provides additional evidence that
ertapenem can be used as effectively and safely, as other recommended
antimicrobial regimens, for the treatment of complicated intra-abdominal
infections.
O80 Efﬁcacy and safety of linezolid versus vancomycin for the
treatment of complicated skin and soft-tissue infections
proven to be due to meticillin-resistant Staphylococcus aureus
K. Itani, J. Weigelt, D. Stevens, M. Dryden, H. Bhattacharyya, M. Kunkel,
A. Baruch (Boston, Milwaukee, New York, Boise, US; Winchester, UK)
Objectives: Linezolid (LZD) is an oxazolidinone antibiotic used to
treat infections caused by Gram-positive pathogens, including MRSA.
A randomised, open-label, controlled, multicentre phase 4 study was
conducted comparing LZD to vancomycin (VAN) in the treatment of
complicated skin and soft-tissue infections (cSSTI) proven due to MRSA.
Methods: Subjects 18 years with deﬁned, proven MRSA cSSTI were
randomised to receive either LZD (600 mg IV/PO q12h) or VAN
(15 mg/kg IV q12h, adjusted for CLCR) for 7−14 d. Aztreonam and
metronidazole coverage were permitted. The primary efﬁcacy endpoint
was clinical outcome at end of study (EOS; 7−10 d after the last dose) in
subjects with MRSA who met inclusion/exclusion criteria (per protocol
[PP] population). Secondary endpoints included clinical outcome at end
of therapy (EOT) and microbiological outcome at EOS and EOT as well
as analyses based on the modiﬁed intent-to-treat (mITT) population.
Noninferiority was assessed by a 2-sided 95% conﬁdence interval (CI)
for the difference in the success rate at EOS (delta = 10%).
Results: Subjects included 537 randomised to LZD and 515 to VAN, for
a total of 1052. There were 481 with abscess (243 LZD, 238 VAN), 234
with surgical wound infection (111 LZD, 123 VAN), 106 with diabetic
ulcer (61 LZD, 45 VAN), and 231 with other cSSTI (122 LZD, 109
VAN). 452 subjects were in the PP population (235 LZD, 217 VAN)
and 654 in the mITT group (329 LZD, 325 VAN). Success at EOS
was comparable between the 2 groups (193 LZD [83.2%] 171 VAN
[79.5%]; P = 0.321; 95% CI [−0.036, 0.109]) demonstrating that LZD
was noninferior to VAN (Table). For microbiological success, treatment
groups were comparable at EOS. At EOT, there was a statistically
signiﬁcant difference between LZD and VAN (211 LZD [85.8%]; 158
VAN [69.3%]; P = 0.000; 95% CI [0.091, 0.239]). Overall, in the
ITT population, the mean treatment durations were comparable for the
groups, with 8.8 d for LZD subjects and 7.6 d for VAN subjects. PP mean
IV treatment lasted 5.4 d (LZD) and 10.3 d (VAN). The 3 most common
drug-related adverse events were gastrointestinal (65 LZD [12.1%], 23
VAN [4.5%]), infection/infestation (26 LZD [4.8%], 10 VAN [1.9%]),
and skin/subcutaneous tissue disorder (10 LZD [1.9], 35 VAN [6.8%]).
There were 18 deaths: 11 LZD (2.0%), 7 VAN (1.4%), and 1 VAN
considered study drug-related.
Table. Clinical and microbiological response in the per protocol (PP) population
Linezolid
N (%)
Vancomycin
N (%)
P-value 95% CI
Clinical outcome EOT
Subjects in analysis 246 (100) 227 (100)
Success 224 (91.1) 199 (87.7) 0.231 (−0.022, 0.090)
Failure 22 (8.4) 28 (12.3)
Clinical outcome EOS
Subjects in analysis 232 (100) 215 (100)
Success 193 (83.2) 171 (79.5) 0.321 (−0.036, 0.109)
Failure 39 (16.8) 44 (20.5)
Microbiology outcome
EOT
Subjects in analysis 246 (100) 228 (100)
Success 211 (85.8) 158 (69.3) 0.000 (0.091, 0.239)
Failure 35 (14.2) 70 (30.7)
Microbiology outcome
EOS
Subjects in analysis 234 (100) 215 (100)
Success 174 (74.4) 147 (68.4) 0.160 (−0.024, 0.143)
Failure 60 (25.6) 68 (31.6)
Conclusion: LZD was at least as effective as VAN for the treatment of
proven MRSA cSSTI, and was well-tolerated.
O81 Fluoroquinolones versus b-lactam-based regimens for the
treatment of osteomyelitis: a meta-analysis of randomised
controlled trials
E. Karamanis, D. Matthaiou, L. Moraitis, M. Falagas (Athens, GR)
Objective: To compare ﬂuoroquinolones to b-lactams for the treatment
of osteomyelitis. Treatment of osteomyelitis remains a real challenge in
medicine necessitating the use of broad-spectrum antibiotics, because of
the variety of the pathogens causing the infection and the fact that the
infected bone may become necrotic and avascular preventing systemic
antibiotics from adequately penetrating to the infection site.
Methods: A literature search was performed by two reviewers
independently (PubMed database and the Cochrane Central Register of
Controlled Trials).
Results: We identiﬁed 7 studies eligible for inclusion in our meta-
analysis; ciproﬂoxacin, oﬂoxacin and peﬂoxacin were used in 3, 3,
and 1 study, respectively, while various b-lactams (mainly in the
intravenous form) were used as comparators. There was no difference
in treatment success for osteomyelitis between ﬂuoroquinolones and
b-lactams [194 patients, ﬁxed effect model (FEM), odds ratio (OR)=0.99,
95% conﬁdence interval (CI) 0.51−1.91], bacteriological success (201
isolates, FEM, OR=0.88, 95% CI 0.45−1.70), superinfections (173
patients, FEM, OR=1.75, 95% CI 0.63−4.90), relapses (153 patients,
FEM, OR=1.23, 95% CI 0.46−3.31), or adverse events (170 patients,
FEM, OR=0.47, 95% CI 0.21−1.06).
Conclusion: Fluoroquinolones are as effective as b-lactams for the
treatment of osteomyelitis and can be considered as a useful alternative
in the physician’s armamentarium. The value of ﬂuoroquinolones for the
treatment of osteomyelitis lies in the fact that they can be administered
in an outpatient setting. However, they should be used with caution, so
as to preserve their activity against increasingly resistant bacteria.
Molecular and clinical epidemiology of emerging MDR Gram-negatives S17
O82 Effectiveness and safety of short versus long duration of
antibiotic therapy for acute bacterial sinusitis: a meta-analysis
of randomised trials
M. Falagas, D. Karageorgopoulos, A. Grammatikos, D. Matthaiou
(Athens, GR)
Objectives: Traditionally, 10 to 14-day duration antibiotic therapy is
recommended for acute bacterial sinusitis (ABS). Shorter duration regi-
mens, if proven equally effective, may be associated with better patient
compliance and less toxicity, antimicrobial resistance development, and
economic burden. To evaluate the effectiveness and safety of short-course
antibiotic treatment for ABS compared to treatment of longer duration,
by performing a meta-analysis of randomised controlled trials (RCTs).
Methods: Relevant studies were retrieved by searching PubMed and the
Cochrane Central Register of Controlled Trials. We included RCTs that
compared short-course (up to 7 days) versus long-course therapy (at least
2 days longer than short-course), with the same antimicrobial agent, in
the same daily dosage, for patients with ABS.
Results: Twelve RCTs (10 with double-blind design) involving adult
patients with radiologically conﬁrmed ABS, were included. There
was no difference in the comparison of short-course treatment (3−7
days) to long-course treatment (6−10 days) regarding clinical success
(cure or improvement) [12 RCTs, 4430 patients, ﬁxed effect model
(FEM), odds ratio (OR)=0.95, 95% conﬁdence interval (CI)=0.81−1.12];
bacteriologic efﬁcacy (eradication or presumed eradication); relapses;
adverse events (10 RCTs, 4172 patients, random effects model, OR=0.88,
95% CI=0.71−1.09); or withdrawals due to adverse events. Findings were
not signiﬁcant in the subset analysis limited to b-lactam agents (6 RCTs).
In the sensitivity analysis comparing 5 to 10-day regimens (7 RCTs),
clinical success was not different but adverse events were fewer with
short-course treatment (5 RCTs, 2151 patients, FEM, OR=0.79, 95%
CI=0.63−0.98).
Conclusion: In patients with ABS, short-course antibiotic treatment
proved equally effective to a longer course with the same antibiotic. An
initial strategy of a shorter than traditionally recommended duration of
treatment may be favoured, particularly for patients without complicating
factors, considering the advantages of fewer adverse events and
potentially lower rates of resistance development.
O83 Efﬁcacy and tolerability of moxiﬂoxacin versus clindamycin
in the treatment of odontogenic abscesses and inﬂammatory
inﬁltrates (MOCLI Study)
G. Cachovan, I. Giersdorf, O. Hallier, T. Streichert, M. Haddad,
U. Platzer, R.H. Bo¨ger, K. Wegscheider, I. Sobottka (Hamburg, Berlin,
Rotenburg, DE)
Objectives: Odontogenic infections of bacterial origin penetrate primar-
ily into the soft and bony oromaxillofacial tissues to produce submucosal
inﬁltrates and abscesses there. These infections are typically mixed
infections, and anaerobic bacteria are thought to have a central aetiologic
role. Often taking a mild course, these infections may, depending on a
patient’s immunocompetence and the site of the inﬂammatory process,
also produce life-threatening complications. The availability of effective
and efﬁcient antibiotics for the treatment of odontogenic infections is
therefore essential. Preclinical studies have shown good oromaxillary
tissue penetration for moxiﬂoxacin (MXF), and early clinical reports
suggest that MXF may be effective in the treatment of odontogenic
infections. The objective of our study was to systematically evaluate the
efﬁcacy of MXF in a larger comparative clinical trial.
Methods: A prospective, randomised, double-blind, multicentre, phase
II trial compared the efﬁcacy and tolerability of MXF with that of
clindamycin (CLI) in the treatment of inﬂammatory inﬁltrates and
odontogenic abscesses. Patients received either MXF 400 mg once daily
or CLI 300 mg four times daily for 5 days. The primary efﬁcacy endpoint
was the percent reduction in patients’ perceived pain on a visual analog
scale (VAS) on day 2−3 from day 1.
Results: The primary endpoint analysis included 21 MXF-treated
patients and 19 CLI-treated patients with inﬂammatory inﬁltrates and
15 MXF and 16 CLI patients with odontogenic abscesses (intention-to-
treat population). Mean pain reduction among patients with inﬂammatory
inﬁltrates was 61.0% (SD, 46.9%) with MXF versus 23.4% (SD,
32.1%) with CLI (p = 0.006). Mean pain reduction among patients with
odontogenic abscesses was 55.8% (SD, 24.8%) with MXF versus 42.7%
(SD, 48.5%) with CLI (p = 0.358).
Conclusion: Moxiﬂoxacin was signiﬁcantly more effective at reducing
pain in patients with inﬂammatory inﬁltrates on day 2−3, compared with
clindamycin. No signiﬁcant differences between the treatment groups
were found among patients with odontogenic abscesses.
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O84 Association of plasmid-mediated quinolone resistance genes,
DHA-1 b-lactamase, and extended-spectrum b-lactamase
SHV-12 in Enterobacter cloacae isolated in Moroccco
M. Bouchakour, M. Timinouni, K. Zerouali, J.D. Perrier-Gros-Claude,
M.C. Ploy, N. El Mdaghri, P. Courvalin (Casablanca, MA; Limoges,
FR; Paris, FR)
Objective: To determine the genetic environment of qnr genes among
Enterobacteriaceae isolated at the university Hospital Ibn Rochd
Casablanca, Morocco.
Methods: Third generation cephalosporin resistant unrelated E. cloa-
cae strains (n = 8) have been isolated at the Ibn Rochd Hospital
(Casablanca) during a survey conducted between October 2006 and
March 2007. Antibiotic susceptibility (disc diffusion method and
MIC) and screening for Extended Spectrum Beta-Lactamase (ESBL)
were performed according to the French Society for Microbiology
guidelines. Characterisation of quinolone resistance genes (qnrA, qnrB,
qnrS, aac(6′)-Ib-cr) was investigated by PCR. Identiﬁcation of ESBL
(TEM, SHV, CTX-M1, CTX-M2, CTX-M8 and CTX-M9 groups) was
performed by PCR. Identiﬁcation of plasmid AmpC b-lactamases was
performed by multiplex PCR. All PCR products were sequenced on both
strands. Conjugation experiments were performed using azide-resistant
Escherichia coli K12J5 as a recipient strain.
Results: Among the 8 ESBL-producing strains, 4 were resistant to all
third generation cephalosporins tested except cefepime (MIC 1−4 mg/l).
qnrB4, DHA-1, TEM-1, SHV-12, aac(6′)-Ib-cr (except 1 strain with
aac(6′)-Ib) were identiﬁed in all strains. Transfer of plasmid DNA was
successfully obtained for 3 strains. Transconjugants were conﬁrmed to be
E. coli using biochemical tests. All transconjugants expressed resistance
to third generation cephalosporin except cefepime. With speciﬁc primers,
qnrB4, DHA-1, aac(6′)-Ib-cr were proved to be co-transferred for the 3
transconjugants. SHV-12 was co-tranferred in two transconjugants.
Conclusion: This study demonstrated the association between qnrB4,
aac(6′)-Ib-cr and DHA-1 determinants in E. cloacae strains isolated
in Casablanca. Moreover, this is the ﬁrst report of E. cloacae isolates
containing transmissible plasmid-mediated DHA-1.
O85 The high prevalence of plasmid-mediated quinolone
resistance gene (qnr) and aac(6′)-Ib-cr in clinical isolates of
Enterobacteriaceae from nine teaching hospitals in China
H. Wang, H. Yang, Q. Yang, L. Peng, H. Sun, Y. Xu, M. Chen (Beijing,
Shenzhen, CN)
Objective: To investigate the prevalence of plasmid-mediated quinolone
resistance qnr and aac(6′)-Ib-cr genes in Enterobacteriaceae in China.
Methods: A total of 197 of Escherichia coli, Klebsiella pneumoniae,
Citrobacter freundii, and Enterobacter cloacae, with ciproﬂoxacin 
0.25 ug/ml, cefotaxime 2.0 ug/ml) were screened from the 974 non-
repetitive clinical isolates collected from the nine teaching hospitals in
China. qnrA, qnrB, qnrS and aac(6′)-Ib genes were detected by PCR.
aac(6′)-Ib-cr gene was further identiﬁed by the digestion with BtsCI
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and direct sequencing. Conjugation experiment was performed for 20
isolates. Plasmid AmpC and ESBL genes were detected by PCR for the
transconjugants. The MIC of ciproﬂoxacin and other antibacterial agents
were determined by agar dilution.
Results: Qnr was present in 65.7% of E. cloacae, 65.5% of
K. pneumoniae, 63.3% of C. freundii, and 6.5% of E. coli, respectively.
aac(6′)-Ib-cr was found in 8.6% of E. cloacae, 21.8% of K. pneumoniae,
26.7% of C. freundii, and 16.9% of E. coli, respectively. Seventeen
isolates carried qnrA, 46 isolates with qnrB, 24 with qnrS, 2 with qnrA
and qnrB, and 2 with qnrB and qnrS. Eighteen isolates carried both
qnr and aac(6′)-Ib-cr. The 13 transconjugants showed 16- to 250-fold
increases in the MICs of ciproﬂoxacin compared to that of the recipient.
Six transconjugants carried plasmid AmpC enzyme (including DHA,
ACT and CMY-like) and 7 produced CTX-M ESBL.
Conclusions: Qnr and aac(6′)-Ib-cr widely existed in the enterobacteri-
aceae and perhaps contribute to the rapid increase of bacterial resistance
to quinolones in China.
O86 Independent emergence of quinolone resistance in CTX-M-5
b-lactamase-producing isolates of Salmonella typhimurium
from Russia, Belarus and Kazakhstan
V. Kozyreva, D. Tapalski, I. Azizov, M. Edelstein (Smolensk, RU;
Gomel, BY; Karaganda, KZ)
Objectives: Extended-spectrum cephalosporins and quinolones are
used as primary treatment for severe salmonellosis. Therefore, the
emergence of simultaneous resistance to these drugs in clinical isolates
of Salmonella is of great therapeutic concern. This study was performed
to investigate the molecular epidemiology of resistance to cefotaxime
(CTX) and nalidixic acid (NA) among S. Typhimurium (Sty) isolates
from Russia, Belarus and Kazakhstan.
Methods: A total of 44 clinical Sty isolates collected in 2002−07
were studied including 11 from Gomel region (Belarus), 24 from
Irkutsk, Smolensk and Voronezh regions (Russia) and 9 from Karaganda
(Kazakhstan). Four additional CTX-M-5-producing strains isolated in
1996−99 in various regions of Russia and Belarus and reported earlier
to belong to a single clonal group [Edelstein et al. 2004] were included in
this study for comparison. Susceptibility testing was performed by agar
dilution method according to CLSI guidelines. Molecular typing was
done using ﬂuorescent multiple-locus variable-number tandem-repeats
analysis (MLVA). PCR and sequencing were used to identify the CTX-M
b-lactamase genes and to characterise their genetic context as well as
to determine the gyrA QRDR sequences. The CTX-M-coding plasmids
were compared using RFLP analysis with PstI and PvuII endonucleases.
Results: All the isolates studied shared a common phenotype of CTX
resistance reversible by clavulanic acid. The resistance was due to
production of CTX-M-5 ESBL whose gene was associated with ISEcp1
element and located on small (~7.4 kb) plasmid exhibiting identical
RFLP pattern in all the isolates. Eighteen isolates were resistant to
NA, none of them were resistant to ciproﬂoxacin. MLVA grouped the
isolates into 8 types linked to each other with only 1 or 2 VNTR
loci distinguishing each type. The quinolone-resistant isolates were
distributed among 6 MLVA types, 3 of which also included NA-
susceptible isolates. Resistance to NA strongly correlated with the
presence of known mutations: Ser83-Phe, Asp87-Asn, -Tyr, or -Gly
in the GyrA QRDR sequences which were otherwise identical in all
isolates. Notably, the isolates of different MLVA types had different GyrA
mutations.
Conclusions: This study supports the clonal origin of CTX-M-5-
producing Sty isolates which continue to spread in Russia, Belarus
and Kazakhstan and provides the evidence of frequent and independent
acquisition of quinolone resistance among these isolates.
O87 A nationwide survey of extended-spectrum b-lactamases and
metallo-b-lactamases produced in Pseudomonas aeruginosa in
France, 2007
D. Hocquet, P. Ple´siat, B. Dehecq, H. Varlet, D. Talon, X. Bertrand
on behalf of the ONERBA
Objectives: The aim of this study was (i) to evaluate the incidence
of ESBL- and MBL-producing Pseudomonas aeruginosa (PA) in a
representative panel of French hospitals in 2007 and (ii) to identify the
b-lactamases responsible for the resistance to cefazidime (CAZ).
Methods: Isolates of PA resistant to CAZ, according to the French
criteria (MIC> 32mg/l), were collected from diagnostic samples in 85
participating medical centres during June 2007. Cystic ﬁbrosis samples
were excluded. Resistance to CAZ was conﬁrmed by agar diffusion
in the reference laboratory. Chromosomally-encoded cephalosporinase
overproduction was assessed by isoelectrofocusing. ESBLs and MBLs
were identiﬁed by isoelectrofocusing and gene sequencing.
Results: One-hundred and forty-three of the 2,200 isolates collected
were resistant to CAZ (6.5%). Incidence of CAZ-resistant PA ranged
from 0 to 50% according to the centres. Average incidence of
patient infected/colonised with a CAZ-resistant PA was 0.1 per 1000
days of hospitalisation (from 0 to 0.72). Overproduction of AmpC
cephalosporinase was observed in 142 strains (99.3%). Sixteen isolates
were found to harbor an additional ESBL: OXA-19-like (n =11), OXA-28
(n = 1), PER-1 (n = 2), SHV2a (n = 1) or unidentiﬁed enzyme (n = 1).
Two isolates expressed an additional MBL (VIM-2 and an unidentiﬁed
enzyme). Incidence of ESBL-producing isolates among CAZ-resistant
PA was much higher (11.2%; 0.7% of the whole collection) than that of
MBL-producing isolates 0.01%.
Conclusion: These results show the variability in term of frequency
and incidence in PA resistance to CAZ among French hospitals.
Resistance to CAZ and to imipenem in France is mostly related to the
overproduction of cephalosporinase AmpC and to the underexpression of
porin OprD, respectively. Interestingly, eleven out of 16 BLSE-producing
isolates expressed an OXA-19-like enzyme. Routine tests (double-disk
synergy and inhibition by cloxacillin) failed to detect this OXA-type
ESBL, which is poorly inhibited by clavulanic acid while inhibited
by cloxacillin, like AmpC. In conclusion, ESBL- and MBL-producing
PA are still rather unfrequent in France, with the predominance of an
underrecognised OXA-type ESBL.
O88 Study of the molecular epidemiology of metallo-b-lactamase-
producing Klebsiella pneumoniae in Greece
S. Vourli, P. Giakkoupi, M.Z. Polemis, A.C. Vatopoulos on behalf of
the Greek Network for the Surveillance of Antimicrobial Resistance
Objectives: Greece suffers since 2002 from an extensive epidemic of
infections in hospitalised patients, due to metallo-b-lactamase (MBL)-
producing Klebsiella pneumoniae. Our study aimed to contribute to
the understanding of the molecular epidemiology of MBL-producing
K. pneumoniae isolated in Greek hospitals.
Methods: Forty-ﬁve MBL-producing K. pneumoniae clinical isolates
from ten hospitals, isolated during the ﬁrst semester of 2006, were
studied. Susceptibility levels to b-lactams were deﬁned by standard
methods. MBL-production was assessed based on the Imp-EDTA disk
synergy test and conﬁrmed by PCR. Integron structure was preliminary
assessed by PCR. Typing was performed by PFGE. Representative strains
were used as donors in mating experiments.
Results: All isolates were resistant to 3rd generation cephalosporins, but
MICs to imipenem varied signiﬁcantly. The Imp-EDTA disk synergy test
was positive for all isolates. PCR revealed the presence of blaVIM-
1 genes, related to class 1 integrons. Typing of strains showed ﬁve
genetic types. All but three hospitals had more than one type. Typing
revealed also the occurrence of clonal epidemics in two hospitals. Mating
experiments revealed the presence of self transferable VIM-harboring
plasmids in only two of the ﬁve types.
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Conclusions: Increase of carbapenem resistant K. pneumoniae in Greek
hospitals seems to be accompanied by the emergence and intra- and
inter-hospital spread of multiple VIM-producing clones. Clonal spread
identiﬁed in some occasions underlines the need of thorough infection
control, as a key issue in the strategy to contain the epidemic
O89 Emergence of metallo-b-lactamase producing Pseudomonas
aeruginosa and Klebsiella pneumoniae in Scandinavia
Ø. Samuelsen, L. Buarø, B. Aasnæs, K. Fuursted, B. Haldorsen,
T. Leegaard, Y. Rajendra, J. Rydberg, G.S. Simonsen, M.A. Toleman,
M. Walder, D. Yong, T.R. Walsh, A. Sundsfjord, C.G. Giske (Tromsø, NO;
Aarhus, DK; Oslo, NO; Stockholm, Lund, SE; Cardiff, UK; Malmo¨, SE)
Objectives: Scandinavian countries have a history of low levels of
antibiotic resistance due to effective infection control measures and
restricted use of antibiotics. New resistance mechanisms are therefore
less likely to emerge from endogenous sources. This study assesses the
epidemiology and characterisation of MBL producing clinical isolates
detected in Denmark, Norway, and Sweden between 2003–2007.
Methods: MBL genes and their genetic support were evaluated by PCR
and DNA sequencing, while epidemiological typing of host isolates
was performed by pulsed-ﬁeld gel electrophoresis (PFGE), multilocus
sequence typing (MLST) and serotyping. Susceptibility testing was
performed with Etest.
Results: Since the ﬁrst MBL positive isolate was identiﬁed in Sweden in
2003, a total of 17 MBL isolates have been identiﬁed in Norway, Sweden
and Denmark by 2007, including eleven Pseudomonas aeruginosa strains
and six Klebsiella pneumoniae strains. Many of the infected patients
have a history of recent hospitalisation outside Scandinavia including
Southern-Europe, Asia and Africa. However, MBL isolates are now
being identiﬁed in patients precluding travel or hospitalisation outside
Scandinavia in the last twelve months. VIM-enzymes constitute the
predominant MBL genotype, found in all K. pneumoniae isolates and ten
P. aeruginosa isolates. IMP was detected in one P. aeruginosa isolate.
Genetic characterisation of the isolates revealed that the genes encoding
MBL are located in class 1 integrons including TniC-class 1 integrons
of variable size and with a plethora of other resistance gene cassettes.
Accordingly, the susceptibility proﬁles of the isolates show a multi-drug
resistant phenotype and some isolates are only susceptible to colistin.
Interestingly, the qnrS gene, conferring low-level quinolone resistance,
was identiﬁed in the two Norwegian K. pneumoniae isolates. Serotyping
of P. aeruginosa indicate that O11 and O12 isolates predominate, and
some isolates within the serotypes were found to be related by PFGE
and MLST.
Conclusion: The spread of MBL-producing clinical isolates to
Scandinavia is likely to initially have occurred through importation of
the MBL positive isolates. However, such isolates have now appeared in
patients with no history of travel or hospitalisation outside Scandinavia.
VIM was the dominant MBL and always present in a multi-drug resistant
background. PFGE and MLST revealed that some isolates of the same
serotype were related.
O90 Complex emergence of VIM-1 producing Pseudomonas
aeruginosa in Spain during epidemics involving VIM-1
producing Enterobacteriaceae
M. Tato, M.T. Coque, F. Baquero, R. Canto´n (Madrid, ES)
Objectives: Acquired metallo-betalactamases (MBL)-producing isolates
are uncommonly described in Spain and mostly conﬁned to VIM-2
and P. aeruginosa. We describe the emergence of VIM-1 producing
P. aeruginosa isolates in our hospital during epidemics involving
different VIM-1 producing enterobacterial species (Tato et al. CID 2007;
24:472−3) and identiﬁed the genetic context of blaVIM-1.
Methods: Two MBL producing P. aeruginosa isolates (PA1 and PA2)
were recovered in April-2006 and January-2007, respectively. MBL
production was detected by the double-disc synergy test (EDTA-10mcl
0.5M versus imipenem and ceftazidime). Clonal analysis was determined
by SpeI-PFGE. PCR for blaVIM, class 1 integron, and Tn402 sequences
was performed and further sequenced. Transfer of antibiotic resistance
was determined by ﬁlter-mating using P. aeruginosa PAO1 strain.
Results: PFGE revealed different restriction patterns for these P. aerugi-
nosa isolates. blaVIM-1 gene was located within class 1 integrons in both
cases. In PA1, the MBL gene was carried by a Tn402 derivative lacking
the 3′CS but containing tniCTn402 (blaVIM-1-aadB-tniC). A different
class 1 integron was detected in PA2 (blaVIM-1-aadA1). These integrons
were also different to those found in contemporary MBL-enterobacterial
isolates in our hospital. blaVIM-1 gene was transferred (frequency range
10−5–10−7).
Conclusions: We ﬁrstly report VIM-1 producing P. aeruginosa in
our country. The integron platforms containing blaVIM-1 gene in
these isolates were different to those found in enterobacterial species
contemporarily recovered during a VIM-1-Enterobacteriaceae epidemics
in our hospital. Dissemination of blaVIM-1 gene was associated with
different genetic structures and bacterial hosts, depicting complex
scenario of this emerging threat in our hospital.
O91 Predisposing factors for CTX-M or SHV extended-
spectrum b-lactamase-producing Escherichia coli in
community-acquired infections
J. Rodrı´guez-Ban˜o, J. Alcala´, J. Cisneros, F. Grill, A. Oliver,
J. Horcajada, T. To´rtola, B. Mirelis, G. Navarro, M. Cuenca, M. Esteve,
C. Pen˜a, A. Llanos, R. Canto´n, A. Pascual on behalf of REIPI
Objectives: Extended-spectrum b-lactamase-producing Escherichia coli
(ESBLEC) is an increasingly signiﬁcant cause of community-acquired
(CA) infections worldwide. While much attention has been paid to
CTX-M-producing isolates, there is scarce data about the epidemiology
of SHV in the community. We compared the epidemiological features
of CTX-M and SHV-producing ESBLEC causing community-acquired
infections.
Methods: A multicentre cohort study including all CA infections caused
by ESBLEC from 4 geographical areas in Spain was performed (Feb-
2002 to May-2003). ESBL production was inferred following CLSI
recommendations. ESBL was characterised by IEF, PCR and sequencing.
The following data were collected: demographics, previous healthcare
relation, co-morbidities, use of antimicrobials, invasive procedures and
type of infection. Patients with CTX-M and SHV-producing isolates were
compared using logistic regression.
Results: 122 cases (95% urinary tract infections) were included. ESBL
was characterised in 112 isolates; 77 isolates (69%) produced CTX-M
enzymes (40 produced CTX-M-9, 25 CTX-M-14), 36 (32%) SHV (31
SHV-12), and 7 (6%) TEM (4 TEM-116); 8 isolates produced >1
ESBL. Also, TEM-1 was produced by 52 isolates. CTX-M were the
most frequent ESBL in the 4 areas (range, 56%-82%). Patients with
isolates producing only CTX-M enzymes (CTX-M group, n = 70) and
only SHV enzymes (SHV group, N=31) were compared; 70% of patients
in the CTX-M group and 42% in the SHV group were >60 years old
(p = 0.08); Charlson index >2 was found in 14% of patients in the
CTX-M group and in 32% in the SHV group (p = 0.03). No differences
in underlying diseases, previous healthcare relation, invasive procedures,
antibiotic use or type of infections were found. Multivariate analysis
including the geographical area showed that Charlson index >2 (OR=4.0,
IC 95%: 1.2−12.6) was associated with SHV isolates, while age >60
(4.7; 1.7−12.5) was associated with CTX-M isolates.
Conclusions: SHV-producing ESBLEC are also a signiﬁcant cause of
community-acquired infections in Spain; the clinical epidemiology of
such isolates seems much similar to CTX-M-producing ESBLEC. These
data suggest that SHV-producing E. coli are also spreading in the
community.
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O92 Emergence of ciproﬂoxacin-gentamicin resistant Escherichia
coli: implications for the empirical management of urinary
tract infections
M. Plamondon, J. Pe´pin, C. Lacroix, S. Deslandes, I. Alarie, E´. Frost
(Sherbrooke, CA)
Objectives: An increased incidence of urinary tract infections (UTI)
caused by ciproﬂoxacin-gentamicin resistant E. coli (CiGREC) has been
observed in our hospital, a tertiary care centre in Canada. Thus, we
aimed to determine the risk factors associated with CiGREC UTI and
its outcomes, in order to improve the empirical management of patients
with UTI pending results of in vitro susceptibility.
Methods: A case control study was conducted between 2000 and 2007.
Eighty-four cases and 168 randomly selected controls were identiﬁed
using laboratory records of patients with >108 CFU of E. coli in a
urinary specimen. Cases had E. coli with MIC to ciproﬂoxacin >2ug/L
and MIC to gentamicin >8ug/L (CiGREC), and controls had E. coli with
any other susceptibility pattern to ciproﬂoxacin and gentamicin. Clinical
and laboratory data were collected. Univariate and multivariate analyses
were used for case-control comparisons.
Table 1. Risk factors associated with urinary infection with a
ciproﬂoxacin–gentamicin resistant strain of Escherichia coli
Cases
(n = 84)
Controls
(n = 168)
p-value
Age
<18 4 (5%) 40 (23%) <0.001
18–64 29 (35%) 78 (46%)
65 51 (60%) 50 (31%
Sex
Male 36 (57%) 126 (25%) 0.005
Female 48 (43%) 42 (75%)
Charlson score
0 24 (29%) 86 (51%) 0.001
1−3 35 (42%) 56 (33%)
4 25 (30%) 26 (16%)
Underlying urologic abnormality
Yes 60 (71%) 74 (44%) <0.001
No 24 (29%) 94 (56%)
Acquisition
Community acquired 21 (25%) 78 (46%) <0.001
Healthcare associated 26 (31%) 40 (24%)
Nosocomial 37 (44%) 50 (30%)
Received quinolones in the last month
Yes 36 (44%) 9 (5%) <0.001
No 45 (56%) 158 (95%)
Received quinolones in the last year
Yes 32 (40%) 18 (11%) <0.001
No 47 (60%) 150 (89%)
Results: Prevalence of CiGREC increased four-fold during the study
period, from 0.5% to 2.1%. Strains resistant to both ciproﬂoxacin
and gentamicin were more likely than susceptible strains to harbour
concomitant resistance to TMP-SMX (62% vs 11%), ampicillin (90%
vs 26%) and tobramycin (47% vs 0.4%) (all with p< 0.001), but
conserved susceptibility to carbapenems. Risk factors associated with
urinary tract infection with the resistant strain were: advanced age, male
sex, underlying urologic abnormality, presence of comorbidities with a
Charlson score >4, previous use of quinolones in the last month or
year and hospital or healthcare acquisition (see table 1). Cases were
also more likely to receive inactive antibiotics during the ﬁrst 48h of
treatment (70% vs 28%, p< 0.001) and even after the documentation
of the resistance (37% vs 2%, p< 0.001). They also experienced more
frequent relapses (28% vs 15%, p = 0.03) and a higher mortality than
controls (6% vs 0%, p = 0.04).
Conclusion: The incidence of CiGREC as a cause of urinary tract
infection is increasing in our hospital and impacts on the outcomes of
our patients. Ciproﬂoxacin and gentamicin should no longer be used as
empirical treatment of UTI among patients who have received quinolones
in the previous year.
O93 Risk factors associated with the isolation of colistin-resistant
Gram-negative bacteria: a matched case-control study
D. Matthaiou, A. Michalopoulos, P. Rafailidis, D. Karageorgopoulos,
V. Papaioannou, G. Ntani, G. Samonis, M. Falagas (Athens, GR)
Objective: The emergence of multidrug resistant Gram-negative
bacteria, has led to the re-use of colistin, but resistance to this
agent has already been reported. We aimed to investigate the
potential risk factors for the isolation of colistin-resistant Klebsiella
pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa
from hospitalised patients.
Methods: We performed a matched case-control study in a tertiary care
hospital in Athens, Greece. Case patients were those that had provided
a clinical specimen from whom a colistin-resistant K. pneumoniae,
A. baumannii, and P. aeruginosa was isolated. Controls were selected
from a pool of patients with susceptible to colistin isolates and were
matched (1:1) to cases for species of microorganism and site of isolation.
Susceptibility to colistin was determined with the E-test. Data regarding
patient demographics, comorbidities, admission to the intensive care
unit (ICU), prior antibiotic use, and invasive procedures performed
were analysed as risk factors in a matched bivariable model. Variables
signiﬁcantly associated with colistin-resistant isolates (p< 0.05) were
entered in a backward multivariable logistic regression model.
Results: Forty-one colistin-resistant unique patient isolates were
identiﬁed from 01/01/2006 until 31/03/2007. These isolates represented
infection in 35/41 patients. Risk factors signiﬁcantly associated with
the isolation of colistin-resistant isolates were age, duration of ICU
stay, duration of mechanical ventilation, surgical procedures, use of
colistin, use of monobactams, and duration of use of 3rd generation
cephalosporins. In the multivariable model, use of colistin was identiﬁed
as the only independent risk factor (adjusted odds ratio=7.78, p = 0.002).
Conclusion: Colistin-resistant K. pneumoniae, A. baumannii, and
P. aeruginosa pathogens may be encountered in clinical practice, in
association with inappropriate colistin use. To prevent this phenomenon,
colistin should be used judiciously, given that treatment options for
colistin-resistant Gram-negative bacteria are currently limited.
Interesting cases of susceptibility and
resistance to antibiotics
O94 Reversal of meticillin resistance in Staphylococcus aureus by
thioridazine
J.K. Christiansen, M.N. Skov, B.H. Kallipolitis, H.J. Kolmos (Odense,
DK)
Objectives: Thioridazine, a phenothiazine agent, has been shown to
reverse oxacillin (meticillin) resistance in meticillin-resistant Staphylo-
coccus aureus (MRSA) in vitro. The mechanism behind this observed
effect has not yet been clariﬁed. The aim of this study was to determine
if thioridazine, alone or in combination with oxacillin affects the
transcription of the meticillin resistance gene, mecA and the protein
level of the coding protein, Penicillin Binding Protein 2a (PBP2a).
Methods: Growth of MRSA (ATCC 33591) was examined in liquid
media in the presence of the meticillin analogue oxacillin and the
non-antibiotic thioridazine alone and in combination. Furthermore, the
transcription of mecA was analysed by Northern blotting and Primer
extension and the protein level of PBP2a was analysed by Western
blotting under the same conditions.
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Results: We observed an increased susceptibility of MRSA towards
oxacillin in the presence of oxacillin and thioridazine compared to
bacteria grown with oxacillin or thioridazine alone. Transcription of
mecA was reduced with increasing concentrations of thioridazine in
the presence of oxacillin compared to bacteria grown with oxacillin
or thioridazine alone. Additionally, the protein level of PBP2a was
reduced when bacteria were treated with the combination of oxacillin
and thioridazine. Thioridazine itself did not affect the growth of MRSA
or mecA and PBP2a.
Conclusion: Results of the present study indicate that reversal of
meticillin resistance by thioridazine in MRSA may be explained by a
reduced transcription of the meticillin resistance gene, mecA, and protein
level of the coding protein, PBP2a.
O95 Determination of the minimum inhibitory concentration and
mutant prevention concentration of tigecycline against clinical
isolates of meticillin-resistant Staphylococcus aureus: impact
of blood on susceptibility results
C. Hesje, S. Borsos, J. Blondeau (Saskatoon, CA)
Objectives: Tigecycline, a member of a new class of antimicrobials
(glycylcyclines) has been shown to have in vitro activity against
clinical isolates of meticillin-resistant (MR) Staphylococcus aureus (SA)
by minimum inhibitory concentration (MIC) measurements. We were
interested in determining if the low MIC values would translate into low
MPC values and to investigate if the presence of blood in the test media
inﬂuences the mutant prevention concentration (MPC) results.
Methods: MIC was in accordance with the recommended CLSI
procedure by microbroth dilution using 105 cfu/ml tested against
doubling drug dilutions in appropriate media. For MPC testing 1010
CFUs were added to drug containing agar plates: 1) Mueller-Hinton
(MH) agar without blood, 2) MH with 5% sheep red blood cells
(MH+SRBC). The lowest drug concentration preventing growth was
recorded as the MIC or MPC depending on method.
Results: For the MRSA strains (n = 29) MIC50, MIC90 and MIC range
values (mg/ml) were 0.125, 1 and 0.063−1. By MPC testing on MH, the
MPC50, MPC90 and MPC range values (ug/ml) were 1, 4 and 0.5−4; on
MH+SRBC, the values respectively were 0.5, 4, 0.5−4. In all instances,
MPC values were the same or within 1 doubling dilution on MH or
MH+SRBC.
Conclusion: By MIC testing, tigeycline was highly active in vitro against
MRSA strains with MICs 1 ug/ml. Tigecycline MPC values were
2 ug/ml for 80% of MRSA strains and not inﬂuenced by blood
in the test media. Tigecycline appears to be a promising agent for
treating Staphylococcus aureus infections and appears to have a reduced
likelihood for selecting for resistance based on MPC measurements.
O96 Comparative antibacterial activity of retapamulin,
cephalothin, gentamicin and erythromycin against Staphylo-
coccus aureus, including molecularly characterised isolates of
MRSA recovered from uncomplicated skin infections
N. Scangarella, R. Shawar, G. Li, M. Twynholm, M. Dalessandro,
J. Breton, J. West, L. Miller, P. O’Hara, J. Becker, H. Madsen,
R. Goering, D. Payne (Collegeville, US; Greenford, UK; Research
Triangle Park, Omaha, US)
Objectives: In order to better recognise differences in susceptibility
proﬁles, the in vitro activity of retapamulin, a new topical antibacterial
agent, and comparators was determined against Staphylococcus aureus,
including molecularly characterised isolates of MRSA from uncompli-
cated skin infections.
Methods: Bacterial isolates were obtained from the skin specimens of
patients enrolled in ﬁve global phase III clinical trials conducted to
evaluate the safety and efﬁcacy of retapamulin. Susceptibility testing
was conducted according to current CLSI standards. Susceptibility to
retapamulin, cephalothin, gentamicin and erythromycin was determined
on all S. aureus isolates using broth microdilution panels and
susceptibility to meticillin was determined by disk diffusion using
cefoxitin and/or oxacillin disks. All meticillin-resistant Staphylococcus
aureus (MRSA) isolates were further analysed by pulsed-ﬁeld gel
electrophoresis (PFGE), multilocus sequence typing, SCCmec typing,
and testing for the Panton-Valentine leukocidin genes.
Results: The overall rate of meticillin resistance among S. aureus
isolates was 7% (105/1,442). Of the 105 MRSA isolates, 50% (53) were
determined to be USA300. MIC90s (mg/mL) against S. aureus isolates
obtained at the baseline visit are shown in the table.
Retapamulin demonstrated excellent in vitro activity against all S. aureus
with a MIC range of 0.008−0.5mg/mL and MIC90s of 0.12mg/mL.
Erythromycin demonstrated poor in vitro activity against all S. aureus
with MIC90s of 32mg/mL. Based on MIC90 values, gentamicin was
>128-fold more active and cephalothin was 32-fold more active against
USA300 MRSA isolates than against non-USA300 MRSA isolates.
Conclusions: Retapamulin was highly active in vitro against all S. aureus
tested, irrespective of meticillin resistance or PFGE type. However, the
MIC results for cephalothin and gentamicin suggest a possible difference
between in vitro activity against USA300 and non-USA300 MRSA types.
It should be noted that in vitro activity does not always correlate with
clinical efﬁcacy.
Baseline Pathogen (n) MIC90 (mg/mL)
Retapamulin Cephalothin Genta-
micin
Erythro-
mycin
S. aureus (1,442) 0.12 1 1 32
MRSA (105)* 0.12 64 64 32
USA300 (53) 0.12 4 0.5 32
Non-USA300 (52) 0.12 128 64 32
MSSA (1,333) 0.12 0.5 0.5 32
*3 MRSA isolates for which meticillin resistance could not be conﬁrmed
were removed from this analysis.
O97 Bactericidal activity of iclaprim in rat and human ﬁbrin clots
against wild type and thymidine kinase-deﬁcient MRSA
J.M. Entenza, A. Haldimann, M. Giddey, S. Lociuro, S. Hawser,
P. Moreillon (Lausanne, Reinach, CH)
Background and Objectives: Iclaprim is a novel diaminopyrimidine
with potent activity against Gram-positive bacteria, including meticillin-
resistant Staphylococcus aureus (MRSA). It is known that uptake of
thymidine (dT) and its conversion in dT-monophosphate by thymidine
kinase (TK) bypass the activity of diaminopyrimidines. dT levels in
rodents are very high and antagonize diaminopyrimidine, thus precluding
reliable evaluation of their efﬁcacy in vivo. On the contrary, dT levels
in humans are low and do not affect their activity. It is hypothesised that
iclaprim should be effective against MRSA in a human environment and
that its efﬁcacy should be restored in a rodent milieu using TK-deﬁcient
strains. We tested this concept in human and rat ﬁbrin clots in vitro,
simulating amorphous cardiac vegetations in vivo.
Methods: MICs of iclaprim were tested in MHB and in MHB
supplemented with 25% human serum (MHB-HS), 25% rat serum
(MHB-RS) or an excess (1 mg/L) of dT (MHB-dT). Fibrin clots were
made from human or rat plasma containing the parent MRSA AW6 or its
TK-deﬁcient derivative AH1252, and treated for 48h with homologous
serum supplemented with either saline (controls), iclaprim (3.5 mg/L),
trimethoprim-sulfamethoxazole (SXT) (8−40 mg/L) or vancomycin (40
mg/L). The extent of drug exposure mimics standard treatment length
in animal models of endocarditis.
Results: MICs of iclaprim in MHB/MHB-HS/MHB-RS and MHB-dT
were 0.06/0.06/>2/>2 for AW6 and 0.03/0.03/0.06/0.03 for AH1252.
Median CFU/clot values in controls as well as in clots after drug
treatment are shown in the Table.
S22 18th ECCMID, Oral presentations
CFU/clot values, Human/Rat
Controls Iclaprim SXT Vancomycin
AW6 0 h 6.56/6.21
48 h 8.81/8.67 3.20†/5.89 2.84†/5.96 2.30†/2.00†‡
AH1252 0 h 6.68/6.32
48 h 8.97/8.97 2.15†/3.46†# 2.00†/3.44†# 2.00†/2.00†
† p< 0.05 vs controls at 0 h; ‡ p< 0.05 vs ICL and SXT; # p< 0.05 vs
AW6 in rat clots.
Conclusions: Iclaprim was bactericidal in human clots against both wild
type AW6 and TK-deﬁcient AH152 strains, and was equipotent to SXT
and vancomycin. Iclaprim was bacteriostatic against parent AW6 in rat
clots but killed the TK-deﬁcient mutant AH1252 in the same media.
The bactericidal activity of iclaprim against MRSA in human clots, a
setting mimicking the intravascular milieu, shows the potential of this
drug for the treatment of MRSA infections in humans. TK-deﬁcient
mutants could also prove useful for studies of diaminopyrimidines in
rodents.
O98 Inﬂuence of thymidine on bactericidal activity of iclaprim
against vancomycin-intermediate and vancomycin-resistant
Staphylococcus aureus strains
G. Pankuch, P. Appelbaum (Hershey, US)
Background: Iclaprim is a bactericidal diaminopyrimidine antibiotic that
exhibits potent and bactericidal activity against Gram-positive pathogens,
notably MRSA. Previous studies have shown that excess thymidine
(1mg/ml) in the growth medium abolishes the bactericidal effect of
the drug in vitro. Importantly, thymidine levels in humans are extremely
low (0.01mg/ml). This study used time-kill analysis to determine the
effects of adding or removing excess thymidine in growth medium on the
bactericidal potential of iclaprim against one vancomycin intermediate
(VISA) and one vancomycin resistant (VRSA) S. aureus isolate.
Methods: Media included 1) Oxoid Mueller-Hinton broth, previously
proven to have minimal amounts of thymidine; 2) The latter Oxoid broth
+ 2mg/ml thymidine; 3) BBL cation adjusted Mueller-Hinton broth +
0.2 units/ml thymidine phosphorylase; 4) BBL cation-adjusted Mueller-
Hinton broth + 2mg/ml thymidine. MICs were by CLSI macrodilution
in each of the four above media. For time-kills organism suspensions
(5×105–5×106 cfu/ml) were incubated overnight with iclaprim at MIC,
2 x MIC and 4 x MIC in all four media, in a shaking water bath at 35ºC.
Viability counts were done at 0, 3, 6, 12, and 24 h on BBL trypticase
soy agar plates + 5% sheep blood.
Results: Iclaprim MICs for the VRSA and VISA were as follows:
1) Oxoid Mueller-Hinton broth without added thymidine: 0.06 and
0.25mg/ml, respectively. 2) Cation-adjusted Mueller-Hinton broth with
thymidine phosphorylase: 0.12 and 0.5mg/ml respectively. On BBL
medium with no added thymidine or thymidine phosphorylase, iclaprim
MICs were 0.125 and 0.25 mg/ml, respectively. Iclaprim MICs were
>8.0mg/ml after 2mg/ml thymidine was added to either media. Iclaprim
at 2 x MIC showed 3 log10 (99.9%) killing after 12 h in Oxoid
Mueller-Hinton broth and BBL cation-adjusted Mueller-Hinton broth
with thymidine phosphorylase. By contrast, no killing by iclaprim
occurred in either media after adding thymidine (2 mg/ml).
Conclusions: Iclaprim yielded low MICs and was bactericidal against
VRSA and VISA strains when tested in broth media without signiﬁcant
levels of thymidine. For accurate determination of the bactericidal
activity of iclaprim, media without signiﬁcant levels of thymidine should
be used.
O99 In vitro activity of gallium against meticillin-susceptible and
meticillin-resistant Staphylococcus aureus and S. epidermidis
D. Baldoni, A. Steinhuber, W. Zimmerli, A. Trampuz (Basel, CH)
Objectives: Gallium (III) is a semi-metallic element physically similar
to iron (III) and competes for iron-binding sites of transporters and
enzymes. Since gallium (III) is not reducible like iron (III), it is unable
to participate in biologically important redox reactions, which represents
the presumed mode of antimicrobial action. We investigated the in
vitro anti-staphylococcal activity of gallium maltolate (GaM), an oral
formulation with good bioavailability and a favourable safety proﬁle in
clinical studies.
Methods: GaM in vitro susceptibility was performed in triplicate by a
macrodilution assay with 105 CFU/mL in iron-limited RPMI 1640 for
determination of MIC and logarithmic MBC (MBClog) or in PBS for
determination of stationary MBC (MBCstat). The following standard
strains were tested: S. aureus ATCC 29213 (MSSA), S. aureus ATCC
43300 (MRSA), S. epidermidis 1457 (MSSE) and S. epidermidis B3972
(MRSE). Time-kill studies were performed with GaM at 105 CFU/mL
in RPMI 1640 over 24 h (for MSSA) or 48 h (for MSSE) and expressed
as reduction of viable counts in log CFU/mL.
Results: GaM MIC/MBClog/MBCstat values were (in mg/mL):
1.5/>6/>6 (for MSSA) and 1.1/6/>6 (for MRSA), 0.10/1.5/4.5 (for
MSSE) and 0.14/1.5/1.5 (for MRSE). The ratio MBCstat/MBClog was
3 (for MSSE) and 1 (for MRSE). Figure shows the time-kill curve of
MSSE at GaM concentrations at 0.1×, 1×, 10× and 20× MIC. In
time-kill studies, GaM at 0, 0.2, 2 and 6 mg/mL reduced after 24 h
incubation MSSA bacterial load (in log CFU/mL) of −2.3, −1.5, 0.8 and
1.3, respectively (positive values denote net growth).
Conclusion: GaM inhibits growth of S. epidermidis at considerable
lower concentrations than of S. aureus (0.1 vs. 1 mg/mL). Against
S. aureus, GaM was only bacteriostatic at concentrations up to 6 mg/mL.
In contrast, GaM kills S. epidermidis in both logarithmic and stationary
growth phases exhibiting a 3-log CFU reduction at 2 mg/mL GaM in
24 h. GaM is a potential anti-staphylococcal drug and may be especially
useful in combination with other antimicrobials to prevent development
of resistance.
O100 The activity of iclaprim against European Streptococcus
pyogenes and S. agalactiae
I. Morrissey, L. Williams, A. Colclough, B. Jones, S. Hawser, K. Islam,
K. Maher (London, UK; Reinach, CH)
Objectives: Iclaprim (ICL) is a novel diaminopyrimidine within the same
class as trimethoprim but with more potent broad-spectrum bactericidal
activity in vitro. An intravenous formulation of ICL has just successfully
completed phase III trials for complicated skin and skin structure
infections and a phase II trial for hospital- and ventilator-associated
pneumonia is underway. An oral form of ICL is also being evaluated in
phase I trials. This current study ascertained the in vitro activity of ICL
and comparators against S. pyogenes (GAS) and S. agalactiae (GBS).
Methods: MIC was determined by CLSI broth microdilution method-
ology against 500 recent GAS primarily from respiratory infections
and 44 recent GBS from predominantly wound swabs originating
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from European countries. Clarithromycin (CLA), clindamycin (CLI),
trimethoprim-sulphamethoxazole (SXT), levoﬂoxacin (LVX), linezolid
(LNZ), penicillin G (PEN) and vancomycin (VAN) were used as
comparators.
Results: 9% of the GAS tested were resistant to CLA and 4% resistant
to CLI. For GBS, resistance to CLA and CLI was around 14% and
11%, respectively. Three GAS isolates were intermediate to levoﬂoxacin.
Summary MIC data are shown in the Table.
MIC mg/L
MIN MIC MIC50 MIC90 MAX MIC
GAS (N= 500)
ICL 0.004 0.015 0.06 0.25
SXT 0.03 0.25 1 2
CLI 0.015 0.06 0.06 64
CLA 0.015 0.03 0.06 64
LVX 0.25 0.5 1 4
LNZ 0.5 1 2 2
PEN 0.004 0.015 0.015 0.03
VAN 0.25 0.5 0.5 1
GBS (N= 44)
ICL 0.03 0.12 0.25 0.5
SXT 0.12 0.25 0.5 1
CLI 0.03 0.06 64 64
CLA 0.03 0.03 2 64
LVX 0.5 1 1 2
LNZ 1 1 2 2
PEN 0.06 0.06 0.12 0.12
VAN 0.5 0.5 0.5 1
ICL was active against all isolates, being slightly more active against
GAS than GBS, including isolates resistant to CLA or CLI. Trailing
end-points were observed with SXT against about 9% of GAS producing
false-resistance unless read strictly at 80% growth reduction according
to CLSI methods. This potentially subjective reading procedure was not
necessary with ICL.
Conclusion: ICL showed excellent activity in vitro against GAS and
GBS, which supports the use of iclaprim in the treatment of infections
caused by these bacteria.
O101 Efﬂux pump inhibitors may overcome antibiotic resistance
in multi-resistant bacteria by increasing intracellular drug
concentration
I. Leitner, J. Nemeth, A. Abrahim, H. Lagler, T. Erker, M. Zeitlinger
(Vienna, AT)
Introduction: Multi drug resistance (MDR) of bacteria is an increasing
problem in clinical practice of antimicrobial therapy. Inhibition of
bacterial efﬂux mechanisms appears to be a promising target in order to
restore antimicrobial susceptibility in MDR bacteria. Previous in-vitro
studies have shown that inhibitors of bacterial efﬂux pumps may improve
the antimicrobial effect of ﬂuoroquinolons. However, for most substances
concentrations necessary to restore antimicrobial susceptibility were too
high for clinical use, which might be ascribed to insufﬁcient increase
of intracellular concentrations of antimicrobials. The present study set
out to investigate the potency of various efﬂux pump inhibitors (EPI) to
overcome MDR and to explore changes of intracellular concentrations
of ciproﬂoxacin for the most potent substances.
Methods: Two previously described EPIs, 1-(1-naphthylmethyl)-
piperazine (NMP) and phenyl-arginine-beta-naphthylamide (PAbN) and
with two novel, speciﬁc p-glycoprotein (PGP) inhibitors, tariquidar
and elacridar, were investigated in terms of effects on in vitro
antibacterial activity. Antimicrobial susceptibility to ciproﬂoxacin in
the absence and presence of EPIs were tested in the following
strains: Staphylococcus aureus ATCC 29213 (SA), ciproﬂoxacin resistant
S. aureus SA-1199B (rSA), Pseudomonas aeruginosa ATCC 27853 (PS)
and MDR Stenotrophomonas maltophilia ATCC BAA-85 (SM). Changes
in intracellular concentrations of ciproﬂoxacin were determined by use
of [14C]Ciproﬂoxacin.
Results: Inhibition of PGP mediated drug efﬂux by tariquidar and
elacridar reduced MICs of ciproﬂoxacin for rSA from 16 mg/l to 2
mg/l in a dose depended manner, whereas only minor effects were
observed for SA and Gram-negative strains. Addition of MNP and PAbN
at high concentrations increased susceptibility towards ciproﬂoxacin in
all resistant strains tested. By addition of tariquidar and elacridar a dose
dependent increase of intracellular [14C]Ciproﬂoxacin was detected.
Conclusions: Our ﬁndings suggest that tariquidar and elacridar are
potent inhibitors of PGP mediated bacterial efﬂux. Both substances
may restore susceptibility for PGP over expressing pathogens by
dose dependent increase of intracellular ciproﬂoxacin. MDR in
Stenotrophomonas maltophilia could not be overcome by speciﬁc PGP
inhibitors but susceptibility could be increased by addition of high doses
of MNP and PAbN.
O102 Microbicidal activity of monochloramine and chloramine T
compared
R. Arnitz, M. Nagl, W. Gottardi (Innsbruck, AT)
Objectives: Chloramine T (CAT) and monochloramine (NH2Cl) are
active chlorine compounds and well-known antiseptics with broad-
spectrum microbicidal activity. CAT has stronger oxidative activity than
NH2Cl, while the latter one is a smaller molecule and more lipophilic.
The question arose if lower oxidative activity can be compensated by
higher lipophilicity regarding microbicidal effectiveness.
Methods: Bacterial strains (Escherichia coli ATCC 11229, Staphylococ-
cus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853) and
clinical isolates of Aspergillus fumigatus, Aspergillus ﬂavus and Candida
albicans were used for quantitative killing assays. All microorganisms
were tested separately in equimolar solutions of CAT and NH2Cl,
respectively. Pathogens treated in buffer without antiseptics served as
controls.
Result: NH2Cl showed a markedly stronger bactericidal and fungicidal
activity than CAT.
At a concentration of 0.011 mM, NH2Cl killed all test bacteria within 30
min, while 0.011 mM CAT did not cause a reduction in colony forming
units after that time. At a concentration of 0.036 mM and 0.107 mM,
NH2Cl led to a 3−4 log10 reduction of E. coli approx. 200 times faster
than CAT. The killing of S. aureus and P. aeruginosa by NH2Cl was
4−6 times faster. NH2Cl (0.355 mM) caused a 3 log10 reduction of
C. albicans after 1 min compared to a 2 log10 reduction by the same
concentration of CAT after 60 min. Conidia of Aspergillus were even
killed approximately 200 times faster by NH2Cl than by CAT.
Conclusion: The enormous difference between both agents can be
attributed to the lipophilicity and lower bulk of NH2Cl which by far
overcompensate its lower oxidative activity.
O103 Prevalence and antibiotic susceptibilities of Yersinia
enterocolitica and other Yersinia species recovered from meat
and chicken in Tehran, Iran
F. Golkar, M.M. Soltan Dallal, K. Baghai, M. Azimi, K. Zolfaghari,
S. Moezardalan, M. Zali (Tehran, IR)
Objectives: Yersinia enterocolitica is known as a psychrotrophic
waterborne and food borne enteropathogen.Yersinia can grow to large
numbers at refrigeration temperatures, so meat, chicken, milk, cheese
contaminated with that organism could become a signiﬁcant health
risk for consumers. The aims of this study addition to investigate the
prevalence of Y. enterocolitica and other Yersinia species in meat and
chicken samples in different seasons, were to determine the antimicrobial
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susceptibility pattern of Yersinia enterocolitica and other Yersinia species
isolated from meat and chicken in Tehran, Iran.
Methods: 189 peaces of meat and 190 chickens purchased from 28
different local butcher’s shops and supermarkets in Tehran that examined
for the presence of Yersinia species between April 2005 and March
2006.25 gr sample of homogenised food was pre-enriched in PBS
medium then it was transferred to cefsulodin-irgasan-novobiocin (CIN)
agar. Susceptibility testing of bacterial strains was achieved at 28ºC by
the agar diffusion method.
Results: Yersinia spp. was recovered from 60 of 379 (15.8%) peaces
of meat and chickens samples. Y. enterocolitica was found in 48 of 60
(80%) positive samples. The other 3 Yersinia spp. were Y. frederiksenii,
intermedia, kristensenii in 7 (11%), 4 (6%) and 1 (0.01%) of 60 isolates,
respectively. Also the most prevalence of Yersinia spp. was in early spring
and in mid autumn.
All 4 strains (98%) were susceptible to choloramphenicol and gentamicin
and 95%, 86%, 78%, 76%, 63%, 41% were susceptible to trimethoprim
and ciproﬂoxacin, cephotaxim, Tetracycline, nalidixic acid, streptomycin
and ampicilin respectively. the most antibiotic resistance belong to
cephalothine (98%).
Conclusion: Several factors such as isolation method, season, and
geographical location play an important role in reports of increase
or decrease in the prevalence of the Yersinia spp. Y. enterocolitica
had the most prevalence among other species. Our results show
isolation ratio of Y. enterocolitica and other species is higher in colder
climates. The majority of isolates were resistant to ﬁrst generation
cephalosporins (cephalothine). The most active pharmacologic agents
were choloramphenicol, aminoglycozide and sulfunamdes. Regarding
to high Sensivity of Yersinia spp. to gentamicin and chloramphenicol,
these agents should be effective in the treatment of Yersinia spp. when
clinically indicated.
The genetics of host susceptibility to
infectious diseases
S120 Mannose-binding lectin genetics as an example of single gene
inﬂuences on host susceptibility towards infection
N. Klein (London, UK)
In 1968 a report appeared in the literature of a patient who had suffered
from recurrent upper respiratory tract infections in the ﬁrst 2 years
of life whose only defect appeared to be a failure to phagocytose
Saccharomyces cerevisiae (Baker’s yeast) efﬁciently. The defect was
reversed when serum of other donors was used in the same assay. This
opsonic defect could be found in a high proportion (5−8%) of apparently
healthy populations, but was found frequently in children with recurrent
unexplained infections. It is now known that this ‘common opsonic
defect’ is due to a deﬁciency of a protein termed mannan or mannose-
binding lectin (MBL). It is a member of the collectin sub-family of
C-type lectins, and initiates the lectin pathway of complement activation
following binding to mannose, N-acetylglucosamine, fucose and glucose
residues presented in the orientations and densities commonly found on
microorganisms. Once bound, MBL activates the complement system in
an antibody and C1-independent manner. This is predominantly mediated
through a serine protease, MASP-2, which cleaves C4 and C2 to generate
a C3 convertase.
The human collectin genes are located in a cluster on chromosome
10. The MBL-2 gene comprises four exons and it is now known
that three single point mutations in exon 1 lead to a functional
deﬁciency of the MBL protein. Several polymorphisms have also been
identiﬁed in the promoter region of the MBL gene. Largely through
a combination of structural gene and promoter polymorphisms, MBL
concentration can vary thousand-fold in apparently healthy individuals,
and approximately a third of the Caucasian population has genotypes
conferring concentrations deemed “insufﬁcient”.
Numerous studies have now been performed to determine the role of
MBL in a clinical setting. It would appear that individuals who are
deﬁcient in this protein are prone to getting a range of infections,
particularly in the context of another immune defect. However, there are
also situations and diseases in which MBL deﬁciency may be protective.
This talk will outline the current thinking on the role of MBL in
susceptibility to infection.
Update on the perils of Gram-negative
bacteria (Symposium jointly arranged with
the ICAAC Program Committee)
S126 Extended-spectrum b-lactamases spreading in the community
R. Canto´n (Madrid, ES)
Since ﬁrst description in 1983 and during the eighties and nineties,
most of the detected extended-spectrum b-lactamases (ESBL) were SHV
and TEM types. They were mainly described in Klebsiella pneumoniae
and associated with nosocomial outbreaks. This situation dramatically
changed in the last few years worldwide, and most of the ESBL-
producing isolates are now Esherichia coli expressing CTX-M enzymes.
The majority of them are now recovered from community patients,
mainly from urinary tract infections (UTIs) and new risk factors have
been identiﬁed. Moreover, an increase of ESBL-producing isolates has
been detected in nursing homes and healthcare associated facilities in
the community, with the potential inﬂux of ESBLs from the community
to the hospital. Also, an increasing prevalence of faecal carriage with
ESBL-producing isolates in outpatients and healthy volunteers has
been described. ESBL producers are also recognised in other non-
hospital compartments, including farm and companion animals and in the
environment. The population structure of CTX-M-producing isolates is
complex and was initially associated with a polyclonal spread of ESBL-
producers (described as allodemia) and/or speciﬁc plasmids or other
mobile platform genetic elements. Nevertheless, the application of an
MLST typing scheme on ESBL-producing E. coli isolates in addition
to a PFGE based scheme shows a new situation with the description of
successful internationally disseminated multiresistant clones harbouring
speciﬁc (epidemic) plasmids. The case of CTX-M-15 illustrates this
situation. The ST131 E. coli clone belonging to phylogroup B2 and
associated with a multidrug-resistant IncFII plasmid harbouring the
blaCTX-M-15 gene has been found in different countries all over the
world and mostly isolated in patients with UTIs in the community. Other
examples of well dispersed ESBL in the community are CTX-M-14,
CTX-M-1 and CTX-M-2. The former has been frequently reported in
West Europe and North America with the potential dispersion of an
epidemic plasmid in different clones. CTX-M-1 is prevalent all over
Europe while CTX-M-2 in South America and Asia. Moreover, ESBLs
belonging to classical groups, such as SHV-12 and TEM-52, seem
to be also well dispersed in the community compartments. TEM-52
is widespread in Europe and associated with Salmonella isolates, and
more recently with E. coli isolates in UTIs. Although the association
of blaESBL genes with successfully mobile genetic platforms has been
magniﬁed as an important factor for the increasing prevalence of ESBLs,
the presence of speciﬁc virulence determinants in ESBL producers might
also has facilitated the persistence and subsequent dispersion of ESBLs.
In addition, co-resistance to non-b-lactam antibiotics not only decreases
therapeutic treatment options in community patients but also might has
facilitated co-selection processes and maintenance of ESBL producers.
It is remarkable that most of the new plasmid mediated resistance
genes, including qnr, aac(6′)-Ib-cr and qepA affecting ﬂuoroquinolones
or the methylase genes affecting aminoglycosides (armA and rmtB),
have been found in ESBL-producing organisms in several community
compartments. With this landscape, reversion of the current pandemic
situation of ESBLs in the community seems to be difﬁcult and new
strategies should be designed at local and international levels to curtail
the spread of these enzymes.
Nosocomial infections and infection control S25
S127 AmpCs, carbapenemases and carbapenem resistance
P. Nordmann (Le Kremlin Bicetre, FR)
Emerging resistance to broad spectrum b-lactams is increasingly
observed in the main Gram-negative species that are involved in
human infections i.e Enterobacteriaceae, Pseudomonas aeruginosa
and Acinetobacter baumannii. Besides the clavulanic-acid inhibited
extended-spectrum b-lactamases, the plasmid-mediated clavulanic-acid
resistant cephalosporinases are increasingly reported in enterobacterial
species that do not express naturally AmpC (Escherichia coli,
Proteus mirabilis, Salmonella sp., Klebsiella pneumoniae). They
confer resistance to expanded-spectrum cephalosporins. Chromosome-
encoded cephalosporinases with extended spectrum of activity towards
ceftazidime or cefepime have been also reported in E. coli, Serratia
marcescens and Enterobacter sp. The carbapenemases that hydrolyse
at least imipenem, ertapenem or/and meropenem are of the Ambler
molecular classes A, B, and D in Enterobacteriaceae. The emerging
carbapenemases in are mostly the plasmid-mediated KPC, VIM/IMP
and OXA-48 enzymes in Enterobacteriaceae. Because most of these
carbapenemases confer only reduced susceptibility to carbapenems, they
may remain underestimated as a consequence of the lack of their
detection. In P. aeruginosa and A. baumannii, b-lactamase mediated
resistance to carbapenems is also emerging. In P. aeruginosa, the
metallo-b-lactamases (IMP, VIM; SPM, GIM) are reported worldwide
as a source of nosocomial outbreaks. In A. baumannii, although
metallo b-lactamases are known, the acquired oxacillinases that are
quite speciﬁc to Acinetobacter sp. (OXA-23, OXA-40, OXA-58-types)
are the main source of carbapenem resistance. The natural reservoir
of carbapenemases is unknown with the noticeable exception of the
blaOXA-23 and the blaOXA-48 genes that we have identiﬁed as being
Acinetobacter radioresistens and Shewanella sp., respectively. Finally,
resistance to carbapenems may result in all Gram-negative species from
impaired permeability (or/ and overexpression of efﬂux) together with
overexpresssion of b-lactamases with very weak carbapenemase activity.
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O133 Healthcare-associated infection in acute hospitals: what
makes a difference? Exploration of national English data
B. Cookson, A. Mears, A. White, E. Phillips, J. Sedgwick, H. Jenkinson,
M. Devine, M. Bardsley (London, UK)
Objectives: To investigate the practice-related factors linked to
Healthcare Associated Infection (HCAI) rates in English acute hospitals.
Methods: A questionnaire tool was developed using expert input to
cover what were considered to be important elements related to the
management and control of HCAI. Questionnaires sent to all trust
directors of infection prevention and control and chief executives
in all acute hospital trusts in England for further distribution and
completion by the relevant healthcare workers in the trust. Other data
were collected for responding trusts from the Patient Environment
Action Team (PEAT) and the Clinical Negligence Scheme for Trusts
(CNST)). Infection outcomes comprised the mandatory surveillance data
for meticillin-resistant Staphylococcus aureus (MRSA) bacteraemias
and Clostridium difﬁcile associated diarrhoea (CDAD. Univariate and
multivariate analyses were performed.
Results: Trust level data were received from 155 of the 173 acute
NHS trusts in England. A lower MRSA infection rate was linked to
hand hygiene performance measures and isolation practices, whereas a
lower rate of CDAD was linked to cleanliness (PEAT Scores), good
practice in antimicrobial prescribing and surveillance of infections.
Lower rates of MRSA and CDAD, were related to strategic, planned
interventions such as the inclusion of infection control (IC) in the staff
development programme. However, certain interventions, for example
increased levels of training, were related to a higher infection rates.
There are many aspects of the outcome data that will be described as
possible confounding factors to such studies in England.
Conclusions: The associations we have found between lower rates of
MRSA and CDAD have “face value” in that they can be supported by
evidence from the infection control literature. We have, however, found
relationships between interventions and higher infection rates that are
counter-intuitive and may represent examples of what we are calling
‘reactive practice’ to higher rates of infection. Whilst it is interesting
to hypothesise that these interventions may be swift and simple to
introduce and may not be sustained compared to more strategic and
planned interventions linked to lower infection rates, this will have to be
conﬁrmed by further studies over time.
O134 Prevalence of nosocomial infections, France, 2006
J.M. Thiolet, L. Lacave´, P. Jarno, H. Tronel, C. Gautier, F. L’He´riteau,
M.H. Metzger, B. Coignard on behalf of the RAISIN Study Group
Background: A prevalence survey of nosocomial infection (NI) was
conducted in French healthcare facilities (HCF) in June 2006 to assess
the burden of NI, describe their characteristics and by comparison to
the 2001 NI survey assess the impact of the national infection control
programme.
Methods: The survey was proposed to public and private HCF and
used CDC deﬁnitions. Data were collected in a standardised manner
by trained personnel in HCF and sent by encrypted e-mail to regional
infection control coordinating centres (CClin) and the French Institute
for Public Health Surveillance (InVS). The prevalence of patients with
a NI (PPNI) was compared between 2001 and 2006 by multiple logistic
regression, adjusting for characteristics of HCF, wards and patients.
Results: Among 358 353 patients included from 2 337 HCF (accounting
for 95% of all French hospital beds), 17 817 (4.97%) were infected
and 19 294 NI were documented; 1 406 (0.39%) patients were infected
by meticillin-resistant Staphylococcus aureus (MRSA). Urinary tract,
lower respiratory tract and surgical site infections accounted for 30, 15
and 14% of NI, respectively. Among 15 800 isolated micro-organisms,
the 3 most frequent were Escherichia coli (25%), S. aureus (19%)
and Pseudomonas aeruginosa (10%). The PPNI varied with type of
HCF or wards and was greater among the elderly, males, patients with
severe underlying disease, immunocompromised, undergoing surgery or
exposed to invasive devices. Compared to 2001, the prevalence in 2006
was signiﬁcantly lower for NI (adjusted odds ratio [ORa] = 0.88, 95%CI:
0.85−0.90) and MRSA infection (ORa = 0.60, 95%CI: 0.54−0.66).
Conclusion: The participation of HCF to the survey was a success. The
decrease observed, particularly for MRSA infections, suggests a positive
impact of the national infection control plans.
O135 Infectious complications of short-term ventricular assist
devices
P. Mun˜oz, C. Padilla, J.M. Barrio, M. Ruiz, J. Yan˜ez, E. Bouza
(Madrid, ES)
Background: VAD are mechanical pumps that take over the function of
damaged ventricle/s in patients with heart failure until the recovery of
myocardial function or as effective bridge before heart transplantation
(HT). These critically-ill patients are prone to nosocomial and device-
related infections and to non-infectious complications such as bleeding or
thromboembolism. Most reports come from countries with long waiting-
lists for heart transplantation (HT) with average supports that may exceed
100 d. In Spain, the average waiting time for HT is shorter, and VAD-
related infections in this setting have not been sufﬁciently analysed.
Methods: During the period Jan 1989-March 2007, 58 patients required
a VAD in our institution. Clinical and microbiological records were
reviewed to determine the incidence, risk factors and outcome of
nosocomial infections in these patients. Standard CDC (Centers for
Disease Control) criteria were used for syndrome deﬁnitions.
Results: Mean age was 52 years and 62% were male. Median VAD
support length was 3 days (1−52). Most common reason for VAD
was postcardiotomy ventricular failure (56.9%), followed by allograft
failure after HT (22.4%) and medical cardiogenic shock (20.7%). An
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infection (34 episodes) was diagnosed in 28 patients (50.9%): pneumonia
(41%), urinary tract (14.7%), VAD infection (11.7%), wound infection
(8.8%), catheter related (5.8%) and others (11.7%). S. aureus followed
by Enterobacteriaceae, CNS and P. aeruginosa were the most common
pathogens. In non-transplanted patients 27/32 died (85.1% of them due
to a non-infectious cause) and 26 reached transplantation (80.8% despite
having suffered an infection). At the end of VAD support, 38% of the
patients were alive, 15.5% died due to cardiogenic failure and 15.5%
of neurological complications. Infection accounted for 3.4% of the early
deaths and for 19% of late demise.
Conclusion: Infections complicate the course of 51% of the patients
requiring short-term VAD in our study but they do not preclude heart
transplantation.
O136 Ventilator-associated pneumonia and attributable mortality:
a systematic review of observational studies
W.G. Melsen, M.M. Rovers, M.J.M. Bonten (Utrecht, NL)
Objective: To determine the attributable mortality of Ventilator-
associated Pneumonia (VAP) based upon the results of observational
studies.
Methods: A systematic review and meta-analysis was performed. The
studies were identiﬁed by performing a systematic search strategy using
PubMed, Web of Science and Embase through February 2007. Only
studies reporting mortality rates of patients with and without VAP were
included. The data were extracted using standardised forms and the
quality of all studies was determined by a validated scoring system.
Results: 52 studies with a total of 17.347 patients met the inclusion
criteria. Mortality rates of patients with VAP ranged from 14 to 78%.
Pooling of all studies resulted in an I2 statistic of 69%, indicating
considerable heterogeneity and, therefore, precluding estimation of an
overall effect. A signiﬁcant association between VAP and mortality,
in univariate analyses, was observed in 17 of 52 studies (33%). Yet,
nine studies also performed multivariate analyses, and signiﬁcance of
independent association persisted only in four of these studies. The
origin of heterogeneity could not be explained by differences in study
design, study quality and diagnostic approach. However heterogeneity
was limited for studies investigating only trauma patients (I2=1.3%)
or acute respiratory distress syndrome (ARDS) patients (I2=0%). The
estimated relative risk of mortality of patients with VAP in these patient
groups were 1.09 (95% CI 0.87−1.37) among trauma patients and 0.86
(95% CI 0.72 to 1.04) among ARDS patients.
Conclusions: The widely held belief that VAP is associated with
attributable mortality cannot be based on the available evidence from
observational studies. In fact, for two speciﬁc patient groups (trauma
and ARDS) there is evidence of absence of such an association.
Only analyses including more patient speciﬁc data, thereby allowing
to adjust for possible confounders, might conﬁrm or reject the presumed
association for other patient groups.
O137 Effect of 10 years of surveillance on the incidence of surgical
site infections in the Netherlands
J. Mannie¨n, S. van den Hof, J.C. Wille, B. van Benthem (Bilthoven,
The Hague, Utrecht, NL)
Objectives: Surgical site infections (SSI) continue to present a major
proportion of adverse events in surgical patients. Many countries have
established national surveillance systems, which aim to reduce the
patients’ risk of infection. This study evaluates the time-trend in SSI
rate for ﬁve frequently-performed surgical procedures in the Netherlands,
between 1996 and 2006.
Methods: Hospitals that participated for at least three consecutive years
in the Dutch PREZIES surveillance network were included, and CDC
deﬁnitions for SSIs were used.
Hospitals receive a feedback report per surgical procedure, including
crude and expected SSI rates, which are usually spread and discussed
in the hospital with involved personnel. Per surgical procedure, the
association between SSI rate and surveillance year was estimated by
odds ratios, which were obtained by logistic regression and adjusted
for confounders and method of postdischarge surveillance. A random
coefﬁcient model (multilevel logistic modelling) was used to adjust the
risk estimates for random variation among hospitals.
Results: Among the ﬁve surgical procedures, the number of included
surveillance years varied between 6 and 10 years, the number of hospitals
between 19 and 34, the number of procedures between 3,031 and 31,407,
the number of SSIs between 249 and 766, and the overall SSI rate
between 1.6% and 12.2%. The results of the multilevel logistic modelling
are presented in the Table.
Table Results of multilevel logistic regression analysis. Odds ratio (OR)
with 95% conﬁdence interval (95% CI) and p-value of change in SSI
rate per 1-year increase in surveillance time to operation.
OR (95% CI) P
Mastectomy1 1.04 (0.96–1.08) 0.46
Colectomy2 0.92 (0.83–1.02) 0.10
Replacement of the head of the femur3 0.94 (0.88–1.00) 0.07
Total hip prosthesis4 0.94 (0.90–0.98) 0.01
Knee prosthesis5 0.97 (0.91–1.03) 0.32
1Adjusted for: postdischarge surveillance (PDS), age, duration of
surgery, gender.
2Adjusted for: PDS, ASA classiﬁcation, wound contamination class,
duration of surgery, duration of preoperative hospitalisation, emergency
procedure.
3Adjusted for: PDS.
4Adjusted for: PDS, age, ASA classiﬁcation, duration of preoperative
hospitalisation, wound contamination class, duration of surgery.
5Adjusted for: PDS, university-afﬁliated hospital, duration of surgery,
gender, age.
A non-signiﬁcant increase in SSI rate was found for mastectomies. A
signiﬁcant decrease in SSI rate of 6% per surveillance year occurred
for total hip prosthesis, indicating a 60% decrease after 10 years. And
decreasing trends in SSI rate per 1-year increase in surveillance time
appeared of 6% for replacement of the head of the femur, of 8% for
colectomy, and of 3% for knee prosthesis, although statistically not
signiﬁcant.
Conclusion: For one of the ﬁve surgical procedures the decreasing
trend in SSI rate was statistically signiﬁcant and three procedures
showed a non-signiﬁcant decreasing trend. These encouraging results
are most likely a result of an improvement in the quality of care,
caused by changes in infection control in the hospitals. This study
showed that an active surveillance system with feedback of infection
rates to hospital staff might be an effective strategy to reduce the SSI
incidence. Additional interventions might further decrease the SSI rate,
and sustaining control efforts are necessary to maintain a low SSI level.
O138 Cost effectiveness of employing a TPN surveillance nurse for
the prevention of catheter-related bloodstream infections
M. Fraher, C. Collins, C. Walshe, J. Bourke, D. Phelan, M. Lynch
(Dublin, IE)
Objectives: The cost of catheter-related bloodstream infection (CR-BSI)
is substantial in terms of morbidity, mortality and ﬁnancial resources.
Guidelines recommend dedicated multi-disciplinary teams to reduce the
incidence of these infections. Total Parenteral Nutrition (TPN) is a
well-recognised risk factor for CR-BSI. In our hospital, a dedicated
TPN surveillance nurse was promoted from staff grade in 1997 and
quarterly multi-disciplinary meetings were introduced. This study shows
the reduction in CR-BSI and annual cost savings.
Methods: This study was performed in a 535-bed tertiary referral
university hospital. Data was prospectively collected over a 13-year
period using speciﬁc TPN records and TPN nurse notes. A total of 21,871
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CVC days and 453 CR-BSI’s were recorded as per CDC guidelines. All
CVCs were non-antibiotic impregnated and other lines such as PICC,
hickman, peripheral and home TPN were excluded.
Results: We compared the mean number of infections prior to and after
the introduction of a dedicated TPN nurse. The location of patients
was highest on general wards (58.1%) followed by ITU (27.9%) and
HDU (13.4%). Mean CR-BSI /1000 catheter days was 19.2 prior to
1997 and 14.48 after this date. This resulted in a mean reduction of CR-
BSI /1000 catheter days by 4.94. The annual mean of 28.3 infections
prior to 1997 and 17.8 after this date resulted in a mean decrease of 10.5
infections per year. The saving made by preventing 10.5 infections/year
was calculated using data on cost of bed days obtained from the hospital
ﬁnance ofﬁce. We used 12 days as the increased hospital stay attributable
to CR-BSI, with 8 of these days being in the ITU and 4 days on the
general ward. The cost in hospital days saved as a result of the reduction
in infection rate was 127,955 Euro (excluding the cost of antimicrobials
and laboratory investigations). Taking into account the salary of a TPN
nurse, this resulted in a saving to the hospital of 71,255 Euro per annum.
Conclusion: This study shows that there was a decrease in the CR-
BSI rate after the introduction of a dedicated TPN nurse and quarterly
multi-disciplinary meetings. By calculating the saving made in reduction
in CR-BSI we conclude that it is clinically and economically viable to
employ a dedicated TPN nurse. These ﬁgures do not take into account
other savings such as cost of antimicrobial treatment and other medical
and laboratory investigations
O139 Building a benchmark through active surveillance: the
Italian network SPIN-UTI
A. Agodi, F. Auxilia, M. Barchitta, S. Brusaferro, D. D’Alessandro,
M.T. Montagna, G.B. Orsi, C. Pasquarella, V. Torregrossa, I. Mura
on behalf of GISIO – Italian Study Group of Hospital Hygiene, SLTL
Objectives: The Italian Nosocomial Infections Surveillance in Intensive
Care Units (ICUs) (SPIN-UTI) project of the Italian Study Group of
Hospital Hygiene (GISIO) – Italian Society of Hygiene, Preventive
Medicine and Public Health (SItI), was implemented to ensure
standardisation of deﬁnitions, data collection and reporting procedures
coherently with the HELICS-ICU benchmark.
Methods: Hospitals were invited to join the SPIN-UTI project by
GISIO members. Before starting surveillance, participant ICUs were
gathered in order to involve the key stakeholders in the project through
participated planning. A ﬁrst phase consisted in a training session to
share and further reﬁne the protocol and the data collection tools. Four
electronic data forms, designed using SPSS Data Entry Enterprise Server
(SPSS Inc.) for web-based data collection, were presented and discussed.
After a monitoring phase, the ﬁnal SPIN-UTI protocol and tools were
produced integrating as much as possible the conclusions of debates and
discussions and the analysis of the methods used in the existing national
surveillance protocols. The six-months patient-based prospective survey
was performed from November 2006 to May 2007, preceded by a
one-month surveillance pilot study to assess the overall feasibility of
the programme, and to determine the needed time and resources for
participant hospitals.
Results: The SPIN-UTI project included 53 ICUs, 3,046 patients
with length of stay longer than two days and 35,152 patient-days.
A total of 619 infections were reported accounting for an incidence
rate of 20.3 per 100 patients and an incidence density of 17.6 per
1000 patient-days. The most frequently encountered infection site was
pneumonia and “Pseudomonas aeruginosa” the most frequent infection-
associated microorganism, followed by “Staphylococcus aureus” and
“Acinetobacter baumannii”. Site-speciﬁc infection rates, for pneumonia,
bloodstream infections, central venous catheter-related bloodstream
infections and urinary tract infections, stratiﬁed according to patient risk
factors, were below the 75th percentile reported by the HELICS network
benchmark.
Conclusion: The SPIN-UTI project showed that introduction of ongoing
surveillance does seem to be possible in many Italian hospitals. The
study provided the opportunity to participate in the HELICS project
using benchmark data for comparison and for better understanding of
factors that impact on associated risks.
O140 E. faecalis and P. aeruginosa are useful epidemiological
markers for the analysis of transmission events on intensive
care units
A. Kola, F. Schwab, S. Ba¨rwolff, T. Eckmanns, K. Weist, E. Dinger,
I. Klare, W. Witte, H. Ru¨den, P. Gastmeier (Hannover, Berlin,
Wernigerode, DE)
Objectives: At least 15% of nosocomial infections in intensive care
units are due to the cross-transmission of causative organisms between
patients. In contrast to endogenous infections, these exogenous infections
are more likely to be prevented by infection control measures. Therefore,
knowledge of surrogate organisms for the analysis of patient-to-patient
transmissions would be useful.
Methods: As known from KISS, the German hospital infection surveil-
lance system, A. baumannii, E. faecium, E. faecalis, K. pneumoniae,
P. aeruginosa and S. aureus are amongst the most common pathogens
responsible for nosomial infections in ICUs. Over a two years period,
primary isolates of these six “indicator” organisms cultured from clinical
samples of patients who stayed at 11 ICUs at two University hospitals
were genotyped by PFGE (pulsed ﬁeld gel electrophoresis). Genetically
indistinguishable isolates from different patients were considered as
cross-transmissions if the patients were hospitalised on the same ICU
in a temporal proximity of at least 9 days. The association between
the isolation of each of the six pathogens and cross transmission
(transmission events per 1000 patient days and per 100 cultured
organisms) was analysed.
Results: During 100 781 patient days, 100 829 microbiological
specimens from 24 362 patients were sampled (average investigation
density of 1.0 sample per patient * day) and 3 370 indicator
organisms were cultured (29.1% S. aureus, 22.6% E. faecalis,
22.2% P. aeruginosa, 14.6% E. faecium, 8.3% K. pneumoniae, 3.1%
A. baumannii). Altogether, 416 cross-transmissions (incidence density of
4.1 transmissions per 1 000 patient days, ranging between 1.4−8.4 per
1 000 patient days depending on the respective ICU) were discerned.
Of these, 19% were due to E. faecalis, 14% to E. faecium, 11%
to P. aeruginosa resp. S. aureus, and 6.4% to A. baumannii. There
was a signiﬁcant correlation between the isolation of E. faecalis and
P. aeruginosa, and transmissions per 1000 patient days resp. per 100
cultured organisms (Spearman correlation coefﬁcient >0.8, p< 0.01).
Conclusion: E. faecalis and P. aeruginosa are useful epidemiological
markers for the analysis of patient-to-patient transmissions on ICUs
in non-outbreak settings. As cross-transmissions are indicative of poor
clinical care, transmission analysis of E. faecalis and P. aeruginosa may
be used to monitor adherence to standard infection control precautions.
O141 Is screening for colonisation of extended-spectrum
b-lactamase producing Klebsiella pneumoniae in intensive
care unit necessary in the absence of an outbreak?
G. Metan, C. Ozkuyumcu, O. Koseoglu Eser, A. Topeli Iskit,
G. Hascelik, S. Unal (Kayseri, Ankara, TR)
Objectives: Extended-spectrum b-lactamase producing Klebiella pnemo-
niae (ESBL-KP) is a concern of importance for nosocomial infections
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and responsible for outbreaks particularly in intensive care units (ICUs).
Colonisation is a prerequisite for infection by ESBL-KP. The aim of this
study was to evaluate the impact of routine detection for colonisation
with ESBL-KP in the absence of an outbreak and to detect the rate of
infections related to colonisation or transmission.
Methods: This prospective study was conducted in a medical intensive
care unit (MICU) with nine beds at Hacettepe University Hospital, a
tertiary care centre in Ankara, Turkey. The study was approved by
the local ethical comittee. Patients admitted to MICU between August
2002-March 2003 were screened for ESBL-KP by obtaining pharyngeal
and rectal swab cultures upon admission, 48th hour of admission and
weekly until discharge. The staff of the MICU were not informed
about the colonisation status of the patients. Standard infection control
practices continued during the study period. All lactose positive and
oxidase negative colonies isolated from swabs and cultures, taken when
there is a suspicion of infection, were tested for ESBL production and
antimicrobial susceptibility testing were performed for ESBL positive
isolates according to CLSI recommendations. Enterobacterial repetitive
intergenic consensus PCR (ERIC-PCR) method was performed for the
evaluation of the genetic diversity.
Results: A total of 100 patients were included in the study and 332
rectal, 332 oropharyngeal swabs were performed from these patients.
Eight patients were found to have rectal colonisation with ESBL-KP after
48 hours of ICU admission. ERIC-PCR revealed six different genotypes.
One of the colonised patient developed a catheter infection with ESBL-
KP. The isolate that was recovered from the catheter infection was found
genotypically identical with the colonised strain. The strains that were
isolated from three other patients who shared MICU in the same period
were all in an unique ERIC-PCR pattern.
Conclusion: Performing routine surveillance cultures for detection of
colonisation with ESBL-KP is a hard work for clinical microbiology
laboratories. This study indicates that the addition of microbiological
screening does not improve the detection or prevention of ESBL infection
in the absence of an outbreak.
O142 Impact of routine surgical and intensive care units admission
surveillance cultures on hospital-wide nosocomial MRSA
infections in a university hospital
I.F. Chaberny, F. Schwab, S. Ziesing, S. Suerbaum, P. Gastmeier
(Hannover, Berlin, DE)
Objectives: Despite the existence of an established infection control
programme to combat MRSA transmission that includes effective barrier
precautions, an alert system for readmitted MRSA patients and screening
of roommates, a steady increase in nosocomial MRSA infections was
observed at Hannover Medical School – a 1400-bed university hospital –
in 2004. In reaction to this, an extended admission screening policy was
established in mid-2004 which included surgical wards and intensive
care units (ICUs). The aim of this study was to assess the impact of this
intervention.
Methods: The study used a single-centre prospective quasi-experimental
design to evaluate the effect of MRSA admission screening policy on
the incidence density of nosocomial MRSA infected patients per 1000
patient-days (MRSA-infpat/1000pd) in the whole hospital. The screening
policy was implemented during a six month period (July to December
2004). The effect on MRSA-infpat/1000 pd was calculated by segmented
regression analysis of interrupted time series with 30 months prior and
24 months after the implementation period.
Results: As a consequence of the implementation of admission
screening, the number of surveillance cultures increased nine-fold
increase, from 2.3 in 2002 to 20.4 nares cultures per 1000 patient-days
in 2006. The intervention had a highly signiﬁcant hospital-wide effect
on the incidence density of MRSA infections. Segmented regression
analysis showed both a signiﬁcant change in level (−0.122 MRSA-
infpat/1000pd, 95%CI, −0.205 to −0.004) and a signiﬁcant change
in slope (−0.008 MRSA-infpat/1000pd per month, 95%CI, −0.013 to
−0.003) after the intervention. A decrease of MRSA infections by 63%
is a conservative estimate of the reduction between the last month before
intervention (0.259 MRSA-infpat/1000pd) and the last month in the
analysed post-intervention period (0.096 MRSA-infpat/1000pd).
Conclusion: This is the ﬁrst hospital-wide study which investigates the
impact of introducing admission screening in ICUs and non-ICU wards
as single intervention to prevent nosocomial MRSA infections performed
with a time series regression analysis. Admission screening is a potent
tool in controlling the spread of MRSA infections in hospitals.
Pharmacokinetics and pharmacodynamics
O143 Intracellular activity of antibiotics against Staphylococcus
aureus internalised human skin keratinocytes: comparison
with THP-1 macrophages
S. Lemaire, F. Van Bambeke, J.P. Pirnay, G. Verween, P. De Corte,
D. De Vos, P.M. Tulkens (Brussels, BE)
Objectives: Relapsing and chronic S. aureus infections has been ascribed
to intracellular persistence. While the activity of antibiotics against
S. aureus in macrophages has already been extensively studied, little
is known in keratinocytes. We examine here the activity of antibiotics
commonly used for the treatment of SSSI infections (oxacillin,
vancomycin, linezolid, rifampicin) and of more recently approved ones
(quinupristin-dalfopristin, daptomycin, moxiﬂoxacin) in a model of
human keratinocytes in comparison to human macrophages.
Methods: We used a fully susceptible S. aureus strain (ATCC
25923). MICs were determined by broth microdilution. Infection of
human skin keratinocytes and THP-1 macrophages was performed
following published methods (Br. J. Dermatol. 2002; 146:943−51; AAC
2006;50:841−51). Activity was measured after 24 h of exposure to a
wide range of drug extracellular concentrations and data [change in log
CFU vs. log of extracell. conc.] analysed using a pharmacological dose-
response model (Hill equation).
Results: The table shows MICs values. Sigmoidal dose-responses were
seen for al drugs (R2 > 0.9) and allowed to calculate static concentrations
(SC) and Emax values.
Antibiotic MIC Intracellular activity in
(mg/L) THP-1 macrophages Keratinocytes
Static concentr.
(mg·L−1)/×MICa
Emaxb Static concentr.
(mg·L−1)/×MICa
Emaxb
Oxacillin 0.25 0.60/2.4 −0.8±0.1 0.70/2.8 −0.9±0.1
Vancomycin 0.5–1 3.26/3.2–6.5 −0.8±0.1 3.10/3.1–6.2 −1.1±0.3
Linezolid 0.5 4.74/9.5 −1.2±0.4 2.40/4.8 −1.3±0.2
Rifampicin 0.03 0.06/2 −1.4±0.1 0.001/0.03 −2.8±0.1
Daptomycin 0.125 1.63/13 −1.4±0.3 1.74/13.9 −1.4±0.2
Moxiﬂoxacin 0.06 0.20/3.3 −2.2±0.1 0.08/1.3 −1.7±0.1
Quinupristin-
Dalfopristin
0.5 0.50/1 −2.4±0.2 0.70/1.4 −1.9±0.4
aextracellular concentration of antibiotics resulting in no apparent bacterial
intracellular growth (no change of CFU); bmaximal effect for drug concentration
at inﬁnity.
Conclusions: Pharmacological parameters were similar in both cell types
for all drugs (except rifampicin, which showed higher Emax and lower
static concentration in keratinocytes). The data extend to keratinocytes
the poor activity of oxacillin, vancomycin and linezolid seen against
intracellular S. aureus in macrophages. They also suggest to further
assess the potential advantages offered in this context by daptomycin,
moxiﬂoxacin, quinupristin/dalfopristin, and rifampicin.
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O144 Ceftobiprole and Levoﬂoxacin are synergistic against
an isolate of Pseudomonas aeruginosa as evaluated in a
neutropenic mouse thigh infection model
A. Louie, C. Fregeau, W. Liu, K. Bush, G. Noel, G.L. Drusano
(Albany, US)
Objectives: The pharmacodynamic interaction of Ceftobiprole (Cefto)
plus Levoﬂoxacin (Levo) was examined in a mouse thigh infection
model, as judged by the Greco Interaction Model.
Methods: The mouse thigh infection model described by Craig was
employed. Mice were made neutropenic by cyclophosphamide, 150
mg/kg day −4 and 100 mg/kg day −1. P. aeruginosa ATCC 27853 was
injected into the posterior thighs of mice at a burden of 106 CFU. A
preliminary study was performed as a dose range of Cefto alone and Levo
alone. Sigmoid Emax analysis was employed to identify areas of greatest
Fisher Information. As this model has 3 parameters, each preliminary
experiment allowed identiﬁcation of 3 doses most informative as to
linking exposure to response. This allowed a second experiment to be
performed (16 cohorts): no-treatment control; 3 Cefto alone; 3 Levo
alone and 9 combination therapy cohorts (3X3). At 24 h, mice were
sacriﬁced, the posterior thighs dissected, homogenised and plated after
serial dilution on plates without drug (estimation of total bacterial load)
and on plates containing 3 x baseline MIC of either Cefto or Levo
(isolates resistant to one of the drugs). The Greco URSA model was ﬁt
to the data using ADAPT II. Weighting was the inverse of the observation
variance.
Results: For Cefto as a single drug, Emax (cell kill) was 4.1 log (CFU/g)
and EC50 was 12.6 mg/kg. For Levo as a single drug, Emax was 6.9
log (CFU/g) and EC50 was 145.4 mg/kg. Combination therapy was
statistically signiﬁcantly synergistic (a – interaction parameter 5.13;
95%CI 0.644−9.62). The cell kill is demonstrated in the Figure. Perhaps
more importantly, the combination efﬁciently suppressed resistance
emergence to either of the two drugs. Doses of Levo greater than 50
mg/kg, combined with Cefto doses greater than 15 mg/kg generally
suppressed all resistant bacteria.
Ceftobiprole-levoﬂoxacin combination therapy against P. aeruginosa
ATCC27853.
Conclusion: Combining two agents may be preferred as empiric
therapy for patients with serious infections suspected to be caused by
P. aeruginosa. In this in vivo model, Cefto-Levo combination therapy was
synergistic against this P. aeruginosa isolate and suppressed emergence
of resistance. The importance of this ﬁnding warrants further evaluation
with other isolates of P. aeruginosa including those with derepression of
the AmpC b-lactamase.
O145 Pharmacodynamics of amikacin against Acinetobacter
baumannii: modelling bacterial response to drug-selective
pressures
V.H. Tam, K.R. Ledesma, T.P. Lim, K.M. Lee, M. Nikolaou (Houston,
US; Singapore, SG)
Objective: We have previously developed a mathematical model
predicting the response of P. aeruginosa to meropenem (J Antimicrob
Chemother 07) and levoﬂoxacin (Ann Biomed Eng 07). However, the
applicability of the model to other pathogens is unknown. We extended
our model to predict the effect of various ﬂuctuating amikacin (AMK)
exposures on A. baumannii (AB), an emerging bacterium associated with
multidrug resistance.
Methods: Time-kill studies (TKS) with 107 CFU/ml of AB ATCC BAA
747 at baseline were performed. AMK at 0−32× MIC was used for 24h
(MIC = 4 mg/l). The experimental data were used to derive estimates
of the best-ﬁt model parameters, and AB response to various AMK
exposures over 72h was predicted via a 3-dimensional response surface.
The computer model predictions were subsequently validated using an
in-vitro hollow ﬁber infection model (HFIM); AMK proﬁles (t1/2 =
2.5h) corresponding to 7.5 mg/kg every 12h and 30 mg/kg every 24h
were investigated over 72 hours.
Results: TKS data were satisfactorily captured by the mathematical
model (r2 = 0.93). A signiﬁcant initial reduction in bacterial burden
was predicted for both AMK exposures examined. Regrowth over time
due to resistance emergence was predicted for 7.5 mg/kg every 12h,
while eradication of bacterial population was predicted with 30 mg/kg
every 24h. These predictions correlated well with our experimental data
in HFIM.
Conclusions: The mathematical model was reasonable in predicting ex-
tended AB response to various ﬂuctuating AMK exposures qualitatively,
based on limited input data from TKS. In view of its robustness and
efﬁciency, our mathematical modeling approach holds great promise
as a high throughput screening tool for dosing regimen selection in
antimicrobial (pre)-clinical development.
O146 Temocillin protein binding is concentration-dependent and
not restricted to albumin
S. Carryn, J.W. Mouton, N. Couwenbergh, P.M. Tulkens (Brussels,
BE; Nijmegen, NL)
Objectives: Temocillin (TMO), a 6-alpha-methoxy penicillin, is highly
protein bound in healthy volunteer (85%). However, we recently observed
that the level of protein binding (PB) is lower in critically ill patients
receiving TMO during continuous infusion (down to less than 70% for
some individual patients). This variation could have a major therapeutic
impact as it is generally presumed that only the free form of b-lactams
is active. We have therefore studied the binding properties of temocillin
to whole human serum and puriﬁed human serum albumin (HSA).
Method: Solutions of HSA in water (1, 2.5, and 5%), whole serum, and
PBS-diluted serum solutions were spiked with known concentrations of
TMO (25 to 1000 mg/L). Free fractions of TMO were measured by
HPLC after separation from proteins by ultracentrifugation through 30
kDa cut-off membranes (Centrifree®, Millipore, MA).
Results: PB of TMO in HSA and serum was concentration-dependent
and decreased with increasing concentrations of TMO. A sigmoid
function (Hill equation) could be ﬁtted to all PB-binding data (see
parameters estimates in the table).
In HSA, EC50 values were proportional to the HSA concentration and
residual binding increased with the concentration. In serum, the maximal
PB observed was 86% (consistent with the observations made in healthy
volunteers), and the Hill’s slope was much less steep than for HSA.
The serum PB decreased gradually to 24% at 1000mg/ml. Interestingly,
PB remained unchanged (about 20%) when serum spiked with high
TMO concentrations (1000 mg/L) were diluted with PBS, except for
high dilutions (>40×).
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Matrix Max binding
%
Min binding*
%
EC50
mg/ml
Hill’s
slope
HSA 1% 96 3 116 −2.14
HSA 2.5% 96 11 286 −3.28
HSA 5% 96 38 514 −4.35
Serum 86 3 329 −1.05
*Calculated residual binding.
Conclusion: TMO PB is concentration-dependent. Considering the
normal concentration of HSA in serum (around 4%), the shapes and
values of the binding curves, and the maximum binding observed in
serum, our data suggests that other factors are involved in TMO protein
binding and does not bind exclusively to albumin. Moreover, our data
may partially explain the observations made in critically ill patient (an
increased free fraction) because these patients often have low serum
proteins levels.
O147 MDR1 (P-glycoprotein) and MRP1 (multidrug resistance-
related protein 1) eukaryotic efﬂux transporters do not
affect the cellular accumulation and intracellular activity of
tigecycline towards intraphagocytic Staphylococcus aureus
S. Lemaire, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens
(Brussels, BE)
Objectives: Efﬂux pumps expressed by eucaryotic cells can reduce
antibiotic accumulation, impairing thereby their activity towards
intracellular bacteria (JAC 2003, 51:1167−73). We have examined
whether this could apply to tigecycline, a new glycylcycline for which
intracellular activity against S. aureus has been evidenced in infected
polymorphonuclear leucocytes (JAC 2005, 56:498–501).
Methods: The cellular accumulation of tigecycline was assessed by
microbiological assay after 5 h of incubation in 3 cell lines differing by
their level of expression of multi-drug efﬂux transporters (human THP-
1 [expressing MDR1]; Madin-Darby Canine Kidney Cells [MDCK]:
wild type cells and variants overexpressing either MDR1 or MRP-1).
Intracellular activity was determined against S. aureus (ATCC 25923)
phagocytosed by THP-1 macrophages after 24 h exposure to increasing
concentrations of tigecycline and ﬁxed concentrations of inhibitors of
P-gp (verapamil) or MRP (gemﬁbrozil).
Results: Tigecycline accumulated 3−4 times in all 3 cell types,
disregarding their level of expression of MDR1 or MRP-1 transporters.
Against phagocytosed S. aureus, tigecycline exerted a concentration-
dependent activity (sigmoidal concentration-effect relationship obeying
to the Hill equation) with static effect for an extracell. conc. of 0.15
mg/L, and maximal effect (Emax) of −0.76±0.05 log CFU. These
parameters were not modiﬁed in the presence of efﬂux pump inhibitors.
Conclusions: In contrast to daptomycin (AAC 2007, 51:2748−57) and
azithromycin (JAC 2003, 51:1167−73), for wich accumulation and
intracellular activity are reduced by MDR1, tigecycline is substrate of
neither MDR1 or MRP-1 efﬂux transporters, two well characterised
multidrug efﬂux pumps widely expressed in many eucaryotic cells.
O148 Selection of daptomycin (DAP)-resistant Staphylococcus
aureus mutants with DAP alone and in combination with
rifampicin at subtherapeutic concentrations: simulations
using an in vitro dynamic model
M. Smirnova, E. Strukova, S. Vostrov, I. Lubenko, S. Zinner (Moscow,
RU; Cambridge, US)
Objective: A bell-shaped relationship between the ratio of area under
the curve (AUC) to the MIC and the enrichment of daptomycin (DAP)-
resistant S. aureus have been reported in our simulations of multiple-
dose DAP pharmacokinetics. AUC/MICs near 200 h (that are lower than
the therapeutic AUC/MICs) protected against the selection of resistant
mutants whereas they were maximally enriched at AUC/MICs of 32−64
h. To determine if such selection could be prevented with DAP in
combination with other agents, the pharmacodynamics of DAP alone
and combined with rifampicin (RIF) at the subtherapeutic AUC/MICs
were studied in an in vitro model.
Methods: S. aureus ATCC 43300 and a clinical isolate S. aureus 866
with MICDAPs of 0.2 and 0.4 mg/L, respectively, and MICRIF of 0.012
mg/L were exposed to ﬁve-day dosing of DAP (AUC/MIC 64 h) alone
and in combination with RIF (AUC/MIC 100 and 500 h). Bacterial
growth on agar plates containing 0x, 2x and 4xMICDAP was examined
daily. The cumulative effect of each simulated treatment on susceptible
S. aureus sub-populations was expressed by area under the time-kill
curve (AUBC) measured from time zero to 120 h.
Results: Both simulated DAP+RIF regimens were more efﬁcient against
the two organisms and the DAP-resistant mutants. With S. aureus ATCC
43300, RIF100 and RIF500 lowered the AUBC 1.4- and 1.9-fold relative
to DAP alone. With S. aureus 866, 1.6- and 1.8-fold reductions in AUBC
were observed, respectively. With both organisms, mutants resistant to 2x
and, to a lesser extent, 4xMICDAP were enriched in the mono-treatments
with DAP but not in the DAP+RIF500 treatments. RIF500 resulted in a
1.3 (S. aureus ATCC 43300) and 3.4 (S. aureus 866) fold reduction in
the area under the bacterial mutant curve (AUBMC) for mutants grown
in the presence of 2xMICDAP. The protective abilities of DAP+RIF100
were similar to those of DAP+RIF500 for S. aureus 866 but were weaker
for S. aureus ATCC 43300. The DAP+RIF100 combination postponed
but did not prevent the production of DAP-resistant mutants.
Conclusions: This study suggests that DAP+RIF combinations can
reduce the selection of DAP-resistant S. aureus mutants.
O149 Efﬁcacy of antibiotics in cerebrospinal ﬂuid
R. Sauermann, M. Fille, M.L. Camuz Ligios, R. Schwameis,
M. Zeitlinger (Vienna, Innsbruck, AT)
Objectives: Treatment of shunt-associated ventriculitis (SAV) requires
administration of an effective antibiotic regimen to avoid life-threatening
sequelae. Due to their antimicrobial spectrum and penetration properties
fosfomycin, cefepime and rifampicin are frequently considered for
treatment of SAV. The present study aimed at describing killing
kinetics of fosfomycin, cefepime and rifampicin in cerebrospinal ﬂuid
(CSF) compared to conventional growth medium. In addition, the
general applicability of human CSF as growth medium for bacteriologic
experiments was explored.
Methods: CSF was collected from over 700 patients who did not
receive antibiotics. Time-kill curves over 24 hours were performed using
drug concentrations of 0.25, 0.5, 1, 2, 4, and 8-fold the MIC of the
Staphylococcus aureus test strain. Time-kill curves were preformed in
Muller-Hinton-broth (MHB), in CSF, and in CSF incubated with 5%
CO2. Ambient CO2 served to adjust the pH of CSF to physiological
values.
Results: As expected drug concentrations above the MIC led to effective
bacterial killing in MHB. Addition of fosfomycin to CSF did not
induce any inhibition of bacterial growth if incubated at ambient air.
Experiments performed in CSF with physiological pH achieved by 5%
CO2 incubation showed sustained growth inhibition only at fosfomycin
concentrations of 8-fold the MIC, while re-growth was observed for all
lower fosfomycin concentrations. For rifampicin killing patterns similar
to those of fosfomycin were observed. In contrast, cefepime exerted
higher killing in CSF with CO2 incubation than in MHB, while being
less effective in CSF at ambient air than in MHB.
Conclusions: CSF is eligible for performing bacteriologic experiments.
CSF and MHB differ substantially with regard to bacterial growth
and killing. In CSF with CO2 incubation bacterial re-growth occurs
at fosfomycin or rifampicin levels above the MIC, while cefepime
concentrations below the MIC exert inhibitory effects. We conclude
that dependent of the investigated antibiotic the use of MHB might
overestimate or underestimate the efﬁcacy of antibiotics in CSF. Thus,
CSF should be considered as medium for evaluation of the efﬁcacy of
antimicrobial drugs for intracerebral infections in order to better reﬂect
the clinical setting.
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O150 Temocillin 6g daily in critically ill patients: continuous
infusion vs. conventional administration
P.F. Laterre, T. Dugernier, X. Wittebole, N. Couwenbergh, P.M. Tulkens,
S. Carryn (Brussels, Ottignies, BE)
Objectives: Temocillin (TMO) is currently used in critically patients
but PK data in this population are scarce. TMO has recently been
proven to be suitable for continuous infusion (De Jongh et al., JAC
in press). However, serum free concentrations (SFC) achieved with the
conventional posology (2g q12h) may be close to the MIC in critically
ill due to increased volume of distribution and altered PK/PD. In order
to achieve acceptable SFC we have therefore administered 6g of TMO
daily either as 2g q8h (TID) or in continuous infusion (CI).
Method: ICU patients with documented Gram-negative infection
susceptible to TMO were included and randomised in both groups.
Patients with renal replacement therapy were excluded. Blood samples
were collected after the 1st and 7th dose for the TID group and daily
for 4 days for the CI group and assessed by HPLC. SFC of TMO were
measured after separation from proteins by ultracentrifugation through
30 kDa cut-off membranes (Centrifree®, Millipore, MA). Safety was
assessed through adverse events monitoring.
Results: 8 patients were included in each group (8 intra-abdominal
infections, 6 LRTI, and 2 UTI; 4 patients had a positive bloodculture).
No signiﬁcant differences were observed between groups for age (SEM)
[TID: 70 (4), CI: 64 (5)], SOFA scores (SEM) [TID: 8.4 (1.3), CI 6.5
(1.1)], or creatinine clearance (SEM) [TID: 52 (10), CI: 71 (14)]. TMO
total and free concentrations for both dosing regimen are shown in the
ﬁgure (value are represented as mean±SEM).
For TID the time above the Belgian susceptibility breakpoint (i.e. 16
mg/L) for the SFC reached 86% on average. For CI, the SFC remained
100% of the time above the breakpoint and even reached 2-times
this concentration for more than 60% of the time (lowest mean free
concentration: 28.8 mg/L). As expected in critically ill patients the alpha
half-life in the TID group was highly decreased during the ﬁrst injection
(less than 1h) while the terminal half-life remained close to 3h. Finally,
despite the high serum concentrations reached, no adverse events related
to TMO were observed
Conclusion: TMO is safe at the posology of 6g per day. If TID seems
sufﬁcient to achieve PK/PD goal for b-lactam efﬁcacy, CI allows a better
margin of security compared to the breakpoint. These data suggests that
the optimal dose for TMO in critically ill without renal replacement
therapy should be increased to 6g daily.
O151 An exploratory analysis of the relationships between
voriconazole plasma concentrations and clinical efﬁcacy
P.F. Troke, H. Hockey (Broadstairs, UK; Hamilton, NZ)
Objective: To explore possible relationships between voriconazole
concentrations in plasma and efﬁcacy in the Phase II/III clinical studies.
Methods: Plasma samples taken randomly during voriconazole therapy,
in 1008 ITT patients from 9 Phase II/III clinical studies of fungal
infection, were analysed using a validated hplc assay. Data were
summarised as weekly mean concentrations with one/weekly window.
The relationship between plasma concentration and efﬁcacy was
investigated by logistic regression (using one overall mean plasma
concentration/patient) upon the binary outcome variable – success or
failure – as determined by the investigator at end of therapy. Success
was deﬁned as a complete or partial response and failure as any other.
Polynomial models were used to investigate linearity and curvature. The
impact of covariates was assessed. MICs were determined using CLSI
methodology (M27A-2 for yeasts and M38A for moulds).
Results: There were 529 yeast (70% success) and 479 mould (59%
success) infections identiﬁed at clinical baseline. Mean voriconazole
plasma concentrations were divided into 11 bands. The relationship
between response and mean plasma level was non-linear and best
ﬁtted to a quadratic polynomial model (p = 0.001). Mean plasma levels
<0.5mg/L or >6.0mg/L were associated with clinical responses of <60%.
Individually signiﬁcant covariates were: study (p< 0.001), protocol
(p< 0.001), primary/salvage therapy (p< 0.001), region (p = 0.0165),
yeast/mould (p = 0.004), duration of therapy (p< 0.001), site of infection
(p = 0.003), underlying disease (p< 0.001) and mean levels < or >6mg/L
(p< 0.001). When combined in the quadratic model none of these
covariates altered the non-linearity. In 469/1009 (46%) patients where
a baseline pathogen MIC was available there was a linear relationship
between mean voriconazole free drug level/MIC ratio and clinical
response (p = 0.014).
Conclusions: There is a signiﬁcant, non-linear relationship between
voriconazole mean plasma concentration and efﬁcacy. Covariates with
a signiﬁcant impact on their own, when combined do not change the
curvilinear relationship. There is a signiﬁcant and linear relationship
between mean voriconazole free drug/MIC ratio and clinical response.
O152 Use of pharmacokinetic-pharmacodynamic principles
for decision support for short-course oritavancin dosing
regimens for complicated skin and skin structure infections
C.M. Rubino, S.M. Bhavnani, A. Forrest, O.O. Okusanya, D. Lehoux,
G.L. Drusano, K.A. Rodvold, W.A. Craig, T.R. Parr Jr., P.G. Ambrose
(Albany, Chicago, Madison, US; Montreal, CA)
Objectives: Optimal dose selection for Phase 2/3 clinical trials is critical
for successful drug development. Application of pharmacokinetic-
pharmacodynamic (PK-PD) principles provides a scientiﬁc basis for
optimising both dose and duration of therapy. Dosing regimens for
short-course therapy were evaluated for oritavancin (ORI), a novel
glycopeptide currently in development for complicated skin and skin
structure infections (cSSSI).
Methods: Using PK data from 20 intensively-sampled subjects who
received ORI 800 mg IV Q24h x 5 days, a population PK model was
developed. PK parameter estimates based on this model were used to
conduct simulations to evaluate daily and cumulative free-drug plasma
AUC values following front-loaded ORI regimens (i.e., the majority of
the AUC is delivered on Day 1) of 800 to 1200 mg. Both single-and
multiple-dose regimens were evaluated. Multiple-dose regimens involved
a loading dose followed by a booster dose (400 or 800 mg) on Day 4, 5
or 6. Population PK analysis and simulations were performed using S-
ADAPT 1.53. Free-drug AUC values for each regimen were assessed
relative to those associated with a 1 and 2 log10 CFU decrease in
S. aureus using data from a neutropenic murine-thigh infection model
(Craig WA, Andres DR. ICAAC 2004, Abstr. A-1863). Single-dose free-
drug AUC values in mice corresponding to a 1 and 2 log10 CFU decrease
were 61 and 159, respectively. Free-drug AUC values were also assessed
relative to those successfully studied for previous cSSSI studies (200 mg
Q24h X 3−7 days) and S. aureus MIC population statistics.
Results: A 3-compartment model with zero-order input and linear
clearance best described the PK data. Plasma concentrations were well
ﬁt by the model (r2 = 0.966). ORI 1200 mg X 1 dose or 800 mg on
Day 1 followed by 400 mg on Day 5 provided mean cumulative free-
drug AUC values which exceeded non-clinical free-drug AUC targets
and which were similar to those values for the previously studied 3−7
day 200 mg Q24h regimen (see Table).
Discussion/Conclusion: The approach to support selection of short-
course dosing regimens described herein is especially useful for agents
such as ORI, which display a concentration-dependent pattern of
bactericidal activity and a long half-life. It is predicted that front-loaded
ORI regimens will result in improved response rates for patients with
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cSSSI relative to those regimens previously studied. These data were
used to support dose selection for a Phase 2 cSSSI study.
Mean cumulative
free-drug AUC in
plasma
Regimen (Infusion duration in minutes) Day
4
Day
5
Day
6
Day
7
200mg Q24h×3 days (45) 180 196 206 214
200mg Q24h×4 days (45) 218 249 267 279
200mg Q24h×5 days (45) 218 287 320 340
200mg Q24h×6 days (45) 218 287 358 393
200mg Q24h×7 days (45) 218 287 358 432
800mg on Day 1 (90) 263 276 286 293
800mg on Day 1, 400mg on Day 4 (90/60) 339 382 407 424
800mg on Day 1, 400mg on Day 5 (90/60) 263 352 391 415
800mg on Day 1, 400mg on Day 6 (90/60) 263 276 362 399
800mg on Day 1, 800mg on Day 4 (90) 415 487 529 556
800mg on Day 1, 800mg on Day 5 (90) 263 428 497 536
800mg on Day 1, 800mg on Day 6 (90) 263 276 438 504
1000mg on Day 1 (120) 328 345 357 366
1200mg on Day 1 (120) 394 414 428 439
Challenges from the rise of resistant
pathogens: Part 1 (Symposium organised by
Janssen Cilag)
S157 Changing landscape of antimicrobial resistance in Europe:
focus on Gram-positives
M. Wilcox (Leeds, UK)
Antimicrobial resistance patterns are constantly changing throughout
the world. Starkly different resistance patterns have arisen among
countries within Europe, and between Europe and North America.
The distinction between hospital-acquired and community-acquired
infections is becoming blurred, with strains that once were prevalent
in the hospital now found in the community and vice versa. For
example, the virulence determinant Panton-Valentine leukocidin (PVL)
can no longer be considered a marker of just community-acquired
staphylococcal infections. For both meticillin-resistant Staphylococcus
aureus (MRSA) and meticillin-sensitive S. aureus (MSSA), the
traditional opinion on the role of PVL as a virulence determinant is
being questioned.
The success of a particular organism does not depend on where it arose
initially but rather on whether it can enter and prosper in speciﬁc niches.
Successful control of a pathogen depends upon eliminating the niche
or preventing transmission. A notable example is MRSA in hospitals
in England, where the prevalence of MRSA-related infections rose to
among the highest in Europe. The incidence of MRSA bacteraemia
has decreased markedly in response to major evidence-based healthcare
initiatives and infection targets that were introduced to combat the spread
of the resistant pathogen. Reservoirs of MRSA are still prevalent, notably
among the elderly in care homes in the United Kingdom.
Resistance development by one organism can be an unintended response
to measures taken against other organisms. In Canada, for example,
the prevalence of vancomycin-resistant enterococci (VRE) markedly
increased with the change in use of antimicrobial agents (from
metronidazole to vancomycin) to treat Clostridium difﬁcile infections.
Data indicate that usage of some antibiotics correlates with the
nosocomial prevalence of MRSA. However, compared with data on
Gram-negative bacterial infections, information is limited regarding the
effect of the changing use of antibiotics for Gram-positive bacterial
infections within the hospital setting. Hospitals should take measures to
ensure that resistance does not continue to spread among Gram-positive
organisms. Increasing therapeutic options for Gram-positive infections
open up new opportunities to alter antibiotic prescribing practices, with
the potential to impact on the prevalence of endemic resistant pathogens.
S158 Critical success factors for the management of complicated
skin infections
J. Solomkin (Cincinnati, US)
To guide the development of agents to treat skin and skin structure
infections (SSSIs), the FDA has created two categories: uncomplicated
infections (eg, simple abscesses, impetiginous lesions, furuncles,
cellulitis) and complicated infections (deeper tissue involvement, often
requiring signiﬁcant surgical intervention, eg, abscesses, extensive
cellulitis, diabetic foot infections, and necrotising infection). The
latter infections, often with associated underlying disease, carry an
increased risk of Gram-positive and Gram-negative co-pathogens. These
infections, occurring in hospitalised patients, are unlikely to rapidly
resolve with surgical measures alone; assessment of severity may help
determine when emergency surgery and antibiotics are required. Severity
assessments for SSSIs include clinical signs of systemic inﬂammation
and local ﬁndings, particularly the size of abscesses or cellulitis, or signs
of necrotising infection, including bullae and subcutaneous haemorrhage.
In these more severe cSSSIs, empiric therapy effective against the
organisms subsequently identiﬁed on culture is important in limiting the
extent of tissue loss and more rapidly resolving the acute illness. In the
US and some European areas, the frequency of MRSA associated with
SSSIs has risen dramatically in the past 5 years, reaching up to 60%.
Because of the high prevalence of resistant strains in the community
(community-acquired MRSA), recommendations in the US are to treat
Staphylococcus aureus infections with agents active against MRSA and
to assess microbiologic sensitivities when available.
Vancomycin has been the standard parenteral treatment for MRSA,
but concerns exist regarding toxicity and increasing hetero- and
other forms of resistance. New cephalosporins with activity against
MRSA may provide clinicians with useful options for the treatment
of cSSSIs. Ceftobiprole, an investigational broad-spectrum anti-MRSA
cephalosporin, has demonstrated efﬁcacy in two multi-centre, double-
blind, active controlled trials in various types and severity of skin and
soft tissue infections, including diabetic foot infections.
S159 From CAP to HCAP to HAP: new considerations and
approaches
T. Welte (Hannover, DE)
Pneumonia acquired outside the hospital or identiﬁed within 48 hours of
admission (with presumed acquisition prior to hospitalisation) is deﬁned
as community-acquired pneumonia (CAP). Pneumonia acquired in the
hospital or up to 1 week after discharge (with presumed acquisition
during hospitalisation) is deﬁned as hospital-acquired pneumonia (HAP).
Healthcare-associated pneumonia (HCAP) is acquired by patients
in frequent contact with the healthcare system (eg, haemodialysis
patients, nursing home patients). HCAP deserves separate recognition,
as treatment issues are more similar to HAP than CAP.
Scoring systems may aid the decision of where (eg, outpatient setting
or in hospital) and how aggressively to treat pneumonia patients.
Appropriate sampling with sufﬁcient sputum for culture can be obtained
in only half of pneumonia patients, so antibiotic therapy is often based
on suspected infection and knowledge of probable pathogens. Most
prevalent in CAP is Streptococcus pneumoniae followed by Haemophilus
inﬂuenzae, while Gram-negative bacilli and Staphylococcus aureus are
most common in HAP, with risk of Pseudomonas aeruginosa and
S. aureus highest in pneumonia that develops from 2 days to a week
after hospitalisation.
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Pneumonia in nursing home patients, the elderly, and multi-morbid
patients is commonly due to Gram-negative bacilli, S. aureus or
S. pneumoniae, including multi-drug resistant S. pneumoniae (MDRSP).
Prior antibiotic treatment increases the risk of meticillin-resistant
S. aureus (MRSA) and P. aeruginosa in pneumonia in all settings.
Staphylococcus aureus may cause severe CAP, especially after inﬂuenza
infection.
Resistance can increase both mortality and costs. Reports of community
acquired (CA)-MRSA are increasing in the United States and are already
high in some European countries (eg, Greece, the UK). However,
European countries with lower resistance patterns have also reported
cases of CA-MRSA, suggesting that this pathogen will be more
important in the future.
S160 The role of MRSA in pneumonia
R.G. Wunderink (Chicago, US)
The spectrum of meticillin-resistant Staphylococcus aureus (MRSA)
pneumonia now extends across all categories of pneumonia, including
CAP, HAP, HCAP, and pneumonia in immunocompromised patients.
Origin may not be as important as formerly; distinctions between
CAP, HCAP, and HAP are blurring as strains move from institutions
to the community and vice versa. In general, resistance in HCAP in
Europe is less common than in the US due to differences in nursing
home populations, or because deﬁnitions of HCAP differ. In the US,
nursing home patients may be sicker, with a greater frequency of
comorbidities such as chronic tracheotomies, multiple decubiti, and
impaired consciousness.
Risk factors for MRSA HAP and VAP are similar to other multidrug
resistant pathogens. The exception is that the reservoir for MRSA is
often the nares and nasopharynx. For this reason, screening for MRSA
on admission for patients at high risk for pneumonia or skin and soft-
tissue infections is increasingly common. This has important implications
for VAP prevention strategies as none of the components of most VAP
prevention “bundles” speciﬁcally address this issue. Our research also
suggests that conventionally-accepted risk factors for CA-MRSA CAP
may not be good predictors.
Time to the ﬁrst antibiotic dose has been a measure of quality of
care in pneumonia. Delays of several days in initiating appropriate
therapy, as may occur while awaiting culture results, are associated with
worse outcomes. Given the difﬁculties, delays, and low yield inherent
in diagnosing the aetiology of pneumonia, antibiotic treatment often
is empiric. As MRSA is a common pathogen, empirical anti-MRSA
coverage is increasingly common. The negative predictive value for
MRSA in an adequate lower respiratory tract sample is very high.
However, despite microbiologic results, clinicians are often reluctant
to narrow antibiotic therapy. Delayed response to therapy even when
appropriate antibiotics are used is common.
Vancomycin is the most commonly used antibiotic for MRSA but success
rates range from only 35% to 57% in MRSA VAP. Treatment failures due
to vancomycin MICs in the upper range of sensitive may not be overcome
without pushing vancomycin levels above the tolerated dose. Vancomycin
also does not affect exotoxin production, an important aspect of CA-
MRSA. Currently available agents or those in development may offer
advantages over older agents for the treatment of MRSA pneumonia.
Community MRSA: hyper virulent or just
hype?
K172 Community meticillin-resistant Staphylococcus aureus:
hypervirulent or just hype?
F. Tenover (Atlanta, US)
Reports of community-associated meticillin-resistant Staphylococcus
aureus (CA-MRSA) infections among healthy persons who have had no
recent contact with healthcare and who have none of the traditional risk
factors for MRSA infection have been increasing at a substantial rate in
the last 7 years. Children in daycare, sports participants, military recruits,
prisoners in institutional settings, pig farmers, and men who have sex
with men are among the many diverse groups who appear to be at risk
for CA-MRSA infections. While these are primarily skin and soft tissue
infections, severe and rapidly fatal syndromes, including necrotising
pneumonia, also have been reported, particularly among young adults.
The pulsed-ﬁeld gel electrophoresis type USA300 (ST-8; SCCmec type
IV) is prominent among CA-MRSA infections in the United States,
and recent evidence conﬁrms that USA300 has spread to Europe,
South America, and the Paciﬁc Islands. Genomic sequencing data from
multiple USA300 isolates conﬁrm the dramatic clonal expansion of the
USA300 MRSA strain, which has been the predominant strain type
isolated both from patients with invasive CA-MRSA infections and from
patients presenting to emergency departments with uncomplicated skin
infections. However, data on the virulence of USA300 strains and the
outcomes of CA-MRSA infections are quite divergent. Is this really a
fearful new epidemic strain, or is CA-MRSA more a media event than
a medical problem?
The myth and realities of decision making in
national vaccination programmes
S173 Funding drugs based on cost-effectiveness: do vaccines
warrant a different approach?
P. Beutels (Antwerp, BE)
Vaccines and vaccination programmes have features that require special
consideration when assessing their effectiveness and cost-effectiveness
for public funding. Special features of vaccines are related to herd
immunity, quality of life losses in very young children, parental care
and work loss, time preference, uncertainty, eradication, macroeconomics
and tiered pricing. These features are discussed, and related to speciﬁc
topical childhood vaccinations against rotavirus, human papillomavirus,
varicella-zoster virus, inﬂuenza and pneumococcus.
Advisory committees on public funding for vaccines (which often give
advice on all pharmaceuticals in a country) should be knowledgeable
about the nature and the impact of these special features, and ﬂexible
enough to allow these features to be explored in cost-effectiveness
calculations presented to them.
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O175 A novel method for the rapid detection of Mycobacterium
tuberculosis complex in respiratory and non-respiratory
specimens
V. Drouillon, G. Delogu, G. Dettori, P. Lagrange, M. Benecchi,
F. Houriez, K. Baroli, F. Ardito, R. Torelli, C. Chezzi, G. Fadda,
J.L. Herrmann (Paris, FR; Rome, Parma, IT; Garches, FR)
Objective: Rapid detection of Mycobacterium tuberculosis complex
(MTB) directly on clinical respiratory and non-respiratory specimens
is essential for an efﬁcient management of patients suspected of
tuberculosis. A new method, based on the Transcription Reverse-
transcription Concerted reaction (TRC; Tosoh Corporation, Japan)
enables one step ampliﬁcation and real-time detection of the MTB 16S
rRNA target directly on respiratory and non-respiratory specimens. The
performance of the EXTRAGEN M.TB kit, TRCRapid M.TB kit and
TRCRapid-160 analyser was evaluated in three laboratories.
Method: An analytical sensitivity assay was performed by adding MTB
reference strains at known concentrations to an MTB negative sputum
sample and assayed in triplicate. The TRC results were compared to
smear and culture and the exact number of bacilli was determined by
counting the colony forming units (CFU) in solid media.
In addition, 633 respiratory and non-respiratory specimens were tested
and all results were compared to smear and culture. All specimens were
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subjected to standard procedures and 500ml of the processed samples
were used for RNA extraction following the TRCRapid-160 protocol.
Finally, 126 patients (Paris cohort only) were followed-up to evaluate
clinical performances of the TRC-method.
Results: The analytical sensitivity assay results showed that the TRC
method can detect as little as 50 CFU/ml.
Of the 633 clinical specimens evaluated, 22 were excluded from the
evaluation (1 contaminated, 11 showed inhibition and 10 were identiﬁed
as Mycobacteria Other Than Tuberculosis (MOTT)), thus a total of 552
respiratory specimens and 59 extra-pulmonary specimens were included.
Overall sensitivity and speciﬁcity of TRC for pulmonary specimens was
86.8% and 96.3% respectively. Sensitivity and speciﬁcity of TRC for
extrapulmonary specimens was 83.3% and 95.7% respectively.
Of the 126 patients analysed, 15 patients presented and were treated for
pulmonary tuberculosis. Twelve out of 15 treated patients had a positive
culture and 13 out of 15 treated patients had a positive TRC. This gave a
sensitivity of culture and TRC of 80% and 86.7% respectively. Speciﬁcity
of culture and TRC were 100% and 93.9% respectively.
Conclusion: Theses results showed that a rapid detection of MTB was
possible (less than 2 processing hours for 14 specimens) using ready to
use reagents for real time detection of MTB in clinical samples with a
high sensitivity and speciﬁcity.
O176 The impact of a PCR assay for detection of candidaemia on
antifungal drug prescribing in critically ill adults
R. McMullan, L. Metwally, P. Coyle, S. Hedderwick, B. McCloskey,
H. O’Neill, H. Webb, R. Hay (Belfast, UK)
Objectives: Molecular assays for the diagnosis of fungal infection from
clinical specimens are increasingly described. However, the extent to
which these are adopted by clinical staff and, critically, the extent to
which their results impact therapeutic decisions is not well described.
Such information is important to justify the cost of developing and
delivering novel diagnostic tests. The aim of this study was to evaluate
the extent to which a clinically validated PCR assay for candidaemia
impacted antifungal drug prescribing.
Method: A prospective observational study was conducted in a mixed
17-bed ICU in which the assay, with turn-around-time of 24-hours, was
made available for a period of six months. Physicians were encouraged
to use the assay particularly when considering prescribing an antifungal
drug in the context of probable Candida infection. Each assay request
was recorded, as well as whether the patient received an antifungal drug
within 72hr of the test request and whether this prescribing decision
reﬂected the test result. When the prescribing decision and assay result
were discordant, a reason for this was sought.
Results: In all, 55 PCR tests were requested on 45 patients. Overall,
the PCR test appeared to strongly inﬂuence the prescribing decision in
44 (80%) instances whether negative or positive. An antifungal drug
was prescribed within 72hr of PCR requesting in 14 (25%) instances;
of these PCR requests, 4 were positive and a further one was from a
patient who had a positive blood culture within 72hr of a negative PCR.
For the remaining nine PCR-negative patients who received an antifungal
drug, various factors were considered to over-rule the PCR test; these
included drug prescribed prior to test ordering, compliance with the
ward prophylaxis policy and high likelihood of infection as determined
by extant pre-emptive prescribing practice.
Conclusions: While the availability of the rapid molecular assay
displayed substantial capacity to modify antifungal drug prescribing
in certain circumstances, it is clear that physician behaviour cannot
be completely inﬂuenced by a single test result regardless of other
factors. Indeed it is unlikely that this is desirable, given that no test
has been shown to perform with 100% reliability. Nonetheless, rapid
diagnostic methods may help to improve antifungal conservation and
their contribution to the ‘model’ therapeutic algorithm merits further
evaluation.
O177 Performance of an automated platform
R. Sahli, K. Jaton, C. Andre, P. Meylan, A. Telenti, J. Bille, G. Greub
(Lausanne, CH)
Objectives: Polymerase chain reaction (PCR) is commonly used to
detect microbial nucleic acids in clinical samples. However, signiﬁcant
risk of PCR contamination, high reagents costs, and signiﬁcant workload
precluded the wide use of PCR for the aetiological diagnosis of infectious
diseases. We thus established a high throughput versatile automated
molecular platform and analysed its performance including the critical
aspects of troubleshooting.
Methods: DNA and RNA were extracted with MagNApure (Roche) and
EasyMAG (BioMe´rieux), respectively. RNA was converted to cDNA
prior to PCR. A TECAN liquid handling system (LHS) was used for
384 well PCR plate setup. Real-time PCR was performed with an ABI
7900HT.
Results: A total of 5953 analyses and 3037 runs have been done during
the study period. The median time from reception of the sample to
results was overall of 28.3 hours. Time to results were signiﬁcantly longer
when the pathogen to be detected was a RNA virus (because of the
retrotranscription step), a fungus (lysis step before DNA extraction) or
a CMV/EBV quantitative PCR (runs performed only three time a week;
p< 0.001). Longer time to results were also due to invalid runs, with need
of repetition of the PCR reactions in a subsequent run: the median time
to results was 27 hours for 5097 analyses that did not need to be repeated,
54 hours for 646 analyses repeated twice and 100 hours for 154 analyses
repeated three times. Among all 3037 runs, 264 runs were invalid (8.7%).
Runs were mainly considered invalid because of the negativity of the ten
copies positive control (7.1% of a total of 3037 runs). Major causes of
invalid runs were hardware problems with the liquid handling system
(2.3% of all runs), use of a defective real time PCR master mix (1.8%),
human procedural errors (1.8%), progressive degradation of the positive
control (1.4%) and defective primer and probes (0.49%). Contaminations
were detected in only 21 runs (0.7%).
Conclusions: Our platform allows to perform a comprehensive set
of microbiological diagnostic tests with a high success rate (>91%).
Improvements in terms of time to result and reduction of repeats are
being addressed thanks to this evaluation.
O178 A mass spectrometry-based approach for Neisseria
gonorrhoeae species identiﬁcation
E. Ilina, A. Borovskaya, S. Sidorenko, A. Kubanova, T. Maier,
M. Kostrzewa, V. Govorun (Moscow, RU; Leipzig, DE)
Objectives: Correct species identiﬁcation of N. gonorrhoeae remains
an actual problem of sexual transmitted diseases monitoring. A large
collection of gonococci isolated in Russian clinics was studied by the
MALDI BioTyper system which allows to perform rapid microorganism
identiﬁcation based on mass spectrometry (MS) proﬁles.
Methods: Gonococci were grown under standard conditions (ASM,
IHO). Single colonies of fresh bacterial cultures were transferred into
a 1.5 ml tube (Eppendorf, Germany) with 300ml of water (Fluka,
Switzerland) and suspended well. Then, 1 ml of 96% ethanol was
added. The pellet obtained by centrifugation (12000 rpm, 5 min) was
suspended in 35% formic acid/50% acetonitrile and centrifuged again.
Supernatant was used for further MS analysis using saturated solution
of alpha-cyano-4-hydroxy cinnamic acid in 50% acetonitrile/2.5% TFA
as matrix. Mass spectra were collected on a Microﬂex LT MALDI-TOF
mass spectrometer, followed by analysis with the BioTyper 1.1 software
(Bruker Daltonics, Germany).
Results: Totally, 293 bacterial isolates identiﬁed as N. gonorrhoeae in
clinical bacteriology laboratories were investigated. For 280 (95.6%)
samples the mass spectrometry proﬁles were matched to N. gonorrhoeae
ATCC strain 49226 with excellent scores (2.3−2.9 with species threshold
sets at 2.0). Comparative analysis of spectra showed good reproducibility
within N. gonorrhoeae species with slight differences between isolates.
The majority of peaks were constant; only three ones with m/z 4473,
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5051, and 8165 changed their m/z value to 4487, 5081, and 8146,
respectively, for several strains. The remaining isolates (n = 13) obtained
similar mass spectra which were rather different from N. gonorrhoeae
ATCC strain 49226 as well as from main spectra generated for 13
N. meningitidis, 15 non-pathogenic Neisseria strains and further 1671
different microorganisms stored in the BioTyper library. The initial
misidentiﬁcation was conﬁrmed by Crystal Haemophilus/Neisseria
(BBL) test which allowed to identify these bacteria as Oligella urethralis.
Although O. urethralis is a commensal inhabitant of urogenital tract in
rare cases it can be infectious. The main spectra of O. urethralis have
been included in the new generation of BioTyper library.
Conclusion: The MALDI BioTyper system is an easy to use and highly
suitable tool for the correct N. gonorrhoeae species identiﬁcation in
routine settings.
O179 Rapid screening of the human microbiome by bacterial
proﬁling
A. Budding, H. Akol, A. van Bodegraven, P. Savelkoul (Amsterdam, NL)
Objectives: It is well known that the human microbiota plays an
important role in health and disease. However, the exact role of the
commensal bacteria and the ways in which they inﬂuence our wellbeing
remains elusive. One of the major obstacles in solving these and related
questions is the analysis of the microbiome. New insights have recently
been gained with high throughput sequence analysis but, although
valuable, these methods are not suited for large scale screening. Here we
present a rapid and straightforward assay for the proﬁling of the human
microbiota.
Methods: The molecular method involves two features: the length of the
interspace (IS) region between the 16s and the 23s rDNA and speciﬁc
primer sequences discriminating Firmicuta and Bacteroidetes, the two
major phyla in the human colon. The IS region is conserved within
a species, but varies between species. Thus bacteria can in principle
be identiﬁed by the length of their IS region. Unknown species can
be recognised using the speciﬁc primer sequences. The primers were
combined with non-speciﬁc reverse primers in a double label multiplex
PCR. Size and colour sorting of fragments was performed in an ABI
3130XL sequencer.
For validation purposes an in silico proﬁle of 5 bacteria was constructed
based on known sequence information and tested with the cultured
bacteria. Then, colonic mucosal biopsies from 20 patients were analysed
using this method. Intra- and interpatient composition of colonic
microbiota was analysed in 5 biopsies per patient, from coecum, ﬂexura
hepatica, ﬂexura lienalis, sigmoid and rectum.
Results: All cultured bacteria showed a proﬁle identical to the in silico
proﬁle. Subsequently, excellent bacterial proﬁles were obtained for the
clinical samples. Each patient had a unique bacterial proﬁle, with only
a few fragments being identical between patients. These fragments
corresponded to well known colonic bacteria such as Faecalibacterium
prausnitzii and Bacteroides thetaiotaomicron. Patterns obtained from the
different sites of the colon of a single patient were almost identical.
Conclusions: The bacterial proﬁling method proved to be identical to
expected proﬁles based on sequence data. In addition, the method was
suited for characterisation of the complex human microbiome. With this
method, proﬁles of the human colonic microbiota can be obtained in a
straightforward fashion. The method is universal, fast, reproducible and
ideally suited for analysis of large sample sets.
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O180 HBV lamivudine resistance mutations in a cohort of
mono-infected and HIV-co-infected patients
G. Antonucci, M. Solmone, P. Piselli, F. Vairo, D. Vincenti, F. Iacomi,
V. Puro, M.R. Capobianchi (Rome, IT)
Objectives: Pattern and prevalence of mutations between HIV-HBV
coinfected (HIVpos) and HBV monoinfected (HIVneg) individuals on
lamivudine (LAM) therapy have not been extensively documented.
We investigated the frequency of mutations and variables potentially
associated with an increased risk of HBV mutations in HBsAg+
individuals.
Methods: Among 128 patients tested for LAM resistance, after the
exclusion of inappropriate tests (performed <90 days from LAM
initiation or >180 days from last LAM treatment) we analysed 102
pts (64 HIVneg and 38 HIVpos). pol gene mutations were assessed
by direct sequencing reverse transcriptase fragment 125–213aa, while
HBV genotype by comparison with reference sequences. Association
of pol mutations with selected factors was assessed by means of odds
ratios ﬁtting multiple logistic regression (MLR) equations and their
95% conﬁdence intervals (CI), adjusting for sex, age, HIV- and HCV-
coinfection, LAM exposure, HBeAg positivity and HBV genotype.
Results: Average LAM exposure was higher in HIVpos than in HIVneg
(39 vs. 29 months, p = 0.054) as well as genotype A prevalence
(58% vs. 14%, p< 0.0001). LAM-resistance mutations were detected
in 71/102 individuals (69.6%): 26/38 (68%) HIVpos and 45/64 (70%)
HIVneg patients. Mutation was signiﬁcantly associated with prolonged
LAM exposure (MLR-OR=4.9 CI:1.2−20.3, >3 vs <1 years) and
older age (MLR-OR=1.2 CI:1.0−1.6, for each 5 years increase).
M204V mutation was observed in 42 patients (60%); interestingly this
mutation was found in almost all HIVpos (24/25, 92%) and only
in 18/45 (40%) HIVneg patients (p< 0.0001). Prevalence of triple
mutations (M204V+L180M+V173L) was higher in HIVpos (31% vs.
2%, p< 0.001). Independently to HIV-infection, HBeAg expression is
more likely to be associated with M204V than M204I mutation (MLR-
OR=7.9 CI:1.5−42.8).
Conclusions: In conclusion, main predictor for pol mutations is
prolonged LAM exposure. In HIVpos patients, M204V and multiple
mutation were more prevalent; independently from HIV positivity,
M204V mutation was associated with HBeAg expression. Further studies
are needed, to clarify the kinetics and signiﬁcance of different mutation
patterns observed in monoinfected and HIV-HBV-coinfected pts.
O181 MicroRNA deregulation in HCV-associated hepatocellular
carcinoma
A. Sinigaglia, L. Barzon, E. Lavezzo, M. Trevisan, F. Farinati, G. Palu`
(Padua, IT)
Objectives: Recent evidences on the role of microRNAs (miRNAs) in
human cancers and their possible effects on HCV replication led us
to investigate miRNAs expression proﬁle in HCV-related hepatocellular
carcinoma (HCC) as compared to adjacent non-neoplastic liver and its
relationship with the presence of HCV infection.
Methods: Tissue samples from 22 HCCs and adjacent non-tumoral tissue
were obtained from surgical specimens removed during HCC resection.
RNA extraction from samples was performed using miRNA-compatible
protocols and reagents. miRNAs expression proﬁle was investigated by
microarray analysis and conﬁrmed by real-time RT-PCR. HCV detection
and typing was performed by RT-PCR-sequencing by using PCR primer
pairs targeting different regions of viral genome.
Results: HCV RNA was detected in 17 out of 22 HCCs; HCV genotype
1b accounted for 60% positive cases and HCV-1a and 2 for 20% each.
Analysis of miRNA expression proﬁle in HCCs showed deregulation of
a group of miRNAs, including miR-122a, which was down-regulated in
15 (76%) cases as compared with non-neoplastic adjacent liver samples;
miR-195, miR-199a, and miR-199b, which were consistently under-
expressed in about 60% of HCCs, and miR-145, under-expressed in
40% of cases. At variance, miR-222 was up-regulated in 50% HCCs.
MiR-145, miR-222, and miR-199a showed a stronger deregulation in
HCV-positive HCCs than in HCV-negative cancers. These miRNAs could
play an important role in the development of HCC since they target
many genes involved in the control of cell cycle and cell proliferation,
as predicted by the Sanger miRBASE Sequences Database. Among
target genes, there are cyclin G1 (regulated by miR-122a), cyclin E1
(potentially regulated by miR-195), map3k4 and map3k11 (targeted by
miR-199a and miR-199b, respectively), junB (targeted by miR-199b),
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bcl-w and cdc42 (targeted by miR-195), and ras-related protein rreb1
(targeted by miR-199a).
Conclusions: While investigating a larger number of HCC samples,
these results indicate that HCC, and in particular HCV-related HCC,
is characterised by deregulation of a set of miRNAs involved in the
control of the cell cycle.
O182 Comparison of the COBAS Taqman PCR and b-DNA
PCR in patients treated for hepatitis C genotype 1, partly
co-infected with HIV
J.E. Arends, G.J. Boland, I.M. Hoepelman (Utrecht, NL)
Background/Aim: Treatment decisions (e.g. discontinuation or short-
ening of therapy) are based on plasma hepatitis C (HVC) RNA
measurements. Both quantitative and qualitative detection systems are
commercially available. These systems rely either on target (Roche
Cobas Taqman RT-PCR) or signal ampliﬁcation (Bayer Versant b-DNA
V3). Differences in linear ampliﬁcation, sensitivity and speciﬁcity, lower
limit of detection and standard of automated testing makes comparison
between these assays mandatory. The aim of this study is to correlate
plasma HCV RNA values of both the COBAS Taqman PCR and the
Versant b-DNA PCR assay.
Methods: From 20 HCV genotype 1 positive patients treated with
peginterferon alfa-2a and weight-based ribavirin, plasma samples at
baseline, day 2 and at weeks 1, 2, 4, 8, 12, 48 of treatment and 24
weeks after therapy are collected for measurements of plasma HCV-RNA
loads. Totally, paired samples with a quantitative range from undetectable
to 1.6 10E7 IU/mL are compared, excluding those values that were
undetectable. For both the COBAS Taqman (lower limit of detection
10 IU/mL) and the Versant b-DNA (lower limit of detection 615 IU/ml)
50 uL of plasma is used.
Results: A total of 86 paired samples are analysed with a median value
for the Taqman assay of 5.05 log IU/mL versus a median value of 4.93
log IU/mL for the Versant b-DNA assay. In 69% of the measurements
the Taqman PCR shows a higher HCV viral load than the b-DNA PCR.
This is mainly for measurements in the higher viral loads, i.e. above
5log10 IU/mL. There is an excellent correlation between both assays
(Spearman ranks coefﬁcient 0.902, p< 0.01). A Bland-Altman analysis,
shows a bias of 0.23 log10 IU/mL with a standard deviation of 0.45
(95% CI of −0.66 to 1.12 log10 IU/mL).
Conclusion: There is an excellent correlation between the COBAS
Taqman and the Versant b-DNA assay. Overall, compared to the bDNA
assay, the COBAS Taqman PCR measurements are higher, mainly within
the higher viral loads.
O183 The ﬁrst 48 hours of viral response during therapy
differentiate between rapid viral response and null response
in hepatitis C genotype 1 patients
J.E. Arends, J. Cohen Stuart, L.C. Baak, I. van der Ende, K.J. van
Erpecum, G.J. Boland, D. van Baarle, I.M. Hoepelman (Utrecht,
Amsterdam, Rotterdam, NL)
Background / Aim: During peginterferon/ribavirin therapy, decrease of
plasma HCV RNA occurs in a biphasic pattern, consisting of a rapid ﬁrst
phase (48 hours) of eliminating free virus and a slower second phase of
clearing infected hepatocytes. Previous models showed no difference in
rapid ﬁrst phase between patients with an early viral response (EVR)
versus a null response. Recently, a rapid viral response (RVR) proved
important in shortening therapy. Because viral decay rates in these
patients have not been analysed, our aim is to compare the ﬁrst and
second phase decay in patients with a RVR versus those with an EVR
or a null response.
Methods: From HCV genotype 1 positive patients treated with
peginterferon alfa-2a and weight-based ribavirin, plasma samples at
baseline, day 2 (48 hours) and at weeks 1, 2, 4, 8, 12, 48 of treatment
and 24 weeks after therapy, are collected. The viral decay rates/ day
are calculated for both the rapid ﬁrst phase after 48 hours (rate c) and
the slower second phase from day 2 until week 12 (rate d). Standard
accepted deﬁnitions for both EVR and null response are used whereas
RVR is deﬁned as a qualitatively undetectable HCV-RNA at week 4 of
treatment.
Results: A total of 13 patients are analysed with 5 patients showing a
RVR, 4 a null response and 4 an EVR. The viral decay rates for both the
ﬁrst and second phases are statistically signiﬁcant between RVR and null
responders; pc = 0.0159 with c = 2.04 vs. 0.61 and pd = 0.0159 with d
= 0.22 vs. 0.03 respectively (see ﬁgure). Between patients with a RVR
and an EVR there is a trend toward a faster response in the ﬁrst phase
decay but no difference in second the phase decline. Baseline viral load
(below or above 800,000 IU/ml) and body weight at baseline were of no
inﬂuence on viral kinetics in both the ﬁrst and second phase between
clinical patient groups.
Conclusion: A faster decline of plasma HCV RNA during the ﬁrst 48
hours of therapy differentiates between patients with a RVR and null
responders.
O184 Comparison of quality of life in inactive hepatitis B virus
carriers versus chronic hepatitis B patients versus normal
Turkish population
M. Tasbakan, O. Sertoz, H. Pullukcu, S. Calik, O. Sipahi, T. Yamazhan
(Izmir, TR)
Objective: It was aimed to evaluate the QOL in inactive HBsAg carriers
with a control group who had a diagnosis of chronic hepatitis B and had
not received any antiviral therapy, yet.
Methods: The study sample was consisted of two groups. First group
was comprised of inactive HBsAg carriers recruited from individuals
who were regularly followed-up in Infectious Diseases & Clinical
Microbiology outpatient clinic of our setting due to inactive HBV
infection [HBV DNA levels <103 copies/mL, Robogene Hepatitis B
virus quantitation kit, Roboscreen, Germany) and normal biochemical
parameters (Aspartat amino transferase-AST, alanine amino transferase-
ALT, bilirubin, no HIV or HCV infection, no drug abuse.)]. Second
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group was recruited among patients who had a diagnosis of chronic HBV
infection [Hepatic activity index 4 in liver biopsy, HBVDNA >20,000
IU/ml and AST, ALT 2× normal] and who were not undergoing active
treatment yet. Both groups were requested to ﬁll health related quality
of life by means of short form 36 (HRQOL-SF-36) questionnaire and a
form asking data of age, gender and education. The data of two groups
were compared between each other and both groups were compared with
QOL data of normal Turkish population.
Results: Of 131 inactive HBsAg carriers and 38 patients with chronic
HBV diesease 128 (50 females, 78 males, mean age 41.4±12.3) and
28 (9 males, 19 females, mean age 36.68 ±10.56) accepted to be
included in the study. The QOL data of group 1 and 2 are shown in
Table 1. The groups did not show any signiﬁcant difference by means
of age and gender, though a signiﬁcant difference was observed in
educational level. HRQOL of patients showed a proﬁle similar to that
of the general Turkish population, with normal physical functioning,
and vitality scores, but statistically signiﬁcant lower role limitations due
to emotional problems, bodily pain, general health perceptions, social
functioning, role limitations due to physical health problems, and mental
health domain scores (p< 0.001). HRQOL of patients with chronic HBV
disease was also signiﬁcantly lower in role limitations due to emotional
problems, bodily pain, general health perceptions, social functioning, and
role limitations due to emotional problems scores (p< 0.001).
Table 1: Comparison of quality of life between inactive HBsAg carriers
and patients with chronic HBV infection and not undergoing active
treatment
SF-36 domains Inactive
HBsAg
carriers
n = 128
Chronic
HBV
infection
n = 28
Covariance
analysis
Physical functioning 86.05±15.01* 80.71 (22.8) F = 1.55
Df = 1.153
P = 0.22
Role limitation – physical* 77.15±35.49 54.46 (37.3) F = 9.52
Df = 1.153
P = 0.002
Bodily pain 79.43±21.47* 70.25 (22.2) F = 2.47
Df = 1.153
P = 0.11
General health perception 61.82±19.01* 59.59 (22.7) F = 0.29
Df = 1.153
P = 0.59
Vitality 67.89±19.74 64.58 (22.7) F = 0.29
Df = 1.153
P = 0.59
Social functioning 79.29±19.43* 71.42 (27.6) F = 2.27
Df = 1.153
P = 0.13
Role limitation – emotional 76.04±34.73* 58.33 (42.2) F = 3.64
Df = 1.153
P = 0.06
Mental health 66.58±16.89* 65.85 (22.5) F = 0.00
Df = 1.153
P = 0.9
Means (with standard deviations), *p< 0.05.
Conclusion: QOL in inactive HBsAg carriers was quite similar to that
of patients with chronic HBV disease and both inactive HBsAg carriers
and patients with chronic disease had lower QOL than normal Turkish
population.
Bacterial virulence factors: does in vitro
activity reﬂect in vivo relevance?
S188 The Panton-Valentin leukocidin as an example of a bacterial
toxin underestimated clinical relevance
G. Lina, M. Dumitrescu, A. Tristan, C. Badiou, F. Vandenesch,
J. Etienne (Lyon, FR)
The history of Panton Valentine leucocidin (PVL), one of the toxins of
Staphylococcus aureus, began in 1894. The torch of PVL research was
then handed down over the decades between small groups of scientists
fascinated by S. aureus toxins. Knowledge advanced in ﬁts and starts,
notably with the advent of new research tools.
The ﬁrst studies focused on the effects of S. aureus on leukocytes,
while the latest, 100 years on, involves genetic characterisation of
the leucocidin. In addition, highly epidemic PVL positive meticillin-
resistant S. aureus strains have recently emerged as a worldwide health
issue, leading to a further upsurge of interest in PVL. Confusion has
been recently introduced in the PVL literature because one group of
scientists recently failed to express PVL in their experimental models.
However epidemiological, clinical and biological data obtained from
staphylococcal infections in human concur to demonstrate that PVL is
a virulence factor in human involved in human primary skin infection,
necrotising pneumonia and bone and joint infection but not in other
diseases. The relationship between PVL and virulence is independent of
meticillin resistance phenotype.
Is the case for antifungal prophylaxis in the
ICU now established beyond doubt?
S189 Is the case for antifungal prophylaxis in the ICU now
established beyong doubt? PRO
P. Eggimann (Lausanne, CH)
Fungal infection are suspected in many critically ill patients who failed
to respond to empirical treatment of nosocomial infections. However, if a
substantial proportion of patients become colonised with Candida during
ICU stay, only a minority subsequently develop an invasive candidiasis.
Clinical signs of invasive candidiasis manifest only late, representing
a particular challenge for diagnosis, and remains characterised by a
mortality similar to septic shock (40% to 60%). An improved knowledge
of the pathogenesis of candidiasis and the availability of new compounds
for pre-emptive and prophylactic therapy have contributed to improve
the prognosis of severe Candida infections, to the possible cost of the
emergence of non-albicans Candida strains with reduced susceptibility
to imidazoles. Despite growing evidence in the literature, guidelines do
not integrate systematic antifungal prophylaxisfor patients at risk and
empiric treatment for those who are septic with major risk factors and
without documented source of infection. The Figure propose a practical
approach (Adapted from: P. Eggimann, J. Garbino, D. Pittet. Management
of Candida species infections in critically ill Patients Lancet Infectious
Diseases 2003; 3:772−85). In order to avoid exposure of patients at
lower initial risk, pre-emptive antifungal treatment should be based
on the combination of the presence of risk factors with the dynamics
of Candida colonisation. Finally, in non-immunocompromised patients
critically ill patients, prophylaxis should be strictly restricted to highly-
selected groups of patients in whom it’s efﬁcacy is proven.
S190 The case against antifungal prophylaxis in the ICU
R.A. Barnes (Cardiff, UK)
Up to half of all invasive fungal infections (IFIs)occur in non-neutropenic
ICU patients and the majority are due to Candida species. Despite
this, incidence of IFIs on most ICUs is low and ranges from 1−5%
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in most European units. Many candidal infections are nosocomial and
preventable.
Several RCTs have looked at prophylaxis, predominantly with ﬂu-
conazole in ICU patients and three systematic reviews have been
performed. Meta-analyses reportedly demonstrates a reduction in proven
IFI. However, ICU populations are heterogenous:there are marked
differences between Europe and North America, diagnostic criteria are
not deﬁned and prophylaxis and targeted therapy are not distinguished.
Widespread use of azole drugs promotes resistance, pathogen shifts
and adverse drug related events. It is necessary to establish methods
to identify patients at greatest risk of IFI who will beneﬁt most from
antifungal drugs.
Numerous risk factors have been identiﬁed including length of
stay, colonisation, antibiotics, surgery, central venous catheters, total
parenteral nutrition, gastric acid suppression, bacterial sepsis etc. but
none accurately predict IFI or fungal related mortality. Several prediction
rules and scoring systems have been proposed to identify subpopulations
of ICU patients who would beneﬁt from prophylaxis. These rules identify
different percentages of patients – up to 85% in some centres. Many
have been created and validated within the same database and none are
practical or have proven robustness across all ICU populations. Cost
effectiveness has never been evaluated and numbers needed to treat to
prevent a single case remain high in centres with a prevalence of less
than 20%. Centres reporting high prevalence of candidal infection should
address infection control issues before resorting to prophylactic drugs.
Diagnosis still relies on conventional microbiological techniques of
culture from sterile sites but the role of biomarkers (antigen and PCR
testing) merit further investigation in ICU populations. The high negative
predictive value of these newer assays has the potential to inﬂuence
antifungal strategy by identifying patients who do not have fungal
infection. Combined with a robust and simple model to predict the
risk of developing invasive Candida infection, these tests that can
rapidly exclude fungal infection in high-risk groups and allow a targeted
(pre-emptive strategy) to be developed and supersede unnecessary
prophylactic treatment.
Genetic diversity and mechanisms of genetic
diversiﬁcation in bacteria
O195 Characteristics of Neisseria meningitidis isolates causing
fatal disease
S. Jacobsson, P. Olce´n, H. Fredlund, P. Mo¨lling (O¨rebro, SE)
Neisseria meningitidis, named meningococci (Mc), is a major cause of
acute bacterial meningitis and septicaemia worldwide. The spectrum of
human meningococcal relation goes from asymptomatic carriage to fatal
infection. Despite modern medical treatment about 10% of the cases
with invasive meningococcal disease are fatal. The reason why some Mc
causes invasive disease while others are harmless is basically unknown.
Part of the explanation refers to factors within the patient, for example,
the status of innate and adaptive immunity and part of the explanation
is probably found within in the bacterium as such.
Objectives: The objectives of the present study were to compile and
describe a selection of characteristics of fatal meningococcal isolates
(n = 62) as compared to invasive non-fatal ones (n = 474) collected in
Sweden during 1995 to 2004. The coverage of the fatal serogroup B
isolates by four different outer membrane vesicle (OMV) vaccines was
also estimated.
Methods: The isolates were characterised by serogroup, serotype,
genosubtype, multilocus sequence type and antibiogram. Basic epidemi-
ological data were also gathered.
Results and Conclusion: The results for the 62 fatal isolates (fatality
rate 12%) comprised of 34 serogroup B (11%), 17 C (12%), 9 Y
(17%) and 2 W-135 (8%). Characteristics that were associated with a
higher mortality were age, gender, serogroup Y, serotype 14 and 15,
genosubtypes P1.7,16-29,35 and P1.5-1,10-4,36−2. On the contrary were
non14/non15 serotypes, the genosubtypes P1.5-1,10-8,36-2; P1.7-2,4,37
and P1.7,16,35, and reduced sensitivity for penicillin G associated with a
decreased mortality. The presently discussed OMV vaccines could, based
solely on the complete genosubtype, theoretically cover up to 44% of
the fatal serogroup B cases and up to 100% if every variable region by
itself is capable to induce protection. Alarming is however the fact that
among the invasive but non-fatal ones three isolates did not express a
functional PorA protein and will thereby not be covered by any PorA
components in these vaccines.
Our present 62 fatal respectively 474 non-fatal isolates form a well-
deﬁned basis that can be further characterised with supplementary
methods and for example investigated concerning new vaccine antigens
and potential pathogen-speciﬁc genes.
O196 Identiﬁcation of a “hot spot” for integration of mobile
elements in Enterococcus faecium
J. Top, W. van Schaik, M. Bonten, R. Willems (Utrecht, NL)
Objectives: The aim of the current study was to determine the inte-
gration site and exact size of the esp containing putative pathogenicity
island (PAI) of Enterococcus faecium strain E1162 and to investigate
sequence heterogeneity adjoining the PAI integration site in PAI positive
and negative isolates.
Methods: The genome sequences of the PAI-negative strain E1071 and
the PAI-positive strain E1162 have been determined in our laboratory
(Van Schaik et al., in preparation). From the genome sequences, regions
that were homologous to the ﬂanking sequence of the esp containing
PAI in E1162 were identiﬁed in E1071 and in another PAI negative
strain, E. faecium DO, which has a publicly available genome sequence.
This allowed us to identify the PAI integration site. Subsequently, PAI
integration and sequence heterogeneity adjoining the integration site was
determined using normal and long-range PCR in 17 PAI-positive and
34 PAI-negative strains using combinations of PAI speciﬁc primers and
primers speciﬁc for the ﬂanking genes.
Results: DNA alignments between E1162 and DO revealed integration
in E1162 of a 61-kb large DNA fragment, containing the esp gene, in
the 3′ end of an open reading frame with high identical to orf1671 of
E. faecium DO. This integration resulted in a 54-bp duplication. At the 5′
end of the E1162 PAI a 22-kb region with high similarity (up to 100%) to
an E. faecalis mobile element was found, while the 3′-end is homologous
to orf13 to orf23 of Tn916. Interestingly, in strain E1071 another 8.3-kb
element with no homology to the PAI of E1162 was integrated at the
same position. PCR demonstrated that in all 17 PAI-positive isolates the
PAI was integrated in the DO orf1671 homolog. In 23/33 PAI-negative
strains, PCR conﬁrmed no integration at this site, however, in one isolate
PCR indicated integration of a fragment of at least 13-kb. In 9 strains no
PCR product using primers spanning the integration site was obtained
suggesting either integration of DNA elements too large to amplify or
polymorphisms at the primer annealing site.
Conclusions: The striking variety of mobile DNA inserted into the
DO orf1671 homolog suggests that this site may be a “hot spot” for
integration of exogenously acquired genetic elements in E. faecium.
O197 Variability of Inc group of conjugative plasmids and CTX-M
gene environments in Enterobacteriaceae nosocomial strains
isolated from Russia
N.K. Fursova, I.V. Abaev, S.D. Pryamchuk, N.A. Shishkova,
E.I. Pecherskikh, O.V. Korobova, A.N. Kruglov, L.M. Weigel,
J.K. Rasheed (Obolensk, RU; Atlanta, US)
Objectives: CTX-M is the most prevalent type of extended-spectrum
b-lactamase (ESBL) among clinical isolates [85% including Escherichia
coli (n = 205) and Klebsiella pneumoniae (n = 151)] collected from
2003 to 2007 in Russia. Subtypes of blaCTX-M genes were identiﬁed:
blaCTX-M-1 (92%), blaCTX-M-9 (6%), blaCTX-M-2 (1%), and a com-
bination of blaCTX-M-1 and blaCTX-M-9 (1%). Plasmid localisation of
blaCTX-M genes and a description of their gene environments are the
focus of this study.
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Methods: PCR mapping and DNA sequencing were used for detection,
localisation, and identiﬁcation of the genes under study. Conjugation
was performed in broth using E. coli C600 (RifRAzR) as the recipient
strain. Antimicrobial resistance phenotypes were determined by broth
microdilution. Plasmid DNA was extracted by the method of Kado &
Liu (1981) and plasmid incompatibility (Inc) group identiﬁcation was
determined by PCR-based replicon typing (Carattoli et al., 2005).
Results: All isolates examined carried blaCTX-M genes on large plas-
mids (~70–160 kb). Sixty plasmids were conﬁrmed to be conjugative.
Restriction fragment length polymorphism (RFLP) analysis indicated
several different subgroups among plasmids of equivalent size. Plasmids
appeared to belong to different Inc groups varying by genus and
blaCTX-M allele (Fig.1). IncF, a major conjugative plasmid group in
E. coli producing CTX-M1-like enzymes, included ISEcp1, IS26, and
mucA structures. IncL/M, a major plasmid group in K. pneumoniae
CTX-M1-positive strains demonstrated the same gene arrangement,
but with more variants because of additional combinations and small
insertions. Gene environments of CTX-M9-like genes include ISEcp1,
IS26, and IS903 structures on IncI1, IncF, IncA/C (E. coli), and IncN
(K. pneumoniae) plasmids. A unique E. coli strain had ORF153 upstream
of a CTX-M2-like gene on an IncI1/IncP plasmid.
Conclusion: Nosocomial E. coli and K. pneumoniae isolates from
different regions of Russia carry blaCTX-M genes on high-molecular
weight plasmids belonging to various Inc groups. CTX-M gene
environments are different for blaCTX-M subgroups and bacterial genera
indicating differences in gene transmission mechanisms.
Acknowledgements: This study was done on the frame of the
ISTS#2913/BTEP#62 Project.
O198 Genetic diversity and evolution of group A Streptococcus
M protein
P.R. Smeesters, P. Mardulyn, A. Vergison, R. Leplae, L. Van Melderen
(Gosselies, Brussels, BE)
Objective: Group A Streptococci (GAS) are divided in 150 emm-
types based on the sequence of the N-terminal 50-amino acids (aa)
hypervariable region of the M protein. M is a major virulence factor,
anchored in the membrane through a conserved C-terminal region. M is
composed of 4 regions (A, B, C and D) formed of repeat blocks. Such
structures are substrates for intragenic homologous recombination which
may lead to antigenic variation. Epidemiological studies performed in
developed countries underlined the small number of different emm-
types. However, a larger diversity of emm-types was found in developing
countries, notably Brazil. To gain insights into the molecular bases for
such difference, the genetic relatedness of the whole surface exposed
part of M proteins of Belgian and Brazilian isolates was investigated.
Methods:Multiple alignments of the M sequences (from the N-terminus
to a conserved sequence in the D2 repeat; 200 to 435 aa) from 51
representative emm-types (selected among a well-characterised Belgian
and Brazilian epidemiological collection by a clustering method) were
performed. A phylogenetic tree was constructed using the neighbour-
joining algorithm. Several methods were assayed on the same dataset
with congruent results.
Results: The prevalence of the Belgian and Brazilian isolates was similar
in clades A and B. Clade B contains two monophyletic groups showing
geographical preference, sub-clade B1 was mainly composed of Brazilian
isolates while sub-clade B2 contained 55% of the Belgian isolates and
only 14% of the Brazilian ones. B2 presented the particularity of being
composed of isolates that are distantly related. Multiple alignments
revealed that (i) the genetic diversity is mostly generated by a high degree
of sequence variation in the C repeat region and (ii) by an increase of
the number of A and B repeat leading to an overall increase of the size
of the M proteins. The Dn/Ds analysis showed that purifying selection
drives the evolution of M.
Conclusion: Despite a small number of different emm-types and
consequently an apparent low diversity, the overall genetic diversity of
the M proteins from the Belgian isolates was comparable to that of the
Brazilian ones. The evaluation of the whole surface exposed sequence
variations will shed light on the molecular mechanisms involved in
virulence and host colonisation as well as the selective pressure driving
the antigenic variation and evolution of the M protein.
Genetic diversity of M protein among Belgian and Brazilian GAS
isolates. The emm-type of each sequence is indicated next to the bar.
Green and red squares indicate Brazilian and Belgian strains respectively.
REA indicate a rearranged emm pattern. The evolutionary history was
inferred using the Neighbor-Joining method. Bootstrap value higher than
70% are shown next to the branches (500 replicates). The tree is drawn to
scale, with branch lengths in the same units as those of the evolutionary
distances used for the phylogenetic tree. The evolutionary distances were
computed using the Poisson correction method and are in units of the
number of amino acid substitutions per site. The rate variation among
sites was modeled with a gamma distribution (shape parameter = 0.5).
Thirteen clusters (A−M) were deﬁned based on an arbitrary deﬁned
maximal genetic distance of 0.37 substitutions per site in each cluster.
Clade A and B group Sof-positive and -negative emm-types respectively.
Sof activity is unknown (*).
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O199 The Mycoplasma pneumoniae MPN229 gene encodes a
protein that selectively binds single-stranded DNA and
promotes Escherichia coli RecA-promoted homologous DNA
recombination
M. Sluijter, T. Hoogenboezem, N.G. Hartwig, C. Vink (Rotterdam, NL)
Objectives: Mycoplasma pneumoniae has previously been characterised
as a micro-organism that is genetically highly stable. In spite of this
genetic stability, homologous DNA recombination has been hypothesised
to lie at the basis of antigenic variation of the major surface protein,
P1, of M. pneumoniae. In order to identify the proteins that may be
involved in homologous DNA recombination in M. pneumoniae, we set
out to characterise the MPN229 open reading frame (ORF). This ORF
bears sequence similarity to the gene encoding the single-stranded DNA-
binding (SSB) protein of Escherichia coli, which is known to play a vital
role in DNA recombination as well as DNA replication and repair.
Methods: The MPN229 ORF was ampliﬁed by PCR on genomic DNA
from M. pneumoniae strain MAC, cloned into a protein expression
vector, and expressed to high levels in E. coli. The resulting protein,
which was termed Mpn SSB, was puriﬁed, and its activity was
determined in various DNA binding and recombination assays.
Results: The MPN229 ORF has the capacity to encode a 166-amino
acid protein with a calculated molecular mass of 18.4 kDa. The amino
acid sequence of this protein (Mpn SSB) is most closely related to
that of the protein predicted to be encoded by the MG091 gene from
Mycoplasma genitalium (61% identity). Mpn SSB was expressed in
E. coli and puriﬁed to >95% homogeneity. The puriﬁed protein was
found to: (i) exist primarily as dimer in solution, (ii) strongly and
selectively bind single-stranded DNA (ssDNA) in a divalent cation- and
DNA substrate sequence-independent manner, and (iii) stimulate E. coli
RecA-promoted DNA strand exchange.
Conclusion: The Mpn SSB protein represents the M. pneumoniae
counterpart of SSB proteins from other bacteria. The protein efﬁciently
binds ssDNA and stimulates E. coli RecA-promoted homologous DNA
recombination. As a consequence of these activities, the Mpn SSB
protein may play a crucial role in DNA recombinatorial pathways in
M. pneumoniae. The results from this study will pave the way for
unraveling these pathways and assess their role in antigenic variation
of M. pneumoniae.
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O200 PTX3 and C-reactive protein in severe meningococcal disease
T. Sprong, P. Giuseppe, C. Neeleman, A. Mantovani, S. Signorini,
J.W.M. van der Meer, M. van Deuren (Nijmegen, NL; Rozano, Milan, IT)
The long pentraxin PTX3 is an important element of the innate
immune system and has potential as a diagnostic tool in inﬂammatory
conditions. We studied PTX3 in patients admitted to an ICU with severe
meningococcal disease and compared it with the short pentraxin CRP.
26 patients with meningococcal disease were studied, 17 patients
presented with meningococcal septic shock (shock group) and 9 patients
with meningococcal meningitis or bacteraemia (no shock group). PTX3
and CRP were measured by ELISA.
High plasma concentrations of PTX3 (median 579 mg/L) were seen at
admission in patients with meningococcal disease. Concentrations were
signiﬁcantly higher in patients with shock compared to patients without
shock (median 801 mg/L and median 256 mg/L, P = 0.006, respectively).
In contrast, CRP at admission was lower in the shock group as compared
to the no shock group (median 58 mg/L and median 165 mg/L, P = 0.008,
respectively). Time course of PTX3 and CRP showed that in patients
with shock, PTX3 concentration was highest at admission, whereas CRP
peaked 48 hours after admission. In patients with meningitis however,
CRP peaked within the ﬁrst 24 hours after admission (Figure 1).
Figure 1. Time course of PTX3 and CRP in meningococcal disease.
Closed squares indicate patients with shock, open circles patients with
meningitis. Medians and interquartile ranges are shown.
High PTX3 and low CRP concentration at admission discriminated
between presence and absence of shock (area under the ROC curve
0.85, P = 0.007 for PTX3 and 0.84 P = 0.01 for CRP). PTX3 was not
correlated with disease severity (PRISM) and days spent in ICU. CRP
concentration at admission showed a strong negative correlation with
parameters of disease severity.
In conclusion, PTX3 was an early indicator of shock in patients with
severe meningococcal disease that followed a pattern of induction distinct
from CRP. High PTX3 and low CRP plasma concentrations discriminated
between the presence or absence of shock. Thus, a high PTX3 level at
admission may alert the clinician for imminent deterioration and shock.
O201 Short versus long course antibiotic therapy for acute
pyelonephritis in adults: a meta-analysis of randomised
controlled trials
K. Kyriakidou, P. Rafailidis, S. Athanassiou, D. Matthaiou, M. Falagas
(Athens, GR)
Objective: Despite the high incidence of acute pyelonephritis in the
community setting, there is no consensus on the optimal duration
of treatment. To our knowledge, no quantitative synthesis has been
previously performed investigating the issue of shortening the prevailing
therapeutic schemes for the treatment of this disease.
Methods: We searched PubMed and Cochrane Central Register of
Controlled Trials to identify and extract data from relevant RCTs for
a meta-analysis comparing the effectiveness and toxicity of short versus
long regimens for the treatment of acute pyelonephritis. Inclusion criteria
were: RCTs involving adult patients with acute pyelonephritis and
comparing regimens with the same antibiotic, in the same daily dosage
but administered for a different duration of time (a short-course and a
long-course).
Results According to our initial search, 205 potentially relevant articles
were retrieved from PubMed and 136 from the Cochrane Central
Register of Controlled Trials. Finally, 4 RCTs were eligible for inclusion
in our meta-analysis. There was no difference between the short
course treatment (7−10 days) and the long course treatment (14−21
days) for acute pyelonephritis regarding clinical success [odds ratio
(OR)=1.27, 95% conﬁdence interval (CI) 0.59−2.7] and microbiological
eradication (OR=0.80, 95% CI 0.13−4.95), and relapse (OR=0.92, 95%
CI 0.29−2.88). Also there was no difference between the short course
and the long course treatment regarding adverse events (OR=0.57, 95%
CI 0.29−1.11) and withdrawals due to adverse events (OR=0.37 95% CI
0.09−1.45)
Conclusions: The ﬁndings of our meta-analysis suggest that short course
regimens are as effective and safe as long course regimens for the
treatment of acute pyelonephritis. However, due to the relative scarcity of
data, more RCTs focused on this important clinical question are needed
in order to come to a deﬁnitive conclusion.
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O202 Procalcitonin and C-reactive protein as markers for infection
and mortality in patients with severe sepsis and septic shock
J. Koeze, E. Metz, R.M.L. Brouwer (Enschede, NL)
Introduction. Procalcitonin (PCT) is used as a marker to differentiate
sepsis from other non-infectious causes of the systemic inﬂammatory
response syndrome (SIRS). C-reactive protein (CRP) is also used as
a marker for sepsis and severity of disease. The Surviving Sepsis
Campaign (SSC) has been developed to improve the management,
diagnosis, and treatment of sepsis. In March 2007 the SSC guidelines
were introduced in the ICU and the departments of Internal Medicine
and Surgery of our hospital. We studied the clinical application of PCT
and CRP plasma concentrations in the detection of severe sepsis /septic
shock and the assessment of severity of disease.
Hypothesis. PCT and CRP are useful in discriminating bacterial
infections from other causes of SIRS and can be used as markers for
mortality.
Methods. Prospective observation study in patients admitted to the
departments of internal medicine, surgery and the ICU of a large
non-academic teaching hospital who were enrolled in the SSC. PCT
and CRP plasma levels were determined at inclusion (0) and 24 hour
(24) after inclusion in de SSC registration. Patients were classiﬁed
according to outcome (hospital discharge / mortality), presence of
infection conﬁrmed by microbiological culture and PCT / CPR levels.
Data were analysed using non-parametric statistical methods (Pearson
Chi-Square and Kruskal-Wallis test).
Results. Ninety one patients (age 65±1.6 mean±s.e.m., 70% male) were
included. 46 (50%) were admitted to the ICU, 45 patients (50%) were
treated in the wards. Infection was conﬁrmed by cultures in 50% of
patients. There was no difference in PCT (0/24) between patients with
and without microbiological culture proven infection. 45 patients (50%)
were classiﬁed as severe sepsis, 46 (50%) as septic shock. Overall
hospital mortality was 21% and there was no difference in PCT (0/24)
and CRP (0/24) between survivors and non-survivors.
Conclusion. PCT does not differentiate patients with culture conﬁrmed
infection and severe sepsis/septic shock from patients with severe SIRS
and suspected but no proven infection. PCT and CRP are no indicators
of outcome in patients with severe sepsis and septic shock.
O203 Streptococcus suis infection and risk factors for death in
northern Thailand
W. Wangsomboonsiri, T. Luksananun, S. Saksornchai, K. Ketwong,
S. Sungkanuparph (Bangkok, Nakornsawan, TH)
Objectives: To describe clinical characteristics of Streptococcus suis
infection, a re-emerging zoonotic disease in Northern Thailand, and to
determine the risk factors for death of this disease.
Methods: The retrospective cohort study was conducted among
patients who were diagnosed culture-conﬁrmed S. suis infection in
Sawanpracharak Hospital, a tertiary care centre in Nakornsawan
Province, Northern Thailand, between January 2005 and October 2007.
The medical records were reviewed and clinical data was extracted. Risk
factors for death were determined by multivariate analysis.
Results: There were 66 patients with a mean (SD) age of 52.9 (11.5)
years and 68% were male. The most common risk of S. suis infection
was eating of unwell-cooked pork or internal organs (87%). Clinical
presentations included acute meningitis (52%), sepsis without localised
infection (27%), septic shock (12%), endocarditis (8%), and septic
arthritis (1%). Hearing loss was observed in 35% and signiﬁcantly
associated with meningitis. Positive cultures of S. suis were recovered
from blood (92%) and cerebrospinal ﬂuid (CSF, 73%). All strains
were susceptible to penicillin, cefotaxime and levoﬂoxacin. CSF proﬁles
(median values) among patients with meningitis were as follows: white
blood cell, 450 cells/mm3; PMN 48%; L 45%; protein 309 mg/dl;
glucose 3 mg/dl; and 40% had positive Gram stain. The mortality rate
was 17% and 64% of death occurred in the ﬁrst 24 hours. Patients
who died were more likely to have occupational contact with raw pork
(p = 0.016), headache (p = 0.021), gastroenteritis (p = 0.008), septic shock
(p< 0.001), low platelet (p = 0.025), low serum bicarbonate (p< 0.001),
low albumin (p< 0.001), high ALT (p = 0.040), and high total bilirubin
(p = 0.001). Multivariate analysis revealed that only occupational contact
with raw pork (p = 0.008) and high ALT (p = 0.001) were the only
signiﬁcant risk factors for death.
Conclusion: S. suis infection commonly presented with acute meningitis
or sepsis without localised infection. The most common risk of S. suis
infection is eating unwell-cooked pork. The risk factors for death are
occupational contact with raw pork and high ALT. Education for people
in Northern Thailand to eat well-cooked pork and parts and safely contact
with raw pork is crucial. Patients who present with high ALT need
intensive care and closed monitoring. A prospective interventional study
is needed to minimize the incidence of disease and death from S. suis
infection.
O204 Association between group A beta-haemolytic streptococci
and vulvovaginitis in adult women: a case control study
M.J. Bruins, R.A.M.J. Damoiseaux, G.J.H.M. Ruijs (Zwolle, Hattem, NL)
Objectives: Vulvovaginitis including ﬂuor vaginalis accounts for
approximately 250,000 visits in the Netherlands to general practi-
tioners (GPs) each year. Guidelines for managing vaginal discharge
mention Candida albicans, Trichomonas vaginalis, bacterial vaginosis,
Chlamydia trachomatis and Neisseria gonorrhoeae as the usual suspects.
Culturing for other agents is not recommended, unless symptoms recur
or persist despite treatment. Lately, we noted a high isolation rate of non-
group B (A, C, F, G) beta-haemolytic streptococci from ﬂuor vaginalis
samples from women with recurrent vulvovaginitis in our region. Group
A streptococci are known as a cause of vulvovaginitis in children, but
evidence of infection in adult women is limited to a few case reports
and two methodologically ﬂawed studies lacking well-deﬁned control
groups. The signiﬁcance of group C, F and G streptococci in vaginal
ﬂora is unclear. To investigate the association between non-group B
beta-haemolytic streptococci and vulvovaginitis in adult women, we
conducted a case control study.
Methods: Cases (n = 1010) were women consulting their GP with an
abnormal non-bloody vaginal discharge with or without itch, irritation,
redness or pain from whom a ﬂuor sample was cultured. Controls
(n = 206) were asymptomatic women consulting their GP to have a
smear taken for the cervical cancer screening programme, who consented
to having a vaginal swab taken. Additionally, asymptomatic volunteers
among hospital personnel submitted a self-obtained vaginal swab. Ages
of cases as well as controls ranged from 30−60 years.
Results: Non-group B streptococci were isolated from 86 (8.5%) cases
and from 6 (2.9%) controls (OR 3.1, 95% CI 1.4−7.2; P< 0.01). The
signiﬁcant difference was caused by group A streptococci, that were
isolated from 49 (4.9%) cases and not from any of the controls (P< 0.01).
Isolation rates of group C, F and G streptococci from cases were low
(1.2, 0.1 and 2.4% respectively) and did not differ statistically from those
from controls (1.0, 0.0 and 1.9% respectively).
Conclusion: Group A beta-haemolytic streptococci are associated with
persistent vaginal discharge in women aged between 30−60 and should
be diagnosed and reported as a pathogen in vulvovaginitis. The role
of other non-group B streptococci requires more study because of the
low numbers isolated. For adequate management of vaginal discharge
culturing is necessary if initial treatment fails. Guidelines should be
adapted to this effect.
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New resistance mechanisms
O205 Hyperexpression of MexXY-OprM and MexCD-OprJ in
clinical isolates of Pseudomonas aeruginosa with decreased
susceptibility to cefepime
A.B. Campo-Esquisabel, M.C. Rodriguez, C. Rodriguez,
L. Martı´nez-Martı´nez (Santander, ES)
Background: In P. aeruginosa ceftazidime (CAZ) and cefepime (FEP)
show a similar susceptibility pattern but in some isolates FEP is less
active than CAZ, which has been related to active efﬂux or production
of some oxacillinases. We have studied the level of expression of two
efﬂux pumps in clinical P. aeruginosa isolates with MICs of FEP higher
than those of CAZ.
Methods: Nine P. aeruginosa isolates from different patients for which
the MICs of FEP were  1 dilution higher than those of CAZ and where
production of oxacillinases was excluded by multiplex polymerase chain
reaction (PCR) were selected. MICs of CAZ and FEP were determined
in triplicate in three different days by microdilution (CLSI guidelines).
Clonal relationship was determined by REP-PCR. Quantitative reverse
transcriptase-PCR was performed to identify expression of MexXY-
OprM and MexCD-OprJ. Pump overexpression was considered when
the level of speciﬁc mRNA of mexD or mexY in the tested strains was
>4 times compared with the PAO-1 strain (real-time PCR). Mutations in
nfxB (negative regulator of MexCD-OprJ) were studied in all the strains.
Results: All isolates were clonally unrelated. Three isolates were
susceptible to FEP (MICs: 4−8 mg/L), 4 intermediate (16 mg/L), and 2
resistant (32−64 mg/L). Eight isolates were susceptible to CAZ (MICs:
1−8 mg/L) and 1 intermediate (16 mg/L). In all strains mexY expression
levels ranged from 18.32 to 186.7 fold relative to the reference PAO-
1 strain; three isolates had mexD expression levels of 4.05 to 150.45
fold relative to PAO-1. MICs of FEP were not higher for strains
overexpressing both mexY and mexD than for strains with mexY
overexpression alone. In one strain (MICs FEP/CAZ: 16/4 mg/L; mexD
hyperexpression 150.45 fold) a mutation in N180 of nfxB modiﬁed the
protein structure and changed its conformation in the C-terminal region.
Conclusions: Hyperexpression of MexXY-OprM in clinical isolates of
P. aeruginosa is related to higher MICs of FEP than of CAZ. Additional
overexpression of MexCD-OprJ does not contribute to this phenotype.
O206 Evolution of quinolone resistance mediated by genetic
changes in qnrA, qnrB and qnrS genes
J.M. Rodrı´guez-Martı´nez, A. Briales, C. Velasco, M.C. Conejo,
L. Martı´nez-Martı´nez, A´. Pascual (Seville, Santander, ES)
Objectives: Plasmid-mediated quinolone resistance is increasing world-
wide in Enterobacteriaceae. Pentapeptide repeat proteins QnrA, QnrB
and QnrS confer reduced susceptibility to quinolones. In this study the
genetic evolution of quinolone resistance mediated by changes in the
coding sequences and promoter regions of qnrA1, qnrS1 and qnrB1
genes are analysed in vitro.
Methods: qnr genes, containing coding sequences and putative promoter
regions, were cloned and expressed in E. coli DH10B. Random
mutagenesis assays were performed and the mutants obtained were
selected on plates with or without quinolones. Comparing the aminoacid
sequences of these and other pentapeptide proteins with activity against
quinolones several conserved positions were found. The role of these
positions in the activity of these proteins against quinolones was
evaluated by site directed mutagenesis. The residues analysed were G56,
C72, C92, G96, F114, C115, S116, A117 and L159, according to the
sequence of QnrA1. Further, the quinolone susceptibility of the mutants
obtained by random or site directed mutagenesis were analysed by disk
diffusion, E-test or microdilution methods.
Results: Three different phenotypes were obtained in the random
mutagenesis assays compare with the wild-type phenotypes: (i) similar
activity against nalidixic acid and ciproﬂoxacin, (ii) higher activity
against nalidixic acid and ciproﬂoxacin and (iii) lower activity against
nalidixic acid or ciproﬂoxacin. Only two mutants increased the quinolone
resistance: QnrA1 containing R103C+K111M (two folds for nalidixic
acid); and QnrS1 containing D185Y (four folds for ciproﬂoxacin). By
site directed mutagenesis, only one change in several conserved positions
(G56-, G56D, C72Y, C92Y or L159D) produced complete lost of activity
for QnrA1, QnrB1 or QnrS1. The effect on the activity of these proteins
was not identical in different positions.
Conclusions: Aminoacid sequences of pentapeptide repeat proteins
QnrA1, QnrB1 and QnrS1 could be optimised in its activity against
quinolones. One or several changes seem to be insufﬁcient to obtain
variants producing ﬂuoroquinolones clinical resistance. In spite of the
high aminoacid variability of these pentapeptide proteins, several of the
conserved residues analysed are critical in the activity of these proteins
against quinolones.
O207 A new plasmid-mediated gene for quinolone resistance, qnrC
M.H. Wang, X. Xu, S. Wu, D. Zhu, M.G. Wang (Shanghai, CN)
Objectives: Since the discovery of qnrA in 1998 two additional qnr
genes, qnrB and qnrS, have been described. These 3 plasmid-mediated
genes contribute to quinolone resistance in Gram-negative pathogens
worldwide. A new gene, qnrC, was cloned from a transferable plasmid
pHS9.
Methods: Plasmid pHS9 came from a clinical strain of Proteus mirabilis,
which transferred low-level quinolone resistance but was negative by
PCR for the known qnr genes. Plasmid pHS9 was transferred to azide-
resistant E. coli J53 by conjugation. The plasmid was digested by HindIII
and a fragment containing the new gene was cloned into plasmid puc18
and sequenced. The ciproﬂoxacin MICs for clinical and transconjugant
strains were determined by Etest.
Results: The strain of P. mirabilis was isolated from an outpatient with
a urinary tract infection. It was susceptible to most antimicrobials, but
resistant to ampicillin and trimethoprim-sulfamethoxazole. Ciproﬂoxacin
MICs for the clinical strain, J53 R-, and a J53 pHS9 transconjugant were
0.25, 0.008, and 0.125mg/ml, respectively. A 4.49-kb HindIII fragment
of pHS9 was cloned into puc18, and recombinants were transformed
into E. coli DH5alpha. Sequencing showed that the responsible 537-bp
gene, designated qnrC, encoded a 178 amino acid protein. QnrC shared
67.6%, 48.0% and 63.1% amino acid identity with QnrA1, Qnr B1 and
Qnr S1, respectively. An integrase-like gene and an amidase gene were
found upstream and downstream from qnrC.
Conclusion: A new quinolone resistance gene, qnrC, was characterised
from plasmid pHS9 carried by a clinical isolate of P. mirabilis.
O208 The overexpression of SdiA and SoxS is associated with
the development of multiple antibiotic resistance induced by
diazepam and haloperidol in Escherichia coli AG100
M.M. Tavı´o, V.D. Aquili, J. Vila, J.B. Poveda (Las Palmas de Gran
Canaria, Barcelona, ES)
Objectives: The previously described multidrug antibiotic resistance
(MAR) phenotype, which is induced in Escherichia coli AG100 by
diazepam and haloperidol (drugs used in surgery) is comparable to MAR
phenotype resulting from marAB operon activation by salicylate (OmpF
loss and enhanced active efﬂux). Nevertheless, MAR phenotype can also
result from the overexpression of other transcriptional regulators such
as SoxS. This work studied some transcriptional activators that could be
involved in the induction of MAR phenotype by diazepam or haloperidol
in the susceptible E. coli AG100 strain.
Methods: The effect of several subinhibitory concentrations of diazepam
and haloperidol in the AG100 strain was evaluated on outer membrane
protein (OMP) expression, cyclohexane tolerance and the expression of
the marA, soxS, rob and sdiA genes. OMP expression was analysed
by SDS-PAGE. Expression of the marA, soxS, rob and sdiA genes was
studied by reverse transcription of total RNA and PCR of cDNA (RT-
PCR), using gapA gene as internal control of expression. PCR products
were separated in SDS-PAGE and silver stained, quantifying the levels
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of gene expression by using ImageQuant TL. AG100 (induced or non-
induced with 5 mM salicylate or 0.2 mM paraquat) was the control
strain.
Results:MAR phenotype, which was induced by growing concentrations
of diazepam or haloperidol, was accompanied by a signiﬁcant
increased expression of sdiA and soxS genes, coinciding with previous
results on MAR and increased active efﬂux induced by subinhibitory
concentrations of any of both drugs. A large up-regulation of 8.9-fold
for sdiA gene and 12.8-fold for soxS gene was induced by 0.05−0.1
mM haloperidol. The induced decreased expression of OmpF, increased
cyclohexane tolerance as well as increased expression of sdiA and soxS
genes occurred in a reversible and concentration-dependent manner.
AG100 induced by diazepam or haloperidol did not show a signiﬁcant
increment in the expression level of MarA or Rob.
Conclusions:
i. SdiA, a homologous to the LuxR family of quorum-sensing
transcription factors, as well as SoxS were involved in MAR
phenotype induced by diazepam or haloperidol.
ii. The MAR phenotype, increased cyclohexane tolerance, and the up-
regulation of sdiA and soxS genes were always induced by any of
the two studied drugs in a reversible and concentration-dependent
manner.
iii. The decreased expression of OmpF induced by diazepam or
haloperidol could be related to SoxS overexpression.
O209 Genetic structure at the origin of acquisition of blaOXA-18
gene, encoding an emerging class D clavulanic-acid inhibited
extended-spectrum b-lactamase
T. Naas, P. Bogaerts, F. Namdari, T. Huang, Y. Glupczynski,
P. Nordmann (Kremlin-Bicetre, FR; Mont-Godinne, Brussels, BE)
Objectives: Pseudomonas aeruginosa (Pa) is an important noso-
comial pathogen that may acquire resistance to expanded-spectrum
cephalosporins mostly by overproducing its cephalosporinase and/or
acquiring Ambler class A, B and D b-lactamases. Several clavulanic acid-
inhibited Ambler class A extended-spectrum b-lactamases (ESBLs) and
extended-spectrum class D enzymes (OXA-ESBLs) have been isolated
in Pa. OXA-18 is a peculiar OXA-ESBL, since it is not a point mutant
derivative of broad-spectrum OXA enzymes and is well inhibited by
clavulanic acid. It was initially reported along with OXA-20 in Pa MUS
from France in 1996, and very recently in several Pa isolates involved
in an outbreak in Tunisia.
Methods: Genetic structures surrounding the blaOXA-18 gene of the
prototype Pa MUS strain were characterised by cloning, PCR analysis
and sequencing and compared with those found in three Pa isolates from
Belgium. The strains were analysed by plasmid extraction, conjugation
and electroporation assays, and by PFGE.
Results: The three Belgian isolates originated from sputum and blood
specimens of three patients hospitalised in different wards over a
six-month period. The presence of ESBLs detected by double-disk
diffusion tests on cloxacillin-containing plates, and PCR followed by
sequencing revealed the presence of blaOXA-18 and blaOXA-20 genes.
Both were chromosomally-encoded and PCR mapping revealed identical
genetic environments for Pa MUS and the Belgian isolates. While
most oxacillinases are integron located, blaOXA-18 lacked gene cassette
speciﬁc sequences but was inserted into an aac6′ Ib gene cassette. In
addition, it was bracketed by two novel insertion sequences of ISCR
family. It is likely that these ISs were at the origin of the blaOXA-18
gene mobilisation. Furthermore, detailed analysis of an 8.5-kb cloned
genomic fragment containing blaOXA-18 gene revealed co-linearity of
the blaOXA-18 gene and the integron containing blaOXA-20 gene. PFGE
deﬁned genetic relatedness between the three Belgian Pa isolates and
Pa MUS strain. The recently identiﬁed OXA-18-producing Pa isolates
from Tunisia were blaOXA-20-negative (but positive for either TEM-1
or SHV-1), genetically different from Pa MUS, thus suggesting that at
least two OXA-18-producing Pa clones are currently spreading.
Conclusion: This report characterised the genetic elements at the origin
of blaOXA-18 ESBL in Pa and suggests the emergence of this type of
ESBLs in Pa in Belgium.
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O210 Emergence of a single ST-8 clone of Panton-Valentine
leukocidin-positive meticillin-resistant Staphylococcus aureus
in an ambulatory paediatric population, Madrid, Spain
M. Daskalaki, P. Rojo-Conejo, M. Marin-Ferrer, J.R. Otero, F. Chaves
(Madrid, ES)
Objectives: Community-acquired, meticillin-resistant Staphylococcus
aureus (CA-MRSA) infections in children are increasing in frequency.
The aim of this study was to report the frequency of CA-MRSA
and the prevalence of Panton-Valentine leukocidine (PVL) among the
children population as well as to determine the clinical, epidemiologic
and molecular characteristics of these patients with community-acquired
infections.
Patients and Methods: We conducted a prospective study from January
to November 2007. The study included all patients attended in the
Paediatric Emergency Department (PED) with a S. aureus infection.
All isolates underwent polymerase chain reaction analysis for the LPV
gene. Molecular characterisation of LPV(+) isolates was performed using
PFGE following DNA extraction with SmaI and multilocus sequence
typing (MLST).
Results: During the study period, S. aureus was detected in 58 samples
taken from 53 children.
They had a median age of 42 months (0–170 months), and 70% were
boys. An MRSA was detected in 7 patients (13.2%). Forty six patients
were tested for PVL genes, and a positive result was obtained in
12 (26%).The prevalence of LPV was 71% in the group of MRSA
(5/7)and 18% in the MSSA group (7/39) Final diagnosis of patients
comprised superﬁcial infections 57%, cellulitis or abscess 31%, and deep
infections 10%. A 33% of the children were admitted in the hospital
and a 30% required drainage. Although no signiﬁcant differences in
clinical characteristics or classic risk factors were observed between
CA-MRSA and CA-MSSA, we found signiﬁcant differences related to
the country of origin of the children: CA-MRSA isolates were more
frequent isolated from children with an origin in Ecuador (44% vs. 7%;
P = 0.002) and all of them belonged to the same ST 8 IV clone according
to the PFGE and the results of MLST, whereas all the MSSA PVL(+)
isolates belonged to different clones. Regarding to the epidemiologic
characteristics, infections by isolates with and without PVL gene did
not show signiﬁcant differences but it is to mention that isolates with
PVL gene were clearly associated with need of drainage (75% vs. 27%;
P = 0.001).
Conclusions: There is an emergence of a single clone (ST 8 IV) of the
CA-MRSA infections among children in Madrid and is clearly associated
with children with an origin in Ecuador. Infections with isolates PVL(+)
required a more aggressive treatment with drainage as a result of the
isolates’ increased virulence.
O211 Diagnosing congenital cytomegalovirus infection: will the
universal Guthrie card (dried blood spot) testing hinder
more than help?
C.F. De Gascun, A. Waters, P. Holder, P.G. O’Reilly, J. Connell,
S.J. Knowles, W.W. Hall (Dublin, IE)
Objectives: Previous population studies have identiﬁed Ireland as having
a low prevalence of CMV infection. However, the changing demographic
has resulted in an increase in CMV seroprevalence; this may result
in an increased risk of infection in susceptible pregnant women. The
aim of this study is to determine if laboratory investigation of neonatal
dried blood spots (DBS) collected on Guthrie cards can be used as the
sole diagnostic approach to accurately identify cases of congenital CMV
(cCMV) infection.
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Diagnosis of cCMV infection requires detection of CMV in the neonate
in the ﬁrst three weeks of life. Culture of CMV from urine remains
the gold standard for the detection of live virus, although a deﬁnitive
diagnosis by traditional culture may take up to three weeks. More
rapid results can be obtained through the complementary use of urinary
DEAFF (detection of early antigenic ﬂuorescent foci) testing. Advances
in molecular methods have resulted in a move away from DEAFF/culture
to the detection of CMV DNA by PCR in urine samples or DBS. PCR
testing may be supplemented with serology for CMV speciﬁc IgM.
Methods: We conducted a retrospective review of all neonates from
the three Dublin maternity hospitals clinically diagnosed with cCMV
infection over a three year period, 2004 to 2007. All testing was
performed in a single specialist virology centre, the National Virus
Reference Lab (NVRL), which provides serological, molecular (PCR)
and cell culture methods (traditional & DEAFF) for the diagnosis of
cCMV in the Republic of Ireland. Of note, there is no national screening
programme for cCMV.
Results: Thirty-two children were diagnosed with cCMV in Dublin over
the period studied. Thirty-one of 32 (97%) children were urinary DEAFF
test positive; 17/31 (55%) were culture positive; 12/26 (46%) were IgM
positive; 8/13 (62%) were CMV DNA positive in blood. Eighteen of 28
(64%) neonates were positive in blood for either CMV DNA or IgM;
2/11 (18%) were positive for both DNA and IgM. If the only test offered
were PCR for CMV DNA in DBS, 38% of children would not have been
diagnosed.
Conclusions: This study illustrates that DBS testing alone is not an
adequate strategy for the clinical diagnosis of, or as a screening tool
for, cCMV infection in a low seroprevalence population. DBS testing
provides virological data of prognostic value in those neonates known to
be CMV infected, but it lacks the sensitivity required to be a satisfactory
screening test.
O212 Human Bocavirus quantitative DNA detection and phyloge-
netic analysis in children hospitalised for acute bronchiolitis
L. Andreoletti, J. Jacques, F. Renois, H. Moret, J. Motte, N. Leveque
(Reims, FR)
Objective: Human Bocavirus (HBoV) is a newly discovered parvovirus,
but its role as causative agent of respiratory disease remains unclear.
Methods:We investigated the presence of HBoV by quantitative PCR of
nasopharyngeal samples of 192 French consecutive children hospitalised
for acute bronchiolitis. The detection of the other common respiratory
viruses was performed using classical immunoﬂuorescence antigens, cell
culture detection, or RT-PCR assays.
Results: HBoV was the unique viral pathogen detected in 14 (7%) and
was associated with another viral respiratory pathogen in 10 (5%) of
192 study children. This virus was identiﬁed as the third aetiological
cause of bronchiolitis after respiratory syncytial virus and rhinovirus (45
(23%) and 24 (12%) of 192 cases, respectively), occurring more often in
infants aged 1−12 months (P = 0.002). The median levels of the HBoV
DNA genomes in respiratory samples appeared to be signiﬁcantly higher
in patients with single HBoV infection than those observed in patients
with a mixed respiratory viral infection with HBoV (4.108 copies/ml vs.
2.103 copies/ml, P< 0.001).
Conclusion: Our data suggest that HBoV at a high viral load could be
an aetiologic agent of respiratory tract disease, whereas the exact role of
HBoV at a low viral load, as aetiological cause or as pathophysiological
co-factor of respiratory diseases, remains to be determined.
O213 Chronic in utero exposition to nevirapine does not cause
hepatotoxicity in HIV-uninfected healthy infants
A. Felipe, A. Noguera, C. Fortuny, E. Sa´nchez, N. Rovira, M. Simo´
(Esplugues, Barcelona, ES)
Objective: Liver function abnormalities and clinical hepatitis have been
associated with NVP use, also in the paediatric age. NVP crosses the
placenta and achieves neonatal blood concentrations equivalent to that
in the mother (cord-to-maternal blood ratio 0.90). NVP elimination is
prolonged in infants. While single-dose NVP regimens at delivery have
proved safe, little is known about chronic in utero exposure to NVP and
hepatotoxicity in these otherwise healthy HIV-uninfected infants.
Methods: Prospective observational study on a cohort of HIV-uninfected
healthy infants born to HIV-infected mothers and exposed in utero
to either NVP-based or non-NVP-based HAART regimens. Infants
perinatally infected with HIV and/or HCV, and those who received
neonatal NVP were excluded. Plasmatic alanine aminotransferase (ALT,
normal values up to 40 IU/l) levels obtained up to the age of 12wk were
compared between groups; in Exposed, total time of in utero HAART
exposure (12wk or less) was also taken into account. Student’s t-test and
other parametric tests were used.
Results: Overall, 170 infants (76 females, 44.7%) were included, 80
(47.1%) of them (33 females, 41.2%) exposed in utero to a NVP-
based HAART regimen. ZDV+3TC (n = 100) and 3TC+d4T (n = 39)
were the most commonly used nucleoside analogue backbones; mothers
of the Non-exposed group mostly received a PI-based therapy during
gestation (NFV, n = 57; LPV/r, n = 19). Mean duration of HAART during
pregnancy was 28wk (range: 3−40wk). Mean gestational age and weight
at birth were 37wk and 2767g, respectively. At delivery, 98.2% of the
mothers received intravenous ZDV; all infants received a 4 to 6-wk
course of oral ZDV.
None of the patients showed clinical symptoms consistent with hepatitis
during follow-up, except for 8 patients (3 Exposed, 5 Non-exposed)
who developed self-limited neonatal jaundice. ALT plasmatic levels were
obtained at a median age of 26 days (range: 1−84 days). No differences
are reported in ALT levels between Exposed (mean value: 19.8, range:
5−31 IU/l) and Non-exposed (mean value: 20.0, range: 1−79 IU/l); in
the Non-exposed group, differences were neither observed when length
of exposure (12 weeks or less) was considered. Three infants in the Non-
exposed group developed non-symptomatic elevation of ALT values that
had spontaneously normalised by the age of 6 months.
Conclusions: In this study, chronic in utero exposure to NVP did not
cause elevation of ALT levels in HIV-uninfected infants.
O214 Pneumococcal carriage in a geographically isolated
indigenous community in Venezuela before, during and after
an outbreak of acute respiratory tract infection
I. Rivera-Olivero, P. Vigilanza, M. Bell, D. Bogaert, P.W.M. Hermans,
J.H. de Waard (Caracas, VE; Boston, US; Nijmegen, NL)
Background: We evaluated pneumococcal carriage rates in children
from a geographically very isolated indigenous population, only
reachable by plane, that was struck by an outbreak with the clinical
criteria that met a bacterial acute respiratory tract infection (ARTI),
affecting more than 70% of all the members of the community.
Objective: To evaluate the carriage rates and the serotype/genotype
distribution of S. pneumoniae strains isolated before, during and after
the ARTI outbreak.
Methods: The community consists of about 900 people with 150
younger than 5 years old. Contact with other indigenous communities is
rare. Nasopharyngeal swabs were cultured from 321 children aged 3−84
months before (October 2004: n = 118), during (November 2005; n = 123)
and after (March 2006: n = 80) the outbreak. The S. pneumoniae isolates
were serotyped with the Quellung reaction, genotyped by restriction
fragment end labelling (RFEL) analysis, and their susceptibility to
antibiotics was assessed by disk diffusion.
Result: In total, 117 pneumococcal strains were isolated and carriage
rates in the three time periods before, during and after the ARTI outbreak
were 16%, 60% and 32%, respectively. 83% (95/115) of the children
under 5 years old was diagnosed with ARTI in the second time period
of which 66% (63/95) was clinically classiﬁed as pneumonia. Before
the outbreak the prevalent serotype was 6B (80%). The most prevalent
capsular serotypes during outbreak were 6B (40.3%), 9V (13.4%) and
15B (13.4%), and 18C (10.5%). The latter 3 serotypes were not present
before the outbreak. After the outbreak, in the third sample period
serotype 9V and 15B disappeared completely, and the other serotypes
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remained. RFEL analysis clustered all the serotypes isolated during the
outbreak in very related genotypes; per serotype 1 cluster or a clade with
at least 85% homology. All isolates were susceptible for the antibiotics
tested with exception of TMPS harbouring 20.5% resistance.
Conclusions: The increase in carriage rate during disease was mainly
due to serotypes not isolated before the outbreak. Hence, we consider
that the introduction of the new serotypes in the community might have
been related to the outbreak of lower respiratory tract infections. The
highly related genotypes found for all the serotypes indicate limited
introduction of new serotypes and genotypes in this community. Future
investigation should monitor the impact of a pneumococcal vaccine on
disease incidence and strain substitution in this isolated community.
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O215 Candida albicans signalling alcohols as players of cellular
cross-talk with Candida tropicalis
M. Martins, M. Henriques, J. Azeredo, R. Oliveira (Braga, PT)
Objective: Candida species are the most common agents of oppor-
tunistic mycoses, which are often associated with bioﬁlms. Candida
albicans and Candida tropicalis bioﬁlms develop most frequently in
intracardiac prosthetic devices and voice prostheses with an infection
risk of 1−3% and 50–100%, respectively. In natural environments
polymicrobial bioﬁlms are observed, but interactions between organisms
are not well understood. This study focused on the evaluation of the effect
of recently characterised C. albicans alcohols signalling molecules, in
C. tropicalis regarding two hypothetical clinical scenarios: C. tropicalis,
adhered and within a mature bioﬁlm.
Methods: All experiments were performed in RPMI medium and cells
(initial cell density of 1×106 cells/ml) grown at 37ºC, 130 rpm. For all
experiments, endpoints were determined at the end of 24 h. C. tropicalis
ATCC 750 bioﬁlms were developed on the surface of microtriter plates.
C. albicans CECT 1472 secreted alcohols were added after 3 h of
adhesion or to 48 h grown bioﬁlms. Isoamylalcohol, 2-phenylethanol,
1-dodecanol, nerolidol, farnesol and tyrosol were independently assayed
at physiological levels. Bioﬁlm quantiﬁcation was performed using
two different approaches: total biomass by crystal violet staining and
quantiﬁcation of bioﬁlm cells activity by the reduction of a tetrazolium
salt (XTT).
Results: At initial bioﬁlm stages C. tropicalis metabolic cell activity was
signiﬁcantly decreased by isoamylalcohol, 2-phenylethanol, E-nerolidol
and tyrosol treatments, while cellular mass was positively affected
by isoamylalcohol but negatively by E-nerolidol. Nevertheless, mature
bioﬁlms were more resistant to the action of these alcohols. Speciﬁcally,
only isoamylalcohol induced alterations, with the same response pattern
observed at earlier stages.
Conclusion: Results obtained show that C. albicans extracellular
alcohols regulate C. tropicalis behaviour, depending on bioﬁlm growth
time, suggesting that C. tropicalis mature bioﬁlms are more resistance
to C. albicans signalling crosstalk.
O216 A novel Staphylococcus aureus bioﬁlm phenotype mediated
by the ﬁbronectin-binding proteins, FnBPA and FnBPB
E. O’Neill, C. Pozzi, T. Foster, H. Humphreys, J. O’Gara (Dublin, IE)
Device-associated infections involving bioﬁlm remain a persistent clin-
ical problem. Our research group has recently reported that meticillin-
resistant Staphylococcus aureus (MRSA) strains can form bioﬁlm
independent of the icaADBC-encoded exopolysaccharide. Here we report
that mutation of sortase, which anchors LPXTG-containing proteins
to peptidoglycan, impaired MRSA bioﬁlm development. Furthermore
deletion of fnbA and fnbB, which encode the LPXTG-anchored
multifunctional ﬁbrinogen and ﬁbronectin-binding proteins, FnBPA
and FnBPB impaired MRSA but not meticillin-sensitive S. aureus
(MSSA) bioﬁlm development, apparently at the level of intercellular
accumulation and not primary attachment. The MRSA fnbAB bioﬁlm
defect was complemented by fnbA or fnbB alone. Correspondingly,
mutation of fnbA or fnbB alone did not substantially affect bioﬁlm
and overexpression of either gene alone in MRSA and MSSA activated
bioﬁlm. Interestingly FnBP-promoted bioﬁlm was dependent on SarA,
but not at the level of fnbA or fnbB transcription. Using plasmid
constructs lacking regions of FnBPA to complement an fnbAB mutant
revealed that the A domain alone and not the BCD domain required
for ﬁbronectin binding could promote bioﬁlm. Additionally, an A
domain N304A substitution which abolished ﬁbrinogen binding did not
affect bioﬁlm. These data identify a novel S. aureus bioﬁlm phenotype
promoted by FnBPA and FnBPB, which is apparently independent of the
known ligand-binding activities of these multifunctional surface proteins.
Given that implanted surgical and medical biomaterials are rapidly
coated by a conditioning ﬁlm composed primarily of extracellular matrix
proteins, our ﬁndings suggest that these cell-wall-anchored proteins
are important virulence factors in device-related S. aureus infections,
particularly those caused by MRSA strains, and may represent attractive
therapeutic targets.
O217 Roles of ﬂagella and effect of curcumin against bioﬁlm
formation by Helicobacter pylori
P. Pattiyathanee, N. Dorrell (Bangkok, TH; London, UK)
Objectives: The gastric pathogen Helicobacter pylori is shown to have
alternate life style as a bioﬁlm. In human infection, a presence of mature
bioﬁlm attached to cell surface has been shown and hypothesised that
H. pylori infections resulting in gastric ulcers may be a manifestation
of bioﬁlm. Flagella have been considered to have a possible role during
initial step of bioﬁlm formation. Here we have investigated roles of
three ﬂagellar genes, including the ﬂaA gene encoding ﬂagellin protein,
the ﬂgR regulatory gene and the ﬂiQ export apparatus gene, in the
production of bioﬁlm and control of adherence in H. pylori. The effect
of curcumin against H. pylori bioﬁlm formation and adherence to the
human cancer cells has also been investigated.
Methods: Isogenic ﬂaA, ﬂgR, and ﬂiQ mutants were constructed from
H. pylori wild-type 26695 and N6 by inverse PCR mutagenesis. A min-
imum inhibitory concentration (MIC) of curcumin (diferuloymethane)
against H. pylori was determined using agar dilution technique. The
ability to form bioﬁlm in liquid culture and on glass surface, and adhere
to the HEp-2 cells was examined in vitro in a presence of curcumin
compared to the controls.
Results: Two different types of bioﬁlm were observed in this study,
including pellicle and attached bioﬁlm. The wild-type H. pylori 26695
and N6 strains formed bioﬁlm and adhered to HEp-2 cells more
efﬁciently than the isogenic mutants, including ﬂaA mutants; PA315 and
NA2, ﬂgR mutants; PR611and NR, and ﬂiQ mutants; PQ and NQ. These
results indicate that these genes are involved in the bioﬁlm formation
and adhesion of H. pylori. Our results showed that curcumin not only
inhibited bacterial growth, but also greatly decreased the number of
bioﬁlm formation and the ability to adhere to the HEP-2 cells.
Conclusion: We have demonstrated that H. pylori in monoculture can
form bioﬁlm. It attached to a glass surface and formed a pellicle at air-
liquid interface. Flagellar components were found to be important for
bioﬁlm formation on abiotic glass surface, pellicle formation in liquid
culture, and adherence to HEp-2 cells. Curcumin has been demonstrated
an effect against to H. pylori bioﬁlm and shown a signiﬁcant inhibitory
action on adherence of H. pylori to HEp-2 cells.
O218 agr/RNAIII expression in bioﬁlms in vivo
V. Pintens, R. Merckx, J. Van Eldere (Leuven, BE)
Objectives: To assess the role of agr in bioﬁlm formation, we studied
gene expression of agr in well-established bioﬁlms in an in vivo rat
model.
Methods: agrA and RNAIII expression was evaluated during in vivo
foreign body colonisation over a period of 2 weeks. Catheter fragments
(n = 180), inoculated with a low inoculum of S. epidermidis, were
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implanted subcutaneously in rats as described (Vandecasteele et al.
BBRC. 2002; 291: 528). After explantation, gDNA and RNA was
isolated from adherent (bioﬁlm-associated) bacteria (n = 108), detachable
bacteria (bacteria loosely adherent to the catheter and removed by
washing) (n = 36) and from bacteria which colonised the surrounding
tissue (n = 36). Gene expression was quantiﬁed by real-time PCR. The
amount of bacteria was calculated by absolute quantiﬁcation of gDNA
copies of the housekeeping gene gmk, recalculated to bacteria/mm2 (with
catheter surface of 79.17mm2).
Results: Bacterial density decreased till 6 h post-implantation, again
increased in the 1-day old bioﬁlm and subsequently slowly decreased.
However it was still higher than in planktonic cultures. In spite of this,
expression of the quorum-sensing system genes argA and RNAIII was
low 1 day after implantation. RNAIII expression decreased to a minimum
in the 2 weeks old bioﬁlm, whereas agrA expression remained at a low
level during the whole implantation period.
The number of bacteria that detached and colonised the surrounding
tissue signiﬁcantly decreased from 1 towards 2 weeks post implantation.
The number of bioﬁlm-forming bacteria was stable, suggesting a more
stable and well-formed bioﬁlm after 2 weeks of implantation. agrA and
RNAIII expression were signiﬁcantly higher in detachable bacteria than
in tissue-colonising bacteria for which agrA and RNAIII expression was
comparable to that of bioﬁlm-associated bacteria.
Conclusion: Expression of agr is low in bioﬁlms, but high in detachable
bacteria. This correlates with a role for agr in active tissue invasion but
not in bioﬁlm formation.
O219 Bioﬁlm models for Streptococcus pneumoniae
C. Trappetti, L. Gualdi, G. Pozzi, M.R. Oggioni (Siena, IT)
Objectives: Recent data indicate that pneumococci during otitis media,
pneumonia and meningitis may form bioﬁlms in vivo. In order to better
characterise pneumococcal bioﬁlm formation we evaluated different
models in which to analyse the various phases of bioﬁlm development.
Methods: Static bioﬁlm models were developed in microtiter plates
both using low inocula in rich media and high inocula in poor media.
Pneumococcal cells adhering to solid support were characterised for
viability, extracellular matrix production and responsiveness to quorum
sensing signals.
Results: Adherent pneumococci could be recovered few hours after
incubation. When using low incula bioﬁlm was found to increase during
exponential phase and, after a decline of about half a log, remain stable
over time. This stability in stationary culture was dependent on addition
of CSP to growth medium. The addition to the growth medium of
BLP, the second type of cell-cell signalling peptide of S. pneumoniae,
had no effect on bioﬁlm formation or stability. Mutants for the cps
locus (capsule), comC (CSP), comD (CSP receptor), blpH (receptor
of BLP bacteriocin), luxS (quorum sensing molecule) and further 10
TCS were assayed for their ability to form bioﬁlm. Only for the comD
mutant was found to be impaired in the formation of mature bioﬁlm,
while independence form capsule expression and any type of cell-cell
signalling mechanism was shown for the other phases of pneumococcal
bioﬁlm. The model relying on high inocula in poor media showed
stable bioﬁlm formation for over a week independently from addition
of exogenous CSP. Despite difference in CSP dependence in both
bioﬁlm model systems the comD mutant shows identical deﬁciency in
extracellular matrix production, indicating the most probable reason for
the instability of bioﬁlm. Quantitative analysis of gene expression for
a panel of 30 genes did not show signiﬁcant variation between the two
model systems.
Conclusions: Pneumococcal bioﬁlm formation can be assayed in
different systems which provide alternative models for the analysis
of this complex phenotype. The cell-cell signalling system related to
competence development is signiﬁcantly involved in the stabilisation
of pneumococcal bioﬁlms, most probably through involvement of
extracellular matrix production.
Foreign body infections: diagnostic and
therapeutic implications of basic research
S220 Serological tests to detect antibodies against bioﬁlm speciﬁc
antigens
T. Elliot (Birmingham, UK)
Staphylococci produce a wide range of antigenic components including
macromolecules found in the cell wall (peptidoglycan, teichoic acids and
surface proteins), wall-associated capsular and slime polysaccharides as
well as a range of potent exported toxins. Knowledge of the antigenic
properties of staphylococci in health and disease is important for the
development of protective vaccines and antibodies for passive therapy.
Design of kits for sensitive and speciﬁc serodiagnosis of infection,
detection of microbial contaminants and microbial identiﬁcation
also requires detailed understanding of the antigenic properties of
staphylococci.
Serological methods have been applied to the study of staphylococci
over many years and indicate the complexity and diversity of antibody
responses following exposure to staphylococci, either during infection,
response to commensal organisms or administration of exploratory
vaccines. Variations occur in antibody levels to the staphylococcal
peptidoglycan, ribitol (wall) teichoic acid, and lipo (membrane) teichoic
acid in sera from both blood donors and patients with veriﬁed or
suspected staphylococcal infections. Of these antigens, a short chain
excreted form of cellular lipoteichoic acid (called lipid S) has been
shown to be of some value in the diagnosis of infections associated
with orthopaedic prostheses, native and prosthetic valve endocarditis and
sepsis associated with central venous catheters.
The experience with StaphVax (a S. aureus capsular polysaccharide
conjugate vaccine) and Veronate (a polyclonal antibody product directed
against protein virulence factors) also suggest that active or passive
protection against staphylococcal infection is complex. A number
of other products are under clinical evaluation including: AuroGrab
(antibody targeting the ABC transporter of S. aureus); Altastaph
(capsular polysaccharide vaccine); Aurexis (monoclonal antibody frag-
ment targeting S. aureus clumping factor) and Pagibaximab (targeting
lipoteichoic acid). These may also give a clearer indication of possible
antigens for use in serological tests. Many commercial serological
kits are already available for identiﬁcation of staphylococci. These
include rapid latex agglutination tests for example the Slidex Staph Plus
(bioMe´rieux), Staphaurex Plus (Murex Diagnostics), Staphytect (Oxoid),
Bacti Staph (Remel) and Pastorex Staph-Plus (Sanoﬁ Diagnostics
Pasteur). All these tests detect clumping factor and staphylococcal
protein A, in addition, the Slidex Staph Plus and Staphaurex Plus tests
detect group-speciﬁc antigens on the S. aureus cell surface, and Pastorex
Staph-Plus detects capsular polysaccharides.
S222 Suppression of MRSA by the quorum sensing inhibitor RIP
N. Balaban (North Grafton, US)
Wound, or bioﬁlm-related infections can become chronic, leading to
economic loss secondary to patient morbidity and possible mortality.
Many of these infections involve Staphylococci spp. which are capable
of developing antibiotic resistance. Community or nosocomial acquired
microbial antibiotic resistance is eroding the miracle of antibiotics
and jeopardising both human and animal welfare. With evidence of
increased frequency of resistance to vancomycin, our current most potent
antibiotic, the drive is on to develop novel therapeutic agents. RNAIII
inhibiting peptide (RIP) therapy represents an exciting alternative.
Staphylococci (like S. aureus and S. epidermidis) can become virulent
and cause diseases through the formation of bioﬁlms and production
of toxins. This process is regulated by cell-to cell communication
mechanisms, termed quorum sensing (QS). RIP is a heptapeptide
(YSPWTNF-NH2) that inhibits QS, and in its presence, the bacteria
are no longer virulent and do not cause disease. RIP has been shown
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to be extremely effective in preventing and treating drug resistant
staphylococcal infections in multiple experimental infection models
(tested in mice, rats, rabbits, cows) against various drug resistant
strains like MRSA, VISA, MRSE, and VISE. RIP has also been
demonstrated as very effective in treating clinical human chronic wound
infections in a polymicrobial setting involving multiple types of bacteria.
RIP is synergistic to antibiotics and thus can be used (alone or in
combination) systemically, topically, or by coating medical devices to
suppress infections, including those caused by antibiotic resistant strains.
Molecular epidemiology update on
antimicrobial-resistant Streptococcus
pneumoniae in Europe
S225 Macrolide resistance in Streptococcus pneumoniae: from
phenotype to genotype
A. Pantosti (Rome, IT)
In recent years, resistance to macrolides in Streptococcus pneumoniae
has increased in many areas of the world, including Europe. According
to the European Antibiotic Resistance Surveillance System, that collects
data from invasive isolates, in 2006 most European countries reported
a proportion of erythromycin-resistant pneumococcal isolates between
10 and 25% with 6 countries, including Italy, reporting a proportion
higher than 30%. The bimodal distribution of the erythromycin
minimal inhibitory concentrations of resistant isolates reﬂects the well-
known resistant phenotypes and the corresponding genotypes: high-
level macrolide resistance associated with resistance to lincosamides
and streptogramin B (the MLSB phenotype) conferred by the Erm(B)
ribosomal methylase, or low-level resistance to macrolides only (M
phenotype) due to an efﬂux pump encoded by the mef-msr(D) genes.
The relative proportion of isolates carrying either mechanism varies
between the different countries and is changing with time. In addition,
isolates carrying both resistance mechanisms are becoming increasingly
common. Other uncommon genotypes, generally associated with low
to moderate-level erythromycin resistance, are represented by point
mutations in domain V of the 23S rRNA genes or in the ribosomal
proteins, and by the erm(A) gene, encoding for an inducible methylase.
Although the main genotypes responsible for erythromycin resistance
in S. pneumoniae are well known, the genetic elements on which
the resistance genes reside and that represent the vehicle for their
transmission are only recently starting to be elucidated. The elements
carrying the macrolide efﬂux pumps in S. pneumoniae are defective
transposons: mef(A) is carried by Tn1207.1 and mef(E) is carried
by mega. These two elements are similar, but their distribution and
properties are very different. mefA/Tn1207.1 is characteristic of a
serotype 14 international clone (England14−9) and its insertion in
a competence gene makes the isolates unable to be transformed.
Therefore mefA-carrying isolates are usually susceptible to penicillin
and most other non-macrolide antibiotics. Isolates carrying mef(E)/mega
are heterogeneous in serotype and genetic background and tend to be
multidrug-resistant, due to the capability of mega to associate with
other antibiotic-resistance transposons, notably with Tn916, carrying
tetracycline resistance. Transposons of the Tn916 family are vehicle
also for high-level macrolide resistance due to erm(B). Recent studies
have shown that erm(B) is often associated with Tn916-like transposons,
although tetracycline resistance can be phenotypically unexpressed. The
composite transposons have a modular structure, where Tn916 represents
the backbone and the modules include one or more macrolide resistance
elements, such as mega, Tn917, or the erm(B) element. Although these
composite transposons are not conjugative in S. pneumoniae, the natural
transformability of the pneumococcus ensures their transmission within
the species. The study of the resistance elements carried by particular
clones can contribute to the understanding of the evolution of macrolide
resistance in S. pneumoniae: for instance, the low-level erythromycin-
resistant international clone Taiwan19F-14 has evolved into the double-
macrolide gene isolates of the CC271 complex.
S226 Fluoroquinolone resistance in Streptococcus pneumoniae and
competitive cost
A. Gonza´lez de la Campa, L. Balsalobre (Majadahonda, ES)
Resistance to ﬂuoroquinolones (Fq) in S. pneumoniae (SPN) occurs
mainly by alteration of their targets, the DNA topoisomerase IV
(ParC2ParE2) and DNA gyrase (GyrA2GyrB2) essential enzymes.
Resistance mutations are found in the quinolone-resistance determining
regions (QRDRs) of ParC, ParE or GyrA and can be acquired
by point mutation, by intraspeciﬁc recombination or by interspeciﬁc
recombination with the viridans streptococci of the mitis group (SMG).
The current prevalence of Fq-resistant (FqR) SPN is lower than 3% while
in the SMG is higher than 13%. Acquisition of resistance by interspeciﬁc
recombination could be much more common than by point mutation,
considering the frequencies of these events in laboratory conditions
(10−3 and 10−9, respectively). However, recombinants account for less
than 11% of the SPN FqR isolates. Besides other factors, such as the
availability of DNA in the natural environment and the competence
state of the cells, one cause that could account for the low frequency
of the FqR recombinant isolates is the ﬁtness cost imposed by the
DNA interchange that often implies the acquisition of larger parE-
parC intergenic regions. A parallel study of transcription of parE-parC
and of the ﬁtness cost of 24 isogenic FqR strains derived from R6
was performed. Six ﬁrst-level transformants were obtained either with
PCR-products containing parCQRDRs of SPN FqR point mutants or
with a PCR-product carrying parEQRDR-ant-parCQRDR from a FqR
SMG isolate. The latter yielded two strains, T6 and T11, carrying
parCQRDR and parEQRDR-ant-parCQRDR, respectively. The ﬁrst-level
transformants were used as recipients in further transformations with
gyrAQRDRs PCR products to obtain 18 second-level transformants. RT-
PCR experiments showed cotranscription for parE and parC in R6, T6
and T11, and a single promoter located 5′ of parE was identiﬁed in R6
by primer extension. Fitness of transformants were estimated by pairwise
competition with R6 in both 1-cycle and 2-cycle experiments. In 1-cycle
experiments, only strains carrying the GyrAE85K change showed ﬁtness
cost, with the exception of recombinant T14. In 2-cycle experiments, cost
was observed in ﬁrst-level transformants carrying FqR changes S79F,
S79Y, D83Y and GyrA E85K, with the exception of recombinants T6
and T11. Results suggest that there is no impediment due to ﬁtness
cost for the spreading of recombinant FqR SPN isolates, since some
recombinants exhibited a compensation of the cost.
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S229 Severe diabetic foot osteomyelitis
B.A. Lipsky (Seattle, US)
Infections of bones in the foot in patients with diabetes occur in 20−60%
of patients who develop a foot wound. These infections usually occur
by contiguous spread from soft tissue infection, and markedly increase
the risk for hospitalisation and amputation. Most infections are caused
by staphylococci, but other organisms can be involved, sometimes in
a polymicrobial infection. The ﬁrst task for the treating clinician is to
diagnose bone infection accurately. This is best done by obtaining a
bone specimen (either percutaneously or at surgery) for both culture
and histology. Among the available imaging tests, MRI is clearly the
best; bone scans are too non-speciﬁc. Clinical signs and symptoms
are unreliable, but the probe-to-bone test is easy and relatively helpful.
Recently, the International Working Group on the Diabetic Foot proposed
a diagnostic scheme that estimates the likelihood of osteomyelitis based
on combinations of various clinical and laboratory test results.
After conﬁrming a bone infection, the clinician must plan its treatment.
Most authorities recommend resecting any necrotic (and in many
cases grossly infected) bone, but evidence supporting this advice is
sparse. Recently, retrospective case series have shown that some cases
of presumed osteomyelitis can be put into long-term remission with
antibiotic therapy alone, usually with highly bioavailable antibiotics (e.g.,
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ﬂuoroquinolones) given for a prolonged period (3 months or longer). If
one removes all infected and necrotic bone, the duration of treatment
can be considerably shorter (days to weeks).
No available data support parenteral over oral antibiotic therapy, nor
has one antibiotic agent has been found to be superior to others.
Some evidence suggests that including rifampin (combined with at least
one other anti-staphylococcal antibiotic) improves outcome; clindamycin
and b-lactam agents are also frequently used. No adjunctive treatment
(e.g., hyperbaric oxygen, granulocyte colony stimulating factor, larval
biotherapy) has been proven beneﬁcial. When treatment of osteomyelitis
fails, surgeons should opt for the most minor amputation compatible
with good residual foot function. Clinicians should monitor patients for
at least a year to ensure that they have achieved apparent resolution of
infection.
S230 MRSA endocarditis
F. Gudiol (Barcelona, ES)
Nowadays, S. aureus is the leading cause of infective endocarditis (IE)
in most regions of the developed world. This is a consequence of the
increasing rates of healthcare-associated staphylococcal bacteraemias
and also of the increasing number of patients with implanted medical
devices.
In non-addicts, infection primarily involves the left side of the heart and
is associated with mortality rates ranging from 25% to 40%, whereas in
addicts often involves the tricuspid valve, and mortality rates are much
lower.
An increasing percentage of S. aureus strains in both hospital and
community settings are meticillin-resistant. In recent series of S. aureus
endocarditis, MRSA accounts for around 30% of cases. Patients with
MRSA-IE are more likely to have chronic conditions, healthcare-
associated infections, persistent bacteraemia and higher mortality rates.
In those with left-sided endocarditis (especially among patients in
maintenance hemodialysis) mortality may be as high as 80%.
According to the current guidelines, vancomycin remains the reference
standard for the treatment of both prosthetic and native right-sided and
left-sided MRSA-IE. Both slow bactericidal activity and poor penetration
into vegetations have been advocated as the main reasons to explain the
limited efﬁcacy of the drug. More recently, the emergence of isolates
with reduced susceptibility to vancomycin, and the observation of an
excess of failures among patients with MRSA bacteraemia caused by
"susceptible" strains with MICs  2mg/ml, have emphasised the need
for alternative therapies.
The addition of aminoglycosides (MRSA usually are non-susceptible) or
rifampin, has not been associated with better outcomes.
Among older antibiotics, trimethoprim-sulfamethoxazol and combina-
tions of fosfomycin with carbapenems, which are highly synergistic
against most strains, might be reasonable alternatives for selected
patients.
New therapeutic options include quinupristin/dalfopristin, linezolid,
tigecicline and daptomycin. All these drugs have shown an efﬁcacy equal
or better than vancomycin in experimental models of MRSA, h-GISA
and GISA endocarditis, but clinical experience is scarce. Among them,
daptomycin – which has been approved for use in S. aureus right-sided
endocarditis – is probably the best alternative due to its rapid bactericidal
effect. However, the best dose regimen of daptomycin in this setting,
the risk for developing resistance during therapy and the potential for
combinations with other agents are largely unknown.
Additionally, a number of new anti-MRSA compounds with good "in
vitro" activity and promising results in experimental models are in
development, including novel glycopeptides (dalbavancin, telavancin and
oritavancin), ceftobiprole, and iclaprim.
An early identiﬁcation of patients with persistent MRSA bacteraemia and
an aggressive multidisciplinary management of those with endocarditis
may help to improve prognosis. Especially important, surgical valve
replacement may play a relevant role in maximising outcomes in MRSA
left-sided and prosthetic valve endocarditis. Patients who fail vancomycin
therapy should have a prompt expert evaluation and receive alternative
compassionate drugs.
Emerging issues of Clostridium
difﬁcile-associated disease (Symposium
jointly arranged with IDSA and ESGCD)
S233 Antibiotic susceptibility patterns in Europe
J. Brazier (Cardiff, UK)
A selection of isolates of C. difﬁcile have been tested for their
susceptibilities to a range of antibiotics using both agar dilution and the
E test methods. Isolates were of known PCR ribotypes mainly originating
from a surveillance study of over 1,000 isolates from symptomatic
patients in hospitals in England.
The agents tested included; metronidazole, vancomycin, erythromycin,
imipenem, moxiﬂoxacin, levoﬂoxacin, co-amoxyclav, penicillin, pipera-
cillin–-tazobactam.
A separate selection of European isolates of C. difﬁcile present in the
culture collection of the Anaerobe Reference Laboratory of the UK
in Cardiff, were also studied for their susceptibilities to these drugs.
Representatives from Austria, Germany, Italy, Poland, Hungary, The
Netherlands, Sweden and Spain were included and the data will be
presented.
For the UK isolates, a strong relationship was noted between resistance
to certain agents and PCR ribotype, particularly amongst the common
strains known as Types 027, 106 and 001. This raises the question as
to if resistance mechanisms harboured by strains of C. difﬁcile offer a
selective advantage over strains that do not. The susceptibility of older
isolates of a given PCR ribotype was compared to contemporary isolates
to investigate if resistance is increasing and this will be discussed.
S234 Clostridium difﬁcile: new and old treatment options
E. Bouza (Madrid, ES)
A high percentage of C. difﬁcile strains are resistant to antimicrobials
such as cephalosporins, clindamycin, macrolides, aminoglycosides, tetra-
cyclines, cotrimoxazole, ertapenem, imipenem, and chloramphenicol. On
the contrary, the microorganism shows “in vitro” susceptibility to ampi-
cillin, meropenem, metronidazole, penicillin, piperacillin, teicoplanin
and vancomycin. Until recently, the activity of both ﬁrst-line drugs for the
therapy of CDAD, vancomycin and metronidazole, was not argued and
susceptibility testing was not even routinely recommended. At present,
metronidazole resistance, uncommon but present, is an heterogeneous
resistance with clinical consequences that have yet to be elucidated.
Metronidazole and vancomycin remain the drugs of choice for the
treatment of CDAD but, both have important limitations and adverse
effects. Metronidazole has been linked to a high rate of non-responses
and relapses mainly in patients infected with the 027 epidemic strain.
Patients with severe or recurrent disease require Vancomycin in higher
doses and during longer periods of time.
New antimicrobial agents active “in vitro” against C. difﬁcile include:
teicoplanin, ramoplanin, daptomycin, telavancin, linezolid, nitazoxanide,
tiacumicins B and C and rifaximin. Their role as alternative antimicrobial
agents against C. difﬁcile is still being deﬁned.
Nitazoxanide is an antihelminthic and antiprotozoal agent that is at least
as effective as metronidazole in treating C. difﬁcile colitis.
Intravenous immunoglobulins have been used in patients with severe
disease or multiple recurrences but there is not any prospective and
comparative study to establish their role in the treatment of this disease.
A hyperimmune bovine gammaglobulin that neutralizes the effects of
C. difﬁcile toxins is under development
Data regarding the role of oligofructose in the prevention of relapses
of CDAD are still conﬂicting. Tolevamer (GT160–246) is a polyanionic
polymer chain with a high molecular weight that has clinical cure rates
similar to oral Vancomycin when administered to humans at 6 g/day but
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failed to achieve non-inferiority when used at 9g/day in a recent clinical
trial.
Local bacteriotherapy is the name for the lavage of the lumen of the
colon or for the administration of enemas prepared with fresh faeces
from healthy volunteers. Reports are almost always of isolated cases or
short series and there is no relevant study that allows for giving any
recommendations on this method, with obvious drawbacks. This therapy
has the additional risk of the transmission of other infectious agents.
Exchange resins such as colestipol or colestyramine that are able to bind
to C. difﬁcile toxin, may also bind to antimicrobials used to treat CDAD;
therefore, their clinical use is not recommended..
Surgery is a last resource for the treatment of unmanageable CDAD with
toxic megacolon or colon perforations.
Finally, the perspective for a C. difﬁcile vaccine look very promising at
the present time.
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O236 Surfactant protein A promotes the interaction of
Pseudomonas aeruginosa with the airway epithelial cells and
enhances the inﬂammatory response
M. Barbier, L. Garcı´a-Sureda, S. Albertı´ (Palma de Mallorca, ES)
Background: The association of surfactant protein A with P. aeruginosa
enhances uptake by alveolar macrophages and modulates inﬂammatory
responses including cytokine production and the oxidant burst. However,
the role of this association in the interaction with the airway epithelial
cells is poorly investigated.
Objective: The aim of this study was to characterise the role of surfactant
protein A in the interaction of P. aeruginosa with the airway epithelial
cells and its biological signiﬁcance in the pulmonary pathogenesis of
this microorganism.
Methods: Surfactant protein A was puriﬁed by afﬁnity chromatography
from human bronchoalveolar lavage. Binding of puriﬁed surfactant
protein A to of 22 genetic unrelated P. aeruginosa isolates (11 from
chronic infections and 11 from acute infections) was analysed by ELISA
and Western blot analysis using speciﬁc monoclonal anti-surfactant
protein A antibody.
To investigate the role of surfactant protein A in the interaction of
P. aeruginosa with the airway epithelial cells, standard adhesion and
invasion assays were performed using 16HBE14- bronchoepithelial cells
and A549 pneumocyte type II cells incubated with P. aeruginosa pre-
opsonised with surfactant protein A either in the presence of calcium or
EDTA.
The production of IL-8, TNF-alfa and IL-6 by airway epithelial cells
was determined by ELISA according to the manufacturer’s instructions.
Results: Binding of puriﬁed surfactant protein A varied widely among
P. aeruginosa clinical isolates. However, the isolates from acute
infections bound surfactant protein A more efﬁciently than those from
chronic infections. Surfactant protein A opsonisation of P. aeruginosa
in the presence of calcium enhanced dramatically bacterial attachment
and internalisation by both bronchoepithelial cells and pneumocytes
type II. This interaction facilitated the airway epithelial cells mediated
inﬂammatory response increasing the synthesis of IL-8, TNF-alfa and
IL-6.
Conclusions: Surfactant protein A promotes the interaction of P. aerugi-
nosa with the airway epithelial cells and enhances the production of IL-8,
TNF-alfa and IL-6 by these cells. This mechanism is more effective with
the isolates from acute infections than from chronic infections.
O237 Fine tuning of P. aeruginosa physiology during chronic cystic
ﬁbrosis lung disease
M. Hogardt, C. Hoboth, C. Henke, A. Eichner, R. Hoffmann,
J. Heesemann (Munich, DE)
To provide a detailed survey of adaptation of P. aeruginosa during
chronic infection of the cystic ﬁbrosis (CF) lung, we performed a
comparative proteome and transcriptome analysis of isogenic non-
mutator and mutator isolates from three selected CF patients. Recently,
we showed that during CF lung persistence PA mutators converge
to a virulence-attenuated phenotype. In this study, we demonstrate
that the adaptation process of PA predominantly comprises metabolic
pathways. In end-stage mutator strains, several transcripts of genes or
proteins involved in metabolism of fatty acids, nucleotides, amino acids
and the generation of energy were increased. Of particular interest is
the increased expression level of genes involved in (i) the anaerobic
arginine-deiminase pathway, (ii) the anaerobic respiration (iii) the
tricarboxylic acid cycle (TCA) and glyoxylate shunt and (iv) the
uptake of dicarboxylates. These changes in transcriptome and proteome
indicate an adaptive shift towards constitutive expression of genes of
metabolic pathways obviously required for growth under micro-aerobic
and nutritional conditions of suppurative CF lung tissue. Strikingly, these
data provide us with new potential targets for antimicrobial agents to
combat chronic CF lung disease.
O238 Effect of antibiotics, alone and in association, on Panton-
Valentine leukocidin production by Staphylococcus aureus
O. Dumitrescu, C. Badiou, M. Bes, M.E. Reverdy, F. Vandenesch,
J. Etienne, G. Lina (Lyon, FR)
Objectives: To examine the capacity of Staphylococcus aureus to release
Panton-Valentine leukocidin (PVL) in the presence of subinhibitory
concentrations of the main anti-staphylococcal drugs.
Methods: S. aureus reference and clinical strains were grown in presence
of subinhibitory concentrations of ten antibiotics (oxacillin, vancomycin,
oﬂoxacin, co-trimoxazole, pristinamycin, clindamycin, fusidic acid,
linezolid, tetracycline and rifampicin) and of four antibiotic associations
(oxacillin + clindamycin; oxacillin + linezolid; oxacillin + fusidic acid
and oxacillin + rifampicin). The PVL concentration was measured in
the supernatant with an ELISA method after 18 h of culture. Pellets
of cultures grown with 14 MIC of antibiotics were used for quantitative
RT-PCR with speciﬁc lukSF-PV and gyrA primers.
Results: The effect of subinhibitory concentrations depended on the
antibiotics: oxacillin enhanced PVL level by up to 3-fold, while
clindamycin, linezolid, fusidic acid and rifampicin were inhibitory, and
vancomycin, pristinamycin, tetracycline, oﬂoxacin and co-trimoxazole
had roughly no effect. We then examined whether the inhibitoriest
molecules for PVL could abolish the PVL increase induced by oxacillin.
Subinhibitory concentrations of clindamycin and rifampicin dramatically
inhibited PVL induction by oxacillin. Linezolid had a slighter dose-
dependent inhibitory effect on PVL release. By contrast, fusidic acid was
not able to inhibit the PVL induction by oxacillin, except at 50%of the
MIC. RT-PCR results conﬁrmed PVL induction by oxacillin and lukSF-
PV inhibition of transcription by clindamycin and rifampicin. RT-PCR
results of cultures grown with antibiotic associations showed lukSF-PV
inhibition of transcription for oxacillin + clindamycin and oxacillin +
rifampicin and PVL induction for oxacillin + fusidic acid.
Conclusion: These data support that for staphylococcal infections related
to PVL production, antibiotic can either up-regulate or down-regulate
PVL release. Against PVL-producing MSSA, b-lactams should be
associated with either clindamycin or rifampicin while in PVL-producing
MRSA infections, linezolid may be of more beneﬁt than is vancomycin.
O239 Toll-like receptor agonists stimulate phagocytosis of
Escherichia coli by murine microglial cells
S. Ribes, S. Ebert, T. Hoffmann, S. Bunkowski, R. Nau (Go¨ttingen, DE)
Objectives: Bacterial phagocytosis by microglia during infections
contributes to the resistance of the brain. Microglia cells express toll-
like receptors (TLR) which can be stimulated by pathogen-associated
molecular patterns (PAMPs). Escherichia coli is one of the leading
Gram-negative bacteria that cause sepsis or neonatal meningitis. We
hypothesised that PAMPs may stimulate microglia thereby increasing
their ability to phagocytose bacteria.
S50 18th ECCMID, Oral presentations
Methods: Primary cultures of mouse microglia were exposed to the TLR
agonists: tripalmitoyl-S-glyceryl-cysteine (Pam3Cys; TLR 2), endotoxin
(LPS; TLR 4) and oligonucleotides containing unmethylated cytosin-
guanosin motifs (CpG; TLR 9) alone and in combination with interferon-
gamma (IFN-g) for 24h. After stimulation, cultures were challenged with
E. coli DH5alpha at a ratio of 100 bacteria per cell. Phagocytosis was left
to proceed for 30 and 90 min at 37ºC. Then, after washing, the microglial
cultures were incubated in medium containing gentamicin (200 mg/l) for
1 h to kill extracellular bacteria. Thereafter, cells were washed and lysed
with distilled water. For phagocytosis inhibition studies, cytochalasin
D (CD) was used at 10 microM. Viable intracellular bacteria were
enumerated by quantitative plating of serial 10-fold dilutions. To monitor
intracellular survival, microglia cells were allowed to ingest bacteria
for 1.5 h. Then, incubation in medium with gentamicin and CD was
performed for 1h. Thereafter, intracellular bacteria were determined at
various time points by quantitative plating after cell lysis. Kruskall-Wallis
test (followed by Dunn’s multiple comparisons test) was performed to
analyse differences in phagocytosed bacteria between groups (n  10);
p< 0.05 was considered statistically signiﬁcant.
Results: Unstimulated and IFNg-stimulated microglia ingested bacteria
at a low rate. LPS, Pam3Cys and CpG strongly increased the number
of phagocytosed bacteria (p< 0.01 at 30 and 90 min). Co-stimulation by
a TLR agonist and IFNg did not signiﬁcantly increase the number of
phagocytosed bacteria compared to stimulation by a TLR agonist alone.
CD inhibited phagocytosis >99% in all groups. Intracellular survival
assays showed that the number of viable intracellular bacteria reached a
plateau at 3h and then started to decrease in all groups.
Conclusion: After stimulation with bacterial TLR agonists, phagocytosis
of bacteria by microglial cells is increased. This increase is not dependent
on the presence of IFNg.
O240 The pathophysiological importance of apoptosis for the
septic patient
I. Vaki, H. Kranidioti, A. Pelekanou, A. Kotsaki,
E.J. Giamarellos-Bourboulis (Haidari, GR)
Objectives: The early apoptosis of the monocytes is related to good
prognosis in septic shock (Giamarellos-Bourboulis et al. Crit Care 2006).
The precise mechanism of the latter process has not yet been investigated.
The purpose of this study is to clarify whether the apoptotic procedure
is stimulated by the septic patient’s serum.
Methods: Serum from 48 patients was isolated within 24 hours from
the diagnosis of sepsis. The patients had severe sepsis or septic
shock according to the ACCP/SCCM CRITERIA 1992. Serum sampled
from healthy donors was used as the control group. Peripheral blood
mononuclear cells (PBMC’s) were isolated after gradient centrifugation.
5×106/ml PBMC’s were incubated with septic patient’s serum or serum
of healthy controls for 24 hours in 5% CO2 at 37ºC. PBMC’s were
washed and stained with Annexin-V-FITC-anti-CD4-PE-PI and annexin-
V-FITC-anti-CD14-PE-PI and analysed by ﬂow cytometry.
Results: Median (IQR) expression of ANNEXIN(+)/CD14(+)/PI(−) on
PBMC’s incubated with serum of patients and with serum of healthy vol-
unteers was 6.01 (15.28)% and 24.12 (37.56)% respectively (p: 0.004).
Respective values for the expression of ANNEXIN(+)/CD4(+)/PI(−)
on PBMC’s were 7.93 (18.52)% and 3.65 (4.22)% (p< 0.0001). After
incubation with serum of non-survivors, median (IQR) of the rate of
apoptosis of PBMC’s was 16.80 (25.18)%; after stimulation with serum
of survivors it was 5.04 (8.47)% (p: 0.015).
Conclusion: Serum of patients with severe sepsis or septic shock induces
the apoptosis of the lymphocytes and inhibits the apoptosis of the
monocytes. This could explain why the induction of CD4-lymphopenia
is connected with poor survival and how circulating factors in serum
contribute to the perpetuation of the septic procedure through the non-
apoptotic monocyte.
O241 Role of the AcrAB efﬂux pump in Klebsiella pneumoniae
respiratory infections
E. Padilla, A. Dome´nech-Sa´nchez, M.A. Campos, L. Martı´nez-Martı´nez,
J.A. Bengoechea, S. Alberti (Palma de Mallorca, Bun˜ola, Santander, ES)
Background: AcrAB efﬂux pump activity is critical to mediate
antimicrobial resistance in K. pneumoniae. However, the role of this
efﬂux pump in the virulence of this opportunistic pathogen has been
poorly investigated.
Objective: The aim of this study was to investigate the role of the AcrAB
efﬂux pump of K. pneumoniae in the respiratory infections caused by
this microorganism.
Methods: We constructed by insertion-duplication mutagenesis a
speciﬁc AcrB mutant, designed as 52DB, from the K. pneumoniae
virulent strain 52145. Characterisation of the mutant was performed
by Southern blot analysis, RT-PCR analysis of AcrB expression, and
determination of the MIC of several antimicrobial agents.
To investigate the virulence of the AcrB-deﬁcient mutant, standard
survival assays were performed incubating the bacterial cells with human
bronchoalveolar lavage, polymyxin B or human beta-defensin. Virulence
was also tested in a murine model of pneumonia.
Results: Southern blot and RT-PCR analysis conﬁrmed the interruption
of the AcrB gene and the abolishment of the expression of AcrB in
52DB. The mutant was more susceptible to cefoxitin, erythromycin, and
nalidixic acid than the parent strain. MICs (mg/l) of antibiotics for strain
52145 and its 52DB mutant were respectively; 8 and 1 (cefoxitin), 64
and 1 (erythromycin), and 4 and 0.5 (nalidixic acid).
The mutant 52DB exhibited a signiﬁcant reduction of more than three-
folds in its capacity to survive in the presence of bronchoalveolar lavage,
polymixin or human beta-defensin compared with the parent strain.
Furthermore, the mutant was less virulent than the parent strain in a
murine model of pneumonia.
Conclusions: AcrAB efﬂux pump contributes to both antimicrobial
resistance and virulence of K. pneumoniae.
O242 The two predominant HA-MRSA clones in France exhibit
speciﬁc adhesive and virulence properties in vitro and in vivo
in a mice sepsis model in comparison with MSSA isolates
H. Karauzum, T. Ferry, S. de Bentzmann, G. Lina, M. Bes, G. Durand,
F. Vandenesch, R. Landmann, J. Etienne (Basel, CH; Lyon, Marseille,
FR)
Objectives: To determine if the two predominant pandemic hospital-
acquired (HA) meticillin-resistant S. aureus (MRSA) clones in France
have speciﬁc adhesive properties in vitro and virulence properties in a
mouse sepsis model in vivo.
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Methods: 26 S. aureus isolates responsible for bloodstream infections in
France in 2003–2007 were included: 10 HA-MRSA isolates belonging to
the predominant “Lyon clone” in France (sequence type [ST] 8, SCCmec
type IV), 8 HA-MRSA isolates belonging to a minor but emergent
MRSA clone in France (ST5, SCCmec type IV), and 10 MSSA isolates
with various genetic background. The in vitro binding to human airway
epithelial cells (HAECs) and the virulence in a mouse sepsis model were
determined. C57Bl/6 and Balb/C mice were i.v. infected with inocula of
107 to 108 (ﬁve to ten female per isolate). agr dysfunction (that may
enhance adhesion) and virulence factors such as the capsular type (CP)
and the toxin gene proﬁle were screened in all isolates to interpret the
results.
Results: In comparison to the MSSA group, a higher adhesion (mean of
69.1±10.9 versus 42.2±3.7 adherent bacteria per cell, P< 0.001; Figure,
panel A) and a higher virulence in the mouse sepsis model (P = 0.072
with C57BL/6 and P = 0.01 with Balb/c) was observed for the MRSA
ST8 group (Figure, panel B). The MRSA ST5 group was signiﬁcantly
less adhesive to HAECs (mean of 12.1±3.3, P< 0.001; Figure, panel
A), but induced a high mortality (79% at day nine; Figure, panel B) in
the sepsis model in comparison with MSSA (P< 0.001). We observed
heterogeneity in the results obtained with the MRSA ST8 group both
in the adhesion and in the sepsis model, with three MRSA ST8 isolates
not being lethal at all. The higher adhesion of MRSA ST8 isolates did
not correlate with agr dysfunction. Virulence of MRSA ST8 and ST5
isolates may be due, at least in part, to the combination of expression of
CP5 and production of superantigenic toxins. Indeed, all MRSA isolates:
(i) expressed CP5, contrary to four MSSA, only; (ii) harbored genes
encoding SEA (MRSA ST8) or TSST-1 (MRSA ST5) whereas none of
the MSSA isolates were positive for these genes.
Conclusion: The two pandemic MRSA clones in France exhibit speciﬁc
adhesive and virulence properties that may explain their success. CP5
and production of superantigenic toxins may be key virulence factors for
these pandemic MRSA clones.
O243 The ferric yersiniabactin uptake receptor FyuA is required
for efﬁcient bioﬁlm formation by urinary tract infectious
Escherichia coli in human urine
V. Hancock, P. Klemm (Lyngby, DK)
Objectives: Urinary tract infection (UTI) is the most common infection
in patients with indwelling urinary catheters and bacterial bioﬁlm
formation is a major problem in this type of infections. Bacterial bioﬁlms
are highly resistant towards ﬁerce ﬂows and high concentrations of
antibiotics. Understanding the mechanisms behind bioﬁlm formation is
necessary in order to combat these infections.
Methods: Microarray analysis was performed on samples from E. coli
UTI strain VR50 grown in MOPS/shake ﬂask, urine/shake ﬂask and
urine/bioﬁlm. Bioﬁlm formation of knockout mutants and wild-type
strains was investigated in microtitre plates and ﬂow-cell chambers.
Results: The ferric yersiniabactin uptake receptor (FyuA) which is
encoded on the high pathogenicity island (HPI) was found to be
highly important for bioﬁlm formation by UTI E. coli in human urine.
Global gene expression proﬁling of UTI strain VR50 during bioﬁlm
formation in urine showed that all genes located on the HPI were
signiﬁcantly up-regulated; interestingly, this was the only iron acquisition
system displaying up-regulation in bioﬁlm urine growth compared with
planktonic urine that was not up-regulated in planktonic urine compared
with minimal medium.
The fyuA gene was among the highest up-regulated of all genes, 63-fold.
Furthermore, an fyuA mutant showed signiﬁcant reduction in bioﬁlm
formation compared with its parent – both on polystyrene (microtitre
plates) and on glass (ﬂow chambers). In urine ﬂow-cell chambers the
mutant showed 92% less bioﬁlm compared with the wild-type (Fig.
1). However, when complemented in trans or supplied with extra iron
the mutant regained its bioﬁlm-forming faculty. Also, introduction of
an fyuA-encoding plasmid into three UPEC strains increased bioﬁlm
formation signiﬁcantly.
Figure 1. Bioﬁlm formation of VR50 and the fyuA mutant in ﬂow
chambers in human urine. The mutant showed 92% less bioﬁlm
compared with the wild-type. Scale bars, 30 mm.
Conclusion: Free iron is strictly limited in the human urinary tract and
there is ﬁerce competition between the host and infectious bacteria for
this essential metal. UTI E. coli has highly efﬁcient mechanisms of iron
acquisition, one of which is yersiniabactin encoded on the HPI. Here
we demonstrate a direct link between FyuA and bioﬁlm formation in
iron-poor environments such as human urine. We also show that the
availability of iron greatly inﬂuences the UTI strains’ ability to form
bioﬁlm.
O244 SgrA, a serine-glutamate repeat containing MSCRAMM of
Enterococcus faecium CC17 binds ﬁbrinogen
A.P.A. Hendrickx, M. van Luit-Asbroek, J.C. Braat, W.J.B. van Wamel,
M.J.M. Bonten, R.J.L. Willems (Utrecht, Rotterdam, NL)
Objectives: The incidence of infections caused by Enterococcus faecium
has dramatically increased in hospitals world wide. Nosocomial outbreak
associated and most clinical isolates cluster together by multilocus
sequence typing in a hospital-adapted genogroup, designated as clonal
complex-17 (CC17). Recently, ﬁve genes encoding LPXTG surface
proteins were found to be enriched in CC17 E. faecium isolates. One
of these ﬁve, sgrA, formerly known as orf2351, is present in all of the
CC17 E. faecium isolates and in only 26% of the non-CC17 E. faecium
isolates. The objective was to functionally characterise SgrA, which is
a potential target for immunotherapy to prevent and treat E. faecium
infections.
Methods: Sequence encoding sgrA was cloned, expressed as a 6xHis
fusion protein (rSgrA) in Escherichia coli and puriﬁed using afﬁnity
chromatography. Binding of rSgrA to extracellular matrix molecules as
ﬁbronectin, ﬁbrinogen, laminin, vitronectin and BSA (negative control)
was assessed by ELISA and ligand-afﬁnity Western blotting. Reverse
transcriptase (RT) PCR was used to detect mRNA transcripts of
sgrA. Transmission immuno electron microscopy (TEM) was used to
determine association of the SgrA surface protein with the cell wall.
Results: SgrA has similarities with the Clumping factor B protein of
Staphylococcus aureus and contains a serine-glutamate repeat region. In
an ELISA, the puriﬁed rSgrA protein showed concentration dependent
binding to immobilised ﬁbrinogen in a saturable manner and to a
lesser extend to vitronectin and not to ﬁbronectin or BSA. By use of
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ligand-afﬁnity blotting, rSgrA showed to bind to the alpha, beta and
gamma subunits of ﬁbrinogen. Using RT-PCR, mRNA transcripts of sgrA
were detected in all phases of growth at 37ºC and TEM demonstrated
association SgrA with the cell wall.
Conclusion: We showed that sgrA is constitutively expressed at mRNA
level at 37ºC, encodes a LPXTG surface protein, and mediates adherence
to ﬁbrinogen. This makes SgrA the second member of the MSCRAMM
(microbial surface component recognising adhesive macromolecules)
family identiﬁed in E. faecium. The ability to adhere to ﬁbrinogen
may play a role in the pathogenesis of CC17 E. faecium in hospital-
related infections and may have contributed to successful adaptation in
the hospital setting.
O245 Gliotoxin is an important virulence factor in cerebral
aspergillosis
C. Speth, C. Kupfahl, M. Hagleitner, M. Deutinger, G. Rambach,
I. Mohsenipour, M.P. Dierich (Innsbruck, AT; Heidelberg, DE)
Objective: The high lethality of cerebral aspergillosis urgently asks for a
deeper insight into the pathogenic mechanisms of this disease. Therefore
we studied whether mycotoxins, especially gliotoxin, contribute to neural
damage and to the inefﬁcient immune response in cerebral aspergillosis.
Furthermore we tested the putative capacity of antioxidant components
to interfere with the harmful activity of gliotoxin.
Methods: The secretion of gliotoxin after fungal growth in cerebrospinal
ﬂuid (CSF) was measured using HPLC and tandem mass spectrometry.
An effect of gliotoxin on the viability and proliferation of astrocytes,
neurons and microglia was tested by MTS assays. Phagocytic activity of
cells in the presence of gliotoxin was quantiﬁed using ﬂuorescent latex
beads and subsequent microscopic analysis; oxidative burst was studied
by FACS.
Results: Pathogenic Aspergillus species like A. fumigatus secrete
signiﬁcant levels of gliotoxin when cultivated in CSF. The corresponding
concentration of gliotoxin was sufﬁcient to affect the viability of
astrocytes, neurons and microglial cells, with neurons and microglia
being the most sensitive cell types. Subtoxic concentrations of
gliotoxin diminished the capacity of microglia to phagocyte pathogens.
Furthermore gliotoxin exaggerated the oxidative burst in inﬁltrating
granulocytes induced by stimuli such as PMA.
Therapeutic approaches might aim to neutralize the inhibitory or even
toxic effect of gliotoxin and thus to reconstitute the potency of cerebral
immunity. We used glutathione for this purpose, a tripeptide made up
from cysteine, glutamate and glycin which act as a reducing compound.
In ﬁrst promising experiments with glutathione we were able to protect
brain cells from gliotoxin concentrations which otherwise were shown
to kill the cells. Furthermore glutathione reconstituted the phagocytic
activity of immune cells in the presence of gliotoxin.
Conclusions: These data indicate an essential contribution of gliotoxin
to the pathogenesis of cerebral aspergillosis. As a therapeutic approach
neuroprotective substances such as glutathione might be used to
neutralize the toxic or immune-inhibitory activity of gliotoxin.
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O246 Current status of diphtheria and related infections in Europe
K.S. Wagner, J.M. White, S. Neal, A. Efstratiou (London, UK)
Objectives: To describe the current status of diphtheria and related
infections caused by Corynebacterium diphtheriae and C. ulcerans in
Europe, as well as the changing epidemiology with respect to C. ulcerans
infection. Also in liaison with the ECDC and WHO EURO to compare
the different surveillance systems across the European region, leading to
the development of a European surveillance database.
Methods: A survey was undertaken of the number of microbiologically
conﬁrmed cases due to C. diphtheriae and C. ulcerans, and the
current surveillance systems of the 25 Diphtheria Surveillance Network
(DIPNET) member countries. DIPNET was ofﬁcially recognised as
a Dedicated Surveillance Network by the European Commission in
2006, and originates from the European Laboratory Working Group on
Diphtheria, formed in 1993 because of the re-emergence of diphtheria
to epidemic levels in the Russian Federation and Newly Independent
States during the 1990s. One of DIPNET’s projects is the development
of a database in order to link surveillance, microbiological and
molecular data, creating an integrated tool for both microbiologists and
epidemiologists.
Results: The number of toxigenic strains reported in the last seven
years (2000–2006) varied widely from none (in 12 countries), to 487
(in Latvia). Some countries, mainly those with strong microbiological
support reported mild cases of diphtheria caused by toxigenic
C. diphtheriae and C. ulcerans. Interestingly, the isolation of toxigenic
C. ulcerans is increasing, relative to toxigenic C. diphtheriae in some
countries. All member countries provided information about their current
surveillance systems for diphtheria, and their potential to collect case-
based data as part of a standardised European dataset.
Conclusion: Whilst diphtheria is generally well controlled by vac-
cination in most European countries, there is a continued threat of
re-emergence. The absence of reported cases in some countries may
reﬂect the lack of appropriate epidemiological and microbiological
investigation. The increasing prevalence, in some countries, of C.
ulcerans infection, which can present with symptoms of classical
diphtheria, also highlights the need for increased understanding of this
pathogen, associated with contact with domestic animals. Development
of the integrated surveillance database should provide a useful tool
for monitoring changes in the epidemiology and increasing our
understanding of both C. diphtheriae and C. ulcerans infections.
O247 Recent temporal trends in morbidity and mortality due to
pneumonia in the Netherlands
A.B. van Gageldonk-Lafeber, M.A.H. Bogaerts, R.A. Verheij,
M.A.B. van der Sande (Bilthoven, Utrecht, NL)
Objective: Community acquired pneumiae (CAP) remains a major
cause of morbidity and mortality in the Netherlands, however little is
known about recent temporal trends in the general population, which is
essential for an adequate policy on infectious diseases. We conducted
a population-based retrospective study to examine and compare these
recent trends in the Netherlands between 1997 and 2006
Methods: We analysed three national databases to assess incidence
of general practitioner consultations (1) and hospitalisation (2) and
mortality rates due to pneumonia (3) (1:Netherlands Investigation
Network of General Practice (LinH), 2:Dutch Monitoring Network
(LMR), 3:Statistics Netherlands (CBS)). We assessed incidences and
mortality rates for respiratory years (May 1st year N until April 30th
year N+1), adjusted for demographic changes in age and gender. For
the GP visits we excluded repeated visits for pneumonia by the same
patient within 90 days after the initial consult. Hospital admissions
were included when pneumonia was the main diagnosis of a patient.
For mortality we included cases with pneumonia being the primary or
secondary cause of death
Results (preliminary): Between 1997/1998 and 2005/2006, the adjusted
mortality rate of pneumonia decreased with about 1% per year. The
adjusted hospital admission rates increased with approximately 7% per
year in the period between 1999/2000 and 2005/2006.
The incidence of patients visiting their GP with a (suspected) pneumonia
did increase with about 8% per year between 2001/2002 and 2005/2006.
Conclusion: Though the Dutch population is aging, the mortality rate
of pneumonia is slowly but surely decreasing. On the other hand, the
morbidity has increased considerably in the recent years, which proves
that pneumonia remains a great clinical and public health concern.
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O248 Body mass index at age 50 to 64 and risk of subsequent
hospitalisation with pneumonia
M. Nørgaard, C. Dethlefsen, J.B. Kornum, R.W. Thomsen, A. Tjønneland,
H.T. Sørensen, K. Overvad (Aalborg, Copenhagen, Aarhus, DK)
Objectives: The incidence of hospitalised pneumonia in Denmark has
increased considerably during the last decade. Little information is
available on the impact of body mass on the risk of pneumonia. The
aim of this study was thus to examine the association between BMI and
risk of hospitalised pneumonia.
Methods: We conducted this large prospective cohort study using
data from the Danish cohort "Diet, Cancer and Health" including
individuals 50−64 years of age recruited during 1993−97 with
detailed information concerning diet and other lifestyle factors and
anthropometric measurements. We linked data from the cohort study
to the Danish National Patients Registry and retrieved information on
all incident hospitalisations with pneumonia before 2006. We excluded
individuals with a prior hospitalisation for pneumonia and those with
incomplete information on anthropometric measurements or potential
confounders (n = 1,102), leaving 55,951 for the analysis. We categorised
BMI into ﬁve groups (<22.5, 22.5−24.9, 25.0−29.9, 30.0−34.9, 35+) and
estimated the cumulative risk of hospitalisation for pneumonia within the
ﬁrst 5-years of observation. We used Cox’s regression to compute hazard
ratios as measure of relative risk (RR) for hospitalisation for pneumonia
(reference: BMI = 22.5−24.9). We adjusted for comorbidity, smoking,
and alcohol intake. Since changes in body composition differ in men
and women we stratiﬁed the analysis according to gender.
Results: A total of 2,664 subjects had a ﬁrst episode of hospitalised
pneumonia during a median follow-up of 8.9 years. The 5-year risks
of hospitalisation with pneumonia were 7% for BMI< 22.5, 5% for
BMI = 22.5−24.9, 5% for BMI = 25.0−29.9, 6% for BMI = 30.0−34.9,
and 7% for BMI = 35+. The association between BMI and adjusted
relative hazard of pneumonia (Reference is BMI = 23.8)is shown in ﬁg.
1. Compared with participants with a BMI of 22.5−24.9 the adjusted
RRs were for men: 1.5 (95% CI:1.2−1.8) for BMI< 22.5, 1.1 (95%
CI:1.0−1.3) for BMI = 25.0−29.9, 1.2 (95% CI:1.0−1.4) for BMI =
30.0−34.9, and 1.8 (95% CI:1.4−2.4) for BMI of 35+. For women the
adjusted RRs were 1.3 (95% CI:1.1−1.5) for BMI< 22.5, 0.9 (95%
CI:0.8−1.0) for BMI = 25.0−29.9, 0.9 (95% CI:0.7−1.0) for BMI =
30.0−34.9, and 0.9 (95% CI:0.6−1.2) for BMI of 35+.
Conclusion: We found a clearly increased risk of pneumonia among
individuals with a BMI below 22.5 and for men also among those with
a BMI of more than 35.
O249 Guidelines observance by general practitioners for
respiratory tract infections: a quantitative study using the
"Small Samples Approach" for in-depth, case-based analysis
in French-speaking Belgium
J.M. Feron, D. Legrand, P.M. Tulkens (Brussels, BE)
Background and Objectives: Belgium is a "high antibiotics prescribing"
country in Europe for outpatients (Clin Infect Dis. 2007, 44:1091−5;
44:1259). This has triggered (i) the development of national guidelines
for ambulatory practice using Evidence-Based Medicine data (supported
by the ofﬁcial Belgian Antibiotic Policy Coordination Committee), and
(ii) the sending to each general practitioner (GP) of an individual feed-
back comparing her/his personal prescribing habits with an "average GP"
in her/his region. We wanted to assess how these guidelines and feed-
backs are perceived by GPs, and to determine how they are followed for
respiratory tract infections (RTI).
Methods: SSA (in-depth analysis of actors’ behaviour aiming to
identify the rationale of a decision when faced with actual data)
was used retrospectively on a cohort of patient contacts (n = 150) for
antibiotic prescription for RTI. GPs (n = 38) were randomly selected
and approached for data collection from medical records and direct
interview (n = 30), to document medical history, reasons for encounter,
symptoms, clinical examination, patient’s demand, imaging or laboratory
tests, diagnostic, prescribed antibiotic, and compliance with guidelines.
Data were anonymously analysed in a double-blinded fashion by
two independent researchers (both GPs) for assessment of guideline
observance (antibiotic need and choice).
Results: Level of enrolment was 79%. Observance of guidelines
(with CI 95%) as assessed by the GPs themselves was 41%
(33−49) [non-observance: 26% (18−34); guidelines not know: 32%
(24−40)]. Inappropriateness of antibiotic prescription, as assessed by the
independent researchers, was 56% (48−64). Reasons for non-observance
of guidelines (as expressed by the GP’s; by order of frequency) were that
guidelines are (i) too restrictive; (ii) unusable in everyday practice, (iii)
not credible, (iv) only money-saving oriented, or (v) not known. Patients’
expectations were judged as a major factor in the prescribing decision,
overtaking the opinion of ofﬁcial scientiﬁc authorities.
Conclusions: Ofﬁcial guidelines and recommendations have only
a limited impact on actual prescribing behaviour. Efforts to curb
overprescription of antibiotics in RTI for community patients must aim at
(i) decreasing patients’ demands, and (ii) making guidelines more usable
in everyday practice, independent of ﬁnancial considerations, based on
more credible sources, and with goals that the practitioner consider as
being reachable.
O250 Do Bugs Need Drugs? Pharmacist train-the-trainer
programme in Alberta, Canada
M. Carson, S. Mitchell, S. Fryters, M. Tomney, D. Wilson,
E. Blondel-Hill (Edmonton, St. Albert, Vancouver, CA)
Objective: To increase the capacity to deliver education about
appropriate use of antibiotics in communities in Alberta, Canada
(population 3.3 million).
Methods: Previous studies showed that parents whose children received
Do Bugs Need Drugs? (DBND) instruction in school or daycare were
better informed about appropriate antibiotic use than controls. A train-
the-trainer programme was designed to increase capacity to deliver
DBND key messages: 1) handwashing prevents infections, 2) bacteria
and viruses are different, and 3) use antibiotics wisely. The DBND
programme is funded by Alberta Health and Wellness.
Based on interest and enthusiasm expressed by pharmacists, DBND
training workshops were provided for pharmacists in ﬁve communities
March-June 2006 and were monitored by before and after surveys.
Pharmacist trainers received an antimicrobial handbook, educational
tools and honoraria for teaching others, including nursing and
early childhood education (ECE) students and daycare managers.
Subsequently, nursing students used DBND kits to teach 7−8 year olds
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in grade two classrooms. ECE students and daycare managers were given
a kit to teach children and staff in daycares. Signs and booklets were
provided for the school, daycare and parents.
Results: After the training session, pharmacists knew signiﬁcantly more
about antibiotic use, were more conﬁdent about recommending treatment
options and were more comfortable in contacting a prescriber to change
an antibiotic prescription (Fig).
Of the 176 pharmacists attending training workshops, 50 became DBND
trainers. By 13-Nov-07, 50 lectures had been provided by DBND trainers
at 6 nursing schools and 19 ECE programmes, targeting over 600
nursing and 250 ECE students or managers. Over 450 classrooms and
13 childcare agencies have participated in this programme, impacting
over 12,500 children, their teachers and families.
Feedback from pharmacist trainers, nursing instructors and students,
children and teachers has been positive. The programme has opened
new lines of communication with school boards and public health
departments.
Conclusions: This multi-step approach has improved pharmacists’
knowledge about antibiotic resistance and conﬁdence in communicating
with others. Involvement of nursing and ECE students has increased the
capacity to provide community education about appropriate antibiotic
use in Alberta with the aim of reducing rates of antibiotic resistance.
O251 Q fever outbreak in southeastern Netherlands
M.H. Nabuurs-Franssen, G. Weers-Pothoff, C.A.R. Groot, R. Besselink,
P. Steenberger, G. Morrow, F. Dijkstra, A. Horrevorts (Nijmegen,
Den Bosch, Oss, Herpen, Bilthoven, NL)
Objectives: Q fever is a worldwide zoonosis caused by Coxiella burnetii.
Goats, sheep and cattle have been described as the most common animal
reservoir and birth products from infected animals are an important
source of environmental contamination. Transmission to humans occurs
by the aerosol route or by ingestion of non pasteurised milk products.
In the late spring of 2007 there was an outbreak of Q fever in the South
East of the Netherlands.
Results: From January until November there were 150 conﬁrmed (and
23 probable) cases of Q fever in the South East of the Netherlands
whereas normally 5−20 cases would be expected annually in the whole
country. The area has a population of 90.000 and is primarily rural.
Patients reported a sudden onset of high fever, sweats, cough, headaches
and muscle pain. There were 3 to every 2 females, their median age was
51 years and 71% had a history of smoking. Forty-nine percent of the
patients were admitted to the hospital all with pneumonia except two
patients who had hepatitis and one patient who had endocarditis. Most
patients were treated with moxiﬂoxacin 400 mg once daily for 7 days
and recovered within 24−48 hours. However, 15% of the patients still
had complaints, mainly fatigue and may develop chronic Q fever. Of the
18 pregnant women who were screened 2 (11%) had an active infection
and were treated with co-trimoxazole for the rest of their pregnancy.
There was a long dry and hot spell during the spring of this year and
Coxiella burnetii is highly resistant to chemicals and heat and can survive
for long periods in the environment which may have contributed to this
outbreak. The source of the outbreak is still under investigation but
transmission was almost certainly by way of aerosols.
Conclusion: There was a large outbreak of Q fever in the South East of
the Netherlands. Most patients suffered from a pneumonia implicating
that the transmission is probably causes by the aerosol route and climate
change may have contributed to this exceptionally large outbreak of Q
fever in the Netherlands.
O252 Co-infection with zoonotic Campylobacter and Salmonella
K.O. Gradel, B. Kristensen, T. Ejlertsen, H.C. Schønheyder, H. Nielsen
(Aalborg, Aarhus, DK)
Objectives: We hypothesised that patients co-infected with thermophilic
Campylobacter (TC) and non-typhoid Salmonella (NTS) had different
characteristics than patients with TC or NTS mono-infections.
Methods: Population-based registry study comprising all TC/NTS co-
infected patients (0−7 days between TC and NTS detection) and all ﬁrst-
time mono-infected TC or NTS patients in two Danish counties from
1991 through 2003. Data on recorded comorbidity were retrieved from
the Danish Hospital Discharge Registry and data on one-year mortality
from the Danish Civil Registration System.
Results: A number of 114 patients were co-infected and 13,335 had
mono-infections (6,768 TC [50.8%] and 6,567 NTS [49.2%]). The age
distribution (median [1st-3rd quartile]: 26.2 [19.2−44.4] years for co-
infected vs. 29.7 [17.6−48.2] years for mono-infected), comorbidity
(15 co-infected (13.2%) vs. 1,611 mono-infected [12.1%]; OR [95%
CI] = 1.1 [0.6−1.9]), and seasonal distribution (peak date and peak-
to-trough ratio [95% CI]: 22 August and 2.6 [1.4−4.9] for co-infected
vs. 28 August and 4.4 [4.1−4.8] for mono-infected) did not differ
between the two patient groups. All co-infected and 13,100 mono-
infected patients (98.2%) were alive after one year (p = 0.15). Co-
infected patients had a higher ratio of exotic NTS serotypes (in contrast
to Salmonella Enteritidis and S. Typhimurium) than mono-infected NTS
patients (53.5% vs. 21.8%; OR [95% CI] = 4.1 [2.8−6.1]), whilst there
were no differences between S. Enteritidis and S. Typhimurium (OR
[95% CI] = 1.1 [0.6−2.0]).
Conclusion: Co-infected patients were not frailer than mono-infected
patients. The differences in serotype distribution amongst NTS infected
patients indicate that infection sources and behavioural factors (e.g.,
travel) are more important determinants of co-infection vs. mono-
infection than baseline patient characteristics.
O253 Waterborne gastro-enteritis at a scout camp caused by
Norovirus types 1 and 2
H.L.G. ter Waarbeek, N.H.T.M. Dukers-Muijrers, H. Vennema,
E.I.G.B. de Brauwer, R.C.H. Boesten, C.J.P.A. Hoebe (Geleen,
Bilthoven, Heerlen, NL)
A gastro-enteritis outbreak in July 2007 at a scouting camp (77
children/29 leaders), 40% hospital admission, was investigated.
A retrospective study was performed. Epidemiological investigation
included a standardised questionnaire about sex, age, risks, symptoms
and family members. A primary case was deﬁned as diarrhoea/vomiting
(in any 24-h period). Stool and water was collected for microbiological
analysis. Another questionnaire study was done, to identify household
secondary cases. Attack rates and risk factors were determined.
Questionnaires were returned by 65 children/19 leaders (response rate
82.4%, median age:13 (IQR 11−17.7, range 7−47), female: 50%).
Primary attack rate was 67% (71 cases), with 87% vomiting, 73%
diarrhoea, 41% fever.
Water was obtained from a farmer’s well. Participants who drank water
more often fell ill (RR:3.9, 95%CI:1.5−10.5) with clear dose-response
effect. 97% of the cases drank water. Using the primitive toilet was also
associated with illness (RR: 4.9 (2.0−11.9)), whereas food was not. Stool
samples (68 cases/11 non-cases) were negative for bacteria and parasites.
95.8% of the cases returned stool; PCR showed norovirus in 75% (51):
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51% type 1 only, 25% type 2 only, 24% both 1−2, genotype II.7 Leeds,
I.2 Southampton. Looking only at cases with positive stool revealed
a stronger risk for water (RR=17.0, p = 0.02) than toilet use (RR=2.8,
p = 0.4). Of all cases 77.5% were early cases (day 1−2): more often <16
yrs (RR 1.5), vomiting (RR 4.1), fever (RR 2.1) and often type 1. Of 47
primary cases 32 households (79 members at risk) completed a second
questionnaire (response rate 63%). Secondary AR was 20.3% and did
not differ for the primary cases’ virus type: AR type 1=22.9%, type
2=23.1%, type 1−2=18.2%. Only a small water sample was available.
Analysis showed coliform bacteria, Escherichia coli and Enterococcus.
Norovirus was negative.
This unique outbreak shows a point source infection with two water-
transmitted noroviruses: type 1 and 2, proved by epidemiological and
microbiological ﬁndings, compatible incubation time and symptoms, also
high attack rate, clear secondary attack rate, faecal water contamination
and detection of mostly type 1 but also type 1−2. Not enough water was
at hand to detect norovirus.
Waterborne norovirus outbreaks regularly occur, but probably often stay
undetected. Monitoring water for viruses should be encouraged. At this
camp using bottled water and adequate toilets could have prevented this
epidemic.
O254 VZIG administration in pregnant women exposed to
chickenpox
J. Troughton, G. Crealey, V. Crawford, C. McCaughey, D. Wyatt,
H. O’Neill, P. Coyle (Belfast, UK)
Objectives: Varicella infection during pregnancy poses a serious risk
for both foetus and mother. The current UK practice regarding exposure
in pregnancy is immunity testing and varicella immunoglobulin (VZIG)
administration to non-immune women. This may not provide best patient
care, since a vaccine is now available. Additionally verbal followed
by serological screening of primigravidas giving a negative history at
antenatal booking with post-natal vaccination of those non-immune may
be more cost-effective than current policy.
The study aims to retrospectively compare the cost of the current policy
with a cost estimate for antenatal screening with post-partum vaccination
in N. Ireland.
Method: The cost of VZIG issued in 2006 was calculated from the
number of vials issued to pregnant women, at £280 per vial.
A cost estimate of antenatal screening of primigravidas, with post-
partum vaccination, was calculated for two models: 1) verbal screening,
with serological testing of those with no history of varicella infection;
2) serological screening of all primigravidas. The calculation included:
number of ﬁrst pregnancies in N. Ireland; cost per varicella immunity
test; estimated number of non-immune primigravidas; and cost of a
varicella vaccine course.
Results: The varicella epidemic curve spans the entire 12 month period
(see graph). The cost of VZIG issued to pregnant women in 2006 was
£100,800; 43% of births were to primigravidas therefore the estimated
cost of VZIG issued to multigravidas was £58,100. The cost of verbal
screening with serological screening of those with no history followed
by post-partum vaccination is estimated at £23,750 p.a, saving £34,350
over current policy.
The estimated cost of serological screening of all primigravidas with
post-partum vaccination is £43,000, saving £15,100.
Conclusion: This retrospective study suggests that in N. Ireland either
of the proposed antenatal screening strategies with post-natal vaccination
would be less costly than current practice, and may improve patient care.
Graph 1. Vericella Notiﬁcations, Tests and Immunoglobulin in 2006.
O255 Sustained mumps transmission in a highly vaccinated
population
M. Wohoush, M. Obeidi, M. Hindiyeh, F. Riccardo, G. Sabatinelli
(Jerusalem, IL; Amman, JO)
Objectives: To describe a parotitis outbreak in a highly vaccinated
population of Palestine refugees in West Bank (WB).
Methods: The United Nations Relief and Works Agency (UNRWA)
surveillance system targets various diseases including mumps. In
December 2003, following an increase in the reported incidence of
mumps among WB Palestinian refugees, an outbreak line listing was
established, serum IgM and IgG test was adopted for conﬁrmation
and RT-PCR for differential diagnosis and parotitis virus isolation. The
immunisation status of patients was assessed from immunisation cards.
Univariate analysis was performed and attack rates calculated.
Results: On average 3 cases meeting the WHO clinical case deﬁnition
for mumps are reported each month from WB (670,613 refugees of
whom 176,726 living in 19 refugee camps). When 5 mumps cases were
reported from a single camp in northern WB in December 2003 the
system was alerted. In 2004 and 2005, mumps cases increased by more
than 4 folds the baseline. The epidemic started in north-eastern WB
(Nablus) spread westwards and extended to central WB (Jerusalem).
Only one case was reported in 2005 in southern WB (Hebron). A total
of 3928 cases were detected (males 56%, mean age 11.7±7 years, 70.8%
in the 6−15 years age group). Attack rates in the camps varied between
0.03% and 4.3% (overall 1.2%). Complications were reported in 1%
of cases and all outcomes were favourable. UNRWA introduced MMR
vaccination (single dose) in 1988. 67.5% of all patients and 80% of
those born after 1988 had been immunised at least one month before the
onset of symptoms. 6 year-olds in 2004 and 7 year-olds in 2005 were
the mostly affected age groups suggesting a cohort effect for vaccinated
in 1999 (Fig.) moreover almost 30% of all vaccinated patients had been
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immunised between 1999 and 2000. In order to control the outbreak
an MMR vaccination campaign was conducted in May 2005 targeting
58,561 students from UNRWA schools and vocational training centres
(coverage 96%). In 2006 and 2007 cases dropped below the outbreak
threshold line but settled at higher than pre-outbreak levels.
Conclusions: High immunisation coverage did not prevent the parotitis
outbreak although complications seemed to occur more rarely than
expected. Although preliminary data suggests a cohort effect pointing
to a problem occurred during a speciﬁc vaccination year, further
investigations are planned to explain this event and avoid future
epidemics.
Antibiotic stewardship in the ICU: today
and tomorrow (Symposium arranged with
ESGAP)
S280 Future antibiotics for intensive care patients?
U. Theuretzbacher (Vienna, AT)
Although there are good treatment options available for most common
infections, antibacterial resistance has risen dramatically in ICUs and
the need for new compounds without cross-resistance to existing
drugs is apparent. Meticillin-resistant Staphylococcus aureus, pan-
resistant Pseudomonas and Acinetobacter have been recognised as
major resistance threats in many ICUs. Some patients are left
without a therapeutic option because of resistance against all available
antibiotics. No doubt, resistance is outrunning antibacterial research
and development. Since the 1980s, the focus of most pharmaceutical
companies shifted from antibacterial to more lucrative disease areas
that promise to meet the ﬁnancial targets of the big companies. To
reduce the risk and to speed up development time, many companies are
presently limiting their antibacterial programmes to building on existing
classes of antibiotics – developing analogues that lead to second and
third generations of the original compound. Thus, cross-resistance to the
newer agents can develop in short order because of the abundant pool
of existing resistance genes.
In general, development efforts are mainly focused on anti-
staphylococcal drugs that target a sufﬁciently large market. These new
drugs are analogues of known antibacterial groups. In any case, the
medical need for new anti-staphylococcal drugs will be met with several
new antibiotics expected to be launched within the next two years.
Clinical development activities against multi-resistant Gram-negative
pathogens including Pseudomonas and Acinetobacter are virtually non-
existent. Looking towards the coming years, no new antibiotics are
anticipated and no new scaffolds are close to preclinical stages of
development.
Recently, there have been signs of regained interest in the ﬁeld of resis-
tant Gram-negative infections from a few companies. These companies
and also academic research sites are exploiting unconventional high-
risk approaches and pursuing new targets. It is difﬁcult to assess the
potential of such new approaches and it remains to be seen if they will
yield useful antibiotics for ICUs in the future. In any case, it will take at
least 10 years before we can see the fruits of current research efforts in
the Gram-negative ﬁeld. Therefore, prudent use of existing antibiotics,
improved dosage regimes, surveillance efforts, and stringent adherence
to infection control guidelines are essential to preserve the power of
existing antibiotics.
S281 Consumption, resistance and policies in European ICUs
H. Hanberger (Linko¨ping, SE)
Critically ill-patients admitted to ICUs are highly susceptible to
infections because of predisposing illnesses and the use of invasive
procedures, and are therefore exposed to high antibiotic pressure. The
high and increasing prevalence of antibiotic resistant bacteria among
patients admitted to European hospitals in addition to high antibiotic
consumption and shortcomings in infection control measures increase
the risk of signiﬁcant outbreaks caused by antibiotic-resistant pathogens
among the critically ill. In countries with previously low resistance levels
(Scandinavia, Finland and the Netherlands), the frequency of multi-
drug resistance (MDR), particularly MRSA, may increase rapidly if
surveillance and measures to combat outbreaks fails. The need for an
early warning system of emerging and/or increasing antibiotic resistance
for local, national and international use is apparent. A programme for
continuous yearly registration of antibiotic use, resistance and clinical
practices with automatic feedback through a website was developed for
use in ICUs. It was launched as “CARE-ICU” in 2005. Antibiotics to
which >90% of isolates of a species were susceptible were deﬁned as
treatment alternatives (TA90) which is a novel index of susceptibility
to measure the magnitude of MDR. Thirty four ICUs in 8 countries
participated in the large pilot during 2005. The median yearly admissions
and admission days were 551 and 2595 respectively. There were four
important main ﬁndings in this ﬁrst report from CARE-ICU. First,
antibiotic consumption varied widely from 348 to 4992 DDD1000 with
a relatively high median consumption of 1254 DDD1000. Second, levels
of antibiotic resistance was very high in many settings but varied
also greatly between species, ICUs and countries and the ﬁnding that
more than half of all participating ICUs had no or only one treatment
alternative (TA90) for P. aeruginosa with at least 90% susceptibility
to aminoglycoside, ceftazidime, ciproﬂoxacin and carbapenem was
alarming. Third, there was a lack of rooms for isolation precautions and
cohort care for patients colonised or infected with alert organism. Four,
antibiotic guidelines including routines for discontinuation of antibiotics,
was available in some of the high antibiotic consuming ICUs but with
low compliance which shows the need for more effective tools for change
of prescription behaviour and a sustainable surveillance of compliance
to guidelines in general.
Why should adults care about paediatric
vaccination?
S283 Role of pneumococcal conjugate vaccines in protecting adults
from disease and antibiotic resistance
R. Dagan (Beer-Sheva, IL)
Despite the extensive global contribution of paediatric vaccines to
health in all ages in the last decade, the adult infectious disease expert
community continues to show a lack of interest in paediatric vaccines.
Yet, each of the licensed paediatric vaccines has had a tremendous effect
on morbidity of adults. Two main mechanisms are responsible for the
effect of childhood vaccination on adults: 1) A vaccinated child grows
to be a vaccinated adult. In some instances the adult may be protected
and in other he/she might show a modiﬁed disease; and 2) vaccinated
children often show reduction in carriage and then spread of pathogens
to adults, protecting them from disease (herd immunity).
Most of the times these 2 effects are beneﬁcial to adults, but in some
instances, such as pertussis or varicella vaccines, these effects could
increase disease in adults if vaccination programmes are not implemented
properly.
The complex relationship between paediatric vaccines and adult disease
will be demonstrated through the examples of pertussis, varicella,
pneumococcal and Hepatitis A vaccines.
Time has come to change the term “paediatric vaccines” for a more
appropriate term such as “vaccines for life”.
S284 Can paediatric inﬂuenza vaccination protect adult
populations?
C. Weil-Olivier (Colombes, FR)
Children, especially infants, toddlers and school-age ones, have a high
attack rate during yearly inﬂuenza seasonal epidemics. Epidemiological
data conﬁrm the anteriority of children’ epidemics peak from the adults’
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one by two weeks. A longer duration of viral shedding and higher
viral titres in the naso-pharynx compared with adults, associated with
promiscuity (day care centres, school) explain the children’ major vector
role in this respiratory transmission. Any intervention in childhood
limiting Inﬂuenza virus circulation in the community should provide
indirect protection (“herd immunity”) to adults.
Large immunisation programmes in children have been investigated in
different settings measuring the protection of contacts (households) or the
community at large. So far, routine immunisation of school-age children
appear to be effective in preventing the disease burden in the community
and adults contacts in several studies. Nevertheless, methodological
discrepancies between them render imprecise the estimation of this
strategy on effectiveness: which preventable fraction is achievable in
adults? The impact in the community depends on the coverage rate
achieved, the vaccine efﬁcacy and the contact patterns. Some simulation
models taking in account different efﬁcacy ﬁgures of Inﬂuenza vaccines
(most assume a protective efﬁcacy of 70% and a 80% efﬁcacy for
infectiousness) and different coverage levels suggest that a coverage rate
of 20% of schoolchildren would result in as much mortality reduction
in elderly as vaccinating 90% of persons aged 64 and over.
Nevertheless, if the universal inﬂuenza immunisation strategy in school-
children has demonstrated some beneﬁts in term of reduction of the
disease burden – either in observational studies or in mathematical
models – in adults or elderly, some points must be raised:
– Routine vaccination of school aged children has not been shown to
decrease by indirect effect the burden of disease in infants and younger
children who are highly infectious (thus transmitting the virus) or
more at risk of hospitalisation for severe Inﬂuenza disease. So far the
American recommendation of immunisation ﬁrst before 23 months of
age, then, since 2006 up to 59 months of age is mainly based on a
reduction of morbidity, hospitalisation, mortality in the targeted group.
– An other source of concern is the low coverage rates achieved post-
recommendation in the US, especially for the full primo-vaccination
demanding two doses below 9 years of age.
– It has not been demonstrated yet that routine vaccination of children
below 2 years of age has an indirect impact in the population.
– In Europe, the injectable trivalent inactivated inﬂuenza vaccine TIV,
sole available raises the issues of acceptability by the families, and
on a national public health point of view the feasibility of such
a programme, the huge increase of resources and the adequate
information strategies.
– TIV efﬁcacy may vary depending of the child’s age, the matching of
the strains – wild/vaccine – although mathematical models assume its
upper range (70%) and never more conservative hypothesis (the real
life).
– Clearly the availability of an intra-nasal live attenuated inﬂuenza
vaccine in Europe could be an opportunity to enlarge the strategies
due to its higher protective efﬁcacy and easiness of administration.
S285 Pertussis in children, adolescents and adults: mutual
protection by mutual vaccination
N. Guiso (Paris, FR)
Pertussis is a human respiratory disease due to a bacterium, Bordetella
pertussis. Since the generalised use, for newborns and children only, of
the ﬁrst pertussis vaccines, called Pertussis whole-cell (Pw) vaccines,
because composed of inactivated bacterial suspensions, Pertussis is still
endemic. Why? The use of Pw vaccines led to a dramatic decrease in
the incidence of the disease in children but conducted to demonstrate
and conﬁrm that Pertussis is not a paediatric disease. Pertussis can infect
children, as well as adolescents or adults. The disease is dramatic for
newborns but also for persons at risk such as elderly and pregnant
women. One of the characteristics of Pertussis is to induce a short
immunity, as well as Pw vaccines. A human can be infected two or
three times during its life. Twenty years after the introduction of Pw
vaccines for children, adults are no more immune and can contaminate
newborns too young to be vaccinated. For this reason, the introduction of
vaccine boosters was needed. This was possible after the development
of Pertussis acellular (Pa) vaccines, composed of puriﬁed inactivated
bacterial proteins. Since 1995, these vaccines are used for newborns and
children but also for adolescents and adults in many developed countries
in Australia, North America and Europe. However, vaccine coverage of
adolescents and adults is still low and mortality of newborns less than 2
months of age is now again observed in developed countries. Adequate
pertussis surveillance and reporting system are important to implement
vaccine strategy. They must be reinforced to evaluate the consequences of
the changes of (i) pertussis vaccine used (Pa instead of Pw), (ii) vaccine
strategy (addition of adolescents and adults boosters), (iii) characteristics
of the disease necessitating the development of new speciﬁc, sensitive
and standardised biological diagnoses, (iv) bacteria circulating since herd
immunity will be modiﬁed by universal immunisation and might have
an impact on the properties of the agent of the disease.
S286 Rotavirus – does it affect adults and will infant vaccination
protect adults?
T. Vesikari (Tampere, FI)
Worldwide, rotaviruses are responsible for half a million deaths from
severe acute childhood gastroenteritis annually. In developed countries
deaths are rare, but hospitalisation because of rotavirus-associated
dehydration is common. With dehydration corrected, the disease in
well-nourished children is self-limiting. Most hospitalisations occur in
children 6 to 24 months of age, when susceptibility to life threatening
dehydration is highest. However, both rotavirus infections and rotavirus
gastroenteritis continue to occur in older children as well as adults.
In adults rotavirus infections occasionally may lead to symptomatic
disease. There is evidence of endemic circulation of rotavirus in adults
that is independent from the winter epidemic cycle in children. In
addition, adults exposed to children with rotavirus gastroenteritis are
frequently infected and often come down with symptoms. Rotaviruses
may also cause outbreaks in adults in closed communities and,
particularly, in the elderly.
Two live oral rotavirus vaccines have been licensed recently. These
are: RotarixTM (GSK), a human G1P[8] vaccine given in two doses,
and RotaTeqTM (Merck & Co., Inc.), a human-bovine reassortant
vaccine given in three doses. Both induce protection against severe
rotavirus gastroenteritis caused by multiple serotypes of rotavirus, and
neither protects against rotavirus infection. Both vaccines are being
shed and might be rarely transmitted, but they do not remain in
circulation. Vaccine induced protection will be sustained for a few
years – enough to pass the most susceptible age for dehydration.
However, both asymptomatic rotavirus infections and mild breakthrough
cases of rotavirus gastroenteritis will occur in vaccinated children.
Universal mass vaccination against rotavirus has been introduced in a
number of countries, including USA, Brazil, Venezuela, Mexico, and,
in Europe, Austria and Belgium. While both licensed rotavirus vaccines
effectively protect the immunised individual, the long term consequences
of mass vaccinations are uncertain and purely speculative. There is no
evidence of herd immunity. As a result of vaccination, exposure of
adults to wild type rotavirus gastroenteritis in children might result in
waning immunity and actual increase in rotavirus gastroenteritis in adult
populations. The prospect of immunising target populations of adults
with rotavirus vaccines remains a distant possibility to be explored in
the future.
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The role of modelling in understanding the
dynamics and prevention of antimicrobial
resistance
S287 Transmission dynamics of infectious diseases – the inclusion
of evolutionary concepts with our thinking on transmission
and control
R. Anderson (London, UK)
Conventional approaches to the study of the transmission dynamics and
control of infectious diseases rest on the principles of population ecology
and to a degree on traditional statistical methods. With the rise and rise
of ever cheaper tools to examine the structure, and changes their in over
time and space, of both pathogen and host genomes, the need arises to
modify population and transmission dynamic frameworks to encompass
natural selection acting on both host and pathogen, and more generally
the concepts of evolutionary change. The talk will discuss recent work
to examine evolutionary concepts based on (a) stimulated phylogenetic
trees for pathogens within a transmission framework and (b) the evolution
of drug resistance in pathogen populations including both viruses and
bacteria, and the parasitic tropical diseases.
S288 Catastrophic failure of MRSA control in the hospitals: myth
or reality?
B.S. Cooper (London, UK)
Successful control of an infectious disease has a precise mathematical
deﬁnition: if the mean number of secondary cases caused by a typical
infectious case is maintained below one, an epidemic is said to be
under control. When this condition is met, though transmission may still
occur, and infection rates may temporarily increase as well as decrease,
the long-term reduction in incidence and ultimately the termination of
the chain of transmission is guaranteed (provided immigration of the
infectious agent into the population can be prevented).
While some interventions, such as hand hygiene, may be expected to
be equally effective regardless of the number of cases, resource-limited
control measures, such as nurse cohorting and side-room isolation, can
become less effective as the number of cases increases. For example,
in a low-level MRSA setting isolation facilities or stafﬁng levels may
be sufﬁcient to allow all detected cases to be effectively and promptly
isolated. In contrast, in high-level MRSA settings resource limitations
(e.g. limited availability of isolation beds and insufﬁcient stafﬁng levels)
can delay the time to effective isolation or make some interventions,
such as nurse cohorting, entirely unfeasible. Under such circumstances
an intervention that results in epidemic control in a setting with a low
MRSA prevalence can fail in a high prevalence setting. Thus, two stable
outcomes are possible even with identical control measures are in place.
If interventions are put in place early enough they can successfully
maintain infection at a low level preventing high-level MRSA becoming
established. If put in place too late, or compromised by immigration
of MRSA from other settings, identical interventions can have a much
smaller effect, only slightly suppressing MRSA levels, and failing to
reduce prevalence to a low level. Transitions between these two outcomes
are known mathematically as catastrophes, and can also have catastrophic
consequences for patient welfare. Simulation models have shown that
both stochastic ﬂuctuations, and immigration of MRSA cases from other
settings can, in principle, lead to such catastrophic shifts from successful
control to control failure. In this talk, the evidence that such catastrophic
transitions also occur in practice will be reviewed, making use of new
statistical developments for analysing hospital infection data and highly
detailed MRSA transmission data.
New aspects of Enterococcus faecalis and
E. faecium infections, including VRE
S291 New insights into the pathogenesis and treatment of
enterococcal endocarditis
B.E. Murray (Houston, US)
Enterococci were ﬁrst identiﬁed in the late 1890s from the blood of
a patient with infective endocarditis (IE) and, since then, enterococci
(primarily E. faecalis) have been recognised as causing 5−15% of cases
of IE, 3rd behind staphylococci and streptococci. They have also been
reported as the 2nd most common cause of nosocomial IE. Because
cell-wall active agents are not bactericidal against many enterococci,
the recommended therapy for enterococcal IE has, for many decades,
been a synergistic combination including 4−6 weeks of a cell-wall
active agent plus an aminoglycoside (AG). Recent studies have suggested
that shorter AG regimens and, for strains with high-level resistance to
all AG, the combination of ampicillin with ceftriaxone may also have
adequate efﬁcacy for E. faecalis IE. Therapy for endocarditis caused by
vancomycin resistant E. faecium remains more problematic.
Relatively little is known about the pathogenesis of enterococcal IE.
Our recent studies have identiﬁed pili in E. faecalis, encoded by the
ubiquitous ebp (for endocarditis and bioﬁlm related pili) locus and
made up of 3 subunits, each of which have the characteristics of cell
wall anchored MSCRAMMs. We showed the importance of these pili
in initiating bioﬁlm, in experimental IE (EIE) and in serum-induced
adherence to ﬁbrinogen, suggesting these pilus structures are involved
in initiating E. faecalis IE. The ebp locus is regulated in part by
the Fsr system, a homologue of the Agr system of staphylococci.
We have also identiﬁed a ubiquitous collagen adhesin, Ace (also an
MSCRAMM), whose expression is induced by serum and collagen, and
found that this adhesin is also important in E. faecalis EIE. Similarly,
we have shown that its homologue (Acm, an adhesin to collagen of
E. faecium), is important in the pathogenesis of E. faecium EIE and
adherence to heart valves, the ﬁrst factor shown to be important for
virulence in that species. Preliminary data suggest that immunisation
against recombinant Ace or Acm is protective against EIE by the
producing species. Based on genome searchs, both E. faecalis and
E. faecium have a number of other MSCRAMM genes encoding adhesins
to ECM proteins, and future studies may reveal additional contributions
to IE. Another factor shown to be importance in E. faecalis IE is
gelatinase, a protease produced by only ~60% of E. faecalis despite
the fact that the encoding gene gelE is found in over 90% of stains;
deletion of part of the regulatory locus, fsr, explains the lack of
gelatinase production by many strains. Aggregation substance, encoded
by pheromone responsive plasmids found in some E. faecalis, and
a cytolysin/hemolysin may inﬂuence the size of EIE vegetations and
mortality produced by E. faecalis, respectively. Additional studies are
needed to deﬁne the role of other factors in enterococcal EIE and the
ability of passive or active immunisation to prevent this disease.
S292 Conserved, co-evolved genes of invasive Enterococcus faecium
and Enterococcus faecalis and insights into special lineages
R.J.L. Willems (Utrecht, NL)
Enterococcus faecalis and Enterococcus faecium have both evolved in
so-called high-risk enterococcal clonal complexes (HiRECC), deﬁned
as speciﬁc clades of isolates with multiple antibiotic resistance traits,
epidemiological associated with either colonisation or infection of
hospitalised patients. One of these HiRECC is E. faecium CC17,
which represents a distinct pandemic clonal complex of extremely
successful hospital acquired isolates. Also in E. faecalis speciﬁc genetic
subpopulations exist, like CC2, CC9, and CC40, which are enriched
among nosocomial isolates and as such can be classiﬁed as HiRECC.
Thus E. faecalis and E. faecium isolates belonging to these HiRECC
share niches with the potential of virulence gene exchange. The extent
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of genetic exchange, especially of virulence genes between these two
species is unknown but can be disclosed by assessing the presence of
orthologs in E. faecalis and E. faecium clinical isolates. Comparative
genomic hybridisation and whole genome sequencing, implemented to
identify genes speciﬁc for CC17, distinguished more than 100 genes
with most notably CC17 speciﬁc IS elements, resistance genes, genes
putatively encoding cell surface proteins and metabolic pathways. Of a
subset of these E. faecium CC17 genes orthologous genes were identiﬁed
among E. faecalis bloodstream isolates. Eight of these orthologs were
highly similar to genes previously found on EfaB5, an E. faecalis
Tn916-like element containing several genes related to virulence in other
species. The sequence identity of EfaB5 orthologous genes between
E. faecalis and E. faecium was >85%, which is considerably higher than
the sequence identity of the core genomes of the two species, based on
an in silico comparison and reﬂected by the relative high average of
16S rRNA sequence divergence (4.1%) and the low average nucleotide
identity of housekeeping genes (74.2%). The E. faecium EfaB5-like
orthologs, though highly similar to the E. faecalis EfaB5-like element,
are not similarly organised in one cluster but separated by stretches of
other genes and the order partially inverted. The presence of highly
similar genes in HiRECC E. faecium CC17 and E. faecalis CC2, 9,
and 40, suggests genetic exchange between the most prevalent clinical
enterococcal subpopulations. A common EfaB5-like element, in addition
to E. faecium and E. faecalis speciﬁc virulence determinants, might have
contributed to pandemic spread and nosocomial enterococcal infections.
S293 Novel immunotherapy strategies to prevent enterococcal
infections/colonisations
J. Huebner (Freiburg, DE)
Enterococci are among the three most common nosocomial pathogens
and due to their multiple antibiotic resistances cause substantial
morbidity and mortality, especially among intensive care patients and
the immunocompromised. While several new antibiotics have been
introduced in the last decade, resistance against these new drugs is
developing and spreading rapidly. Alternative treatment and prevention
strategies are desperately needed to counter the rise of multiply resistant
clones in hospitals and nursing homes worldwide.
There is only a basic understanding of the mechanisms that are
responsible for the transition of a normally benign commensal into
a dangerous pathogen. A better understanding of the virulence
factors that enable enterococci to access the bloodstream and cause
systemic infections will help to target new therapeutic and prophylactic
approaches.
Compared to other Gram-positive pathogens, relatively little is know
about surface antigens in enterococci that may be used as vaccine
targets. Several proteins such as aggregation substance, ACE (adhesin
to collagen), EfaA, an ABC transporter complex, and Esp have been
studied, although only few data exist on the protective efﬁcacy of these
antigens in appropriate animal models. Newly identiﬁed pili in E. faecalis
are associated with adhesion, bioﬁlm formation and pathogenicity, and
since these antigens are highly immunogenic antibodies against these
structures may be promising candidates for immunotherapy.
Several carbohydrate antigens have been identiﬁed in E. faecalis, while
so far no information exists for E. faecium. Similar to other Gram-
positive bacteria, enterococci possess membrane-associated lipoteichoic
acid (LTA) and peptidoglycan-associated wall teichoic acids (WTA).
While LTA has been shown to be the target of protective antibodies
for E. faecalis and E. faecium infections, no information exists for
WTA. Additional capsular polysaccharide antigens consisting of a
diheteroglycan have been identiﬁed in some E. faecalis strains and these
antigens also elicit opsonic antibodies making them likely candidates for
vaccine approaches.
Taken together, there are several promising vaccine candidates among
surface carbohydrate antigens, as well as among the protein antigens
studied so far. Conjugation of a protein target to a carbohydrate
component may enhance immunogenicity and broaden the coverage
of such a vaccine. Knowledge of the clinical application, mode of
vaccination (passive vs. active immunotherapy), timing of application
and the identiﬁcation of a patient population that will proﬁt most needs
to be acquired in order to develop a successful immunotherapy strategy.
S294 The emergence of VRE (multi-resistant enterococci) and its
clinical impact in hospitals in Europe
T. Coque (Madrid, ES)
The epidemiology of vancomycin-resistant enterococci (VRE) in Europe
has recently changed. The initial scenario consisted of polyclonal
enterococcal population with a high diversity of strains and transposable
elements encoding vancomycin resistance in the community and with
scarce presence in the nosocomial setting. In the last few years
six European countries have reported prevalence rates in hospitals
>20% and nosocomial VRE outbreaks are frequently described. Clonal
and plasmid outbreaks have been documented in European hospitals
but complex epidemiological situations involving strains (Enterococcus
faecalis and/or Enterococcus faecium) and different mobile genetic
elements are frequently reported in institutions with high VRE rates.
Population genetics studies have shown that most VRE isolates from
hospitalised patients belong to worldwide disseminated hospital high-risk
clonal complexes (HHRCCs) of E. faecalis (CC2, CC9, CC21, CC87)
and E. faecium (CC17) often resistant to multiple antibiotics, while VRE
from non-hospitalised individuals or animals belong to other CCs. In
addition, speciﬁc HHRCCs or clones within these HHRCCs become
relevant in the persistence and dissemination of VRE. Horizontal transfer
is also important in the recent spread of VRE in European hospitals
although plasmid outbreaks have been described since early 90’s. The
most frequent type of acquired glycopeptide resistance found is VanA
and the genes coding for resistance are part of Tn1546, usually located
in conjugative plasmids. Variants of Tn1546 containing mutations,
deletions and different insertion sequences have been described and an
apparent high diversity and host speciﬁcity of these genetic elements
has been suggested. However, the detection of different Tn1546 variants
in common plasmids platforms suggests frequent genetic exchange
events within particular wide disseminated plasmids. A change in the
epidemiology of VRE in European hospitals seems to have occurred
with the emergence and dissemination of speciﬁc plasmids and HHRCCs
resistant to multiple antibiotics and possibly more transmissible and
virulent.than others Situations of endemicity or polyclonal outbreaks
are difﬁcult to handle since limite therapeutic options and require
genotyping-targeted infection containment. Detailed characterisation of
epidemic VRE strains and mobile elements will help to understand the
reasons involved in the evolutionary outcomes of HHRCC in different
countries.
MDR Acinetobacter from molecular biology
to hospital epidemiology
O295 In vivo transposition of insertion sequence ISAba1 at the
origin of genome plasticity and acquired antibiotic resistance
in Acinetobacter baumannii
L. Poirel, P. Mugnier, P. Nordmann (Le Kremlin Bicetre, FR)
Background: Insertion sequence ISAba1 belonging to the IS4 family
has been identiﬁed repeatedly in Acinetobacter baumannii, being
often associated with antibiotic resistance genes. In particular, it
has been shown to provide promoter sequences enhancing expression
of the natural cephalosporinase AmpC and oxacillinase OXA-51 of
A. baumannii. In addition, two copies of ISAba1 bracketing blaOXA-23
may form composite transposon Tn2006 at the origin of acquisition
of this carbapenem-hydrolysing oxacillinase gene. The transposase of
ISAba1 is formed by two open reading frames Orf1 and Orf2 likely
giving rise to a functional transposase when a frameshift occurs. Our
study was aimed to evaluate the transposition ability of ISAba1.
Methods: We evaluated experimentally the ability of ISAba1 to
transpose in Escherichia coli. In a ﬁrst step, the b-lactamase gene
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blaTEM-1 was inserted into ISAba1 to provide an ampicillin resistance
marker allowing its tracing. This ISAba1::blaTEM-1 structure was
cloned into pTOPO vector and then transformed into recA(−) E. coli
RZ201 harboring conjugative plasmid pOX38-Gen used as a target
for transposition events. Transposition events onto pOX38-Gen were
selected by conjugating this plasmid into azide-resistant E. coli J53.
The same technique was used to evaluate the transposition ability of
Tn2006. Also the role of the frameshift in the transposase expression
was evaluated by eliminating the frameshift in the transposase encoding
gene by site-directed mutagenesis.
Results: Transposition of ISAba1 was obtained at a frequency of
1×105 (±0.7×105) per E. coli donor. Sequencing of the target
sites of transposition revealed i) a systematic 9-bp duplication upon
transposition, and an adenine-rich hotspot of target transposition.
Transposition frequency of the mutated ISAba1 with a transposase gene
made of a unique frame was 2×103 (±0.2×103). The mobility of Tn2006
was demonstrated and its frequency of transposition was estimated to be
1.6×108 (±2.5×102).
Conclusion: This study iss the very ﬁrst demonstration of the
functionality of the widespread ISAba1 as a mobile element. The
frameshift-mediated down-regulation of transposition has been assessed,
as well as the functionality of the ISAba1-made composite transposon.
This in-vivo model will allow further experiments able to evaluate the
possible selective factors such as antibiotics for ISAba1-transposition
enhance
O296 The OXA-51-like enzymes of Acinetobacter baumannii:
markers of success?
B. Evans, A. Hamouda, K. Towner, S. Amyes (Edinburgh, Nottingham,
UK)
Objectives: Acinetobacter baumannii has become a prevalent noso-
comial pathogen due to the spread of major epidemic lineages. The
diversity of the intrinsic blaOXA-51-like genes may provide insights
into the evolution of this species. This study aimed to examine the
relationship between the sequences of the OXA-51-like enzyme family
and the properties of a collection of A. baumannii isolates.
Methods: Sixty A. baumannii isolates had their blaOXA-51-like gene
ampliﬁed by PCR using external primers, and the products sequenced
and identiﬁed using BLAST and MultAlin software. The external
primers allowed the simultaneous identiﬁcation of ISAba1 upstream of
the blaOXA-51-like genes. MICs for imipenem and meropenem were
determined according to British Society for Antimicrobial Chemotherapy
(BSAC) guidelines. Isolates were assigned to sequence groups (SGs)
based on PCR ampliﬁcation of fragments of their blaOXA-51-like,
ompA and csuE genes. All publicly available OXA-51-like amino-acid
sequences were retrieved and used to construct a linkage map showing
the relationships of the enzymes to one another.
Results: The linkage map revealed that some of the enzymes form
closely related clusters while others are less closely related. The largest
number of isolates, including European clone II, contained enzymes in
the OXA-66 cluster, and were assigned to SG1. The second largest
group of isolates, including European clone I, contained enzymes in
the OXA-69 cluster, and were assigned to SG2. The third largest isolate
group, including European clone III, were assigned to SG3 and contained
an OXA-71 enzyme. Eight isolates contained enzymes not found in a
major cluster, or could not be assigned to a SG. ISAba1 was found
upstream of the blaOXA-51-like gene in ten isolates, but was only
associated with enzymes on branch tips in the OXA-66 and OXA-69
clusters. MICs for imipenem and meropenem ranged from 0.06 and
0.12 mg/L respectively up to >128 mg/L for both antibiotics. Isolates
with ISAba1 upstream of the blaOXA-51-like gene tended to have MICs
towards the higher end of this range, from 0.5 and 2 mg/L up to 8 and
32 mg/L.
Conclusion: SG1 and SG2 represent the most prevalent epidemic
lineages of A. baumannii and encode speciﬁc sub-sets of OXA-51-like
enzymes. SG3 is not as prevalent, but is also associated with a speciﬁc
OXA-51-like enzyme. A minority of isolates cannot be grouped using
this typing scheme. Evolution of the OXA-51-like enzymes appears to
be occurring in real time.
O297 Outbreak of multidrug-resistant Acinetobacter baumannii-
producing OXA-23 carbapenemase at one Belgian acute
care hospital
B. Lissoir, P. Bogaerts, C. Bauraing, A. Deplano, M. Fossion,
A. Bodson, Y. Glupczynski (Gilly, Yvoir, BE)
Objectives: Acinetobacter baumannii (Ab) is a well recognised
nosocomial pathogen, especially for critically-ill patients. The emergence
of multi-drug resistant (MDR) and carbapenem-resistant Ab isolates
constitutes a major therapeutic challenge. Outbreaks caused by MDR
Ab are mostly reported from tropical or sub-tropical areas and from
Mediterranean countries. Here we report the characterisation of OXA-23
producing Ab strains isolated in an acute Belgian hospital.
Methods: All MDR Ab isolates recovered from patients and from
the environment were phenotypically and genetically (PCR-sequencing
and PFGE) characterised. Resistance patterns were analysed by disc
diffusion and MICs determination. PCR-sequencing was performed for
blaIMP, blaVIM, blaOXA-23-like, blaOXA-26-like, blaOXA-58 genes,
blaOXA-51-like genes, blaTEM gene, blaOXA-20, and the chromosomal
class C b-lactamase blaAmpC gene. The presence of insertion sequence
(IS) elements upstream the detected b-lactamases genes was also
analysed.
Results: In 09/2007, a MDR- and carbapenem-resistant Ab was
recovered from one Belgian resident transferred from Morocco with a
diagnosis of pneumonia. Subsequently, over a 2 month period, similar
MDR-Ab isolates were found in 6 patients (4 with pneumonia, 2 with
asymptomatic throat colonisation). Five of the patients were hospitalised
in the pneumology ward and 2 in the intensive care unit where the
outbreak secondarily spread.
All MDR-Ab clinical isolates were positive for blaOXA-23 with an
ISAba4 sequence being present immediately upstream this gene. Further,
14 environmental samples obtained during the outbreak also yielded
the same MDR OXA-23-producing Ab. All clinical and environmental
isolates were conﬁrmed by PFGE to be clonally related. After the
implementation of reinforced infection control measures no additional
MDR Ab were isolated neither from patient nor from the environment.
Conclusion: Our data highlight the importance of inter-country transfer
in the spread of MDR carbapenem-resistant OXA-23 producing Ab
and the propensity of this opportunistic pathogen to cause major
nosocomial outbreaks. Systematic screening, and implementation of
additional precautions are mandatory for any patients transferred from
high-risk areas.
O298 Outbreak of carbapenem-resistant Acinetobacter baumannii
carrying the carbapenemase OXA-23 in a German university
medical centre
A. Kohlenberg, S. Bruemmer, D. Sohr, P. Higgins, B. Piening,
H. Rueden, H. Seifert (Berlin, Cologne, DE)
Objective: Investigation and control of an outbreak of carbapenem-
resistant Acinetobacter baumannii.
Methods: An outbreak investigation with a descriptive analysis, a
case-control study, environmental sampling and molecular typing of
Acinetobacter baumannii isolates using randomly ampliﬁed polymorphic
DNA (RAPD) with M13 primer and pulsed-ﬁeld gel electrophoresis
(PFGE) was carried out. Detection of OXA-type carbapenemases was
performed by multiplex PCR. For the case-control study cases deﬁned
as patients with the outbreak strain and controls deﬁned as patients with
a minimum duration of intensive care unit (ICU) stay of 5 days were
selected from the mainly affected ICU during the outbreak period. Odds
ratios (OR) were calculated in a univariate analysis and a multiple logistic
regression analysis was performed to identify independent risk factors
for acquisition of the outbreak strain.
Results: 35 patients acquired carbapenem-resistant A. baumannii with
a similar antibiogram in ﬁve ICUs and two wards of two different
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tertiary care hospitals within a time period of ten months in 2006.
All but two isolates were resistant to all penicillins, cephalosporins,
ciproﬂoxacin, gentamicin, tobramycin, imipenem, and meropenem, and
remained susceptible only to colistin and tigecycline, i.e. isolates were
pandrug-resistant. All isolates belonged to one major strain type with
RAPD pattern a and pulsotype A with subtypes A1−A4. All but two
isolates belonging to subtypes A2 and A3 carried the OXA-23-like gene
in addition to the intrinsic OXA-51-like gene. The most likely mode of
transmission was cross-transmission from colonised or infected patients
and the environment via the hands of personnel. The multiple logistic
regression analysis showed that severity of illness (mean daily SAPS
II score > median) and intensity of care (mean daily TISS-28 score
> median) were independent risk factors for acquisition of the outbreak
strain (OR 6.67; CI95 1.55−36.56 for both variables).
Enhanced infection control measures with enforcement of standard
precautions, education of personnel, cohorting of patients with the
outbreak strain in separate ward areas and screening of ICU patients
for A. baumannii on admission and once weekly were successful in
controlling the outbreak.
Conclusion: This is the ﬁrst report of an outbreak of Acinetobacter
baumannii carrying the carbapenemase OXA-23 in Germany.
O299 Switching populations: establishment of OXA-40-producing
Acinetobacter baumannii within a hospital setting
S. Quinteira, F. Grosso, H. Ramos, L. Peixe (Porto, PT)
Objectives: Endemicity of an OXA-40-producing A. baumannii clone
has been observed at numerous hospitals within the Iberian Peninsula
associated with mortality events in Portugal. In this study, the epi-
demiological evolution, within a university hospital, of 3 A. baumannii
imipenem-resistant clones is described throughout a period of six
consecutive years.
Methods: From 2001 to 2006, 252 imipenem-resistant Acinetobacter
baumannii (IRAb) were collected from several specimens and different
wards, where A. baumannii was associated with nosocomial infections
and colonisations.
Isolates were identiﬁed by API32GN and by 16S rRNA sequencing.
PFGE (ApaI restriction enzyme) was performed in representative
isolates. Oxacilinase genes were sought by PCR.
Results: Clonal dissemination of 3 pulsetypes (A,B,C), widespread
throughout the hospital, contributed to the observed A. baumannii
imipenem resistance, which has persisted since 2001 despite several
elimination attempts, including the use of polymyxin. Pulsotype B was
predominant from 2001 to 2002, after which clone A (identical to the
previously described Iberian OXA-40-producing clone) emerged as the
dominant type. Pulsotype C (2 isolates) seemed to represent a sporadic
event within the prevalence of clones A and B. Absence of imipenem-
hydrolysing enzymes was observed for both B and C.
Resistance to b-lactams (including carbapenems) and variable suscepti-
bility to aztreonam, amikacin and tobramycin was a common in clone
A. B and C clones showed lower resistance proﬁles (e.g. susceptibility
to ceftazidime, netilmicin and minocycline; variable susceptibility to
meropenem, cefepime, and aztreonam). Curiously, excluding one isolate,
all the remaining IRAb isolates (n = 27), recovered in 2006, produced an
OXA-carbapenemase (OXA-40 and, for the ﬁrst time in this hospital,
OXA-23). blaOXA-40 producers were characterised as pulsotype A
while clones B and C were not detected.
Conclusion: The strong selective forces within hospital settings have
been historically implicated in the establishment of resistance pheno-
types. The evolution of bacterial resistance together with aggressive
therapeutic strategies envisions the maintenance of only the best adapted,
able to cope with various stressful agents. Our data highlights an apparent
succession in IRAb populations, from more susceptible bacteria to
the establishment of an OXA-40 producing clone expressing a wider
resistance proﬁle to several antibiotics (including tigecycline).
O300 First detection of carbapenem-resistant Acinetobacter
baumannii producing the OXA-24 carbapenemase in Italy
M.M. D’Andrea, T. Giani, F. Luzzaro, G.M. Rossolini (Siena, Varese, IT)
Background: Acinetobacter baumannii is an important opportunistic
pathogen responsible of serious nosocomial infections. Multi-drug
resistance is common, and carbapenems often remain among the few
therapeutic options. Production of acquired OXA-type carbapenemases
(Ambler class D) of the OXA-23, OXA-24/40 and OXA-58 lineages
appears to be a major mechanism of acquired carbapenem resistance
in A. baumannii. Here we report the ﬁrst detection of a carbapenem-
resistant A. baumannii producing the OXA-24 carbapenemase in Italy.
Methods: Bacterial identiﬁcation was carried out with phenotypic and
molecular approach. Susceptibility testing were carried out by broth
microdilution and Etest. Genotyping was carried out by RAPD and
typing of the blaOXA-51-like, csuE and ompA genes. OXA-type and
metallo-carbapenemase determinants were investigated by PCR and
sequencing.
Results: Two carbapenem-resistant A. baumannii were isolated in 2000,
at Varese University Hospital (northern Italy), from the BAL of two
ICU-patients. The isolates differed from other carbapenem-resistant
A. baumannii from the same hospital for a very high level of carbapenem
resistance (imipenem and meropenem MICs, >32 mg/L). They were
also resistant to expanded-spectrum cephalosporins, aminoglycosides
(amikacin and gentamicin), ciproﬂoxacin, but susceptible to colistin.
Characterisation of carbapenemase genes revealed the presence of a
blaOXA-24 allele in both isolates. Genotyping showed that the two
isolates were identical to each other and belonged to European clone II.
They were also clonally related to other lower-level carbapenem-resistant
isolates from the same hospital, which were found to produce OXA-58.
The blaOXA-24 determinant was surrounded by a genetic context similar
to a previously described plasmid-mediated blaOXA-24 determinant.
Conclusions: To our best knowledge this is the ﬁrst report of
A. baumannii producing OXA-24 in Italy. The isolates, noticed for
their exceedingly high level of carbapenem resistance, did not spread
in the hospital. Interestingly, they were clonally related to the European
clone II, which exhibits a remarkable propensity to evolve carbapenem
resistance by different mechanisms.
O301 Dissemination of OXA-23-producing Acinetobacter
baumannii Iberian clone in hospitals and ambulatory
F. Grosso, S. Quinteira, L. Cavaleiro, L. Peixe on behalf of the
Portuguese Resistance Study Group
Objectives: Class D carbapenemases carrying Acinetobacter spp. have
been conﬁned, in Portugal, to OXA-40 producers. Recently, we identiﬁed
the ﬁrst OXA-23-producing A. baumannii in a clinical isolate. The
aim of this work was to characterise the recently isolated strains of
OXA-23-producing A. baumannii, some of them associated to outbreaks
in Portuguese hospitals, and to investigate the clonal relatdness between
them and the endemic OXA-40-producing clone
Methods: Nineteen imipenem-resistant isolates of A. baumannii
revovered from four Portuguese hospitals and an ambulatory patient
between 2006 and 2007 were studied. Isolates were identiﬁed by
API32GN and by sequencing the 16S rRNA gene. Susceptibility to
antibiotics was tested by disk diffusion method and Vitek 2 system. MICs
for tigecycline and colistin were determined by the agar dilution method.
Oxacillinase genes (OXA-23, 40, 51, and 58) were sought by a multiplex
PCR. ISAba1 insertion sequence upstream of blaOXA-23 gene was also
searched by PCR.
PFGE (ApaI) was performed for comparison of these isolates with the
endemic clone.
Results: A. baumannii isolates were resistant to all b-lactamic antibiotics
tested, tigecycline and colistin. The isolates involved in hospital
outbreaks were mostly susceptible to aminoglicosides, being one
susceptible only to amikacin and another one resistant to all antibiotics.
PCR assays detected the presence of blaOXA-23. ISAba1 was detected
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upstream of the OXA-23 gene for all isolates except one. PFGE
showed that the isolates’ proﬁle was related with the imipenem-resistant
A. baumannii clones disseminated throughout the country, including the
endemic OXA-40 producing A. baumannii clone.
Conclusions: Emergence of OXA-23 producing A. baumannii is
occurring in several Portuguese hospitals associated to outbreaks and
sporadic cases. Of interest is the relatdness with the endemic OXA-40
clone, although with an enlarged resistance proﬁle, which supports
the plasmidic acquisition of these two oxacillinases by a well adapted
A. baumannii clone. It is of note the recovery of an OXA-23 producer
from an ambulatory patient which can further promote community
dissemination.
O302 Emergence during therapy of efﬂux-mediated tigecycline
resistance in Acinetobacter baumannii belonging to a UK
epidemic clone
M. Hornsey, M. Ellington, M. Doumith, C. Thomas, D. Livermore,
N. Woodford (London, UK)
Objectives: Up-regulation of the RND-type efﬂux system AdeABC has
been implicated in reduced susceptibility to tigecycline in A. baumannii.
AdeABC expression is controlled by the two-component regulatory
system AdeRS. We investigated the role of this pump in the emergence
of tigecycline resistance using a pre- and post-treatment pair of clinical
isolates.
Methods: Isolates were identiﬁed by API20NE proﬁle, and suscepti-
bilities were ﬁrst determined by BSAC disc methodology, then by agar
dilution and Etest on IsoSensitest agar. PFGE was used to determine
relatedness. Expression of the efﬂux pump, AdeABC, and its regulatory
proteins, AdeRS, was examined by real-time reverse transcriptase (RT)-
PCR using primers speciﬁc for adeB and adeR, respectively, and
quantiﬁed relative to the RNA polymerase beta subunit gene, rpoB,
which was used as a reference.
Results: The two A. baumannii isolates were recovered from abdominal
drain ﬂuid of a 38-yr old woman who had undergone a cholecystectomy.
Inter alia she had received a 14-day course of tigecycline, and a 32-
fold difference in susceptibility was observed between pre- and post-
treatment isolates (MICs, 0.5 mg/L and 16 mg/L, respectively). The
patient has since made a full recovery. The isolates had identical PFGE
proﬁles and belonged to a prevalent UK strain, OXA-23 clone 1, with
OXA-23 carbapenemase and initial susceptibility only to tigecycline and
polymyxin. Real-time RT-PCR identiﬁed a 24-fold increase in adeB gene
expression in the post-treatment isolate. No concomitant difference in
adeR expression was observed.
Conclusions: OXA-23 clone 1 is a widespread multi-resistant lineage
and we report here the emergence of resistance to tigecycline during
therapy in a representative. This resistance was associated with increased
expression of the AdeABC efﬂux system, but not with altered expression
of its known regulatory genes adeRS. This suggests that there may be
‘cross-talk’ between adeABC and other trans-acting regulatory factors.
O303 The recent increase in Acinetobacter baumannii resistance
to carbapenems in the Czech Republic is associated with the
spread of genotypically highly related strains of European
clone II
A. Nemec, M. Maixnerova, T.J.K. van der Reijden, L. Krizova,
L. Dijkshoorn (Prague, CZ; Leiden, NL)
Objective: In 2003, a signiﬁcant increase of Acinetobacter resistance
to carbapenems has been noted in the Czech Republic. The aim of this
study was to assess the prevalence and epidemiology of this resistance
among hospital strains of Acinetobacter spp.
Methods: Isolates were collected prospectively via a network of
diagnostic laboratories between January 2005 and April 2006. The
laboratories were asked to send clinical isolates of Acinetobacter spp.
from intensive care units (ICUs), with no more than one isolate per
patient and 10 isolates per ICU. The isolates were identiﬁed to species by
AFLP and assessed for relatedness using AFLP and PFGE. Susceptibility
to 12 antimicrobial agents primarily effective against A. baumannii was
tested by disk diffusion, and MICs were determined for carbapenems.
Results: A total of 150 Acinetobacter isolates were obtained from 56
ICUs of 20 hospitals in 15 cities. They were identiﬁed as A. baumannii
(n = 108), genomic sp. 3 (n = 30), genomic sp. 13 TU (n = 8) or other
species (n = 4). Using AFLP cluster analysis, A. baumannii isolates
were allocated to EU clone II (n = 66), EU clone I (n = 5), 6 clusters
with 2−5 isolates (n = 15) or 22 unique genotypes. Nearly all clone II
isolates yielded identical or highly similar PFGE and AFLP patterns.
A total of 24 (16%) isolates were resistant to at least one carbapenem.
Seventy isolates were susceptible to all antimicrobials while 7 isolates
showed resistance to 1−3 agents and 73 isolates were resistant to >3
agents. Resistance to >3 agents and/or carbapenem MICs >1 mg/l were
found only in the EU clones and four unique strains while resistance to
one or two carbapenems (MIC >8 mg/l) was conﬁned to EU clone II.
The 66 EU clone II isolates originated from 37 ICUs in 12 cities and
showed the following susceptibility rates: piperacillin (0%), ceftazidime
(5%), ampicillin-sulbactam (23%), imipenem (71%), meropenem (67%),
gentamicin (15%), tobramycin (97%), amikacin (61%), netilmicin (52%),
oﬂoxacin (0%), doxycycline (0%), co-trimoxazole (12%).
Conclusion: The increase in Acinetobacter resistance to carbapenems in
the Czech Republic is associated with the spread of multidrug resistant
A. baumannii strains belonging to EU clone II. The high genotypic
similarity of the isolates suggests that they represent a recent subgroup
within this clone.
Supported by grant NR8554−3 of the Ministry of Health of the Czech
Republic.
O304 Nosocomial multidrug-resistant Acinetobacter baumannii
bloodstream infections: epidemiology, clinical features,
treatment, and outcome, Bangkok, Thailand
G. Suwanpimolkul, T. Chatsuwan, C. Suankratay (Bangkok, TH)
Objective: To determine the epidemiology, clinical features, antibiotic
susceptibility, treatment, and outcome of nosocomial Acinetobacter
baumannii bacteraemia.
Design: A retrospective study was conducted at KCMH in all
hospitalised patients with microbiologically and clinically documented
A. baumannii bacteraemia from January 2005 to February 2007.
Results: A total of 83 patients with nosocomial A. baumannii
bacteraemia were identiﬁed. There were 51 males and 32 females
with the mean age of 62 years (range: 19 to 99 years). Most
patients had received antibiotics within three months before the
diagnosis of A. baumannii bacteraemia. Third-generation cephalosporin
was the most commonly prescribed antibiotic (78.9%). Ventilator-
associated pneumonia (VAP) was the most common primary site of
infection, followed by catheter-related blood stream infection (CRBSI),
intraabdominal infection, and skin and soft tissue infection (45.8%,
20.5%, 7.2% and 2.4%, respectively). There were 16 patients (19.3%)
with unknown source of infection. The mean duration of intubation in
the patients with VAP and that of central venous catheter insertion in
those with CRBSI before the diagnosis of A. baumannii infection were
9.46 days and 12.07 days, respectively. Most A. baumannii isolates were
susceptible to cefoperazone-sulbactam (48.2%), followed by netilmicin
(44.6%) and amikacin (31.3%). Of all isolates, the frequency of
carbapenem-, multidrug-, and pan-drug-resistant A. baumannii was 69%,
45.8%, and 27.7%, respectively. The overall inhospital mortality rate was
69.9%, with high mortality rate in the patients in medical intensive care
units (ICUs), compared to those in non-medical ICUs [92.6% and 58.9%,
odds ratio (OR): 8.712, 95% conﬁdence interval (CI): 1.876−40.457,
p = 0.002]. The patients infected by multidrug- and pandrug-resistant
strains had much higher mortality rate than those infected by non-
multi- and pandrug-resistant strains (80.3% and 40.9%, OR: 5.898, 95%
CI: 2.046−17.002, p = 0.001). Pneumonia had higher mortality rate
than other source of infections (81.6% and 60%, OR: 2.952, 95% CI:
1.071−8.136, p = 0.03)
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Conclusions: Multidrug- and pandrug-resistant A. baumannii bacter-
aemia are a common cause of nosocomial infections in KCMH. The
high inhospital mortality rate is observed in the patients in medical ICUs.
This situation emphasizes the importance to maintain rigorous measures
of infection control as well as appropriate antibiotic prescription in our
institute.
Mycobacterial infections
O305 Identiﬁcation of Mycobacterium tuberculosis-speciﬁc CD4
and CD8 IFN-gamma and/or IL-2 secreting cells by a
novel method contributes to deﬁning the different stages of
tuberculosis
V. Sargentini, S. Mariotti, S. Carrara, M.C. Gagliardi, R. Teloni,
D. Goletti, R. Nisini (Rome, IT)
Objectives: A more detailed characterisation of the immune response to
Mycobacterium tuberculosis (Mtb) antigens would provide new insights
into the complex host-parasite interactions that take place in the course
of tuberculosis (TB) and offer new tools for a more accurate diagnosis
of the different stages that characterise TB as a disease.
Methods: Here we measured CD4 and CD8 T-cell responses to
Bacillus Calmette-Gue´rin (BCG), puriﬁed protein derivative (PPD),
early secretory antigenic target-6 (ESAT-6) protein and culture ﬁltrate
protein-10 kDa (CFP-10), measured as interferon (IFN)-gamma and
interleukin (IL)-2 release, using the ﬂow cytometric cells-secreting
cytokine detection technique on peripheral blood mononuclear cells
(PBMC) obtained from active TB patients, latently Mtb infected
individuals, patients with pulmonary diseases different from TB and
healthy donors. IL-10 and IL-17 were also measured to test their possible
role as indicators of disease activity.
Results: We conﬁrmed that the enumeration of IFN-gamma releasing
cells upon Mtb-speciﬁc stimulation is sufﬁcient to identify TB patients
and that CD8 T cells contribute to the speciﬁcity of the response. IL-
2 secreting cells were more frequently observed in latent TB infected
individuals than in active TB patients, suggesting that measurement of
cells secreting this cytokine could be a marker of disease stages. No
discriminating role was associated to IL-10 and IL-17 release in TB
patients.
Conclusions: Together, data indicate that the ﬂow cytometric cytokine-
secreting cell detection technique is a powerful tool for TB diagnosis
which allows the analysis of the immune response to Mtb-related
antigens in the different stages of TB.
O306 RD-1 antigen based in vitro diagnosis of TB infection:
IP-10/CXCL10 is a novel potent biomarker with comparable
performance to the Quantiferon In Tube test
M. Ruhwald, T. Bodmer, C. Maier, M. Andersen, J. Eugen-Olsen,
P. Ravn (Copenhagen, DK; Berne, CH)
Objectives: A major breakthrough in clinical management of tubercu-
losis infection has been the development of in vitro diagnostic tests
measuring IFN-g in response to stimulation with RD-1 antigens (IGRA
tests). The tests perform with excellent speciﬁcity, but there is a concern
that the sensitivity is not optimal, especially in patients with immune-
suppression and in children. We have identiﬁed the chemokine IP-
10/CXCL10 as a novel potential diagnostic biomarker for TB. The aim
of the study was to establish a diagnostic test algorithm based on IP-10,
and compare it with the QFT-IT results.
Materials and Methods: We measured IP-10 levels in plasma
supernatants from Quantiferon In Tube (QFT-IT) stimulated whole
blood from 80 patients with culture and/or PCR proven active TB, 86
unexposed Danish high school students, and 38 unexposed high school
teachers. Based on ROC curve analysis we established two IP-10 cut-
off points and constructed a diagnostic test algorithm inspired by the
QFT-IT test; with positive, negative, and indeterminate test outcome.
Results: TB patients produced signiﬁcantly higher levels of IP-10 and
IFN-g compared with controls: for IFN-g median 215 pg/ml (IQR 22–
651 pg/ml) vs. 0 pg/ml (IQR 0−0 pg/ml), for IP-10 median 2158 pg/ml
(IQR 582–5882 pg/ml) vs. 37 pg/ml (IQR 13−99 pg/ml. IP-10 and IFN-g
responses were highly correlated (0.81, p< 0.0001). Based on ROC curve
analysis we selected a sensitive IP-10 cut-off (237 pg/ml), and a speciﬁc
cut-off (673 pg/ml). A cut off for indeterminate test was established by
comparing the mitogen IP-10/IFN-g ratio. QFT-IT and the speciﬁc IP-10
test showed comparable performance with equal sensitivity/speciﬁcity
and 90% agreement (kappa 0.79), table 1. The sensitive IP-10 test had
a higher sensitivity 71/80 (90%), but also a high degree of positive
responders among the controls 14/124 (11%), primarily among the older
teachers (10/14)
Table 1. Concordance between Quantiferon in Tube test (QFT-IT) and
the Speciﬁc IP-10 test.
Quantiferon In Tube test
Speciﬁc IP-10-test Neg. Pos. Indet. Total
Neg. 128 7 1 136
Pos. 7 54 1 62
Indet. 0 4 2 6
Total 135 65 4 204
Agreement 90%, kappa= 0.79.
IFN-g and IP-10 levels were measured in plasma supernatants of 80
patients with culture and/or PCR proven active TB, 86 unexposed Danish
high school students, and 38 unexposed high school teachers. IFN-g
levels were analysed according to the QFT-IT test algorithm (cut off
for positive test 17.5 pg/ml and 25 pg/ml for indeterminate test). IP-10
levels were analysed according to an IP-10 inspired algorithm (cut off
for positive test 637 pg/ml and 201 pg/ml for indeterminate test). Cut offs
were calculated using ROC curve analysis.
Discussion: IP-10 is expressed in response to the RD1 antigens
in consistent and signiﬁcant higher levels than IFN-g. IP-10 has
properties that enable the development of diagnostic test algorithm with
positive, negative and indeterminate outcomes, performing with excellent
concordance and comparable or even superior discriminatory power
compared with the QFT-IT. As IP-10 is expressed in high amounts, it
holds promise for the development of a new generation of more sensitive
TB tests with simpler and potentially ﬁeld-friendly read out formats, such
as the lateral ﬂow dipstick.
O307 Biodiversity of M. tuberculosis complex strains circulating
in Greater London area: implications for prospective
epidemiology and phylogenesis
V. Nikolayevskyy, P. Velji, T. Brown, F. Drobniewski (London, UK)
Objectives: i) To characterise M. tuberculosis complex (MTBC) isolates
circulating in the Greater London area with respect to drug resistance,
geographic origin and phylogeny; ii) To evaluate the discriminatory
power of various genotyping methods and select highly discriminant
reproducible loci for prospective molecular epidemiological studies and
phylogenetic analysis.
Methods: A total of 2261 individual MTBC isolates (one isolate per
patient) representing 95.7% of the total number of bacteriologically
conﬁrmed TB cases reported in the Greater London area over the 12
month period (1/04/2005 – 31/03/2006), were genotyped using 22 loci
VNTR typing (MIRU2, 4, 10, 16, 20, 23, 24, 26, 27, 31, 39, 40; ETR-
A, -B, -C; VNTR 2163A, 2163B, 2347, 3232, 1982, 3336, 4052) and
spoligotyping, followed by detection of deletions in RD9 and TbD1
regions in a selection of isolates. Diagnostic identiﬁcation and drug
resistance testing was performed on liquid media followed by a range of
phenotypical and molecular tests. Limited demographic data, including
gender, date of birth, and country of birth was available for these patients.
Results: Most (84.7%) of M. tuberculosis (strictly sensum) isolates
were fully drug sensitive and 83.7% strains were isolated from patients
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born outside the UK (primarily in the Indian Subcontinent and Africa).
Analysis of discriminatory power of different genotyping methods and
their combinations have demonstrated that inclusion of additional VNTR
loci allows to improve discrimination signiﬁcantly and avoid formation of
false clusters which is critical for prospective molecular epidemiological
studies (Table 1).
Table 1.
Genotyping method No. of distinct
proﬁles
(variety of
types)
No. of
clusters
Size of
clusters
(isolates)
Clustering
rate (%)
No. of
unique
isolates
Spoligotyping 656 198 2–221 79.7% 458
MIRU15 1271 235 2−53 54.2% 1036
MIRU15 + Spoligotyping 1619 196 2−48 37.1% 1423
MIRU15 + VNTR7 1888 158 2−35 22.2% 1730
All three methods 1897 153 2−35 21.6% 1744
The CAS family was the most prevalent in the study population (24.7%)
followed by the T, EAI, and LAM families comprising 16.4%; 15.9%,
and 15.5% of total isolates respectively; CAS and EAI strains were
dominant in patients born in the Indian subcontinent, East Africa and
South-East Asia, and LAM and T families were more common in patients
born in Europe, UK and other parts of the world.
Analysis of allelic diversity within certain loci in combination with
results of spoligotyping and deletion mapping allowed the selection of
loci of greater phylogenetical relevance (MIRU4, 24, 26, ETR-A, -B,
-C) and propose VNTR codes (combinations of allelic variants) which
can be potentially used for identiﬁcation of families, major lineages and
species within MTBC.
O308 Multiple-mutations in the katG gene of Mycobacterium tuber-
culosis isolates correlate with high-level of resistance to isoni-
azid in patients with active pulmonary tuberculosis in Belarus
S. Zakerbostanabad, A. Bahrmand, E. Graviss, L. Titov (Tehran,
Houston, Minsk, IR)
The aim of this study was to investigate the signiﬁcance of multiple-
mutations in the katG gene, predominant nucleotide changes and its
correlation with high level of resistance to isoniazid in Mycobacterium
tuberculosis isolates that were randomly collected from sputa of 42
patients with primary and secondary active pulmonary tuberculosis
from different geographic regions of Belarus. Drug susceptibility testing
was determined using the CDC standard conventional proportional
method. DNA extraction, katG gene ampliﬁcation, and DNA sequencing
analysis were performed. Thirty four (80%) isolates were found to have
multiple-mutations (composed of 2−5 mutations) in the katG gene.
Increased number of predominant mutations and nucleotide changes
were demonstrated in codons 315 (AGC→ACC), 316 (GGC→AGC),
309 (GGT→GTT) with a higher frequency among patients bearing
secondary tuberculosis infection with elevated levels of resistance to
isoniazid (MICmg/ml  5−10). Furthermore it was demonstrated that
the combination of mutations with their predominant nucleotide changes
were also observed in codons 315, 316, and 309 indicating higher
frequencies of mutations among patients with secondary infection
respectively. In this study 62% (n = 21) of multi-mutated isolates found
to have combination of mutations with predominant nucleotide changes
in codons 315 (AGC→ACC), 316 (GGC→GTT), 309 (GGT→GGT),
and also demonstrated to be more frequent in isolates of patients with
secondary infections, bearing higher level of resistance to isoniazid (
5−10mg/ml).
O309 Outcomes of patients with XDR-TB in Iran
P. Tabarsi, P. Baghaei, S. Jalali, P. Farnia, R. Masjedi (Tehran, IR)
Introduction: To date there has been little information reported about
the outcome of treatment in XDR-TB cases around the world. Here, we
will report the outcome of the ﬁrst cohort of XDR-TB patients in Iran.
Material and Method: All patients with documented MDR-TB based
on drug susceptibility tests (DST) are treated with the standard second-
line regimen, consisting of cycloserine, prothionamide, amikacin, and
oﬂoxacin since 2002 in Iran. After performance of second line drug
susceptibility in 2006, all XDR-TB cases were identiﬁed and treatment
outcome was extracted from their medical records.
Results: Between 2002–2006, 105 patients with MDR-TB were
identiﬁed at Masih Daneshvari Hospital in Tehran, Iran. Of those
patients, seven (6.6%) were diagnosed with XDR-TB. Four (57.1%)
patients were male and three (42.9%) were female. All seven patients
were HIV-negative. Mean age was 52.85± 21.61.4 patients were Iranian,
however 2 were from republic of Azerbaijan and one from Afghanistan.
One of the seven patients had primary XDR-TB, with no history of
previous treatment and no known close contact. Of the remaining six
patients, all had a history of anti-TB treatment.
Cure, failure and death each occurred in 2 cases (28.6%).Treatment
outcome was unknown in one patient from republic of Azerbaijan.
Conclusion: Our study shows a poor prognosis in patients with XDR-
TB, since only two patients out the seven were successfully treated
without relapse.
Table 1. Drug susceptibility tests and outcomes of patients with XDR-TB
in Iran
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1 22 M Azerbaijan R R S R R S R R R R Cure
2 63 F Iran R R S R R R R R R R Cure
3 63 M Iran R R R R R R R R R R Relapse
4 55 F Afghanistan R R S R R R S R R R Failure
5 64 M Iran R R S R R S S R S S Death
6* 79 F Iran R R R R S R S R R R Death
7 24 M Azerbaijan R R R R R R R R R R Unknown
*Primary XDR-TB. Summary of abbreviations: S = Sensitive, R =
Resistant, OFX = Oﬂoxacin, CIP = Ciproﬂoxacin, CS = Cycloserine,
AM = Amikacin, KM = Kanamycin, ETO = Ethionamide, PAS = Para-
aminosalicylic Acid, CM = Capreomycin, PZA = Pyrazinamide, EMB =
Ethambutol.
O310 A comparison between QuantiFERON and tuberculin skin
test during screening for tuberculosis infection in a contact
investigation among students
M. Jepsen, T. Krause, D. Moryl, N. Seersholm, M. Ruhwald, B. Søborg,
I. Brock, P. Ravn (Copenhagen, Hvidovre, DK)
Introduction: Two cases of tuberculosis (TB) were discovered at a
high school in Copenhagen. A contact investigation was performed with
Mantoux skin test (TST) and QuantiFERON® TB In Tube test (QFT)
and all staff and students were asked to participate in the study.
Objective: To compare QFT with TST in a contact investigation.
Methods: Students and staff were screened with TST, QFT and risk
factors were registered in a questionnaire.
Results: A total of 724 had a TST applied of which 689 (94%) were read.
Twenty-seven (4%) were TST positive. A total of 490 (62%) had a QFT
done and 11 (2.2%) were positive and 4 (0.8%) inconclusive. We found
that 17/603 (2.8%) of the students and 24/87 (28%) of the staff were
TST positive whereas, 8/419 (1.9%) of the students and 3/71 (4.2%) of
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the staff were QFT positive. Agreement between the TST and the QFT
was moderate 97% (Kappa 0.407, CI (0.124−0.689)) among students and
poor among staff, 68 (Kappa 0.036, CI (−0.102−0.175)). The majority
of positive QFT and TST persons were found in the index class and the
neighbouring classes. Logistic regression analysis showed a signiﬁcant
association between positive TST results and BCG vaccination and we
concluded that prior BCG vaccination could explain the high prevalence
of TST positive staff. Only 5/10 (50%) of the QFT positive individuals
were also TST positive indicating a suboptimal sensitivity of TST among
persons at risk.
Conclusion: The two tests found an equally amount of M tuberculosis
infected amongst the young non BCG vaccinated group taking into
account that not everyone volunteered for both tests. 50% (4/8) of the
QFT positives students were not detected with the TST. Among the
staff, the high frequency of TST positives was explained by former BCG
vaccination.
The choice of test preferred for a TB contact investigation should be
based on the proﬁle of the screening population. BCG status, age,
country of origin, the use of both tests at the same time or in two
steps should be evaluated according to the risk in the population of
developing TB.
O311 In only half of the tuberculosis cases diagnosed in Zambia,
Mycobacterium tuberculosis is the causative agent
P.C.A.M. Buijtels, M.D. Iseman, S. Parkinson, C.S. de Graaff,
H.A. Verbrugh, P.L.C. Petit, D. van Soolingen (Rotterdam, NL; Denver,
US; Katete, ZM; Alkmaar, Schiedam, Bilthoven, NL)
Diagnosis of tuberculosis (TB) in resource-poor countries is almost
exclusively based on microscopy of Ziehl-Neelsen stained (ZN) sputum
smears; in some settings supplemented by chest X-ray.
Objectives: The aim of this study was to determine the accuracy of
this diagnosis of TB in Zambia in the era of increasing HIV prevalence.
By applying MGIT liquid culture technique, this study distinguished
between (i) TB cases conﬁrmed by positive Mycobacterium tuberculosis
cultures, (ii) mycobacteriosis caused by non-tuberculous mycobacteria
(NTM) and, (iii) tuberculosis-like disease caused by organisms other
than mycobacteria.
Methods: Adult patients were included who had been diagnosed with
TB on basis of respiratory complaints lasting two or more weeks, failure
to improve on two courses of empiric antibiotics, a positive ZN sputum
smear and/or ﬁndings on the chest X-ray consistent with TB. Sputa of
the presumptively diagnosed TB cases were subjected to MGIT liquid
culture. Mycobacterium isolates were identiﬁed using a nucleic acid
ampliﬁcation method and 16S DNA sequencing.
Results: In only 47% of the 187 presumptively diagnosed TB cases
was M. tuberculosis cultured. In 19% exclusively NTM were found. In
another 12% of the presumptive cases, a combination of M. tuberculosis
and NTM was isolated. In the remaining 29% of cases in which TB was
diagnosed, no mycobacteria were cultivable. HIV positivity was signiﬁ-
cantly correlated with the isolation of NTM from sputum and inversely
associated with the isolation of exclusively M. tuberculosis (p< 0.05).
Conclusions: Basing the diagnosis of tuberculosis on symptoms, sputum
smear and/or chest X-ray may lead to signiﬁcant numbers of false-
positive cases of tuberculosis in Zambia, due to the increased prevalence
of HIV.
O312 A rapid, fully-automated PCR system for sample
processing, diagnosis, and rifampin resistance detection of
Mycobacterium tuberculosis
M. Jones, D. Helb, K. Ho, J. Kop, P. Nguyen, E. Story, E. Wallace,
D. Alland, L. Christel, C. Boehme, M. Perkins, P. Nabeta, G. Skenders,
M. Levi, H. Saﬁ, R. Rodgers, E. Winn-Deen, D. Persing, P. Dailey
(Sunnyvale, Newark, US; Geneva, CH; Lima, PE; Riga, LV; Bronx, US)
Background: Current methods for the detection and determination of
drug resistance of Mycobacterium tuberculosis (MTB) are insensitive
and slow. PCR is a more accurate and rapid technique, but requires
substantial labour and technical competence. PCR is also affected by
inhibitors, sample cross-contamination, and limited ability to concentrate
samples. All of these limitations are overcome by the GeneXpert®
system. This automated system uses a low-cost plastic cartridge to
concentrate all the bacilli present in a sputum sample, remove inhibitors,
lyse cells, and transfer the DNA into an integrated PCR tube. This DNA
is ampliﬁed in a nested, real-time PCR using an optimised, six-colour
Molecular Beacon assay to detect more than 95% of all rifampin-resistant
TB strains. An internal sample processing and reagent control is also
included. Sample processing and nested PCR occur within the same
cartridge and no external manipulation is required after the sample is
initially loaded.
Objectives: To comprehensively evaluate the GeneXpert MTB assay
using sputum and sputum pellet samples and simultaneously detect
rifampin resistance-associated mutations in the rpoB core region. Key
evaluation criteria were analytical performance, stability of reagents, and
sample inactivation.
Methods: Proﬁciency panels, clinical and spiked samples are mixed
with a sample treatment buffer (STB), incubated and added to the
cartridges containing reagent beads and buffer. Wild type and mutant
MTB strains were used to determine the system’s analytical performance.
Inactivation studies determined the amount of viable TB cells before and
after treatment with STB. Stability was assessed by testing cartridges
incubated from 4 ºC to 45 ºC.
Results: The STB kills >6 logs of MTB organisms in sputum,
disinfecting the sputum and reducing the risk from infectious aerosols.
The GeneXpert detected as few as 50 bacilli/mL of sputum in 90 min,
making it as rapid as microscopy, but much more sensitive. Eleven out
of 12 of the QCMD 2002 TB panel samples were correctly identiﬁed.
At two alpha test sites this system diagnosed and provided semi-
quantitative information about TB infections and accurately detected
rifampin resistance. To date reagent stability is >3 months at 45ºC.
XpertTM MTB sensitivity & speciﬁcity (per patient analysis)
Sensitivity: Speciﬁcity:
smear-pos, cul-pos smear-neg, cul-pos smear-neg, cul-neg
Peru 100% (99/99) 71.4% (10/14) 95.6% (130/136)
Latvia 100% (14/14) 66.6% (10/15) 97.6% (40/41)
Total 100% (113/113) 68.9% (20/29) 96.0% (170/177)
XpertTM MTB – Rif resistance detection (per patient analysis)
Sensitivity in
Rif resistant cases
Speciﬁcity in
Rif sensitive cases
Peru 100% (13/13) 100% (88/88)
Latvia 100% (6/6) 100% (7/7)
Total 100% (19/19) 100% (95/95)
Conclusion: The combination of sample processing with real-time PCR
into a single automated step makes this assay simple to perform, in
near-patient and laboratory settings, with minimal effort in <2 h.
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O313 Tuberculosis and HIV in Mexico City: a single-centre cohort
L. Espinosa, A. Ponce de Leon, A. Villasis-Keever, J. Sierra-Madero,
A. Galindo-Fraga, M. Bobadilla-Del Valle, J. Sifuentes-Osornio
(Mexico City, MX)
Objective: To determine the frequency, clinical characteristics, anti-
tuberculosis drug resistance pattern, and mortality in HIV and TB co-
infected patients.
Methods: A cohort of all HIV infected patients was followed at a tertiary
care referral centre in Mexico City. Speciﬁc endpoints were deﬁned and
analysed in relation to tuberculosis infection, and other co-morbidities.
Results: We found 92 cases of active TB (5.5%) among 1651 HIV
patients. The rate of co-infection was 3% in 1998, 2% in 2003, and
1% in 2007. In 32 (34%) of the 92 cases, TB and HIV were diagnosed
simultaneously (± 30 days). Their median age was 36.9 years and 91.3%
were male. We observed a statistical difference in the median CD4
cell count between co-infected [74 X 106 cells/L (IQR 25–169)] and
non-co-infected [197 X 106 cells/L (IQR 66–346)] patients (p< 0.007).
Forty-eight (52%) patients had extra-pulmonary TB of whom 11 (23%)
had disseminated disease. Chest x-rays in the 44 (48%) patients with
pulmonary involvement showed: bilateral diffuse inﬁltrates in 70%,
localised inﬁltrates in 9%, cavitations in 14%, and no inﬁltrates in
7%. Tuberculosis was diagnosed with culture in 64 patients (69%):
Mycobacterium tuberculosis was isolated in 47 cases andMycobacterium
bovis in 17. Acid-fast staining contributed to diagnosis in 39% of the
cases, and histopathology in 15%. Of the 86 patients (92%) that started
treatment for TB, 7 (8.4%) experienced liver toxicity, 51 (56%) achieved
cure, 5 (5%) relapsed, and 17% (16) were lost to follow-up. Primary
resistance to anti-TB drugs was 9.3%, whereas secondary resistance
was 5.4%. Only two cases of MDR-TB were detected, both in patients
with relapses and poor compliance to anti-TB treatment. Mortality was
observed in 18.5% (17 cases) at their last visit. Tuberculosis was the
cause of death in 11% (10). The median time to death attributed to TB
was 12 days (IQR 3–428).
Conclusions: The frequency of co-infection in this population was lower
than expected for a medium income country; primary resistance to anti-
TB drugs was similar to that observed in Mexico; mortality attributed
to TB was low but it happened shortly after diagnosis. Of note, extra-
pulmonary TB was common in this cohort, and Mycobacterium bovis
was a frequent pathogen.
O314 Epidemiological study of an outbreak of non-tuberculous
Mycobacteria subcutaneous infections after mesotherapy
A. Carbonne, I. Arnaud, F. Brossier, I. Bougmiza, E. Cambau,
J. Meningaud, V. Jarlier, E. Caumes, P. Astagneau (Paris, FR)
Objectives: Mesotherapy is an increasing used technique involving
subcutaneous injections of minute quantity of various medical drugs for
cosmetic or rheumatism purposes. This practice was already reported to
be related to infection risk.
In January 2007, a general practitioner notiﬁed to the health authorities
and the regional centre for infection control a cluster of subcutaneous
infections due to non-tuberculosis Mycobacteria (NTM) following
mesotherapy. An epidemiological investigation was performed to
describe the outbreak, to identify the source and the mechanism of
contamination and to determine risk factors.
Methods: The case deﬁnition was based on typical clinical subcutaneous
lesion associated with positive specimens for NTM. An assessment
practice study was performed to determine potential risk factors to
be tested in a comparative epidemiological study. Data were collected
including schedules of outpatient visits, localisation of injections, and
type of injected products. Tap water of the medical examination room
was sampled for search of Mycobacteria. Mycobacterium chelonae
strains were compared using Pulsed Field Gel Electrophoresis (PFGE).
Results: Overall, 16 cases were identiﬁed among 105 outpatients (attack
rate: 15.2%), including 11 positive for Mycobacterium chelonae and
2 for M. frederiksbergense. M. chelonae was found in the tap water.
Assessment practice study identiﬁed inappropriate cleaning and rinsing
of the multiple injection device (automatic repetitive machine) using tap
water which was likely to be the source of NTM contamination. Indeed,
PFGE M. chelonae strains patterns were similar between patients and
tap water samples. The multivariate logistic regression analysis showed
that to be at the second rank during a mesotherapy session (Odds ratio =
4.15 [1.2−13.9]) and to have more days of mesotherapy cares delivered
after room closure (Odds ratio = 1.03 [1.01−1.05]) were independent
risk factors of NTM infection.
Conclusion: This outbreak investigation highlights that failure in
disinfection of injecting material could generate severe infections with
highly resistant bacteria related to non regular medical cares. Efforts
should focus on control of hygiene practices in non hospital settings
based on appropriate guideline recommendations.
Antifungal therapy: optimisation for
life-threatening Candida infections
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S315 Epidemiology of Candida infections: European focus
A.M. Tortorano (Milan, IT)
Invasive candidiasis and candidaemia are the most common systemic
fungal infections observed in hospitals. The increased prevalence of risk
factors for these infections over the past two decades have dramatically
increased their incidence during that period. These infections are
frequently severe, with a crude mortality rate of 38%.
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Underlying condition
Surgery (933) 58.0 16.3 12.6 6.1
Intensive care (839) 60.5 11.9 12.9 6.1
Solid tumour (471) 58.0 15.9 10.6 8.3
Haematological malignancy (257) 34.6* 9.7 14.8 17.9*
Foetal immaturity (125) 60.8 4.8* 28.8* 2.4
HIV infection (63) 65.1 9.5 6.3 6.3
Age group
<1 y (158) 59.6 3.1* 27.9* 3.1
1−19 y (144) 47.9 3.6* 32.9* 5.7
20−69 y (1189) 57.1 14.0 11.2 8.3
70 y (590) 60.0 19.3* 6.9* 7.1
Total population 56.4 13.6 13.3 7.2
*p 0.01 for comparison of percentage for each underlying condition/
age group vs. percentage in total population.
Table reproduced from Tortorano AM, et al. Eur J Clin Microbiol Infect
Dis 2004; 23: 317–322.
The nature of systemic Candida infections appears to be changing. Until
recently, the majority of infections were caused by Candida albicans,
but this species is becoming less common as non-albicans Candida
species begin to proliferate, particularly in certain patient types. In a
recent survey of the epidemiological and mycological proﬁle of Candida
species in Europe, while Candida albicans was still the most common
cause of infection overall, 43.6% of infections were caused by non-
albicans Candida species [1]. Furthermore, in surgical patients and those
with solid tumours, and in patients aged 70 years, the prevalence of
C. glabrata approached 20% (see Table) [1].
The signiﬁcance of these changes in Candida epidemiology may be
profound, since non-albicans Candida species seem to be associated
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with an increased risk of mortality compared with C. albicans (C. krusei:
55.3%; C. glabrata: 45.0%; C. tropicalis: 41.4%; C. albicans: 38.5%).
However, these differences may be explained by the increased prevalence
of these species in patients with more severe underlying illness [2].
While isolates of C. albicans are generally susceptible to most antifungal
agents, non-albicans Candida species, particularly C. glabrata and
C. krusei, are often non-susceptible to older agents, such as ﬂuconazole
[3]. This has important implications for the selection of appropriate
antifungal therapy in patients with systemic Candida infections.
Reference(s)
[1] Tortorano AM, et al. Eur J Clin Microbiol Infect Dis 2004; 23:317–
322.
[2] Tortorano AM, et al. Int J Antimicrob Agents 2006; 27:359–366.
[3] Messer SA, et al. J Clin Microbiol 2006; 44:1782–1787.
S316 Antifungals: in vitro activity
M.C. Arendrup (Copenhagen, DK)
In vitro activity is an important measure of the potency of antifungal
agents as well as a useful guide to their relative clinical activity
and to the extent of resistance development. Over recent decades, an
increasing proportion of candidaemia cases involve species not fully
susceptible to ﬂuconazole (mainly C. glabrata and C. krusei) [1,2].
Furthermore, although Candida isolates with acquired azole resistance
are still observed only sporadically, recent studies have documented the
increased emergence of C. glabrata isolates against which voriconazole
has elevated MICs.2 Conversely, amphotericin B and the echinocandins
(anidulafungin, caspofungin and micafungin) are potent and cidal in
vitro against isolates of the major Candida spp., including C. glabrata,
although slightly higher MICs have been observed for the echinocandins
against the less virulent species C. parapsilosis (see Table) [3].
Table
Organism MIC90 (mg/ml)
Number of
isolates
Anidulafungin Caspofungin Micafungin
C. albicans 2,869 0.06 0.06 0.03
C. parapsilosis 759 2 1 2
C. glabrata 747 0.12 0.06 0.015
C. tropicalis 625 0.06 0.06 0.06
C. krusei 136 0.06 0.25 0.12
G. guilliermondii 61 2 1 1
C. lusitaniae 58 0.5 0.5 0.25
C. kefyr 37 0.12 0.015 0.06
C. famata 24 2 1 1
Candida spp. 30 1 0.25 0.5
Total 5,346 2 0.25 1
While in vitro activity alone is a useful measure of potency, susceptibility
data can be applied further to the development of susceptibility
breakpoints. Studies examining the correlation between PK/PD, MICs
and clinical success rates have resulted in the establishment of
breakpoints for ﬂuconazole against Candida spp. of 2 microg/ml by
EUCAST and 8 microg/ml by CLSI. CLSI have suggested further
breakpoints of 1 microg/ml and 2 microg/ml for voriconazole and the
echinocandins, respectively. However, in a recent large population-based
survey, including 410 micafungin-treated patients, a lower susceptibility
breakpoint for micafungin of 1 microg/ml was suggested [4]. As
clinical experience is still very limited regarding isolates with MICs
above the normal range predicted by the species identiﬁcation, further
studies are warranted.
The results of in vitro activity studies have a substantial impact on
treatment choices for systemic Candida infections in an era when 1) non-
albicans Candida species are prevalent, 2) susceptibility testing methods
applicable for routine testing are available, but 3) species identiﬁcation
is often not rapidly available. The echinocandins are likely to play an
important role in the treatment of systemic Candida infections and with
their increased use, continued close monitoring of susceptibility and
epidemiology is necessary.
Reference(s)
[1] Messer SA, et al. J Clin Microbiol 2006; 44:1782−87.
[2] Arendrup MC, et al. Clin Microbiol Infect; in press.
[3] Pfaller MA, et al. J Clin Microbiol 2008;46: 150−56.
[4] Ostrosky-Zeichner L, et al. 47th ICAAC. Chicago, September 2007;
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S317 Antifungals for life-threatening candidiasis
O. Cornely (Cologne, DE)
Invasive candidiasis and candidaemia are rarely seen in normal, healthy
hosts, since Candida spp. are opportunistic pathogens. Risk factors that
increase the likelihood of development of a systemic Candida infection
include malignant diseases, diabetes, deeply invasive medical procedures
(e.g. intravenous catheters, central lines, major abdominal surgery) and
prematurity.
Treatment success of systemic Candida infections may also depend
on patient conditions and other factors, such as age, gender, type of
infection, neutropenic status and severity of illness. For example, removal
of catheters is regarded as standard of care in patients with systemic
Candida infections, since Candida bioﬁlms that may form on these
invasive devices can act as a reservoir of continued infection. In a
multivariate logistic regression analysis of Phase III trials conducted with
the echinocandin agent micafungin in patients with systemic Candida
infections, a number of factors were associated with a reduction in the
likelihood of treatment success. These included higher APACHE II score,
non-removal of catheters, disseminated infection, age 70 years and
steroid treatment.
Micafungin has demonstrated efﬁcacy in adults with invasive candidiasis
and candidaemia and is also the echinocandin with the most extensive
experience in children and neonates with these infections. Furthermore,
micafungin has been shown to be effective in both neutropenic and non-
neutropenic patients and in both deep invasive Candida infections and
candidaemia. Micafungin also has broad-spectrum efﬁcacy across all
major Candida species. These data suggest that micafungin is a valuable
option for the treatment of serious invasive Candida infections.
S318 Optimising antifungal therapy – key points
D. Denning (Manchester, UK)
Effective treatment of invasive candidiasis and candidaemia is currently
limited by the lack of accurate, reliable diagnostic tools, although steps
towards this ideal are being taken presently. Furthermore, resistance
in certain Candida species, such as C. glabrata and C. krusei, is
a signiﬁcant and growing problem with some antifungal treatments,
particularly ﬂuconazole and other agents of the azole class.
Micafungin, a new echinocandin agent, offers much promise for the
treatment of invasive candidiasis and candidaemia, having demonstrated
high treatment success rates in adults, children and neonates. Micafungin
has been approved for the treatment of systemic Candida infections
in Japan for a number of years, accounting for 157,069 patient-
months’ exposure, during which time it has been shown both to be
effective and to have excellent tolerability. Globally, micafungin has
been administered to around 365,000 patients, including 3,300 patients
in clinical studies. Pooled analyses of safety data from all clinical
studies, which were conducted in a wide range of indications including
systemic Candida infections, prophylaxis against fungal infections
in haematopoietic stem cell transplant recipients and treatment of
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oesophageal candidiasis, demonstrate the excellent tolerability associated
with micafungin treatment in a broad range of patient types (see Table).
Common treatment-related adverse events (2%) by age group
Age group, patients, n (%)
Overall Adults,
non-elderly
(16−64 years)
Adults,
elderly
(65 years)
Paediatrics
(<16 years)
AE N= 3028 n = 2345 n = 387 n = 296
Hypokalaemia 63 (2.1) 45 (1.9) 9 (2.3) 9 (3.0)
Phlebitis 75 (2.5) 65 (2.8) 7 (1.8) 3 (1.0)
Diarrhoea 61 (2.0) 52 (2.2) 6 (1.6) 3 (1.0)
Vomiting 75 (2.5) 62 (2.6) 9 (2.3) 4 (1.4)
Nausea 84 (2.8) 73 (3.1) 8 (2.1) 3 (1.0)
Pyrexia 63 (2.1) 51 (2.2) 8 (2.1) 4 (1.4)
AST increased 71 (2.3) 63 (2.7) 2 (0.5) 6 (2.0)
ALT increased 61 (2.0) 49 (2.1) 3 (0.8) 9 (3.0)
Alk Phos
increased
81 (2.7) 65 (2.8) 10 (2.6) 6 (2.0)
Alk Phos: alkaline phosphatase; ALT: alanine aminotransferase; AST:
aspartate aminotransferase.
Challenges from the rise of resistant
pathogens: Part 2 (Symposium organised by
Janssen Cilag)
S319 Changing landscape of resistance in Europe: focus on
Gram-negative bacteria
D.M. Livermore (London, UK)
The 1970s and 1980s saw development of many cephalosporins and
ﬂuoroquinolones, and it brieﬂy appeared that these had beaten Gram-
negative pathogens. But, as so often occurs in the battle between man and
microbe, victory proved illusory, and resistance is now widespread. This
has serious clinical implications, because inadequate treatment, owing
to resistance, correlates with increased mortality among seriously ill
patients.
Recent critical shifts in Europe and elsewhere include a huge increase
of quinolone resistance in Enterobacteriaceae, particularly Escherichia
coli, where rates among bacteraemia isolates mostly now exceed 25%.
Cephalosporin resistance has increased too, largely via the spread
of plasmids, encoding extended-spectrum b-lactamases (ESBLs). Until
2000, most ESBLs in Europe were mutants of the old TEM or
SHV penicillinases and largely occurred in nosocomial Klebsiella spp.
Subsequently “CTX-M” ESBLs have spread extensively, becoming
frequent in E. coli as well as Klebsiella spp. Producers cause infections
in “complicated community” patients as well as those in hospitals. The
predominant CTX-M types and the clonality of their producers vary
among countries, but their “takeover” is remarkably consistent. Many
producers are resistant to all antibiotics except carbapenems, fosfomycin,
and nitrofurantoin.
This accumulation of cephalosporin and quinolone resistance is driving
use of carbapenems. These largely evade ESBLs and AmpC enzymes,
although resistance can arise if a strain with one of these enzymes
is unusually impermeable. At present, true acquired carbapenemases
remain rare in most species, but there are disturbing pointers to
their future spread. First, Acinetobacter baumannii clones with OXA
carbapenemases are already prevalent in intensive care units (ICUs)
worldwide. Secondly, Klebsiella clones with KPC carbapenemases are
spreading in the United States, with a few reports from Europe. Thirdly,
there is a growing scatter of Enterobacteriaceae and non-fermenters with
IMP and VIM metallo-b-lactamases, particularly in Greece and Italy.
Perhaps most disturbing of all is that there is no new, consistently active
family of anti-Gram-negative agents in reserve behind the carbapenems,
nor any likely to become available in the next decade.
S320 Nosocomial pneumonia in the critical care setting
J. Rello (Tarragona, ES)
Hospital-acquired pneumonia (HAP) is the most common healthcare-
acquired infection contributing to death and has been estimated to
increase the length of hospitalisation by 7 to 9 days. Ventilator-
associated pneumonia (VAP) is also associated with increased mortality,
increased length of stay, and need for continued mechanical ventilation,
and therefore, presents its own unique management challenges. Key
pathogens associated with nosocomial pneumonias include meticillin-
resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Acine-
tobacter baumannii. Effective management involves accurate diagnosis,
timely selection of initial appropriate antibiotics at effective doses
and administration routes, and implementation of optimal prevention
strategies. Due to variability of offending organisms within different
treatment settings, initial therapy for HAP and VAP should be
individualised. Selection of broad-spectrum agents should be based on
many variables, including patient risk factors (eg, recent antibiotic expo-
sure, comorbidities, duration of hospitalisation), suspected pathogens,
pharmacokinetic considerations, and resistance dynamics. Following
48 to 72 hours of therapy, the patient should be assessed for de-
escalation strategies based on clinical response and laboratory tests.
Dosing ﬂexibility in patients with VAP or severe sepsis is crucial to
ensuring optimal resolution. Recent clinical trials suggest that doripenem
might provide additional value for therapy of HAP, including VAP.
A multidisciplinary approach with implementation of pan-European
guidelines for HAP based on care bundles should be viewed as an
opportunity to optimise management of HAP in Europe.
S321 New options for the management of complicated
intra-abdominal infections
J. Solomkin (Cincinnati, US)
Complicated intra-abdominal infections (CIAIs) are a therapeutic
challenge and consume signiﬁcant hospital resources. The infecting
organism can often be suspected based on the likely source of the
infection (eg, community acquired or healthcare associated) and the
location of insult or intestinal perforation(s). Therapy is complicated
by the infection’s polymicrobial nature. The continued rise of resistant
organisms in the community (eg, Escherichia coli) and in the hospital
setting (eg, Pseudomonas aeruginosa) has made antibiotic selection even
more challenging. Effective management strategies for the treatment of
CIAI include, but are not limited to: rapid and accurate diagnosis, anti-
sepsis therapy, and the timely administration of empiric antimicrobial
therapy. Clinical features associated with poor outcomes include: acute
physiologic severity and an inability to obtain adequate control of the
source of infection. Patients with severe CIAIs may beneﬁt from broad-
spectrum and more active agent(s). These agents include carbapenems,
b-lactam/b-lactamase inhibitor combinations, select cephalosporins, or
other combined classes of agents. Recent clinical trials suggest that
doripenem may be an effective initial therapy for CIAIs due to its
enhanced microbiologic potency and resistance proﬁle for P. aeruginosa,
as well as its dosing optimisation ﬂexibility.
S322 Optimising outcomes: getting it right from the start
Y. Carmeli (Tel Aviv, IL)
Resistance to antimicrobial drugs is a growing health and economic
concern. Rates of resistance to community- and hospital-acquired
Gram-negative and Gram-positive pathogens have risen signiﬁcantly
over the past several years. Infections caused by these drug-resistant
pathogens are associated with greater morbidity and mortality, prolonged
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hospitalisations, and increased costs, compared with infections from
sensitive strains. The early identiﬁcation of patients at higher risk
for polymicrobial-resistant infections is a key factor in guiding the
selection of empiric antibiotic therapy. Selection of agent(s) from various
classes of antibiotics should be individualised based on the patient’s
clinical status and renal function and by the agent’s microbiologic
activity (coverage), resistance characteristics, and therapeutic dynamics.
The prompt selection of appropriate broad-spectrum empiric antibiotic
therapy is essential to provide adequate coverage for the pathogens of
concern and Getting it Right from the Start! The use of pharmacokinetic
(PK) and pharmacodynamic (PD) simulations can help guide the
decision-making process for the selection of antibiotic(s), dosage(s), and
duration of infusion(s). For example, extending infusion times may lead
to better outcomes for the treatment of infections caused by organisms
with high minimum inhibitory concentration (MIC) values by extending
the time above the MIC without requiring an increase in dosage. The
use of PK/PD data for augmenting antibiotic exposure with carbapenems,
including doripenem, will be presented.
Neonatal immunisation – Needs and reality
K330 Neonatal immunisation – needs and reality
C-A. Siegrist (Geneva, CH)
Millions of infants die annually of acute respiratory and diarrhoeal
infections that could have been prevented, had these infants been
immunised earlier. Unfortunately, the immune immaturity that is
responsible for their increased vulnerability to infections also limits
vaccine responses. This major challenge is being addressed, and
information is rapidly accumulating on the mechanisms that limit vaccine
responses in early life and potential circumventing strategies.
The recognition of limited B cell responses to bacterial polysaccharides
led to the development of conjugate vaccine which had a major impact in
preventing infant disease by encapsulated bacteria. However, even potent
conjugate or protein vaccines require multiple vaccine doses to overcome
immune immaturity when given early in life, an issue which limits their
introduction in many countries of the world. The limitations of infant
B cell responses result not only from the interference by antibodies of
maternal origin but also from the weaker induction of antibody-secreting
plasma cells within Germinal Centres, which has emerged as a generic
determinant of the magnitude of early life antibody responses and calls
for the development of speciﬁc adjuvant or formulations. Importantly,
infant antibody responses are also of much shorter duration than those
elicited later in life, which may result into secondary vaccine failure.
In infant mice, this rapid decline of vaccine-induced antibodies results
from the failure of bone marrow niches to efﬁciently support plasma
cell survival through the production of sufﬁcient level of APRIL, a
limiting factor that is unlikely to be easily circumvented and calls for
the administration of early booster doses.
In contrast to the limitations of antibody-secreting-cells, the induction
of memory B cells may be readily elicited already in the neonatal
period. This understanding led to clinical studies in which human
neonates received a ﬁrst dose of pertussis vaccine in their ﬁrst week
of life. Markedly enhanced responses to subsequent vaccine doses were
observed in certain studies, whereas others were confronted to the issue
of vaccine interference. Numerous questions therefore remain open,
including the relative magnitude and persistence of vaccine memory
elicited early or later in life.
Aiming at “zero”. Impact of “bundles” and
other new initiatives to reduce nosocomial
infections
K331 Aiming at “zero”: impact of “bundles” and other new
initiatives to reduce nosocomial infections
D.A. Goldmann (Cambridge, US)
For decades, the infection prevention and control community has
regarded nosocomial infections as a “right of passage”, especially for
critically ill patients with invasive devices. Now there is cause for
optimism as an increasing number of hospitals and intensive care
units report dramatic reductions in the rates of catheter-associated
bloodstream infections, ventilator-associated pneumonias, and other
serious infections. At last, evidence regarding effective infection control
processes of care is being translated into practice. Progress has been
facilitated by: 1) application of principles of reliability science (in which
failures to adhere to best practice are regarded as “defects” in care);
2) development of concise “bundles” of evidence-based practices (culled
from exhaustive and somewhat cumbersome guidelines); 3) application
of an “execution framework” (including clear aims supported by
leadership, multi-disciplinary teams employing quality improvement
methods at the bedside in clinical microsystems, clear measures of
outcomes and success, and a parsimonious set of “drivers” required
to achieve these outcomes); and 4) advances in technology. These
principles can be illustrated by examining methods used to reduce major
nosocomial infection problems, such as MRSA, catheter-associated
bloodstream infection, and ventilator-associated pneumonia. In deploying
these strategies, it is important not to underestimate the complexity of
working on multiple problems at the same time, as well as the impact
on cost/resources and the potential for unintended consequences.
Molecular basis and clinical impact of
mutators
S335 Mutators: mechanisms and roles in bacterial infections
A. Oliver (Palma, ES)
Laboratory and theoretical approaches have shown that under particular
circumstances such as exposure to new environments or stressful
conditions, cells with increased (up to 1000-fold) spontaneous mutation
rates (hypermutable or mutator) are frequently selected in bacterial pop-
ulations, speeding up bacterial evolution (adaptation to the environment).
The ﬁrst surveys in natural bacterial populations, conducted in E. coli
and Salmonella spp., revealed a higher than expected prevalence of
mutators (around 1%), supporting the hypothesis that hypermutation
could act as a mechanism for acceleration of bacterial evolution in nature.
Nevertheless, the ﬁrst evidence for a speciﬁc role of hypermutation in
human infections was obtained from the study of P. aeruginosa chronic
lung infection in cystic ﬁbrosis (CF) patients, in which the prevalence
of hypermutable strains was by far the highest ever found in nature.
Subsequent studies have demonstrated that hypermutation is indeed a
common feature of P. aeruginosa chronic respiratory infections occurring
in patients with chronic underlying respiratory diseases such as CF,
bronchiectasis, or COPD with a prevalence ranging from 30 to 60%
of the patients, whereas the prevalence of mutator strains is very low
(<1%) in acute infections. A high prevalence of mutators in the CF
setting was also found later for other pathogens such as S. aureus and
H. inﬂuenzae. Results from recent studies, involving mouse models of
chronic infection and long-term longitudinal studies of CF isolates,
have shown that hypermutation indeed plays a relevant role in two
major aspects of P. aeruginosa chronic respiratory infections: bacterial
adaptation for long-term persistence of infections and antimicrobial
resistance development. The molecular basis of hypermutation are
defects in genes involved in DNA repair or error avoidance system which
have been deeply studied in E. coli. Among them, the gene coding for
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the Epsilon subunit of the DNA polymerase III (dnaQ or mutD), the
genes involved in the Mismatch Repair (MMR) System, mutS, mutL,
mutH, and UvrD (mutU) or the genes belonging to the GO system for
DNA oxidative lesion repair, mutT, mutM and mutY. In CF P. aeruginosa
strains, as well as in other natural bacterial populations, the most frequent
mechanism leading to hypermutation is the inactivation of the MMR
System, that along with mutation rates, increases also by 1000-fold the
rates of recombination between divergent DNA sequences.
S336 The role of mutators in emergence of antibiotic resistance
in the clinical setting
I. Chopra (Leeds, UK)
Mutation plays an important role in the evolution of antibiotic resistance
mechanisms in bacteria either by reﬁning existing horizontally acquired
genetic determinants (e.g. those encoding b-lactamases), or by giving rise
to variant drug targets with decreased afﬁnity for antibiotics through
point mutations (e.g. in the case of resistance to ﬂuroquinolones.
rifampicin, mupirocin and fusidic acid). Therefore bacteria exhibiting
elevated mutation frequencies, known as mutators or hypermutators, may
have a selective advantage when exposed to antibiotics in the clinical
setting.
Naturally occurring hypermutators have been described in a number
of pathogenic Gram-negative species. They appear to be particularly
prominent in isolates of Pseudomonas aeruginosa from cystic ﬁbrosis
patients and the possible molecular basis for their selection in this
environment will be discussed. Although S. aureus hypermutators,
deﬁcient in the methyl-directed mismatch repair (MMR) system have
been created in the laboratory (e.g. mutS and mutL mutants), the
occurrence of staphylococcal hypermutators in the clinical setting
appears to be variable, with some groups reporting their presence
and others not. Furthermore, a S. aureus mutL mutant has recently
been reported to exhibit decreased ﬁtness in a model of chronic
bone infection and there is no evidence that intermediate susceptibility
to vancomycin in clinical isolates of S. aureus (VISA) evolves in
hypermutable hosts, despite the fact that resistance to vancomycin in
these strains probably requires multiple mutations in chromosomal genes.
Therefore hypermutation may not play a major role in the development
of antibiotic resistance in S. aureus. Possible reasons for this situation
will be discussed.
Innovative treatment of experimentally
infected animals
O337 New osteotropic prodrugs prevent bone infection in a rat
model of osteomyelitis
D. Lehoux, V. Ostiguy, I. Fadhil, K. Laquerre, K.S.E. Tanaka, T. Kang,
Y. Lafontaine, T.J. Houghton, R. Reddy, G. Moeck, A. Rafai Far,
T.R. Parr Jr. (St-Laurent, CA)
Objectives: Osteomyelitis is a difﬁcult to treat bone infection mainly
caused by Staphylococcus aureus. Its treatment often requires a
combination of surgical intervention and prolonged antibiotic therapy.
Recently, new prodrugs were synthesised by attaching ﬂuoroquinolone
(FQ) or rifamycin (RIF) antibiotics to a bisphosphonate (BP) moiety,
to target bone, including prodrugs of moxiﬂoxacin (MOX), gatiﬂoxacin
(GAT), rifabutin (RFB) and rifalazil (RFZ). Here we tested the in vivo
efﬁcacy of these prodrugs as prophylactic treatments in a rat model of
osteomyelitis.
Methods: S. aureus ATCC 13709 (MSSA) was used for all in vivo
studies. Minimum inhibitory concentrations (MICs) were determined
by CLSI broth microdilution. MICs for the parent drugs GAT, MOX,
RFB and RFZ were 0.12, 0.06, 0.016, and 0.001 mg/L, respectively.
Osteomyelitis was established in anaesthetised CD rats by injecting
0.05 mL of 5% sodium morrhuate followed by 0.05 mL of 105
cells of S. aureus into the medullar cavity of the tibia. Groups of
rats (n = 5/group) received no treatment, or single doses of parent
drugs (MOX, GAT, RFB and RFZ) or prodrugs (intravenously (IV))
administered before infection. Treatments were initiated: (1) −24h for
MOX (IV) and TT99000520 (MOX-BP) at 10 mg/kg parent equivalent
(eq.), or −28 days at 20 mg/kg eq., (2) −48h for GAT (IV) and
TT99000559 (GAT-BP) at 10, 1, 0.1 mg/kg eq. (3) −5 days for RFB
(subcutaneous (SC)) and TT99000647 (RFB-BP) at 20 mg/kg eq., and
(4) −3 days for RFZ (SC) and TT99000665 (RFZ-BP) at 10 mg/kg eq.
Tibiae were harvested 24h after the infection and ground to determine
the bacterial titer in CFU/g of bone.
Results: 1) Prophylactic treatment with TT99000520 resulted in greater
efﬁcacy (−2.8±0.2 Log CFU/g) than MOX. Also, TT99000520 remained
statistically (p = 0.004) more active even when injected 28 days before
the infection. 2) Prophylaxis with GAT was completely ineffective, while
TT99000559 at 10, 1, and 0.1 mg/kg eq. resulted in a dose dependent
efﬁcacy (2.8±0.9, 5.0±1.5 and 5.8±0.8 Log CFU/g, respectively). 3)
Prophylaxis with TT99000647 reduced the bacterial load by 3.5±1.5 Log
CFU/g as compared to RFB. 4) 40 and 100% of rats treated with RFZ
and TT99000665 had sterilised tibia, while untreated rats had 6.1±0.9
Log CFU/g.
Conclusion: Bisphosphonated prodrugs tested under this format were
highly efﬁcacious, demonstrating the potential of a single dose of these
prodrugs to prevent osteomyelitis.
O338 Sequential combination of rifampicin and ceftriaxone
for bacterial meningitis treatment reduced the release of
bacterial compounds by Streptococcus pneumoniae in vitro
and attenuated inﬂammation and neuronal damage in vivo
A. Spreer, R. Lugert, V. Stoltefaut, A. Hoecht, H. Eiffert, R. Nau
(Go¨ttingen, DE)
Objectives: In bacterial meningitis, severe systemic and local inﬂamma-
tory processes cause long-term impairment and death. Current standard
therapy relies on members of the group of b-lactam antibiotics such
as ceftriaxone. By inhibition of cell wall synthesis these antibiotics
induce bacteriolysis, which leads to a sudden release of high amounts
of proinﬂammatory and toxic bacterial products including bacterial
DNA and haemolysins (e.g. pneumolysin produced by S. pneumoniae).
Bactericidal protein-synthesis inhibiting antibiotics like rifampicin
prevent bacteriolysis and the resulting burst of inﬂammation. With
respect to a certain risk of secondary resistance development during
rifampicin monotherapy, combination of rifampicin with other antibiotics
is mandatory. Therefore, we evaluated a sequential combination regimen
with a short-time rifampicin pretreatment followed by the addition of
ceftriaxone.
Methods: In vitro we analysed the release of pneumolysin and bacterial
DNA from pneumococcal broth culture by quantitative immunoblotting
and real-time-PCR. In vivo, we evaluated in a rabbit model of
pneumococcal meningitis the inﬂuence of rifampicin pretreatment on
cerebrospinal ﬂuid (CSF) inﬂammation and on hippocampal neuronal
damage.
Results: In pneumococcal broth culture, rifampicin pretreatment for
only 30 minutes signiﬁcantly reduced the ceftriaxone-induced release
of pneumolysin and bacterial DNA. Likewise, in vivo, rifampicin
pretreatment for 1 hour followed by the addition of ceftriaxone
signiﬁcantly reduced markers of neuroinﬂammation in the CSF, i.e.
prostaglandin E2 and total protein 2 hours after initiation of antibiotic
therapy. Reduced inﬂammation resulted in a signiﬁcantly reduced density
of apoptotic neurons in the hippocampal dentate gyrus compared
to animals treated with ceftriaxone alone. The combined antibiotic
treatment resulted in a slight decrease in the speed of bacterial killing,
but was nevertheless rapidly bactericidal.
Conclusion: A pretreatment of only 1 hour with the bactericidal broad-
spectrum antibiotic rifampicin prior to therapy with a b-lactam antibiotic
reduced the release of proinﬂammatory bacterial products in vitro and
attenuated inﬂammation and neuronal damage in vivo. This concept
holds promise to reduce inﬂammation-associated damage in severe
bacterial infections and should therefore be evaluated for meningitis
therapy in clinical trials.
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O339 Augmented effect by early antibiotic treatment of
lung infected mice using sequentially adapted mucoid
Pseudomonas aeruginosa
M. van Gennip, C. Moser, L. Dahl Christensen, T. Bjarnsholt,
H. Calum, P. Østrup Jensen, B. Lee, O. Ciofu, M. Givskov, S. Molin,
N. Høiby (Copenhagen, Lyngby, DK)
Objective: During chronic pulmonary infection of cystic ﬁbrosis (CF)
patients there is a continuous adaptation of Pseudomonas aeruginosa.
One important trait is overproduction of alginate, which results in
appearance of mucoid phenotypes and contributes to protection against
antibiotic treatment and the host immune response.
We have recently introduced a novel chronic P. aeruginosa lung infection
model in mice using three pairs of sequentially isolated (1988, 1997 and
2003) isotypic, non-mucoid and mucoid strains from one patient. The
model provides a CF-like time perspective of the chronic lung infection
and previous bacteriological results indicate that the mucoid phenotype
becomes more virulent with time.
Methods: Seaweed alginate embedded mucoid isolates were installed in
the lungs of female BALB/c mice (n = 8/gr). For every isolate there were
three groups: 1) Treatment initiated 1 hour after infection, 2) Treatment
initiated 24 hours after infection and 3) Untreated control group. Mice
were treated s.c. with 120 mg/kg tobramycin q.d. On day three mice
were euthanised for histopathology. The inﬂamed part of the lung was
removed, ﬁxed in formalin and slides were prepared for evaluation of
pathological changes.
Results: Early treatment signiﬁcantly reduced quantitative bacteriology
compared to delayed treatment for isolates 1997 and 2003 (p< 0.0004).
Early treatment and delayed treatment differed signiﬁcantly when
compared to the untreated group for all the isolates (p< 0.02).
A shift from the acute, severe inﬂammatory response dominated by
PMNs to the chronic inﬂammatory response also involving mononuclear
cells (MNs), was seen when comparing the mucoid isolate from 2003
with the isolates from 1988 and 1997 (p< 0.0001).
When comparing the degree of inﬂammation, treatment initiated after 1
hour resulted in less inﬂammation compared to the untreated group in
all the isolates (p< 0.01). The importance of early treatment compared
to delayed treatment was seen with the two late isolates from 1997
and 2003, where a signiﬁcant reduction was observed (p< 0.0015).
Only the isolates from 1988 and 2003 showed a reduction in degree of
inﬂammation between treatment initiated after 24 hours and the untreated
group (p< 0.02).
Conclusion: The present histopatological study emphasizes the impor-
tance of early treatment, which should be aimed at the mucoid phenotype
in patients with CF. Such strategy reduce the inﬂammation and thereby
decrease lung tissue damage.
O340 Thioridazine and other helper compounds as enhancers of the
killing activity of macrophages infected with Mycobacterium
tuberculosis: correlation with the curing of infected mice
M. Martins, M. Viveiros, L. Amaral (Lisbon, PT)
Objectives: The emergence of Multi-Drug Resistant and Extensively-
Drug Resistant Mycobacterium tuberculosis (MDRTB/XDRTB) repre-
sents a major threat to public health worldwide, as many of these
resistant strains are untreatable with available drugs. In order to control
these infections, there is the need for new and non-toxic antimicrobial
compounds. Phenothiazines have been shown to have direct and indirect
activities against a large gamut of bacteria and may be considered for the
therapy of these infections. We have demonstrated with previous studies
that Thioridazine (TZ) enhances the killing of MDRTB phagocytosed
by human monocyte-derived macrophages. However, the mechanism by
which this agent enhances the killing of intracellular bacteria is not
fully understood. The killing activity of some phagocytic cells, such
as the neutrophils have been demonstrated to be correlated with the
K+ availability which is dependent upon transport processes affected
by agents that inhibit Ca2+-activated K+ pumps. In order to clarify
the mechanism by which TZ enhances the killing activity of infected
macrophages, we have studied the activity of TZ, twenty-two TZ
derivatives, ouabain, reserpine and verapamil (other known inhibitors
of K+ and Ca2+ transport) against intracellular bacteria.
Methods: Ex vivo studies were conducted using human monocyte-
derived macrophages infected with MDRTB and subsequently treated
with TZ, its derivatives and other inhibitors of K+ and Ca2+ transport.
Animal studies were conducted using BALB/c mice infected with
M. tuberculosis and daily treated with different doses of TZ. The bacterial
load in the lungs was monthly assessed by CFU counting.
Results: Each of these compounds enhanced the killing of intracellular
MDRTB ex vivo and TZ showed a signiﬁcant effect in the mouse curing
of the M. tuberculosis infection.
Conclusion: Because each of these compounds also inhibit Ca2+
and K+ transport processes, enhanced killing is postulated to be due
to the inhibition of Ca2+ and K+ transport, processes which when
inhibited promote the activation of hydrolases and subsequent killing
of intracellular bacteria. A model that provides the sequence of events
that lead to killing of intracellular bacteria by non-killing human
macrophages will be presented in detail and related to the curing of
BALB/c mice infected with M. tuberculosis by administration of TZ
at dose and interval equivalent to that employed for the therapy of
psychosis.
O341 Daptomycin therapy is associated with less demonecrosis
compared with vancomycin therapy in a murine soft tissue
infection model caused by community-associated isolates of
Staphylococcus aureus
B. English, R. Kudumula, A. Rye, A. Talati, E. Meals (Memphis, US)
Objectives: We have previously reported that exposure of clinical
isolates of community-associated isolates of Staphylococcus aureus
(CA-MRSA) to daptomycin (DAP) compared with vancomycin (VAN)
results in a dampened macrophage inﬂammatory response with reduced
production of tumour necrosis factor (TNF) and nitric oxide (NO).
We hypothesised that daptomycin therapy of soft tissue infections
caused by CA-MRSA would be associated with a blunted host
inﬂammatory response and result in less severe soft tissue lesions and
less dermonecrosis.
Methods:We injected groups of 10 Charles River hairless (immunocom-
petent) mice in the right upper thigh muscle with 5×107–1×109 cfu of
three different clinical isolates of CA-MRSA. Two USA300 isolates were
employed: 6U24, a previously-studied clinical isolate from a paediatric
patient in Memphis with osteomyelitis and bacteraemia; and LAC, a
well-characterised California isolate. One USA 400 isolate was used –
the well-characterised Minnesota strain, MW2. After inoculation, we
initiated antibiotic treatment (either DAP or VAN) at either 18 hours or
40 hours after bacterial inoculation. All animals were observed daily and
lesion size and character were recorded.
Results: Mice injected with the higher inoculum (109 cfu) of either
of the two USA300 isolates (6U24 or LAC) – but not the USA400
isolate, MW2 – consistently developed large soft tissue lesions with
dermonecrosis. Lesions in the mice treated with DAP compared with
VAN developed markedly less dermonecrosis and were also somewhat
smaller (approximately 20% reduction in size).
Conclusions: We found that in this mouse model, DAP is more effective
than VAN treatment of severe soft tissue infections caused by USA300
strains of CA-MRSA.
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Resistance and ﬁtness
O342 Evolutionary trajectories among ESBL enzymes belonging
to the CTX-M-1 cluster
A. Novais, I. Comas, R. Canto´n, T.M. Coque, F. Baquero, A. Moya,
J.C. Gala´n (Madrid, Valencia, ES)
Objectives: To deﬁne the different mutational pathways driving the
diversiﬁcation of blaCTX-M-1-like genes, and to establish a hypothetical
evolutionary scenario among CTX-M-1-cluster enzymes.
Methods: All known CTX-M-1-like sequences were aligned using
clustalW. MODELTEST programme was used to establish the best model
of DNA substitution and parameters for phylogenetic reconstruction.
Maximum likelihood trees were estimated with PhymL. The obtained
consensus tree was used to reconstruct the most likely ancestral sequence
by Mesquite software. Changes in positions 77, 114, 140, 167, 240 and
288 were considered as they are frequently found among CTX-M-1-like
enzymes. As distinct phenotypic proﬁles might be observed depending
on the allelic background (epistasis), 30 combinations of mutations
on these positions were constructed by site-directed mutagenesis using
blaCTX-M-3 as template DNA. blaCTX-M mutants were cloned in
pBGS18 plasmid and transformed into E. coli MI1443 (delta-ampC).
Cefotaxime (CTX), ceftazidime (CAZ), and cefepime (FEP) MICs were
determined by E-test.
Results: Phylogenetic reconstruction analysis predicted that CTX-M-
3 might be the ancestor of all CTX-M-1-like enzymes, except of
CTX-M-10, -34, -37 and -53. The branch-site model indicated a
strong positive selection in CTX-M-3 sub-branch, with ﬁve positions
(A77V, N114D, P167S, D240G and D288N) being implicated. Four of
these mutations (A77V, N114D, P167S, and D288N) were required in
successive steps to obtain CTX-M-58, which showed the highest CAZ
MIC (256mg/mL). Distinct evolutionary pathways to obtain CTX-M-58
are possible. Moreover, A140S change (also present in CTX-M-58) was
highly beneﬁcial to the CAZ/CTX resistance phenotype when introduced
in the last step, although its presence in intermediate mutants yielded a
neutral or even deleterious effect (sign epistasis). In evolutionary routes
involving D240G change, lower increases in MIC values than those
observed among P167S route were observed, being the presence of both
changes in the same background selectively inaccessible. This result
would suggest that the ﬁtness landscape in CTX-M-1 cluster is two-
peaked.
Conclusions: All aminoacid changes associated with positive selection
by bioinformatics tools contributed to favourable resistance phenotypes
in speciﬁc contexts. Different evolutionary paths leading to more efﬁcient
enzymes have been identiﬁed, indicating a rugged ﬁtness landscape for
CTX-M-1-like enzymes.
O343 Relative ﬁtness of different plasmids carrying blaCTX-M-15
gene
A. Ripoll, M. Rodrı´guez-Domı´nguez, A. Novais, T. Coque, R. Canto´n,
F. Baquero, J. Gala´n (Madrid, ES)
Objective: The presence of plasmids harbouring resistance genes has
been associated with relative ﬁtness. In this study we analyse, in
competition experiments, if there are different ﬁtness among isogenic
strains harbouring related plasmids carrying the blaCTX-M-15 gene.
Methods: Three related IncFII plasmids carrying blaCTX-M-15 gene
(RFLP patterns denominated A, M and J) identiﬁed in our hospital
were selected. Plasmids belonging to RFLP patterns A and M showed
only one replicon (RepFII) and similar size (85Kb), while the plasmid
with RFLP pattern J showed two replicons (RepFII+RepFIA) and its
size was 100 Kb. Only plasmid belonging to pattern A is epidemic
in our environment (highly related to pC15−1a). The plasmids were
transformed in two Escherichia coli isogenic strains, REL606(ara−)
and REL607(ara+). Competition experiments were performed in Davis
minimal (DM) broth supplemented with glucose during seven days. Each
day 50 mcl from coculture were inoculated into 20mL of fresh DM and
another sample was spread onto MacConkey plates with arabinose to
estimate the relative ﬁtness (W) of each plasmid alone and between
them (in this case 1 mg/L cefotaxime was added to plates). The values
expressed the mean of six independent experiments. The magnitude of
the ﬁtness difference corresponds to how much more slowly one strain
grew relative to the other during the course of the experiments.
Results: Strains harbouring the epidemic plasmid (pattern A) yielded a
growth rate 9% slower than its parental strain (W=0.91±0.09). On the
contrary, strains harbouring the non-epidemic plasmids (pattern M and J)
showed higher cost than epidemic plasmid, growing 16% and 17% slower
than its parental strain (W=0.84±0.08 and W=0.82±0.02) respectively.
However, in competition assay between isogenic strains harbouring
epidemic (pattern A) and non-epidemic plasmid (pattern M), the relative
ﬁtness was next to 1. The competition assay between strains harbouring
plasmids belonging to pattern A and J showed a slight advantage (10%)
for the plasmid carrying two replicons (W=1.09±0.10), although this
advantage was detected after ﬁve days of competition.
Conclusion: The epidemic plasmid show higher ﬁtness, which might
facilitate its dissemination. Although other posibilities can not be
excluded, the presence of plasmids with multireplicons could give even
more advantage in stable environments.
O344 Increased ﬂuoroquinolone resistance co-selected with
improved bacterial ﬁtness
D. Hughes, L. Marcusson (Uppsala, SE)
Objectives: We asked how ﬂuoroquinolone-resistant clinical isolates of
E. coli maintain ﬁtness despite accumulating several mutations affecting
DNA gyrase, topoisomerase IV and drug efﬂux. We investigated the
possibility that different resistance-associated mutations might mutually
compensate ﬁtness costs. We also asked whether bacterial ﬁtness itself
might be a selected parameter driving the evolution of ﬂuoroquinolone
resistance.
Methods: To test this experimentally we constructed a set of 29 isogenic
strains carrying combinations of up to 5 resistance mutations found
commonly in clinical isolates, and measured their associated levels
of resistance and ﬁtness. Fitness was measured in pairwise growth
competition in vitro.
Results: The mean MIC for ciproﬂoxacin increased as a simple function
of the number of resistance mutations in the isogenic strains. As
expected, mean relative ﬁtness decreased as a function of addition of
the ﬁrst three resistance mutations (1; 0.95; 0.89; 0.8). However, the
downward trend was reversed by the addition of 4th and 5th mutations
(0.8; 0.87; 0.9). We identiﬁed 6 strains in which an additional resistance
mutation increased both resistance and ﬁtness. These strains were
deconstructed and reconstructed to conﬁrm the relationship between
the resistance mutations present and the resulting ﬁtness/resistance
phenotype. We also evolved strains for increased ﬁtness in the absence of
drug and observed the selection of variants with decreased susceptibility
to ﬂuoroquinolones.
Conclusions: Bacteria can use different strategies to minimize the ﬁtness
costs of the genetic alterations selected for drug resistance. Two of
these are well documented: the selection of low-cost mutations, and
the selection of additional ﬁtness compensating mutations. Here we
identify a third strategy that reduces the ﬁtness costs of resistance to
ﬂuoroquinolones: particular resistance mutations, when in combination,
increase both resistance level and bacterial ﬁtness. This relationship
between drug-resistance mutations and improved bacterial ﬁtness could
be one force driving the evolution of ﬂuoroquinolone resistance. An
important implication is that strains carrying low level resistance
mutations could evolve by Darwinian selection to higher levels of
resistance, in the absence of direct selection by the drug.
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O345 Fitness cost of linezolid resistance in Enterococcus faecalis
N. Bourgeois-Nicolaos, P. Kharrat, M.J. Butel, F. Doucet-Populaire
(Paris, FR)
Objectives: Resistance to linezolid (LZ) in clinical isolates of
Enterococcus faecalis is associated to the substitution G2576U in domain
V of 23S rRNA. All previously described LZ resistant (R) clinical
isolates of E. faecalis harboured at least 2 mutated copies of the four
23S rRNA genes (rrl). The associated ﬁtness cost of LZ resistance in
E. faecalis was investigated according to the number of mutated copies
of the rrl gene.
Methods: Four LZ-R strains obtained in the digestive tract of gnotobiotic
mice colonised by E. faecalis JH2−2 and treated orally by LZ, were
studied (Bourgeois-Nicolaos et al., J. Inf. Dis., 2007). These LZ-R
strains, 2576−1, 2576−2, 2576−3 and 2576−4 had the mutation G2576U
in 1, 2, 3 and 4 copies of 23s rRNA. Growth rates of LZ-R mutants
were determined in brain-heart infusion broth and compared with
JH2−2 growth. The ﬁtness of these mutants was estimated by pairwise
competition experiments into batch cultures and into chemostats.
Competition index (CI) was calculated as (X −Y)/(X +Y) where X was
the number of resistant colonies and Y was the number of susceptible
colonies. CI values approaching +1 indicated dominance by resistant
strains, whereas CI values approaching −1 indicated dominance by
susceptible strains.
Results: 2576−1 LZ-R mutant was associated with a generation time
(GT) longer (38.9 min) than the one of the parental strain JH2−2 (31.8
min); 2576−2 mutant’s GT (32.4 min) was similar to the GT of JH2−2.
On the contrary, the mutants 2576−3 (29.6 min) and 2576−4 (29.2 min),
were associated with a GT, signiﬁcantly shorter (p< 0.05). In competition
experiments into batch cultures, CIs after 3 days were negative for the 4
mutants. In the chemostats experiments, we have observed after 6 days
a negative CI for the 2576−1 mutant (CI = −0.64) and a positive CI for
2576−2 mutant (CI = 0.06) and 2576−4 mutant (CI = 0.82).
Conclusions: The impact of the acquisition of the mutation G2576U
depends on the number of mutated copies of the 23S rRNA and on, the
environment in which the cost of the resistance is testing. The presence
of the mutation G2576U in 4 copies seems to confer an advantage for
E. faecalis. On the contrary, the presence of only one mutated copy leads
to a disadvantage for growth and ﬁtness, which could explain the scarcity
of this type of mutant in the clinical isolates selected under treatment.
O346 A quantitative-PCR based method to estimate the ﬁtness
cost of antibiotic resistance in competition experiments
M. Rodriguez-Dominguez, A. Ripoll, M.C. Turrientes, J.C. Galan,
F. Baquero (Madrid, ES)
Objective: To describe a robust molecular protocol based on real-
time PCR method able to discriminate strains in pairwise competition
experiments, in order to estimate easily the relative ﬁtness.
Methods: Two E. coli isogenic strains, REL606 and REL607, which
differ in only one base pair (SNP) were used. This SNP, located in the
arabinose operon, allowed us to discriminate between those strains by
phenotypic (capacity to use arabinose as energy source) and genotypic
methods (RT-PCR). Two forward primers (differing only in the SNP)
and only one reverse primer were design to amplify speciﬁcally each
one of the strains. The ampliﬁed product was detected with Sybr-green
as detector dye. A calibration curve was made in each experiment
using chromosomal DNA of known concentration. To validate the
method, we quantiﬁed the relative ﬁtness (W) in standard competition
experiments between REL606 and REL607 wild-type strains. Moreover,
two rifampicin-resistant spontaneous mutants, carrying the mutations
S531F and L533P in RpoB obtained from REL606 and REL607
respectively, were coculture with their parental strains and between them
during three days, plating each day and taking an aliquot for DNA
extraction. Six replicates of each competition experiment were performed
and W was calculated for both methods. The magnitude of the ﬁtness
difference corresponds to how much more slowly one strain grew relative
to the other.
Results: The competition assay between REL606 (ara−) and
REL607(ara+) wild-type strains did not yielded difference in ﬁtness
(W=1.03±0.01 by plates and 1.03±0.05 by RT-PCR). REL606 rif-
R(S531F) strain grew 25% and 33% slower than REL607 by plates
and RT-PCR respectively (W=0.75±0.13 vs 0.67±0.06). On the other
hand REL607 strain grew 71% (plates) or 74% (RT-PCR) slower
than REL606 (W=0.29±0.04 vs 0.26±0.02). Finally, the competition
experiments between REL607 rif-R(L533P) and REL606 rif-R(S531F)
showed 83% (W=0.17±0.08) and 69% (W=0.31±0.05) by plates and
RT-PCR respectively.
Concluison: Similar values of W were found using the classical method
or the new protocol based in RT-PCR. We proposed the use of RT-
PCR technology to estimate the ﬁtness cost, because presents several
advantages respect to the traditional one: i) the huge manipulation of
lots of plates is completely reduced, ii) it is possible to carry out more
than one experiment at the same time and iii) it is possible to speciﬁcally
detect a strain inside an heterogeneous population.
Resistance from the middle of nowhere
S349 Erythromycin resistance plasmids isolated from the bacterial
community of a municipal wastewater treatment plant encode
an interesting spectrum of macrolide resistance determinants
A. Schlu¨ter, R. Szczepanowski, A. Goesmann, L. Krause, A. Pu¨hler
(Bielefeld, DE)
Wastewater treatment plants (WWTP) are a reservoir for bacteria
harbouring antibiotic resistance plasmids. Genomics of resistance
plasmids isolated from WWTP bacteria revealed a high diversity of
plasmid replicons and accessory genetic modules carrying resistance
genes. Five of the completely sequenced plasmids confer resistance to
macrolides and other antimicrobial compounds. Two of these plasmids,
namely pB4 and pRSB111, belong to the IncP-1 incompatibility
group combining very promiscuous, self-transmissible broad-host-range
plasmids. The pB4 tripartite multidrug efﬂux system consisting of
a permease of the resistance-nodulation-division (RND) family, a
periplasmic membrane fusion protein (MFP) and an outer membrane
factor (OMF) confers resistance to erythromycin and roxithromycin.
Plasmid pRSB111 encodes a macrolide phosphotransferase and a
transmembrane transport protein that are both required for high-level
macrolide resistance. Different variants of these enzymes are also
encoded on the mobilisable multidrug resistance plasmid pRSB101
and the IncF-like plasmid pRSB107 which also contains virulence-
associated modules. Finally, the IncP-6 erythromycin resistance plasmid
pRSB105 harbours the resistance genes mel and mph, encoding,
respectively, a predicted ABC-type efﬂux permease and a macrolide-
2’-phosphotransferase. Many more macrolide resistance genes could
be detected in plasmid-DNA preparations from WWTP bacteria
by hybridisation experiments using a resistance gene microarray
representing 192 different resistance genes. Among these are different ere
genes encoding erythromycin esterases, erm genes for rRNA adenin N-
6-methyltransferases and mef genes specifying macrolide efﬂux proteins.
To get a more complete picture of the plasmid metagenome of WWTP
bacteria an ultrafast sequencing approach applying the 454-technology
was carried out. Bioinformatic analysis of the obtained sequence data
set also conﬁrmed that WWTP bacteria are a reservoir for different
macrolide resistance determinants.
Reference(s)
Schlu¨ter, A., Szczepanowski, R., Pu¨hler, A. & Top, E.M. (2007).
Genomics of IncP-1 antibiotic resistance plasmids isolated from
wastewater treatment plants provides evidence for a widely accessible
drug resistance gene pool. FEMS Microbiol Rev 31, 449–477.
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S350 Beta-lactamase genes from environmental bacteria
L. Poirel (Le Kremlin Bicetre, FR)
b-Lactamase genes are of concern in clinical isolates since they hydrolyse
b-lactams, the most commonly used antibiotics in human medicine.
Four molecular classes of b-lactamases do exist, and they possess
variable hydrolysis spectra, including penicillinases, expanded-spectrum
b-lactamases, and carbapenemases. Some clinically-relevant species
produce naturally b-lactamases (i.e. SHV in Klebsiella pneumoniae),
but most natural producers are non pathogens. Some of these natural
producers have been demonstrated to be the source of b-lactamase
genes known to have spread in other species and thus at the
origin of acquired resistance to b-lactams. Kluyvera spp. are good
examples since those environmental species possess naturally on
their chromosome those CTX-M-like encoding genes now emerging
worldwide in Enterobacteriaceae. Another example is Acinetobacter
radioresistens being the progenitor of the carbapenemase OXA-23-
encoding gene known to be at the origin of carbapenem resistance in
Acinetobacter baumannii worldwide.
Also possible is to observe some environmental species as intermediate
reservoirs in dissemination of plasmid-mediated b-lactamase genes from
their progenitor to the clinically-relevant species. The identiﬁcation of
the IMI-2 carbapenemase encoding gene on plasmids in Enterobacter
asburiae strains from different US rivers is a good example of such
threat. The identiﬁcation of some plamids harboring b-lactamase genes
from waste-water treatment plants, sewages or sludges is also of concern.
The role of genetic structures like insertion sequences, transposons,
and integrons in the mobilisation of those b-lactamase genes from
environmental bacteria to clinical ones seems crucial, as well as that
of plasmids and phages in their diffusion.
Studies are needed to better evaluate the epidemiology of b-lactamase
genes in the environment, and of course to evaluate the factors favouris-
ing their dissemination (antibiotic selection pressure, temperature, ?. . . ).
Surveillance of healthcare-related infections
S355 Is it time for pan-European surveillance of healthcare-related
infections?
P. Gastmeier (Berlin, DE)
International comparisons yield interesting insights regarding quality of
care, beyond the ﬁeld of healthcare associated infection (HAI) preven-
tion. Therefore, the exchange of experiences of national surveillance
systems should be encouraged. However, the interpretation of differences
of HAI rates should be made very carefully. Differences in healthcare
systems, legal and cultural aspects, as well as differences in the methods
of the surveillance systems, may have an enormous inﬂuence. A further
most crucial aspect of surveillance data is their validity, and its evaluation
is very difﬁcult.
The European Centre for disease prevention and control has to decide
in the future which level of European surveillance of HAI should be
achieved. Of course there are several options:
1. The harmonisation process of the individual national surveillance
networks should be continued to ﬁnally achieve a uniform European
HAI surveillance system. This process already started with HELICS
(Hospitals in Europe Link for Infection Control through Surveillance;
since 1994) and was continued with IPSE activities (Improving
patient safety in Europe, since 2005) for surveillance of surgical site
infections and HAI surveillance in Intensive care units.
2. The harmonisation process should be stopped because it is not really
feasible to create a useful European database, and the efforts should
be concentrated on a regular exchange of experience between the
national networks, on the organisation of validation studies, joint risk
factor studies etc.
3. ECDC should create a pan-European surveillance for infections with
minor problems in identiﬁcation and application of the deﬁnitions,
e.g. nosocomial CDAD/1000 patient days or nosocomial laboratory
conﬁrmed BSI per 1000 patient days (adjusted according to the
frequency of diagnostics).
4. ECDC should start pan-European surveillance with a totally new
European surveillance system with interesting patient groups at risk
and without existing systems for these patient groups in most of
the countries in order not to create problems due to the need for
modiﬁcation of the existing systems (e.g. bone marrow transplant
patients, very low birth weight newborn etc.).
The talk will discuss advantages and disadvantages of the different
strategies in order to stimulate further discussion.
Emerging viral and bacterial diseases
O359 Phylogenetic analysis of autochthonous and imported Italian
Chikungunya virus strains
L. Bordi, C. Castilletti, R. Chiappini, G. Ippolito, M.R. Capobianchi,
A. Di Caro, V. Sambri, F. Cavrini, F. Carletti (Rome, Bologna, IT)
Objective: A large outbreak of Chikungunya virus (CHIKV), a
mosquito-borne viral disease, has begun in the Comoro islands in 2005.
In few months many other countries of the Indian Ocean have experi-
enced a dramatic increase of cases. During the last years many imported
cases in returning travellers have been detected and autochthonous cases
have been recently described in Italy (Emilia Romagna), where a suitable
the vector is present. Molecular characterisation of 8 Chikungunya virus
isolates, 6 imported to Italy from Mauritius and from India in 2006 and
2007, 2 coming from the 2007 Italian outbreak is reported.
Methods: CHIKV sequences, targeting partial nsP1 and E1 genes,
were ampliﬁed directly from serum samples from 8 and 7 patients,
respectively; almost whole E1 gene sequences were obtained from virus
isolates on C6/36 cells from 6 patients. RT PCR, targeting both nsP1
and E1 regions, was performed by slight modiﬁcation of a previously
published method
Results: Phylogenetic analysis of E1 and nsP1 showed that all strains
belong to Indian Ocean cluster within the East/Central/South Africa
genotype, grouping with the Indian Ocean Islands and Indian subclusters,
according to geograﬁc provenance. All the strains carried in E1 the
M269V and D284E signatures of the Indian Ocean outbreak, while the
A226V mutation was present in all isolates imported from Mauritius, in
those imported from India in 2007 and in those from the Italian outbreak,
while it was absent in the isolates imported from India in 2006
Conclusions: Our ﬁndings indicate that, during 2006 and 2007, multiple
strains have been imported to Italy from countries where explosive
Chikungunya outbreaks were ongoing. The presence of A226V mutation
in the isolate imported from India in July 2007 and in the isolates
from the 2007 Italian outbreak, originating from a case imported from
India, may suggest that the virus envelope sequence of Indian strains is
changing towards the spread of this mutation, with possible impact on
virus spread in the vector as well as in humans.
O360 Epidemiology of Puumula virus infections in Denmark,
1996–2007
S. Skarphedinsson, H. Thiesson, S. Simonsen, L. Teglbjaerg (Odense,
Svendborg, DK)
Nephropathia epidemica (NE) caused by Puumula virus has been
recognised in Denmark as a clinical entity since 1958. It has remained
highly focal in distribution with clinical cases limited to the island of
Funen.
Previous studies on Puumla virus (PUUV) strains isolated from Danish
bank voles (Clethrionomys glareolus), the major reservoir, have revealed
that Danish PUUV strains form a distinct genetic linage with no
particularly close relatedness to the other PUUV lineages in Europe.
Objectives: The aim of this study was to further characterise the
epidemiology of Puumula virus infections in Denmark and describe the
clinical manifestations in Danish Puumula virus patients.
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Methods: Retrospective case description study among patients with
serologically conﬁrmed PUUV infections and a seroprevalence study
in a high-risk population of 140 orienteers living and training on the
island of Funen. The study period was 1996–2007.
Results: Serologically veriﬁed PUUV infection was found in 128
patients. Mean age 40 years (9−70y), with a male/female ratio 2.4/1.
Dominant initial symptoms were acute onset of fever, abdominal and
lower-back pain, while blurred vision was rare. 7% of patients required
dialysis.
NE cases were found distributed throughout the whole year but with
the highest number of cases in November–February. Marked regional
difference within Funen was found with most cases occurring in rural
parts of southern and South-eastern Funnel. Cyclic variation in the
annual number of NE cases was seen with a periodicity of 3 years.
Among orienteers 7% were seropositive, but none had a history of NE.
Conclusions: Our ﬁndings indicate that the clinical manifestations of
PUUV infections in Denmark are similar to what has been described
from Fennoscandinavia. A signiﬁcant number of infections may be
asymptomatic. The distribution of NE remains mainly focal and limited
to a part of Funen. Further studies to clarify the ecological factors
responsible for PUUV distribution are needed to enable better risk
evaluation.
O361 International Circumpolar Surveillance of invasive bacterial
diseases, 2000–2006
T. Zulz, M.G. Bruce, D. Parks, T. Tam, F. Stenz, A. Nystedt, O. Lovell,
A.J. Parkinson (Anchorage, US; Ottawa, CA; Nuuk, GL; Lulea, SE;
Oslo, NO)
Background: The International Circumpolar Surveillance (ICS) system
conducts population-based surveillance of invasive bacterial diseases in
Greenland (GN), Northern Canada (N Can), Northern Sweden (N Swe),
Norway (Nor) and in the U.S. Arctic (Alaska [AK]).
Methods: Isolates from patients with invasive diseases caused by
Haemophilus inﬂuenzae (Hi), Neisseria meningitidis (Nm), Group A
Streptococcus (GAS), and Group B Streptococcus (GBS) were forwarded
to reference laboratories in AK (2000–2006), N Can (2000–2006), GN
(2001–2006), Nor (2005–2006) and N Swe (2003–2005) for conﬁrmation
and serotyping. Norway did not provide data for GAS and GBS.
Clinical and demographic information were collected using standardised
surveillance forms.
Table 1: Rates* of Invasive Disease, ICS Data, 2000–2006
Country Hi Nm GAS GBS
AK 2.1 0.8 4.7 3.6
GN 0 2.6 0.6 1.2
N Can 8.4 1.1 6.9 2.1
N Swe 0.7 0.1 1.3 3.7
Nor 1.6 0.8 N/A N/A
*Annualised crude rate per 100,000.
Results: The total numbers of reported cases were 249 Hi, 128 Nm,
289 GAS, and 215 GBS. Crude annualised rates of invasive disease
per 100,000 population varied by country and organism (Table 1).
AK Native and N Can Aboriginal people had higher rates of disease
[(AK Native: Hi=5.7/100,000, GAS=11.5/100,000), (N Can Aboriginal:
Hi=11.5/100,000, GAS=10.2/100,000)] than non-Aboriginals [(AK non-
Native: Hi=1.2/100,000, GAS=3/100,000), (N Can non-Aboriginals:
Hi=1.1/100,000, GAS=1.1/100,000)]. Of the 221 Hi cases that were
serotyped, 37 (17%) were Hib [AK 22 cases (rate 0.5), N Can 13 cases
(rate 1.4), Nor 2 cases (rate 0.04] and age ranged from <1 to 69 years;
Hib disease occurred in persons <2 years of age in AK (41%) and N Can
(77%). Fifty-one (23%) Hi cases were serotype a (Hia) [AK 13 cases
(rate 0.29), N Can 38 cases (rate 4.15)]. Non-typeable Hi comprised
37% of serotyped cases in AK, 26% in N Can and 63% in Nor. Age
distribution of Hi cases differed between countries; 49% of AK cases
and 89% of Nor cases were >40 years compared with 13% in N Can
(p< 0.001, p< 0.000).
Conclusion: Aboriginal peoples of AK and N Can have higher rates of
invasive bacterial disease caused by Hi and GAS than non-aboriginals.
Overall rates of Nm disease are higher in GN than AK, N Can, N Swe
and Nor. Cases of invasive Hib disease continue to occur in children <2
years of age in the North American Arctic. Hi cases are more likely to
occur in older persons in AK and Nor and young children in N Can; age
distribution differences warrant further study.
O362 Shiga toxin-producing Escherichia coli carrying stx2f as an
emerging cause of diarrhoea in the Netherlands
T. Schuurman, A. Roovers, W.K. van der Zwaluw, A.A. van Zwet,
L.J.M. Sabbe, A.M.D. Kooistra-Smid, Y.T.H.P. van Duynhoven
(Groningen, Goes, Bilthoven, Arnhem, NL)
Objectives: Shiga toxin-producing Escherichia coli (STEC) that carry
the stx2f gene are considered to be host-adapted to pigeons, and therefore
of limited clinical relevance to humans. In fact, to date only 6 cases
have been documented in the recent literature (1990–2007), and with
the exception of a single case, all have been linked with uncomplicated
diarrhoea. Due to this low incidence, routine diagnostic procedures have
not been adapted to detect this variant. In this study we investigated the
possible role of stx2f-carrying STEC in the aetiology of diarrhoea.
Methods: A total of 2155 stool specimens, for which routine
screening for gastrointestinal pathogens was requested, were analysed
between September 2006 and March 2007. DNA was extracted from
the specimens using the NucliSENS easyMAG speciﬁc A protocol.
STEC were detected by internally controlled multiplex real-time PCR
(Schuurman et al J Microb Meth 2007:406–415) adapted for detection
of the stx1c, stx1d, and stx2f genes. Positive specimens were partially
subtyped using the monoplex real-time PCRs to identify stx1, stx1c,
stx1d, stx2f, and the group containing stx2, stx2c, stx2d, stx2e, and
stx2g (stx2cdeg). Isolation of STEC strains was performed from stx2f
positive specimens by culture on sorbitol MacConkey agar and colony
screening by PCR.
Results: A total of 37 specimens showed STEC speciﬁc ampliﬁcation
signals. Subtyping was successful in 35 of 37 specimens, and revealed
stx2f (n = 4) as the third most prevalent genotype after stx2cdeg (n = 13)
and stx1 (n = 6). Other genotypes detected included stx1 + stx1c (n = 2),
stx1c (n = 2), stx1 + stx2cdeg (n = 1), and stx1/stx1c + stx2cdeg (n = 1).
Patients positive for stx2f had uncomplicated diarrhoea (n = 2) and
bloody diarrhoea (BD) (n = 2), although the BD could also be explained
by co-infection/morbidity these patients. Isolation of an STEC strain
was successful in 2/4 stx2f-positive specimens, and yielded an O63:H6
serotype, eae gene (intimin) positive in both cases. Both strains were
also shown to be highly related based on pulsed ﬁeld gel electrophoresis,
although no epidemiological link was apparent between both patients.
Conclusions: STEC that carry the stx2f gene were the third most
prevalent stx-genotype in The Netherlands during the study. Our results
suggest that stx2f-carrying STEC may be an overlooked cause of
diarrhoea. Diagnostic screening strategies need to be adapted to detect
this variant in the routine diagnostic laboratory.
O363 First description of Enterococcus faecalis small colony
variant in a patient with aortic valve endocarditis
N. Wellinghausen, A. Sigge (Ulm, DE)
Objective: Small colony variants (SCV) constitute a slow-growing
subpopulation of bacteria with distinctive phenotypic and pathogenic
traits. To our knowledge, SCV are not yet described in enterococci.
We discovered SCV of Enterococcus faecalis in blood cultures of a
patient with aortic valve endocarditis and characterised the structural
particularities of the phenotype.
Case report and results: A 74-year old female patient who underwent
aortic valve replacement with a bovine bioprothesis three years ago
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presented to the emergency department with persistent fatigue. By
transoesophageal echocardiography vegetations on the aortic valve were
documented. In two out of two blood cultures E. faecalis susceptible
to ampicillin and imipenem, and intermediate susceptible to rifampicin
was grown. In addition to typical E. faecalis colonies, a SCV phenotype
consisting of small pin-point colonies was detected in both blood
cultures. Typing by pulsed-ﬁeld gel electrophoresis revealed clonal
identity of both phenotypes. Antimicrobial susceptibility as tested on
blood-containing Mueller-Hinton agar was comparable. In order to
characterise the SCV further we performed light, scanning electron
microscopy (SEM), and transmission EM (TEM) of both phenotypes.
In the Gram-stain, the SCV showed Gram-positive, inhomogenous
cocci with irregular size while the isogenic normal phenotype appeared
homogenously. By SEM, SCV varied in size between one-fourth and up
to eight times the size of the normal phenotype. Irregular and multiple
divisions were observed in SCV. In addition, debris covered SCV isolates
and an intercellular substance was more abundant in SCV than in the
normal phenotype. By TEM, multiple and irregular cross walls, large
swollen-appearing cells as well as empty cells were observed in the
SCV (Fig. 1). Growth curves of both phenotypes revealed marked slower
growth of the SCV. The patient was treated with imipenem and rifampicin
for six weeks and suffered from a relapse of the endocarditis three weeks
later, requiring replacement of the prosthetic aortic valve. After another
six weeks of antimicrobial therapy with ampicillin and gentamicin the
patient recovered.
Conclusion: Enterococcus faecalis is able to form a SCV phenotype with
impaired growth characteristics and distinctive ultrastructural alterations
observed by light microscopy and EM. Further studies are underway to
investigate alterations in cellular metabolism in enterococcal SCV.
Technological innovation of bacterial typing
O364 Development of a molecular typing scheme by mass
spectrometry
C. Honisch, M. Mosko, C. Arnold, S. Gharbia (San Diego, US;
London, UK)
Objectives: Comparative sequence analysis in large collections of
microbial isolates utilising marker regions provides the framework in
molecular typing and a combination of PCR, electronically accessible
databases, standardised protocols and automated, high-throughput
technologies make the analysis of these regions easily achievable.
We have recently developed a comparative sequence analysis tool based
on mass spectrometry, which serves these needs. The technology has
successfully been applied to 16S based typing (1) and multi-locus
sequence typing (2). Here, we present the workﬂow, data analysis and
statistical measures of the technology for the development of a novel
molecular typing scheme for Neisseria gonorrhoeae.
Methods: Marker regions are ampliﬁed by PCR with a tagged
primer system, which facilitates in vitro transcription of both DNA
strands. Subsequent base-speciﬁc endonuclease digests of the two RNA
transcripts at the bases cytosine and uracil result in four mixtures of RNA
cleavage products. The high precision measurement obtained by a mass
spectrometer is used to resolve the mixtures. Nucleic acid sequences
are identiﬁed by correlating the acquired spectra with theoretical peak
patterns predicted for in silico cleavages of each sequence contained
in a reference sequence database. Microheterogeneities between the
best reference and the sample sequence are identiﬁed and deliver new
reference sequences.
Results: 32 marker regions of potential importance for the development
of a molecular typing scheme for N. gonorrhoeae and a set of
267 phenotypically characterised samples were subject to comparative
sequence analysis by mass spectrometry. 94% of the marker regions
were converted into PCR assays and 83% of all samples resulted in
high quality data throughout the set of 30 markers. Data analysis was a
result of UPGMA peak pattern clustering for sample grouping, statistical
analysis and sequence analysis by a time-efﬁcient SNP Discovery
algorithm. Dideoxy sequencing was used to resolve samples of high
variance and showed concordance with the mass spectrometry data.
Conclusion: The introduced mass spectrometry based comparative
sequence analysis tool provides a rapid alternative to dideoxy sequencing
for microbial identiﬁcation and the development of molecular typing
schemes.
Reference(s)
[1] Lefmann, M. et al. (2004). J Clin Microbiol 42(1): 339−46.
[2] Honisch, C. et al. (2007). PNAS 104(25): 10649−54.
O365 High resolution melting curve analysis and strain-speciﬁc
SNPs: a new method for differentiation of the Ames strain
from other Bacillus anthracis strains
W. Ruppitsch, J. Calaway, M. Van Ert, T. Hadﬁeld, A. Sto¨ger, K. Grif,
A. Pietzka, F. Allerberger (Vienna, AT; Palm Bay, US; Innsbruck, AT)
Objectives: The aim of this study was to assess the usefulness of high-
resolution melting (HRM) curve analysis on the LightCycler 480 PCR
system as a tool for the correct identiﬁcation of Bacillus anthracis and
to assess its utility as a method to recognise the Ames strain, the strain
used in the 2001 anthrax attacks in the USA.
Methods: DNA from nine bacterial isolates [eight B. anthracis and one
B. cereus DSM 4312], including one strain originating from an American
diplomatic postal bag in December 2001 in Vienna [1], was isolated
using the Qiagen Blood & Body Fluid Spin Protocol as described by
the manufacturer. All B. anthracis isolates were subtyped by VNTR
analysis as described previously using a 25 VNTR system [2]. For HRM
curve analysis six speciﬁc primer combinations were chosen and tested
for the identiﬁcation of the Ames strain by speciﬁc single nucleotide
polymorphisms [3] using the LightCycler 480 High Resolution Melting
Master as described by the manufacturer. The obtained data were
analysed with the HRM gene scanning software (Roche).
Results: VNTR analysis conﬁrmed the 2001 ‘postal bag’ isolate as a
B. anthracis Ames strain and the other B. anthracis isolates as ‘non-
Ames’ genotypes. HRM curve analysis allowed 1) the differentiation of
B. cereus DSM 4312 from the B. anthracis isolates and 2) the rapid
and accurate discrimination of the B. anthracis Ames strain from the
other seven B. anthracis isolates. Of interest, the VNTR data from three
B. anthracis isolates from Tyrol, Austria were shown to be European B2
strains and extremely similar to French and Italian B2 genotypes. Two
B. anthracis isolates from the country of Georgia were also subtyped; one
was identical to the vaccine strain 34F2 Sterne, and the other (411-G)
was an A3a isolate.
Conclusion: We were able to show that HRM curve analysis is a
fast, simple and cost effective screening method for identiﬁcation of
B. anthracis strains. HRM curve analysis, coupled with strain-speciﬁc
SNP signatures, allows differentiation of the Ames strain from other
B. anthracis strains using a single PCR. As the source of the intentional
release of B. anthracis spores in 2001 has never been elucidated, the
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ability to identify or exclude the presence of the Ames strain in clinical
and environmental samples is of great importance.
Reference(s)
[1] Allerberger F, et al. (2002) Lancet 359: 710
[2] Lista F, et al. (2006) BMC Microbiol. 6: 33
[3] Van Ert MN, et al. (2007) J. Clin Microbiol. 45: 47−53
O366 Bacterial multistrain genomotyping arrays: optimal choice
of control in two-colour experiments
F. Pinto, S. Aguiar, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objectives: Comparative genomic hybridisation (aCGH) studies use
microarrays to evaluate the distribution of genes of sequenced bacterial
strains among unsequenced strains. The use of this technology to study
different strains of the same species has led to important insights into the
identiﬁcation of the species “core-genome” as well as the distribution
of the genes in the “accessory genome” in the population. As genomic
sequences from multiple strains of the same species become available,
multistrain microarrays are designed, containing spots for every unique
gene in the sequenced strains. In two-colour aCGH experiments with
multistrain microarrays, the choice of control sample can be the genomic
DNA of one strain or a mix of the genomic DNA of all the strains used
in the array design. This important problem has no universally accepted
solution. The aim of this study was to evaluate the relative performance
of each of the two types of control in two-colour aCGH experiments.
Methods: We performed a comparative study of the two control sample
options with a microarray designed with three fully sequenced strains.
We hybridised two of these strains as test samples using only the third
strain as a control or a mix of the three strains as the control sample. The
strain used in the single control was the one with more speciﬁc spots in
the array. Resulting Log-ratios of test over control sample signal were
used to classify genes as present or absent. We evaluated classiﬁcation
performance through the area under a receiver operating characteristic
curve (AUC), accuracy, sensitivity and speciﬁcity. AUC measures the
probability that the Log-ratio of a present gene is higher than that of an
absent gene.
Results: We show that for both types of control sample it is beneﬁcial
to analyse spots in separate classes according to their expected control
channel signal (0.05−0.15 AUC increase). The use of a mix control
leads to higher accuracies (0.05 increase). This best performance is due
to gains in sensitivity (0.21 increase, p = 0.001) that compensate minor
losses in speciﬁcity (0.05 decrease, p = 0.014). Moreover, the use of a
single strain control increases the error rate in genes that are not present
in all reference strains, the set of genes where more variation across
unsequenced strains is expected.
Conclusion: The use of a mix control in multistrain microarrays leads
to better performances than using a single strain control.
O367 Rapid extended-spectrum b-lactamases detection using DNA
chips
D. Leinberger, V. Grimm, M. Rubtsova, A. Henn, A. Egorov,
K. Schroeppel, T. Wichelhaus, C. Knabbe, R. Schmid, T. Bachmann
(Edinburgh, UK; Stuttgart, DE; Moscow, RU; Frankfurt, DE)
Objectives: Conventional culture based bacterial identiﬁcation and
antimicrobial susceptibility testing methods are too slow to enable
prospective therapy and provide limited information depth and there
is a high demand for improved alternatives. Molecular methods such
as DNA chips open the way for rapid testing and prospective therapy.
A continuously emerging problem of microbial resistance is related to
Extended Spectrum Beta-Lactamases (ESBL). The majority of clinically
relevant ESBL variants derive from the genes blaTEM-1 or blaSHV-1 by
mutations that alter the amino acid conﬁguration and increasingly from
the acquisition and mutation of genes from the CTX-M gene family. In
the past decade further enzymes like the OXA lactamases and plasmid-
mediated AmpC lactamases have emerged in the clinics as a new severe
problem as they are likely to hydrolyse modern cephalosporins. The
presentation will demonstrate developments made under the German
PathoGenoMik programme on the example of the ESBL chips as well
as future routes for rapid microbial diagnostics in the clinic with special
focus on novel technologies for faster assay times and microﬂuidic
integration.
Methods: Here we describe the development and application of
ﬂuorescence based diagnostic oligonucleotide microarrays for the
genotyping of TEM, SHV, and CTX-M b-lactamase variants based on
allele speciﬁc hybridisation. To increase the coverage, we developed
chip modules to genotype plasmid-mediated AmpC and OXA-type beta
lactamases. To enable a single all-in-one b-lactam resistance test for the
clinic, we fully integrated individual chip modules (TEM, SHV, CTX-M)
to a single ESBL chip platform.
Results: The ESBL chip was validated using 60 clinical samples taken
over one year in the clinical routine of different Gram-negative organisms
(phenotypically characterised as ESBL). The detected variants included
TEM-1, SHV-1, SHV-5, SHV-12, CTX-M3, CTX-M9, CTX-M14 and
CTX-M15. Analytically difﬁcult samples were correctly identiﬁed such
as mixed resistances of various genotypes. All ESBL phenotypes could
be ascribed to the presence of a CTX-M variant (78%) or SHV variant
(22%), whereas no ESBL TEM variant was found. As the total assay
could be performed in 4h.
Conclusion: The ESBL chip presents a promising example in our
development of a panel of diagnostic microbial chips. They can now be
further integrated with the whole analytical chain to provide clinically
meaningful and cost effective tools.
O368 Terminal restriction fragment length polymorphism as a
diagnostic tool in gastrointestinal disease: a preliminary study
D. Soeltan-Kaersenhout, H. Panneman, H. Akol, S. Gierveld,
A. Catsburg, A. van Bodegraven, P.H.M. Savelkoul (Amsterdam,
Wageningen, NL)
Objective: Terminal restriction fragment length polymorphism (T-RFLP)
has been utilised as a typing method to examine microbial community
structure in human faecal samples. Adherence of microbes to the
gastrointestinal mucosa rather than luminal presence however is a
prerequisite for development of intestinal disease.
To this date, the T-RFLP method has not yet been evaluated for the
possibility to obtain a rapid, broad view of the (adherent) microbial
composition of the human intestine and its dynamics in diseased states.
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This evaluation might result in a screening tool for abnormalities in
the adherent gastro-intestinal microﬂora by way of analysing changes in
terminal restriction fragment (TR-F) proﬁles. This study was done to
obtain evidence on the performance of the T-RFLP method.
Method: The technique involves ampliﬁcation of the 16S rRNA gene
with two differently labeled primers, digesting the amplicon with
restriction endonucleases, and retrieving the molecular weight of the
labeled terminal restriction fragments (the outer ends of the amplicon)
in an automated DNA sequence apparatus. The labeling of both the
forward and reverse primers might lead to a more accurate identiﬁcation
of species within a community proﬁle since the presence of two peaks
instead of one conﬁrm the presence of a certain species.
Firstly, cultures of three common intestinal habitants of the human gut
were subjected to T-RFLP analyses, alone and in mixtures, to determine
if competition in the PCR between species has an effect on the T-RFLP
proﬁles.
Secondly, mucosal biopsies from ﬁve colon locations per patient
were gathered from 20 patients for analysis by T-RFLP. The three
aforementioned species were quantiﬁed in the samples by quantative real-
time PCR to determine if adequate amounts were present for detection
by T-RFLP.
Results: It was shown that the T-RFLP method produces consistent,
reproducible proﬁles. The patient samples showed little to no intrapatient
varation in T-RFLP proﬁle compared to interpatient variation.
Conclusion: For reasons of simplicity, similarity between T-RF sizes of
different genera should be omitted or reduced to a minimum by way of
careful restriction enzym selection. Furthermore, a database containing
DNA sequences of the adherent human intestinal microbial community,
combined with adequate computer software capable of performing meta-
analyses of forward and reverse peak presence, is essential for obtaining
rapid T-RFLP proﬁle results.
In vitro susceptibility and mechanisms of
resistance of antifungals
O369 Emergence of azole cross-resistance in Candida glabrata
following exposure to azole antifungals in a surgical intensive
care unit
F. Grenouillet, L. Millon, X. Fournel, G. Blasco, S. Roussel,
S. Pili-Floury, E. Samain, R. Piarroux (Besancon, FR)
Objectives: Fluconazole (FLC) is widely used for prophylactic,
preemptive and curative treatments of invasive candidiasis in surgical
intensive care unit (SICU) patients. Acquired resistance to azoles in
Candida glabrata (Cg) strains after exposure were not rare but data on
its incidence were lacking.
The aim of this study was to assess the incidence of acquired FLC
resistance and azole cross-resistance in Cg following azoles exposure in
SICU.
Methods: Three-year prospective survey (02/2003–01/2006) with
systematic mycological screening performed on all patients admitted
to the SICU, immediately at admittance, then weekly until discharge.
Patients with more than 2 weeks of Cg colonisation were retrospectively
included in this study. For each patient, each isolate was genotyped
using microsatellite-based MLVA method. Susceptibilities of Cg isolates
to azoles were determined with NCCLS reference method (ﬁrst and
last isolate per strain per patient, susceptibilities to FLC, itraconazole,
voriconazole VRC and posaconazole). Patient data (including azoles
exposure during SICU stay) were retrospectively collected. Acquired
FLC resistance was deﬁned by MIC of the last isolate for FLC> 8mg/mL
and a 4x-fold increase of this MIC during SICU stay.
Results: Thirty nine patients out of 1218 admitted in SICU were
included. Characteristics of patients included were: mean age 65 years
(±15), median SICU stay 30 days [range: 18–160], mean SAPS II
score 44 (±14). Main underlying disorders were abdominal surgery and
polytrauma.
All patients harbored only one Cg strain, except one patient colonised
with two different strains. Acquired azole resistance was not observed
in six patients without azole exposure. Thirty three patients were given
azole antifungals during SICU stay, all with high daily dose (DD) of
FLC or VRC (mean DD: 470 mg/day). Nine out of 33 (27%) presented
SICU-acquired resistance of their own Cg strain. Cg strains with FLC
acquired resistance all showed cross-resistance to other azoles.
No signiﬁcant risk factor of acquisition was identiﬁed among patient
data, characteristics of azole regimens used (duration, total dose) and
Cg genotypes.
Conclusion: Acquisition of cross-azole resistance following azoles
exposure occurs frequently in SICU patients. Antifungal agents others
than azoles (i.e. candins, polyenes) should be considered as initial therapy
in SICU patients with suspected invasive candidiasis in the setting of
prior azole exposure.
O370 Investigation of mutations in ERG11 gene of ﬂuconazole-
resistant Candida albicans isolates from Turkish hospitals
L. Manastir, C. Ergon, M. Yucesoy (Izmir, TR)
Background: Life-threatening Candida infections have become an
important clinical problem. Fluconazole is one of the azoles widely used
for both prophylaxis and therapy of Candida infections. This widespread
and repeated use of ﬂuconazole has resulted in resistance in Candida
isolates.
Objectives: The aim of our study was to investigate Y132H and other
mutations in the ERG11 gene and to determine the possible contribution
of efﬂux pumps in conferring ﬂuconazole resistance to C. albicans
isolates.
Methods: Seven ﬂuconazole-resistant / susceptible dose-dependent
(R/SDD) and ten ﬂuconazole-susceptible (S) C. albicans isolates cultured
from various clinical specimens were included in this study. The suscep-
tibility of the strains against amphotericin B, ﬂuconazole, itraconazole,
ketokonazole, clotrimazole and ﬂucytosine were determined by broth
microdiltion method according to CLSI M27-A2 standards. Restriction
enzyme analysis was performed by using PagI enzyme after PCR on
all isolates for Y132H mutation, and sequence analysis was done for
other mutations in the ERG11 gene. Overexpression of efﬂux pumps
was also investigated by microdilution method M27-A2 using substrates
and inhibitors.
Results: All seven ﬂuconazole R/SDD isolates were found to be resistant
to ﬂucytosine except one, all were susceptible to amphotericin B and
all isolates except one were resistant to itraconazole and ketoconazole
and all of them except one were susceptible to clotrimazole. Y132H
mutation was not detected in all strains. K143R, G464S, G465S and
V488I mutations were determined in three of the R/SDD isolates. S412T
and R469K mutations determined only in this group of strains by
sequence analysis were thought to play a role in resistance but they
should be evaluated with advanced studies. Possible overexpression of
efﬂux pumps was determined especially in three ﬂuconazole-resistant
C. albicans isolates.
Conclusion: Mutations such as K143R, G464S, G465S and V488I in
ERG11 gene and overexpression of efﬂux pumps were determined to
be effective mechanisms in our R/SDD C. albicans isolates; however
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other mechanisms of resistance, such as overexpression of ERG11 and
mutations in the ERG3 gene should also be investigated.
O371 Azole resistant clinical Aspergillus fumigatus isolates are
genetically clustered
E. Snelders, A.J.M.M. Rijs, H.A.L. van der Lee, J. Kuijpers,
W.J.G. Melchers, P.E. Verweij (Nijmegen, NL)
Objectives: Resistance to triazoles was recently reported in Aspergillus
fumigatus (AF) isolates cultured from patients with invasive aspergillosis.
We investigated the genetic relatedness of these clinical isolates.
Methods: A collection of 26 triazole resistant AF isolates that were
phenotypically and genotypically characterised was used. The isolates
were resistant in vitro to itraconazole and exhibited elevated MICs of
voriconazole and posaconazole. A combination of a tandem repeat of
the promoter and a amino acid substitutiton (L98H) in the cyp51A gene
was the predominant genetic change. These isolates had been cultured
from patients admitted to our University Medical Centre between 2000
and 2006. Twenty-six azole susceptible isolates were randomly selected
as controls. Genetic relatedness was investigated and phylogenetic trees
were made.
Results: Genetical analysis indicated the presence of 3 clades within the
collection of 52 AF isolates. All azole-resistant isolates were genetically
distinct from each other, but 24 of 26 azole-resistant isolates clustered
together in a single clade indicating genetic relatedness. The branches of
the azole-resistant isolates had shorter genetic distances than the matched
azole susceptible control isolates.
Conclusion: The clustering of the azole-resistant AF isolates into a
distinct clade with short genetic distances suggests a close genetic
relatedness between these resistant isolates. Since azole resistance
appears to have emerged only recently, the evolution of this resistance
mechanism needs to be further investigated.
O372 Environmental Aspergillus fumigatus isolates resistant to
triazoles are genetically related to resistant clinical isolates
E. Snelders, R.A.G. Huis in’t Veld, A.J.M.M. Rijs, H.A.L. van der
Lee, J. Kuijpers, W.J.G. Melchers, P.E. Verweij (Nijmegen, NL)
Objectives: Recently the emergence of triazole-resistance was reported
in clinical Aspergillus fumigatus (AF) isolates. It is unclear if azole
resistance arises during therapy or that it is due to other causes of azole
exposure. We investigated the possibility that azole-resistance is present
in environmental AF isolates.
Methods: Soil, leaves, seeds and compost samples were obtained from
local plant nurseries and a local garden centre. Soil was also sampled in
the surroundings of the Radboud University Nijmegen Medical Center,
Nijmegen, The Netherlands. In addition AF isolates from the hospital
indoor environment present in our fungus culture collection were tested
for resistance. All samples were cultured on Sabouraud agar plates with
and without itraconazole. Azole-resistant AF isolates were matched with
representative azole-sensitive control isolates. Phenotypic susceptibility
proﬁles (CLSI reference method) and molecular resistance mechanisms
(cyp51A gene) were determined as well as molecular strain identiﬁcation.
Genotypical analysis was performed to determine if the environmental
isolates clustered with clinical isolates.
Results: AF was cultured from 49 of 79 environmental samples, with
10 exhibiting an azole resistant phenotype. Resistant isolates were also
cultured from soil from ﬂower beds (6 isolates), seeds (1), compost
from a plant nursery (1) and compost from the garden centre (2).
Five of 248 isolates from the hospital indoor environment were azole-
resistant: patient rooms (3) and hospital water (2). A tandem repeat
and a L98H substitution were present in 13 of the 15 resistant isolates.
This resistance mechanism was previously described to be the dominant
change in triazole-resistant clinical isolates. Genotypical analysis showed
that all isolates are unique but genetically clustered, 13 of the 15
environmental resistant isolates were clustered together in one clade.
These environmental isolates also showed clustering with azole resistant
clinical isolates.
Conclusion: Azole-resistant AF is present in the environment. Since
azole-resistant AF was cultured only from the environment that had been
manipulated by humans, a link with exposure to azole fungicides seems
plausible. Molecular analysis of the azole resistant environmental isolates
may suggest that patients acquire azole resistant aspergillus disease by
inhaling resistant conidia from their environment.
O373 Epidemiological amphotericin B cut-off values in Aspergillus
species using EUCAST methodology and an extended
dilution series
C. Lass-Flo¨rl, S. Leitner, P. Warn, D. Denning (Innsbruck, AT;
Manchester, UK)
Objectives: Testing of amphotericin B for Aspergilli is problematic.
Amphotericin B minimum inhibitory concentrations (MICs) for most
Aspergillus species cluster between 0.5−2mg/ml. MICs are not helpful
in distinguishing between susceptible and resistant Aspergillus spp. with
the exception of some isolates of Aspergillus terreus complex.
Methods: We performed a continuous 20 step dilution series of
amphotericin B between 0.2 and 3mg/ml in 0.2mg/ml steps, and
evaluated the MICs in 115 isolates of Aspergillus spp. Isolates of
Aspergillus fumigatus complex (n = 63), A. terreus complex (n = 35),
Aspergillus ﬂavus complex (n = 26) and Aspergillus niger complex
(n = 16) were obtained from patients suffering from invasive aspergillosis
and stored in water at room temperature. Susceptibility testing was
performed according the EUCAST methodology for conidia forming
moulds. An inoculum size of 2×105–5×105 CFU/ml and RPMI 1640
supplemented with 2% glucose (RPMI 2% G) as culture medium was
used. MIC reading was done after 48hours of incubation at 37ºC. The
MIC value was deﬁned as a no-growth visual endpoint. In addition,
we studied the in vivo response of several isolates to amphotericin
B. Outcome data were obtained earlier in a temporarily neutropenic
disseminated mouse model of invasive aspergillosis.
Results: MIC distributions were as follows: for A. fumigatus complex
ranging from 0.4 – 1.4mg/ml, with modal MIC of 0.8mg/ml; for A. ﬂavus
complex from 0.8 – 2.4 mg/ml with modal MIC of 1.2−1.4 mg/ml; for
A. terreus complex from 1 – >3mg/ml with a biphasic distribution
with one modal MIC at 1.0mg/ml and another at 2.4mg/ml; and for
A. niger complex from 0.4 – 1.2 mg/ml with modal MIC of 0.8 mg/ml.
Only A. ﬂavus and A. niger complex distributions were approximately
Gaussian. Suggested epidemiological cut-offs are therefore 1mg/ml for
A. fumigatus, A. niger and A. terreus complex, and 1.4mg/ml for A. ﬂavus
complex.
We were able to correlate in vivo and in vitro data. Mice infected
with Aspergillus spp. showing MICs <1mg/ml (n = 9) had a successful
outcome, with MICs >1mg/ml (n = 3) failed amphotericin B therapy
(p< 0.05).
Conclusions: The extended serial amphotericin B dilutions allow for
clear and different susceptibility patterns within the various aspergilli
tested. Clinical studies are needed to evaluate the usefulness of the
suggested epidemiological cut-off values for deﬁning clinical breakpoints
for amphotericin B.
Novel vaccine antigens and host response
O374 Do vaccines increase the risk of Guillain-Barre syndrome?
R. Baxter, B. Fireman, N. Lewis (Oakland, US)
Guillain-Barre´ Syndrome (GBS) is an acute neurologic syndrome
which may lead to paralysis. It has a known association with
infections (Campylobacter, Mycoplasma, etc.) In 1976 during the Swine
ﬂu vaccination programme, an increase in GBS cases was tied to
vaccination. Since that time, there have been concerns about other
vaccines (eg Menactra, Td).
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Kaiser Permanente (KP) is a medical care organisation (MCO) with 3.2
million members in Northern California. They have complete electronic
medical records on all members.
The VSD (Vaccine Safety Datalink), a collaborative project with the
CDC Immunization Safety Ofﬁce (ISO), is composed of 8 medical care
organisations which collect medical and vaccination data on more than
5.5 million members annually. Data from these organisations is compiled
to conduct studies of vaccine adverse advents.
Methods: In a preliminary analysis, we looked at GBS occurring within
3, 6, or 10 weeks after vaccination, in KP NCAL members of all ages
from 1994–2005.
For the analysis we used a novel “case series”-like approach. Instead of
looking at a vaccination and potential GBS in a time window related
to it (the usual case series approach), we looked at all vaccinated
persons with GBS, and examined the proportion of vaccinated cases that
were vaccinated in the window vs. the remainder of the year. We used
logistic regression to compare the proportion of vaccinated cases whose
vaccination occurred in the window versus the expected assuming there
is no association with the vaccine. For seasonal vaccines, like inﬂuenza,
we estimate the expected odds from the proportion of vaccines given
inside vs. outside the window. This new method controls for seasonality
and other confounders.
In this exploratory analysis of multiple vaccines and risk windows,
using a novel analytical method, we found a possible increase in the
risk of GBS in the 6-week period after vaccination with Td. After
veriﬁcation by chart review we plan to extend the analysis to the entire
VSD study population. As the analytical method controlled very well
for confounders, including seasonality, this model may be applicable to
other vaccine safety studies.
Table: Risk of GBS inside-versus outside the 6-week risk window among
vaccinated GBS cases (only vaccines occurring in a 6 week window
before the GBS are included)
Vaccine Exposed
inside
risk
window
Exposed
outside
risk
window
Odds
Ratio
estimate
P-value 95%
Conﬁdence
Interval
Td 8 27 2.271 0.043 (1.02, 5.03)
Inﬂuenza 29 113 1.422 0.443 (0.58, 3.50)
Hep A 2 3 5.241 0.072 (0.86, 31.92)
Pneumococcal 3 26 0.680 0.541 (0.20, 2.34)
Hep B 4 14 1.324 0.623 (0.43, 4.05)
O375 Immunological evaluation of recombinant human serum
albumin–L7/L12 (Brucella abortus ribosomal protein) fusion
protein in animal model
I. Pakzad, A. Rezaee, B. Tabaraiee, M. Rasaee, A. Zavaran Hosseinee
(Ilam, IR)
Objectives: Brucellosis is the most important common bacterial
zoonoses. Various vaccines such as subunit vaccine were proposed for
prevention of this disease. The immunogenic Brucella abortus ribosomal
protein L7/L12 is a promising candidate antigen for the development
of subunit vaccines against brucellosis. In this research, protection of
recombinant HSA–L7/L12 fusion protein in Balb/c mouse was evaluated.
Methods: The ampliﬁed gene was cloned in pYHSA5 vector
then pYHSA5–L7/L12 construct was transformed in Saccharomyces
cerevisiae and expressed protein from supernatant was puriﬁed by
afﬁnity chromatography column. Balb/c mouses were immunised in
four groups by HSA–L7/L12 fusion protein (group 1), Brucella abortus
S19 (group 2), HSA (group 3), PBS (group 4). ELISA, LTT tests and
challenging one week after last injection were carried out. Bacterial
count of spleen of immunised Balb/c mouse was done one month after
challenging with virulent strain B. abortus 544.
Results: In ELISA test antibody titer HSA–L7/L12 fusion protein group
was high. In LTT test the differnce of SI in HSA–L7/L12 compared with
HSA and PBS was signiﬁcant (p 0.002). Bacterial count of spleen in
goup 1 was decreased and the difference of bacterial count of spleen in
goup 1 with groups 3 and 4 was signiﬁcant (P 0.005).
Conclusion: The results indicate that recombinant protein has the
ability of proliferating lymphocytes, stimulating humoral immunity and
protecting.
O376 Novel multiple epitopes containing vaccine against
extraintestinal pathogenic Escherichia coli
A. Wieser, S. Schubert (Munich, DE)
Objectives: Extraintestinal pathogenic Escherichia coli (ExPEC) cause
a wide variety of pathology such as sepsis, neonatal meningitis or
urinary tract infections, and are responsible for a signiﬁcant mortality
and morbidity in humans and animals resulting in tremendous costs for
the healthcare system. As ExPEC strains become increasingly resistant
to antibiotics, preventive measures such as vaccination against these
pathogenic E. coli strains are an achievable goal.
Methods: Based on previous ﬁndings in genome analysis we selectively
target virulence factors and uropathogen associated proteins. To identify
the relevant immunogenic regions, the unknown three dimensional
structure of these proteins was simulated. Furthermore MHCI and
MHCII epitopes as well as proteasome cleveage sites were predicted.
Considering these data two recombinant modular proteins were designed,
containing several epitope bearing subfragments separated by linker
sequences unlikely to be presented on MHCI or MHCII receptors. To
express the recombinant vaccine proteins, two fully synthetic genes have
been synthesised using an optimised codon bias to enhance protein
expression in Enterobacteriaceae.
We evaluated two different application routes in the mouse model for
these new multi-epitope vaccine proteins to obtain both, a high humoral
and cellular immune response.
First, we used puriﬁed vaccine proteins and administered them nasally.
Second we used a novel bacterial antigen delivery system which is
efﬁcient if administered orally, and targets the vaccine directly into the
cytoplasm of mammalian cells in vivo to enhance the cellular T-cell
mediated immune response.
Results: The elicited cellular and humoral immune response was
evaluated using IFN-g ELISpot and sub-class speciﬁc antibody ELISA.
Immunised mice showed titre increases of speciﬁc IgG in their serum
as well as IgA antibodies in vaginal wash and an increase in IFN-g
secreting T-cells speciﬁc for the recombinant vaccine proteins. In the
challenge model of peritonitis a signiﬁcant reduction of bacterial load
could be achieved in immunised mice.
Conclusion: Subfragment vaccines containing multiple epitopes are
effective against ExPEC in the mouse model. Further research has to
be done to evaluate the potential of this approach in humans.
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O377 Therapeutic immunisation with Streptococcus sobrinus
enolase protects against dental caries in rats
M. Dinis, G. Trigo, D. Tavares, E. Bonifa´cio Andrade, I. Veiga-Malta,
A. Fonseca, A. Ribeiro, A. Cabrita, P. Ferreira (Porto, Coimbra, PT)
Virulence-associated immunomodulatory proteins produced by Strepto-
coccus sobrinus were used as therapeutic vaccine against dental caries in
rats. Enolase was identiﬁed as one of the S. sobrinus immunomodulatory
proteins. In this study we used a recombinant S. sobrinus enolase
(rEnolase) as a target antigen to assess its therapeutic effect in dental
caries rat model.
Methods: Groups of 19-days-old Wistar rats were orally infected with
approximately 109 S. sobrinus for ﬁve consecutive days and fed with
a cariogenic solid diet. Five days later, they were orally immunised
with rEnolase, or PBS (sham-immunised) plus alum as adjuvant, and
re-immunised 3 weeks later. Throughout the study the S. sobrinus
colonisation was assessed. The caries lesions were evaluated when rats
completed 120-days and the levels of salivary IgA, IgG and serum IgG
antibodies against the recombinant enolase were determined and the
antibodies produced in rEnolase-immunised animals were tested against
human enolase. Moreover, several organs where collected for histological
observation.
Results: Higher levels of salivary IgA and IgG speciﬁc for the
recombinant protein were detected in immunised rats than in controls. A
signiﬁcant decrease in sulcal, proximal enamel, and dentin caries scores
was observed in the rEnolase-immunised animals. Histopathological
analysis of various organs showed that oral immunisation with rEnolase
did not induce any detectable tissue modiﬁcation. Moreover, the
antibodies produced by immunisation with rEnolase showed no cross-
reactivity with recombinant human enolase.
Conclusion: The therapeutic vaccination with recombinant S. sobrinus
enolase confers protection against rat dental caries and seems to have no
harmful physiological effect on these animals rats. These results indicate
that S. sobrinus rEnolase could be a promising and safe candidate to be
tested in vaccination trials against dental caries in humans.
a) Portuguese patent nº102907 and USA Patent pending
This work was supported by Fundac¸a˜o para a Cieˆncia e a Tecnologia
(FCT) and FEDER, grant nº POCTI/SAU-IMI/60014/2004.
O378 Broad-coverage infant vaccine offering protection against
invasive meningococcal group B disease
P. Oster (Siena, IT)
Although MenB is the predominant strain in many region of the world
today, there is no truly global vaccine available to prevent this particular
meningococcal infection.
In 2006, a two-year nationwide vaccination campaign in New Zealand
with a OMVMenB vaccine developed speciﬁcally for the clonal outbreak
of one speciﬁc serosub type (B:4 P1.4) responsible for a 10-year
epidemic in that country was successfully concluded.
However to date, a broad-coverage MenB vaccine has been elusive
because unlikely other serogroups the MenB polysaccharide producing
only a poor response from the immune system.
Vaccine development is applying their technical expertise to develop safe
and effective meningococcal vaccines to overcome these obstacles and
to pioneer new recombinant vaccines against MenB (rMenB).
In a technique known as “reverse vaccinology”, potential vaccine
candidates were created by analysing the entire genome sequence of a
highly powerful MenB strain. Through genetic engineering and from the
investigation of 350 potential antigens, scientists identiﬁed those strains
with surface proteins that best induced an antibody response.
Building on this genomics approach, Novartis is developing a broad-
coverage vaccine to offer protection against multiple strains of MenB.
Phase II trials have demonstrated satisfactory safety, tolerability and
immunogenicity. In addition, rMenB is the ﬁrst recombinant MenB
protein vaccine to induce an immune response in infants.
Water in hospitals: a reservoir for
nosocomial pathogens? (Symposium
arranged with EFWISG)
S379 Nosocomial legionellosis
G. Wewalka (Vienna, AT)
In most European countries the number of notiﬁed cases of Legionnaires’
Disease (LD) increased during the last decade because of easier
diagnostic and more reliable reporting. Data collected from 35 countries
by EWGLI (European Working Group for Legionella Infections) showed
a 4.7 fold increase of cases of LD from 1997 (1344 cases) to 2006 (6280
cases). On the other hand the number cases of nosocomial LD increased
(1.4 fold rise) much less from 215 cases (16% of all) in 1997 to 309 cases
(4.9% of all) in 2006. This decrease of the proportion of the nosocomial
cases is discussed as result of intensive control measures to prevent LD
in healthcare facilities (HCF) in many countries. In Austria the situation
is similar. In 1997 7 (35%) out of 20 cases of LD and in 2006 11 (15.9%)
out of 69 cases were nosocomial cases.
A total of 410 cases of LD were reported to the Austrian reference
centre of Legionella infections during 1996 and 2005 including 66 (16%)
nosocomial cases, 131 (32%) travel associated-cases and 214 (52%)
community acquired cases. In these 10 years 27 different Austrian HCF
(25 hospitals, 2 elderly care facilities) were affected by nosocomial LD.
Among these a university hospital in Western Austria accounted for
25.7% of all the nosocomial cases (18/66) as the most likely source of
infection. Microbiological and epidemiological investigations indicated
aerosolised potable water (tap water) as the most likely source of
infection in the majority of the Austrian nosocomial cases.
A comparative analysis of the nosocomial (n = 66) vs. non-nosocomial
(n = 344) cases was performed: Nosocomial cases suffered signiﬁcantly
more frequently from neoplastic disease (33.3% vs. 6.9%) or were more
frequently immunosuppressed (15.0% vs. 6.3%). The median age was
64 years (interquartile range: 54−74yrs) in nosocomial cases vs. 53
years (interquartile range: 41−64yrs). No difference in sex distribution
between nosocomial and non-nosocomial LD was observed. Mortality
was signiﬁcantly higher among the nosocomial cases (48% vs. 9.7%,
p< 0.001).
Thirty-seven patients (56.1%) among the nosocomial cases and 36
patients (16.3%) among the non-nosocomial cases were diagnosed by
culture of the organism. For 33 isolates the species serogroup and
monoclonal subgroup were determined. Nosocomial LD is more often
caused by less virulent Legionella strains, such as L. non-pneumophila,
L. pneumophila non-serogroup (sg) 1 and L. pneumophila sg 1 belonging
to Mab 3/1-negative subgroups.
S380 Hospital water and invasive fungal infections
P. Gaustad (Oslo, NO)
Invasive mould infections present problems in terms of diagnosis and
therapy. They are increasingly common in the nosocomial setting.
The predominant fungal pathogens in hospital water, in most cases
detected as spores, are moulds such as Aspergillus spp., Mucorales
and Fusarium spp. Immunocompromised patients are at risk. Mould
infections cause high morbidity and mortality despite antifungal therapy.
The incidence of nosocomial mould infections continues to increase
despite the widespread use of air ﬁltration systems, suggesting that
other hospital sources for moulds exists. Water systems worldwide have
been shown to be colonised with pathogenic moulds. The moulds are
present the hospital water system, and the same genera are recovered
from the municipal water. The number of species isolated in surfaced-
sourced water is higher than the number isolated in groundwater
water. The moulds are probably part of bioﬁlms in the water system.
Mould spores and hyphal fragment may be released into the water.
Aerosolisation by showerheads, taps or toilet cisterns, aspiration or
drinking of contaminated water may lead to patient exposure.
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In the literature only a few reports connect recovered moulds from
hospital water to patient isolates (Anaissie EJ CID 2001, Anaissie EJ
Blood 2003, Warris J. Hosp. Incect 2001, Warris J Clin Microbiol
2003). Molecular epidemiological investigations of strains are hampered
by the genetic diversity of moulds. The ampliﬁed fragment length
polymorphism and the short tandem repeat analysis seem to be the most
discriminative typing methods.
Early initiation of antifungal therapy and reversal of underlying host
defects remain the cornerstones of treatment for nosocomial fungal
infections. The mortality of nosocomial fungal infections remains high,
and new therapeutic and preventive strategies are needed.
The current water treatment is insufﬁcient in removing moulds from the
hospital water. Prevention of waterborne nosocomial mould infections
in high risk patients will include point-of-use ﬁltration, sterile water
for drinking, and bathing and not showers to avoid aerosolisation.
Investigations of the water and its tubing system should be done properly
to identify the water quality of the hospital. The surface-sourced water
is more likely to contain pathogenic moulds than underground water and
moulds are more likely to be present in cold water and showers than in
hot water.
At this stage more data are needed to assess the exact role of water in
nosocomial fungal infection.
S381 Pseudomonas, Stenotrophomonas and Burkholderia – are they
in your hospital’s water and does it matter if they are?
K.G. Kerr (Harrogate, UK)
Debilitated patients on intensive care units and individuals rendered
profoundly neutropenic following chemotherapy for haematological ma-
lignancy are at risk of developing infections including those associated
with Gram-negative bacteria of environmental origin. Infections caused
by these bacteria are difﬁcult to manage, partly because of inherent or
acquired antimicrobial resistance manifested by these microorganisms
and partly because of deﬁcits in patients’ host defences as a result of
neutropenia or other underlying condition. There is thus a pressing need
to develop effective interventions to prevent exogenous acquisition of
infection from environmental sources. In this respect a wide range of
aquatic sources, including ice-making machines, aqueous solutions of
disinfectants and nebulizer apparatus have been considered as being
of importance in outbreaks of infection associated with Gram-negative
bacteria such as Pseudomonas and Stenotrophomonas spp.
The application of discriminative molecular typing techniques, such
as pulsed-ﬁeld electrophoresis, to characterise the relatedness of
environmental and patient isolates has highlighted the increasing
importance of hospital water supply systems, including potable water and
water faucets, in the epidemiology of infections caused by environmental
Gram-negatives. More recently, prospective studies conducted in non-
outbreak situations have suggested that hospital water systems may also
be of signiﬁcance in endemic or sporadic infections associated with these
bacteria.
However, isolation of environmental bacteria from potable water supplies
which are indistinguishable from patients’ clinical isolates cannot,
in itself, answer the question as to whether patients acquire the
bacteria from water faucets or whether faucets are directly or indirectly
contaminated by the patients. Nevertheless, there is now accumulating
evidence to suggest that interventions, such as point-of-use water
ﬁltration, to minimise or eliminate Gram-negative bacteria from aquatic
sources in the patient environment may be effective as infection control
interventions. These ﬁndings should now provide the impetus for further
systematic prospective studies to establish whether these interventions
can be adopted as integral components of infection control programmes
for facilities which provide care for patients at risk of Gram-negative
infection.
Issues in the way of treating chronic viral
hepatitis (Symposium arranged with ESGVH
& EASL)
S385 How to treat HBV mono-infected patients?
D. Salmon (Paris, FR)
In the recent years, there has been considerable progress in the treatment
of chronic hepatitis B. Interferons (conventional then PEG) were the
ﬁrst drugs used. Although they have the advantage of a ﬁnite duration
of therapy, a persistent response (loss of DNA-HBV and of AgHbe) is
obtained after the end of therapy in only one third of cases. They should
only be proposed in patients with factors known to inﬂuence positively
the outcome. A large number of nucleoside/nucleotide analogues are,
at present, available to treat hepatitis B. The efﬁcacy of lamivudine
alone, the ﬁrst nucleoside analogue used, is limited by the high rate
of resistance. Adefovir has efﬁcacy comparable to that of lamivudine,
but with low resistance rate. Entecavir and tenofovir are particularly
active in the control of hepatitis B virus replication and are associated
with minimal resistance development, even with long treatment duration.
Other drugs, such as telbivudine, emtricitabine and clevudine, will
become new treatment options in the near future. First-line therapeutic
regimen usually include either a monotherapy with a potent agent
that has a low rate of resistance; or could in the future include a
combination of 2 nucleos(t)ide analogues. These agents have been shown
to be effective in improving virological, biochemical, and histological
features in high proportion of the patients with chronic hepatitis B.
However, they can not eliminate hepatitis B virus and only suppress
HBV replication. Furthermore, the emergence of drug resistant HBV is
becoming problematic over the long-term. Therefore, physicians should
be careful in selecting whom to treat, when to start treatment, how to
monitor patients before, during and after the treatment.
MDR efﬂux pumps of Gram-negative
bacteria: their development, genetic
regulation and control
S387 Bacterial membrane drug efﬂux and receptor proteins
P.J.F. Henderson, D. Leng, J. Liu, P. Ma, G. Szakonyi, I. Nes, A. Kolsto,
P. Roach, H. Yuille, V. Blessie, M.K. Phillips-Jones (Leeds, UK; Oslo,
NO)
Multidrug (Mdr) efﬂux proteins (1) are widespread amongst microor-
ganisms, including pathogens. These membrane proteins contribute to
emerging antibiotic resistance. Two-component system (TCS) receptor
membrane proteins (2) play key roles in metabolism and sensitivity to
antibiotics of many microorganisms. The design of novel antibacterial
drugs would be greatly facilitated by knowledge of the structures of
these membrane proteins, which are poorly understood because of the
difﬁculties of obtaining puriﬁed protein and crystals of quality. We
describe a structural genomics strategy for the ampliﬁed expression,
puriﬁcation and characterisation of such proteins.
Over thirty Mdr and TCS membrane proteins have been puriﬁed from
Bacillus cereus, Bacillus subtilis, Brucella melitensis, Campylobacter
jejuni, Escherichia coli, Enterococcus faecalis, Helicobacter pylori,
Neisseria meningitidis, Staphylococcus aureus, and Streptomyces coeli-
color. Proteins from B. cereus, E. faecalis, H. pylori and S. aureus will
be used as detailed examples to illustrate the strategy.
The success of this strategy is an important step towards reproducible
production of transport and receptor proteins for the screening of drug
binding and for optimisation of crystallisation conditions to enable
subsequent structure determination and drug design.
Acknowledgements: This research is supported by the BBSRC, the EU
European Membrane Protein Consortium EMeP, EU COST Action B16,
and the Wellcome Trust.
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S388 Response of regulatory, efﬂux pump transporter and Omp
genes during prolonged antibiotic stress and development of
MDR in Gram-negative bacteria
L. Amaral, M. Viveiros, L. Rodrigues, M. Martins, G. Spengler,
A. Martins, J-M. Pages, S. Fanning (Lisbon, PT)
Multi-drug resistance of Gram-negative bacteria is now known to be the
result of over-expressed efﬂux pumps that extrude a variety of unrelated
antibiotics prior to their reaching their targets. Although a number of
methods have been developed for the assessment of over-expressed efﬂux
such as the use of the universal efﬂux pump substrate ethidium bromide
(EB) or the use of radiolabeled antibiotics in the presence and absence
of an inhibitor of efﬂux pumps, these methods are labour intensive, are
relatively imprecise and do not lend themselves for inter-laboratory use.
We have developed a number of methods that A) identify over-expressed
efﬂux activity of mdr pathogenic bacteria without the use of specialised
instrumentation (1); B) assess speciﬁc activity of genes that regulate or
code for transporter component of RND efﬂux pumps (2); C) assess
and evaluate over-all efﬂux pump activity via a semi-automated system
that distinguishes accumulation of EB from its efﬂux, can also identify
agents that inhibit efﬂux activity as well as deﬁne conditions that control
accumulation and efﬂux (3). Method C will be fully described for the
assessment and evaluation of intrinsic and over-expressed efﬂux activity
of mdr E. coli, Enterobacter aerogenes and Salmonella.
Reference(s)
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[3] Viveiros M, Martins A, Paxa˜o L, Rodrigues L, Kern W, Couto
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S389 Regulation and control of membrane permeability (Inﬂux
and Efﬂux) in Enterobacteriaceae
J.M. Pages (Marseille, FR)
In Enterobacteriaceae, membrane permeability plays a “key” role in
the level of susceptibility/resistance to antimicrobials. In recent years,
modiﬁcation of the bacterial envelope by decreasing the production
of porins or increasing the expression of efﬂux pump systems has
been reported. These modiﬁcations are frequently associated with other
resistance mechanisms such as alteration of antibiotic molecules or
modiﬁcation of the drug targets, in various clinical isolates showing
a MultiDrugResistant (MDR) phenotype.
In Enterobacter aerogenes, Klebsiella pneumoniae and Salmonella
enterica, several genes and various chemical factors are involved in the
emergence/selection of MDR isolates. These bacterial isolates exhibit a
noticeable reduction of the number of functional porins per cell (strong
decrease, no synthesis or expression of a functionally altered porin) and
a high-level expression of efﬂux systems (e.g. over-expression of the
AcrAB-TolC pump). The simultaneous presence of these mechanisms
confers efﬁcient resistance to the strain ensuring its dissemination, the
colonisation of the patient and favours the acquisition of additional
mechanisms of resistance. marA, ramA, and ompX are involved in
a complex regulation cascade controlling membrane permeability and
actively participate in triggering the MDR phenotype. Certain mutations
in regulator genes induce the overexpression of efﬂux system and the
downregulation of porin synthesis. In addition, speciﬁc molecules such
as salicylate, imipenem or chloramphenicol are able to activate the MDR
response. This phenomenon has been observed in vitro during culture
of bacteria in the presence of drugs and during antibiotic treatment
of colonised/infected patients. These effectors trigger the expression
of speciﬁc genes, marA, ramA, or target some other genes located
downstream in the regulation cascade.
The redundancy of regulators, the overlap in control pathways and
the effect of external inducers actively contribute to the selection,
dissemination and preservation of Enterobacter aerogenes MDR strains.
S390 Inﬂuence of local and global regulators on efﬂux-mediated
resistance of Salmonella enteritidis: contributions to a
pleiotropic phenotype
E. O’Regan, T. Quinn, S. Fanning (Dublin, IE)
Salmonella Enteritidis is the most common aetiological agent of
foodborne salmonellosis worldwide. Fluoroquinolones are the most
widely used family of antibiotics in the treatment of life threatening
salmonellosis. Of signiﬁcant public health concern is the emergence
of Salmonella isolates with reduced ﬂuoroquinolone susceptibility.
Resistance to ﬂuoroquinolones is largely attributible to mutations in
the quinolone resistance-determining regions (QRDRs) in target genes
and overproduction of efﬂux pumps. In this paper we present data
describing the role of local (eg: acrR) and global regulators (including
marA, soxS, rob and ram) on efﬂux-mediated resistance (to nalidixic acid
and ciproﬂoxacin) in ﬁeld isolates and in in-vitro selected ciproﬂoxacin
resistant Salmonella Enteritidis isolates. Gene expression was assessed
by ‘real-time’ PCR and invasiveness was determined by co-culture of
bacterial and CaCo-2 cells. The ﬁtness cost of antibiotic resistance
was examined and a high-throughput phenotype microarray was used
to assess any pleiotropic effects.
Insertional mutants were constructed by P22 phage transduction using
a number of these global regulators. The geno- and phenotypes of
these mutants were re-examined to determine what (if any) effects these
insertions had.
Based on this analysis, our ﬁndings do not support the adoption of
a unifying functional model to describe regulation. Rather, these data
suggest that the evolutonalry history of a strain may be a consideration
in determining the inﬂuence that these regulators have in controlling
gene expression of the RND efﬂux pump in S. Enteritidis along with
some pleiotropic phenotypes.
Meningococci and meningococcal invasive
disease
S391 New insights into the pathogenic mechanisms
A. Jonsson (Uppsala, SE)
Neisseria meningitidis is a human-speciﬁc pathogen that causes sepsis
and meningitis with high mortality. We have used a transgenic mouse
model and bioluminescently labelled meningococci to monitor bacterial
spread after infection. Bacteria accumulated in the nasal mucosa, and the
colonisation was dependent of meningococcal pili and of GNA992, an
outer membrane protein. Lethal disease was accompanied by bacterial
enrichment in the thyroid gland, and by decreased thyroid hormone
S84 18th ECCMID, Oral presentations
T4 levels. Bacterial visualisation demonstrated waves of bacterial
clearance and growth, which selected for bacteria expressing the phase
variable outer membrane protein Opa, indicating the importance of this
bacterial factor. Meningococcal lipooligosaccharide (LOS) has long been
identiﬁed as a major inﬂammatory mediator of fulminant meningococcal
sepsis and meningitis. However, both wild-type meningococci and
an LOS mutant induced equivalent disease severity and similar
proinﬂammatory responses in TLR4+/+ mice, but failed to cause fatal
sepsis in TLR4−/− mice. Taken together, these data reveal novel disease
dynamics and organ targeting during meningococcal disease. Further,
fatality associated with meningococcal sepsis in mice is induced by
the proinﬂammatory host response by recognition of one or more
unidentiﬁed non-LOS components by TLR4.
S392 Role of virulence, antimicrobial resistance and host
susceptibility for the outcome of meningococcal disease
R. Read (Shefﬁeld, UK)
Across Europe the incidence of meningococcal disease varies from
between 1 per 100,000 up to 14.3 per 100,000 population per annum.
The case fatality rate overall is approximately 8%, but amongst survivors
there is a relatively high frequency of severe sequelae including hearing
impairment, neuro-cognitive abnormalities, severe skin and soft tissue
abnormalities including loss of limbs, and renal failure. Physicians
and paediatricians who treat meningococcal disease observe a range of
severity from relatively benign disease to severe physiological disruption
leading to death. In general terms, those who present with meningitis
tend to have a better prognosis, whilst those who present with severe
sepsis syndrome have the worst prognosis. Study of factors associated
with the severity of meningococcal disease is difﬁcult and confounded by
factors such as the sporadic nature of the disease and marked differences
in access to health systems between individuals. Many studies have
shown that the outcome of meningococcal disease is associated with the
phenotype of the infecting organism. The odds of death from disease are
highest for certain sequence types, for example ST-11/ET-37 complex
and ST-32/ET-5 complex. The precise phenotypes responsible for the
enhanced virulence of these sequence types has not been precisely
deﬁned. The major virulence determinants of Neisseria meningitidis
include the polysialic capsule, LPS immunotypes, sialylation, and outer
membrane proteins including Opa and Opc. Whilst there is no consistent
segregation of virulence determinants in clonal groups associated with
the most severe disease, organisms expressing serogroup C have been
associated with fatal outcome.
A number of host factors have been identiﬁed as important in
determining severity of disease. Chief amongst these is age at
presentation, with the worst prognosis being associated with adults.
Some of this may be explained by the increasing sophistication of
paediatric intensive care. Twin studies have indicated that death from
severe infectious disease has a familial component and in the case of
meningococcal disease a large number of studies have been conducted to
investigate the role of genes encoding components of the immune system,
the inﬂammatory response and coagulation pathways. The difﬁculty
faced by geneticists is that death is the most easily veriﬁable end point
for the purpose of studying genetic modiﬁers of severity of disease.
Because of the death rate of only 8% this means that very small cohorts
are available for study. However, association studies have revealed a
relationship between a number of genes and the likelihood of death
in meningococcal disease. These include Fc receptors, polymorphisms
of plasminogen activator inhibitor type 1, properdin deﬁciencies, and
polymorphisms within interleukin 1 and the interleukin 1 receptor
antagonist.
In several countries, there have been increasing reporting of isolates of
Neisseria meningitidis with reduced sensitivity to penicillin. Treatment
failure has been reported extremely rarely and studies have failed to
demonstrate any association between reduced penicillin susceptibility
and fatal outcome. Most doctors consider that emergency treatment of
newly-presenting cases with penicillin in the community is mandatory.
Controversially, a recent study has suggested that treatment in the home
with injected penicillin may be associated with increased severity of
disease. This will be discussed.
S393 Immunological issues in anti-meningococcal vaccination
D. Goldblatt (London, UK)
Meningococcal infections continue to cause signiﬁcant morbidity and
mortality, especially in young children and adolescents in Europe where
Neisseria meningitidis serogroups B and C cause the majority of
disease. While no effective licensed vaccine exists for Group B, vaccines
consisting of the puriﬁed capsule of serogroup C (and A, W and Y)
have existed for many years. Their use has been limited to outbreak
control and for travellers due to (i) the limited duration of protection
afforded after a single dose and (ii) their poor immunogenicity in
young infants. Conjugate meningococcal C vaccines, which overcome
these limitations, were the ﬁrst meningococcal conjugate vaccines to
be licensed and entered use ﬁrst in the United Kingdom in 1999
and subsequently introduced in many European countries where they
have had an impressive impact on reducing the incidence of infection.
Ongoing surveillance of meningococcal infection following introduction
of the vaccine together with immunological studies has provided insights
into the mechanism of immune protection and the role of immunological
memory. These will be discussed and the areas that remain poorly
understood highlighted.
S394 Trends in the management of meningococcal meningitis
D. van de Beek (Amsterdam, NL)
Neisseria meningitidis most commonly causes (meningococcal) menin-
gitis in young adults and is a major cause of endemic meningitis.
Identiﬁcation of patients with meningococcal meningitis can be difﬁcult.
Typical sings and symptoms of bacterial meningitis may not be present.
Petechial skin rash has traditionally been considered the hallmark of
meningococcal disease, but is absent in one third of patients presenting
with meningococcal meningitis and can also occur in viral meningitis.
Physical examination alone may not perform well enough to accurately
diagnose or rule out meningitis. Examination of cerebrospinal ﬂuid is
important; it is required to conﬁrm the diagnosis, identiﬁes the causative
organism, allows the testing of antibiotic sensitivities, and so helps to
rationalise treatment. In view of the urgent nature of this testing, one of
the issues physicians are faced with in an emergency department setting
is whether cranial computed tomography is required before lumbar
puncture.
Timing is critical in the management of patients with suspected meningo-
coccal meningitis: the ﬁrst step in the management of meningococcal
meningitis is to obtain blood cultures and start antimicrobial therapy,
and adjunctive dexamethasone when indicated. Prehospital parenteral
antibiotic therapy is recommended in many countries but its use remains
controversial. A ﬁrst difﬁculty in this setting is how to identify a
patient with meningococcal meningitis. A second dilemma is whether
patients beneﬁt from such pre-hospital treatment. And if general
practitioners decide to treat patients with suspected bacterial meningitis
with parenteral antibiotics, should dexamethasone be given before or
with this ﬁrst dose?
The management of the critically ill neurological patient with meningo-
coccal meningitis can be difﬁcult and poses important dilemmas. Signs
of systemic disease occur frequently in patients with meningococcal
meningitis and are associated with mortality and unfavourable outcome.
Systemic disease frequently necessitates cardiopulmonary support and
admission on an intensive care unit. Meningococcal sepsis is frequently
associated with coagulation disorders such as disseminated intravascular
coagulation. Intracranial complications as raised intracranial pressure,
hydrocephalus, and brain infarction do occur. Arthritis occurs in 12%
of patients; bacterial arthritis requires prolonged antibiotics and joint
drainage. Adjunctive treatment strategies with dexamethasone, anti-
endotoxin antibodies (HA-1A), recombinant bactericidal permeability
increasing protein (rBPI21), and activated protein C have been described.
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These important and controversial areas will be reviewed and relevant
literature will be discussed in the framework of current treatment
guidelines.
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O395 Usage of carbapenems signiﬁcantly increase the rate of
new colonisation due to antibiotic-resistant bacteria in
hospitalised patients
E. Tacconelli, G. De Angelis, M. Cataldo, E. Mantengoli, T. Spanu,
A. Pan, G. Corti, A. Radice, S. Antinori, F. Paradisi, G. Carosi,
M. Antonelli, G. Rossolini, R. Cauda (Rome, Siena, Brescia, Florence,
Milan, IT)
Objectives: Accurate assessment of risk factors for colonisation with
antibiotic resistant bacteria (ARB) is often confounded by scanty data
on antibiotics use. The aims of the study were: to prospectively deﬁne the
incidence of new colonisation due to ARB per 1,000 days of antibiotics;
to determine mean time of acquisition; to measure patients’risk factors
for acquiring ARB; and to compare genotypic patterns of the strains.
Methods: A 12-month prospective multicentre cohort study including
all in-patients (pts) starting antibiotics was planned. Samples of nose
and rectum were taken before and after starting antibiotics (day 2,
4, 7, 15, and 30). ARB included: meticillin-resistant Staphylococ-
cus aureus (MRSA), vancomycin-resistant enterococci (VRE), and
ciproﬂoxacin-resistant Pseudomonas aeruginosa (CR-PA). Pulsed-ﬁeld
gel electrophoresis was done to deﬁne genetic relatedness of the strains.
Results: In total, 6245 swabs from 864 pts were processed. The overall
carriage rate of newly acquired ARB was 5%. The mean duration
(days±standard deviation) of antibiotic therapy prior to the detection
of a new colonisation was 8 (±4) for MRSA (range, 2−16), 6 (±6) for
VRE (range, 2−19) and 9 (±8) for CR-PA (range, 2−28). The incidence
of ARB per 1,000 days of therapy was 14 for carbapenems, 9 for
glycopeptides, and 6 for cephalosporins of 3rd gen. and quinolones.
Highest rates were observed for carbapenems in dialysed (29) and
diabetic (28) pts and for 3rd gen. cephalosporins in pts with cronic
renal impairment (27). Speciﬁc rates for MRSA were 8.2 per 1,000
days of macrolides, 7.9 of carbapenems, 3.2 of glycopeptides and 2.4
of cephalosporins. In the multivariate analysis length of hospitalisation
>16 days (odds ratio [OR] 2.5, 95% conﬁdence interval [CI] 1.2−5.1),
HIV infection (OR 2.1, 95% CI 1.1−4.4), use of carbapenems (OR
2, 95% CI 1−3.8), and age >70 (OR 1.5, 95% CI 1.1−2) were
signiﬁcant predictors for new ARB acquisition (P< 0.05). All strains
were genetically unrelated except for serial isolates from single patient.
Conclusions: The risk of ARB colonisation deeply varies during
exposure to different antibiotics and is mainly related to pts underlying
conditions and length of hospitalisation. Periodic screening of high
risk pts undergoing antibiotics, in particular carbapenems, might be
suggested.
O396 Temporal effects of antibiotic use and hand-rub consumption
on incidence of MRSA and Clostridium difﬁcile
N. Vernaz-Hegi, H. Sax, D. Pittet, P. Bonnabry, J. Schrenzel,
S. Harbarth (Geneva, CH)
Objectives: To determine the temporal relation between use of
antibiotics and alcohol-based hand rubs (ABHR) on the incidence
of meticillin-resistant Staphylococcus aureus (MRSA) and Clostridium
difﬁcile at the Geneva University Hospitals.
Methods: Using interventional time-series analyses, we (1) evaluated
the impact of 2 hand hygiene campaigns in 2003 and 2005 on the
consumption of ABHR; (2) combined this model with a transfer function
model on aggregated data on antibiotic use; and (3) assessed their
effect on the incidence of clinical isolates of MRSA and C. difﬁcile
from February 2000 through September 2006. The WHO ATC/DDD
classiﬁcation was used as reference, normalised per 100 patient-days
(PD).
Results: From the 84% of total antibiotic use (average, 33 DDD/100PD)
analysed, 38% showed to have a temporal relation with MRSA incidence
while no association was detected for C. difﬁcile (except usage of broad-
spectrum cephalosporins). The model indicated a signiﬁcant impact
of consumption of ABHR on MRSA, but not on C. difﬁcile. The
intervention model integrated to a transfer model showed the efﬁciency
of the second hand hygiene campaign and an additional temporal effect
of the use of ﬁve broad-spectrum antimicrobials, explaining 57% of
the incidence of MRSA over time. An increase of 1DDD/100PD of
antibiotic use increased the incidence of MRSA isolates per 100 PD
from the current level, i.e. 0.01 for ﬂuoroquinolone (signiﬁcant impact
1 month later), 0.03 for macrolides (1 and 4 m), 0.03 for 3rd generation
cephalosporins (4 and 5 m), 0.014 for cefepime (3 m) and 0.04 for
piperacillin/tazobactam (3 m). Conversely, the hand hygiene campaign in
2005 reduced MRSA incidence; 1L of ABHR/100PD decreased MRSA
by 0.03/100PD.
Conclusion: We observed an aggregate level relation between trends in
MRSA incidence and the use of ABHR and different antibiotic classes,
while no association with ABHR use was detected for C. difﬁcile.
Modelling drug-use-versus-susceptibility relations using time-series
analyses is a useful tool complementing traditional epidemiologic
approaches.
O397 The use of geographical information system to map
antibiotic consumption
F. Marra, S. Mak, M. Chong, D. Patrick (Vancouver, CA)
Background: Antibiotic consumption in human populations is a factor
in the emergence of resistant organisms. As such, it is important to track
population-based consumption data on an ongoing basis and to explore
the determinants for regional variations in antibiotic consumption for the
province of British Columbia (BC).
Methods: We obtained data from the BC PharmaNet database on
all outpatient oral antibiotic prescriptions for 2005. Prescriptions were
expressed as their deﬁned daily dose (DDD) per 1,000 inhabitants ac-
cording to the 2006 World Health Organization Anatomical Therapeutic
Chemical system. Geographic Information Systems (GIS) mapping was
used to display the spatial variations of antibiotic consumption in BC.
We explored the relationships between antimicrobial consumption and
socioeconomic and climatic factors using Pearson’s correlation. Overall
and class-speciﬁc rates of consumption were described by the Health
Service Delivery Area geography.
Results: Overall antibiotic consumption was highest in the northern
health regions and lowest in the interior health regions. Correlations
were found between antibiotic consumption and socioeconomic and
climatic factors. Higher rates of antibiotic consumption were associated
with the aboriginal population, higher family income, and July total
precipitation. An inverse relationship was found between consumption
and July average temperature. Further analysis of class-speciﬁc antibiotic
consumption identiﬁed different geographic patterns of consumption
and socioeconomic associations. Higher rates of penicillin, b-lactam,
and macrolide consumption were seen with the aboriginal population,
younger population (age <15 years), higher ratio of physicians to
population, higher family income, and greater July total precipitation.
An inverse correlation was found between antibiotic consumption and
older age (age >65 years), mortality rate, and warmer July temperatures.
Conclusions: Different rates of antibiotic consumption exist within
the province. Appropriate policies affecting antibiotic consumption
in the community can be designed by looking at the relationships
between antibiotic consumption and socioeconomic determinants, and
their related impact.
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O398 Hospital antibiotic prescribing in hospitals from 18
European countries 2000–2005: longitudinal analysis with
comparison of adjustment for changes in clinical activity
using admissions or occupied bed days
F. Ansari, H. Goossens, M. Ferech, A. Muller, H. Molana, P.G. Davey
on behalf of the European Surveillance of Antimicrobial Consumption
Project
Objective: To collect data about hospital antibiotic use with standardised
methods in different European countries. The data were used to answer
two research questions:
1. What is the trend in hospital antibiotic use over time?
2. What effect does adjustment for bed days or admissions have on
trends in hospital antibiotic use?
Methods: A total of 18 hospitals participated in the study, one hospital
from each of 18 countries. We collected monthly data about total
antibiotic use over 6 years starting from January 2000. Crude data about
antibiotic use was converted to the ATC drug classiﬁcation and Deﬁned
Daily Doses (DDD).
Results: Antibiotic use measured in DDD increased in 14 hospitals and
decreased in 4 hospitals. There was an underlying trend of reducing
length of stay in 16 of the 18 hospitals. Consequently annual changes in
DDD per 100 occupied bed days (DBD) were also greater than annual
changes in DDD per 100 admissions (DAD) in 16 of the 18 hospitals.
Overall there were ﬁve distinct patterns of antibiotic use over time:
1. Increasing antibiotic use that was not fully explained by increased
clinical activity (11 hospitals). Increases in DDD over time remained
after adjustment with either bed days or admissions.
2. Increasing antibiotic use was entirely explained by increased clinical
activity (1 hospital). The increase in DDD over time reversed to a
decrease in DBD and DAD. Hence the apparent increase in antibiotic
use was entirely due to a large increase in clinical activity.
3. Divergence between DBD and DAD (2 hospitals). The increase in
DDD was reversed when adjusted for admissions but persisted when
adjusted for bed days. The divergent results were a consequence of an
increasing number of admissions combined with reducing length of
stay. The apparent increase in antibiotic use was likely to be explained
by increase in clinical activity.
4. Decreasing antibiotic use that was not fully explained by decreased
clinical activity (3 hospitals).
5. Decreasing antibiotic use that was entirely explained by decreased
clinical activity (1 hospital).
Conclusions: Interpretation of longitudinal surveillance data about
antibiotic use is facilitated by presentation of changes in DDD without
adjustment for clinical activity in addition to adjusted data. Antibiotic
use is inﬂuenced by number of admissions and by length of stay;
consequently adjustment for clinical activity should be done with both
admissions and occupied bed days.
O399 Performance of the TREAT decision support system in an
environment with low prevalence of resistant pathogens
A. Zalounina, K. Kofoed, M. Paul, G. Lisby, L. Leibovici,
S. Andreassen, O. Andersen for the TREAT Working Group
Objectives: The decision support system for antibiotic treatment TREAT
[1] has been shown to improve appropriateness of antibiotic therapy and
reduce cost in regions with intermediate or high prevalence of resistant
bacterial strains. The purpose of this study was to explore if TREAT can
achieve similar improvements in Denmark, which has a low prevalence
of resistant bacterial strains.
Methods: A retrospective trial of TREAT has been performed at
Copenhagen University, Hvidovre Hospital. The system was calibrated
by local data (e.g., distribution of pathogens, resistance to antibiotics,
various administrative factors). The study was based on a database
with detailed clinical data on adult patients with suspicion of moderate
to severe infections, collected in 2005–2006. The data included risk
factors for infections and pathogens, clinical and microbiological data,
physicians chosen therapy and results for susceptibility tests of isolated
pathogens. TREAT was tested empirically, i.e. in all cases (with
exception of 2) the morphology/identity of the isolate was neither known
to the physician nor to the system. Coverage (deﬁned as the percentage
of antibiotic treatment matching the susceptibility of isolated pathogen)
and cost of treatment obtained by TREAT were compared to clinical
practice.
Results: Out of 171 patients in the database, 161 fulﬁlled the inclusion
criteria previously applied in clinical trials of TREAT. Signiﬁcant clinical
isolates were found in 65 (40%) cases, among them 25 isolates from
the blood. Coverage achieved by TREAT in 65 patients with signiﬁcant
clinical isolates was 86%, while coverage achieved by the ﬁrst attending
clinical physician was 66% (OR 3.2, 95%CI 1.3−7.6, p = 0.009). The
mean costs (in Euro) per episode for TREAT were 76 for direct expenses
for antibiotics and administration, 96 for side effects, 310 for future
resistance; and in clinical practice 54, 126 and 289, respectively.
Conclusion: Coverage achieved by TREAT was signiﬁcantly higher than
coverage achieved by the physician. The costs obtained by the system
are lower in regard to side effects, and higher for direct expenses and
the pressure for future resistance. These results suggest that TREAT can
markedly improve appropriateness of antibiotic therapy and reduce cost
for side effects in regions with low prevalence of resistant pathogens.
Reference(s)
[1] The TREAT Working Group. J Antimicrob Chemother 2006; 58:
1238−45.
O400 European Surveillance of Antimicrobial Consumption
(ESAC): outpatient parenteral antibiotic treatment in Europe
S. Coenen, A. Muller, N. Adriaenssens, V. Vankerckhoven, E. Hendrickx,
H. Goossens and the ESAC Project Group
Objectives: To assess the proportion of outpatient parenteral antibiotic
treatment on the total outpatient antibiotic use in Europe, and to identify
the antibiotic groups and substances most commonly administered this
way.
Methods: The European Surveillance of Antimicrobial Consumption
(ESAC; www.esac.ua.ac.be) project, now funded by the European
Center for Disease Control and Prevention (ECDC; agreement number
2007/001), continues to collect data on antimicrobial consumption for
all Member States, candidate countries and EFTA-EEA countries using
the anatomic chemical therapeutic (ATC) and deﬁned daily dose (DDD)
classiﬁcation. For 2005, data on outpatient use of antibacterial for
systemic use (ATC J01), aggregated at the level of the active substance
and expressed in DDD per 1000 inhabitants per day (DID; WHO version
2007) were extracted by route of administration and by country. The
primary outcome measure is the total parenteral use expressed as a
percentage of the total outpatient antibiotic use in DID.
Results: The average proportion of outpatient parenteral antibiotic
treatment in 20 (total use data for Greece, Bulgaria and Iceland)
European countries in 2005 is 1.77%, ranging from 12.33% in Russia
to 0.01% in Czech Republic (see ﬁgure), while the total outpatient use
ranges from 28.94 DID in France (34.73 DID in Greece is total use) to
in Russia 9.16 DID. The three most commonly used antibiotic groups
for parenteral treatment are the cephalosporins (J01D; 43.36%, from
73.68% in Finland to 0% in Norway), the penicillins (J01C; 24.44%,
from 74.49% in Hungary to 0% in Norway) and the aminoglycosides
(J01G; 13.81%, from 75.28% in Norway to 0% in Estonia). The three
most commonly used antibiotic substances for parenteral treatment are
cefazolin (J01DB04; 12.02%, from 35.89% in Russia to 0% in more than
one country), ceftriaxone (J01DD04; 10.89%, from 50.04% in France to
0% in more than one country) and cefuroxime (J01DC02; 7.32%, from
48.35% in Poland to 0% in more than one country).
Conclusion: Outpatient parenteral antibiotic treatment only represents
more than 1% of the total outpatient antibiotic use in 6 out of the 20
European countries studied. However, as for the total outpatient antibiotic
use and the use of different antibiotic groups and substances, there is a
striking variation in the proportions of parenteral antibiotic use in Europe
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as well. More in-depth data on outpatient antibiotic use are needed to
explain this variation.
O401 Prevalence of antibiotic prescriptions in healthcare facilities,
France, 2006
S. Maugat, L. Lacave´, F. L’He´riteau, C. Gautier, H. Tronel,
M.H. Metzger, P. Jarno, J.M. Thiolet, B. Coignard on behalf of the
RAISIN Study Group
Background: Antibiotic (ATB) consumption in healthcare facilities
(HCF) in France is one of the highest among European countries. In
June 2006, we conducted a prevalence survey of nosocomial infections
(NI) in French HCF in which we also assessed the prevalence of ATB
prescriptions, described their characteristics and by comparison to the
2001 survey assessed the impact of the national ATB programme.
Methods: The survey was proposed to public and private HCF and used
ATC5 codes. Data were collected in a standardised manner by trained
personnel in HCF and sent by encrypted e-mail to regional infection
control coordinating centres (CClin) and the French Institute for Public
Health Surveillance (InVS). The prevalence of patients with an ATB
prescription (PPATB) was compared between 2001 and 2006 among
HCF that participated in both surveys.
Results: Among 358 353 patients included from 2 337 HCF (accounting
for 95% of all French hospital beds), 55 624 (15.5%) received an ATB
and 74 515 compounds were given to patients. PPATB was higher
in acute care (24.8%), especially intensive care units (49.0%), than
in rehabilitation (9.9%) or in long term care (4.3%). PPATB varied
with treatment indication: community-acquired infection (7.4%), NI
(3.9%), surgical antibioprophylaxis (2.4%), prophylaxis of opportunistic
infections (1.3%) or multiple indications (0.5%). The ﬁve more
prescribed molecules were amoxicillin-clavulanic acid (PPATB= 4.4%),
oﬂoxacin (1.8%), amoxicillin (1.5%), ceftriaxone (1.4%) or ciproﬂoxacin
(1.3%). In the 1 351 HCF participating in both surveys, PPATB
slightly increased from 2001 to 2006 (16.4% vs. 16.7%), especially
in intensive care units, but decreased in obstetrics, rehabilitation, long
term care or psychiatry. PPATB decreased for NI (4.5% vs. 4.1%) or
prophylaxis (4.1% vs. 3.8%). For community-acquired infections, it
evolved differently according to patients’ age, decreasing (10.2% vs.
8.6%) before 6 years, and increasing (8.2% vs. 8.8%) after 44 years.
PPATB for ﬂuoroquinolones or third-generation cephalosporins increased
(+9% and +15%, respectively).
Conclusion: The overall prevalence of patients with an ATB prescription
in French HCF did not decrease from 2001 to 2006. Further studies are
needed to understand the reasons. Prudent use of ATB remains a priority
in France.
O402 Restriction of cephalosporins do not alter the burden
of cephalosporin resistant Klebsiella pneumoniae and
Escherichia coli in a surgical ICU
E. Meyer, M. Lapatschek, A. Bechthold, G. Schwarzkopf, D. Monnet,
P. Gastmeier, F. Schwab (Freiburg, Munich, DE; Stockholm, SE;
Berlin, DE)
Objective: To test whether a reduction of third-generation cephalosporin
(3GC)use has a sustainable positive impact on the high endemic
prevalence of 3GC-resistant K. pneumoniae and E. coli in a surgical
intensive care unit (ICU).
Intervention: Switch from 3GC to piperacillin in combination with
a b-lactamase-inhibitor as standard therapy for peritonitis and other
intraabominal infections in 7/2004.
Methods: Segmented regression analysis of interrupted time series was
used to analyse antibiotic consumption and resistance data 30 months
before and 30 after the intervention. Antimicrobial usage density (AD)
was expressed as daily deﬁned doses (DDD) and normalised per 1000
patient-days. The proportion of resistant isolates (RP) is calculated by
dividing the number of resistant isolates by the total number of the
isolates of this species tested against this antibiotic multiplied by 100.
The resistance densities (RD) are expressed as the number of resistant
isolates of a species/1000 pd.
Results: The intervention was associated with a signiﬁcant and
sustainable decrease in the use of 3GC. Use decreased from 178.9 before
to 68.7 DDD/1000 pd. The intervention resulted in a mean estimated
reduction of total antibiotic use of −375.0 DDD/1000 pd, which is
equivalent to a 27% reduction. Total antibiotic use showed no signiﬁcant
month to month change before and after the intervention. Piperacillin
and piperacillin/tazobactam showed a signiﬁcant increase in level of 64.4
DDD/1000 pd and continued to increase by 2.3 DDD/1000 pd per month
after the intervention.
The intervention was not associated with a signiﬁcant quarterly change
in the RD of K. pneumoniae and E. coli resistant to 3GC. In contrast,
the reduced use of 3GC and the switch to piperacillin was followed by a
continuous increase in the RD of E. coli resistant to piperacillin by 0.5
per 1000 pd per quarter and by a continuous decrease of P. aeruginosa
resistant to piperacillin of 0.1 per quarter.
Conclusion: We conclude that concentratiing on the reduction of 3rd
generation cephalosporins is not necessarily followed by a positive
impact on the resistance situation in the ICU setting. Replacement with
piperacillin with b-lactamase inhibitor might likewise provide a selection
pressure on 3GC-resistant E. coli and K. pneumoniae. To improve
resistance it might not be sufﬁcient to restrict interventions to a risk
area, rather, it may be essential to include the whole hospital and even
the community.
O403 Consensus development of quality indicators for hospital
antibiotic use: the ABS International Quality Indicators
Sub-Project
M.J. Struelens, F. Buyle, R. Mechtler, S. Metz-Gercek, W. Kern,
A. Lechner, H. Mittermayer, F. Allerberger and the ABS QI Team
Members
Objectives: To develop valid Quality Indicators (QI) to assess clinical
performance of antibiotic use, as part of the Antibiotic Strategy
International, an EU-Project aiming at improving antibiotic therapy in
hospital care.
Methods. An international team of 12 experts in four disciplines
developed and selected QIs for structure (hospital organisation and
resources), processes of care (diagnostic, treatment and prophylactic
practice) and outcome (drug use). The development of QIs was achieved
in 3 steps: a) identiﬁcation of QIs in the literature; b) multi-criteria
scoring and ranking based on scientiﬁc value and applicability; c) general
discussion and ﬁnal consensus QIs selection.
Results: Based on 105 potential QIs, 55 structural, 13 process
and 3 outcome QIs were selected and developed. Structural QIs
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described the organisation and resources as well as communication
and evaluation tools available at hospital level for implementing a
multimodal, multidisciplinary antibiotic stewardship programme. Process
QIs focussed on four care processes: 1) surgical prophylaxis (indication,
drug choice, timing and duration of administration); 2) management of
community-acquired pneumonia (blood culture and Legionella antigen
tests and drug choice for empirical treatment); 3) management of
Staphylococcus aureus bacteraemia (echocardiography, IV catheter
removal and duration of effective therapy); and 4) IV-PO switch for
treatment with equivalent bio-available antibiotics. Outcome indicators
focussed on antibiotic use.
Conclusions: This international consensus development of structural
and process QIs provides tools for evaluating the intensity of hospital
antibiotic stewardship programmes and auditing key treatment and
prophylactic practices. Process QIs will be tested for feasibility,
reliability and sensitivity to improvement in pilot hospitals.
O404 Changes in patterns of antimicrobial use in Swedish
hospitals from 2003 to 2006 following the introduction of
large-scale nationwide point prevalence studies
M. Erntell, G. Skoog, O. Cars, S. Elowson, H. Hanberger, C. Jorup,
I. Odenholt, M. Prag, K. Ska¨rlund, J. Struwe, E. Torell, P. Ulleryd
(Stockholm, SE)
Objectives: The objective of the studies was to perform descriptive point
prevalence studies (PPS) of antimicrobial use in relation to diagnoses in
Swedish hospitals.
Method: The protocol was designed to present demographic data as
well as the amounts and indications for antimicrobial agents. Treatments
were recorded in relation to diagnoses, prophylactic use, community
acquired (CAI) and hospital acquired infection (HAI). Three nation-wide
PPS were performed in November 2003, 2004 and 2006. Three areas
were identiﬁed for intervention before the last PPS; duration of peri-
operative prophylaxis, treatment of community-acquired pneumonia, use
of ﬂuoroquinolones in community-acquired cystitis in women. Direct
information to all hospital physicians and feed-back of earlier results
was used as the intervention strategy.
Results: 13,420 patients treated with antimicrobial agents in 54, 49 and
64 hospitals were included in the three PPS. The number of admitted
patients corresponds to 50−75% of all admitted patients in Sweden
during one day. 32.5−34.9% of the admitted patients were treated with
antimicrobials. The indication for treatment was CAI in 17.0−18.0%,
HAI in 9.2−9.9% and prophylaxis in 6.3%. For adults cultures were taken
before oral treatment in 60% and before parenteral treatment in 70%.
Only minor changes in the patterns of the overall use of antimicrobials
were observed. However, in lower urinary tract infections of women the
relative use of mecillinam and trimethoprim increased from 36 to 44%
and from 22 to 26%, respectively, while the use of ﬂuoroquinolones
decreased from 25 to 13%. For community acquired pneumonia no
signiﬁcant changes were observed. The 2006 PPS result shows a decrease
of peri-operative treatments longer than one day from 47% in 2003
to 31% in 2006. The one-dose peri-operative prophylaxis in the lower
gastrointestinal tract has increased from 62% to 77%. The total amount
of antimicrobials used for adults was 40.3, 43.1 and 43.3 DDD/100
admitted patients, respectively.
Conclusions: The PPS method has become a valuable tool in Sweden to
describe the patterns of antibiotic use. The 2006 PPS showed after the
interventions during 2005 and 2006 changes of antimicrobial use in peri-
operative prophylaxis with shorter therapies and less ﬂuoroquinolones
in treatment of community acquired cystitis in women. However,
in treatment of community acquired pneumonia cephalosporins still
dominates and are included in more than 35% of all therapies.
Travel medicine, tropical and parasitic
diseases
O405 Molecular methods for accurate diagnosis and
epidemiological picture of imported malaria
A. Calderaro, G. Piccolo, C. Gorrini, S. Peruzzi, G. Dettori, C. Chezzi,
G. Snounou (Parma, IT; Paris, FR)
Objectives: Malaria is the most frequent imported infection in Italy,
related to the increasing number of travellers and migratory ﬂows from
endemic countries.
Microscopic examination has poor sensitivity and may give problems
in the differentiation of Plasmodium falciparum (Pf), P. malariae (Pm),
P. ovale (Po), and P. vivax (Pv), especially in cases of low parasitaemia or
mixed infections: to circumvent these limitations molecular assays based
on 18S-rDNA were developed by several research groups, including us.
Our study aimed to accurately and promptly diagnose cases of malaria
and to describe their occurrence in our area comparing the results of
microscopy and molecular assays, in order to assess the usefulness of
these assays in the diagnostic practice.
Methods: Blood samples from 701 patients presenting to the University
Hospital of Parma from 2000 to 2007 with clinical suspicion of
malaria were subjected to microscopic examination and to 6 different
PCR protocols targeting plasmodial 18S-rDNA alternatively used during
2000−07, including nested- and Real-time PCR assays.
Results: By microscopy 153 cases of malaria were diagnosed [129 Pf
(84.3%), 7 Po (4.6%), 10 Pv (6.5%), 5 P. spp. (3.3%), 1 Pf/P. spp.
(0.65%), 1 mixed infection (0.65%)], whilst 159 were diagnosed by PCRs
[129 Pf (81.1%), 14 Po (8.8%), 6 Pv (3.8%), 3 Pm (1.9%), 7 mixed
infections (4.4%)].
Conclusion: Despite microscopy remains the reference diagnostic
method (rapid and inexpensive), in some cases molecular assays are
the only ones allowing a correct diagnosis of malaria, particularly to
detect infections by species other than Pf and mixed infections.
However, in our study only one PCR assay developed by us showed the
higher accuracy in Po detection due to speciﬁc primer design done to
recognise all the variants in Po 18S-rRNA gene.
PCR proved to be more sensitive and speciﬁc than microscopy and
changed the picture of malaria epidemiology in our area detecting 5
single and 1 mixed infections missed by microscopy, revealing 5 single
and 2 mixed infections incorrectly diagnosed by microscopy and giving
speciation in 6 cases in which microscopy had limited the result to genus
identiﬁcation.
The most prevalent malaria cases in our area as well as in Italy were
imported from Africa and due to Pf, followed by Po and Pv.
In our experience a rapid and accurate diagnosis of malaria allowed to
administer a prompt and targeted therapy with positive impact on the
clinical management of the patients.
O406 Seroprevalence of Chagas’ disease in a general university
hosiptal in Valencia, Spain
T. Fraile Farin˜as, S. Martin Guerra, L. Almin˜ana Martinez, P. Tamarit
Del Horno, N. Gomez Mun˜oz, M. Garcia Rodriguez, P. Segarra Perez,
C. Parada Barba (Valencia, ES)
Introduction: Chagas’ disease is caused by infection with the protozoan
agent Trypanosoma cruzi (T. cruzi).
Represents a serious blood safety problem due to increasing inmigration
from Latin America. Outside of endemic areas, Chagas disease may
be transmitted from the transfusion of infected blood components,
congenital infections and organ transplantations.
The aim of this study is to determinate the seroprevalence of the T. cruzi
antibodies in samples of people from endemic countries, people that
travelling at these countries and sons from affected mothers born in
Spain.
Methods: In 246 samples of 234 patients from 11 countries,
we were tested by enzyme-linked inmunoassay (ELISA) (Dade
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Behring CHAG0560DB) for IgG antibodies against T. cruzi, and
indirect inmunoﬂuorescence (IFI) (Biocientı´ﬁca SA Inmunoﬂuor Chagas
NF09−60) for IgG (Bio-Me´rieux 75 692) and IgM (Bio-Me´rieux 75 672)
antibodies.
Results: The percentage of positive samples was 58 (23.58%)and their
distribution as follows: 40 Bolivia’s patients (69%), 2 from Ecuador
(3.5%), 2 from Colombia (3.5%), 1 from Chile (1.75%) and 13 from
Spain (22.25%).
Between the 13 Spanish’s patients 7 of them were children (age between
0 and 6 years old); and the other 6 remaining patients were adult women.
These 6 women, ﬁtting of endemic areas were obtained nationality in
Spain.
We were detected IgM antibodies in 4 of the 7 children and also one
child we were found a positive result by PCR.
Conclusion: The seroprevalence that we found in our considered samples
was about 23.58% and the country with higher seroprevalence was
Bolivia.
Many other countries showed relevant seroprevalence especially Latin-
American countries; and that suppose migrations are a risk factor in
destinations countries.
For this reason, Spain could be in a near future in Chagas’s disease world
distribution.
It’s remarkable one case of vertical transmission with IgG and IgM
antibodies and positive PCR. According to vertical transmission; children
become a high risky population sector and this fact may be considered,
not only about infected mothers.
O407 10 years of cutaneous leishmaniasis treatment in Liverpool.
Outcomes and complications with sodium stibogluconate
D. Sloan, H. Williamson, A. Young, T. O’Dempsey, A. Miller,
N. Beeching (Liverpool, UK)
Background: The incidence of cutaneous leishmaniasis (CL) in the
UK is rising. Adverse events associated with intravenous sodium
stibogluconate (SbV) therapy include biochemical, haematological and
cardiac toxicity, and intravenous catheter problems. An audit of CL in-
patients receiving parenteral SbV in Liverpool from 1998–2007 was
conducted to assess the cure rate and identify treatment complications.
Methods: CL was diagnosed by impression smear, culture, histology or
PCR. SbV was given for 10−20 days, often via a Peripherally Inserted
Central Catheter (PICC). Blood and ECG monitoring was done thrice
weekly. Case-notes were reviewed retrospectively. Drug delivery and
treatment outcomes were recorded for every patient. PICC complications
with SbV infusion were compared with those for other drugs on the
same ward. Abnormal blood results and ECG changes were analysed.
Treatment interruptions due to adverse events were documented.
Results: 72 patients were studied. 23 (32%), mainly with Old
World CL, received 10mg/kg SbV for 10−20 days (Group A). 49
(68%), mainly with New World CL, received 20mg/kg for 20 days
(Group B). 71 (99%) patients were cured or clinically improved
by discharge. 5 (7%) subsequently developed disease recurrence.
14/58 (24%) patients receiving SbV via PICCs required premature
line removal with thombophlebitis. Line infection was microbiologically
conﬁrmed in 6 (10%) cases. SbV was associated with signiﬁcantly
more PICC complications than other drugs (Relative Risk 3.53, 95%
Conﬁdence Interval: 1.68−7.40). Hyperamylasaemia, thrombocytopenia
and QTc prolongation were statistically more common amongst Group B
patients but never required cessation of therapy. All patients developed
biochemical transaminitis but this resulted in treatment interruption on
only 4 (5.9%) occasions.
Conclusions:
1. Intravenous SbV achieves a high cure rate in CL.
2. Biochemical, haematological and cardiac toxicity is well reported but
rarely requires interruption of therapy.
3. PICC lines for SbV infusion are associated with more complications
than those inserted for other drugs. Frequently changed peripheral
cannulae may be preferable.
O408 A water ﬁltration method using river sand and activated
carbons for the removal of intestinal protozoan parasites in
contaminated drinking water at a point-of-use treatment
S. Zinyowera, C. Muchaneta-Kubara, N. Midzi, S. Moyo, D. Saungweme,
P. Nziramasanga, T. Mduluza (Harare, ZW; Baltmore, US)
Introduction: Drinking water that is contaminated with micro-organisms
causes an estimated 6 to 60 million cases of gastrointestinal illness
annually, worldwide. WHO and UNICEF estimate that approximately
2.2 million die of waterborne diseases each year. Clean safe water
is mendatory to every household. Chlorine which is used for water
disinfection does not kill protozoan parasites.
Objectives: To analyse sand ﬁlters and different types of activated
carbons, experimentally in their capability in removing protozoan
parasites from drinking water.
Materials and Methods: Known human intestinal protozoan parasites
were put in water which was poured in to either a metal or plastic bucket
with a mesh screen at the bottom. The bucket contained either coarse
or very ﬁne sand. The water collected after ﬁltration was then spun
and analysed for protozoan parasites. Activated carbons; namely baobab
shells, macadamia nut shells, amarula stones, local wood carbons,
commercial activated carbons and the activated carbons used by the
Zimbabwe National Water Authority (ZINWA) at their water treatment
plants, were analysed separately. Each activated carbon was placed in
distilled water that had known amounts of protozoan parasites and
incubated for 24 hours with constant shaking at room temperature. The
water was then sieved using a tested cotton cloth that allowed parasites
to pass through, spun and then analysed for protozoan parasites.
Results and Conclusions: Very ﬁne sand was more efﬁcient in capturing
protozoan parasites (99%) than coarse sand (80%). Activated local wood
charcoal reduced the number of parasites in water by 17%, whilst
commercial activated carbon adsorbed all other intestinal protozoan
parasites except for Entamoeba coli that was reduced by 98%. Amarula
stones reduced parasites by 33.5%, activated carbon from ZINWA
reduced parasites by 99.6% whilst activated carbons from baobab shells
and macadamia nut shells completely adsorbed parasites by 99.99%.
All the activated carbons were capable of adsorbing Giardia lamblia by
99.99% except for the ZINWA activated carbon (99.6%). Very ﬁne sand
in combination with either commercial carbon, activated wood carbon
or activated carbons from baobab shells and macadamia nutshells are
potential useful media to use as household point of use treatment of
water for the removal of parasites before application of another method
such as chlorination in order to kill bacterial cells.
O409 Implementing molecular detection of gastro-intestinal proto-
zoa and implications for an algorithm for complete parasito-
logical diagnostics in the microbiological laboratory routine
L.E.S. Bruijnesteijn van Coppenraet, J.A. Wallinga, G.J.H.M. Ruijs,
M.J. Bruins, M.J.H.M. Wolfhagen, J.J. Verweij (Zwolle, Leiden, NL)
Introduction: Molecular assays for detection of Entamoeba histolytica,
Giardia lamblia, Cryptosporidium hominis/parvum, and, respectively,
Dientamoeba fragilis have already been described. They were more
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sensitive and/or speciﬁc than microscopy but are to date not routinely
applied as replacement of the time-consuming microscopic analysis for
protozoal gastrointestinal (GI) pathogens.
An internally controlled molecular assay for the simultaneous detection
of all four protozoa in a single faeces sample was validated and compared
to the Triple Feces Test (TFT) microscopic analysis. Also, an algorithm
for the complete parasitological diagnosis after implementation of the
real-time PCR assay in the laboratory routine was created.
Methods: TFT sets (2 ﬁxed and 1 unpreserved faecal sample), were
collected from 397 consecutive patients. The complete TFT set was
examined for GI parasites by microscopy and compared to multiplex
real-time PCR for E. histolytica, G. lamblia, C. hominis/parvum, and
D. fragilis, applied on the unpreserved faeces samples. Faecal DNA
was extracted by Nuclisens easyMAG (Biomerieux) with Phocid Herpes
Virus added as internal inhibition control.
Also, microscopic results and clinical patient information of 2887 TFT
sets were analysed retrospectively to determine local risk-factors for
infection with non-protozoal GI parasites.
Results: Real-time PCR of 397 unpreserved samples yielded 169 (43%)
positives (44 (11.1%) samples positive for G. lamblia, 122 (30.7%)
positive for D. fragilis and 3 (0.8%) positive for C. hominis/parvum),
while microscopy of the TFT samples yielded 100 (25%) positives (29
(7.3%) samples positive for G. lamblia, 69 (17.4%) positive for D. fragilis
and 2 (0.5%) positive for C. hominis/parvum, respectively).
Analysis of the 2887 TFT sets showed eosinophilia, elevated IgE and
travelling to (sub) tropical areas to be risk-factors for non-protozoal GI
parasites. The resulting diagnostic algorithm includes application of real-
time PCR on all samples, adding microscopy on an unpreserved faecal
sample only in case of presence of a risk factor.
Conclusions: 1) Application of real-time PCR improved the diagnostic
yield with 18%. 2) A single unpreserved faecal sample is sufﬁcient for
complete parasitological diagnosis when an algorithm based on clinical
patient information is applied.
O410 Travel characteristics and main diagnoses observed in ill
returned travellers
A. Perez-Ayala, J. Perez-Molina, P. Zamarron, F. Norman, C. Jimenez,
M. Navarro, R. Lopez-Velez (Madrid, ES)
Objectives: To study the main diagnoses among returning travellers with
respect to the geographical area visited, length and type of travel
Methods: The Tropical Medicine Unit at the Ramon y Cajal Hospital, is
a referral unit where immigrants and ill returned travellers are attended
since year 1989. A comprehensive microbiological study was performed
in all the cases.
Length of travel was divided into three groups: <30 (Short), 30–180
(Medium) and >180 days (Long-term); whereas type of travel was
classiﬁed into four groups: professional high and low risk (PHR; PLR),
tourism high and low risk (THR, TLR).
Discrete variables were compared by means of Chi squared or Fisher
exact test. For quantitative data an independent samples t-test was used.
Results: 2993 travellers consulted our department during 1989–2006,
with a progressive increase in the number of patients over the years. The
mean age of the travellers was 35 years (interquartile range: 28−40) and
there were 47.9% of women.
The main diagnoses were: suspected bacterial gastrointestinal infections
(16.3%), 16.7% of them had bacterial growth conﬁrmation (S. sonnei:
36.5%, Salmonella sp: 29.2%, Campylobacter sp: 13.4% and C. difﬁcile:
9.7%) and were observed mainly in travellers to North Africa and South-
West Asia. The second most frequent diagnosis was parasitic intestinal
infection (12.8%): G. lamblia: 28.2%, E. histolytica: 14.9%, T. saginata:
6.2%, A. lumbricoides: 3.3% and S. stercoralis: 2.6%; in 42.7% of the
cases more than one parasite was found. The third diagnosis in order
of frequency was malaria (9.5%. produced by P. falciparum: 53.7%,
followed by P. vivax: 17.5%), acquired mainly in Subsaharan Africa
(16.9%)
Conclusion: Both type and length of travel were associated with bacterial
GI infections (TLR and <30 days). Only travel length was a determinant
for parasitic GI infections (increased risk for travel >30 days) Malaria
was only associated with type of travel (less risk in TLR).
Type of Travel
Diagnose (%) PLR TLR THR PHR p
Bacterial GI infection 12.5 20.0 17.8 13.9 <0.001
Parasitic GI infection 12.1 10.9 14.3 14.4 ns
Malaria 12.1 6.3 10.2 11.1 <0.001
Travel Length
Diagnose (%) <30 days 30–180 days >180 days p
Bacterial GI infection 19.7 15.1 10.0 <0.001
Parasitic GI infection 11.2 14.5 14.8 0.02
Malaria 9.0 10.3 10.0 ns
O411 Cutaneous myiasis in two Dutch patients with and without
a history of recent travel
F. Bosma, R. Koopman, M. van Kerckhoven, B. Mulder (Enschede, NL)
Objectives: Myiasis is caused by infestation of the skin by larvae
of several dipterous (2-winged) ﬂies and occurs mainly in tropical
climates, predominantly affecting animal hosts. Human infection can
occur through wearing egg-contaminated clothes or through an insect
bite, when the insect carries eggs. After penetrating the skin painlessly,
stage I larvae mature subcutaneously and emerge ﬁnally through the skin.
This leads to erythematous nodules containing a single larva. Gradually
a central hole develops, which may discharge ﬂuid or pus and the white
body of the larva may protrude.
Cutaneous myiasis is endemic to South and Middle America (Dermato-
bia hominis) and Sub-Sahara Africa (Cordylobia antropophaga; tumbu
ﬂy).
Methods: We describe two patients with furuncular myiasis, one with
and another without a history of travel to an endemic area. Myiasis is
rarely seen in the Netherlands.
Results: Case 1. A Dutch patient with no history of recent travel
presented at his general practitioner with two furuncular lesions at his
back, which were itchy and painfull. Four weeks earlier, the patient had
noticed an insect bite at the same location. When the patient did not
respond to one week of doxycycline, the diagnosis cutaneous myiasis
was established.
Case 2. A 50-year-old man travelled through the Amazon region for
several months. Two months after his return to the Netherlands, he visited
a dermatologist as he had a persistent skin lesion on his left shoulder
and was worried about having acquired Leishmaniasis. This was ruled
out by microscopy and culture of a skin biopsy. At his second visit to
the dermatology department, a central hole had occurred in the lesion
and a Dermatobia hominis larva was noticed and removed. Afterwards,
he reported having felt movements in his skin, but had contributed this
to his imagination.
Conclusion: Cutaneous myiasis is rarely seen in the Netherlands and
should not only be considered in a traveller returning from an endemic
area, but also in patients with persistent skin lesions after an insect bite
and no history of travel.
O412 Schistosomiasis in Shefﬁeld 2002–2007. Our experience
R. Gowda, A. Vedio, M.W. McKendrick (Shefﬁeld, UK)
Objectives: Schistosomiasis is a parasitic infection acquired in the
tropics by exposure to freshwater. Chronic infection may result in serious
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sequelae such as portal hypertension & bladder cancer. Early diagnosis
& therapy is thus crucial.
We describe the epidemiology, clinical features & management of
schistosomiasis in Shefﬁeld
Methods: Pharmacy records were used to identify all patients treated
with Praziquantel between 2002–2007. Case notes of patients treated for
Schistosomiasis were reviewed retrospectively. Best practice guidelines
were devised following a literature review and then data on country
of infection, appropriate history, clinical features, laboratory data, HIV
status and details of treatment were collected.
Results: 90/105 cases treated with praziquantel during the period were
for schistosomiasis. A proven diagnosis of schistosomiasis was made
in 13 patients by ova detection; others were diagnosed by serology.
69 (77%) cases were migrants and only 19 (23%) were travellers. The
majority were from Africa. Only 29 (32%) cases had a full history and
only 42 (47%) were investigated fully. Clinical presentation was often
subclinical or non-speciﬁc. Eosinophilia was present in only 32/87 (37%)
cases tested and only 15/32 (47%) of these cases resolved after treatment.
86 (96%) cases were treated with the appropriate doses of praziquantel
but only 22 (24%) had a repeat course 6 months later. 18 of 34 (53%)
cases of schistosomiasis tested for HIV were positive although 56 cases
were untested.
Conclusions: Schistosomiasis is a huge global burden affecting 200
million people. Increasing migration from and travel to endemic areas
has lead to an increase in incidence in Shefﬁeld.
In our study, history and investigation was often incomplete with a risk
of cases being missed. Eosinophilia was inconsistent and not reliable
marker.
Only 24% of cases had the recommended repeat course of praziquantel.
Although HIV was common in our patients, our HIV patients are
routinely screened for schistosomiasis and thus this may represent a bias.
Other study limitations are that diagnosis was usually made by serology
and only patients identiﬁed by praziquantel treatment are included.
Nevertheless, this study raises important issues of screening, awareness
of epidemiology and the importance of prompt effective treatment of
even subclinical infection. Other issues such as the best method of
diagnosis and sensitivity of serology will also be discussed.
O413 Travel-associated enteric fever in England, Wales, and
Northern Ireland: results from an enhanced surveillance pilot
J. Lawrence, J. Jones, E.J. Threlfall (London, UK)
Objectives: On average, 178 cases of typhoid and 203 cases of
paratyphoid (181 A, 22 B) have been diagnosed in England, Wales,
and Northern Ireland (EWNI) each year. Routine laboratory reporting
systems only capture two thirds of travel history information, and other
information such as reason for travel, ethnicity, country of birth, and
vaccine history is not routinely collected. To learn more about enteric
fever reported in EWNI, a pilot study of enhanced surveillance of cases
began 1 May 2006. The main ﬁndings from this pilot after one year of
data collection are outlined.
Method: An enhanced questionnaire was completed for each laboratory-
conﬁrmed case of enteric fever as part of routine follow up according
to United Kingdom (UK) guidelines. The information was collected in
a MS Access database and cases known to have travelled abroad from
the UK, with onset dates between 1 May 2006 and 30 April 2007, were
extracted and analysed using MS Excel.
Results: During the report period, there were 163 cases of paratyphoid
A, two cases of paratyphoid B, and 129 cases of typhoid associated
with travel abroad. The majority (93%) had travelled to the Indian
sub-continent (ISC) (India, Pakistan, or Bangladesh). The highest rate
of infection per 100,000 visits was in all cases who had travelled to
Bangladesh (29.09 per 100,000 visits), followed by Pakistan (22.31),
and India (14.17). The rates increased in those who travelled to visit
friends and relatives (VFRs). Of 252 VFRs, 87% (219/252) were of
Indian, Pakistani, or Bangladeshi ethnicity, of which 34% were UK born
and 51% were non-UK born, the majority of which were born in their
country of ethnic origin and had travelled back as VFRs.
Fifty-four cases (12 with typhoid and 42 with paratyphoid A) had
received typhoid vaccine within the three years before travel. This varied
by ethnicity; of those of Indian, Pakistani, or Bangladeshi ethnicity, 18%
received typhoid vaccine compared to 47% of cases of white ethnicity.
Conclusion: The pilot has provided evidence that the majority of typhoid
and paratyphoid cases reported in EWNI are in those of Indian, Pakistani,
or Bangladeshi ethnicity (either UK born or non-UK born), who have
travelled to the ISC as VFRs. Ethnicity may affect whether a traveller
is vaccinated against typhoid before travel. Enhanced surveillance of
enteric fevers in EWNI promises to be a useful tool for providing
an evidence base on which targeted pre-travel health advice can be
developed.
O414 Isolation of late-stage Plasmodium falciparum infected red
blood cells using a new cost- and time-saving magnetic cell
separation kit
S.C. Bhakdi, A. Hartmann, P. Sratogno, A. Chuncharunee,
H.P. Neumann, P. Malasit, K. Pattanapanyasat (Bangkok, TH; Mainz,
DE; Freiburg, DE)
Objectives: In malaria research, a large variety of assays require highly
puriﬁed infected red blood cells (iRBCs). Magnetic separation relies
on intrinsic magnetic properties of trophozoite and schizont (late-
stage) iRBCs and offers an alternative to conventional separation by
Percoll® gradients. Concentration of late-stage iRBCs by high gradient
magnetic separation (HGMS) was ﬁrst reported in 1981. In the nineties,
commercial HGMS columns with a polymer coated matrix became
available for high purity separation of malaria-iRBCs. Unfortunately,
high costs render their use unattractive for many laboratories. We adapted
a new low-cost HGMS kit for isolation of late-stage iRBCs from
Plasmodium falciparum cultures and compared costs to polymer-coated
HGMS columns and separation with Percoll® gradients.
Methods: Isolation of late-stage iRBCs from P. falciparum TM 267
cultures was performed in a Skypure HGMS system. 70–500ml of packed
RBCs with late-stage parasitaemias of 1.7−17.2% were used (total
parasitaemias 8.5−29.9%). This corresponded to app. 7−50×108 total
RBCs containing 2.6−49.4×107 late-stage iRBCs. Puriﬁcation results
were analysed by ﬂow cytometer and microscopy. Viability was evaluated
by calculation of infection rate after re-culture of isolates.
Results: Purity of iRBC isolates consistently ranged from 93.2% to
99.0% (mean 95.4%). Under optimised conditions, over 90% of isolated
iRBCs contained segmented schizonts (Figure 1). Maximum column
capacity was found to be 1 to 1.2×107 iRBCs. Processing time was
less than 45 min. Infection rate ranged from 21.0% to 56.4%. Cost
comparison showed 1.5−3 Euros for Percoll® gradient separation and
18−20 Euros for HGMS systems employing polymer-coated columns,
compared to 5−6 Euros for the HGMS system tested in this study (cost of
consumables per separation of 200ml packed cells from malaria cultures).
Conclusion: Compared to separation by Percoll® gradient, the new kit is
about 30% more time efﬁcient and offers highly consistent results, even
for isolation of segmented schizont iRBCs. When compared to polymer
coated columns, it offers app. 70% cost savings for consumables.
Therefore, the HGMS kit examined is considered highly suitable for
puriﬁcation of late-stage iRBCs.
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S415 Dual mode of action of telavancin against Staphylococcus
aureus
P. Courvalin (Paris, FR)
Glycopeptides, vancomycin and teicoplanin, bind to the C-terminal D-
alanyl-D-alanine (D-Ala-D-Ala) of lipid II peptidoglycan precursors
and block transglycosylation and transpeptidation reactions. Acquired
VanA- and VanB-type resistance in enterococci results from the
production of modiﬁed precursors ending in D-Ala-D-lactate (D-
Lac) to which glycopeptides exhibit low binding afﬁnities, and the
elimination of the D-Ala-D-Ala ending precursors synthesised by the
host Ddl ligase. VanA-type strains show high-level inducible resistance
to both glycopeptides, whereas VanB-type strains have variable levels
of inducible resistance to vancomycin only, as teicoplanin is not an
inducer. Six VanA-type meticillin resistant Staphylococcus aureus, that
have acquired the glycopeptide resistance vanA operon from enterococci,
have been isolated in North America. In contrast to VanA-type resistant
strains, S. aureus with intermediate level resistance to vancomycin
(GISA) and heterogenous GISA (hGISA) are becoming prevalent
worldwide. The mechanism of intermediate resistance in S. aureus is
not well understood. Telavancin is a lipoglycopeptide that possesses a
lipophilic decylaminoethyl sidechain added to the vancosamine sugar
of vancomycin; this substituent confers a dual mode of action: 1)Like
glycopeptides, telavancin binds to the C-terminus D-Ala-D-Ala of lipid
II intermediates in peptidoglycan synthesis. Molecular studies have
indicated that telavancin binds with 35-fold enhanced afﬁnity to the
membrane-embedded lipid II compared to the soluble target, thus
providing an explanation for the enhanced transglycosylation inhibition.
2)Direct interaction of the drug with lipid II leads to disruption of
the barrier function of the bacterial membrane. Exposure of S. aureus
to telavancin results in time- and concentration-dependant loss of
membrane potential and increased membrane permeability. Quantitative
ﬂow cytometry assays indicate that the majority of S. aureus are fully
depolarised within 1 hour following exposure to clinically relevant
telavancin concentrations. These data provide a mechanistic basis for
the potent activity of the drug against GISA/hGISA clinical isolates,
observed both in vitro and in vivo. In microorganisms with acquired
Van-type glycopeptide resistance, telavancin, like teicoplanin, is not
an inducer of the vanB gene cluster. Thus, VanA-type isolates have
reduced susceptibility to telavancin whereas VanB-type strains remain
fully susceptible.
S416 Telavancin: a novel lipoglycopeptide for treatment of
complicated skin and soft tissue infections
S.L. Barriere (South San Francisco, US)
Meticillin-resistant Staphylococcus aureus (MRSA) is a common
pathogen isolated from complicated skin and soft tissue infections
(cSSTIs). Telavancin is an investigational, rapidly bactericidal lipogly-
copeptide antibiotic with a multifunctional mechanism of action against
Gram-positive bacteria, including MRSA. Two large, international, Phase
3 studies (ATLAS 1 and 2) have compared the efﬁcacy and safety of
telavancin (10 mg/kg IV every 24 hours) with vancomycin (1 g IV
every 12 hours) in 1,867 patients with cSSTIs. Combined data from
ATLAS 1 and 2 have consistently shown that telavancin is non-inferior
to vancomycin for the treatment of patients with a cSSTI (clinical cure
88.3% versus 87.1%), including 579 patients with a cSSTI caused by
MRSA (clinical cure 90.6% versus 86.4%). Furthermore, telavancin had
an acceptable adverse event proﬁle for the treatment of serious infections
caused by resistant bacteria.
A subgroup analysis of the ATLAS studies compared clinical and
microbiological responses to treatment with telavancin or vancomycin in
194 patients with surgical site cSSTIs. Within this subgroup, telavancin
showed numerically superior efﬁcacy when compared with vancomycin
(clinical cure 86% versus 71% in MRSA-infected patients), however,
these differences did not reach statistical signiﬁcance.
Geographic differences were noted in the genotype of S. aureus isolates
from clinically and microbiologically evaluable patients with cSSTIs
enrolled in Phase 2 trials. Meticillin-susceptible S. aureus (MSSA)
isolates from South Africa were signiﬁcantly more likely to carry certain
toxin genes, including pvl, than MSSA isolates from the USA. Of the
MRSA isolates in the study, 86% were SCCmec IV and contained the
pvl gene. Patients infected with strains containing the pvl gene were
signiﬁcantly more likely to be cured of their cSSTI. In the ATLAS
studies, the pvl gene was detected in isolates from 64% (557/870) of
patients, with a higher rate of pvl-positivity in patients with MRSA
(459/543 [85%]) than MSSA isolates (98/327 [30%]). The outcome of
treatment with telavancin was unaffected by pvl status with clinical cure
rates similar for telavancin and vancomycin regardless of pvl status.
Telavancin may provide a useful alternative to vancomycin for treatment
of patients with cSSTIs, including those caused by MRSA, independent
of the expression of toxin genes such as pvl.
S417 Exploring new therapeutic options for hospital-acquired
pneumonia
A. Torres (Barcelona, ES)
Hospital-acquired pneumonia (HAP) is the most common healthcare-
acquired infection contributing to death. An increasing body of evidence
demonstrates that delayed HAP treatment or use of an inappropriate
antibiotic dramatically increases mortality. HAP is deﬁned as a
respiratory infection developing more than 48 hours after hospital
admission. In a proportion of patients, HAP is associated with
mechanical ventilation, in which case it is termed ventilator-associated
pneumonia (VAP). In patients with VAP there is a 20−55% mortality rate,
which increases to >70% if infection is caused by multidrug-resistant
pathogens.
Over the past 15 years, the incidence of nosocomial pneumonia due
to Gram-positive relative to Gram-negative organisms has increased.
Staphylococcus aureus, especially meticillin-resistant Staphylococcus
aureus (MRSA), and penicillin-resistant pneumococci are replacing
Gram-negative bacteria as predominant causes of nosocomial pneu-
monia. Telavancin is a novel, investigational, rapidly bactericidal
lipoglycopeptide with a multifunctional mechanism of action against
Gram-positive bacteria, including inhibition of cell wall peptidoglycan
synthesis and disruption of the functional integrity of the bacterial
membrane. Telavancin is rapidly bactericidal against a broad range of
clinically relevant Gram-positive bacteria, including MRSA.
Telavancin was recently evaluated in two large Phase 3 studies involving
patients with HAP, including patients with VAP, caused by Gram-positive
bacteria such as MRSA. These identical, multinational, multicentre,
randomised, double-blind studies compared the efﬁcacy and safety of
telavancin 10 mg/kg IV every 24 hours with vancomycin 1 g IV every
12 hours (dosing optimisation allowed per individual site guidelines)
for 7−21 days. Eligible patients included men and women, aged 18
years or older with HAP caused by suspected or conﬁrmed Gram-
positive pathogens. The primary efﬁcacy analysis in each study was
non-inferiority of telavancin compared with vancomycin in clinical cure
rates in clinically evaluable (CE) patients at the test-of-cure visit, 7 to
14 days after the end of study treatment.
Severe community-acquired pneumonia update: mortality, mechanisms and medical intervention (Symposium organised by Novartis Pharma) S93
Severe community-acquired pneumonia
update: mortality, mechanisms and medical
intervention (Symposium organised by
Novartis Pharma)
S418 Epidemiology, guidelines, processes of care and clinical
experience in severe community-acquired pneumonia
J. Rello (Tarragona, ES)
Mortality in CAP patients is <1% in outpatients, 5% in inpatients and
up to 25% in intubated patients. A recent study estimated mortality near
50% in ICU patients requiring inotropes. Site of care assessment based
on severity of illness is key, affecting diagnostic workup and empirical
antibiotics.
The Pneumonia Severity Index (PSI) can predict patients who can
be discharged home safely, but occasionally underestimates severity,
particularly in young patients without comorbidities who have severe
respiratory failure. The PSI has been useful in documenting outcomes
equivalence with empiric antibiotics, whereas delaying appropriate
antibiotics worsens survival in classes IV-V pneumococcal bacteremic
pneumonia.
CRB-65 is easy to use and identiﬁes patients at high risk of mortality
(who might beneﬁt from early ICU admission).
Recently updated IDSA/ATS guidelines for CAP (2007) include both
major and minor criteria indicative of the need for ICU admission.
These scores do not generally account for comorbidities, a potential
problem in older patients. Biomarkers may complement scores in
predicting outcomes.
Severity assessment based on the PIRO concept includes comorbidities
(COPD, immunocompromise), age >70years; multilobar opacities;
shock, severe hypoxaemia; acute renal failure; bacteraemia and ARDS.
PIRO score was obtained at ICU <24 h from admission and 1 point
given for each present feature (range 0−8 points). Mean PIRO score
was signiﬁcantly higher in non-survivors than in survivors (4.6±1.2
vs 2.3±1.4). Higher scores were signiﬁcantly associated with higher
mortality, prolonged length of ICU stay, and days of mechanical
ventilation (all p< 0.001). ROC curves showed PIRO score (AUC=0.88)
outperformed APACHE II (AUC=0.75, p< 0.01) and ATS/IDSA criteria
(AUC=0.80, p< 0.001) to predict 28-day mortality. CURB-65 achieved
an AUC of only 0.79.
As a predictor of admission to hospital, and HDU or ICU care, it
achieved an AUC of 0.88 and 0.64 respectively. We believe this highlights
the limitations of CURB-65 as a track and trigger tool. Postponing
oxygenation assessment >1h is associated with a signiﬁcant delay (>6h)
in initiating antibiotics. A delay in oxygenation assessment >3h is
associated with increased mortality (HR 2.06). Therefore we suggest
implementing a simple care bundle to improve management of CAP in
the ED, using 3 or 4 evidence-based variables, with immediate pulse
oxymetry and O2 assessment being the cornerstone and initial step.
S419 Infection as an initiation of coagulation and inﬂammation:
targeting the lung
T. van der Poll (Amsterdam, NL)
Patients with severe infections almost invariably show evidence of
activation of the coagulation system. The lungs are amongst the most
frequently affected organs during severe infection and sepsis. The
abundant presence of intravascular and extravascular ﬁbrin appears to
be a speciﬁc hallmark of acute lung injury following sepsis and is
much more obvious than the ﬁbrin deposition in other organs. Tissue
factor (TF) is regarded as the primary initiator of coagulation in severe
infection. Effective blocking of the tissue factor pathway by either
recombinant tissue factor pathway inhibitor (rTFPI) or anti-tissue factor
antibodies in experimental sepsis attenuates lung injury and partially
prevents pulmonary dysfunction. In addition, inhibition of tissue factor
activity prevents local activation of coagulation in models of pneumonia.
Another mechanism that contributes to ﬁbrin deposition in the lung is
the local depression of ﬁbrinolysis, due to the increase of plasminogen
activator inhibitor type I. These effects on pulmonary coagulation and
ﬁbrinolysis are regulated by various pro-inﬂammatory cytokines. This
lecture will discuss the regulation and impact of pulmonary coagulation
during severe infection.
S420 Rationale and the role of biologic adjunctive therapy in sCAP
P.-F. Laterre (Brussels, BE)
Tissue factor pathway inhibitor (TFPI) is an endogenous molecule having
both anti-inﬂammatory and anticoagulant activity. However, TFPI is
overwhelmed by increased expression of tissue factor (TF) in sCAP.
Tifacogin (recombinant TFPI) replenishes endogenous TFPI and restores
haemostasis.
A retrospective analysis of a large, randomised clinical trial of tifacogin
in patients with severe sepsis (OPTIMIST) revealed that patients with
CAP who had a documented microbial source of infection, who did
not receive concurrent heparin, or the combination of both, had lower
mortality compared with patients receiving placebo, even though no
signiﬁcant effect was seen in the overall severe sepsis population (Laterre
et al, Critical Care, submitted). These results suggest that tifacogin may
reduce mortality in patients with sCAP who did not require heparin.
This potential beneﬁt of tifacogin is currently being tested in the Phase
III CAPTIVATE study, in approximately 2100 patients. CAPTIVATE
will compare current sCAP standard of care with a combination of
sCAP standard of care plus adjunctive tifacogin, (either 0.025 mg/kg/hr
or 0.075 mg/kg/hr in a 96 hour continuous infusion). The study
objective is to determine whether treatment with tifacogin early in
the disease process can reduce incidence of mortality by preventing
the development of disseminated intravascular coagulation and multiple
organ system failure. Study entry criteria were based on the 2007
IDSA / ATS guidelines plus a clinical diagnosis of community-acquired
pneumonia. Speciﬁcally required are the presence of either 1 major
criterion (requirement for mechanical ventilation, or need for therapeutic
vasopressors), or 2 or more minor criteria (hypotension despite adequate
ﬂuid resuscitation, PaO2/FiO2 ratio <250, respiratory rate 30/min,
non-invasive ventilatory support, BUN> 7mM, new onset confusion,
multilobar pneumonia, platelet count <100,000 cells/mm3 or a fall of
>25% in previous 48 hours to <120,000, leukopenia or hypothermia).
The primary endpoint of the study is 28 day all cause mortality.
Secondary endpoints include treatment failure, need for mechanical
ventilation, incidence of disseminated intravascular coagulation, duration
of ICU admission, and length of hospitalisation. If an overall treatment
beneﬁt is observed with tifacogin, then pharmacoeconomic analysis will
also be performed. Survival data will also be collected at 90 days, 6
months, and 1 year to assess long-term safety.
S421 The role of biomarkers – predicting patients at risk of
decompensation and responders to adjunctive therapy
J.-P. Mira (Paris, FR)
Patients with severe sepsis show substantial abnormalities in several
biomarkers of inﬂammation and coagulation. These abnormalities have
been inconsistently correlated with syndrome severity, because of both
a major heterogeneity in the sources of infections (lung, abdomen,
urine, . . . ) and variability in causative microorganisms. Community-
acquired pneumonia (CAP) is the most common cause of community-
acquired severe sepsis in ICU, and represents a well characterised disease
with protocolised treatments. Hence, analysis of biomarkers in this
homogeneous population may be important to deﬁne disease severity
and candidates for new therapeutic approaches.
Subgroup analysis of results from the OPTIMIST study of tifacogin in
severe sepsis patients revealed a decrease in mortality in sCAP patients
treated with tifacogin who had a documented microbiological infection
and who were not concurrently treated with heparin. A trend toward
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reduced mortality was also seen in sCAP patients with procalcitonin
 2 ng/mL (Laterre et al, Critical Care, submitted) and in the overall
severe sepsis population with evidence of active coagulation (PF  3nM)
at baseline (Opal et al. IDSA 2004) who were treated with tifacogin.
These results warranted further investigation, and led to the initiation
of the CAPTIVATE study of tifacogin in 2100 patients with sCAP.
Moreover, resolution of the human genome has led to the discovery
of new genomics biomarkers associated with sCAP mortality.
It is hoped that by investigating both genomics markers and “classic”
biomarker level changes over the clinical course of the disease, that it
will be possible in the future to predict which patients are at potential
risk of decompensation, and which patients are most likely to beneﬁt
from early treatment such as tifacogin.
Oropharyngeal candidiasis: impact of new
treatment approaches on patient outcome
(Symposium organised by SpeBio)
S425 Oropharyngeal candidiasis in immunocompromised patients:
which burden? Importance of appropriate antimicrobial
treatment strategy
E. Bouza (Madrid, ES)
Oropharyngeal candidiasis (OPC) displays a prevalence of up to 70%
in oncology patients and 20% in HIV infected (HIV) patients. Although
the prevalence of OPC in HIV patients is decreasing, OPC still occurs
in all subjects who are not treated with HAART, develop AIDS or are
in therapeutic failure. In patients with oncology/haematological diseases,
the prevalence of OPC is conversely increasing, depending on the type
of cancer and anticancer treatments (chemotherapy, radiotherapy, . . . ).
Candida albicans is the main species associated with OPC but non-
albicans are increasing, while mutiresistant Candida albicans and non-
albicans strains have emerged. These changes are a consequence of long
term prescriptions of narrow spectrum antifungal agents and repeated
prescriptions of oral systemic antifungal agents. Moreover, in this heavily
treated immunocompromised population, it is important to limit the
potential for drug-drug interactions. Therefore, national and international
guidelines have been issued and recommend using a local antifungal
therapy with a spectrum extended to all Candida species as ﬁrst line
treatment of OPC. In clinical practice, the treatment compliance of
the immunocompromised patients represents a challenge and should be
favoured by a local antifungal agent easy to use.
S426 Oropharyngeal candidiasis: what to do to face resistance of
Candida species?
M.A. Ghannoum (Cleveland, US)
The widespread and recurrent use of oral systemic antifungal agents
for the treatment of candidiasis in immunocompromised patients had
led to the emergence of resistance of Candida either albicans or non-
albicans to some antifungals. Miconazole (MICON) has long been used
for the topical treatment of oropharyngeal candidiasis (OPC), so that it
was important to generate data on recent clinical isolates and using the
recent CLSI methodology.
In a ﬁrst study, we established the susceptibility proﬁle for MICON
against recent Candida isolates and compared its antifungal activity
to that of other antifungals. In a subsequent study, we determined
the potential of resistance development to MICON. Minimum In-
hibitory Concentrations (MICs) were determined for amphotericin B,
caspofungin, clotrimazole, ﬂuconazole (FLU), itraconazole, nystatin,
voriconazole and MICON against 25 strains of 6 species, including
C. albicans, C. krusei, C. glabrata, C. tropicalis, C. parapsilosis and
C. dubliniensis. MICON demonstrated potent inhibitory activity against
all of the Candida spp. strains tested. The overall MIC range for MICON
was 0.004−1.0mg/ml, while MICON MIC90 (0.5mg/ml) and MIC50
(0.03mg/ml) for all species were comparable to that of other antifungal
agents except for FLU to which they were 4 dilutions lower (Minimum
inhibitory concentration that inhibits 50 and 90% of the strains tested
respectively). No strain obtained from recent clinical isolates were
resistant to MICON among any of the species tested, and importantly,
MICON demonstrated overall MIC range 0.06−1 mg/ml against strains
showing elevated MICs for FLU (8−64mg/ml).
To date, resistance to MICON has not been reported. The objective
of our second study was to determine whether repeated exposure of
Candida spp. to MICON leads to resistance against this antifungal. Two
clinical Candida isolates from oral cavity were selected and included
one FLU-resistant and one FLU-susceptible strain each of: C. albicans,
C. glabrata, and C. tropicalis. The initial MIC of MICON against
each isolate was determined before a repeated exposure to different
concentrations of MICON (from 0.5x MIC to 4x MIC) for a total of
15 passages. In general, there was no increase in MICs with the highest
ﬁnal MIC equal to 0.5 mg/ml.
Our data showed that MICON demonstrated a potent inhibitory activity
against all of the recent C. albicans or non-albicans isolates tested,
including those with known FLU resistance. These data suggest that
MICON could have utility as a ﬁrst line treatment of OPC.
S427 A new targeted and innovative treatment of oropharyngeal
candidiasis in immunocompromised patients
P. Attali (Paris, FR)
Despite the recommendations of international guidelines, topical
antifungal agents are hardly used in the treatment of oropharyngeal
candidiasis (OPC) in immunocompromised (IC) patients because of the
need for 4 to 6 daily dosing, poor taste acceptance that compromise
patient compliance and lessen efﬁcacy.
The pharmacokinetic of once daily miconazole 50mg mucoadhesive
buccal tablet (MBT) (Loramyc®) was compared to that of miconazole
375mg gel administered in three divided doses in 18 healthy volunteers.
Salivary miconazole concentrations after MBT application were higher
(15.1±16.2mg/ml) than those of miconazole gel (1.6± 1.6mg/ml,
p< 0.001) and persisted over the MIC (1mg/ml) for 13.4±5.2 hours
vs 1.2±2.6h (p< 0.001). Miconazole plasma concentrations were rarely
detected with MBT (5/162 samples vs 10/162 with gel). Finally, 17 of
18 volunteers preferred miconazole MBT.
Twenty ﬁve HIV+ patients with documented OPC were enrolled in a
group-sequential dose-adaptative trial with stopping rules and treated
with MBT once daily for 14 days. The trial was halted prematurely
according to the predeﬁned stopping rules because of higher than
expected efﬁcacy. Clinical success was observed in 84% of patients with
52% complete response. Clinical cure was obtained in 52%. Relapses
within 30 days post treatment (32%) only occurred in untreated or
uncontrolled HIV+ patients. Plasma miconazole concentrations were not
detected.
Single daily dose of miconazole 50mg MBT or miconazole 500mg oral
gel (MOG) administered in 4 divided doses for 14 days were randomly
allocated to 282 head and neck cancer patients with documented OPC.
The success rate was statistically not inferior in the MBT group to that
observed in the MOG group (56% vs 49%) with complete response in
52.5% vs 45.4% of patients respectively. After adjustment for the extent
of lesions and salivary secretions because of an uneven distribution of
patients at baseline in favour of MOG, a trend toward superiority was
observed in favour of MBT (p = 0.13), particularly among patients with
multiple lesions (p = 0.013). Clinical cure was obtained in 39%. Relapses
at 45 days post treatment were observed in around 20% (p=NS).
In both trials MBT adhered for more than 6 hours in more than 90% of
applications. MBT was well tolerated.
These trials demonstrated that once daily miconazole MBT is an
efﬁcacious, safe and well accepted topical treatment of OPC in IC
patients. The reduction in drug dose precludes the risk of systemic
exposure, of drug-drug interactions and liver toxicity.
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S428 Challenge of oropharyngeal candidiasis in immunocompro-
mised patients: the need for an optimised treatment
O.A. Cornely (Cologne, DE)
Occurrence of oropharyngeal candidiasis in immunocompromised
patients carries a high burden, not only in terms of patient discomfort.
Since mucosal colonisation is a risk factor for systemic dissemination,
oropharyngeal candidiasis implies an early treatment initiation.
Systemically active antifungals carry the challenge of drug-drug
interactions as well as the potential for a variety of organ toxicities.
Although topical treatment is clearly preferable for localised superﬁcial
infections, systemically active antifungals are used frequently. Most
likely these will be azoles.
Different patient groups will beneﬁt from additional topical treatment
options for oropharyngeal candidiasis. These are in particular patients
with HIV/AIDS and patients with neoplastic disease. In HIV infected
subjects receiving multiple concomitant medications and suffering from
oropharyngeal candidiasis, the risk of interaction of systemic antifungal
treatments with HAART needs to be minimised and thus guidelines do
recommend ﬁrst line local antifungal therapy.
The incidence rates of oropharyngeal candidiasis vary within the
highly complex cancer patient population and depend on the type of
tumour, treatment modalities and cytostatics used. Consequences of
oropharyngeal candidiasis may be: decreased food and sometimes even
liquid intake, loss of weight, and reduced general state and quality of
life. Potentially subsequent decreased chemotherapy doses and increased
intervals between cycles may have a negative impact on therapeutic
success.
For both groups of immunocompromised patients, it is important to
detect and treat oropharyngeal candidiasis from the start. The availability
of a new local antifungal agent with a limited systemic exposure and
a once daily dosing favouring patients’ compliance should optimise
the management of oropharyngeal candidiasis in immunocompromised
patients.
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S437 Microcantilever biosensors and diagnostics
H.P. Lang (Basel, CH)
We have established a new type of biological sensor based on
microfabricated silicon cantilevers arrays. Each cantilever is 500 micron
long, 100 micron wide and less than 1 micron thick. They are
miniaturised, ultrasensitive and fast-responding sensors for application in
chemistry, physics, biochemistry and medicine and respond by bending
due to absorption of molecules or by shift in resonance frequency. They
can be operated in different environments such as gaseous environment
or liquids. When operated in liquid, microcantilever sensors are able
to detect biochemical reactions. Each cantilever is functionalised with
a speciﬁc biochemical probe receptor, sensitive for detection of the
corresponding target molecule. Applications lie in the ﬁelds of label-
and ampliﬁcation-free detection of DNA hybridisation, detection of
proteins as well as antigen-antibody reactions and detection of larger
entities, such as bacteria and fungi. We present detection of fungal
growth within two hours using resonating microcantilevers coated with
nutrition media.
When operated in gaseous environment, polymer-coated cantilever array
sensors can be applied as kind of electronic nose for characterisation of
vapors. Medical application ﬁelds include fast characterisation of exhaled
patient’s breath samples for detection of diseases, based on the presence
of vapors such as acetone in exhaled air, as characteristic of diabetes
II patients. Similarly, patients suffering from uraemia can be identiﬁed
by detection of dimethylamine in exhaled air. Further examples include
characterisation of patients with respiratory tract infections.
Key publications:
– J. Zhang et al., “Rapid and label-free nanomechanical detection of
biomarker transcripts in human RNA”, Nature Nanotechnology 1,
214–220 (2006).
– N. Backmann et al., “A label-free immunosensor array using single-
chain antibody fragments”, Proc. Nat. Acad. Sci. USA 102, 14587–
14592 (2005).
– R. McKendry et al., “Multiple label-free biodetection and quantitative
DNA-binding assays on a nanomechanical cantilever array”, Proc. Nat.
Acad. Sci. USA 99, 9783–9787 (2002).
– J. Fritz et al., “Translating Biomolecular Recognition into Nanome-
chanics”, Science 288, 316–318 (2000).
– H.P. Lang et al., “An Artiﬁcial Nose Based on a Micromechanical
Cantilever Array”, Analytica Chimica Acta, 393, 59 (1999).
– H.P. Lang et al., “An Artiﬁcial Nose Based on Microcantilever Array
Sensors”, Journal of Physics: Conference Series 61, 663–667 (2007).
S440 From lab on a chip to a lab-in-a-cell: the impact of
nanotechnology on biomedicine
A. van den Berg (Enschede, NL)
Over the past 15 years, the concept of Lab on a Chip (LOC) has been
developed to a great level of maturity. These microﬂuidics systems are
nowadays employed in a variety of applications in physics, analytical
chemistry, medical applications and recently more and more in biological
ones. We will show that there is an increasing interest in experiments
with single cells, and it will be shown that there are great opportunities
for doing so.
In this presentation, ﬁrst an example will be given of a LOC for
the analysis of lithium, a drug frequently used by manic-depressive
patients, in whole blood [1]. Subsequently, we will present a sensor
system for the monitoring of cultivation parameters such as temperature,
oxygen content, pH and cell growth. This system is intended to be
used for monitoring of micro-cell cultures, and is compatible with
the standard 96 well-plate format [2]. An another example, a million-
chamber Petri-dish will be shown for cultivation of bacterial cultures
[3].
In a following example, a microﬂuidic cell trap enabling time-lapse
experiments with U937 cells undergoing apoptosis studied with confocal
microscopy [4]. The use of chemically modiﬁed Qdots is shown for
photo-stable cell-imaging of the same apoptotic process [5]. This is
particularly important if long time-lapse experiments are carried out,
that would normally suffer from bleaching of conventional ﬂuorescent
probes.
Finally, a cell-trap chip is shown for gene transfection into individual
cells using electroporation. More speciﬁcally, the transfection of the
GFP-ERK1 construct and subsequent translocation from the cytosol to
the nucleus of human mesenchymal stem cells under inﬂuence of external
bFGF signals is demonstrated [6]. The last example demonstrates that
there is an important future role for experimentation with single cells on
a chip, or using the cell as experimentation space in a new paradigm:
the Lab-in-a-Cell.
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Fig. 1. Schematic presentation of microneedle array sampling blood for
lithium analysis.
Fig. 2. Picture of the anapore substrate, subdivided in > 1 million, 7x7
um cultivation chambers.
Fig. 3. Microfabricated cell trap for time-lapse analysis of apotosis
induced in suspension cells.
Fig. 4. Intensity vs. time curves for Qdot probes (orange) and two
ﬂuorescence probes.
Fig.5. Artists’ impression of single cell electroporation setup.
Reference(s)
[1] E.X. Vrouwe et al., Clinical Chemistry, 53(1), (2007), 117–123.
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[3] C.J. Ingham et al., PNAS, 104(46), (2007) 18217.
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Unforgettable trips and unwanted souvenirs:
issues in travel medicine
S441 Infections and other problems on ferries and cruise ships
E. Dahl (Bergen, NO)
Passenger ships are isolated communities with a high population density,
crowded public rooms and living accommodation, shared sanitary
facilities, and common water and food supplies. Hence, infectious
diseases are easily transmitted aboard. Outbreaks of measles, rubella,
varicella, meningococcal meningitis, hepatitis A, Legionnaires’ disease,
inﬂuenza and gastroenteritis among passengers and crew have been
reported and are feared both for their health and publicity reasons.
However, consequences are usually less serious for ferries, carrying
people between two close ports, than for cruise ships. Vessels doing
cruises that last weeks to months often visit remote areas with varying
sanitation standards, and evacuation may not be possible for days. While
ferries often carry no medical personnel, cruise ships as a rule have 1−2
physicians and 1−3 nurses.
Cruise companies emphasize illness prevention through pre-employment
medical screening and vaccination programmes for their crew, as
well as detailed and rigid ship sanitation procedures. Over one
hundred outbreaks of infectious diseases, particularly gastrointestinal
disease, were reported to be associated with ships between 1970 and
2000. Despite good performance on health inspections, outbreaks of
gastroenteritis per 1000 cruises increased almost tenfold from 2001 to
2004. The increase was mostly attributable to norovirus, and highlights
the inability of environmental programmes to fully predict and prevent
risk factors common to person-to-person and fomite spread of disease.
The much publicised outbreaks and global threats have led the cruise
companies to cooperate closely with local, national and international
public health authorities – and with each other. These efforts have
resulted in detailed protocols on how to deal with every aspect of
shipboard sanitation: under normal circumstances, when there is a threat
of an outbreak, and during an outbreak. They include mandatory hand
disinfection for all persons entering the ship, and strict isolation demands
for all cases of gastroenteritis for a minimum of 24 hours after the last
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symptom. Isolation aboard is difﬁcult and risky. A bedside test to quickly
diagnose or rule out norovirus is therefore high on the cruise industry’s
wish list.
As it is almost impossible for ships to comply with different requirements
in each port, it is a pressing international challenge for all port countries
to agree on a uniform vessel sanitation programme for passenger ships.
S442 Sex, sun, sea and sexually transmitted infections
K.E. Rogstad (Shefﬁeld, UK)
Holidays provide an ideal opportunity for increased sexual contact,
whether taken at home or abroad. Travellers are released form the normal
social restraints of their own community and are more likely to drink
alcohol and take illegal drugs whilst away.
Travel advice usually includes information on prevention and prophylaxis
for traditional infectious diseases but rarely addresses the risks of
planned or unplanned sexual activity whilst abroad. As well as being
at risk of Chlamydia trachomatis and Neisseria gonorrhoeae infections,
travellers are also at risk of HIV, Hepatitis B, syphilis and the tropical
sexually transmitted diseases (STDs) such as chancroid, granuloma
inguinale and lymphogranuloma venereum. The need for advice prior
to travel, prophylaxis and access to care on their return according to risk
and symptoms should be part of the routine consultation in travel clinics.
This is particularly relevant to those who may be sex tourists, who may
also require additional information on potential legal issues.
S443 Fever after travel: what are the causes?
T. Jelinek (Berlin, DE)
Selected diagnosis and individual national surveillance systems apart,
quantity and quality of imported infectious diseases in Europe are largely
unknown. Experience of the last decades has shown that their impact is
increasing on European health systems and, indeed, societies due to
hugely increased travel activities and immigration. Current estimates
assume that in Germany alone, 300,000 patients fall sick every year
after a journey outside of Europe. In addition, health systems have to
cope with an unknown number of migrants that need treatment for
a variety of conditions. Overall, information about relevant infectious
diseases in endemic areas is comparatively easy to get. Information
about the same diseases in returning travellers are much more difﬁcult
to acquire. Only few international studies have been done in regards of
this question. As a result, only limited data are available on imported
infectious diseases in Europe, especially those that are not notiﬁable in
all countries. TropNetEurop, the network on the surveillance of imported
infectious diseases in Europe, has been founded in 1999. The network
is trying to foster collaboration of clinicians throughout the continent in
order to increase information exchange and knowledge about imported
infections. Selected diagnosis are reported regularly in anonymised form.
Several outbreaks among travellers and immigrants have been detected
since the foundation of the network (www.tropnet.net).
Fever is the most important clinical sign of imported infectious diseases
post travel. Common causes include life threatening diseases like malaria
and less dangerous, but quite common diagnoses as dengue fever. The
presentation gives an overview of epidemiological and clinical data. The
most frequent causes of fever post travel are disucussed.
S444 Travellers’ diarrhoea: vaccination, chemoprophylaxis or
treatment
R. Steffen (Zurich, CH)
Three fundamental options exist to prevent Travellers’ diarrhoea (TD):
reduction of exposure, chemoprophylaxis, and immunisation.
According to a recent review evidence is missing that avoidance of
’dangerous’ food and beverages reduces the risk of TD.
Among the many drugs suggeted for chemoprophylaxis, probiotics
showed no or at best a low protective efﬁcacy rate. Bismuth subsalicylate
is modestly effective. Among antibacterial agents, trimethoprim-
sulfamethoxazole, doxycycline and others are considered obsolete
because of antimicrobial resistance by prevalent enteric bacterial
pathogens. Antimicrobial resistance has also become an increasing
problem with widespread use of ﬂuoroquinolones and fear of systemic
reactions has limited the prescription of such medication. Poorly
absorbed antibiotics, mainly rifaximin, are far more attractive, but this
agent is not available in most European countries.
The whole cell/B-subunit (WC/BS) cholera vaccine has repeatedly been
shown to prevent TD by LT-ETEC strains, possibly even by other
pathogens. Similarly a new heat labile LT-ETEC transcutaneous patch
vaccine has been effective beyond just LT-ETEC. If such vaccines are
recommended, it is paramount to underline that the protective efﬁcacy
is far from complete and that TD may still occur en route.
As no current prophylactic measure is truly satisfactory, (self)-therapy of
TD remains an important strategic option against TD. Quinolones seem
still to be effective in most parts of the world, but there is a lack of recent
data on the frequency of resistance from analysis of TD stool samples
on all continents. There are indications that azithromycin is the drug of
choice in SE-Asia. Often a single antimicrobial dose will be sufﬁcient to
cure TD. With increasing concerns about post-infectious irritable bowel
syndrome we should consider a more liberal approach with respect to
inclusion of antimicrobials in the travel kit.
Pros and cons of glycopeptides
S447 Vancomycin is not obsolete
G. Eliopoulos (Boston, US)
Vancomycin is an imperfect agent, like every other antibiotic.
Nevertheless, each day it is used successfully in hospitals, nursing
facilities and homes, as the ﬁrst line agent for treatment of infections due
to meticillin-resistant Staphylococcus aureus and for infections caused by
a broad array of other Gram-positive bacteria in individuals allergic to or
otherwise intolerant of b-lactam antibiotics. This enormously successful
clinical experience comes in spite of its widespread use for non-approved
indications, based on breakpoints that antedate the discovery of isolates
with reduced susceptibility, without detailed appreciation of its tissue
penetration, and sometimes under circumstances of suboptimal ancillary
intervention (drainage, debridement or removal of foreign material).
Most patients tolerate vancomycin well; not surprisingly, adverse effects
do appear to be more frequent as higher than usual doses are utilised
against infections due to organisms at the high end of the MIC
distribution. Randomised, double-blind prospective clinical trials have
largely failed to identify newer agents that are superior in clinical efﬁcacy
to vancomycin, despite tantalising signals of possible advantages of
other agents against MRSA. Which, if any, potential advantages would
support the anticipated differential in cost of the newer agents remains
to be determined. With time, better antibiotics than vancomycin will be
introduced, and they will assume their rightful place in therapy. However,
as long as we do not expect vancomycin to achieve the impossible – to
treat infections due to non-susceptible organisms at sites where it does
not penetrate – this antibiotic will remain an attractive therapeutic option.
Fungal infections
O449 Fungal biomass is a key factor affecting polymorphonuclear
leukocyte-induced hyphal damage of ﬁlamentous fungi
C. Antachopoulos, J. Demchok, E. Roilides, T. Walsh (Bethesda,
US; Thessaloniki, GR)
Objectives: Previous studies of polymorphonuclear leukocyte (PMN)-
induced hyphal damage (HD) of ﬁlamentous fungi have used the effector-
target (E:T) ratio as the only variable for assessment or comparison
of results. However, we hypothesised that the overall hyphal biomass
of organism may also be an important determinant in host-pathogen
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interaction. We therefore investigated the effect of fungal biomass on
PMN-induced HD.
Methods: An inoculum of 2×104 conidia/ml of one isolate each
of Aspergillus fumigatus, Aspergillus ﬂavus, Aspergillus terreus,
Rhizopus oryzae, Rhizopus microsporus, Cunninghamella bertholletiae,
Scedosporium proliﬁcans and Fusarium solani was incubated for 6 one-
to two-hourly different time periods in order to yield biomass values
ranging between 0.01−0.1 optical density (OD, measured at 405 nm).
PMNs from healthy volunteers were then added at E:T ratios of 5:1,
10:1, 20:1, 50:1 and 100:1, and HD was assessed by XTT metabolic
assay. For each E:T ratio, the relationship between HD and OD was
studied using nonlinear regression analysis.
Results: HD decreased with increasing biomass following a sigmoid
pattern described with the Emax model (median R2: 0.87). HD at 0.01
OD exceeded HD at 0.1 OD (P< 0.01 for all E:T ratios) by >2-fold in 64
of 80 comparisons (8 isolates x 5 E:T ratios x 2 replicate experiments).
The sigmoid curves were shifted to the right with higher E:T ratios;
the EC50 values (i.e., the model-derived OD at which HD is reduced
half-way between the maximum and minimum HD values for a given
E:T ratio and isolate) obtained for 50:1 or 100:1 were higher than
those obtained for 5:1 (P< 0.01). Using the same E:T ratio, interspecies
differences were observed; for 5:1, lower EC50 values were obtained for
A. ﬂavus and the three zygomycete species.
Conclusion: PMN-induced HD decreases with increasing biomass at
rates that are species-dependent and that decrease with higher E:T ratios.
This biomass effect may have important implications for understanding
systemic host defences and can be a useful factor in the design and
interpretation of studies of PMN-induced HD of ﬁlamentous fungi.
O450 Development of a nested PCR assay for the detection of
Fusarium solani DNA and its evaluation in the diagnosis of
invasive fusariosis using an experimental mouse model
Z. Khan, S. Ahmad, A. Theyyathel (Kuwait, KW)
Objective: The Fusarium species are common environmental fungi
that enter the body through the lungs or through a cutaneous
source and disseminate through the bloodstream in immunosup-
pressed/immunocompromised patients. Fusariosis is now the second
most common mould infection in immunocompromised patients and
Fusarium solani accounts for nearly half of these infections. The aim of
this study was to develop a speciﬁc nested PCR (nPCR) assay for the
detection of F. solani DNA in culture and in clinical specimens.
Methods: The nPCR assay was developed by using genomic DNA
isolated from Fusarium species and from other common pathogenic and
environmental fungi. The nPCR assay was evaluated by using DNA
isolated from bronchoalveolar lavage (BAL) and serum samples from
mice infected intravenously with F. solani conidia and sacriﬁced on day
1 and then on every third day up to 25 days post-infection. The lung
homogenate, BAL and blood samples were also cultured for F. solani.
Results: The nPCR assay was speciﬁc for F. solani and the lower limit
of detection was 450 fg of template DNA corresponding roughly to
11 F. solani cells. Cultures of lung homogenate of infected animals
up to day 16 yielded F. solani with decreasing fungal load and were
negative thereafter. The nPCR positivity in BAL was 100% concordant
with culture results. Although detection of F. solani DNA in serum was
less sensitive than in BAL, it could be detected for longer duration, i.e.
up to 22 days.
Conclusions: We have developed a sensitive and speciﬁc nPCR assay
for the detection of F. solani DNA. Our data from experimental mouse
model show that detection of DNA in BAL and to a lesser extent in
serum by nPCR offers a sensitive and speciﬁc diagnostic approach for
invasive F. solani infection.
Supported by KURA grant MI 04/02.
O451 Detection of Aspergillus DNA by a nested PCR assay with
high sensitivity and speciﬁcity rates is able to improve the
diagnosis of invasive aspergillosis in paediatric patients
M. Hummel, B. Spiess, J. Roder, G. von Komorowski, M. Duerken,
K. Kentouche, H. Laws, H. Moerz, D. Buchheidt (Mannheim, Jena,
Dusseldorf, DE)
Background. Fungal infections are a leading cause of morbidity and
mortality in severely immunocompromised patients with an increasing
incidence in recent years. IA is the most common ﬁlamentous fungal
infection and is, in adults as well as in children, difﬁcult to diagnose. To
improve the outcome of patients with invasive aspergillosis (IA), early
diagnosis and treatment initiation is crucial.
Several PCR assays to detect Aspergillus DNA have been established,
but so far, studies on molecular tools for the diagnosis of IA in children
are few.
We evaluated the results of a nested PCR assay to detect Aspergillus
DNA in clinical samples from paediatric and adolescent patients with
suspected IA.
Methods. Blood and non-blood samples from immunocompromised
paediatric and adolescent patients with suspected invasive fungal
infection were sent for processing Aspergillus polymerase chain reaction
(PCR) to our laboratory and investigated with our previously described
nested PCR assay. PCR results from consecutive patients from three
university children hospitals investigated between November 2000 and
January 2007 were evaluated. Fungal infections were classiﬁed according
to the EORTC classiﬁcation on the grounds of clinical ﬁndings,
microbiology and radio-imaging results.
Results. 291 samples from 71 patients were investigated for the presence
of Aspergillus DNA by our previously described nested PCR assay. Two,
3 and 34 patients had proven, probable and possible IA, respectively.
Aspergillus DNA was detected in blood, cerebrospinal ﬂuid (CSF) and in
bronchoalveolar lavage (BAL) samples. Sensitivity and speciﬁcity rates
of the PCR assay were 80 and 81%, respectively
Conclusion. Our nested PCR assay is able to detect Aspergillus DNA in
blood, CSF and BAL samples from paediatric and adolescent patients
with IA with high sensitivity and speciﬁcity rates. PCR for Aspergillus
DNA contributes essentially to improve the diagnosis of IA.
O452 Surveillance of aspergillosis by galactomannan testing,
culture and histopathology in lung transplant recipients
M.C. Arendrup, K.L. Mortensen, M. Iversen, N. Milman (Copenhagen,
DK)
Background: The clinical utility of Aspergillus galactomannan detection
(GM) in bronchoalveolar lavage (BAL) ﬂuid for the diagnosis of
aspergillosis in lung transplant recipients has recently been described.
Methods: 68 paired BAL ﬂuid and serum samples from consecutive lung
transplant recipients undergoing routine bronchoscopy were prospec-
tively analysed for GM and results compared with culture, imaging and
histopathology. Underlying diseases were chronic obstructive pulmonary
disease in 24 patients, cystic ﬁbrosis in 19, sarcoidosis in 10, alpha-
1-antitrypsin deﬁciency in 8, pulmonal ﬁbrosis in 8, and others in 2
patients. Patients were classiﬁed according to clinical ﬁndings during the
bronchoscopy as having high risk for aspergillosis (patches involving the
site of anastomosis and the airways of the lung), medium risk (patches
restricted to the site of anastomosis) or low risk (no or minor patches at
the site of anastomosis).
Results: A total of 68 BAL ﬂuids from 51 recipients of single (37) or
double (31) lung tranplants were investigated. 12 patients were classiﬁed
as high risk patients (18%), 17 as medium (25%) and 39 as low risk
patients for aspergillosis (57%). In 22/68 cases (32%) the patient received
antifungal prophylaxis, which in 21/22 cases was voriconazole and in 1
case caspofungin.
The GM index in BAL ﬂuid was >0.5 in 5/68 cases (2/39 low risk (5%),
2/17 medium risk (12%) and 1/12 high risk (8%) cases). 4 of these 5
patients were recipients of double lung transplants. In 2 cases the GM
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index was >0.7 (1 medium (6%) and 1 high risk patients (8%), both
double lung transplant recipients) and in 1 >1.0 (high risk episode in
double lung transplant recipient). No patients had positive GM in serum
at any time. Six patients had a positive BAL ﬂuid culture for aspergillus,
none of whom had positive GM and 4 of whom were classiﬁed as low
risk patients. Five patients had histopathological ﬁndings suggestive for
aspergillus 4 of whom were classiﬁed as high risk patients. The BAL
GM index in these patients was 1, 0.4, 0.3, 0.3 and 0.1 and none had
positive cultures from the BAL ﬂuid.
Conclusions: In the setting of lung transplant recipient with a frequent
use of anti-aspergillus prophylaxis, BAL ﬂuid GM appeared to correlate
better with the clinical risk classiﬁcation than culture, but not as good
as histopathology. BAL ﬂuid GM testing can not be regarded as a stand
alone test in this setting.
O453 Fungiscope – the Global Rare Fungal Infection Registry
M.J. Rueping, J.J. Vehreschild, C. Beisel, U. Auerbach, C. Mueller,
C. Wickenhauser, O. Cornely (Cologne, DE)
Introduction: The incidence of invasive fungal infections increases
worldwide, and rare fungi – neither belonging to the genera Aspergillus,
Candida, Pneumocystis or Cryptococcus, nor being endemic, such as
Histoplasma spp. or Coccidioides spp. – are increasingly identiﬁed as
causative pathogens.
Methods:We are coordinating a global registry for cases of rare invasive
fungi. Our objective is to broaden the knowledge on epidemiology,
to determine the clinical pattern of disease, to describe and improve
diagnostic procedures and therapeutic regimens, as well as to facilitate
exchange of clinical isolates among the contributors.
Entry of retrospective data occurs via a web-based registration
system (MACRO) that focuses on demographic information, underlying
diseases, risk factors, details on the infection (pathogen, localisation,
specimen collection) therapy and outcome.
Inclusion criteria include cultural, histopathological, antigen, or DNA
evidence of invasive fungal infection. Infection due to Aspergillus spp.,
Candida spp., Cryptococcus neoformans, Pneumocystis jirovecii or any
endemic fungal infection, such as coccidioidomycosis or histoplasmosis,
as well as mere colonisation or other non-invasive infection are exclusion
criteria.
Each subset of this cohort will be published at a time. Authorship will
be restricted to those centres, contributing patients or translational work
to the subset.
For evaluable patient documentations ﬁlled in by the participating centre
a compensation of € 100 each will be paid. For isolates made available
to the central laboratory an additional € 50 will be paid.
Results: By now, 28 cases of rare invasive fungal infections have been
identiﬁed, including Absidia corymbifera, Cunninghamella bertholletiae,
Penicillium marneffei, Rhizomucor pusillus, as well as Acremonium spp.,
Fusarium spp., Coccidioides spp., and Trichoderma spp. Clinical results
are partly pending. Most patients were in an immunocompromised state
as a result of their underlying disease, chemotherapy or transplantation.
Discussion: The clinical relevance of invasive fungal infections by rare
fungi is increasing steadily. In a short period of time, actual cases from
Germany, Austria, Italy and the United Kingdom could be documented,
showing the broad spectrum of pathogens.
Further investigators and coordinators are cordially invited to contribute
to the success of Fungiscope.
O454 Candidiasis in patients with haematological malignancies, in
a tertiary care cancer centre (2001–2007): stable incidence
but changing epidemiology of a still frequently lethal infection
N.V. Sipsas, R.E. Lewis, D.P. Kontoyiannis (Houston, US)
Objective: In the era of ever expanding anti-Candida armamentarium,
there has not been recent large series on the incidence, microbiology,
resistance patterns of candidiasis in high risk patients with hematologic
malignancy and or stem cell transplantation.
Methods: We retrospectively reviewed the records of adult patients
with candidaemia and or candidiasis (EORTC criteria), treated for
hematological malignancies (March 2001-February 2007). Demographic
characteristics, clinical and microbiological data, outcomes, as well as
MIC of antifungal agents (CLSI method), were recorded.
Results: A total of 173 episodes of candidaemia (170 patients)
were analysed. C. albicans and C. parapsilosis were isolated most
commonly (25% and 24% respectively). However, frequently azole-
resistant Candida species such as C. glabrata or C. krusei accounted for
only 22% of all episodes (5% and 17% respectively). The incidence of
candidaemia (per 100.000 inpatient days) remained relatively stable from
13.9 in 2001 to 19.2 in 2006 (p=NS). 72% of episodes were breakthrough
candidiasis to prior antifungal prophylaxis. Twenty ﬁve percent of the
173 isolates were resistant to ﬂuconazole (67% of C. glabrata, or 6
out of 9 isolates), and 7% resistant to voriconazole. Of the 59 Candida
isolates with caspofungin MICs, 4 (7%) had an MIC> 2. In contrast,
resistance to amphotericin B (MIC> 2) was uncommon (1%). There
was no trend in prevalent Candida species or patterns of resistance over
the study period. Overall 30 day mortality was 38% and the 30 day
attributable mortality was 17%. Factors associated signiﬁcantly 30-day
overall mortality (multivariate analysis) were age >50 years, intercurrent
infection and neutrophil count <100/ml at diagnosis of candidiasis; for
30-day attributable mortality age >50 years and sustained candidaemia.
The Candida species associated with the highest mortality (44%) was
C. glabrata.
Conclusion: Despite widespread use of antifungal prophylaxis in
high risk hematology patients, the incidence of candidiasis remained
stable. More over, breakthrough infections, frequent in vitro resistance
(especially to ﬂuconazole), the predominance of non-albicans Candida
species and high crude mortality continue to pose signiﬁcant challenges.
O455 Epidemiology, management and risk factors for death of in-
vasive Candida infections in critical care units: a multicentre,
prospective, observational study in France (2005–2006)
O. Lortholary, J.P. Gangneux, P. Montravers, J.P. Mira, F. Gouin,
J.P. Sollet, J. Carlet, J. Reynes, B. Re´gnier, M. Rosenheim, O. Leroy
for the AmarCand Study Group
Objective: To describe the evolving epidemiology, management and risk
factors for death of invasive Candida spp. infections in intensive care
units (ICUs) in France
Methods: This country-based, prospective, observational study (Amar-
Cand study) was carried out in 101 ICUs. 271 adult patients with proven
invasive Candida spp. infection who received a systemic antifungal
therapy were included between October 2005 and May 2006.
Results: The study included 107 (39.5%) patients with isolated
candidaemia, 87 (32.1%) with invasive candidiasis without candidaemia,
and 77 (28.4%) with invasive candidiasis and candidaemia. With
regards to risk factors, 76% of patients had mechanical ventilation,
97% were catheterised, 59% had had prior antibiotherapy, 21% were
immunocompromised, and 34% had a malignancy. C. albicans accounted
for 57.0% of the causative species, followed by C. glabrata (16.7%),
C. parapsilosis (7.5%), C. krusei (5.2%) and C. tropicalis (4.9%).
In 17.1% of the cases, the causative species was less susceptible
or resistant to ﬂuconazole. Fluconazole was the empiric treatment
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most commonly initiated (65.7%), followed by caspofungin (18.1%),
voriconazole (5.5%), or amphotericin B (3.3%). The case fatality ratio at
the end of ICU stay was 45.9%. Multivariate analysis showed that factors
independently associated with death in ICU were: diabetes mellitus (odds
ratio [OR] 4.51, 95% conﬁdence interval [CI] 1.72−11.79, p = 0.002),
immunosuppression (OR 2.63, 95% CI 1.35−5.11, p = 0.0045), invasive
mechanical ventilation (OR 2.54, 95% CI 1.33−4.82, p = 0.0045), and
body temperature >38.2ºC (reference: 36.5−38.2ºC, OR 0.36, 95% CI
0.17−0.77, p = 0.008).
Conclusion: The AmarCand study results show that 68% of patients
with systemic candidiasis in ICU present with candidaemia. C. albicans
remains the most frequent causative species. Reduced susceptibility to
ﬂuconazole is observed in a large number of Candida spp. isolates. 84%
of ICU adult patients receive ﬂuconazole or caspofungin as ﬁrst line
therapy and mortality of invasive candidiasis in ICU remains dramatically
elevated.
O456 Comparison of the risk factors for Candida albicans versus
other Candida spp. bloodstream infections in intensive care
unit patients
F. Timurkaynak, O. Kurt Azap, S. Serin Senger, U. Cagir, H. Arslan
(Ankara, TR)
Objectives: Candida species are the fourth leading aetiologic agent
of bloodstream infections causing high morbidity and mortality rates.
The aim of this study is to determine the risk factors for candidaemia
including Candida albicans and non-albicans strains in intensive care
unit patients.
Methods: Intensive care unit patients who had candidaemia between the
period of January 2004 and October 2007 were included in this study.
A structured form was used to collect data from the patient records
about demographic characteristics, clinical and laboratory values and
interventions for each patient. Chi-square test and logistic regression
methods were used for statistical analysis.
Table: Adjusted odds of covariates, associated with non-albicans
candidaemia, multivariable analysis
Characteristic p OR (CI 95%)
Age 0.400 0.987 (0.956–1.018)
APACHE II score at onset of
candidaemia
0.099 1.111 (0.981–1.259)
CVC 0.452 1.679 (0.435–6.482)
TPN 0.322 1.718 (0.588–5.015)
Entubation 0.149 0.478 (0.175–1.304)
Renal failure 0.089 0.374 (0.120–1.163)
Haematologic malignancy 0.177 5.006 (0.483–51.890)
Solid-organ malignancy 0.278 1.895 (0.597–6.011)
Neutropenia 0.606 0.422 (0.016–11.221)
Solid-organ transplant 0.557 1.755 (0.269–11.453)
Burn 0.792 1.276 (0.209–7.806)
Prior antifungal therapy 0.023 4.174 (1.215–14.345)
CVC: Central venous catheter; TPN: Total parenteral nutration.
Results: A hundred and two candidaemia patients were inluded in the
study. Fifty-nine (57.8%) of the episodes were caused by C. albicans and
43 (42.2%) were caused by non-albicans Candida. The distribution of
non-albicans Candida spp. were as follows; 12.7% Candida tropicalis,
8.8% Candida glabrata, 7.8% Candida famata and 12.9% other Candida
spp. (Candida kefyr, Candida lusitaniae, Candida humicola, Candida
parapsilosis, Candida spp.). There was no statistically signiﬁcant
difference in the distribution of Candida isolates between the years
2004 and 2007 (p> 0.05). The risk factor determined for C. albicans
candidaemia was renal failure (acute or chronic) and risk factors for
non-albicans candidaemia were solid organ transplantation and prior
antifungal therapy. The statistical analysis regarding risk factors was
summarised in the Table. There was no statistically signiﬁcant difference
between the rates of mortality among the two groups.
Conclusion: C. albicans is still the most common Candida species and
there was no major difference in the distribution of the candidaemia
isolates among our patients for the last three years. Renal failure was
found to be the only risk factor associated with C. albicans candidaemia
and prior antifungal therapy, either prohylactic or empirical, was found to
be associated with non-albicans candidaemia. As it is well known that
appropriate empirical antifungal therapy is the most important factor
contributing to low morbidity and mortality rates, each centre should
have their own surveillance data.
O457 Treatment of invasive Candida infections – Systematic review
and meta-analysis
A. Gafter-Gvili, L. Vidal, E. Goldberg, L. Leibovici, M. Paul
(Petah-Tiqva, IL)
Background: Invasive candidiasis (IC) is now the fourth leading cause
of nosocomial blood stream infections. New drugs for IC have been
developed and tested.
Objective: To compare between the available antifungal treatments, in
terms of mortality and efﬁcacy.
Methods: Systematic review and meta-analysis of randomised controlled
trials comparing between different antifungal drugs for the treatment
of candidaemia and other forms of invasive candidiasis. Two reviewers
independently appraised the quality of trials and extracted data. We used
all-cause mortality as the primary outcome; and microbiological failure,
treatment failure and adverse events as secondary ones. Relative risks
(RR) with 95% conﬁdence intervals (CIs) were pooled.
Results: Fifteen trials were included, 9 of which compared ﬂuconazole
to any other drug (amphotericin B, itraconazole, or combination of
ﬂuconazole and amphotericin B), 4 compared echinocandins to other
drugs (ﬂuconazole, amphotericin B, liposomal amphotericin B), one
compared between micafungin and caspofungin, and one compared
between amphotericin B plus ﬂuconazole and voriconazole.
There was no difference in mortality when ﬂuconazole was compared
to amphotericin B (RR 0.92 [95%CI 0.73−1.17], although there was
an increase in microbiological failure in the ﬂuconazole arm (RR 1.77
[95%CI 1.18−2.65]. Anidulafungin decreased microbiological failure
compared with ﬂuconazole (RR 0.50 [95% CI 0.29−0.86]) and with
less adverse events. Caspofungin was comparable to amphotericin B in
mortality and efﬁcacy but with less adverse events (RR 0.56 [95% CI
0.44−0.71]. Micafungin was comparable to liposomal amphotericin B
in mortality and between micafungin and caspofungin demonstrated no
signiﬁcant differences in efﬁcacy or adverse events.
Figure 1. Microbiological Failure for trials comparing ﬂuconazole vs.
any other antifungal drug.
Conclusions: Currently available data support either ﬂuconazole,
amphotericin B and all echinocandins for primary treatment of IC.
For empiric treatment in areas with a high prevalence of non-albicans
Candida species, echinocandins should be considered as ﬁrst line.
When the isolate is identiﬁed, ﬂuconazole may still be considered as
ﬁrst line therapy for Candida albicans, while echinocandins, liposomal
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amphotericin B or amphotericin B should be chosen for the non-albicans
Candida species.
O458 Conversion of intravenous echinocandins to oral azoles
for invasive candidiasis: impact on outcomes and resource
utilisation
S. Davis, A. Kouza, T. Wiegand, J. Vazquez (Detroit, US)
Objectives: Echinocandins are increasingly used in the initial manage-
ment of invasive candidiasis (IC); however these agents are more costly
than alternatives. IV/PO conversion programmes reduce cost for use
of antimicrobials with high oral bioavailability, but conversion to an
agent of a different class is a new concept. The objective of the present
study was to determine the effect of an IV/PO conversion programme
from echinocandins to oral azoles on clinical outcomes and resource
utilisation.
Methods: 160 consecutive patients receiving echinocandins were
evaluated over 2 study periods. Phase 1: data collected retrospectively,
caspofungin and micafungin available on formulary, no IV/PO interven-
tion.
Phase 2: data collected prospectively, anidulafungin only on formulary,
formal IV/PO intervention implemented. Outcomes were compared
among the clinically evaluable (CE) population (documented or
suspected invasive candidiasis and meeting PO conversion criteria at
any time during therapy).
Results: 97 pts met CE population (57 Phase 1, 40 Phase 2).
Patient characteristics: (median or % in Phase1, Phase 2): age (55,
57 years), APACHE (17, 15), prior antifungals (60, 55%), prior ICU
(5, 25%; P = 0.017), prior surgery (0, 30%; p = 0.007), diabetes (9,
30%; p = 0.013), prior antibacterials (96, 80%; p = 0.014). Indication
for therapy: documented candidaemia/invasive candidiasis (44, 28%),
suspected candidiasis (56, 72%). Candida species: none (28, 18%),
albicans (39, 50%), glabrata (16, 10%), multiple (10, 15%), other
(7, 7%). Clinical success rates were 82% Phase 1, 85% Phase 2. All
cause in-hospital mortality (28, 15%, p = NS) PO conversion rates
during hospitalisation: 23% vs 48% (p = 0.011), PO conversion at any
time: 38% vs 53% (p=NS). Post implementation of IV/PO intervention,
antifungal therapy was completely discontinued in 13 patients upon
recommendation of IV/PO switch. Duration of total and intravenous
antifungal therapy was reduced in Phase 2. (Figure 1) Fluconazole was
the most common agent used for PO switch followed by voriconazole.
Figure 1. Median duration of therapy.
Conclusions: Patients initially treated with IV echinocandins and
switched to PO azoles achieved favourable outcomes. An intervention
to implement IV/PO switch therapy is useful for reducing resource
utilisation associated with the treatment of invasive candidiasis.
Clostridium difﬁcile – Changing epidemiology
and treatment options
O459 Mini state-of-the-art lecture: Recurrent Clostridium
difﬁcile-associated disease: an emerging problem requiring
novel treatment strategies
J. Keller (Amsterdam, NL)
Recurrent Clostridium difﬁcile associated diarrhoea (CDAD) is an
emerging problem in hospitalised patients and in nursing homes. The
pathogenesis of CDAD involves disturbance of the homeostasis of
normal bacterial colonisation of the large bowel enabling the outgrowth
of a pathogenic C. difﬁcile strain. Recurrent CDAD may be explained by
failure of antibiotics to eradicate C. difﬁcile spores, which will germinate
and grow out in a bowel that lacks normal colonic ﬂora as host-defence
mechanism. The absence of normal colonisation as defence mechanism
is illustrated by the ﬁnding that 50% of clinical recurrences of CDAD
may be caused by a different strain than the initial infecting strain
(Wilcox, 1998). Furthermore, coinfection with multiple strains has been
described. Patient factors associated with recurrence are older age and
co-morbidity.
Hospitalised patients with CDAD require isolation precautions to
prevent epidemic spread, and CDAD often prolongs hospital stay. Initial
treatment with metronidazole or vancomycin during 10−14 days is
effective in 70−85% of patients (Maroo, 2006). Treatment of relapse
consists of a second course of antibiotics during 14 days, with a
success rate of about 55% (McFarland, 2002). A subsequent relapse can
be treated with 2 weeks of vancomycin followed by a tapered-pulsed
vancomycin regimen lasting for several weeks. Consequently, recurrent
CDAD requires long-term (and often ineffective) antibiotic treatment and
costly isolation precautions in hospitalised patients and a more effective
treatment strategy for recurrent CDAD is needed urgently.
In 1958, Eiseman et al described the successful treatment of 4 patients
with severe antibiotic induced diarrhoea with enemas containing donor
stool. Since this initial report, 81 patients treated with donor faeces for
recurrent CDAD have been reported in the literature (Borody, 2004).
Clinical improvement was mostly seen after 1−4 days, and there was
a response in 90% of the patients without reports of recurrence. Side
effects related to faecal therapy have not been reported. The efﬁcacy of
faecal therapy against CDAD may be explained by (unknown) inhibitory
substances (bacteriocins) produced by the infused donor bacteria and
by restoration of faecal physiology by implantation of missing ﬂora
components. Importantly, randomised controlled trials are lacking and
this may be the reason that faecal therapy has not become a generally
accepted treatment strategy for recurrent CDAD. The apparent lack of
interest in faecal therapy may also relate to reluctance from physicians
to the distasteful nature of the therapy.
We successfully treated 11 patients with recurrent CDAD with a
suspension of donor faeces (protocol is outlined in Table 1). Prior to
our intervention, CDAD recurred after a median duration of 70 days on
antibiotics (metronidazol and vancomycine) and isolation precautions
had been taken during 5−11 weeks in hospitalised patients. Faeces were
delivered to the bowel by colonoscopy or nasoduodenal tube. Of note,
three of these patients were infected with the PCR ribotype 027 strain
that is often not responding to conventional antibiotic therapy.
In conclusion, healthy donor faecal enema administration seems to be
a promising tool in the ﬁght against recurrent CDAD not responding to
conventional antibiotic therapy, also in PCR ribotype 027 strain infected
patients. Recently, a randomised controlled trial to compare the efﬁcacy
of donor stool suspension with vancomycin for recurrent CDAD is
initiated.
Reference(s)
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Table 1. Protocol donor faeces administration.
Donor:
– Screen for HIV, HBV, HCV, acute CMV or acute EBV infection. Test
faeces for C. difﬁcile, Yersinia, Campylobacter, Shigella, Salmonella,
and pathogenic parasites.
– No recent use of antibiotics.
– No risk factors for transmittable diseases.
– Normal defaecation pattern.
Faeces:
– Fresh faeces (<6 hours before infusion), >100 gram.
– Suspend in 300–400 cc NaCl 0.9%.
Patient:
– 4 days vancomycin followed by bowel lavage with kleanprep.
– day 5: infusion of suspension of donor faeces in jejunum
(nasoduodenal tube) or in coecum and colon ascendens (via
colonoscope).
– Stop vancomycin on day of faeces infusion.
O460 The spread of Clostridium difﬁcile PCR-ribotype 027 in the
Netherlands since 2005 and the rise of other types
D. Notermans, A. Goorhuis, T. van der Kooi, S. Debast, B. Van
Benthem, E. Kuijper (Bilthoven, Leiden, Amersfoort, NL)
Objectives: In 2005, outbreaks of Clostridium difﬁcile associated
diarrhoea (CDAD) with the hypervirulent PCR ribotype 027 / toxinotype
III were ﬁrst reported in The Netherlands. C. difﬁcile PCR ribotype
027 was already causing considerable problems in hospitals in the
United States, Canada and England. Several investigations have shown
an increase in morbidity and mortality and an increased relapsing rate
for this type. Studies on risk factors at individual patient level showed
an association with ﬂuoroquinolones.
Methods: The Centre for Infectious Disease Control at the National
Institute for Public Health and the Environment (RIVM) set up a
surveillance for CDAD in collaboration with the Leiden University
Medical Center (LUMC). Hospitals are requested to send isolates or
toxin positive faeces samples for typing, if they suspect type 027 based
on an increased CDAD incidence or a severe clinical syndrome. From
hospitals with an outbreak or transmission of type 027, information is
collected, including monthly CDAD incidence.
Results: Between February 2005 until half August 2007, 1886 samples
have been typed, coming from 75 healthcare institutions. In 418 cases
(22.2%), PCR ribotype 027 was found. PCR ribotypes 001 (17.8%),
014 (7.2%) and 078 (7.6%) were also frequently found. In 26 of the 97
Dutch hospitals, PCR ribotype 027 was present. In one of the hospitals,
a simultaneous outbreak occurred with a second ribotype (017). In 13
of the 26 hospitals, 027 occurred in isolated cases only, without further
transmission in the institution or an increased incidence of CDAD. In the
other 13 hospitals, the incidence was increased. PCR ribotype 027 has
also been detected in 10 nursinghomes. In eight of 11 hospitals where
ribotype 027 was present in 2005 or 2006 and an outbreak occurred, no
ribotype 027 was found anymore since April, 2007. One hospital that
had the epidemic well under control for a long time was faced with a
new increase in incidence. Other PCR ribotypes appear to increase in
The Netherlands and some of these types such as type 078 have the
same virulence factors as type 027.
Conclusion: PCR ribotype 027 continues to spread in our country.
Introduction of 027 into a hospital does not always cause outbreaks,
but may remain limited to one or a few isolated cases, without increase
in CDAD incidence. Ribotype 027 caused new outbreaks in hospitals
that appeared to have controlled the situation.
O461 Lack of identiﬁed association between nosocomial CDAD
and emergency department overcrowding and number of
room changes
J. Yang, B. Brown, E. Belzile (Montreal, CA)
Introduction: Clostridium difﬁcile-associated diarrhoea (CDAD) has
become a common problem in Quebec hospitals, as well as in many
European countries. We examine the association between crowding
of patients in the emergency department and room conditions on the
hospital wards and the acquisition of nosocomial Clostridium difﬁcile
infection. The setting is a 316-bed university-afﬁliated community
hospital in Montreal, Quebec.
Methods: A nested case-control study design with conditional logistic
regression analysis is performed using administrative data on patients
aged 65 and over, admitted through the Emergency Department (ED)
to a medical unit, with a recent antibiotic prescription. The relationship
between three groups of variables – ED exposure measures (length of
stay, level of crowding); inpatient variables (unit and room types, number
of room changes); antibiotic type – and the occurrence of nosocomial
CDAD is examined, while controlling for several factors previously
identiﬁed as associated with CDAD transmission.
Table 1: Baseline characteristics of cases and controls (1:1 match)
Variables and descriptive statistics Cases (n = 68) Controls (n = 68)
Age in years Mean (Std) 83.6 (6.8) 83.6 (6.5)
Median [Q1–Q3] 84.0 [78.5−89.0] 84.0 [79.5−88.0]
Number of admissions 1 March to 30 June n (%) 26 (38.2) 22 (32.4)
1 July to 30 September n (%) 10 (14.7) 13 (19.1)
1 October to 31 December n (%) 17 (25.0) 17 (25.0)
1 January 2004 to 31 March 2004 n (%) 15 (22.1) 16 (23.5)
ED length of stay (hours)* Mean (Std) 21.0 (14.3) 26.3 (17.0)
Median [Q1–Q3] 19.8 [7.8−27.7] 23.2 [16.4−32.5]
Number of ED stretchers Mean (Std) 19.4 (4.1) 19.7 (4.5)
occupied during ED stay** Median [Q1–Q3] 19.4 [16.0−22.9] 19.5 [16.8−23.0]
Unit of initial admission*** GAU: n (%) 8 (11.8) n/a
5 South Medicine: n (%) 32 (47.1)
8 Main Medicine: n (%) 20 (29.4)
ICU/CCU: n (%) 8 (11.8)
Length of stay until C. difﬁcile Mean (Std) 12.8 (11.3) n/a
(days)*** Median [Q1–Q3] 9.5 [5−16.5]
Total length of stay until Mean (Std) 29.9 (23.3) 24.8 (17.4)
discharge (days) Median [Q1–Q3] 24.5 [13.5−36.5] 22.0 [13.0−30.0]
Number of roomsx Mean (Std) 2.1 (1.2) 2.3 (1.5)
Median [Q1–Q3] 2.0 [1.0−3.0] 2.0 [1.0−3.0]
Numer of patient exposureo Mean (Std) 14.3 (16.9) 11.2 (10.7)
days Median [Q1–Q3] 9.1 [4.9−15.3] 7.9 [3.5−15.8]
Number of deaths n (%) 20 (29.4) 12 (17.7)
Numbers of patients
transferred to LTC
n (%) 12 (17.7) 13 (19.1)
Type of antibioticoo Quinolones: n (%) 59 (86.8) 47 (69.1)
Penicillins: n (%) 16 (23.5) 17 (25.0)
Sulfonamides: n (%) 0 (0.0) 7 (10.3)
Nucleosides/nucleotides: n (%) 1 (1.5) 2 (2.9)
Cephalosporins: n (%) 20 (29.4) 8 (11.8)
Azoles: n (%) 1 (1.5) 1. (1.5)
Aminoglycosides: n (%) 1 (1.5) 4 (5.9)
Miscellaneous antiprotozoals: n (%) 12 (17.7) 17 (25.0)
Miscellaneous antibacterials: n (%) 8 (11.8) 11 (16.2)
Miscellaneous b-lactams: n (%) 3 (4.4) 1 (1.5)
*: Time from registration in the ED to leaving for another unit.
**: Indirectly measures the level of crowding in the ED during the whole stay of cases and controls.
***: Matching criteria.
x : Calculated from admission until the date of collection of the ﬁrst specimen that tested positive for Clostridium
difﬁcile in the infected patient for both cases and controls. If diagnosis of Clostridium difﬁcile was done after
discharge, then the study period for cases was from admission to discharge.
o: A private room equals zero patient encounter days; onde day in a four bedded room equals 3 patient encounter
days and one day in a semi-private room equals one patient encounter day. A day in the CCU or ICU rooms 1 to 5
equals two patient encounter days and a day in ICU rooms 6 to 7 zero patient encounter days. Total exposure for
cases and controls is the sum of these values for the time period from admission to the day of specimen collection
for the cases of CDAD (and the calculation made for the same number of days for the controls).
oo: Antibiotics were taken from 14 days before registration at the Emergency Department until the date before
occurrence of CDAD.
n/a: not applicable. Std: standard deviation.
Q1 and Q3: 1st and 3rd quartiles.
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Results: Patients are 83.6 years old on average. There are 73 cases
of CDAD among 824 eligible admissions. Matched analyses for 68
cases and matched controls show no signiﬁcant differences between case
patients and control patients for ED or inpatient variables. Multivariable
analysis conﬁrms that quinolones (OR=2.82 95%CI [1.30;6.13] and
cephalosporins (OR=3.38 95% CI [1.72; 6.61] are associated with the
occurrence of CDAD, and that both groups are the most administered
antibiotics in the sample.
Conclusions: This study fails to identify any signiﬁcant association
between nosocomial CDAD and measures of ED crowding or increased
patient contacts due to room changes or the use of multi-bed ward rooms.
However, the validity of our methodology is supported by the association
between antibiotic prescriptions and nosocomial CDAD occurrence, as
already quoted in the literature. We note a temporal decrease in the
reported rate of Clostridium difﬁcile infection in our institution since the
study period (April 1, 2003 – March 31, 2004) and suggest that the most
likely reason is improving housekeeping practices over this period.
O462 Clostridium difﬁcile in the paediatric population
S.N. Reddy, P. Kalima, M.H.S. Collie, D.N. Anderson, I.R. Poxton
(Edinburgh, UK)
Objectives: Clostridium difﬁcile Associated Disease (CDAD) cases are
increasing.
There has been a shift in trends with a rising number of cases being
reported in low-risk populations, e.g. children and young peri-partum
women. Our aim was to review the prevalence of C. difﬁcile in the in-
patient paediatric population presenting to a Children’s Hospital within
a University Hospitals Trust from 2000–2006 inclusive, and to further
assess the data set for 2006.
Methods: Patients were identiﬁed via Medical Microbiology databases.
Patients ranging from greater than one-month to less than 14 years were
included. Retrospective analysis of prospectively collected outcome data
was then performed.
Results: There has been an increase in the number of diagnosed
paediatric CDAD cases over the last year. (A detailed breakdown is
shown in the table attached).
Further analysis of data for 2006 revealed 603 faecal samples were
tested for C. difﬁcile of which 33 samples were positive. Taking into
account multiple samples testing for individual patients 22 patients were
diagnosed with CDAD out of 335. Of the 22 positive patients there was
no signiﬁcant gender bias (Male:Female=10:12) and the median age was
3 years (range 2 months – 13 years). For this cohort 117 samples were
analysed ranging from 1−31 samples per patient over a time period of
1–331days. Only 54% of patients were found to be toxin positive on
their ﬁrst sample. A median period of 23days (range 2–102 days) was
conceded prior to detection of C. difﬁcile toxin, from the time of their
ﬁrst negative sample being assessed to the ultimate positive sample,
a median of 3 (range 2−6) samples was sent prior to detection. 23%
of positive patients had CDAD re-diagnosed on subsequent samples
following a negative sample. In these cases the median duration was
22 days (range 15–104days) following a median of a further 2 samples
being analysed (range 2−4).
Age range
(years)
2000 2001 2002 2003 2004 2005 2006
>1 month–<1 0 0 0 0 0 0 3
1–4 0 0 0 0 1 2 12
5–13 0 1 2 1 1 2 7
Conclusions: The diagnosis of C. difﬁcile is increasing in this previously
low-risk paediatric population and therefore is a clinical diagnosis that
must be considered early. Culture in conjunction with toxin testing may
have led to an earlier diagnosis in nearly 50% of patients and there is a
possibility that re-infection/re-colonisation may occur in up to a quarter
of Paediatric cases. Mandatory data reporting is only required for patients
over 65 years resulting in this important sub-set being excluded.
O463 Emergence of reduced susceptibility to metronidazole in
Clostridium difﬁcile
S. Baines, R. O’Connor, W. Fawley, P. Mastrantonio, E. Kuijper,
M. Wilcox (Leeds, UK; Rome, IT; Leiden, NL)
Objectives: Resistance to metronidazole (MET) or vancomycin in
C. difﬁcile (CD) has rarely been reported and generally limited to
occasional strains. We have repeated previous surveillance for MET and
vancomycin resistance in common C. difﬁcile ribotypes.
Methods: We screened recently isolated (2005–2006) CD strains from
symptomatic patients in Leeds and compared these results with those
from repeat testing of historic isolates (1995–2001). Isolates of CD
ribotypes 001 (n = 87), 106 (n = 81), 027 (n = 48), the most common UK
types, and 10 other prevalent ribotypes (n = 57) were examined initially
using a spiral gradient endpoint (SGE) method. Isolates displaying a
MET MIC 6 mg/L, as determined by SGE, were analysed further
by agar incorporation (AI) and E-test methods. AI was carried out by
CLSI, and also by culture in pre-reduced Schaedler’s anaerobic broth
at 37ºC for 48 h, followed by multipoint inoculation of 104 cfu per
spot onto Wilkins-Chalgren agar and anaerobic culture at 37oC for 48
h. Isolates were further characterised by multi-locus-variable-tandem-
repeat-analysis (MLVA) to determine clonal relatedness.
Results: No reduced susceptibility to vancomycin was observed. All
CD ribotype 106 or 027 isolates were fully susceptible to MET (MICs
<2mg/L). However, 21 (24%) CD ribotype 001 isolates had reduced
susceptibility to MET by SGE (geometric mean MIC was 3.5 mg/L
(P< 0.001). Results varied according to the method used, and both the
agar base and broth used to prepare inocula affected the METMIC values
for CD. Neither E-test nor CLSI methods detected the CD strains with
reduced susceptibility to MET, but this was conﬁrmed by the alternative
AI method. The geometric mean MICs of CD ribotype 001 isolates
from 1995–2001 (n = 72) and those identiﬁed by SGE with reduced
susceptibility to MET (n = 21) were 1.03 and 5.9 mg/L, respectively
(P< 0.001). MLVA typing revealed subgroups of ribotype 001 isolates
that were more closely associated with reduced susceptibility to MET
than others.
Conclusion: We have detected the emergence of reduced susceptibility
to MET. This phenomenon is easily missed unless appropriate methods
are used. Increased vigilance is needed to identify reduced antibiotic
susceptibility in CD, and to detect increased treatment failure associated
with MET.
O464 Results of a phase III trial comparing tolevamer,
vancomycin and metronidazole in patients with Clostridium
difﬁcile-associated diarrhoea
E. Bouza, M. Dryden, R. Mohammed, J. Peppe, S. Chasan-Taber,
J. Donovan, D. Davidson, G. Short for the Polymer Alternative for
CDAD Treatment (PACT) Investigators
Objectives: Clostridium difﬁcile-associated diarrhoea (CDAD) is an
increasing nosocomial problem. Treatment with vancomycin (V) or
metronidazole (M) is associated with incomplete response rates, frequent
recurrences, and selection for resistant bacteria. In this study, the safety
and efﬁcacy of tolevamer (T) liquid (Genzyme, Cambridge MA), a novel
non-antibiotic toxin binder, was compared to V and M.
Methods: In this double-blind, multicentre (Europe, Australia, Canada)
study in adult patients with acute CDAD appropriate for oral therapy,
patients were randomised (2:1:1) to T 9g (3g tid, 14 days), V 500 mg
(125mg qid, 10 days), or M 1500mg (375 mg qid, 10 days). In the T
group, an initial 9 g loading dose was given. Patients were followed for
recurrence 4 weeks after treatment cessation. The primary endpoint was
non-inferiority of T vs. V for clinical success, deﬁned as resolution of
diarrhoea and absence of severe abdominal discomfort due to CDAD on
Day 10.
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Results: 528 patients (268 T, 125 V and 135 M) comprised the intent-
to-treat population. At enrollment, CDAD was noted as mild (31%),
moderate (43%), or severe (25%), ﬁrst occurrence (83%) or recurrent
(17%), and was similar across the treatment groups. Clinical success
rates were 42% (112/268) T, 81% (101/125) V, and 73% (99/135) M,
indicating similar success rates in the V and M groups (p =0.153), but
a lower T success rate than V or M (p 0.001 for both comparators).
In patients with CDAD resolution sustained through the end of active
treatment, the recurrence rates were 6% for T, 18% for V, and 19% for
M. Adverse events were similar across treatment arms.
Conclusion: T did not meet its primary endpoint of non-inferiority vs.
V. Overall, V and M had similar responses. Recurrent CDAD occurred
frequently with V and M, but was uncommon among those patients who
resolved with T, suggesting that ﬂora-sparing drugs may help reduce
recurrences. These results conﬁrm those from an identically designed
parallel study performed in the US and Canada (ICAAC 2007; poster
3826).
O465 Strong effects of antibiotic stewardship and infection control
measures on Clostridium difﬁcile-associated diarrhoea
incidence rates in northwestern Germany
H.-P. Weil, P. Gastmeier, E.J. Kuijper, U. Fischer-Bru¨gge (Nordhorn,
Hannover, DE; Leiden, NL)
Objectives: To investigate the effects of antibiotic stewardship and
infection control measures on the incidence rates of healthcare-onset
CDAD in 18 hospitals and of community-onset CDAD. The incidence
rates of MRSA, VRE and ESBL in the hospitals were used for
comparison.
Methods: Toxin-testing, cultivation, identiﬁcation and PCR ribotyping
of C. difﬁcile, were performed according to standard procedures.
Results: In 2005, eleven hospitals (group I) in the Southern subregion
had increased CDAD incidence rates (11.6 patients/10,000 patient days),
whereas 7 hospitals in the Northern subregion (group II) had no elevated
CDAD incidence rates (4.0 patients/10,000 PD). PCR-ribotyping of
isolated C. difﬁcile strains revealed that more than 80% belonged to
hyperendemic multiresistant strains (001, 046) in group I hospitals,
whereas no predominant PCR ribotype was detected in group II hospitals.
In 2006, interventions were made in group I hospitals: antibiotic
stewardship, (5/11) and infection control measures (10/11). In group
II hospitals only two hospitals introduced infection control measures.
In 2007 group I hospitals achieved a signiﬁcant reduction of CDAD
(8/10,000 PD); group II hospitals showed a constant increase of CDAD
(6/10,000 PD). No signiﬁcant changes regarding to MRSA, VRE and
ESBL incidence rates were observed, although group I hospitals had
constantly higher MRSA incidence rates. Community-onset CDAD was
rarely detected in 2005 (3.8/100,000 inhabitants). A change of the
diagnostic algorithm for CDAD and the information of the general
practitioners about CDAD led to an increase of community-onset CDAD
in 2007 to 20/100,000 inhabitants. In the Northern subregion the number
CO-CDAD patients were lower (11/100,000), than in the southern
subregion (26/100,000).
2005 2006 2007
Incidence rates* C
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Group I§ 11.6 7.1 0.6 0.5 12.2 9 0.6 1.1 8 11 0.8 1.9
Group II& 4 5.5 0.4 0.7 5 7.9 0.2 1.7 6 7.5 0.7 2.7
*Incidence rates: patients/10,000 patient days.
§11 hospitals in the southern subregion; &7 hospitals in the northern
subregion.
Conclusions: Intervention by antibiotic stewardship t (reduction of
cephalosporins and ﬂuoroquinolones) and infection control measures has
led to an overall decrease of CDAD in hospitals with increased CDAD
incidence rates. There was no signiﬁcant association between CDAD
incidence with the incidence rate of infections due to other multiresistant
bacteria, although MRSA incidence rates were also high.
O466 Comparison of disinfecting efﬁcacy of Hydrogen
peroxide-based dry mist system and hypochlorite 0.5% on
Clostridium difﬁcile contaminated surfaces
D. Menuet, M. Verachten, E. Girou, F. Barbut (Paris, Cre´teil, FR)
Background: During Clostridium difﬁcile-associated diarrhoea (CDAD),
a large number of spores disseminated in the patients’ room. These
spores may survive for weeks and are resistant to commonly used
disinfectants.
Objectives: To compare the disinfecting efﬁcacy of hypochlorite
0.5% (currently recommended in France for disinfection of CDAD
patients’ environment) and hydrogen peroxide-based dry mist system
(Sterinis®/Sterusil®, Gloster Sante´ Europe).
Methods: The efﬁcacy of both disinfectants was assessed in situ, in
the rooms (n = 31) of patients with CDAD. A prospective study was
performed in two French university hospitals from April to August
2007. At discharge, rooms were cleaned and randomised in two groups
to compare the disinfection processes: the HPV group included rooms
treated with 5% hydrogen peroxide-based dry mist system (1 cycle;
18 min. diffusion, 60 min. contact time) and the H group manually
disinfected using 0.5% hypochlorite. Twelve environmental surfaces (100
cm2) were tested for C. difﬁcile before and after disinfection, using
moistened swabs that were inoculated on selective plates (taurocholate,
cycloserine, cefoxitin agar) and broth.
Both disinfectants were also tested in vitro on small pieces (4 cm2)
of two different materials placed in empty rooms and experimentally
contaminated by 106 spores of 3 different strains of C. difﬁcile including
the 027 clone. Spores were numbered before and after disinfection and
the mean reduction factor of contamination was expressed as log10 UFC.
Results: 748 surface samples were collected in the rooms of patients with
CDAD. Before disinfection, the frequency of contamination was 24% and
19% in H and HPV groups, respectively (p = 0.2). After disinfection, a
signiﬁcant reduction of contamination was observed in both groups, with
a relative higher level in the HPV (19% vs 2%) than the H group (24%
vs 12%) (p< 0.005).
Results of the in vitro study showed whatever the strains and materials
used, a mean reduction factor of contamination signiﬁcantly higher in
the HPV than the H group (4.18±0.79 vs 1.8±0.81, p< 0.001).
Conclusion: The hydrogen peroxide-based dry mist disinfection system
is more effective than hypochlorite 0.5% in decreasing C. difﬁcile
contamination in patients’ environment and might represent an
appropriate alternative for the disinfection of rooms of patients with
CDAD at discharge.
O467 Clostridium difﬁcile is not reliably eradicated by ward
bedpan washers unless alkaline detergent is used
M. Alfa, N. Olson, L. Beulow-Smith (Winnipeg, CA)
Objective: The objective of this study was to use simulated-use testing
to evaluate the efﬁcacy of C. difﬁcile spore elimination by W-BPW
compared to Central Processing Dept. washers (CPD-BPW).
Methods: C. difﬁcile spores were suspended in sterile faeces to give
~10E6 cfu/mL and 0.1 mL of this preparation was spread over a deﬁned
surface area of the bedpan and allowed to dry 2.5 Hrs or overnight
at room temperature. The inoculated bedpans were processed using
the W-BPW or the CPD-BPW. Rodac plates containing CDMN media
were used to detect residual C. difﬁcile sporeson processed bedpans. In
addition the faecal-spore suspension was placed in a sealed vial and
processed through the BPWs to determine if the thermal conditions (no
wash off effect) were sufﬁcient to kill the spores. An unprocessed control
was compared to the processed sample in the sealed vial to determine
the Log10 reduction in spores due to thermal exposure. The ability of
Resisting resistance: global trends and therapeutic strategies for MRSA (Symposium organised by Forest Laboratories) S105
thermal conditions to kill C. difﬁcile spores in PBS (i.e. no organic
challenge) was also evaluated using spore suspension testing at 80oC
and 90oC. Two different makes of W-BPWs were evaluated.
Results: Our data on suspension testing showed that the C. difﬁcile
spore count was not reduced after 5 minutes at 90oC. Simulated-use
testing demonstrated that the ward-BPW when used without detergent,
did not effectively eliminate C. difﬁcile spores from inoculated plastic
or stainless steel bedpans whereas the CPD-BPW did. The thermal
disinfection default cycle in the two makes of W-BPW and the CPD-
BPW was 80ºC for 1 minute. The ISO15883−3 guidance document
recommends these thermal conditions as adequate for reprocessing of
bedpans. Exposure to these conditions resulted in ~1 Log10 reduction in
spores. However, the 80oC for 1 min thermal cycle combined with the
116ºC drying cycle for 7 mins used by the CPD-BPW killed 6 Log10
C. difﬁcile spores. Further testing showed that using an alkaline detergent
along with the W-BPW did reliably eliminate C. difﬁcile spores.
Conclusion: Despite the wide use of 80ºC for 1 minute, our data
showed that these thermal conditions alone were not effective in killing
C. difﬁcile spores. Only when alkaline detergent was used was the W-
BPW able to eliminate C. difﬁcile spores from bedpans. We recommend
that alkalkine detergent always be used with W-BPWs to reduce the risk
of C. difﬁcile spores remaining on reprocessed bedpans as this could
pose a risk for nosocomial transmission.
Resisting resistance: global trends and
therapeutic strategies for MRSA (Symposium
organised by Forest Laboratories)
S468 European CA-MRSA: a singular situation?
F. Vandenesch (Lyon, FR)
Community-acquired meticillin-resistant Staphylococcus aureus (CA-
MRSA) was ﬁrst described in Europe at the beginning of this decade,
and since 2003 an impressive worldwide spread of Panton Valentine
leukocidin (PVL)-positive CA-MRSA clones has been observed.
Continuous surveillance of CA-MRSA organised by the French National
Reference Center for Staphylococci has revealed a number of signiﬁcant
trends enumerated below:
• The spread of previously continent-speciﬁc clones of CA-MRSA to
other continents. Schematically in 2003, ST80 was detected in Europe,
ST8 (USA300) and ST1 (USA400) in the USA, and ST30 in Oceania.
In 2006, intercontinental exchanges of several clones were observed:
the ST8 clone from the USA towards Europe; the ST1 clone from the
USA towards Europe and Asia; the ST59 clone (USA1000) from the
USA towards Asia; and the ST80 clone from Europe towards Asia.
• The spread of PVL-positive CA-MRSA from country to country. For
instance, in Europe, PVL-positive CA-MRSA of ST80 was recently
detected in Slovenia, Romania, and Croatia.
• New PVL-positive CA-MRSA clones emerging with different genetic
backgrounds. While most of the clones described in 2003 had an
agr3 background, the newly described clones are agr1 or agr2. Clone
ST22 (agr1) has been found in Europe only, and clone ST377 (agr1
with a type V SCCmec) was reported simultaneously in Europe and
Australia.
• PVL-positive CA-MRSA, which were initially susceptible to most
anti-staphylococcal agents, have acquired new antimicrobial resistance
determinants, for example, to gentamicin and oﬂoxacin.
• In contrast to the USA, where CA-MRSA now accounts for the
majority of S. aureus infections in the community, the prevalence of
PVL-positive CA-MRSA remains low in Northern Europe. However,
Southern European countries, such as Greece, and countries located
at the southern boundaries of Europe, such as Algeria, have a greater
prevalence of PVL-positive CA-MRSA.
• In countries of high prevalence, PVL-positive CA-MRSA are
responsible for an increasing number of hospital-acquired infections.
• Sequence variations of PVL among the different clones have been
observed. The most frequently observed clone in Europe (ST80)
harbours an H2 haplotype which is described as the ancestral allele
that gave rise to the other variants.
These trends, although largely regionalised, must be taken into account
when targeting skin infections as well as other infections, including
community-acquired pneumonia. In summary, these emerging tendencies
towards increased incidence of CA-MRSA and decreased susceptibility
to antimicrobial agents must be considered when choosing empiric
treatment options.
S469 The increasing global burden of MRSA and potential clinical
implications
D.E. Low (Toronto, CA)
Meticillin-resistant Staphylococcus aureus (MRSA) was ﬁrst described
in the 1960s as a source of healthcare-associated (HA) infections. In the
United States (U.S.), the National Nosocomial Infections Surveillance
System reported a 12% increase in MRSA infections in 2003, compared
with the prevalence noted from 1998 to 2002. Now >63% of all
S. aureus isolates recovered from critically ill patients are MRSA and are
prevalent in all regions of the U.S. Additionally, MRSA now represents a
worldwide problem, with the pathogen increasingly noted in Europe and
Asia. Initially, infections with this organism were seen almost exclusively
in people with signiﬁcant healthcare exposure. The ﬁrst reports of MRSA
infections among healthy persons without identiﬁable risk factors for
HA infections were published in the 1980s. MRSA emerged as a more
widespread cause of community-associated (CA) infections in the late
1990s. A comparison of CA-MRSA versus HA-MRSA reported that
skin and soft tissue and otitis media infections were disproportionately
due to CA-MRSA, compared with respiratory tract and urinary tract
infections. However, there has been a dramatic increase in the occurrence
of S. aureus infections in general and CA-MRSA infections in particular.
In most, but not all, U.S. cities, CA-MRSA is now the most common
pathogen cultured from patients with skin and soft tissue infections in
emergency departments. Epidemic community-associated MRSA disease
has also been reported from some rural areas. In Canada, a similar
pattern of emergence is occurring with the West Coast being most
affected. Of concern is the risk of greater incidence of community-
acquired pneumonias caused by MRSA in the future. Although severe
pneumonia caused by CA-MRSA was reported in children soon after
this pathogen emerged in the U.S., reports in adults have been rare and
typically associated with inﬂuenza virus infection. However, the Centers
for Disease Control and Prevention reported 10 cases of severe MRSA
CAP in 2006; six of the 10 patients died. Although a small sampling
of patients, these cases nonetheless underscore the need for healthcare
providers to be extremely vigilant for cases of severe CAP caused by
MRSA.
The emergence of MRSA strains since 1961 has complicated the
treatment of S. aureus infections, and glycopeptides (vancomycin
or teicoplanin) are, in many cases, the only therapeutic alternative.
Glycopeptides remain the ﬁrst-line option when infection due to MRSA
is suspected or diagnosed. However, vancomycin treatment failure is
not uncommon, even when MRSA strains are fully susceptible to
vancomycin (MIC 2mg/mL). A reduction in the efﬁcacy of vancomycin
against MRSA strains with a high vancomycin MIC (1−2mg/mL) has
been described in observational studies with low number of patients,
suggesting that subtle changes in the MIC may explain clinical failures.
These ﬁndings require healthcare practitioners to consider alternative
treatments and look to the future, as newer, more active compounds are
developed to improve the treatment armamentarium against community-
acquired infections with drug resistant S. aureus.
S470 Prevention protocols and the rationale for new therapeutic
strategies
R. Canto´n (Madrid, ES)
“Search-and-destroy” is considered one of the most effective means
to curtail the increased prevalence of nosocomial resistant organisms,
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including meticillin-resistant Staphylococcus aureus (MRSA). The
implementation of this strategy in certain European countries has
decreased the prevalence of MRSA infection in the nosocomial
setting for the ﬁrst time. Nevertheless and in parallel, an increase in
MRSA isolates in the community setting, including nursing homes
and healthcare-associated facilities, has been observed during the past
decade. As a consequence, community-acquired MRSA infections are
increasingly recognised in the nosocomial setting, making it difﬁcult,
to integrate preventive strategies into standard hospital procedures.
Moreover, an inﬂux of well-dispersed community clones – most of them
carrying the type IV staphylococcal cassette chromosome (SCCmec type
IV) – into the nosocomial setting has been demonstrated in countries with
high prevalence of MRSA in the community. The potential association
of these isolates with the production of the Panton Valentine Leucocidin
(PVL) is of clinical concern, as initial empirical coverage for this
pathogenic organism is restricted.
Standard antimicrobial treatment protocols against both community- and
hospital-acquired MRSA infections include non-b-lactam antimicrobials,
among them, glycopeptides have been considered the gold standard.
To date, few isolated cases of complete glycopeptide resistance in
S. aureus (VRSA) have been reported. However, low-level resistance,
or “vancomycin-intermediate S. aureus” (VISA), has been documented
worldwide. These isolates display a thickened cell wall affecting the
activity of glycopeptides. Recent data have also demonstrated the
isolation of MRSA isolates with heterogenous subpopulations with
decreased susceptibility to glycopeptides (“heterogeneous VISA”), and
the possibility that a slight rise in modal vancomycin MIC values within
the susceptible category (MIC range 1.5 to 2 mg/mL) may affect clinical
success of glycopeptide treatment. This possibility has been observed in
different infections, including bacteraemia. The true incidence of MRSA
populations with decreased susceptibility to glycopeptides is unclear and
might depend on population structure distribution. Maintaining vigilant
surveillance of these resistance trends is critical to ensure appropriate
coverage.
Treatment options for invasive MRSA infections currently in-
clude vancomycin, linezolid, daptomycin, tigecycline, and quin-
upristin/dalfopristin. Additionally, a number of compounds to combat
the growing resistance problems are in development, including
novel glycopeptides (dalbavancin, telavancin, and oritavancin), and
next-generation cephalosporins (ceftobiprole and ceftaroline) which
demonstrate excellent in vitro activity against MRSA, VISA and VRSA.
The addition of these new agents to the armamentarium will be critical
in managing patients with infections due to MRSA encountered both in
the hospital and community settings.
ID-TagTM respiratory viral panel
(Symposium organised by Luminex)
S473 Epidemiology of respiratory virus infections using xTAG
RVP test
J.B. Mahony, S. Chong, M. Smieja, A. Petrich, S. Buracond, J. Babwah
(Hamilton, CA)
Background: With the discovery of ﬁve new respiratory viruses since
the year 2000 and advances in molecular technology allowing the
detection of 20 respiratory viruses in a single test, we studied the
epidemiology of respiratory virus infections.
Methods: A total of 1,060 NP specimens collected from symptomatic
patients (526 <20 yr and 534 >20 yr) were used in the study.
Approximately 100 specimens (50 from each age group) were sected
blindly (DFA and culture results unknown) from specimens submitted
to our Regional Virology Laboratory for each month from November
1 2005 to October 31 2006. Nucleic acid was extracted using the
MiniMag extractor (Biomerieux) and tested by the ID-Tag RVP Test
(TmBioscience) for 20 respiratory viruses and for Bocavirus using a
separate PCR. Clinical information was collected by chart review. Results
were analysed by month and age.
Results: Of the 1060 specimens tested, 424 (40%) were positive for one
of 16 respiratory viruses including: 205 (19.3%) Rhino/Enterovirus, 58
(5.5%) Inﬂuenza type A or B, 45 (4.1%) Parainﬂuenza (types 1−4), 41
(3.9%) RSV (type A or B), 41 (3.9%) Metapneumovirus, 39 (39/947,
4.1%) Bocavirus, 20 Adenovirus, 14 Coronavirus (OC43, HKU1, NL63).
Twenty ﬁve of 39 Bocavirus infections were dual infections. Only
Rhino/Entero, RSV and Bocavirus were more prevalent in the <20 age
group (p< 0.05). Inﬂuenza, Metapneumovirus and Coronavirus were
only present in winter/spring months while Parainﬂuenza type 4 was
only present in summer months; all others were distributed across most
months.
Discussion: This study indicated the following: 1) Rhino/Enterovirus
was the most prevalent virus infection of symptomatic children and
adults, 2) only RSV, Rhino/Enteroviurs, and Bocavirus showed higher
infection rates in children compared to adults, 3) 90% of dual infections
(mostly Boca and Rhino/Enterovirus) occured in children summer, and
4) Inﬂuenza, Metapneumovirus and Coronavirus displayed a winter
seasonality. The average rate of positives diagnosed per month for <20
yr group was 63% compared to 23% for adults.
S474 Finding respiratory viruses in nasopharyngeal aspirates:
comparison between direct immunoﬂuorescence and a new
multiplex PCR method
S. Jemielity, M. Barbani, T. Staub, D. Grandgirard,
M. Gorgievski-Hrisoho (Berne, CH)
Respiratory viruses are among the most frequent human pathogens
worldwide, leading to a signiﬁcant number of hospitalisations, especially
in children and in immune-compromised patients. Several new diagnos-
tics tools for respiratory viruses have recently appeared on the market,
including the xTag Respiratory Viral Panel (RVP) by Luminex Molecular
Diagnostics. The goal of the present study was to compare this new
multiplex PCR method with conventional direct immunoﬂuorescence
(DIF) in children’s nasopharyngeal aspirates for the following viruses:
respiratory sincytial virus (RSV), adenovirus (ADV), parainﬂuenza
viruses 1−3 (PIF), inﬂuenza viruses A and B (IF), as well as human
metapneumovirus (hMPV). The RVP kit permits in addition the detection
of entero-/rhinoviruses, coronaviruses and parainﬂuenza virus 4.
In total 240 nasopharyngeal aspirates (126 DIF negative and 114 DIF
positive samples) were analysed. All RSV, PIVA, IF and hMPV DIF
positive samples (43, 15, 18 and 11, respectively) were conﬁrmed as
positive for the same virus by RVP. For ADV, however, only 13 out of
27 DIF positive samples (48%) were also ADV positive by RVP. The
samples with discrepant results are currently being reanalysed by DIF
and by a second, independent PCR.
Of note is the ﬁnding that over 64% (81/126) of all DIF negative samples
were positive when analysed with RVP. This was in great part due to
the additional entero-/rhinoviruses detected by RVP (75/81), but also
because of additional RSV, IF, PIF, ADV and hMPV positive samples
that had been missed with the DIF assays (21/81). Finally, using RVP
we detected as many as 10.4% (25/240) of double and 0.5% (1/240)
of triple infections, versus a single double infection detected by DIF.
The implications of our ﬁndings for both diagnostics as well as clinical
practices are discussed.
S475 Routine use of Tm Biosciences respiratory viral test in a
hospital virology laboratory
F. Stoll-Keller (Strasbourg, FR)
One hundred thirty seven samples (swab specimens, nasopharyngeal
aspirates, bronchoalveolar lavage samples) were collected from the 15th
of October to the 15th of December from hospitalised patients and
investigated for presence of respiratory viruses. Sixty three percent were
positive for one virus and co-infections were detected among 19%.
The test detected 24 RSV (22%) and 14 parinﬂuenza viruses (12%).
Other viruses, not detected by culture and direct tests, were additionally
detected: 24 Metapneumoviruses (21%), and 46 Entero/Rhino viruses
Varicella zoster infection S107
(41%). Luminex RVP was adapted to the routine work of the laboratory
to give results within 36 hours to the clinicians.
S476 Sensitive and speciﬁc detection of a broad range of
respiratory viruses using the Luminex RVP assay: application
to routine viral diagnostics
J. Fox, K. Pabbaraju, K. Tokaryk, S. Wong, A. Wong, K. Ho (Calgary, CA)
Background and Objectives: Detection of a broad range of respiratory
viruses using sensitive nucleic acid ampliﬁcation tests (NATs) is
invaluable for individual patient diagnosis and management of outbreaks.
The wide range of potential pathogens makes such testing expensive and
laborious using individual real-time NATs. The objective of this study
was to compare the multiplex detection of 19 respiratory viral targets
using the Luminex xTagTM Respiratory Viral Panel (RVP) with the
individual real-time NATs used in ProvLab (Alberta).
Methods: Nasopharyngeal samples were pre-screened by DFA for
inﬂuenza (IFV) A and B, parainﬂuenza (PIV) 1−3 and respiratory
syncytial virus (RSV) with direct ﬂuorescent antigen (DFA) positive
samples excluded from this comparative study. Respiratory specimens
were collected between December 2006 and May 2007 with nucleic
acid extraction undertaken using the easyMAG® extractor and reagents
(bioMe´rieux). Individual real-time NATs for comparison with RVP were
directed against IFVA, IFVB, PIV1−4, RSV, human metapneumovirus
(hMPV) and respiratory adenoviruses. A total of 1497 specimens were
part of the analysis with 632 specimens analysed prospectively and
865 retrospectively by RVP. If positive results for coronaviruses or
picornaviruses were obtained in the RVP assay these samples were
subsequently screened by additional real-time NATs against these targets
as such testing is not part of our current diagnostic routine.
Results: A total of 937 specimens were positive for one or more
respiratory viruses by the individual NATs and 948 had one or more
positive results by the RVP assay. The rate of detection for hMPV
and IFVA was comparable by both methods (5.7% and 34.0% positive
results, respectively). Detection rate for IFVB, PIV1−4 and RSV was
5.3%, 13.1%, 12.7% by the real-time assays and 4.9%, 12.6%, 10.7%
correspondingly by the RVP assay. The detection of adenovirus was
superior by the in-house NAT (8.2% positive compared with 4.6% by
the RVP assay). However, the RVP assay identiﬁed 12.1% of samples
as picornavirus positive (conﬁrmed by sequencing), only half of which
were identiﬁed by individual NATs undertaken for enteroviruses and
rhinoviruses. Of the 248 IFVA positive specimens, 85.5% were sub-
typed as H1 or H3 by the RVP assay. A total of 26 samples positive
for coronaviruses were detected by the Luminex RVP, which were all
conﬁrmed by real-time RT-PCR assays.
Conclusion: The Luminex RVP assay meets our current standards of
sensitivity and speciﬁcity and also allows for multiplex detection of
19 respiratory viral targets with considerable time and cost savings
compared with alternative NATs. This method will become front line
for respiratory virus testing in our laboratory.
Pregnancy and parasitic diseases: a focus on
malaria
K477 Pregnancy and parasitic diseases: a focus on malaria
C. Menendez (Barcelona, ES)
Pregnant women are at increased risk for malaria infection. Although
important advances had been made in the last years, the mechanisms
that explain their increased susceptibility to this parasitic disease, are not
yet fully understood. Malaria infection in pregnancy may be associated
with maternal and fetal morbidity and mortality. The severity of this
burden depends on the level of pre-pregnancy acquired immunity against
malaria. Thus, the consequences of the infection are more severe in non-
immune women than in those who have acquired a certain level of anti-
malarial immunity. In highly endemic areas, the frequency and severity
of the infection is higher in primigravidae and decreases with increasing
parity. In non-immune women, the risk is similar across the parities
and malaria may be an important direct cause of maternal mortality.
Malaria infection during pregnancy may have important negative effects
on the infant’s health, through intrauterine growth retardation and
prematurity or directly through congenital infection. Control of malaria
during pregnancy with adequate case management and implementation
of preventive tools, is a public health priority in malaria endemic areas.
Are emerging infections driven by climate
change?
K478 Are emerging infections driven by climate change?
S. Randolph (Oxford, UK)
Of all the past and present (and probably also future) emergent infectious
diseases, those caused by pathogens transmitted by arthropod vectors
are the most sensitive to climate and most commonly assumed to
have been driven by climate change. There is, however, no a priori
reason to expect the rates of each system’s biological and demographic
processes to respond to changing patterns of temperature and moisture
stress in ways that inevitably increase the risk of human (or livestock)
infection. A prerequisite of reliable early warnings about the future is a
system-speciﬁc explanation of the past. Tick-borne encephalitis (TBE),
one of the two most widespread, prevalent and medically signiﬁcant
vector-borne diseases in Europe, will be presented as a case study.
Epidemiological data at ﬁne temporal and spatial resolution record
major upsurges in incidence over recent decades. The timing, degree
and abruptness of these upsurges differ markedly between countries,
and even between districts within countries. A signiﬁcant discontinuity
in temperature conditions in 1989 across Europe could have created a
generally more permissive environment for TBE virus transmission by
improving the circumstances necessary for larval and nymphal stages of
the tick to co-feed on rodents. The pattern of climate change, however,
is too uniform within and between countries to provide the sole, or
even the most important, explanation for the extreme spatio-temporal
heterogeneity in TBE epidemiology. Instead, a nexus of interacting
factors affecting both the risk of infection and exposure of humans
to that risk, and each differing in force in space and time, is a more
powerful model. Analysis of the situation in Central and Eastern Europe
has established that many of these factors were driven by the socio-
economic changes associated with the end of Soviet rule, and include
climate, land cover, land use, wildlife, agricultural practices, industrial
activities, (un)employment and income. Western and Nordic Europe must
be incorporated to achieve a coherent pan-European explanation. The
same principles may apply to the periodic epidemics of Crimea-Congo
haemorrhagic fever.
Varicella zoster infection
S483 Varicella zoster virus latency: implications for new vaccines
J. Cohen (Bethesda, US)
Varicella-zoster (VZV) causes chickenpox and the virus establishes
latency in cranial nerve and dorsal root ganglia. VZV DNA was
detected in 4% of neurons from human trigeminal ganglia at autopsy
with a median of 7 viral genomes per positive neuron. Latent VZV
DNA was rarely, if ever, detected in nonneuronal cells. The virus
can reactivate from latently infected ganglia to cause shingles. The
varicella vaccine virus may also reactivate and cause shingles, especially
in immunocompromised patients. We have used PCR to detect VZV
DNA in the blood of immunocompromised patients who present with
abdominal pain in the absence of a rash, to allow early therapy prior
to development of the rash of shingles. At least six VZV genes (genes
4, 21, 29, 62, 63, and 66) are expressed in latently infected ganglia in
humans. We have constructed VZV mutants lacking ﬁve of these genes
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and found that three of the genes are essential for replication in cell
culture, one is important for efﬁcient replication, and one is dispensable
for replication. Mutations in the coding region of one of the latency genes
(gene 63) resulted in impairment in replication in vitro and a marked
reduction in latency in rodents. Replacement of the native promoter for
one of the latency genes (gene 29), with the major immediate-early
cytomegalovirus promoter, resulted in a virus that replicated to levels
comparable to wild-type virus, but the virus was impaired for latency in
rodents. These studies suggest that changes in the coding or promoter
region of latency genes in VZV might serve as useful vaccine candidates.
Such vaccines might be less likely to establish latency and reactivate in
humans, and may be especially useful in immunocompromised patients.
The role of RNAs in the regulation of
virulence and antibiotic resistance gene
expression
S484 Small non-coding RNAs controlling pathogenesis
K. Xavier (Oeiras, PT)
Many bacteria use a form of cell-cell signaling termed quorum
sensing to coordinate gene expression as a function of the population
density. Quorum sensing enables bacteria to coordinate population-wide
responses that play a crucial role in virulence. Complex quorum sensing
networks enable bacteria to detect signals that provide information
regarding the number of individuals in the population, the different
species of bacteria present in the community, and additional inputs,
such as environmental and metabolic signals. Recently, it has become
clear that small non-coding RNAs (sRNA) are often the central
regulators modulating gene expression at central steps of quorum sensing
cascades and therefore coordinate the complex networks that control
virulence in bacteria. Importantly, multiple functionally redundant
sRNAs act together at the same key step of these regulatory cascades.
These different sRNAs are differentially expressed and respond to
different signals and thus provide a mechanism of integrating different
environmental stimuli and translating the combined information into the
appropriate output. We study a quorum sensing signal named autoinducer
(AI-2), which unlike most quorum sensing signals, it is not species-
speciﬁc. AI-2 is produced and detected by a wide variety of bacteria and
allows interspecies communication. By studying interspecies signalling
in consortia we found that Escherichia coli can manipulate AI-2
signalling in organisms such as the human pathogen Vibrio cholerae
and interfere with other species’ ability to regulate virulence. Here we
show that in this enteric bacterium the AI-2 synthase, LuxS, is regulated
by a sRNA.
New antimicrobials
O486 Mechanism of action of iclaprim in Staphylococcus aureus
C. Oefner, M. Bandera, G.E. Dale, A. Haldimann, S. Mukhija,
S. Parisi, S. Lociuro (Reinach, CH)
Objectives: Iclaprim (ICL) belongs to the diaminopyrimidines class
of antimicrobial dihydrofolate reductase (DFHR) inhibitors for which
trimethoprim (TMP) is the most well known representative. ICL
exhibits an expanded spectrum of activity and is notably very potent
against important Gram-positive pathogens, including meticillin-resistant
S. aureus (MRSA). The purpose of this study was to substantiate
previous studies on the mode of action of ICL in S. aureus.
Methods: One TMP-susceptible (wt-DHFR, ATCC 25923) and two
TMP-resistant DHFRs (one carrying a speciﬁc F98Y point mutation and
one from a multidrug resistant strain 101) were used in this study. The
DHFR’s were overexpressed and puriﬁed and used for the determination
of IC50’s, Ki’s, binding by isothermal titration calorimetry (ITC) and
co-crystallisation with ICL and TMP.
Results: Both ICL and TMP exhibited competitive binding with all three
enzymes. ICL IC50’s and Ki’s were 10-, 44- and 32-fold and 20-, 17-
and 29-fold lower than those of TMP, for wt-, F98Y and 101-DHFR,
respectively. In ITC, both ICL and TMP produced exothermic binding
with negative changes in enthalpy. The association constant (Ka) for
the F98Y enzyme for ICL was 13-fold stronger than for TMP and the
calculated deltaG was −1.88 kcal/mol. Co-crystallisation data showed
that the diaminopyrimidine moiety of ICL and TMP binds similarly
in both wt- and F98Y enzymes and that the lipophilic part of both
molecules is situated in the hydrophobic channel of the enzymes formed
by the side-chains of residues L20, L28, V31, I50 and L54. The larger
size of the ICL lipophilic residue resulted in an enlarged hydrophobic
contact surface area with the protein of about 35 A˚2.
Conclusions: ICL and TMP bind to and inhibit S. aureus enzymes in a
similar manner. The increased potency of ICL towards TMP-R DHFR
enzymes is due to a larger binding contact area which is in agreement
with the enhanced activity of ICL against both TMP-S and TMP-R
S. aureus isolates.
O487 The activity of ME1036 against community-acquired
pneumonia bloodstream isolates
I. Morrissey, J. Curry, Y. Ge, R. Janes (London, UK; Alameda, US)
Objectives: ME1036 is a novel parenteral carbapenem with enhanced
activity against Gram-positive pathogens, including multiple drug
resistant staphylococci, streptococci and Enterococcus faecalis. This
study evaluated the activity of ME1036 against isolates from hospitalised
CAP patient blood samples in the UK during 2000 to 2005.
Methods: The study investigated 1337 recent isolates, including
H. inﬂuenzae: b-lactamase (BL)-positive and -negative; M. catarrhalis;
S. aureus: meticillin-susceptible (MS) and -resistant (MR); S. pneumo-
niae: penicillin-susceptible (PenS), -intermediate (PenI) and -resistant
(PenR); and S. pyogenes. Susceptibility tests with ME1036 and 8
comparators were performed according to CLSI broth microdilution
methods.
Results: MICs required to inhibit 90% of each species (MIC90) are
shown in the Table for ME1036 and other selected comparators. ME1036
was highly active against all CAP bacteraemia isolates and more potent
than all of comparators tested, including meropenem, especially against
H. inﬂuenzae, MRSA, MSSA and PenIR S. pneumoniae. All isolates
tested were universally susceptible to ME1036 with the highest MICs at 2
mg/L. ME1036 was active against isolates resistant to other antimicrobial
agents, including meropenem non-susceptible S. pneumoniae.
MIC90 (mg/L)
Pathogen (# isolates) ME1036 Amoxicillin-
Clavulanate
Meropenem Levoﬂoxacin
H. inﬂuenzae – BL neg (94) 0.015 1 0.12 0.03
H. inﬂuenzae – BL pos (25) 0.015 1 0.12 0.015
M. catharrhalis (9) 0.03 2 0.06 0.25
S. aureus – MS (136) 0.015 1 0.25 0.5
S. aureus – MR (28) 2 32 128 32
S. pneumoniae – PenS (762) 0.008 0.03 0.015 1
S. pneumoniae – PenI (97) 0.015 1 0.25 1
S. pneumoniae – PenR (148) 0.06 4 1 1
S. pyogenes (38) 0.008 0.015 0.015 1
Conclusion: ME1036 is a broad-spectrum carbapenem with exquisitely
potent activity against Gram-positive pathogens and other respiratory
pathogens such as H. inﬂuenzae and M. catarrhalis. ME1036 has
the potential to be a useful new agent for the treatment of serious
community- and hospital-acquired respiratory tract infections.
Ticked off: lyme borrelliosis S109
O488 In vivo bactericidal effect of a new proline-rich peptide
A3-APO on an ESBL-producing Escherichia coli strain
F. Rozgonyi, K. Nagy, D. Szabo´, P. Anderlik, B. Kocsis, L. O¨tvo¨s
(Budapest, HU; Philadelphia, US)
Objectives: The aim of this study was to examine the in vivo efﬁcacy
of a new proline-rich antibacterial peptide A3-APO previously proved
to be in vitro bactericidal on some enteric bacterial strains.
Methods: CD-1 female mice of 15−20 g were pretreated with 18 mg/kg
cisplatin for 3 days to impair kidney clearance similar to that of human.
Then they were challenged intraperitoneally (ip) with 108 CFU per g
mouse of an extended-spectrum b-lactamase producing E. coli strain.
Four, 8 and 12 hours after challenge 40 mg/kg imipenem, 10, 20 and 40
mg/kg A3-APO were administered to 10 mice of each concentration of
the antimicrobials. Prior to drug administration, blood was taken from
the tail vein of 3−5 mice either the infected and untreated or the infected
and treated groups for determining blood bacterial counts.
Results: Blood bacterial counts amounted to 105 CFU/ml by the 4th hour
of challenge and exceeded 107 CFU/ml by the 12th hour in the untreated
mice. In contrast, each concentration of A3-APO decreased the blood
bacterial level by two log10 units four hours after the 1st administration,
e.g. from 105 to 103 CFU/ml similar to that after imipenem treatment.
Continuous dosing of either the peptide or imipenem retained the blood
bacterial counts at the lowest detectable levels.
Conclusion: To our knowledge, this is the ﬁrst antibacterial peptide that
is effective in mortality models of Gram-negative systemic infection and
exerts bactericidal activity in vivo in doses comparable to traditional
antibiotics without notable toxic side effects.
Supported by the Sbarro Health Research Organization and Hungarian
OTKA T46186.
O489 A new approach towards the prevention and treatment
of osteomyelitis: synthesis and in vitro studies of
bisphosphonated rifamycin prodrugs
T. Kang, Y. Lafontaine, R. Reddy, E. Dietrich, Y. Rose, S. Ciblat,
F.F. Arhin, I. Sarmiento, G. Moeck, A. Rafai Far, T.R. Parr Jr.
(Montreal, CA)
Objectives: Osteomyelitis is an infection of bone primarily caused by
staphylococci. Its treatment often requires a combination of surgical
intervention and prolonged antibiotic therapy, generally relying on
outpatient parenteral antibacterial therapies for weeks. Here we report the
development of a new class of prodrugs where rifamycins are tethered
to a bisphosphonate moiety possessing high afﬁnity for osseous tissues.
These compounds deliver the antibiotics directly to the infection site
where they will be concentrated and released over time to exert their
therapeutic activity.
Methods: Compounds were synthesised by tethering rifabutin, rifalazil
or adequately designed rifamycins to a bisphosphonate moiety via
cleavable covalent linkers. The afﬁnity of these compounds towards
bone powder was determined individually by measuring the amount of
unbound prodrug in the supernatant by bioassay against the total amount
of material following the exposure to bovine bone powder in phosphate-
buffered saline (PBS) for 1h at 37ºC and centrifugation. The rate of
cleavage was determined by resuspending the obtained bone pellet in
either PBS or 50% serum in PBS overnight at 37ºC, and measuring by
bioassay the drug content in the supernatant after centrifugation.
Results: A total of 14 prodrugs were synthesised using different chem-
ically and/or enzymatically cleavable linkers on rifamycin derivatives.
Most prodrugs displayed near quantitative bone binding, validating the
selection of a bisphosphonate as the bone-seeking moiety. Following
incubation of the bone-bound prodrugs at 37ºC for 24h, the levels of
regenerated parent antibiotics were in the range of 0 to 2.65 mol% in
PBS and 0 to 2.68 mol% in 50% rat serum.
Conclusions: The ability of bisphosphonated rifamycin class prodrugs
to bind efﬁciently to bone powder and to release their parent antibacterial
agents over time was established in vitro. This suggests they could be
used to deliver their antibacterial rifamycins to the bone after systemic
administration. This augurs well for the potential of this approach
towards the prevention and treatment of osteomyelitis.
O490 Comparative study of the efﬁcacy of low- and high-molecular
inhibitors of inﬂuenza virus haemagglutinin
S. Rak, E. Goncharova, I. Vinogradov, E. Ryabchikova, A. Chinarev,
A. Tuzikov, N. Bovin, A. Ryzhikov (Koltsovo, Moscow, RU)
Background: Human infections with inﬂuenza A and B viruses are
initiated by speciﬁc interactions of the viral glycoprotein hemagglu-
tinin with carbohydrate chains of cell surface receptors, terminating
predominantly in Sia2−6Gal disaccharides. Synthetic analogs of the
cellular receptors, which are able to compete with natural cellular
receptors, have potential for development of anti-inﬂuenza therapeutics.
Synthesis of low-molecular inhibitors of inﬂuenza virus is more
preferable for the development of therapeutics by reason of possible
toxicity, immunogenicity and incomplete biodegradation of polymeric
compounds. The objectives of this study were to compare the
anti-inﬂuenza activity and to clarify the mechanisms of action for
low-molecular and high-molecular (polymeric) compounds, containing
Sia2−6Gal disaccharides.
Methods: We have conducted the comparative study of the antiviral
effect of low- and high-molecular hemagglutinin inhibitors on inﬂuenza
A (H1N1, H2N2, H3N2) and B viruses in the inhibition assay of
infectious focus forming in MDCK cells. To characterise efﬁcacy of
inhibitors in vivo we have investigated a mouse model, based on
measuring the value of ﬁfty percent respiratory infectious dose (RID50)
for mice. To elucidate mechanism of action for hemagglutinin inhibitors
we have examined inﬂuenza virion morphology by the negative contrast
techniques.
Results: The values of ﬁfty percent inhibiting concentration (IC50)
obtained in MDCK were 0.03 (±0.005) microM for low-molecular
hemagglutinin inhibitor and 0.1 (±0.01) microM for high-molecular
hemagglutinin inhibitor. Intranasal administration of 0.25 mg/kg low-
molecular inhibitor or 1.25 mg/kg polymeric inhibitor completely
protected mice from inﬂuenza virus A/Aichi/2/68 (H3N2) infection.
Electron microscope study of the virion morphology showed direct
damage of inﬂuenza virus particles by low- and high-molecular
compounds, and allowed us to propose mechanism of virucidal action
of hemagglutinin inhibitors.
Conclusion: These data show signiﬁcant antiviral effect of low- and
high-molecular hemagglutinin inhibitors on inﬂuenza viruses at low
micromolar concentration. Although we do not consider high-molecular
hemagglutinin inhibitor as candidate anti-inﬂuenza drug due to the
probable toxicity and limited biocompatibility of polymer, low-molecular
hemagglutinin inhibitor has potential for the prevention of inﬂuenza virus
infection as speciﬁc virucidal therapeutic.
Ticked off: lyme borrelliosis
O491 Detection of Borrelia bissettii in the South Bohemia region of
the Czech Republic: cases of single and multiple infections
in humans
N. Rudenko, M. Golovchenko, N. Piskunova, D. Ruzek, L. Grubhoffer
(Ceske Budejovice, CZ)
Twelve serum samples from patients with symptomatic borreliosis and
1 sample (cardiac valve tissue) from patient with endocarditis and
cardial stenosis associated with chronic borrelial infection were collected
in the hospital of Ceske Budejovice (CZ). Serological tests gave the
negative results in all cases. The goal of our project was to analyse the
samples of the human origin with molecular techniques. The serums
and a cardiac valve tissue were used for direct DNA puriﬁcation. The
ﬂagellin gene was chosen as a target for analysis. The PCR primer set
for ampliﬁcation of ﬂa gene from Borrelia burgdorferi sensu lato (Bb
SL) complex was used. The direct sequence of amplicon indicated the
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presence of different sequences. The cloning step allowed the separation
of them. Ninety six recombinants from each sample were sequenced. In
silico RFLP analysis with 5 restriction endonucleases was conducted.
“Virtual” hybridisation with the probes designed for the detection of
Bb SL and specie-speciﬁc probes were used. The Maximum Parsimony
heuristic search was performed in PAUP by implementing the tree-
bisection-reconnection algorithm. Alignment was 488 characters long,
53 of them were parsimony informative. All 13 recognised species
of Bb SL complex were used as controls. As results, 4 cases were
conﬁrmed to carry B. burgdorferi ss, 4 – B. bissettii, 1 – B. garinii,
and 4 – multiple spirochete specie. From the 4 co-infected samples 3
were deﬁned as double infection with B. burgdorferi ss and B. bissettii
and 1 as a triple infection with B. bissettii, B. burgdorferi ss, and
B. garinii. The identity of each species was conﬁrmed by similarity
search using the GenBank, RFLP pattern, virtual hybridisation and PAUP.
Until recently it was thought that only 3 genospecies, ﬁrmly established
and well accepted, might cause Lyme disease (LD), i.e. B. burgdorferi
sensu stricto, B. afzelii, and B. garinii. However, few other genospecies
have also been connected to LD or were isolated from humans with
LD symptoms. They are B. bissettii and B. spielmanii. After the ﬁrst
isolation of B. bissettii from the 9 samples of human origin in Slovenia,
our results are the second evidence of involvement of B. bissettii in
LD in Europe. The presence of B. bissettii as a single strain in humans
with symptomatic borreliosis or chronic borrelial infection is the strong
support of the fact that B. bissettii is not only the member of the LD
complex, but is a causative agent of the disease.
O492 Borrelia burgdorferi in ticks and patients on the Dutch
North Sea island of Ameland
G.T. Noordhoek, J.J.W.N. Jacobs, J.M.M. Brouwers, J.P.A.M. Jacobs,
A.H. Brandenburg (Leeuwarden, Ballum, Groningen, NL)
Objectives: The Dutch island Ameland is described previously as a hot
spot for Borrelia burgdorferi in ticks. We investigated the percentage
infected ticks and the risk of subsequent development of clinical
symptoms of Lyme disease in persons with one or more tick bites
consulting a family practice on the island.
Methods: From January 2004 to December 2006, 214 ticks were
collected from 169 patients and tested for the presence of Borrelia
DNA by PCR. Six to 18 months after the removal, the patients were
questioned about erythema migrans and other symptoms possibly related
to B. burgdorferi infection. Blood samples were taken from a subset of
patients to investigate for B. burgdorferi antibodies.
Results: In 44 (20.6%) ticks B. burgdorferi DNA was detected. Forty
patients were bitten by at least one positive tick. Follow up information
was available from 144 persons, 36 (25%) with a positive tick and 108
(75%) with a negative tick. In 124 of 144 persons the ticks were removed
within 24 hours, including 33 of the 36 persons with positive ticks. None
of the 144 patients reported having an erythema migrans. Twelve persons
reported a non-speciﬁc red discoloration of the skin, not fulﬁlling critera
for EM, on the site of the tick bite during the ﬁrst weeks after the tick
bite. Of these, four were bitten by a positive tick and eight by a negative
tick. Surprisingly the four patients with a positive tick all consulted their
own family doctor and were treated with doxycyclin, whereas none of
the eight with a negative tick did so. One patient, bitten by a positive
tick that had been on the skin for more than 24 hours, reported systemic
symptoms compatible with Lyme disease. She reported no redness on the
site of the tick bite. Lyme serology was performed on 27 persons with
a positive tick, two were positive, including the patient with systemic
symptoms. Of serology performed on seven persons with a negative
tick, one was positive in IgG.
Conclusions: In this cohort of patients with tick bites the chance to
develop Lyme disease was low, even with 20.6% of the ticks positive
with B. burgdorferi. This is probably related to the fact that the majority
of ticks were removed within 24 hours. Our ﬁndings support the policy
described in the Dutch CBO-guideline on Lyme borreliosis to preserve
antibiotic therapy for patients developing symptoms of Lyme disease.
O493 A new (14th) member of Borrelia burgdorferi sensu lato
complex
J. Oliver Jr., N. Rudenko, M. Golovchenko, L. Grubhoffer (Statesboro,
US; Ceske Budejovice, CZ)
Recently, we studied 118 Borrelia isolates, cultured from samples
collected from a variety of rodents, birds and ticks in 9 different localities
of the southern region of the United States. In addition to a large group
of highly diverse strains related to Borrelia bissettii, and another, rather
homogenous group of strains that represent Borrelia burgdorferi sensu
stricto, a group of 16 isolates with unusual characteristics was found. All
16 isolates were cultured from ear biopsies of the rodents Peromyscus
gossypinus and Neotoma ﬂoridana, the main reservoir hosts of Borrelia
in the southern US. The rodents were trapped in 5 different localities
of South Carolina from September 1994 till August 1997. The new
methodology of multilocus sequence analysis (MLSA) that involved the
study of rrf-rrl intergenic spacer region, rrs (16S rRNA) gene, ﬂagellin
gene, ospA gene and p66 gene, was used to clarify the taxonomic
status of this new highly homogenous group of South Carolina isolates.
All 13 recognised species of B. burgdorferi sl complex were used as
controls. The association of this species with the Lyme disease group was
conﬁrmed by multiple results of MLSA. The virtual hybridisation of the
rrf-rrl spacer region, ﬂagellin gene, ospA gene with the probes previously
described, and experimentally used among these loci for identiﬁcation of
B. burgdorferi sl species showed 100% identity. Unique RFLP patterns
were discovered in the rrf-rrl intergenic spacer region and ﬂagellin gene
of these South Carolina isolates. Unique signature nucleotides were
allocated in the 16S rRNA gene. The Maximum Parsimony heuristic
search was performed in PAUP by implementing the tree-bisection-
reconnection algorithm for all 5 loci. Phylogenetic analysis shows that
each of the main species of the B. burgdorferi sl complex forms a
coherent cluster. All sequences from the 16 South Carolina isolates
were clustered together and separately from the other species in the
B. burgdorferi sl complex. Contrary to dogma, B. burgdorferi sl is
present and widely distributed in the southern US. It occurs in many parts
where it was not previously thought to occur. A substantial amount of
additional results highly support the designation of a new B. burgdorferi
sl species from the southern United States. Further analysis of the 16
cultured Borrelia strains from South Carolina is still in progress. The
new species will be described formally in another article.
O494 Three different approaches for detection of Borrelia burgdor-
feri sensu lato antibodies in routine laboratory diagnostics
T. Cerar, E. Ruzˇic Sabljic, K. Ogrinc, F. Strle (Ljubljana, SI)
Objectives: The most common microbiological approach for conﬁr-
mation of borrelial infection is detection of antibodies to Borrelia
burgdorferi sensu lato in body ﬂuids with serological methods. The
methods differ in relation to several characteristics including sensitivity
and speciﬁcity. No ideal serological test has been available. The aim of
the study was to analyse and compare detection of immune response by
three different serological tests.
Materials and Methods: In the present study we tested sera of 249
patients with suspected Lyme borreliosis, collected from routine work,
with three serological methods targeting different borrelial antigens: i)
in immunoﬂuorescence assay (IFA) a local isolate of B. afzelii (strain
SA/91), the most frequently isolated Borrelia species in Slovenia, was
used as an antigen; ii) in Lyme Borreliosis ELISA kit (DakoCytomation,
Denmark) the antigen was puriﬁed native B. burgdorferi ﬂagellum, and
iii) in chemiluminiscence immunoassay LIAISON® (Diasorin, Saluggia,
Italy) antigen for IgM antibodies detection is OspC while for IgG
antibodies Vls E antigen is used.
Results: The presence of borrelial IgM antibodies in patients sera was
ascertained in 1/249 (0.4%), 15/249 (6%), and 9/249 (3.6%) with IFA,
ELISA and LIAISON®, respectively. The presence of IgG antibodies was
established in 31/249 (12.4%), 64/249 (25.7%), and 82/249 (32.9%) with
IFA, ELISA, and LIAISON®, respectively.
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All three tests gave concordant results in 221/249 (88.8%) and 143/249
(57.4%) for IgM and IgG antibodies, respectively.
Conclusion: For detection of borrelial IgM antibodies ELISA was found
to be more sensitive than the other two tests, while LIAISON® was found
to be more sensitive test for detection of IgG antibodies. Differences in
sensitivities of the three tests could be the result of different antigens
and/or distinct method utilised for antibody detection. Discrepancies
in ﬁndings obtained on identical sera strongly indicate the need for
standardisation of the serological methods for detection of Borrelia
burgdorferi sensu lato infection.
O495 Serological indicators of good outcome after antibiotic
treatment in Lyme borreliosis
J. Hyto¨nen, V. Fingerle, S. Hurme, M.K. Viljanen, J. Oksi (Turku,
FI; Munich, DE)
Objectives:We have previously reported the results of an antibiotic treat-
ment study of disseminated Lyme borreliosis (mainly neuroborreliosis
(LNB) and arthritis (LA)) where we analysed whether the treatment with
i.v. ceftriaxone should be followed with a course of oral amoxicillin
(Oksi et al; Eur J Clin Microbiol Infect Dis 2007). No difference
in the clinical outcome, as evaluated with the visual analogue scale,
was observed between the two groups. In addition, borrelia serology
using an in-house whole bacterium ELISA and a commercial assay
based on borrelial ﬂagella as the antigen (IDEIA, Dako) was carried
out on patient samples. No statistically signiﬁcant difference in the
antibody response was found between patients who received amoxicillin
or placebo. Importantly, changes in antibody levels were not associated
with clinical outcome indicating that the above tests can not be used to
predict the outcome.
The objective of the present study was to examine the development of the
borrelia speciﬁc antibodies in these patients using an array of borrelial
antigens. Speciﬁcally, we wanted to look for serological markers for good
response to antibiotic treatment.
Methods: Samples drawn from the patients at the initiation of the
antibiotic treatment and about 12 months after the treatment were
analysed using an in house recombinant IgG and IgM line immunoblot
(19 IgG antigens, 18 IgM antigens; Goettner et al; J Clin Microbiol
2005) and recomBlot Borrelia IgG immunoblot (11 antigens; Mikrogen).
All patients independent of the treatment were included in the analysis
and paired samples were available from 110 patients. The association of
outcome with changes in antibodies directed to individual antigens was
statistically tested using Pearson’s chi-squared test. P-values less than
0.05 were considered statistically signiﬁcant.
Results:
i. Decline in IgG antibodies against VlsE was observed more often in
patients with good outcome than in patients with poor outcome. The
decline was observed more often in patients with LNB than in patients
with LA.
ii. Decline in IgG antibodies against OspC was observed more often
in patients with good outcome compared with patients with poor
outcome. As with VlsE, decline in OspC IgG antibodies was observed
more often in patients with LNB than with LA.
Conclusion: The results suggest that decline in antibodies directed to
VlsE and OspC proteins may be used as an indicator of good outcome
after antibiotic treatment in Lyme borreliosis.
Community-acquired lower respiratory tract
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S496 It takes two to tango – bacterial-viral interactions in the
pathogenesis of respiratory tract infections
J. McCullers (Memphis, US)
Over the last decade, inﬂuenza and pneumonia have ranked as the 7th
leading cause of death in the United States. In the developing world,
the problem is even more acute, as respiratory tract infections are
the leading cause of death in children outside of the neonatal period.
Streptococcus pneumoniae is the leading bacterial cause of pneumonia,
sepsis, otitis media, and meningitis and accounts for a signiﬁcant portion
of this mortality. Inﬂuenza is also a major contributor, both as a
primary infection and by interacting with bacterial pathogens to increase
the incidence and severity of pneumonia. While the pneumococcus is
the most common secondary pathogen following inﬂuenza in typical
inter-pandemic years, affecting mainly the young and the frail elderly,
Staphylococcus aureus is seen more commonly when highly virulent
viral strains circulate, and has been emerging in recent years as a cause
of necrotising pneumonia as a co-pathogen with inﬂuenza in healthy
children and young adults. Our laboratory studies the mechanisms that
underlie the interactions between respiratory viruses such as inﬂuenza
virus and bacterial pathogens such as S. pneumoniae and S. aureus.
The approach we have taken is to isolate speciﬁc virulence factors in
the virus or bacterium and use genetic approaches to modify or delete
them, allowing assessment of their impact in relevant animal models.
Certain themes of cooperation between pathogens have emerged from
this analysis, giving us insight into speciﬁc pathogenic mechanisms and
revealing how these differ for different viral-bacterial pairs, or between
different strains of one of the pathogens. These ﬁndings in the laboratory
can then be related back to the epidemiology of co-infections in humans,
helping deﬁne the challenges we face in moderating morbidity and
mortality from these pathogens. The ultimate goal of this work is to apply
this knowledge to facilitate treatment and prevention of these common
diseases by targeting the cooperative interactions that make co-infections
so deadly.
S497 Implications of bacterial-viral interactions to present day
pandemic preparedness – the Spanish ﬂu revisited
K.P. Klugman (Atlanta, US)
It was recognised during the so-called Spanish inﬂuenza pandemic in
1918 that the majority of deaths due to the ﬂu occurred more than
7 days after the onset of symptoms. In the overwhelming majority of
cases of pandemic inﬂuenza, signs and symptoms resolved by day 6,
but in a subgroup with signiﬁcant mortality, illness worsened in the
second week of illness. There is abundant evidence that most of the
mortality during the pandemic was due to the combination of inﬂuenza
plus bacterial super-infection. The most common bacterial cause of death
was the pneumococcus, but nosocomial spread of group A streptococci
was often lethal, as were staphylcocccal infections. Up to 50% of
young soldiers’ deaths due to inﬂuenza in 1918 were complicated by
bacteraemia. While antibiotics were not available in 1918, it is naive to
believe that antibiotics will reliably save individuals suffering from the
cytokine storm of pandemic inﬂuenza and simultaneous bacteraemia.
Prophylactic antibiotics should be considered, but as progression to
pneumonia may be impossible to predict, the amount of antibiotic
needed to be given will be considerable (to all those infected with
inﬂuenza). An additional approach to reduce mortality is vaccination –
vaccination against the pandemic inﬂuenza strain will be the ﬁrst priority
if such a vaccine is available. Vaccines are currently however available
to prevent pneumococcal infection. Data from a randomised trial of
pneumococcal conjugate vaccine (PCV) show that children immunised
with PCV have 45% less hospitalisation for pneumonia due to endemic
inﬂuenza. The 23 valent pneumococcal vaccine (23v) is highly protective
against bacteraemia when given to healthy young adults. Widespread
PCV administration to children including a booster dose in the second
year of life is essential to ensure their protection plus the best chance
of herd immunity to the PCV types in the older population. Healthcare
workers, military personel and other ﬁrst responders should receive the
23v vaccine when the pandemic threat level reaches level 5. Attempts
should be made at that time to also strengthen existing recommendations
to immunise at risk and elderly persons with the 23v vaccine. Pandemic
inﬂuenza plans at present fail to recognise the potentially essential role
of pneumococcal vaccine in the prevention of mortality from pandemic
inﬂuenza.
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Improving the speed of diagnosing fungal
infections
S500 To culture or not to culture? That is the question
A. Velegraki (Athens, GR)
The number of immunocompromised patients continues to rise globally
promoting increase in the incidence and variety of life-threatening fungal
infections. In addition, the epidemiology of invasive fungal infections
(IFI) is changing; IFI such as aspergilloses, are increasingly reported in
non-neutropenic paediatric and adult critically ill patients. As a result,
there is pressing need to improve the accuracy and speed of diagnosis
to proﬁciently support clinical decisions.
Despite the recognised problematical nature of culture methods for the
identiﬁcation of fungi in clinical specimens, which rely on the isolate’s
phenotypic differences in morphology and physiology, and when possible
on its ability of mating, the clinical value of culture-based diagnosis
remains indisputable. Positive culture establishes the diagnosis of IFI
and inﬂuences therapeutic options either through susceptibility testing or
via accurate characterisation of mould isolates with inherent resistance
to amphotericin B-eg. Scedosporium spp., A. terreus or A. nidulans.
Microscopy of histological specimens, using fungal-speciﬁc stains, like
Gomori’s methenamine silver (GMS) complemented with periodic acid-
Schiff (PAS) can reveal fungal elements and tissue-fungus cellular
interactions. Also, direct microscopy of wet potassium hydroxide mounts
of biological ﬂuids, and ﬂuorescent microscopy with Calcoﬂuor white,
Uvitex 2B or Blankophor P, of either fresh clinical specimens, such
as BAL and corneal specimens or parafﬁn-embedded tissue, provide
rapid results on presence/absence of fungal elements. Although positive
histology and direct microscopy are non-speciﬁc tests, since sporogenous
structures are typically absent in human material, they nonetheless give
a fast diagnostic clue to the presence of regularly or irregularly, septate,
aseptate or rarely septate hyphae, dictate use of selective media for
culture and justify administration of antifungal therapy. Furthermore,
culture-based identiﬁcation by morphological and physiological criteria
is complex. In many taxa deﬁnitive phenotypic features are difﬁcult
to observe or are highly variable. Besides, most clinical isolates lack
a sexual cycle and for many pathogens the concept of a species is still
poorly deﬁned. Consequently, there is compelling need for rapid, precise
and reproducible molecular methods to identify clinical fungi.
To effectively exploit the tremendous variation in the DNA of fungi in
order to (a) determine the source of a fungal infection, (b) to resolve
the status of certain established and emerging pathogenic species, (c)
to track the transmission of strains in the hospital, (d) to recognise
strains of speciﬁc virulence or resistance to antifungals, (e) to elucidate
diversity and population genetics of fungal pathogens, and (d) to identify
genotypes for use in drug research and diagnostics, the question “to
culture or not to culture”, even in the “. . . omics” era, is purely rhetorical.
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O508 High prevalence of “livestock-associated” meticillin-resistant
Staphylococcus aureus ST398 in swine and pig farmers in
Belgium
O. Denis, C. Suetens, M. Hallin, I. Ramboer, B. Catry, B. Gordts,
P. Butaye, M.J. Struelens (Brussels, Brugge, BE)
Backgrounds: Meticillin-resistant Staphylococcus aureus (MRSA) is a
major pathogen in hospitals and in the community. Recently, a novel
MRSA genotype has been reported among livestock animals, farmers
and veterinarians in the Netherlands and neighboring countries. These
animal associated strains are resistant to SmaI macrorestriction and
belong to sequence type (ST) 398 by MLST. The objectives of this study
were to determine the prevalence and risk factors for MRSA carriage
in farmers and their household contacts in Belgian swine farms and
characterise these stains genotypically and phenotypically.
Methods: Farmers and household contacts residing on 49 swine farms
were screened for MRSA carriage by culturing nasal swabs onto selective
agars. MRSA identiﬁcation were conﬁrmed by PCR and genotyped by
pulsed ﬁeld gel electrophoresis (PFGE) after SmaI macrorestriction,
staphylococcal cassette chromosome mec (SCCmec) typing, spa
sequence typing and MLST. Susceptibility to 18 antimicrobials was
determined by the disk diffusion method. Demographic data, animal
exposure and medical history were recorded to determine risk factors of
MRSA carrier status in this population.
Results: Of 127 farmers screened, 48 (38%) were positive for MRSA.
Carriers were found in 25 farms from seven provinces of Flanders and
Wallonia. The prevalence was independently associated with porcine
MRSA carriage and the frequent contact with pigs, horses and dogs.
MRSA carriage was associated with higher levels of personal protection
and hygiene. By molecular typing, all isolates were resistant to SmaI
digestion and belonged to ST398 with spa types t011 or t034 with
SCCmec type IV or type V. MRSA strains were resistant to tetracycline
(100%), trimethoprim (100%), MLS (>50%), aminoglycosides (>40%)
and ciproﬂoxacin (32%). The MRSA strains from human shared the
same characteristics as those found in pigs.
Conclusions: A high prevalence of MRSA carriage was found (38%) in
swine farmers and family members. Risk factors for MRSA colonisation
included frequent contact with pigs and other farm animals and higher
levels of protection and hygiene. MRSA strains from farmers and pigs
belonged to the ST398 “animal MRSA clone” which has been reported
in livestock animals, farmers and veterinarians in Europe.
O509 Emergence and dissemination of USA300 MRSA in Australia
G. Coombs, K. Christiansen, J. Pearson, R. Murray, O. Robinson,
F. O’Brien (Perth, AU)
Objective: To report the emergence of ST8-MRSA-IVa (USA300
MRSA) in Australia.
Background: A state-wide MRSA management programme has
prevented healthcare associated MRSA clones from becoming endemic
in Western Australian (WA) hospitals. The programme that commenced
in 1982 is similar to the “Search and Destroy” policy used in northern
Europe and involves the notiﬁcation of all MRSA positive patients and
healthcare workers with referral of isolates to the Gram Positive Bacteria
Typing and Research Unit for epidemiological typing.
Although multiple clones of community associated MRSA (CA-MRSA)
have been characterised in WA (WA CA-MRSA), they have rarely caused
healthcare associated outbreaks. Several non WA CA-MRSA community
clones have recently been isolated in WA including the “European
CA-MRSA” (ST80-MRSA-IV), the “Taiwan CA-MRSA” (ST59-MRSA-
VT), the “Western Samoan CA-MRSA” (ST30-MRSA-IV) and the
“Queensland CA-MRSA” (ST93-MRSA-IV). Unlike WA CA-MRSA,
these clones are generally Panton-Valentine leucocidin (PVL) positive
and are commonly associated with skin and soft tissue (SST) infections.
Although found in some hospitalised patients, nosocomial transmission
has not been documented.
Methods: Phenotypic and genotypic characterisation of MRSA.
Results: Using MLST/SCCmec typing 38 “ST8-MRSA-IVa” isolated in
WA were found to be PVL positive and had the same pulsed-ﬁeld gel
pattern and spa type (t008) as the USA300 MRSA clone. The majority
of these isolates were from SST infections predominantly with abscess
formation. Over 66% of patients were younger than 40 years. Thirty one
of the strains were erythromycin resistant (EmR), with 87% clindamycin
susceptible (inducible resistance not detected – unlike EmR WA CA-
MRSA which are generally inducibly resistant to clindamycin). From
January 2004 to October 2007 the number of isolates increased several-
fold (from 4 to 17 cases per year) prompting public health concern.
Conclusions: In the United States USA300 MRSA is not only the
predominant cause of community acquired infection but is also rapidly
emerging as a major cause of healthcare acquired infection. It is apparent
that USA300 MRSA has entered the WA community. As a consequence
the WA Health Department has recently commenced a “Search and
Destroy” policy aimed at both this and other PVL positive imported
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strains of CA-MRSA In addition, in some hospitals, screening has been
extended to high risk and surgical unit admissions.
O510 Prevalence of ST398 and other genotypes of
meticillin-resistant Staphylococcus aureus in Dutch hospitals
M.W.M. Wassenberg, A. Troelstra, J.A.J.W. Kluytmans, M.J.M. Bonten
(Utrecht, Breda, NL)
Objectives: To determine prevalence of ST398 MRSA (associated with
professional exposure to animals) and other MRSA isolates within Dutch
hospitals.
Methods: A prevalence survey in 51 Dutch hospitals from July 2006
to January 2007 (3 months retrospectively and 3 months prospectively),
monitoring all patients and healthcare workers (HCWs; only in post-
exposure surveys) screened for and identiﬁed with ST398 or other
MRSA strains (including several clinical characteristics) was carried out.
Participating hospitals were divided into tertiles based on pig-density in
the catchment area.
Results: During 306 months of observation 7802 patients were screened;
12% (642/5543) because of a risk factor for ST398 (79% out-patient
department). Of the 498 new MRSA patients identiﬁed (65% with
screening; 35% unexpected carriers) 31% carried ST398 MRSA (92%
detected through screening). The overall prevalence of MRSA in the
screened population was 3.6% (95%-BI: 3.2−4.0). Prevalence were 2.5%
(95%-BI: 1.9−3.1), 3.8% (95%-BI: 3.1−4.5; p = 0.007) and 4.6% (95%-
BI: 3.7−5.5; p = 0.000), respectively, in low, moderate and high pig
density region hospitals. Prevalence of ST398 MRSA was 12.4% in
patients screened in hospitals in regions with a high or moderate pig
density and 0% in hospitals in regions with a low pig density. The
prevalence of other MRSA isolates in patients screened in these hospitals
was between 1.1−2.9%. In post-exposure screenings, unrelated ST398
MRSA carriers (index case had different genotype) were found in 0.06%
(3/4794) of HCWs and none of the patients (0/1951). Other MRSA
isolates (genotype different from index case and excluding ST398) were
detected in 0.1% (8/5758) of HCWs and 0.5% (10/2134) of patients.
Conclusion: In this ﬁrst large survey of ST398 MRSA in Dutch hospitals
we found that MRSA is more prevalent in regions with a high or
moderate pig density, solely because of an increase of ST398 MRSA.
Almost 80% of new carriers are detected in out-patient departments and
92% because of active surveillance. ST398 MRSA colonisation is rarely
encountered in HCWs and patients during post-exposure screenings of
index cases with different genotypes.
O511 Enterotoxic meticillin-resistant Staphylococcus aureus:
prevention and control
Y. Yoshida, Y. Sumiyama, S. Kusachi, Y. Arima, H. Tanaka, J. Sato,
T. Saito, J. Nagao, Y. Saida, M. Watanabe (Tokyo, JP)
Objectives: Superantigenic exotoxins such as toxic shock toxin 1
appear to be major virulence factors in hospital meticillin-resistant
Staphylococcus aureus clones (HA-MRSA) in Japan, and staphylococcal
enterotoxin may be involved in the septic shock and MRSA enterocolitis.
To control enterotoxic MRSA infections, we examined the homeostasis
of intestinal bacteria.
Methods:
1. MRSA proliferation according to the control of intestinal bacteria:
A. Four GAM broth tubes were prepared, and tubes were inoc-
ulated 105 cfu/ml of viable MRSA328GTS, Escherichia coli
ATCC25922, Enterococcus faecalis ATCC29212, and Bacteroides
fragilis GM7000, and cultivated for 24 hours (= independent
cultivation). Next, a GAM broth tube was prepared, and inoculated
mixed up with above 4 strains (= mixed cultivation).
B. After managed under eight days of total parental nutrition (TPN)
and continuous administration of antacid, viable bacterial counts in
large bowel of male Wistar rats (body weight 250g) were counted
after an inoculation of 109 cfu/rat MRSA238 solution by gastric
tube on day four.
2. Control of intestinal ﬂora and MRSA proliferation:
A.Viable MRSA counts were compared among mixed cultivation
tubes added moxalactam (MOX), metronidazole (MTN), and
MOX+MTN.
B. (1) Chemoprophylaxis (CP) group: rats were inoculated MRSA
solution after three days of oral antibiotic, kanamycin and MTN.
(2) MOX group: rats were administered MOX for three days
after an inoculation of MRSA solution. (3) Probiotics group:
Probiotics, bio-three(R) 1g/day, were orally administered every day
after inoculation of MRSA solution.
Results:
1. (A) Independent cultivations were at 11, 9, 9, and 10, and mixed
cultivations were at 5.2, 7.6, 7.5, 9.5 (logCFU/ml).
(B) Viable bacterial counts of the S. aureus in TPN was 3.6, and
the MRSA in TPN+MRSA was 3.0 (not signiﬁcant), and was able to
consider the MRSA multiplication control by intestinal bacteria.
2. (A) the counts of MRSA were 3.7, 4.5, and 7.5, respectively. MRSA
were proliferated under suppression of two or more major intestinal
bacteria.
(B) The counts of MRSA were elevated to 6.8 in CP+MRSA+MOX,
and diarrhoea was observed. The counts were decreased to 1.8 after
treatment by probiotics, and frequency of the diarrhoea was decreased
from 60% to 25%.
Conclusion: Disturbances on intestinal ﬂora were suggested to be a
major cause of enterotoxic MRSA infections, and a control of intestinal
ﬂora will be important to prevent enterotoxic MRSA infections.
O512 Epidemiological surveillance of MRSA using Raman
spectroscopy
H.F.M. Willemse-Erix, M.J. Scholtes, J.W. Jachtenberg, W.B. van
Leeuwen, M.C. Vos, G.J. Puppels, A. van Belkum, K. Maquelin
(Rotterdam, NL)
Objectives: Meticillin resistant Staphylococcus aureus (MRSA) is a
leading cause of hospital acquired infections. Efﬁcient infection control
and monitoring of this microorganism depends on microbial typing.
Genetic techniques such as Pulsed Field Gel Electrophoresis (PFGE)
provide high discriminating power, but are time consuming and costly. In
the recent years we have transformed Raman spectroscopy into a rapid
identiﬁcation and typing tool in clinical microbiology. This technique
provides information about the overall molecular composition of intact
bacterial cells and is highly speciﬁc. Over 100 isolates were used to
validate Raman spectroscopy as a typing method for MRSA, according
to recently published guidelines.
Methods: All isolates were cultured for 20 hr on Trypticase Soy agar
plates. Biomass was suspended in 10 microliter of sterile distilled
water, transferred onto a quartz slide and allowed to dry. Spectroscopic
ﬁngerprints were obtained using a dedicated Raman spectrometer,
requiring 10 to 60 seconds per sample. Cluster analysis on these
ﬁngerprints was performed using the pair wise correlations as a distance
measure in combination with Ward’s cluster algorithm.
Results: The reproducibility of the Raman procedure is high. Multiple
measurements of the same set of isolates resulted in isolate-speciﬁc
clusters. Using a well-characterised strain collection, we found that the
discriminatory power (D=0.98) is comparable to that of the gold standard,
PFGE (D=0.99−1).
Conclusion: Using Raman spectroscopy as a typing method, a signiﬁcant
decrease of turn-around time can be achieved, allowing interventions to
limit transmission to be taken earlier. The typing information gathered
with this technique is comparable to information obtained by genotyping
methods. Therefore we conclude that Raman spectroscopy is an easy-to-
use and rapid alternative in the battle against MRSA.
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O513 German Enterococcus faecium bacteraemia isolates from
1991 to 2007 show a complex clonal structure and multiple
acquisitions of virulence genes and vancomycin resistance
gene clusters
G. Werner, C. Fleige, I. Klare, J. Laverde-Gomez, W. Witte
(Wernigerode, DE)
Objectives: To investigate the characteristics and molecular dynamics
of Enterococcus faecium bacteraemia isolates from Germany between
1991–2007 in the background of rising VRE rates in Germany.
Methods: Altogether 124 isolates from 35 German cities were included.
The isolates were taken from our strain collection from the last 16
years. Copy isolates were excluded. They were typed by MLST and
MLVA. The presence of virulence marker genes esp and hyl and the
van genotype (vanA/B) were identiﬁed using a multiplex PCR. A
PCR for the enterococcal IS element IS16 enriched in hospital-adapted
strains was also performed. Antibiotic susceptibilities were determined
by microbroth dilution according to the German DIN standard.
Results: Only two isolates were not typeable by MLVA. MLST was
more discriminatory than MLVA (discriminatory index 0.897 vs. 0.824)
giving altogether 31 different MLST vs. 26 MLVA types. Almost all
isolates (n= 119/124) were ampicillin resistant. Based on MLST more
than 95% of the E. faecium isolates belonged to the clonal complex CC17
of hospital adapted, epidemic strains. 63 E. faecium were vancomycin
resistant (51%; 58 vanA, 5 vanB). About half the isolates possessed
the esp gene (n= 64/124; 52%) and 52 (42%) the hyl gene. IS16-PCR
was positive in 98 E. faecium (79%). E. faecium isolated before 2000
seldom possess esp or hyl, among isolates from 2004 on both became
more frequent. Some clonal types like ST17 and ST18 were isolated
over a range of 10−12 years. Possession of virulence genes esp and hyl
varied suggesting acquisition or loss of those markers at multiple times.
Other clonal types like ST192 mainly appeared between 2004–2007 and
showed a ﬁxed virulence gene pattern: 21/24 ST192 isolates possessed
both esp and hyl, each one possessed either hyl or esp and one ST192
from 1998 lacks both determinants.
Conclusions: Only few E. faecium from the early 1990ies were included
and those mostly did not belong to CC17. They were from single
infections and thus not part of a cluster or outbreak. Nowadays the
hospital-adapted E. faecium may represent a different pathogenic quality.
Our data show association of those isolates mainly with clusters or
outbreaks and enrichment of virulence-associated genes (esp, hyl) among
different clonal types over time. Even in settings where VRE are still
rare, hospital-adapted types are widely distributed awaiting acquisition
of vancomycin resistance determinants as a next step.
O514 Environmental contamination: a risk factor for acquisition
of CC17 ampicillin-resistant Enterococcus faecium
M.J.A. de Regt, L.E. van der Wagen, T.E.M. Hopmans, R.J.L. Willems,
M.J.M. Bonten (Utrecht, NL)
Objectives: The last decade colonisation and infections with ampicillin-
resistant Enterococcus faecium (ARE) increased in our hospital, a
trend seen worldwide. Based upon MLST, epidemic and most invasive
ampicillin resistant isolates cluster in clonal complex 17 (CC17). Patient-
to-patient transfer via hands of healthcare workers (HCW)is considered
an important route in the spread of ARE. In addition, environmental
(env.) contamination may contribute to ARE acquisition. In this study
we quantiﬁed ARE colonisation and env. contamination rates on a
haematology ward where patient colonisation is endemic in order to
better understand the role of env. contamination in ARE epidemiology.
Methods: Between March 5th and May 25th ’07, all admissions (adm)
on a 20-beds haematology ward were screened for rectal ARE-carriage
<24 hrs after admission and <48 hrs before discharge. Subsequently, the
environment of ARE-carriers was screened for ARE at 8 predetermined
sites (blood pressure cuff, over-bed table, television remote control, bed
rails, inside handle bathroom door, soap dispenser, toilet seat, control
panel infusion pump) once weekly and after discharge until all swabs
were negative. Swabs, enriched in Enterococcal Broth, were cultured on
Enterococcosel agar plates with ampicillin (16mg/ml). All ARE isolates
were typed with MLVA.
Results: Of 72 adm, 64 (89%) were screened for ARE on adm, of
which 14 (22%) were colonised. Of 35 ARE negative adm that were
screened before discharge, 9 acquired ARE: acquisition rate of 26%.
The mean colonisation pressure was 38% (range: 14−69%). From 18
colonised adm 412 env. swabs were taken of which 98 (24%) were
ARE positive. Sites most often contaminated were the toilet seat (43%),
over-bed table (38%) and television remote control (31%). Genotyping
revealed presence of 3 circulating CC17 strains (MT1, MT159 and
vancomycin-resistant MT287). In 96% of adm the rectal strain was
concordant with the strains isolated from the environment. MT159 was
found predominantly: in 16 (70%) colonised patients and 73% of the
positive env. cultures.
Conclusion: Endemicity of ARE colonisation on our haematology
ward is characterised by high admission, high acquisition and high
env. contamination rates of CC17 ARE. The frequently occurring
env. contamination may act as an additional source for cross-
transmission, propagating ARE directly or via contaminated HCW.
Infection prevention measures for ARE (or VRE) should not only target
on direct patient-to-patient transmission, but also on env. hygiene.
O515 First report of clinical and epidemiologic characterisation
of vancomycin-resistant enterococci from mainland China
B. Cao, Y. Liu, H. Wang, S. Song, R. Li, C. Wang (Beijing, CN)
Objectives: Although infections caused by vancomycin-resistant ente-
rococci (VRE) have been reported increasingly worldwide, there have
been rarely reported in mainland China. We investigated the clinical and
epidemiological characteristics of VRE nosocomial infections in Beijng
Chaoyang Hospital, a 1100-bed tertiary-care teaching hospital in Beijing,
China.
Methods: A matched case-control study was conducted to identify the
individual risk factors for VRE infection/colonisation, and a retrospective
cohort study to examine the prognostic factors of VRE infection. van
genes were detected by multiplex PCR. Pulsed-ﬁeld gel electrophoresis
was used for molecular typing.
Results: The rates of VRE isolation increased from 2.6% for 2003
to 6.8% for 2006. A total of 38 vancomycin-resistant single-patient
isolates of VRE were recovered between June 2003 and March 2007. The
multivariate analysis revealed two signiﬁcant independent risk factors
for VRE versus vancomycin-susceptible enterococci (VSE): previous
use of vancomycin (OR 18.22; 95% CI, 4.57−72.6) and inclusion
in a dialysis programme (OR 8.69; 95% CI, 1.94−38.84). Having
a malignant disease remained protective in the multivariate model
(OR 0.26, 95%CI, 0.07−0.97). Crude mortality rate differences were
not statistically signiﬁcant (VRE 53.6% vs VSE 38.6%; OR, 1.066;
p = 0.915). The only epidemiologic risk factor for associated mortality
by multivariate analysis was increasing severity of illness, measured by
APACHE II score (VRE 17.49± 6.83 vs VSE 11.81±4.85; p = 0.001).
The total hospital stay was longer in VRE-infected patients than in
those with VSE infections (VRE 55.2±27.2 ds vs VSE 39.3±30.7 ds;
p = 0.022). van B gene was detected in 14 E. faecalis isolates, all of
which were identiﬁed as a single clone that was prominent before the
year 2005. vanA gene was positive in 21 E. faecium isolates, 10 of
which showed resistant to vancomycin (MIC  256mg/L), but sensitive
to teicoplanin (MICs 2−12 mg/L). Twenty-one isolates of E. faecium
belonged to 9 different clones, 90.4% of which were isolated in year
2006 and 2007.
Conclusion: There has been a signiﬁcant increase in the numbers of
VRE infections over 3 years in our institute. Previous vancomycin
therapy and involvement in dialysis programme were risk factors for
development of VRE infections. Surveillance for VRE, prudent use
of vancomycin and strict adherence to infection control measures are
required to prevent further emergence and spread of VRE.
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O516 Increase of resistance to glycopeptides and epidemiological
changes among nosocomial enterococci detected during 2007
in a Portuguese hospital
F. Almeida, F. Ferna´ndes, S. Carvalho, T. Ferreira, R. Mato (Oeiras,
Lisbon, PT)
Objectives: To monitor the prevalence and epidemiology of glycopeptide
resistant (GR) and high-level gentamicin resistant (HLGR) Enterococcus
faecalis (Eﬂ) and E. faecium (Efm) in a Lisbon hospital during the ﬁrst
semester of 2007. To compare the results with data obtained during year
2006.
Methods: Microbial identiﬁcation and antimicrobial susceptibility were
performed with the VITEK2 system. GR and HLGR Eﬂ and Efm were
conﬁrmed by PCR detection of vanA/B and aac(6′)-aph(2′′) genes. Other
aminoglycoside resistance genes (aph(2′′)-Ib, aph(2′′)-Ic, aph(2′′)-Id) and
virulence genes (cylA, asaI, gelE, hyl) were detected by Multiplex-PCR.
Clonal relationships were assigned by PFGE and virulence proﬁles.
Multilocus sequence typing was performed among GR isolates.
Results: A total of 138 enterococci were collected in the ﬁrst semester
of 2007: 73% Eﬂ, 26% Efm, and 1% E. casseliﬂavus. 6% of Eﬂ and 14%
of Efm were GR and approx. 46% were HLGR. Most (>80%) Eﬂ were
resistant to erythromycin, quinupristin-dalfopristin-Q/D and tetracycline-
TE, 50% to ciproﬂoxacin-CIP, and 0% to ampicillin-AMP. One and 11 Eﬂ
were resistant and intermediate to linezolid, respectively. Comparing with
Eﬂ, Efm were resistant to AMP/CIP (100%) and resistance to TE (33%)
and Q/D (5%) was lower. Only the aac(6′)-aph(2′′) genes were detected
(56 out of 63 HLGR). GR-Eﬂ (n = 6) and GR-Efm (n = 5) were vanA-
genotype. HLGR/GR-Eﬂ (n = 45) were of 9 PFGE patterns, 6 of them
not identiﬁed in 2006. PFGE-AO was prevalent (36 isolates) associated
with genotypes cylA-asaI-gelE-esp (33%), cylA-asaI-gelE (28%), asaI-
gelE (17%) and asaI-gelE-esp (11%). GR-Eﬂ belong to the lineage
ST6 (PFGE AO/cylA-asaI-gelE-esp or cylA-asaI-gelE). HLGR/GR Efm
(n = 18) were of 10 PFGE patterns of which 5 were co-dominant (11
isolates). Distribution of virulence genes by proportion of PFGE patterns
was: esp-45%; 22%-hyl/esp; 11%-hyl and 22% without virulence genes
detected. GR-Efm belong to lineages ST17 (PFGE-x/hyl-esp), ST18
(PFGE-d/hyl-esp) and ST125 (PFGE-d/hyl).
Conclusions: Enterococcal infections increased in 2007 (138 isolates in
6 months), comparing with 2006 (171 isolates in 12 months) and GR
increased from 3% to 9%. PFGE AO remains prevalent but carriage of
the esp gene decreased from 90% to 40%. New Efm clones with different
genetic backgrounds emerged in 2007 indicating the need for active
surveillance in this particular hospital as well as in other Portuguese
hospitals where a similar trend may be observed.
O517 Ampicillin-resistant Enterococcus faecium clonal complex
17 is widespread in healthy dogs: anthropozoonosis or
zooanthroponosis?
P. Damborg, R.J.L. Willems, N.J. Williams, N. Bøgetoft, L. Guardabassi
(Frederiksberg, DK; Utrecht, NL; Liverpool, UK)
Objectives: An increase in nosocomial infections caused by ampicillin-
resistant Enterococcus faecium (AREfm) has been recently observed in
some European countries. Based on multilocus sequence typing (MLST),
most hospital AREfm isolates belong to one distinct genogroup, clonal
complex 17 (CC17). In this study, we investigated the occurrence of
AREfm CC17 in faecal samples collected from healthy dogs in Denmark
and in England.
Methods: 210 healthy dogs were screened for the occurrence of AREfm
using a selective isolation procedure, i.e. plating on Slanetz Bartley agar
containing 32mg/ml ampicillin. Presumptive AREfm were conﬁrmed by
a species-speciﬁc PCR and their resistance patterns were determined
according to CLSI guidelines. The purK gene was sequenced in all
isolates and a subset of 15 isolates was further analysed by MLST
analysis.
Results: AREfm was detected in 59 (28%) dogs. Based on MLST or
identiﬁcation of the CC17-speciﬁc purK 1 allele, at least 44 (75%) of
the isolates belonged to CC17. Four sequence types were observed:
ST78 (n = 8), ST19 (n = 3), ST192 (n = 3) and ST266 (n = 1). All these
genotypes have been previously isolated from hospitalised patients. In
particular, ST78 and its single-locus variant ST192 are among the
most common STs in European hospitals. ST78 was isolated from a
dog and 10-year old boy living in the same household, suggesting
possible transmission between dogs and humans living in close contact.
Resistance to erythromycin (97%), ciproﬂoxacin (95%), tetracycline
(83%) or rifampicin (56%) was frequent. Only few isolates were resistant
to gentamicin (5%), linezolid (14%) and quinopristin/dalfopristin (15%)
and all were susceptible to vancomycin.
Conclusion: This is the ﬁrst report describing the occurrence of AREfm
CC17 in dogs. The results suggest that dogs may contribute to the spread
of this AREfm genetic lineage in the human population. The unexpected
and widespread occurrence of hospital-adapted clones in dogs raises an
important question concerning the evolution of this clonal complex:
does CC17 originate from humans (anthropozoonosis) or from dogs
(zooanthroponosis)? Canine AREfm are currently screened for putative
virulence genes (esp, acm, hyl, orf903, orf905, orf907, orf2351 and
orf2430) and the results of this screening will be used for discussing
the evolutionary relationship between human and canine strains in the
conference presentation.
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O518 Compliance with screening for hepatitis B virus and hepatitis
C virus infection prior to initiation of antiretroviral therapy
among HIV-1 infected patients in a resource-limited setting
S. Sungkanuparph, P. Wongprasit, W. Manosuthi, K. Atamasirikul
(Bangkok, Nonthaburi, TH)
Objective: To assess the compliance of laboratory screening for hepatitis
B virus (HBV) and hepatitis C virus (HCV) infection prior to initiation of
antiretroviral therapy (ART) among HIV-1 infected patients in a resource-
limited setting.
Methods: This observational study was conducted by including HIV-
1 infected patients from 3 cohorts of ART initiation in a tertiary-care
HIV clinic in Bangkok, Thailand, between January 2004 and October
2007. The medical records were reviewed; demographic data, baseline
CD4 and HIV-1 RNA, ART regimen, and date and test results of HBV
surface antigen for HBV infection and Anti-HCV antibody for HCV
infection were retrieved from the records.
Results: A total of 638 patients were included; mean (SD) age was
of 38.4 (8.4) years and 53% were male. Median (IQR) baseline CD4
cell count and HIV-1 RNA were 246 (77–459) cells/mm3 and 143,000
(45,825–445,000) copies/mL, respectively. Prior to initiation of ART,
HBV infection and HCV infection were screened in 371 (58%) patients
and 273 (43%) patients, respectively. All patients who were screened for
HCV infection were also screened for HBV infection. There were no
differences of demographics or baseline characteristics between patients
who were screened for HBV or HCV infection and those who had never
been screened for HBV or HCV infection (p> 0.05). Among 371 patients
who were screened for HBV infection, 36 (9.7%) had HBV infection.
HCV infection was found in 24 from 273 (8.8%) patients who were
screened for HCV infection. Infection of both HBV and HCV was
observed only one (0.4%) patient. NNRTI-based ART regimens were
initiated in 573 (90%) patients; the rest received PI-based regimens. Of
638 patients, 625 (98%) received 3TC in the regimens. There was no
difference of ART regimen or 3TC use between patients who had and
did not have HBV infection (p> 0.05). After availability of tenofovir
in Thailand in December 2006, patients who were found to have HBV
infection from screening received tenofovir with lamivudine in ART
regimen.
Conclusion: In resource-limited setting, only approximately half of HIV-
1 infected patients get screening for HBV infection and HCV infection
prior to initiation of ART. Lack of screening is observed in generalised
population of HIV-1 infected patients and is not associated with any
factor. Since the prevalence of HBV infection is relatively high, screening
S116 18th ECCMID, Oral presentations
of HBV infection prior to initiation of ART should not be omitted in
resource-limited settings.
O519 Non-AIDS deﬁning non-HAART-related severe clinical
events have a high incidence in HIV-patients on HAART and
are associated with virological failure: a 7-years follow-up
cohort study (ANRS CO8)
T. Ferry, F. Rafﬁ, G. Cheˆne, X. Duval, P. Morlat,
A. Waldner-Combernoux, L. Piroth, F. Collin, C. Leport, V. Le Moing
on behalf of the ANRS CO8 Study Group
Objectives: To determine the incidence and risk factors of non-AIDS
deﬁning and non-HAART-related (NANHR) severe clinical events in a
large cohort of HIV-infected patients in France.
Methods: The APROCO/COPILOTE (ANRS CO8) cohort enrolled
1281 patients, in 1997–1999, at the initiation of a protease inhibitor-
containing antiretroviral regimen. All severe clinical events (grade 3 or
4 events according the ANRS classiﬁcation, hospitalisation, extension
of hospitalisation or death) were reviewed by a validation committee.
Risk factors for NANHR severe clinical events were analysed using
multivariate Cox models with CD4 and plasma HIV RNA viral load
(pVL) as time-dependent covariates.
Results: After a median follow-up of 88 months (7664 patient-
years), 713 NANHR severe clinical events were recorded in 385
patients. Incidence of NANHR severe clinical events was higher than
AIDS-related events one, 9.3/100 patient-years and 2.0/100 patient-
years, respectively. Most frequent NANHR severe clinical events were
bacterial infections (n = 196, 27%), cancer-related events (n = 68, 9.5%),
cardiovascular (n = 68, 9.5%) and psychiatric events (n = 61, 8.5%). In
the adjusted multivariate analysis, occurrence of a ﬁrst NANHR severe
clinical event was signiﬁcantly more frequent in patients older than 60
years (hazard ratio [HR] 2.1; 95% conﬁdence interval [CI] 1.3−3.2), co-
infected with HCV (HR 1.7; 95% CI 1.4−2.1), a CD4 <100 cells/mm3
at the time of the event (HR 2.5; 95% CI 1.8−3.6) and a pVL> 4 log10
copies/mL at the time of the event (HR 1.9; 95% CI 1.5−2.5). Factors
associated with bacterial infections were similar to those associated with
all types of NANHR severe clinical events, and the risk (HR) increased
with the level of virological failure: 2.48 (95% CI 1.48−4.17) for pVL
>4 log10 and <5 log10 copies/mL and 4.08 (95% CI, 2.28−7.36) for
pVL> 5 log10 copies/ml. The only factor associated with non-AIDS
cancers was age (HR 2; 95% CI 1.6−2.6) but a CD4 >500 cells/mm3
at the time of the event tended to have a protective effect (HR 0.5; 95%
CI 0.3−1; p = 0.06).
Conclusions: We recorded a high incidence of NANHR severe clinical
events (4 fold than that of HIV-deﬁning events) in our patient population.
Virological failure may favour the occurrence of NANHR severe clinical
events and especially bacterial infections. These results give further
arguments against interruptions of antiretroviral treatment.
O520 Natural polymorphisms associated with integrase inhibitor
drug resistance in Estonian HIV-1 CRF06cpx strains
R. Avi, K. Huik, M. Sadam, T. Karki, T. Krispin, P. Paap, K. Ainsalu,
J. Schmidt, N. Nikitina, I. Lutsar (Tartu, Kohtla-Jarve, EE)
Objectives: We aimed to characterise the genetic diversity in integrase
(IN) region of HIV-1 circulating in Estonia and to compare their genetic
diversity with that of B-subtype viruses in ARV treatment naive (ARV-
TN) and experienced (TE) patients.
Methods: A total of 104 ARV-TN (median age 26 y; 57 male; 59 IDU)
and 10 TE but none treated with integrase inhibitors (INI) were analysed.
All viruses in the latter population had at least one primary RT DRM
with the average number of 2.8. The most commonly seen mutations
were K103N (n = 9), M184V (n = 7) and V179E (n = 5). A direct
sequencing of plasma viral RNA for both populations was performed
in IN region (aa 1–289). Subtyping was carried out using phylogenetic
analysis (neighbor-joining). The functional positions and the prevalence
of reported INI resistance mutations (A38K, H51Y, T66I, V72I,
L74IMA, V75I, E92QD, T97A, F121NY, T125KY, A128T, E138K,
G140AS, Y143HCR, Q146KR, S147G, Q148H, V151I, S153AY, M154I,
N155HS, K156N, E157Q, K160D, G163KR, V165I, V201I, I203M,
T206S, S230NR, V249I, R263K and C280Y) were analysed.
Results: The phylogenetic analysis in IN region revealed that a total
of 101/114 viruses formed a highly homogenic cluster with CRF06cpx
reference sequences, one with CRF02AG, subtype A1 and subtype B
each, and 10 remained unclassiﬁed.
Mean pair-wise genetic distances in TN and TE populations in IN region
of CRF06cpx viruses were similar, 0.014 and 0.016, respectively. In TN
population 43 integrase inhibitor DRMs were described, of which the
following ones occurred with the highest frequency: V72I in 92%, L74I
in 100%, V201I in 97% and T206S in 96% of cases. The amino acid
distributions in CRF06cpx viruses at any position of IN region in treated
and naive patients were similar. The DDE and HHCC site residues were
absolutely conserved in all populations. Compared with the subtype B
the presence of IN DRMs V72I, V201I and T206S was more common
in CRF06cpx viruses and was seen with the frequency of 17% vs 92%;
11% vs 97% and 9% vs 96%, respectively.
Conclusions: The DRMs in RT region were not associated with the
induction of any compensatory mutations in IN region. Compared with
subtype B in CRF06cpx viruses the presence of naturally occurring
secondary DRMs in IN region was more frequent. The importance of
this during the ARV treatment with INI remains to be identiﬁed in future
clinical trials.
O521 A single planned interruption of treatment in perinatally-
HIV-infected children: effect on HAART-related toxicities
A. Noguera, C. Fortuny, L. Duran, L. Alsina, G. Claret, E. Sa´nchez
(Esplugues, Barcelona, ES)
Objective: HAART-related long-term toxicities are being increasingly
reported in perinatally-HIV-infected children, including hyperlac-
tataemia, dyslipaemias, and hepatic and bone marrow toxicity. Planned
interruptions of HAART (PIH) arise with the potential to reduce drug
exposure and toxicity.
Methods: We present a case series of 14 perinatally-HIV-infected
paediatric patients (10 girls, median age 7.7 years at PIH) with optimal
long-term response to a ﬁrst-line HAART regimen who underwent
a single PIH. Hemoglobin, total neutrophil counts, lactate levels,
triglycerides, total, LDL and HDL cholesterol, alanine aminotransferase
and amylase plasmatic levels were assessed at PIH and 12 months later,
while off therapy. Non-parametric tests were used as appropriate.
Results: At PIH, patients had remained a median time of 4.8 and 4.5
years on therapy (5 out of 14 on a protease inhibitor-based regimen) and
with complete suppression of viral replication, respectively. One month
after treatment interruption, a blip in HIV plasmatic viral load up to
a median value of 4.6 log copies/mL (range 2.9−5.6) was observed in
all cases; HIV viral load stabilised thereafter. No clinical progression
occured, despite a progressive decrease in CD4 cell percentages/counts
was observed in most cases. None of the patients had to reinitiate
therapy during the 12-month follow-up. One year after PIH, decreases
in total cholesterol (median values, from 163 to 134 mg/dL; Wilcoxon
rank test, p = 0.03), LDL cholesterol (from 90 to 77 mg/dL, p = 0.064),
HDL cholesterol (from 60 to 43 mg/dL, p = 0.002) and lactate levels
(from 1.3 to 0.9 mmol/L, p = 0.026) were observed. No changes were
observed in the rest of studied parameters. All variables remained
within normal/acceptables values at both time-points. None of the
patients showed symptoms consistent with hyperlactataemia, hepatitis
or pancreatitis, neither while on HAART nor during PIH.
Conclusions: In this series, a 12-month PIH lead to a signiﬁcant
decrease in total and HDL cholesterol, and lactate levels. However,
all parameters remained within normal values at baseline and after
PIH, and no clinical symptoms were observed. The long-term clinical
consequences of HAART-related toxicities in perinatally-HIV-infected
paediatric patients remain unknown, as well as the potential beneﬁt of
HAART-sparing strategies.
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O522 SIV-speciﬁc CD8+ T-cells mediated protection from
uncontrolled viral replication after vaginal challenge in
live-attenuated immunised rhesus macaques
M. Genesca`, M. Stone, D. Lu, K.M. Bost, J. Li, T.L. Rourke,
M.B. McChesney, C.J. Miller (Davis, US)
Objectives: Live-attenuated lentivirus immunisation protects rhesus
monkeys from uncontrolled viral replication after vaginal challenge with
pathogenic SIVmac239. Local polyfunctional Gag-speciﬁc CD4+ and
CD8+T cell responses are present in the genital tract of SHIV89.6-
immunised rhesus macaques at the time of SIV challenge. To further
assess the role of CD8+ lymphocytes in vaccine-induced protection, a
group of SHIV-vaccinated monkeys was depleted of CD8+ lymphocytes
on the day of challenge with SIVmac239.
Methods: SHIV89.6-immunised (n = 12) and non-immunised (n = 9)
animals where necropsied at 14 days post-challenge (PC). Anti-CD8
(cM T807; 50mg/kg) was administered to an additional group of
immunised monkeys (n = 6) on the day of the intravaginal challenge with
SIVmac239. Lymphocytes from freshly digested cervicovaginal tissues,
lymph nodes and peripheral blood where analysed by polychromatic
ﬂow cytometry for Gag speciﬁc responses (intracellular cytokines,
degranulation and cell death/survival signals).
Results: Viral RNA (vRNA) levels were high in all tissues of non-
immunised animals (GI tract  systemic lymph nodes > genital tract).
In immunised animals, virus replication was controlled in all tissues
and SIV dissemination beyond the genital lymph nodes was limited.
Only 2 immunised animals had moderate levels of vRNA in the GI tract
and systemic tissues, with a similar distribution to the control animals.
Strikingly, CD8+ lymphocyte depletion eliminated the beneﬁcial effect
of the SHIV immunisation, and by 7 days PC, this group had the highest
plasma vRNA levels of all groups. Interestingly, the distribution of viral
replication was different, and the highest levels of vRNA were found in
the genital tract. Moreover, the only Mamu-A01*monkey in this group,
which was the only animal that partially controlled the virus in the
different tissues, was the only monkey with detectable speciﬁc CD8+T
cell response in the genital lymph nodes.
Conclusion: In summary, the establishment of a memory SIV-speciﬁc
polyfunctional T cell response in the genital tract induced by live-
attenuated immunisation may account for protection from intravaginal
SIV challenge. Further, depletion of CD8+T cells eliminates the live-
attenuated lentivirus mediated protection.
O523 Long-term efﬁcacy of nevirapine-based anti-retroviral
therapy among HIV-1 infected patients with/without
previous rifampicin, and treatment outcomes of tuberculosis:
a 144-week prospective study
W. Manosuthi, P. Tantanathip, W. Prasithisirikul, S. Chimsuntorn,
S. Sungkanuparph (Nonthaburi, Bangkok, TH)
Objectives: To evaluate the long-term efﬁcacy of nevirapine (NVP)-
based antiretroviral therapy (ART) among HIV-1 infected patients who
previously received this regimen with rifampicin (RIF) and to assess the
long-term outcomes of tuberculosis (TB) in a resource-limited setting.
Methods: HIV-1/TB co-infected patients receiving RIF (group A) and
HIV-1 mono-infection not receiving RIF (group B) were enrolled to
receive NVP 400 mg/day with stavudine and lamivudine in a prospective
study. Plasma HIV-1 RNA and CD4 cell counts were studied every 12
weeks through 96 weeks and then every 24 weeks until 144 weeks. Re-
evaluation of clinical TB and chest X-ray were performed at week 144.
Genotypic resistance testing was conducted in patients who had HIV-1
RNA >1,000 copies/mL.
Results: Of 140 patients (70/group), 68% were male and median (IQR)
CD4 was 29 cells/mm3. Of 70 patients in group A, 31 (44%), 20 (29%),
14 (20%), 3 (4%), 2 (3%) patients were diagnosed with pulmonary TB,
disseminated TB, cervical TB lymphadenitis, gastrointestinal TB and
TB meningitis, respectively. By intend-to-treat analysis, 61% (43/70)
in group A and 57% (40/70) in group B maintained plasma HIV-
1 RNA <50 copies/mL at 144 weeks of ART (P = 0.731, OR=1.194,
95%CI=0.608−2.346). At week 144, median (IQR) CD4 was 367 (260–
541) cells/mm3 and 393 (286–501) cells/mm3 in the corresponding
groups (P = 0.646). Of 70 patients in each group, 10% (7/70) and
9% (6/70) patients in the corresponding groups developed HIV-1 RNA
>1,000 copies/ml (P=1.000). For NRTI-resistance associated mutations,
M184V was observed 71% (5/7) in group A and 83% (5/6) in group
B (P=1.000). TAMs, K65R, and Q151M were observed 0% (0/7), 29%
(2/7), and 0% (0/0) in group A and 17% (1/6), 0% (0/6), and 0% (0/6)
in group B, respectively (P> 0.05). For NNRTI-resistance associated
mutations, Y181C/I was the most common mutation and found 71%
(5/7) in group A and 50% (3/6) in group B (P = 0.592). For 70 outcomes
of TB in group A, 55 (79%) were cure/completed treatment; 7 (10%), 5
(7%), 2 (3%) and 1 (1%) were lost to follow-up, died, transferred care
and recurrent TB, respectively.
Conclusions: There is no difference of the 144-week efﬁcacy between
HIV-1/TB co-infected patients receiving RIF and HIV-1 mono-infection
not receiving RIF. Long-term TB outcomes are favourable. In resource-
limited settings, NVP 400 mg/day-based ART is an appropriate option
for HIV-1 infected patients who receive RIF.
O524 Efﬁcacy and safety of once-daily atazanavir/ritonavir
compared to twice-daily lopinavir/ritonavir, each in
combination with tenofovir and emtricitabine, in
antiretroviral naive HIV-1 infected subjects. The CASTLE
Study (AI424–138) 48-week results
J-M. Molina, J. Andrade-Villaneuva, J. Echevarria, P. Chetchotisakd,
J. Corral, N. David, G. Moyle, M. Mancini, L. Percival, A. Thiry,
D. McGrath (Paris, FR; Guadalajara, MX; Lima, PE; Khonkaen, TH;
Buenos Aires, AR; Western Cape, ZA; London, UK; Wallingford, US)
Objectives: Atazanavir/Ritonavir (ATV/r) is as effective as Lopinavir/
Ritonavir (LPV/r) with more favourable lipid and GI proﬁles in
treatment-experienced HIV-infected patients. Comparative data in
antiretroviral (ARV)-naive patients are needed.
Methods: CASTLE is a randomised, open-label, multicentre, ongoing 96
week study to assess non-inferiority (10% margin) of ATV/r 300 mg/100
mg once-daily (QD) versus LPV/r 400 mg/100mg twice-daily, both
in combination with ﬁxed-dose tenofovir (TDF) 300mg/emtricitabine
(FTC) 200 mg QD, in treatment-naive patients. The primary endpoint
was the proportion of patients with HIV RNA <50 c/mL at week
48; planned secondary assessments included percent with HIV RNA
<400 c/mL, CD4 cell count change, and safety.
Results: 883 patients randomised, 878 treated. Baseline (BL) demo-
graphics and characteristics were well balanced. Median CD4 205
cells/mm3; median plasma HIV RNA 4.98 log10 c/mL. At week 48,
mean CD4 increases from BL for ATV/r and LPV/r were 203 and
219 cells/mm3, respectively. Fewer patients on ATV/r (2%) than LPV/r
(8%) initiated lipid lowering therapy. The proportion of patients with
a TC: HDL ratio >5 at week 48 was 12% and 20% on ATV/r and
LPV/r, respectively. Patients on ATV/r had a lower incidence of Grade
2−4 treatment-related diarrhoea (2% vs 11%) and nausea (4% vs 8%)
than LPV/r. Grade 3−4 ALT/AST elevations were low ( 2%) on
both arms. Discontinuations prior to week 48 were: ATV/r, 9%; LPV/r,
13%. AE-related discontinuations were 2% and 3% on ATV/r and
LPV/r, respectively. Three patients (<1%) discontinued ATV/r due to
jaundice/hyperbilirubinaemia.
Conclusions: In treatment-naive patients, ATV/r demonstrated similar
efﬁcacy, a lower incidence of GI-related AEs, and a signiﬁcantly better
lipid proﬁle (TC, TG, non-HDL) compared to LPV/r. In combination
with TDF and FTC, both ATV/r and LPV/r were well tolerated with few
discontinuations through 48 weeks.
These data have been accepted for oral presentation at the 15th
Conference on Retroviruses and Opportunistic Infections, February,
2008. ECCMID would be the ﬁrst European presentation of these
important data.
S118 18th ECCMID, Oral presentations
ATV/r LPV/r Difference
Estimate (95% CI)
(ATV/r − LPV/r)
CVRa n = 440 n = 443
% <50 c/mL 78 76 1.7 (−3.8, 7.1)
% <400 c/mL 86 82 3.3 (−1.5, 8.1)
CVRa, Baseline CD4 <50 cells/mm3 n = 58 n = 48
% <50 c/mL 78 63
Fasting Lipid mean % D from BL
at 48 weeksb
n = 421 n = 415
Total-C (TC) 12 24 −9.5 (−11.8, −7.0)c
LDL 12 15 −2.9 (−7.1, 1.5)
HDL 27 32 −3.8 (−7.8, 0.3)
Non-HDL 7 21 −11.6 (−14.5, −8.7)c
TG 13 51 −25.2 (−29.8, −20.2)c
aConﬁrmed Virologic Response (ITT), Non-Completers = Failure.
bLast Observation Carried Forward.
cp< 0.0001.
O525 Safety reporting in randomised clinical trials of HAART:
systematic review
M. Chowers, B. Gottesman, M. Paul, U. Pielmeier, L. Leibovici (Kfar
Saba, Petach Tiqva, IL; Aalborg, DK)
Background: Selection of highly active antiretroviral therapy (HAART)
is currently based on the relative efﬁcacy and toxicity of the different
regimens. While reporting of efﬁcacy is standardised in most studies,
the reporting of adverse events (AE) is highly variable. The CONSORT
statement provides guidance on reporting of adverse events. In this study
we assessed compliance with the CONSORT guidelines and the inﬂuence
of sponsorship on AE reporting.
Methods: PubMed and CENTRAL were systematically searched for
all published randomised controlled trials assessing HAART for naive
adult HIV-infected individuals. Quality of AE reporting was assessed
according to CONSORT guidelines. AE severity grading was based on
the NIAID deﬁnitions.
Results: Forty two articles including 16045 patients met the inclusion
criteria. AE deﬁnition was speciﬁed in 26 of the studies and
discontinuation rules were speciﬁed in 10. AE collection mode
was indicated in two studies only (questionnaire for lipodystropy
development). In 40 studies no information regarding AEs assessment
mode was given. Ten studies presented all harms, 23 presented only AEs
attributed to study drugs and nine studies did not specify any information
regarding AE attribution. Clinical AEs were reported with the following
severity grades: 14 studies reported severity grades of 1−4, 16 studies
2−4, 10 studies 3−4 and two studies reported only AEs that led to
discontinuation. Twenty seven studies reported AE that occurred only
above a threshold. Eight studies reported AEs that occurred in more
than 5% of the patients, 4 above 10%, 2 above 15% and one above 20%.
Moreover, three studies reported selected AE without details of how
or why the selection was done. Of the 42 studies, 14 were academic
and 28 were sponsored by a pharmaceutical company. In 13 of the 14
academically sponsored studies all AE were reported (no threshold set),
whereas only one of the 28 studies sponsored by the industry reported
all AE (p< 0.001).
Conclusions: Substantial variability in AE compilation and reporting
was found. Variability was inﬂuenced by sponsor identity (whether
academic or pharmaceutical). These facts cast doubt on result
completeness and on our ability to choose therapies based on current
published data.
O526 Incidence and predictors of nevirapine-associated rash
in experienced HIV patients who switched from other
antiretroviral regimens to nevirapine-based regimen
O. Putcharoen, S. Satitthummanid, A. Avihingsanon (Bangkok, TH)
Objectives: Nevirapine (NVP)-related rash is well recognised adverse
effect. NVP-related rash and hypersensitivity commonly occur in patients
with high CD4. In naive patients, NVP should be avoided in male
with baseline CD4 400 or female with CD4  250. However, NVP
is alternative choice in some patients who have side effects from
other regimens. Fast CD4 recovery, gender and ethnicity contribute to
development of rash. In HIV-naive Thai patients, risk of rash from
NVP is 30%, which is higher than other reports. NVP-related rash
in experienced HIV patients who switched to NVP-based regimen has
limited data.
Methods: We reviewed data of patients who switched antitretroviral
regimen (ARV) to contain 200 mg bid of NVP in new regimen.
Demographic data, previous ARV regimen, incidence and type of rash
and outcome were analysed. The incidence of rash was compare with
the results from 2NN study. Clinical data of patients with and without
rash were compared. Severe rash is deﬁned as having urticaria or rash
with constitutional symptoms or serum sickness or Stevens Johnson
Syndrome or toxic epidermal necrolysis.
Results: A total of 174 patients switched ARV regimen to NVP-based
regimen and 162 patients had available data for further analysis. Mean
and median CD4 of enrolled patients were 499 and 471 respectively.
Most (95%) of patients had virologic control before switching to NVP.
Most patients had no signiﬁcant changes of CD4 before and after
switching. Prevalence of rash was 21% and 9% of patients had severe
rash. Using cut-off levels of CD4 at 400 in male and 250 in female,
we found no signiﬁcant difference between incidence of rash between
the groups. Severe rash occurred in male and female patients with mean
and median CD4 cells were 430,467 in male and 413, 342 in female
respectively. In female who had rash and CD4 400, signiﬁcantly had
severe rash than female with CD4 <400 (p< 0.05).
Characteristics Rash (35) No rash (127)
Sex (M:F) 1:1.1 1:1.1
Mean body weight (BW) (kg) 55.6 56.6
BW in male patients (mean, median) 59.3, 61 61, 50
BW in female patients (mean, median) 52.8, 52 54.0, 53
CD4 (cell/mm3)
Mean 481 504
Median 474 466
CD4 in male patients
Mean 508 514
Median 474 457
Range 203–841 62−1,251
CD4 in female patients
Mean 463 488
Median 399 473
Range 203−1,023 59−1,233
Mean and median CD4 in male with
severe rash
430, 467
Mean and median CD4 in female with
severe rash
413, 342
Male patients with CD4 400 12/43 (27%) 31/43 (72%)
with CD4< 400 2/25 (8%) 23/25 (92%)
p-value p = 0.05
Female patients with CD4 250 17/68 (25%) 51/68 (75%)
with CD4< 250 4/14 (28%) 10/14 (72%)
p-value p = 0.78
Severe rash is deﬁned as having urticaria or rash with constitutional symptoms or
serum sickness or Stevens Johnson Syndrome or toxic epidermal necrolysis.
Conclusion: Incidence of NVP-related rash in experienced HIV patients
with high CD4, is lower than naive patients (21% VS 30%). No rapid
rising of CD4 levels after switching to NVP, may explain lower incidence
of rash in our patients. Most occurrences of rash are mild. Cut-off levels
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of CD4 could not predict the risk for rash development. However, female
have more chance to develop severe rash from nevirapine compare to
male who have same level of CD4. Switching ARV to NVP-based
regimen should be cautioned and carefully monitored, especially in
female with CD4  400.
O527 CXCR4-using HIV-1 in antiretroviral-naive patients with
primary or chronic infection
S. Parisi, C. Boldrin, M. Cruciani, R. Scaggiante, S. Panese,
P.G. Scotton, R. Ferretto, V. Manfrin, O. Bosco, M. Andreoni, G. Palu`
(Padua, Verona, Venice, Treviso, Schio, Vicenza, Rome, IT)
Objectives: To characterise correlates of CXCR4-using (X4) or CCR5-
using (R5) HIV-1 strains in a cross-sectional analysis of therapy-naive
patients (pts).
Methods: Plasma from 26 pts with acute-recent-infection (<1 year,
AR), 22 with early-chronic- (>300 cd4/ul, ECh) and 24 with advanced-
chronic-infection (<300 cd4/ul, AdvCh), all harbouring HIV-1-B-
subtype, were evaluated by sequencing a 35-amino-acids region from env
gene, and by interpretation with PSSM-genotype prediction. In a subset
of pts, peripheral blood mononuclear cells (PBMC) and cerebrospinal
ﬂuid (CSF) were tested.
Results: The cd4 median was 606 (range 230–1143), 395 (304–1145)
and 153 (2–291) cells/ul for AR, ECh- and AdvCh-infected, cd4
percentage was 25 (8−44.5), 29.5 (15−36.6), and 14 (2.4−24.2), HIV-
RNA plasma viraemia was 150,600 (145–450,294), 78,566 (45–262,900)
and 65,403 (2725–665,993) copies/ml, and HIV-DNA proviral loads was
864 (93−18,005), 1279 (55–6357) and 3237 (45−17,308) copies/106
PBMC, respectively. At sequence evaluation R5-strains were found in
all pts, with the exception of ﬁve X4-strains among AR (19.2%) and
four X4-strains in AdvCh (16.6%) (p = not signiﬁcant in any possible
comparison by Fisher exact test). Among AR pts, those with X4-strains
had similar cd4 (578 vs 633), lower cd4 percentage (24.5 vs 28.6),
similar HIV-RNA plasma levels (150,600 vs 167,616) and higher DNA-
load (2441 vs 696) with respect to R5-strain-harbouring subjects.
At PBMC-strain analysis, 4 AdvCh-pts with plasma-X4-strains revealed
a concordant X4-strain in 3 cases, and an R5-strain in 1. 8 AdvCh-pts
with plasma-R5-strains revealed a concordant R5 strain in 7 cases, and
an X4-strain in 1.
Among 5 plasma-X4 AR-pts, 1 R5-strain was found in PBMC. 7 plasma-
R5 acute-pts had an R5-strain in PBMC. Among few CSF studied, an X4
was found, from a AR-pt harbouring R5-strains in plasma and PBMC.
Conclusion: The presence of X4 variants is described to be more
frequent in the late stages of the disease, but frequently can be
transmitted as a X4/R5 mixture and X4-strains can be demonstrated
without clonal analysis in the early phase of infection. In AdvCh-
pts discordant pictures in different compartments can be found. These
evidences may have implications for therapy, suggesting a co-receptor-
use analysis of both plasma- and PBMC-strains as soon as possible after
diagnosis. Cautions have to be maintained before using CCR5-inhibitors
in the very early stages of disease, monitoring for an early selection of
X4 variants.
